PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Lactamase live!	SCIENCE			English	Editorial Material																		NISWENDER KD, 1995, J MICROSC-OXFORD, V180, P109, DOI 10.1111/j.1365-2818.1995.tb03665.x; Zlokarnik G, 1998, SCIENCE, V279, P84, DOI 10.1126/science.279.5347.84	2	2	2	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					412	412						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9454333				2022-12-28	WOS:000071570800055
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Droplet discovery	SCIENCE			English	Editorial Material									Medsite Commun Corp, Boston, MA USA		Sikorski, R (corresponding author), Medsite Commun Corp, Boston, MA USA.							Borchardt A, 1997, CHEM BIOL, V4, P961, DOI 10.1016/S1074-5521(97)90304-5; Huang J, 1997, P NATL ACAD SCI USA, V94, P13396, DOI 10.1073/pnas.94.25.13396; You AJ, 1997, CHEM BIOL, V4, P969, DOI 10.1016/S1074-5521(97)90305-7	3	2	2	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					412	413						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9454333				2022-12-28	WOS:000071570800056
J	Baughman, RH; Stafstrom, S; Cui, CX; Dantas, SO				Baughman, RH; Stafstrom, S; Cui, CX; Dantas, SO			Materials with negative compressibilities in one or more dimensions	SCIENCE			English	Article							POISSON RATIOS	Rare crystal phases that expand in one or more dimensions when hydrostatically compressed are identified and shown to have negative Poisson's ratios. Some of these crystals (i) decrease volume and expand in two dimensions when stretched in a particular direction and (ii) increase surface area when hydrostatically compressed. Possible mechanisms for achieving such negative linear and area compressibilities are described for single crystals and composites, and sensor applications are proposed. Materials with these properties may be used to fabricate porous solids that either expand in all directions when hydrostatically compressed with a penetrating fluid or behave as if they are incompressible.	Allied Signal Inc, Res & Technol, Morristown, NJ 07962 USA; Linkoping Univ, Dept Phys & Measurement Technol, S-58183 Linkoping, Sweden; UFJF, Dept Fis, BR-36036330 Juiz De Fora, MG, Brazil	Linkoping University; Universidade Federal de Juiz de Fora	Baughman, RH (corresponding author), Allied Signal Inc, Res & Technol, Morristown, NJ 07962 USA.		Stafstrom, Sven/G-2982-2011; Baughman, Ray Henry/A-8628-2018	Stafstrom, Sven/0000-0001-6555-239X; Baughman, Ray Henry/0000-0001-5845-5137				ALDERSON A, 1995, J MATER SCI, V30, P3319, DOI 10.1007/BF00349875; BACON GE, 1980, ACTA CRYSTALLOGR B, V36, P1908, DOI 10.1107/S0567740880007443; Barta C., 1979, Soviet Physics - Crystallography, V24, P608; BAUGHMAN RH, 1993, NATURE, V365, P735, DOI 10.1038/365735a0; Berge PA, 1995, J APPL MECH-T ASME, V62, P1053, DOI 10.1115/1.2896042; BIOT MA, 1962, J APPL PHYS, V33, P1482, DOI 10.1063/1.1728759; CHISTOV SF, 1973, IZV AKAD NAUK NEORG, V9, P1749; DEGUCHI K, 1984, J PHYS SOC JPN, V53, P3074, DOI 10.1143/JPSJ.53.3074; GIBSON LJ, 1982, P ROY SOC LOND A MAT, V382, P25, DOI 10.1098/rspa.1982.0087; GUNTON DJ, 1972, J MATER SCI, V7, P1061, DOI 10.1007/BF00550070; HERAKOVICH CT, 1984, J COMPOS MATER, V18, P447, DOI 10.1177/002199838401800504; Hine PJ, 1997, J MATER SCI LETT, V16, P541, DOI 10.1023/A:1018505503088; KIER WM, 1985, ZOOL J LINN SOC-LOND, V83, P307, DOI 10.1111/j.1096-3642.1985.tb01178.x; LAKES R, 1987, SCIENCE, V235, P1038, DOI 10.1126/science.235.4792.1038; Lee T, 1997, J MATER SCI, V32, P2397, DOI 10.1023/A:1018557107786; MARIATHASAN JWE, 1985, ACTA CRYSTALLOGR B, V41, P179, DOI 10.1107/S0108768185001902; MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010; MILTON GW, 1992, J MECH PHYS SOLIDS, V40, P1105, DOI 10.1016/0022-5096(92)90063-8; MOROSIN B, 1972, SOLID STATE COMMUN, V10, P249, DOI 10.1016/0038-1098(72)90001-4; MUNN RW, 1972, J PHYS PART C SOLID, V5, P535, DOI 10.1088/0022-3719/5/5/005; NELSON DF, 1993, LANDOLTBORNSTEIN A, V29; Nye J. F., 1964, PHYSICAL PROPERTIES, P131; OReilly JC, 1997, NATURE, V386, P269, DOI 10.1038/386269a0; PRAWER S, 1985, AUST J PHYS, V38, P63, DOI 10.1071/PH850063; SAPRIEL J, 1989, APPL PHYS LETT, V55, P2594, DOI 10.1063/1.101989; SKELTON EF, 1976, PHYS REV B, V13, P2605, DOI 10.1103/PhysRevB.13.2605; SORGE G, 1981, PHYS STATUS SOLIDI A, V65, P189, DOI 10.1002/pssa.2210650122; WELLS AF, 1976, ACTA CRYSTALLOGR B, V32, P2619, DOI 10.1107/S0567740876008376	28	284	289	8	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1522	1524		10.1126/science.279.5356.1522	http://dx.doi.org/10.1126/science.279.5356.1522			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488648				2022-12-28	WOS:000072372900061
J	Houde, JF; Jordan, MI				Houde, JF; Jordan, MI			Sensorimotor adaptation in speech production	SCIENCE			English	Article							LANGUAGE PRODUCTION; IMPLICIT SPEECH	Human subjects are known to adapt their motor behavior to a shift of the visual field brought about by wearing prism glasses over their eyes. The analog of this phenomenon was studied in the speech domain. By use of a device that can feed back transformed speech signals in real time, subjects were exposed to phonetically sensible, online perturbations of their own speech patterns. It was found that speakers learn to adjust their production of a vowel to compensate for feedback alterations that change the vowel's perceived phonetic identity; moreover, the effect generalizes across phonetic contexts and to different vowels.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Houde, JF (corresponding author), Univ Calif San Francisco, Keck Ctr, 513 Parnassus Ave,S-877, San Francisco, CA 94143 USA.		Jordan, Michael I/C-5253-2013; Galantucci, Bruno/E-5770-2010					Chomsky Noam, 1968, SOUND PATTERN ENGLIS; Clements G. N., 1985, PHONOLOGY YB, V2, P225, DOI [10.1017/S0952675700000440., 10.1017/S0952675700000440, DOI 10.1017/S0952675700000440]; Cooper W, 1979, SPEECH PERCEPTION PR; DELL GS, 1992, COGNITION, V42, P287, DOI 10.1016/0010-0277(92)90046-K; ERIKSEN CW, 1970, J EXP PSYCHOL, V84, P502, DOI 10.1037/h0029274; FERREIRA F, 1991, J MEM LANG, V30, P210, DOI 10.1016/0749-596X(91)90004-4; Gracco VL, 1994, J ACOUST SOC AM, V95, P2821; HELD R, 1961, J NERV MENT DIS, V132, P26; Helmholtz H., 1925, TREATISE PHYSL OPTIC, V3; HOUDE JF, 1997, THESIS MIT CAMBRIDGE; Kawahara H., 1993, J ACOUST SOC AM, V94, P1883; KLAPP ST, 1973, J EXP PSYCHOL, V100, P368, DOI 10.1037/h0035471; Kohler I, 1955, ACTA PSYCHOL, V11, P176; LANE H, 1971, J SPEECH HEAR RES, V14, P677, DOI 10.1044/jshr.1404.677; LEE BS, 1950, J ACOUST SOC AM, V22, P639, DOI 10.1121/1.1906665; LEVELT WJM, 1989, SPEAKING INTENTION A; Lombard E, 1911, ANN MALADIES OREILLE, P101; MEYER AS, 1991, J MEM LANG, V30, P69, DOI 10.1016/0749-596X(91)90011-8; MEYER AS, 1992, COGNITION, V42, P181, DOI 10.1016/0010-0277(92)90043-H; MOWREY RA, 1990, J ACOUST SOC AM, V88, P1299, DOI 10.1121/1.399706; Shattuck-Hufnagel S., 1979, SENTENCE PROCESSING, P295; Sternberg S., 1978, INFORMATION PROCESSI, P117, DOI DOI 10.1016/B978-0-12-665960-3.50011-6; Stratton GM, 1896, PSYCHOL REV, V3, P611, DOI DOI 10.1037/H0072918; Welch R. B., 1978, PERCEPTUAL MODIFICAT; Wells Rulon, 1951, YALE SCI MAGAZINE, V26, P9; YATES AJ, 1963, PSYCHOL BULL, V60, P213, DOI 10.1037/h0044155	26	472	476	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1213	1216		10.1126/science.279.5354.1213	http://dx.doi.org/10.1126/science.279.5354.1213			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YY119	9469813	Green Submitted			2022-12-28	WOS:000072115200045
J	Parker, JD; Parker, JO				Parker, JD; Parker, JO			Nitrate therapy for stable angina pectoris	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							VASCULAR SMOOTH-MUSCLE; TRANSDERMAL NITROGLYCERIN THERAPY; ORAL ISOSORBIDE DINITRATE; CONGESTIVE-HEART-FAILURE; DOSE-RESPONSE RELATION; ORGANIC NITRATES; N-ACETYLCYSTEINE; NITRIC-OXIDE; GLYCERYL TRINITRATE; EXERCISE CAPACITY		Univ Toronto, Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; Queens Univ, Kingston Gen Hosp, Dept Med, Kingston, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Queens University - Canada	Parker, JD (corresponding author), Univ Toronto, Mt Sinai Hosp, Dept Med, Suite 1609,600 Univ Ave, Toronto, ON M5G 1X5, Canada.			Parker, John/0000-0003-1949-2669				ABDOLLAH A, 1987, J CARDIOVASC PHARM, V9, P445, DOI 10.1097/00005344-198704000-00009; ABRAMS J, 1991, EUR HEART J, V12, P42, DOI 10.1093/eurheartj/12.suppl_E.42; ARMSTRONG PW, 1982, CIRCULATION, V66, P1273, DOI 10.1161/01.CIR.66.6.1273; AXELSSON KL, 1979, LIFE SCI, V24, P1779, DOI 10.1016/0024-3205(79)90067-5; AXELSSON KL, 1983, EUR J PHARMACOL, V88, P71, DOI 10.1016/0014-2999(83)90393-X; BASSAN MM, 1990, J AM COLL CARDIOL, V16, P936, DOI 10.1016/S0735-1097(10)80344-4; BASSAN MM, 1983, CHEST, V83, P233, DOI 10.1378/chest.83.2.233; BATTOCK DJ, 1969, CIRCULATION, V39, P157, DOI 10.1161/01.CIR.39.2.157; BAUER JA, 1991, CIRCULATION, V84, P35, DOI 10.1161/01.CIR.84.1.35; BODEN WE, 1985, CIRCULATION, V71, P1197, DOI 10.1161/01.CIR.71.6.1197; BOESGAARD S, 1994, CIRC RES, V74, P115, DOI 10.1161/01.RES.74.1.115; BOGAERT MG, 1968, ARCH INT PHARMACOD T, V171, P221; BOGAERT MG, 1988, EUR HEART J, V9, P33, DOI 10.1093/eurheartj/9.suppl_A.33; BRIEN JF, 1988, J PHARMACOL EXP THER, V244, P322; BROWN BG, 1981, CIRCULATION, V64, P1089, DOI 10.1161/01.CIR.64.6.1089; CHRYSANT SG, 1993, AM J CARDIOL, V72, P1249, DOI 10.1016/0002-9149(93)90292-K; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COWAN JC, 1987, AM J CARDIOL, V60, P271, DOI 10.1016/0002-9149(87)90226-8; DEMOTS H, 1989, J AM COLL CARDIOL, V13, P786, DOI 10.1016/0735-1097(89)90216-7; DUPUIS J, 1990, J AM COLL CARDIOL, V16, P923, DOI 10.1016/S0735-1097(10)80342-0; ELKAYAM U, 1991, ANN INTERN MED, V114, P667, DOI 10.7326/0003-4819-114-8-667; FAM WM, 1968, CIRC RES, V22, P649, DOI 10.1161/01.RES.22.5.649; FERRATINI M, 1989, EUR HEART J, V10, P998, DOI 10.1093/oxfordjournals.eurheartj.a059425; FUNG HL, 1992, AM J CARDIOL, V70, pB4, DOI 10.1016/0002-9149(92)90588-P; FUNG HL, 1994, CARDIOVASC DRUG THER, V8, P489, DOI 10.1007/BF00877927; FUNG HL, 1988, J PHARMACOL EXP THER, V245, P524; FUNG HL, 1984, J PHARMACOL EXP THER, V228, P334; GLANCY DL, 1977, AM J MED, V62, P39, DOI 10.1016/0002-9343(77)90347-3; GOGIA H, 1995, J AM COLL CARDIOL, V26, P1575, DOI 10.1016/0735-1097(95)00368-1; GOLDSTEI.RE, 1971, CIRCULATION, V43, P629, DOI 10.1161/01.CIR.43.5.629; GOLDSTEIN RE, 1974, CIRCULATION, V49, P298, DOI 10.1161/01.CIR.49.2.298; GRUETTER CA, 1986, CAN J PHYSIOL PHARM, V64, P1395, DOI 10.1139/y86-236; HARRISON DG, 1993, CIRCULATION, V87, P1461, DOI 10.1161/01.CIR.87.5.1461; HOROWITZ JD, 1983, CIRCULATION, V68, P1247, DOI 10.1161/01.CIR.68.6.1247; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; KALA R, 1983, ACTA MED SCAND, V213, P165; KATSUKI S, 1977, MOL PHARMACOL, V13, P330; KATZ RJ, 1991, CIRCULATION, V83, P1271, DOI 10.1161/01.CIR.83.4.1271; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; KOHLI RS, 1986, AM J CARDIOL, V58, P727, DOI 10.1016/0002-9149(86)90345-0; LANGE RL, 1972, CIRCULATION, V46, P666, DOI 10.1161/01.CIR.46.4.666; LOSCALZO J, 1985, J CLIN INVEST, V76, P703, DOI 10.1172/JCI112024; LUBSEN J, 1986, BRIT HEART J, V56, P400; MAY DC, 1987, NEW ENGL J MED, V317, P805, DOI 10.1056/NEJM198709243171305; MELUZIN J, 1992, J CARDIOVASC PHARM, V20, P864, DOI 10.1097/00005344-199212000-00003; MOHANTY N, 1995, AM HEART J, V130, P522, DOI 10.1016/0002-8703(95)90361-5; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MORTON WE, 1977, J OCCUP ENVIRON MED, V19, P197; MUIESAN ML, 1993, EUR HEART J, V14, P1701, DOI 10.1093/eurheartj/14.12.1701; Munzel T, 1996, J CLIN INVEST, V98, P1465, DOI 10.1172/JCI118935; Munzel T, 1996, CIRCULATION, V93, P2052, DOI 10.1161/01.CIR.93.11.2052; MUNZEL T, 1995, P NATL ACAD SCI USA, V92, P5244, DOI 10.1073/pnas.92.11.5244; MUNZEL T, 1995, J CLIN INVEST, V95, P187, DOI 10.1172/JCI117637; MURAD F, 1990, P764; Murrell W., 1879, LANCET, V80, P225; Murrell W, 1879, LANCET, V1, P113; Murrell W, 1879, LANCET, V113, P80, DOI [10.1016/S0140-6736(02)46032-1, DOI 10.1016/S0140-6736(02)46032-1]; MURRELL W, 1879, LANCET, V1, P151; NEEDLEMA.P, 1970, J PHARMACOL EXP THER, V171, P98; NEEDLEMAN P, 1973, J PHARMACOL EXP THER, V184, P709; NEEDLEMAN P, 1973, J PHARMACOL EXP THER, V187, P324; NEEDLEMAN P, 1972, J PHARMACOL EXP THER, V181, P489; OLSSON G, 1992, EUR HEART J, V13, P814, DOI 10.1093/oxfordjournals.eurheartj.a060262; PACKER M, 1990, J AM COLL CARDIOL, V16, P932, DOI 10.1016/S0735-1097(10)80343-2; PACKER M, 1987, NEW ENGL J MED, V317, P769; PARKER JD, 1995, CIRCULATION, V91, P973, DOI 10.1161/01.CIR.91.4.973; Parker JD, 1997, J PHARMACOL EXP THER, V280, P866; PARKER JD, 1991, CIRCULATION, V84, P2336, DOI 10.1161/01.CIR.84.6.2336; PARKER JD, 1992, J AM COLL CARDIOL, V20, P616, DOI 10.1016/0735-1097(92)90016-G; Parker JD, 1996, CIRCULATION, V93, P691, DOI 10.1161/01.CIR.93.4.691; PARKER JD, 1993, J AM COLL CARDIOL, V21, P1445, DOI 10.1016/0735-1097(93)90322-R; PARKER JO, 1992, AM J CARDIOL, V70, pB93, DOI 10.1016/0002-9149(92)90600-4; PARKER JO, 1986, AM J CARDIOL, V57, P1, DOI 10.1016/0002-9149(86)90940-9; PARKER JO, 1993, AM J CARDIOL, V72, P871, DOI 10.1016/0002-9149(93)91098-3; PARKER JO, 1984, AM J CARDIOL, V54, P471, DOI 10.1016/0002-9149(84)90233-9; PARKER JO, 1995, CIRCULATION, V91, P1368, DOI 10.1161/01.CIR.91.5.1368; PARKER JO, 1983, CIRCULATION, V68, P1074, DOI 10.1161/01.CIR.68.5.1074; PARKER JO, 1987, NEW ENGL J MED, V316, P1440, DOI 10.1056/NEJM198706043162303; POORVIN D, 1991, AM J CARDIOL, V68, P1263; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; REICHEK N, 1974, CIRCULATION, V50, P348, DOI 10.1161/01.CIR.50.2.348; REICHEK N, 1984, AM J CARDIOL, V54, P1, DOI 10.1016/0002-9149(84)90295-9; REICHEK N, 1983, MODERN CONCEPTS NITR, P143; RUSSEK HI, 1968, AM J CARDIOL, V21, P44, DOI 10.1016/0002-9149(68)90012-X; SILBER S, 1987, AM J MED, V83, P860, DOI 10.1016/0002-9343(87)90643-7; SUSSEX BA, 1994, CLIN PHARMACOL THER, V56, P229, DOI 10.1038/clpt.1994.128; SUTTON SC, 1983, J CARDIOVASC PHARM, V5, P1086, DOI 10.1097/00005344-198311000-00026; SVENDSEN JH, 1987, DRUGS, V33, P122, DOI 10.2165/00003495-198700334-00022; THADANI U, 1987, AM J CARDIOL, V60, P477, DOI 10.1016/0002-9149(87)90289-X; THADANI U, 1980, CIRCULATION, V62, P491, DOI 10.1161/01.CIR.62.3.491; THADANI U, 1982, AM J CARDIOL, V49, P411, DOI 10.1016/0002-9149(82)90518-5; THADANI U, 1994, ANN INTERN MED, V120, P3353; TORFGARD KE, 1994, CARDIOVASC DRUG THER, V8, P701, DOI 10.1007/BF00877117; WALDMAN SA, 1986, BIOCHEM PHARMACOL, V35, P3525, DOI 10.1016/0006-2952(86)90622-2; Watanabe H, 1997, CIRCULATION, V96, P2545, DOI 10.1161/01.CIR.96.8.2545; WATERS DD, 1989, J AM COLL CARDIOL, V13, P421, DOI 10.1016/0735-1097(89)90521-4; WINNIFORD MD, 1986, CIRCULATION, V73, P138, DOI 10.1161/01.CIR.73.1.138; WINSOR T, 1975, AM HEART J, V96, P611; YEATES RA, 1992, ARZNEIMITTEL-FORSCH, V42-1, P297	99	290	300	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 19	1998	338	8					520	531		10.1056/NEJM199802193380807	http://dx.doi.org/10.1056/NEJM199802193380807			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX639	9468470				2022-12-28	WOS:000072061400007
J	Barron, HV; Viskin, S				Barron, HV; Viskin, S			Autonomic markers and prediction of cardiac death after myocardial infarction	LANCET			English	Editorial Material							SUDDEN-DEATH; ARTERY; REFLEXES; PATENCY; TRIALS		Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cardiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol Biostat, San Francisco, CA 94143 USA; Sourasky Tel Aviv Med Ctr, Dept Cardiol, Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Tel Aviv University; Sackler Faculty of Medicine	Barron, HV (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.							[Anonymous], 1989, NEW ENGL J MED, V321, P406; Barron HV, 1996, J AM COLL CARDIOL, V27, P1053, DOI 10.1016/0735-1097(95)00615-X; Bigger JT, 1997, NEW ENGL J MED, V337, P1569, DOI 10.1056/NEJM199711273372201; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; GRASSI G, 1995, CIRCULATION, V92, P3206, DOI 10.1161/01.CIR.92.11.3206; HERMOSILLO AG, 1993, J AM COLL CARDIOL, V22, P695, DOI 10.1016/0735-1097(93)90179-5; HULL SS, 1994, CIRCULATION, V89, P548, DOI 10.1161/01.CIR.89.2.548; HULL SS, 1995, CIRCULATION, V91, P2516, DOI 10.1161/01.CIR.91.10.2516; Julian DG, 1997, LANCET, V349, P667, DOI 10.1016/S0140-6736(96)09145-3; Julian DG, 1997, LANCET, V349, P1776; JULIAN DG, 1997, LANCET, V349, P1180; KIM CB, 1993, CIRCULATION, V88, P2426, DOI 10.1161/01.CIR.88.5.2426; LaRovere MT, 1996, CIRCULATION, V94, P109; LOWN B, 1979, AM J CARDIOL, V43, P313, DOI 10.1016/S0002-9149(79)80021-1; LOWN B, 1976, NEW ENGL J MED, V294, P1165; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; Mortara A, 1996, CIRCULATION, V93, P1114, DOI 10.1161/01.CIR.93.6.1114; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; SCHWARTZ PJ, 1988, CIRCULATION, V78, P969, DOI 10.1161/01.CIR.78.4.969; SMYTH HS, 1969, CIRC RES, V24, P109, DOI 10.1161/01.RES.24.1.109; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	21	48	58	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 14	1998	351	9101					461	462		10.1016/S0140-6736(05)78676-1	http://dx.doi.org/10.1016/S0140-6736(05)78676-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482432				2022-12-28	WOS:000072097700003
J	Kerkar, N; Hadzic, N; Davies, ET; Portmann, B; Donaldson, PT; Rela, M; Heaton, ND; Vergani, D; Mieli-Vergani, G				Kerkar, N; Hadzic, N; Davies, ET; Portmann, B; Donaldson, PT; Rela, M; Heaton, ND; Vergani, D; Mieli-Vergani, G			De-novo autoimmune hepatitis after liver transplantation	LANCET			English	Article							CLASSIFICATION; REJECTION	Background Late graft dysfunction that does not result from recognised causes, such as rejection, infection, or vascular or biliary complications, can occur after liver transplantation. We investigated a particular type of unexplained graft dysfunction that is associated with autoimmune features in children who underwent transplantation at our unit between 1991 and 1996. Methods Seven (4%) of 180 liver-transplant recipients developed an unexplained but characteristic form of graft dysfunction (five boys, two girls; median age at presentation 10.3 years, range 2.0-19.4). The median period after surgery was 24 months (6-45). The indications for transplantation had been extrahepatic biliary atresia (four patients), Alagille's syndrome (one), drug-induced acute liver failure (one), and alpha(1)-antitrypsin deficiency (one). Four patients were on triple immunosuppression with cyclosporin, azathioprine, and prednisolone; and three were on tacrolimus, Immunoglobulin measurements, autoantibody studies, serological studies, and HLA typing were undertaken. Liver-biopsy samples were taken. Findings Infectious and surgical complications were Liver-biopsy samples showed the histological changes of chronic hepatitis, including portal and periportal hepatitis with lymphocytes and collapse, and perivenular-cell necrosis typical of acute or chronic rejection. All patients had high concentrations of IgG (median 22 g/L [range 17.2-34.4]) and high titres of autoantibodies. All but one patient responded to prednisolone 2 mg/kg daily and an increase in or addition of azathioprine (1.5 mg/kg daily) within a median of 32 days (7-316), One responder relapsed owing to poor compliance but went into remission after treatment was restored. All six respondents remain in remission on a reduced dose of prednisolone (5-10 mg/day) and 1.5 mg/hg daily azathioprine at a median of 283 days (range 108-730) follow-up. Interpretation Our data show that symptoms of autoimmune hepatitis, which are responsive to the classical treatment for this condition, can appear in liver-transplant patients while they are on anti-rejection immunosuppression. Whether the liver damage in these patients is a form of rejection or the consequence of autoimmune attach has yet to be established.	Kings Coll Hosp London, Dept Child Hlth, London SE5 9PJ, England; Kings Coll Hosp London, Dept Immunol, London SE5 9PJ, England; Kings Coll Hosp London, Dept Transplant Surg, London SE5 9PJ, England; Kings Coll Hosp London, Inst Liver Studies, London SE5 9PJ, England; UCL, Sch Med, Inst Hepatol, London W1N 8AA, England	King's College Hospital NHS Foundation Trust; King's College Hospital; King's College Hospital NHS Foundation Trust; King's College Hospital; King's College Hospital NHS Foundation Trust; King's College Hospital; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of London; University College London; UCL Medical School	Mieli-Vergani, G (corresponding author), Kings Coll Hosp London, Dept Child Hlth, London SE5 9PJ, England.	rcjj008@bay.cc.kcl.ac.uk	Heaton, Nigel/AAK-8363-2020					ADAMS DH, 1990, J HEPATOL, V10, P113, DOI 10.1016/0168-8278(90)90081-2; ALBUJAR AH, 1997, J HEPATOL S, V26, P152; Conti F., 1997, Journal of Hepatology, V26, P150; COOPER MH, 1991, TRANSPLANT P, V23, P3234; Demetris AJ, 1997, HEPATOLOGY, V25, P658; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; DOHERTY DG, 1994, HEPATOLOGY, V19, P609, DOI 10.1002/hep.1840190311; DONALDSON PT, 1991, HEPATOLOGY, V13, P701, DOI 10.1016/0270-9139(91)92567-R; ESQUIVEL CO, 1985, SEMIN LIVER DIS, V5, P369, DOI 10.1055/s-2008-1040634; Gregorio GV, 1997, HEPATOLOGY, V25, P541, DOI 10.1002/hep.510250308; HESS AD, 1993, TRANSPLANT P, V25, P2811; JOHNSON PJ, 1993, HEPATOLOGY, V18, P998, DOI 10.1002/hep.1840180435; KEMNITZ J, 1989, TRANSPLANT P, V21, P2208; Kerkar N, 1996, HEPATOLOGY, V24, P435; MieliVergani G, 1996, ARCH DIS CHILD, V74, P2, DOI 10.1136/adc.74.1.2; PAT BR, 1993, J IMMUNOL, V151, P1039; Pratt DS, 1997, GASTROENTEROLOGY, V113, P664, DOI 10.1053/gast.1997.v113.pm9247489; SCHEUER PJ, 1991, J HEPATOL, V13, P372, DOI 10.1016/0168-8278(91)90084-O; VERGANI D, 1993, GASTROENTEROLOGY, V104, P1870, DOI 10.1016/0016-5085(93)90673-Z	19	285	295	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 7	1998	351	9100					409	413		10.1016/S0140-6736(97)06478-7	http://dx.doi.org/10.1016/S0140-6736(97)06478-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482295				2022-12-28	WOS:000071982600013
J	Krezel, W; Ghyselinck, N; Samad, TA; Dupe, V; Kastner, P; Borrelli, E; Chambon, P				Krezel, W; Ghyselinck, N; Samad, TA; Dupe, V; Kastner, P; Borrelli, E; Chambon, P			Impaired locomotion and dopamine signaling in retinoid receptor mutant mice	SCIENCE			English	Article							ACID RECEPTORS; MOLECULAR-BIOLOGY; BINDING-PROTEINS; COCAINE; D2-RECEPTORS; AMPHETAMINE; LACKING; SYSTEM	In the adult mouse, single and compound null mutations in the genes for retinoic acid receptor beta and retinoid X receptors beta and gamma resulted in locomotor defects related to dysfunction of the mesolimbic dopamine signaling pathway. Expression of the D1 and D2 receptors for dopamine was reduced in the ventral striatum of mutant mice, and the response of double null mutant mice to cocaine, which affects dopamine signaling in the mesolimbic system, was blunted. Thus, retinoid receptors are involved in the regulation of brain functions, and retinoic acid signaling defects may contribute to pathologies such as Parkinson's disease and schizophrenia.	Univ Strasbourg 1, Coll France, Inst Genet & Biol Mol & Cellulaire, CNRS,INSERM, F-67404 Illkirch, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chambon, P (corresponding author), Univ Strasbourg 1, Coll France, Inst Genet & Biol Mol & Cellulaire, CNRS,INSERM, Boite Postal 163, F-67404 Illkirch, France.	igbmc@igbmc.u-strasbg.fr	KREZEL, Wojciech/S-8331-2019; GHYSELINCK, Norbert/I-6999-2015; Krezel, Wojciech/H-9080-2017; Borrelli, Emiliana/M-8994-2018; Dupe, Valerie/CJQ-0939-2022; Dupe, Valerie/P-2140-2018; Krezel, Wojciech/I-7886-2016	GHYSELINCK, Norbert/0000-0003-4042-6818; Krezel, Wojciech/0000-0003-1605-3185; Dupe, Valerie/0000-0003-4859-0612; Dupe, Valerie/0000-0003-4859-0612; Krezel, Wojciech/0000-0003-1605-3185				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAIK JH, 1995, NATURE, V377, P424, DOI 10.1038/377424a0; CALLAHAN PM, 1991, PSYCHOPHARMACOLOGY, V103, P50, DOI 10.1007/BF02244073; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Dixon WJ, 1988, BMDP STAT SOFTWARE M; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DOLLE P, 1994, MECH DEVELOP, V45, P91, DOI 10.1016/0925-4773(94)90023-X; EVERITT BJ, 1990, NEUROSCI BIOBEHAV R, V14, P217, DOI 10.1016/S0149-7634(05)80222-2; FAROOQUI SM, 1994, LIFE SCI, V55, P1887, DOI 10.1016/0024-3205(94)00520-6; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; Ghyselinck NB, 1997, INT J DEV BIOL, V41, P425; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; JACKSON DM, 1994, PHARMACOL THERAPEUT, V64, P291, DOI 10.1016/0163-7258(94)90041-8; JANSSEN PAJ, 1960, PSYCHOPHARMACOLOGIA, V1, P389, DOI 10.1007/BF00441186; Kastner P, 1997, DEVELOPMENT, V124, P313; Kastner P, 1996, GENE DEV, V10, P80, DOI 10.1101/gad.10.1.80; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KOOB GF, 1978, J COMP PHYSIOL PSYCH, V92, P917, DOI 10.1037/h0077542; Krezel W, 1996, P NATL ACAD SCI USA, V93, P9010, DOI 10.1073/pnas.93.17.9010; KREZEL W, UNPUB; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7772, DOI 10.1073/pnas.91.16.7772; NESTLER EJ, 1994, CELL, V79, P923, DOI 10.1016/0092-8674(94)90022-1; PEDERSEN WA, 1995, J NEUROCHEM, V65, P50; ROBBINS TW, 1992, SEMIN NEUROSCI, V4, P119; RUBERTE E, 1993, DEVELOPMENT, V118, P267; SARNAD A, 1997, P NATL ACAD SCI USA, V94, P14349; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; WOLFFGRAMM J, 1990, PHARMACOL BIOCHEM BE, V36, P907, DOI 10.1016/0091-3057(90)90099-4; XU M, 1994, CELL, V79, P945, DOI 10.1016/0092-8674(94)90026-4; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	31	281	287	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	1998	279	5352					863	867						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452386				2022-12-28	WOS:000071923500044
J	Nightingale, SL				Nightingale, SL			Health advisory for low-molecular weight heparins and heparinoids	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					346	346		10.1001/jama.279.5.346	http://dx.doi.org/10.1001/jama.279.5.346			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459455				2022-12-28	WOS:000071731300007
J	Jiang, J; Struhl, G				Jiang, J; Struhl, G			Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb	NATURE			English	Article							LONG-RANGE ACTION; MORPHOGEN GRADIENT; BETA-CATENIN; DROSOPHILA; TRANSDUCTION	Members of the Hedgehog (Hh) and Wnt/Wingless (Wg) families of secreted proteins control many aspects of growth and patterning during animal development(1,2). Hh signal transduction leads to increased stability of a transcription factor, Cubitus interruptus (Ci)(3,4), whereas Wg signal transduction causes increased stability of Armadillo (Arm/beta-catenin)(5), a possible co-factor for the transcriptional regulator Lef1/TCF6. Here we describe a new gene, slimb (for supernumerary limbs), which negatively regulates both of these signal transduction pathways. Loss of function of slimb results in a cell-autonomous accumulation of high levels of both Ci and Arm, and the ectopic expression of both Hh(-) and Wg(-) responsive genes. The slimb gene encodes a conserved F-box. WD40-repeat protein related to Cdc4p, a protein in budding yeast that targets cell-cycle regulators for degradation by the ubiquitin/proteasome pathway(7-9). We propose that Slimb protein normally targets Ci and Arm for processing or degradation by the ubiquitin/proteasome pathway, and that Hh and Wg regulate gene expression at least in part by inducing changes in Ci and Arm, which protect them from Slimb-mediated proteolysis.	Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Genet, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Dev, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Columbia University; Columbia University	Jiang, J (corresponding author), Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, 701 W 168th St, New York, NY 10032 USA.							Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Altaba ARI, 1997, CELL, V90, P193, DOI 10.1016/S0092-8674(00)80325-6; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; Irvine KD, 1997, CURR OPIN CELL BIOL, V9, P867, DOI 10.1016/S0955-0674(97)80090-7; Jiang J, 1996, CELL, V86, P401, DOI 10.1016/S0092-8674(00)80113-0; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; KALDERON D, 1995, CURR BIOL, V5, P580, DOI 10.1016/S0960-9822(95)00114-X; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Nusse R, 1996, NATURE, V384, P119, DOI 10.1038/384119a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SPEVAK W, 1993, MOL CELL BIOL, V13, P4953, DOI 10.1128/MCB.13.8.4953; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1; ZECCA M, 1995, DEVELOPMENT, V121, P2265	30	529	551	2	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 29	1998	391	6666					493	496		10.1038/35154	http://dx.doi.org/10.1038/35154			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461217				2022-12-28	WOS:000071701800052
J	Towle, A				Towle, A			Continuing medical education - Changes in health care and continuing medical education for the 21st century	BRITISH MEDICAL JOURNAL			English	Article									Univ British Columbia, Div Educ Support & Dev, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Towle, A (corresponding author), Univ British Columbia, Div Educ Support & Dev, Vancouver, BC V6T 1Z3, Canada.							BANTA HD, 1993, BRIT MED J, V307, P1546, DOI 10.1136/bmj.307.6918.1546; KASSIRER JP, 1995, NEW ENGL J MED, V332, P52, DOI 10.1056/NEJM199501053320110; LENEHAN C, 1994, BRIT J GEN PRACT, V44, P291; Shepperd S, 1996, BRIT MED J, V312, P923; 1994, ECONOMIST       0319, P1	5	61	67	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					301	304		10.1136/bmj.316.7127.301	http://dx.doi.org/10.1136/bmj.316.7127.301			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472525	Green Published			2022-12-28	WOS:000071702100042
J	Stephens, IFD				Stephens, IFD			Effect of calcium supplementation during pregnancy on blood pressure of offspring - Authors cannot be sure of effect's generalisability to all children aged 5-9	BRITISH MEDICAL JOURNAL			English	Letter									Argyll & Clyde Hlth Board, Paisley PA2 7BN, Renfrew, Scotland		Stephens, IFD (corresponding author), Argyll & Clyde Hlth Board, Paisley PA2 7BN, Renfrew, Scotland.							Belizan JM, 1997, BMJ-BRIT MED J, V315, P281, DOI 10.1136/bmj.315.7103.281	1	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					234	234						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468721				2022-12-28	WOS:000071616400075
J	Jones, IR; Sullivan, G				Jones, IR; Sullivan, G			Physical dependence on zopiclone: case reports	BRITISH MEDICAL JOURNAL			English	Article							DISCONTINUATION		Univ Wales Coll Med, Div Psychol Med, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	Jones, IR (corresponding author), Univ Wales Coll Med, Div Psychol Med, Cardiff CF4 4XN, S Glam, Wales.		Jones, Ian R/B-4925-2009	Jones, Ian R/0000-0001-5821-5889	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIANCHI M, 1990, INT CLIN PSYCHOPHARM, V5, P139; LADER M, 1987, PHARMACOPSYCHIATRY, V20, P67, DOI 10.1055/s-2007-1017078; SULLIVAN G, 1995, HUM PSYCHOPHARM CLIN, V10, P351, DOI 10.1002/hup.470100417; THAKORE J, 1992, HUM PSYCHOPHARM CLIN, V7, P143, DOI 10.1002/hup.470070211; WADWORTH AN, 1993, DRUG AGING, V3, P441, DOI 10.2165/00002512-199303050-00006	5	27	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 10	1998	316	7125					117	117						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR408	9462317				2022-12-28	WOS:000071492300023
J	Wang, ZG; Delva, L; Gaboli, M; Rivi, R; Giorgio, M; Cordon-Cardo, C; Grosveld, F; Pandolfi, PP				Wang, ZG; Delva, L; Gaboli, M; Rivi, R; Giorgio, M; Cordon-Cardo, C; Grosveld, F; Pandolfi, PP			Role of PML in cell growth and the retinoic acid pathway	SCIENCE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; RECEPTOR-ALPHA GENE; RAR-ALPHA; TRANSCRIPTIONAL ACTIVATION; T(15-17) TRANSLOCATION; DIFFERENTIATION; SUPPRESSOR; EXPRESSION; TRANSFORMATION; LOCALIZATION	The PML gene is fused to the retinoic acid receptor alpha (RAR alpha) gene in chromosomal translocations associated with acute promyelocytic leukemia (APL). Ablation of murine PML protein by homologous recombination revealed that PML regulates hemopoietic differentiation and controls cell growth and tumorigenesis. PML function was essential for the tumor-growth-suppressive activity of retinoic acid (RA) and for its ability to induce terminal myeloid differentiation of precursor cells. PML was needed for the RA-dependent transactivation of the p21(WAF1/CIP1) gene, which regulates cell cycle progression and cellular differentiation, These results indicate that PML is critical component of the RA pathway and that disruption of its activity by the PML-RAR alpha fusion protein may be important in APL pathogenesis.	Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Dept Human Genet, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Mol Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Erasmus Univ, Fac Med, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Erasmus University Rotterdam	Pandolfi, PP (corresponding author), Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Dept Human Genet, 1275 York Ave, New York, NY 10021 USA.		Giorgio, Marco/I-9425-2012	Giorgio, Marco/0000-0002-5842-6042; DELVA, Laurent/0000-0002-1086-3964	NCI NIH HHS [CA 71692, CA-08748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071692, R37CA071692, P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARKA T, 1980, LAB INVEST, V42, P656; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Conzen SD, 1995, ONCOGENE, V11, P2295; DELVA L, UNPUB; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DOUER D, 1982, EXP CELL RES, V138, P193, DOI 10.1016/0014-4827(82)90105-7; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FAGIOLI M, 1992, ONCOGENE, V7, P1083; GABOLI M, UNPUB; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRATAS C, 1993, LEUKEMIA, V7, P1156; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GUDAS L, 1994, RETINOIDS CELLULAR B; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LAVAU C, 1995, ONCOGENE, V11, P871; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; Manshouri T, 1997, BLOOD, V89, P2507, DOI 10.1182/blood.V89.7.2507; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Pandolfi PP, 1996, HAEMATOLOGICA, V81, P472; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; Stadler M, 1995, ONCOGENE, V11, P2565; WANG Z, UNPUB; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7	41	438	454	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1547	1551						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488655				2022-12-28	WOS:000072372900068
J	Mohri, H; Bonhoeffer, S; Monard, S; Perelson, AS; Ho, DD				Mohri, H; Bonhoeffer, S; Monard, S; Perelson, AS; Ho, DD			Rapid turnover of T lymphocytes in SIV-infected rhesus macaques	SCIENCE			English	Article							HIV-1 INFECTION; LIFE-SPAN; IN-VIVO; CELLS; MEMORY; ACTIVATION; LENGTH; NAIVE; DEATH; CD4	Studies of lymphocyte turnover in animal models have implications for understanding the mechanism of cell killing and the extent of lymphocyte regeneration in human immunodeficiency virus infection. Quantitative analyses of the sequential changes in bromodeoxyuridine labeling of CD4 and CD8 T lymphocytes not only revealed the normal proliferation and death rates of these cell populations in uninfected macaques, but also showed a substantial increase in these rates associated with simian immunodeficiency virus (SIV) infection. Faster labeling and delabeling in memory and naive T lymphocyte subpopulations as well as in NK (natural killer) and B cells were also observed in infected macaques, suggesting a state of generalized activation induced by SIV.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA	Rockefeller University; United States Department of Energy (DOE); Los Alamos National Laboratory	Ho, DD (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.	dho@adarc.org	Bonhoeffer, Sebastian/A-2735-2008; Perelson, Alan S/Z-1959-2019	Bonhoeffer, Sebastian/0000-0001-8052-3925; Perelson, Alan S/0000-0002-2455-0002	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040387, U01AI041534] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40387, AI45128, AI41534] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CARAYON P, 1992, J IMMUNOL METHODS, V147, P225, DOI 10.1016/S0022-1759(12)80012-3; DIMITROV DS, 1995, NATURE, V375, P194, DOI 10.1038/375194b0; Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]; GIORGI JV, 1994, AIDS S1, V8, pS183; Gougeon ML, 1996, J IMMUNOL, V156, P3509; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Lafeuillade A, 1997, J INFECT DIS, V176, P1378, DOI 10.1086/517326; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; MOHRI H, UNPUB; MOSLER DE, 1995, NATURE, V375, P193, DOI 10.1038/375193b0; Nowak MA, 1997, J VIROL, V71, P7518, DOI 10.1128/JVI.71.10.7518-7525.1997; Palmer LD, 1997, J EXP MED, V185, P1381, DOI 10.1084/jem.185.7.1381; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; ROCHA B, 1990, EUR J IMMUNOL, V20, P1697, DOI 10.1002/eji.1830200812; SACHSENBERG N, UNPUB; SPRENT J, 1995, NATURE, V375, P194, DOI 10.1038/375194a0; SPRENT J, 1994, SCIENCE, V265, P1395, DOI 10.1126/science.8073282; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947; TSE D, UNPUB; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WENG NP, 1995, P NATL ACAD SCI USA, V92, P11091, DOI 10.1073/pnas.92.24.11091; Wolthers KC, 1996, SCIENCE, V274, P1543, DOI 10.1126/science.274.5292.1543; Zhang ZQ, 1998, P NATL ACAD SCI USA, V95, P1154, DOI 10.1073/pnas.95.3.1154	28	292	296	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	1998	279	5354					1223	1227		10.1126/science.279.5354.1223	http://dx.doi.org/10.1126/science.279.5354.1223			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469816				2022-12-28	WOS:000072115200048
J	La Rovere, MT; Bigger, JT; Marcus, FI; Mortara, A; Schwartz, PJ				La Rovere, MT; Bigger, JT; Marcus, FI; Mortara, A; Schwartz, PJ		ATRAMI Investigators	Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction	LANCET			English	Article							CONSCIOUS DOGS; SUDDEN-DEATH; VENTRICULAR-FIBRILLATION; AUTONOMIC MECHANISMS; PERIOD VARIABILITY; VAGAL REFLEXES; ISCHEMIA; EXERCISE	Background Experimental evidence suggests that autonomic markers such as heart-rate variabillity and baroreflex sensitivity (BRS) may contribute to post-infarction risk stratification. There are clinical data to support this concept for heart-rate variability. The main objective of the ATRAMI study was to provide prospective data on the additional and independent prognostic value for cardiac mortality of heart-rate variability and BRS in patients after myocardial infarction in whom left-ventricular ejection fraction (LVEF) and ventricular arrhythmias were known. Methods This multicentre international prospective study enrolled 1284 patients with a recent (<28 days) myocardial infarction. 24 h Holter recording was done to quantify heart-rate variability (measured as standard deviation of normal to normal RR intervals [SDNN]) and ventricular arrhythmias. BRS was calculated from measurement of the rate-pressure response to intravenous phenylephrine. Findings During 21 (SD 8) months of follow-up, the primary endpoint, cardiac mortality, included 44 cardiac deaths and five non-fatal cardiac arrests. Low values of either heart-rate variability (SDNN <70 ms) or BRS (<3.0 ms per mm Hg) carried a significant multivariate risk of cardiac mortality (3.2 [95% CI 1.42-7.36] and 28 [1.24-6.16], respectively). The association of low SDNN and BRS further increased risk; the 2-year mortality was 17% when both were below the cut-offs and 2% (p<0.0001) when both were well preserved (SDNN >105 ms, BRS >6.1 ms per mm Hg). The association of low SDNN or BRS with LVEF below 35% carried a relative risk of 6.7 (3.1-14.6) or 8.7 (4.3-17.6), respectively, compared with patients with LVEF above 35% and less compromised SDNN (greater than or equal to 70 ms) and BRS(greater than or equal to 3 ms per mm Hg). Interpretation ATRAMI provides clinical evidence that after myocardial infarction the analysis of vagal reflexes Experimental evidence suggests that markers such as heart-rate variability and sensitivity (BRS) may contribute to poslobjective has significant prognostic value independently of LVEF and of ventricular arrhythmias and that it significantly adds to the prognostic value of heart-rate variability.	Fdn Salvatore Maugeri, Ctr Med Montescano, I-27040 Montescano, PV, Italy; Columbia Univ Coll Phys & Surg, Dept Med, Div Cardiol, New York, NY 10032 USA; Univ Arizona, Hlth Sci Ctr, Dept Internal Med, Cardiol Sect, Tucson, AZ USA; Univ Pavia, Dept Cardiol, I-27100 Pavia, Italy; IRCCS, Policlin San Matteo, Pavia, Italy	Istituti Clinici Scientifici Maugeri IRCCS; Columbia University; University of Arizona; University of Arizona Health Sciences; University of Pavia; IRCCS Fondazione San Matteo; University of Pavia	La Rovere, MT (corresponding author), Fdn Salvatore Maugeri, Ctr Med Montescano, Via Montescano, I-27040 Montescano, PV, Italy.		Schwartz, Peter J/J-4267-2016; La Rovere, Maria Teresa/D-6796-2019	Schwartz, Peter J/0000-0003-0367-1048; La Rovere, Maria Teresa/0000-0002-1884-5058	NHLBI NIH HHS [HL-41552] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041552] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bernardi L, 1996, CARDIOVASC RES, V32, P234, DOI 10.1016/0008-6363(96)00081-8; BIGGER JT, 1989, J AM COLL CARDIOL, V14, P1511, DOI 10.1016/0735-1097(89)90390-2; BIGGER JT, 1992, CIRCULATION, V85, P164, DOI 10.1161/01.CIR.85.1.164; BIGGER JT, 1994, VAGAL CONTROL HEART, P481; BILLMAN GE, 1982, CIRCULATION, V66, P874, DOI 10.1161/01.CIR.66.4.874; BILLMAN GE, 1984, CIRCULATION, V69, P1182, DOI 10.1161/01.CIR.69.6.1182; Camm AJ, 1996, CIRCULATION, V93, P1043; Camm AJ, 1996, EUR HEART J, V17, P354; DEFERRARI GM, 1991, AM J PHYSIOL, V261, pH63, DOI 10.1152/ajpheart.1991.261.1.H63; ECKBERG DL, 1971, NEW ENGL J MED, V285, P877, DOI 10.1056/NEJM197110142851602; Eckberg DL., 1992, HUMAN BAROREFLEX HLT; FARRELL TG, 1991, J AM COLL CARDIOL, V18, P687, DOI 10.1016/0735-1097(91)90791-7; FARRELL TG, 1992, BRIT HEART J, V67, P129; HULL SS, 1994, CIRCULATION, V89, P548, DOI 10.1161/01.CIR.89.2.548; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; La Rovere M. T., 1997, Journal of the American College of Cardiology, V29, p470A; LAROVERE MT, 1995, J CARDIOVASC ELECTR, V6, P761; LAROVERE MT, 1988, CIRCULATION, V78, P816, DOI 10.1161/01.CIR.78.4.816; LEVY MN, 1994, VAGAL CONTROL HEART; LOWN B, 1976, NEW ENGL J MED, V294, P1165; MAGGIONI AP, 1993, CIRCULATION, V87, P312, DOI 10.1161/01.CIR.87.2.312; MALLIANI A, 1994, J CARDIOVASC ELECTR, V5, P274, DOI 10.1111/j.1540-8167.1994.tb01164.x; Mortara A, 1996, CIRCULATION, V93, P1114, DOI 10.1161/01.CIR.93.6.1114; Mortara A., 1996, European Heart Journal, V17, P405; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; SCHWARTZ PJ, 1988, CIRCULATION, V78, P969, DOI 10.1161/01.CIR.78.4.969; SCHWARTZ PJ, 1984, CIRCULATION, V69, P790, DOI 10.1161/01.CIR.69.4.790; SCHWARTZ PJ, 1992, CIRCULATION, V85, P77; SCHWARTZ PJ, 1988, J AM COLL CARDIOL, V12, P629, DOI 10.1016/S0735-1097(88)80048-2; SCHWARTZ PJ, 1990, CARDIAC ELECTROPHYSI, P330; VANOLI E, 1991, CIRC RES, V68, P1471, DOI 10.1161/01.RES.68.5.1471; VOLPI A, 1993, CIRCULATION, V88, P416, DOI 10.1161/01.CIR.88.2.416	32	2372	2451	1	107	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 14	1998	351	9101					478	484						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482439				2022-12-28	WOS:000072097700011
J	Santana, LF; Gomez, AM; Lederer, WJ				Santana, LF; Gomez, AM; Lederer, WJ			Ca2+ flux through promiscuous cardiac Na+ channels: Slip-mode conductance	SCIENCE			English	Article							SODIUM-CALCIUM EXCHANGE; RAT VENTRICULAR MYOCYTES; VOLTAGE-GATED SODIUM; SARCOPLASMIC-RETICULUM; ENDOGENOUS OUABAIN; DEPENDENT PHOSPHORYLATION; ATRIONATRIURETIC-PEPTIDE; SPATIAL NONUNIFORMITIES; RYANODINE RECEPTORS; IONIC SELECTIVITY	The tetrodotoxin-sensitive sodium ion (Na+) channel is opened by cellular depolarization and favors the passage of Na+ over other ions. Activation of the beta-adrenergic receptor or protein kinase A in rat heart cells transformed this Na+ channel into one that is promiscuous with respect to ion selectivity, permitting calcium ions (Ca2+) to permeate as readily as Na+. Similarly, nanomolar concentrations of cardiotonic steroids such as ouabain and digoxin switched the ion selectivity of the Na+ channel to this state of promiscuous permeability called slip-mode conductance. Slip-mode conductance of the Na+ channel can contribute significantly to local and global cardiac Ca2+ signaling and may be a general signaling mechanism in excitable cells.	Univ Maryland, Dept Mol Biol & Biophys, 725 W Lombard St, Baltimore, MD 21201 USA; Univ Maryland, Dept Physiol, Ctr Med Biotechnol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Lederer, WJ (corresponding author), Univ Maryland, Dept Mol Biol & Biophys, 725 W Lombard St, Baltimore, MD 21201 USA.	jlederer@umaryland.edu	Lederer, William/B-1285-2010; Gomez, Ana M./B-5376-2013; Santana, Luis/AAF-9298-2019	Gomez, Ana M./0000-0003-0009-2884; Santana, Luis/0000-0002-4297-8029				Aggarwal R, 1997, J PHYSIOL-LONDON, V505, P353, DOI 10.1111/j.1469-7793.1997.353bb.x; AKAIKE N, 1992, J PHYSIOL-LONDON, V450, P529, DOI 10.1113/jphysiol.1992.sp019141; AKASU T, 1977, JPN HEART J, V18, P860; AKERA T, 1981, CARDIAC GLYCOSIDES 1, P287; ARMSTRONG CM, 1991, P NATL ACAD SCI USA, V88, P6528, DOI 10.1073/pnas.88.15.6528; BAKER PF, 1969, J PHYSIOL-LONDON, V200, P431, DOI 10.1113/jphysiol.1969.sp008702; BAKER PF, 1971, J PHYSIOL-LONDON, V218, P709, DOI 10.1113/jphysiol.1971.sp009641; BARCENASRUIZ L, 1987, CIRC RES, V61, P148, DOI 10.1161/01.RES.61.1.148; BAYLOR SM, 1990, BIOPHYS J, V57; Benitah JP, 1997, BIOPHYS J, V73, P603, DOI 10.1016/S0006-3495(97)78096-2; BERS DM, 1991, EXCITATION CONTRACTI; Blaustein MP, 1996, KIDNEY INT, V49, P1748, DOI 10.1038/ki.1996.260; CAMPBELL DL, 1988, J PHYSIOL-LONDON, V403, P267, DOI 10.1113/jphysiol.1988.sp017249; CANNELL MB, 1987, SCIENCE, V238, P1419, DOI 10.1126/science.2446391; Cannell MB, 1997, BIOPHYS J, V73, P112, DOI 10.1016/S0006-3495(97)78052-4; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; CANNELL MB, 1994, J PHYSIOL-LONDON, V477P, pP25; Chen SF, 1997, J MEMBRANE BIOL, V155, P11, DOI 10.1007/s002329900154; CHENG H, 1995, CIRC RES, V76, P236, DOI 10.1161/01.RES.76.2.236; Cheng H, 1996, AM J PHYSIOL-CELL PH, V270, pC148; Cheng H, 1996, CELL CALCIUM, V20, P129, DOI 10.1016/S0143-4160(96)90102-5; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHIAMVIMONVAT N, 1996, J PHYSL, P51; Cole WC, 1997, AM J PHYSIOL-HEART C, V273, pH128, DOI 10.1152/ajpheart.1997.273.1.H128; Conti F, 1996, BIOPHYS J, V71, P1295, DOI 10.1016/S0006-3495(96)79330-X; COSTA MRC, 1982, J BIOL CHEM, V257, P7918; DEITMER JW, 1978, J PHYSIOL-LONDON, V284, P241, DOI 10.1113/jphysiol.1978.sp012539; deWardener HE, 1996, J HYPERTENS, V14, pS9; DUBELL WH, 1987, CELL CALCIUM, V8, P259, DOI 10.1016/0143-4160(87)90002-9; DUBELL WH, 1989, AM J PHYSIOL, V257, pH746, DOI 10.1152/ajpheart.1989.257.3.H746; Dumaine R, 1996, AM J PHYSIOL-HEART C, V270, pH2029; Evans AM, 1997, CARDIOVASC RES, V35, P294, DOI 10.1016/S0008-6363(97)00117-X; FABIATO A, 1985, J GEN PHYSIOL, V85, P189, DOI 10.1085/jgp.85.2.189; FABIATO A, 1985, J GEN PHYSIOL, V85, P291, DOI 10.1085/jgp.85.2.291; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; Favre I, 1996, BIOPHYS J, V71, P3110, DOI 10.1016/S0006-3495(96)79505-X; FERRIER GR, 1997, BIOPHYS J, V161, pA161; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; FRELIN C, 1986, EUR J PHARMACOL, V122, P245, DOI 10.1016/0014-2999(86)90109-3; FRENCH RJ, 1994, J GEN PHYSIOL, V103, P447, DOI 10.1085/jgp.103.3.447; GADSBY DC, 1984, ANNU REV BIOPHYS BIO, V13, P373; GODFRAIND T, 1982, NATURE, V299, P824, DOI 10.1038/299824a0; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; GONOI T, 1985, J NEUROSCI, V5, P2559; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; Grantham CJ, 1996, CIRC RES, V79, P194, DOI 10.1161/01.RES.79.2.194; GUNDERTREMY U, 1981, CARDIAC GLYCOSIDES 1, P83; Hamlyn JM, 1996, J HYPERTENS, V14, P151, DOI 10.1097/00004872-199602000-00002; HAMLYN JM, 1991, P NATL ACAD SCI USA, V88, P6259, DOI 10.1073/pnas.88.14.6259; HANCOX JC, 1995, PFLUG ARCH EUR J PHY, V430, P887, DOI 10.1007/BF01837401; HEINEMANN SH, 1994, BRAZ J MED BIOL RES, V27, P2781; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; Hille B., 1992, IONIC CHANNELS EXCIT; HOBAI A, 1997, PFLUEGERS ARCH, V435, P164; Howlett S. E., 1997, Biophysical Journal, V72, pA161; HOWLETT SE, 1998, AM J PHYSIOL, V43, pH155; HUME JR, 1991, SCIENCE, V251, P1370, DOI 10.1126/science.251.4999.1370-a; JEWELL EA, 1992, ACTA PHYSIOL SCAND, V146, P161; JOHNSON EA, 1991, SCIENCE, V251, P1370, DOI 10.1126/science.1848371; Jurevicius J, 1996, P NATL ACAD SCI USA, V93, P295, DOI 10.1073/pnas.93.1.295; Klein MG, 1996, NATURE, V379, P455, DOI 10.1038/379455a0; KOHMOTO O, 1994, CIRC RES, V74, P550, DOI 10.1161/01.RES.74.3.550; Laredo J, 1997, HYPERTENSION, V29, P401, DOI 10.1161/01.HYP.29.1.401; LAREDO J, 1994, ENDOCRINOLOGY, V135, P794, DOI 10.1210/en.135.2.794; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; LEDERER WJ, 1995, HEART VESSELS, P161; LEDERER WJ, 1991, SCIENCE, V251, P1371, DOI 10.1126/science.251.4999.1371; LEMAIRE S, 1995, RECEPTOR CHANNEL, V3, P71; LEVESQUE PC, 1994, CARDIOVASC RES, V28, P370, DOI 10.1093/cvr/28.3.370; LEVI AJ, 1994, AM J PHYSIOL, V266, pH1422, DOI 10.1152/ajpheart.1994.266.4.H1422; LEVI AJ, 1997, BIOPHYS J, V161, pA161; Levi Allan J., 1997, Biophysical Journal, V72, pA161; LIPKIND GM, 1994, BIOPHYS J, V66, P1, DOI 10.1016/S0006-3495(94)80746-5; Lipp P, 1996, J PHYSIOL-LONDON, V492, P31, DOI 10.1113/jphysiol.1996.sp021286; LIPP P, 1994, J PHYSIOL-LONDON, V474, P439, DOI 10.1113/jphysiol.1994.sp020035; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; MAKIELSKI JC, 1987, BIOPHYS J, V52, P1, DOI 10.1016/S0006-3495(87)83182-X; MATSUDA JJ, 1992, CIRC RES, V70, P199, DOI 10.1161/01.RES.70.1.199; MEVES H, 1973, J PHYSL, V235, P226; MOGUL DJ, 1989, CIRC RES, V64, P1063, DOI 10.1161/01.RES.64.6.1063; Murphy BJ, 1996, J BIOL CHEM, V271, P28837, DOI 10.1074/jbc.271.46.28837; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; NILIUS B, 1988, J PHYSIOL-LONDON, V399, P537; OBRIEN WJ, 1994, ARCH BIOCHEM BIOPHYS, V310, P32, DOI 10.1006/abbi.1994.1136; ONO K, 1995, PFLUG ARCH EUR J PHY, V429, P561, DOI 10.1007/BF00704162; PerezGarcia MT, 1997, BIOPHYS J, V72, P989, DOI 10.1016/S0006-3495(97)78751-4; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; ROSSI GP, 1995, J HYPERTENS, V13, P1181, DOI 10.1097/00004872-199510000-00013; ROSSIE S, 1987, J BIOL CHEM, V262, P12735; Santana LF, 1996, CIRC RES, V78, P166, DOI 10.1161/01.RES.78.1.166; SANTANA LF, UNPUB; SATIN J, 1994, BIOPHYS J, V67, P1007, DOI 10.1016/S0006-3495(94)80566-1; SCHILD L, 1994, BIOPHYS J, V66, P654, DOI 10.1016/S0006-3495(94)80839-2; Schlief T, 1996, EUR BIOPHYS J BIOPHY, V25, P75, DOI 10.1007/s002490050020; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SCHREIBMAYER W, 1994, RECEPTOR CHANNEL, V2, P339; SHACKLOCK PS, 1995, J PHYSIOL-LONDON, V487, P601, DOI 10.1113/jphysiol.1995.sp020903; SHAM JSK, 1992, SCIENCE, V255, P850, DOI 10.1126/science.1311127; SHEETS MF, 1991, SCIENCE, V252, P449, DOI 10.1126/science.1850170; Soeller C, 1997, BIOPHYS J, V73, P97, DOI 10.1016/S0006-3495(97)78051-2; SORBERA LA, 1990, SCIENCE, V247, P969, DOI 10.1126/science.2154853; TALVENHEIMO JA, 1982, J BIOL CHEM, V257, P1868; TOMASELLI GF, 1995, BIOPHYS J, V68, P1814, DOI 10.1016/S0006-3495(95)80358-9; TSUGORKA A, 1995, SCIENCE, V269, P1723, DOI 10.1126/science.7569901; Tsushima RG, 1997, J GEN PHYSIOL, V109, P463, DOI 10.1085/jgp.109.4.463; Tsushima RG, 1997, J GEN PHYSIOL, V110, P59, DOI 10.1085/jgp.110.1.59; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; Vites AM, 1996, ANN NY ACAD SCI, V779, P521, DOI 10.1111/j.1749-6632.1996.tb44826.x; VORHERR T, 1992, BIOCHEMISTRY-US, V31, P371, DOI 10.1021/bi00117a009; Wasserstrom JA, 1996, J PHYSIOL-LONDON, V493, P529, DOI 10.1113/jphysiol.1996.sp021401; Yamagishi T, 1997, BIOPHYS J, V73, P195, DOI 10.1016/S0006-3495(97)78060-3; YOSHIMURA N, 1996, J PHYSL, P1; ZHU JQ, 1997, BIOPHYS J, V161, pA161	117	150	155	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	1998	279	5353					1027	1033		10.1126/science.279.5353.1027	http://dx.doi.org/10.1126/science.279.5353.1027			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461434				2022-12-28	WOS:000072006400046
J	Decousus, H; Leizorovicz, A; Parent, F; Page, Y; Tardy, B; Girard, P; Laporte, S; Faivre, R; Charbonnier, B; Barral, FG; Huet, Y; Simonneau, G				Decousus, H; Leizorovicz, A; Parent, F; Page, Y; Tardy, B; Girard, P; Laporte, S; Faivre, R; Charbonnier, B; Barral, FG; Huet, Y; Simonneau, G		Prev Risq Embol Pulm Inter Cav Stud Grp	A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GREENFIELD FILTER; VENOUS THROMBOSIS; INITIAL TREATMENT; HEPARIN; RECURRENCE; THERAPY	Background The efficacy and safety of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis are still a matter of debate. Methods Using a two-by-two factorial design, we randomly assigned 400 patients with proximal deep-vein thrombosis who were at risk for pulmonary embolism to receive a vena caval filter (200 patients) or no filter (200 patients), and to receive low-molecular-weight heparin (enoxaparin, 195 patients) or unfractionated heparin (205 patients). The rates of recurrent venous thromboembolism, death, and major bleeding were analyzed at day 12 and at two years. Results At day 12, two patients assigned to receive filters (1.1 percent), as compared with nine patients assigned to receive no filters (4.8 percent), had-had symptomatic or asymptomatic pulmonary embolism (odds ratio, 0.22; 95 percent confidence interval, 0.05 to 0.90). At two years, 37 patients assigned to the filter group (20.8 percent), as compared with 21 patients assigned to the no-filter group (11.6 percent), had had recurrent deep-vein thrombosis (odds ratio, 1.87; 95 percent confidence interval, 1.10 to 3.20). There were no significant differences in mortality or the other outcomes. At day 12, three patients assigned to low-molecular-weight heparin (1.6 percent), as compared with eight patients assigned to unfractionated heparin (4.2 percent), had had symptomatic or asymptomatic pulmonary embolism (odds ratio, 0.38; 95 percent confidence interval, 0.10 to 1.38). Conclusions In high-risk patients with proximal deep-vein thrombosis, the initial beneficial effect of vena caval filters for the prevention of pulmonary embolism was counterbalanced by an excess of recurrent deep-vein thrombosis, without any difference in mortality. Our data also confirmed that low-molecular-weight heparin was as effective and safe as unfractionated heparin for the prevention of pulmonary embolism. (C) 1998, Massachusetts Medical Society.	CHU St Etienne, Hop Bellevue, Clin Pharmacol Unit, Thrombosis Res Grp, F-42055 St Etienne 2, France; Bellevue Hosp, Intens Care Unit, St Etienne, France; Bellevue Hosp, Dept Radiol, St Etienne, France; Cardiol Hosp, Clin Pharmacol Unit, Lyon, France; Hop Antoine Beclere, Resp Unit, Clamart, France; St Vincents Clin, Cardiol Unit, Besancon, France; Inst Mutualiste Montsouris, Paris, France; Trousseau Hosp, Cardiol Unit, Tours, France; Rhone Poulenc Rorer, Paris, France	CHU de St Etienne; CHU de St Etienne; CHU de St Etienne; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Institute Mutualiste Montsouris; UDICE-French Research Universities; Universite Paris Cite; CHU Tours; Sanofi-Aventis	Decousus, H (corresponding author), CHU St Etienne, Hop Bellevue, Clin Pharmacol Unit, Thrombosis Res Grp, F-42055 St Etienne 2, France.		Simonneau, Gerald/ABE-6614-2020					ALEXANDER JJ, 1986, SURG GYNECOL OBSTET, V163, P405; BASU D, 1972, NEW ENGL J MED, V287, P324, DOI 10.1056/NEJM197208172870703; BECKER DM, 1992, ARCH INTERN MED, V152, P1985, DOI 10.1001/archinte.152.10.1985; BERRY RE, 1990, ANN SURG, V211, P719, DOI 10.1097/00000658-199006000-00010; BRANDJES DPM, 1992, NEW ENGL J MED, V327, P1485, DOI 10.1056/NEJM199211193272103; BYAR DP, 1985, CANCER TREAT REP, V69, P1055; COHEN JR, 1991, SURGERY, V109, P12; DORFMAN GS, 1992, RADIOLOGY, V185, P15, DOI 10.1148/radiology.185.1.1523299; FINK JA, 1991, SURG GYNECOL OBSTET, V172, P253; GIRARD P, 1987, THORAX, V42, P481, DOI 10.1136/thx.42.7.481; Goldhaber SZ, 1997, ARCH INTERN MED, V157, P264; GOLUEKE PJ, 1988, SURGERY, V103, P111; Greenfield L J, 1996, Semin Vasc Surg, V9, P50; GREENFIELD LJ, 1988, SURGERY, V104, P706; Hirsh J, 1996, CIRCULATION, V93, P2212, DOI 10.1161/01.CIR.93.12.2212; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; HYERS TM, 1995, CHEST, V108, pS335, DOI 10.1378/chest.108.4_Supplement.335S; KINASEWITZ GT, 1993, CLIN CHEST MED, V14, P523; Leizorovicz A, 1996, DRUGS, V52, P30, DOI 10.2165/00003495-199600527-00006; MAGNANT JG, 1992, J VASC SURG, V16, P701; MOSER KM, 1973, AM J MED, V55, P434, DOI 10.1016/0002-9343(73)90200-3; PAGE Y, 1993, AM REV RESPIR DIS, V147, pA1001; POMPER SR, 1991, ANGIOLOGY, V42, P85, DOI 10.1177/000331979104200201; PRANDONI P, 1993, CIRCULATION, V88, P1730, DOI 10.1161/01.CIR.88.4.1730; Tardy B, 1996, EUR RESPIR J, V9, P2012, DOI 10.1183/09031936.96.09102012; tenCate JW, 1997, NEW ENGL J MED, V337, P657; Trousseau, 1868, CLIN MED HOTEL DIEU, P652; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WALSH DB, 1995, ANN VASC SURG, V9, P483, DOI 10.1007/BF02143864	30	1182	1294	0	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 12	1998	338	7					409	415		10.1056/NEJM199802123380701	http://dx.doi.org/10.1056/NEJM199802123380701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW122	9459643				2022-12-28	WOS:000071900100001
J	Fatovich, D; Prentice, D; Dobb, G				Fatovich, D; Prentice, D; Dobb, G			Magnesium in in-hospital cardiac arrest - Reply	LANCET			English	Letter									Royal Perth Hosp, Dept Emergency Med, Perth, WA 6001, Australia; Royal Perth Hosp, Dept Internal Med, Perth, WA 6001, Australia; Royal Perth Hosp, Dept Intens Care, Perth, WA 6001, Australia	Royal Perth Hospital; University of Western Australia; Royal Perth Hospital; University of Western Australia; Royal Perth Hospital; University of Western Australia	Fatovich, D (corresponding author), Royal Perth Hosp, Dept Emergency Med, Wellington St Campus,Box X2213 GPO, Perth, WA 6001, Australia.		prentice, David/AHB-8030-2022; Fatovich, Daniel/J-5510-2013	prentice, David/0000-0003-1394-8493; Fatovich, Daniel/0000-0001-9414-6905				Fatovich DM, 1997, RESUSCITATION, V35, P237, DOI 10.1016/S0300-9572(97)00062-2; FATOVICH DM, 1997, EMERGEN MED, V9, P59; Thel MC, 1997, LANCET, V350, P1272, DOI 10.1016/S0140-6736(97)05048-4; Woodhouse SP, 1995, RESUSCITATION, V30, P243, DOI 10.1016/0300-9572(95)00890-X	4	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					446	446		10.1016/S0140-6736(05)78392-6	http://dx.doi.org/10.1016/S0140-6736(05)78392-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482331				2022-12-28	WOS:000071982600058
J	Guillemot, D; Carbon, C; Balkau, B; Geslin, P; Lecoeur, H; Vauzelle-Kervroedan, F; Bouvenot, G; Eschwege, E				Guillemot, D; Carbon, C; Balkau, B; Geslin, P; Lecoeur, H; Vauzelle-Kervroedan, F; Bouvenot, G; Eschwege, E			Low dosage and long treatment duration of beta-lactam - Risk factors for carriage of penicillin-resistant Streptococcus pneumoniae	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	36th Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 15-18, 1996	NEW ORLEANS, LOUISIANA	Amer Soc Microbiol			DAY-CARE-CENTER; ANTIBIOTIC-RESISTANCE; CHILDREN; PNEUMOCOCCI; POPULATIONS; PREVALENCE; DISEASE	Context.-The spread of drug-resistant Streptococcus pneumoniae in the community is a public health problem in developed and developing nations, but whether antibiotic use is responsible for the increase in drug resistance is not known. Objective.-To analyze the relationship between penicillin-resistant S pneumoniae (PRSp) pharyngeal carriage and characteristics of beta-lactam use. Design.-Observational study of children attending 20 randomly sampled schools. Setting.-The Loiret, in the center of France. Participants.-A total of 941 children, 3 to 6 years old. Main Outcome Measure(s).-Pharyngeal carriage of S pneumoniae, antibiotic use, and medical events during the preceding 30 days. Pneumococcal penicillin G sodium minimal inhibitory concentrations and serotyping were performed. Results.-Medical illnesses and the use of antibiotics were not associated with PRSp carriage. However, oral beta-lactam use was associated with an increased risk of PRSp carriage (odds ratio [OR], 3.0; 95% confidence interval [CI], 1.1-8.3; P=.03). Children treated by low daily doses of an oral beta-lactam (defined as lower than clinical recommendations) had an increased risk of PR,Sp carriage, as compared with children who did not (OR, 5.9; 95% CI, 2.1-16.7; P=.002). A treatment of long duration (>5 days) with a beta-lactam was associated with an increased risk of PRSp carriage (OR, 3.5; 95% CI, 1.3-9.8; P=.02). Conclusions.-Our results suggest that a low daily dose and a long duration of treatment with an oral beta-lactam contribute to the selective pressure in promoting pharyngeal carriage of PRSp.	INSERM, U21, F-94807 Villejuif, France; Fac Med Paris Sud, Villejuif, France; INSERM, U13, Paris, France; Ctr Hosp Univ Bichat Claude Bernard, Serv Med Interne, Paris, France; Ctr Natl Reference Pneumocoque, Creteil, France; MEDILOG, Senlis, France; INSERM, U21, F-13258 Marseille, France; Hop St Marguerite, Ctr Hosp Sud, Serv Med Interne & Therapeut, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Guillemot, D (corresponding author), INSERM, U21, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.		Guillemot, Didier/AAN-3051-2020	Guillemot, Didier/0000-0002-8497-1765				Arason VA, 1996, BMJ-BRIT MED J, V313, P387; ARMITAGE P, 1995, STATISTICAL METHODS, P620; BAQUERO F, 1991, J ANTIMICROB CHEMOTH, V28, P31, DOI 10.1093/jac/28.suppl_C.31; BARNES DM, 1995, J INFECT DIS, V171, P890, DOI 10.1093/infdis/171.4.890; CHERIAN T, 1994, JAMA-J AM MED ASSOC, V271, P695, DOI 10.1001/jama.271.9.695; CHIDIAC C, 1995, MEDICAMENTS ANTIINFE, P35; COFFEY TJ, 1991, MOL MICROBIOL, V5, P2255, DOI 10.1111/j.1365-2958.1991.tb02155.x; CROWE CC, 1973, J INFECT DIS, V128, P527, DOI 10.1093/infdis/128.4.527; Dagan R, 1996, J INFECT DIS, V174, P1271, DOI 10.1093/infdis/174.6.1271; DUCHIN JS, 1995, PEDIATR INFECT DIS J, V14, P745, DOI 10.1097/00006454-199509000-00004; Facklam RR, 1991, MANUAL CLIN MICROBIO, P238; FEDSON DS, 1994, VACCINES, P543; FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607; Gestin P, 1995, MED HYG, V53, P2111; GUDNASON T, 1996, 36 ICAAC AM SOC MICR; HARRIS J, 1996, 36 ICAAC AM SOC MICR; Hosmer DWJ., 1989, APPL LOGISTIC REGRES, P307; ISTRE GR, 1987, J INFECT DIS, V156, P732, DOI 10.1093/infdis/156.5.732; Jernigan DB, 1996, JAMA-J AM MED ASSOC, V275, P206, DOI 10.1001/jama.275.3.206; JOHNSON WG, 1970, J LAB CLIN MED, V75, P946; Levy S B, 1994, Trends Microbiol, V2, P341, DOI 10.1016/0966-842X(94)90607-6; LEVY SB, 1993, JAMA-J AM MED ASSOC, V269, P1840, DOI 10.1001/jama.269.14.1840; LEVY SB, 1987, REV INFECT DIS    S3, V170, pS313; LINARES J, 1992, CLIN INFECT DIS, V15, P99, DOI 10.1093/clinids/15.1.99; MANDELL GL, 1995, PRINCIPLES PRACTICE, P2804; MASSAD E, 1993, INT J BIOMED COMPUT, V33, P65, DOI 10.1016/0020-7101(93)90060-J; MCCRACKEN GH, 1995, J PEDIATR INFECT DIS, V14, P424; MOREILLON P, 1988, J INFECT DIS, V157, P1150, DOI 10.1093/infdis/157.6.1150; *NAT COMM CLIN LAB, 1995, METH DIL ANT SUSC TE; NEGRI MC, 1994, ANTIMICROB AGENTS CH, V38, P122, DOI 10.1128/AAC.38.1.122; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NISSINEN A, 1995, CLIN INFECT DIS, V21, P1193, DOI 10.1093/clinids/21.5.1193; Obaro SK, 1996, BMJ-BRIT MED J, V312, P1521, DOI 10.1136/bmj.312.7045.1521; PRINCIPI N, 1995, EUR J CLIN MICROBIOL, V14, P669, DOI 10.1007/BF01690872; RADETSKY MS, 1981, LANCET, V2, P771; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; SANDERS E, 1969, J INFECT DIS, V120, P698, DOI 10.1093/infdis/120.6.698; SANFORD JP, 1996, GUIDE ANTIMICROBIAL; Schrag SJ, 1996, NATURE, V381, P120, DOI 10.1038/381120b0; Seppala H, 1995, CLIN INFECT DIS, V21, P1378, DOI 10.1093/clinids/21.6.1378; SPRUNT K, 1968, ANN INTERN MED, V68, P579, DOI 10.7326/0003-4819-68-3-579; *SPSS INC, 1990, STAT PACK SOC SCI VE; STROM BL, 1994, PHARMACOEPIDEM DR S, P29; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; YELLAND MJ, 1993, MED J AUSTRALIA, V17, P697	45	422	437	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					365	370		10.1001/jama.279.5.365	http://dx.doi.org/10.1001/jama.279.5.365			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459469				2022-12-28	WOS:000071731300026
J	Barker, EM				Barker, EM			Informed consent in medical research: the Ethics Committee's view	BRITISH MEDICAL JOURNAL			English	Letter									Univ Natal, Fac Med, Bioeth Reference Grp, ZA-4013 Congella, South Africa	University of Kwazulu Natal	Barker, EM (corresponding author), Univ Natal, Fac Med, Bioeth Reference Grp, Private Bag 7, ZA-4013 Congella, South Africa.							Bhagwanjee S, 1997, BRIT MED J, V314, P1077, DOI 10.1136/bmj.314.7087.1077a; 1997, BMJ, V314, P1477; 1997, BMJ, V315, P247	3	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 31	1998	316	7128					392	393		10.1136/bmj.316.7128.392b	http://dx.doi.org/10.1136/bmj.316.7128.392b			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487191	Green Published			2022-12-28	WOS:000071863900051
J	Bitter, W; Gerrits, H; Kieft, R; Borst, P				Bitter, W; Gerrits, H; Kieft, R; Borst, P			The role of transferrin-receptor variation in the host range of Trypanosoma brucei	NATURE			English	Article							GENE-EXPRESSION SITE; SURFACE GLYCOPROTEIN GENES; BINDING PROTEIN COMPLEX; ANTIGENIC VARIATION; AFRICAN TRYPANOSOMES; CELLS; IDENTIFICATION; INVITRO; FAMILY; GROWTH	Trypanosoma brucei(1) is a unicellular parasite transmitted between African mammals by tsetse flies. T. brucei multiplies freely in the bloodstream of many different mammals, and survives by antigenic variation of the main component of its surface coat, variant surface glycoprotein (VSG)(2,3). Trypanosomes take up transferrin through a heterodimeric transferrin receptor(4-9), the genes for which are expressed in telomeric expression sites along with the VSG gene. There are up to 20 of these expression sites per trypanosome nucleus(3,10-15), but usually only one is active at a time. Different expression sites encode transferrin receptors that are similar but not identical(16). Here we show that these small differences between transferrin receptors can have profound effects on the binding affinity for transferrins from different mammals, and an the ability of trypanosomes to grow in the sera of these mammals. Our results suggest that the ability ro switch between different transferrin-receptor genes allows T. brucei to cope with the large sequence diversity in the transferrins of its hosts(17).	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Borst, P (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Bitter, Wilbert/AAA-6872-2019; Bitter, W/CAJ-5778-2022; Bitter, Wilbert/ABG-3726-2020	Bitter, Wilbert/0000-0001-8347-6511				BORST P, 1994, SCIENCE, V264, P1872, DOI 10.1126/science.7516579; BORST P, 1991, IMMUNOPARASITOL TOD, pA29, DOI 10.1016/S0167-5699(05)80009-X; BORST P, 1991, TRENDS GENET, V7, P307, DOI 10.1016/0168-9525(91)90406-G; BORST P, 1997, TRYPANOSOMIASIS LEIS, V1, P109; Bruce D., 1895, PRELIMINARY REPORT T; BRUN R, 1979, ACTA TROP, V36, P387; CHAUDHRI M, 1994, P NATL ACAD SCI USA, V91, P6443, DOI 10.1073/pnas.91.14.6443; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CULLY DF, 1985, CELL, V42, P173, DOI 10.1016/S0092-8674(85)80113-6; DONELSON JE, 1995, J BIOL CHEM, V270, P7783, DOI 10.1074/jbc.270.14.7783; ENNS CA, 1981, J BIOL CHEM, V256, P2620; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; HOBBS MR, 1990, MOL BIOCHEM PARASIT, V43, P1, DOI 10.1016/0166-6851(90)90125-6; LIGTENBERG MJL, 1994, EMBO J, V13, P2565, DOI 10.1002/j.1460-2075.1994.tb06546.x; LIPS S, 1993, MOL BIOCHEM PARASIT, V62, P135, DOI 10.1016/0166-6851(93)90189-5; LIU AYC, 1985, J MOL BIOL, V182, P383, DOI 10.1016/0022-2836(85)90198-6; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; PAYS E, 1994, ANNU REV MICROBIOL, V48, P25, DOI 10.1146/annurev.mi.48.100194.000325; Retzer MD, 1996, J BIOL CHEM, V271, P1166, DOI 10.1074/jbc.271.2.1166; REVELARD P, 1990, NUCLEIC ACIDS RES, V18, P7299, DOI 10.1093/nar/18.24.7299; RUDENKO G, 1995, CELL, V83, P547, DOI 10.1016/0092-8674(95)90094-2; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; SCHELL D, 1991, EMBO J, V10, P1061, DOI 10.1002/j.1460-2075.1991.tb08045.x; STEVERDING D, 1994, EUR J CELL BIOL, V64, P78; STEVERDING D, 1995, J CELL BIOL, V131, P1173, DOI 10.1083/jcb.131.5.1173; URIEL J, 1983, BRIT J CANCER, V48, P261, DOI 10.1038/bjc.1983.181; VOEST EE, 1993, CELL PROLIFERAT, V26, P77, DOI 10.1111/j.1365-2184.1993.tb00008.x; YOUNG SP, 1990, BIOCHEM J, V265, P587, DOI 10.1042/bj2650587; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P1359, DOI 10.1093/nar/19.7.1359	30	125	126	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	1998	391	6666					499	502		10.1038/35166	http://dx.doi.org/10.1038/35166			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461219				2022-12-28	WOS:000071701800054
J	Hanna, GB; Shimi, SM; Cuschieri, A				Hanna, GB; Shimi, SM; Cuschieri, A			Randomised study of influence of two-dimensional versus three-dimensional imaging on performance of laparoscopic cholecystectomy	LANCET			English	Article							SURGERY	Background Several three-dimensional video-endoscopic systems have been introduced to enhance depth perception during minimum-access surgery. However, there is no conclusive evidence of benefit, and these systems are more expensive than conventional two-dimensional systems. We undertook a prospective randomised comparison of two-dimensional and three-dimensional imaging in elective laparoscopic cholecystectomy for symptomatic gallstone disease, Methods The operations were done by four specialist registrars as part of their higher surgical training. 60 operations were randomised for execution by either two-dimensional or three-dimensional imaging display (30 by each method). The degree of difficulty of the operation was graded by a consultant surgeon on a standard grading system, The primary endpoints were execution time and the errors made during the procedure. The secondary endpoints were subjective assessment of the image quality and adverse effects on the surgeon. Findings There was no difference between the two-dimensional and three-dimensional display groups in median execution time (3160 [IQR 2735-4335 vs 3100 [2379-3710] s; p=0.2) or error rate (six vs six), Surgeons reported adverse symptoms immediately after the operations with both systems. The scores for visual strain, headache, and facial discomfort were higher with the three-dimensional system. Interpretation With the current technology, three-dimensional systems based on sequential imaging show no advantage over two-dimensional systems in the conduct of laparoscopic cholecystectomy.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Surg Skills Unit, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Cuschieri, A (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg, Dundee DD1 9SY, Scotland.	a.cuschieri@dundee.ac.uk	Cuschieri, Alfred/A-7634-2013; Cuschieri, Alfred/O-4092-2019	Cuschieri, Alfred/0000-0003-0764-5947				BIRKETT DH, 1994, SURG ENDOSC-ULTRAS, V8, P1448; Chan ACW, 1997, SURG ENDOSC-ULTRAS, V11, P438, DOI 10.1007/s004649900385; COREN S, 1989, SENSATION PERCEPTION, P480; Coren S, 1989, SENSATION PERCEPTION, P274; CORMACK R, 1985, PERCEPT PSYCHOPHYS, V38, P375, DOI 10.3758/BF03207166; CROSTHWAITE G, 1995, BRIT J SURG, V82, P849, DOI 10.1002/bjs.1800820640; FOLEY JE, 1974, PSYCHOL REV, V81, P183, DOI 10.1037/h0036087; KILLBRIDE PL, 1968, PERCEPT MOTOR SKILL, V27, P601; KIM WS, 1987, IEEE T SYST MAN CYB, V17, P61, DOI 10.1109/TSMC.1987.289333; LEIBOWITZ HW, 1972, PERCEPT PSYCHOPHYS, V12, P430, DOI 10.3758/BF03205856; Merritt JO, 1987, SPIE, V761, P88; NATHANSON LK, 1991, BRIT J SURG, V78, P155, DOI 10.1002/bjs.1800780208; Pietrabissa A, 1994, Endosc Surg Allied Technol, V2, P315; Tendick F., 1993, PRESENCETELEOP VIRT, V2, P66, DOI [DOI 10.1162/PRES.1993.2.1.66, 10.1162/pres.1993.2.1.66]; TYRRELL RA, 1990, HUM FACTORS, V32, P341, DOI 10.1177/001872089003200307; VonPichler C, 1996, MINIM INVASIV THER, V5, P419, DOI 10.3109/13645709609153703; vonPichler C, 1996, ST HEAL T, V29, P523; WENZL R, 1994, LANCET, V344, P1621, DOI 10.1016/S0140-6736(94)90412-X; WICHENS CD, 1989, SOAR8901 CSERIAC WRI; YEH YY, 1991, SID 91 DIGEST, P826	20	239	250	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 24	1998	351	9098					248	251		10.1016/S0140-6736(97)08005-7	http://dx.doi.org/10.1016/S0140-6736(97)08005-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU294	9457094				2022-12-28	WOS:000071702200010
J	Frankel, AD; Smith, CA				Frankel, AD; Smith, CA			Induced folding in RNA-protein recognition: More than a simple molecular handshake	CELL			English	Review							BINDING; DNA; COMPLEX		Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Frankel, AD (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, 513 Parnassus Ave, San Francisco, CA 94143 USA.			Smith, Colin/0000-0001-5652-0855				Allain FHT, 1996, NATURE, V380, P646, DOI 10.1038/380646a0; BAKER D, 1994, BIOCHEMISTRY-US, V33, P7505, DOI 10.1021/bi00190a002; Goldgur Y, 1997, STRUCTURE, V5, P59, DOI 10.1016/S0969-2126(97)00166-4; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; Lentzen G, 1996, RNA, V2, P244; Mogridge J, 1998, MOL CELL, V1, P265, DOI 10.1016/S1097-2765(00)80027-1; NEWMAN M, 1995, SCIENCE, V269, P656, DOI 10.1126/science.7624794; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Su LL, 1997, GENE DEV, V11, P2214, DOI 10.1101/gad.11.17.2214; Su LL, 1997, BIOCHEMISTRY-US, V36, P12722, DOI 10.1021/bi971408k; Sundquist WI, 1996, NAT STRUCT BIOL, V3, P8, DOI 10.1038/nsb0196-8; TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282; TAN RY, 1994, BIOCHEMISTRY-US, V33, P14579, DOI 10.1021/bi00252a025; VanGilst MR, 1997, BIOCHEMISTRY-US, V36, P1514, DOI 10.1021/bi961920q; Weeks KM, 1997, CURR OPIN STRUC BIOL, V7, P336, DOI 10.1016/S0959-440X(97)80048-6; Yonath A, 1997, NAT STRUCT BIOL, V4, P3, DOI 10.1038/nsb0197-3; Zheng N, 1997, MOL CELL, V1, P79, DOI 10.1016/S1097-2765(00)80009-X; Zurdo J, 1997, BIOCHEMISTRY-US, V36, P9625, DOI 10.1021/bi9702400	20	85	87	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					149	151		10.1016/S0092-8674(00)80908-3	http://dx.doi.org/10.1016/S0092-8674(00)80908-3			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458038	Bronze			2022-12-28	WOS:000071672600003
J	Srinivasan, U; Weir, DG; Feighery, C; O'Farrelly, C				Srinivasan, U; Weir, DG; Feighery, C; O'Farrelly, C			Lesson of the week - Emergence of classic enteropathy after longstanding gluten sensitive oral ulceration	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RECURRENT		St James Hosp, Dept Immunol, Dublin 8, Ireland; Trinity Coll Dublin, Dept Clin Med, Dublin, Ireland; St Vincents Hosp, Educ & Res Ctr, Res Lab, Dublin 4, Ireland	Trinity College Dublin; Trinity College Dublin; University College Dublin	Srinivasan, U (corresponding author), Univ Wales Hosp, Dept Rheumatol, Cardiff CF4 4XW, S Glam, Wales.							FERGUSON MM, 1980, GUT, V21, P223, DOI 10.1136/gut.21.3.223; OFARRELLY C, 1991, J ORAL PATHOL MED, V20, P476, DOI 10.1111/j.1600-0714.1991.tb00407.x; WRAY D, 1978, J ORAL PATHOL MED, V7, P418, DOI 10.1111/j.1600-0714.1978.tb01612.x; WRAY D, 1981, DIGEST DIS SCI, V26, P737, DOI 10.1007/BF01316864	4	6	6	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 17	1998	316	7126					206	207						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468690				2022-12-28	WOS:000071616400032
J	Veeken, H				Veeken, H			Russia: Sex, drugs, and AIDS and MSF	BRITISH MEDICAL JOURNAL			English	Article									Med Sans Frontieres, NL-1001 EA Amsterdam, Netherlands	Doctors Without Borders	Veeken, H (corresponding author), Med Sans Frontieres, POB 10014, NL-1001 EA Amsterdam, Netherlands.								0	14	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 10	1998	316	7125					138	139						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR408	9462323	Green Published			2022-12-28	WOS:000071492300031
J	Warren, P; Khalil, N				Warren, P; Khalil, N			Huffing and puffing	LANCET			English	Article											Warren, P (corresponding author), RESP HOSP,810 SHERBROOK ST,WINNIPEG,MB R3A 1R8,CANADA.							ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; COOPER JD, 1995, J THORAC CARDIOV SUR, V109, P106, DOI 10.1016/S0022-5223(95)70426-4; DOYLE IR, 1995, AM J RESP CRIT CARE, V152, P307, DOI 10.1164/ajrccm.152.1.7599839; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; SCHLUGER NW, 1995, AM J RESP CRIT CARE, V152, P11, DOI 10.1164/ajrccm.152.1.7599808	5	0	0	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S21	S21		10.1016/0140-6736(95)90020-9	http://dx.doi.org/10.1016/0140-6736(95)90020-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454039				2022-12-28	WOS:A1995TN12200021
J	Horton, B				Horton, B			Light in the gloom for cell biologists	NATURE			English	Article																			0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					819	820		10.1038/35912	http://dx.doi.org/10.1038/35912			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486656				2022-12-28	WOS:000072089500062
J	Castro-Tirado, AJ; Gorosabel, J; Benitez, N; Wolf, C; Fockenbrock, R; Martinez-Gonzalez, E; Kristen, H; Broeils, A; Pedersen, H; Greiner, J; Costa, E; Feroci, M; Piro, L; Frontera, F; Nicastro, L; Palazzi, E; Bartolini, C; Guarnieri, A; Masetti, N; Piccioni, A; Mignoli, M; Wold, M; Lacy, M; Birkle, K; Broadhurst, T; Brandt, S; Lund, N				Castro-Tirado, AJ; Gorosabel, J; Benitez, N; Wolf, C; Fockenbrock, R; Martinez-Gonzalez, E; Kristen, H; Broeils, A; Pedersen, H; Greiner, J; Costa, E; Feroci, M; Piro, L; Frontera, F; Nicastro, L; Palazzi, E; Bartolini, C; Guarnieri, A; Masetti, N; Piccioni, A; Mignoli, M; Wold, M; Lacy, M; Birkle, K; Broadhurst, T; Brandt, S; Lund, N			Photometry and spectroscopy of the GRB 970508 optical counterpart	SCIENCE			English	Article							GAMMA-RAY BURSTS; VARIABILITY; EMISSION; MODELS	An optical transient within the error box of the gamma ray burst GRB 970508 was imaged 4 hours after the event. It displayed a strong ultraviolet excess, and reached maximum brightness 2 days later. The optical spectra did not show any emission lines, and no variations on time scales of minutes were observed for 1 hour during the decline phase. According to the fireball and afterglow models, the intensity should rise monotonically before the observed optical maximum, but the data indicate that another physical mechanism may be responsible for the constant phase seen during the first hours after the burst.	INTA, Lab Astrofis Espacial & Fis Fundamental, Madrid, Spain; Inst Fis Cantabria, Santander, Spain; Max Planck Inst Astron, D-69117 Heidelberg, Germany; Stockholm Observ, Saltsjobaden, Sweden; Copenhagen Univ Observ, DK-1350 Copenhagen, Denmark; Inst Astrophys, Potsdam, Germany; CNR, Ist Astrofis Spaziale, I-00044 Frascati, Italy; Univ Ferrara, Dipartimento Fis, I-44100 Ferrara, Italy; CNR, Ist Tecnol & Studio Radiazioni Extraterr, I-40126 Bologna, Italy; Univ Bologna, Dipartimento Astron, Bologna, Italy; Osservatorio Astron Bologna, Bologna, Italy; Nucl & Astrophys Lab, Oxford, England; Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Danish Space Res Inst, Copenhagen, Denmark	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Astrobiologia (INTA); Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Fisica de Cantabria (IFCA); Max Planck Society; Stockholm University; University of Copenhagen; Leibniz Institut fur Astrophysik Potsdam (AIP); Consiglio Nazionale delle Ricerche (CNR); University of Ferrara; Consiglio Nazionale delle Ricerche (CNR); University of Bologna; Istituto Nazionale Astrofisica (INAF); University of Oxford; University of California System; University of California Berkeley; United States Department of Energy (DOE); Los Alamos National Laboratory; Technical University of Denmark	Castro-Tirado, AJ (corresponding author), INTA, Lab Astrofis Espacial & Fis Fundamental, Madrid, Spain.		Nicastro, Luciano/F-5866-2015; Nicastro, Luciano/AAU-5914-2021; Wold, Margrethe/CAF-0303-2022; Martinez-Gonzalez, Enrique/E-9534-2015; Broadhurst, Thomas/AAF-9891-2019; Palazzi, Eliana/N-4746-2015; Mignoli, Marco/O-9426-2015; Lund, Niels/ABB-7347-2021; PIRO, LUIGI/E-4954-2013; Martinez-Gonzalez, Enrique/AAB-2741-2019; Benitez, Narciso/C-2065-2017	Nicastro, Luciano/0000-0001-8534-6788; Nicastro, Luciano/0000-0001-8534-6788; Martinez-Gonzalez, Enrique/0000-0002-0179-8590; Broadhurst, Thomas/0000-0002-8785-8979; Mignoli, Marco/0000-0002-9087-2835; PIRO, LUIGI/0000-0003-4159-3984; Wold, Margrethe/0000-0003-3405-0252; Palazzi, Eliana/0000-0002-8691-7666; Feroci, Marco/0000-0002-7617-3421; Castro-Tirado, A. J./0000-0003-2999-3563; Costa, Enrico/0000-0003-4925-8523; Wolf, Christian/0000-0002-4569-016X; Benitez, Narciso/0000-0002-0403-7455; Brandt, Soren/0000-0001-5689-3109				Beskin GM, 1995, LECT NOTES PHYS, V454, P330; BOND H, 1997, 6655 IAU; BRAINERD JJ, 1992, ASTROPHYS J, V394, pL33, DOI 10.1086/186466; CastroTirado AJ, 1997, ASTRON ASTROPHYS, V322, P507; CASTROTIRADO AJ, 1997, 6657 IAU; CASTROTIRADO AJ, 1997, 6598 IAU; CHAKRABARTI SK, 1993, ASTROPHYS J, V411, P602, DOI 10.1086/172862; CHEVALIER C, 1997, 6663 IAU; COSTA E, 1997, 6649 IAU; Djorgovski SG, 1997, NATURE, V387, P876, DOI 10.1038/43126; DJORGOVSKI SG, 1997, 6658 IAU; DJORGOVSKI SG, 1997, 6660 IAU; FISHMAN GJ, 1995, ANNU REV ASTRON ASTR, V33, P415, DOI 10.1146/annurev.astro.33.1.415; Frontera F, 1997, ASTRON ASTROPHYS SUP, V122, P357, DOI 10.1051/aas:1997140; FRUCHTER A, 1997, 6674 IAU; Galama T, 1997, NATURE, V387, P479, DOI 10.1038/387479a0; GALAMA T, UNPUB; GALAMA TJ, 1997, 6655 IAU; GOROSABEL J, UNPUB; GROOT PJ, 1997, 6584 IAU; GROOT PJ, 1997, 6660 IAU; Guarnieri A, 1997, ASTRON ASTROPHYS, V328, pL13; HEISE J, 1997, 6652 IAU; Jager R, 1997, ASTRON ASTROPHYS SUP, V125, P557, DOI 10.1051/aas:1997243; KATZ JI, 1994, ASTROPHYS J, V432, pL107, DOI 10.1086/187523; Katz JI, 1997, ASTROPHYS J, V490, P772, DOI 10.1086/304913; KOPYLOV AI, 1997, 6671 IAU; KOUVELIOTOU C, 1997, 6660 IAU; MESZAROS P, 1993, ASTROPHYS J, V405, P278, DOI 10.1086/172360; MESZAROS P, 1993, ASTROPHYS J, V418, pL59, DOI 10.1086/187116; Meszaros P, 1997, ASTROPHYS J, V476, P232, DOI 10.1086/303625; METZGER MR, 1997, 6676 IAU; METZGER MR, 1997, NATURE, V387, P879; Orosz JA, 1997, ASTROPHYS J, V478, pL83, DOI 10.1086/310553; PEDERSEN H, IN PRESS ASTROPHYS J; Pian E, 1997, ASTROPHYS J, V486, P784, DOI 10.1086/304537; Piro L, 1995, P SOC PHOTO-OPT INS, V2517, P169, DOI 10.1117/12.224910; PIRO L, 1997, 6656 IAU; PIRO L, IN PRESS ASTRON ASTR; SCHAEFER BE, 1997, 6658 IAU; Tavani M, 1996, ASTROPHYS J, V466, P768, DOI 10.1086/177551; vanParadijs J, 1997, NATURE, V386, P686, DOI 10.1038/386686a0; Vietri M, 1997, ASTROPHYS J, V488, pL105, DOI 10.1086/310931; Waxman E, 1997, ASTROPHYS J, V485, pL5, DOI 10.1086/310809; Wijers RAMJ, 1997, MON NOT R ASTRON SOC, V288, pL51, DOI 10.1093/mnras/288.4.L51; XIE GZ, 1994, ASTRON ASTROPHYS SUP, V106, P361	46	44	44	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1011	1014		10.1126/science.279.5353.1011	http://dx.doi.org/10.1126/science.279.5353.1011			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461429				2022-12-28	WOS:000072006400041
J	den Haan, JMM; Meadows, LM; Wang, W; Pool, J; Blokland, E; Bishop, TL; Reinhardus, C; Shabanowitz, J; Offringa, R; Hunt, DF; Engelhard, VH; Goulmy, E				den Haan, JMM; Meadows, LM; Wang, W; Pool, J; Blokland, E; Bishop, TL; Reinhardus, C; Shabanowitz, J; Offringa, R; Hunt, DF; Engelhard, VH; Goulmy, E			The minor histocompatibility antigen HA-1: A diallelic gene with a single amino acid polymorphism	SCIENCE			English	Article							VERSUS-HOST DISEASE; BONE-MARROW TRANSPLANTATION; UNRELATED DONORS; LYMPHOCYTES-T; PEPTIDE; HLA; IDENTIFICATION; PROTEIN	The minor histocompatibility antigen (mHag) HA-1 is the only known mHag for which mismatching is correlated with the development of severe graft versus host disease (GVHD) after human leukocyte antigen-identical bone marrow transplantation. HA-1 was found to be a nonapeptide derived from an allele of the KIAA0223 gene. The HA-1-negative allelic counterpart encoded by KIAA0223 had one amino acid difference from HA-1. Family analysis with HA-1 allele-specific polymerase chain reaction showed an exact correlation between this allelic polymorphism and the HA-1 phenotype. HA-1 allele typing of donor and recipient should improve donor selection and allow the determination of bone marrow transplantation recipients with high risk for HA-1-induced GVHD development.	Leiden Univ, Med Ctr, Dept Immunohaematol, NL-2333 ZA Leiden, Netherlands; Leiden Univ, Med Ctr, Blood Bank, NL-2333 ZA Leiden, Netherlands; Univ Virginia, Dept Chem, Charlottesville, VA 22901 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22901 USA; Univ Virginia, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22901 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22901 USA	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Virginia; University of Virginia; University of Virginia; University of Virginia	Goulmy, E (corresponding author), Leiden Univ, Med Ctr, Dept Immunohaematol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.		Hunt, Donald F/I-6936-2012; den Haan, Joke MM/A-4281-2010	Hunt, Donald F/0000-0003-2815-6368; den Haan, Joke MM/0000-0002-4421-6917; Engelhard, Victor/0000-0002-1741-0925	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021393] Funding Source: NIH RePORTER; NIAID NIH HHS [AI07496, AI3393, AI21393] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEATTY PG, 1991, TRANSPLANTATION, V51, P443, DOI 10.1097/00007890-199102000-00034; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; DEBUEGER M, 1992, J IMMUNOL, V149, P1788; DEBUEGER M, 1993, EUR J IMMUNOL, V23, P614, DOI 10.1002/eji.1830230305; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; Goulmy E, 1996, NEW ENGL J MED, V334, P281, DOI 10.1056/NEJM199602013340501; GOULMY E, 1983, NATURE, V302, P159, DOI 10.1038/302159a0; LINDAHL KF, 1991, TRENDS GENET, V7, P219, DOI 10.1016/0168-9525(91)90368-Z; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; LOVELAND BE, 1991, ANTIGEN PROCESSING R, P173; MARKS DI, 1993, ANN INTERN MED, V119, P207, DOI 10.7326/0003-4819-119-3-199308010-00005; MARTIN PJ, 1991, BONE MARROW TRANSPL, V8, P217; Meadows L, 1997, IMMUNITY, V6, P273, DOI 10.1016/S1074-7613(00)80330-1; Mendoza LM, 1997, IMMUNITY, V7, P461, DOI 10.1016/S1074-7613(00)80368-4; Morse MC, 1996, J IMMUNOL, V156, P3301; Ossendorp F, 1996, IMMUNITY, V5, P115, DOI 10.1016/S1074-7613(00)80488-4; Ottenhoff THM, 1997, J IMMUNOL METHODS, V200, P89, DOI 10.1016/S0022-1759(96)00190-1; RUFER N, 1997, BONE MARROW TRANS S1, V19, pS184; SCHREUDER GMT, 1993, IMMUNOGENETICS, V38, P98, DOI 10.1007/BF00190897; Tan TLR, 1997, J IMMUNOL METHODS, V205, P201, DOI 10.1016/S0022-1759(97)00086-0; TRAVERSARI C, 1992, IMMUNOGENETICS, V35, P145, DOI 10.1007/BF00185107; van Lochem E, 1996, Transpl Immunol, V4, P151, DOI 10.1016/S0966-3274(96)80009-8; VANDERHARST D, 1994, BLOOD, V83, P1060; VANELS CACM, 1992, IMMUNOGENETICS, V35, P161, DOI 10.1007/BF00185109; WANG W, 1995, SCIENCE, V269, P1588, DOI 10.1126/science.7667640	25	322	336	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1054	1057		10.1126/science.279.5353.1054	http://dx.doi.org/10.1126/science.279.5353.1054			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461441				2022-12-28	WOS:000072006400053
J	Bunch, C				Bunch, C			Challenging times for specialist services	BRITISH MEDICAL JOURNAL			English	Article									John Radcliffe Hosp, Oxford Radcliffe Hosp NHS Trust, Oxford OX3 9DU, England	Oxford University Hospitals NHS Foundation Trust; University of Oxford	Bunch, C (corresponding author), John Radcliffe Hosp, Oxford Radcliffe Hosp NHS Trust, Oxford OX3 9DU, England.							*AUD COMM, 1997, HIGH PURCH COMM SPEC; CALMAN K, 1994, POLICY FRAMEWORK COM; *SECR STAT HLTH, 1989, WORK PAT	3	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 31	1998	316	7128					378	379		10.1136/bmj.316.7128.378	http://dx.doi.org/10.1136/bmj.316.7128.378			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487178	Green Published			2022-12-28	WOS:000071863900036
J	Black, N				Black, N			Clinical governance: Fine words or action?	BRITISH MEDICAL JOURNAL			English	Article									Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Black, N (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.							Black N, 1997, BRIT MED J, V315, P1323, DOI 10.1136/bmj.315.7119.1323; Black N, 1997, BRIT MED J, V315, P381, DOI 10.1136/bmj.315.7105.381; FERGUSON B, 1998, J HLTH SERV RES POLI, V3, P3	3	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					297	298		10.1136/bmj.316.7127.297	http://dx.doi.org/10.1136/bmj.316.7127.297			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472521	Green Published			2022-12-28	WOS:000071702100038
J	Verheugt, FWA				Verheugt, FWA			Aspirin, the poor man's statin?	LANCET			English	Editorial Material							PREVENTION; DIPYRIDAMOLE; BRITISH; TRIAL		Univ Nijmegen Hosp, Dept Cardiol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Verheugt, FWA (corresponding author), Univ Nijmegen Hosp, Dept Cardiol, NL-6500 HB Nijmegen, Netherlands.		Verheugt, F.W.A./H-8105-2014					ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; CHESEBRO JH, 1984, NEW ENGL J MED, V310, P209, DOI 10.1056/NEJM198401263100401; GOTTO AM, 1997, 70 SCI SESS AM HEART; HENNEKENS CH, 1988, NEW ENGL J MED, V318, P923; JUULMOLLER S, 1992, LANCET, V340, P1421, DOI 10.1016/0140-6736(92)92619-Q; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; SCHWARTZ L, 1988, NEW ENGL J MED, V318, P1714, DOI 10.1056/NEJM198806303182603; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; *STEER COMM PHYS H, 1989, NEW ENGL J MED, V321, P1299; Verheugt FWA, 1997, LANCET, V349, P1409, DOI 10.1016/S0140-6736(05)63719-1	10	21	21	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 24	1998	351	9098					227	228		10.1016/S0140-6736(05)78280-5	http://dx.doi.org/10.1016/S0140-6736(05)78280-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU294	9457087				2022-12-28	WOS:000071702200003
J	Maley, LE; Marshall, CR				Maley, LE; Marshall, CR			Evolution - The coming of age of molecular systematics	SCIENCE			English	Article							RIBOSOMAL-RNA; PHYLOGENY; PARSIMONY		Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Maley, LE (corresponding author), Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA.							Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Balavoine G, 1997, CR ACAD SCI III-VIE, V320, P83, DOI 10.1016/S0764-4469(99)80090-0; Carranza S, 1997, MOL BIOL EVOL, V14, P485, DOI 10.1093/oxfordjournals.molbev.a025785; DEQUEIROZ A, 1995, ANNU REV ECOL SYST, V26, P657, DOI 10.1146/annurev.es.26.110195.003301; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; Felsenstein J, 1996, MOL BIOL EVOL, V13, P93, DOI 10.1093/oxfordjournals.molbev.a025575; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; HENDY MD, 1989, SYST ZOOL, V38, P297, DOI 10.2307/2992396; Huelsenbeck JP, 1997, SCIENCE, V276, P227, DOI 10.1126/science.276.5310.227; Kim JH, 1996, SYST BIOL, V45, P363, DOI 10.2307/2413570; LECOINTRE G, 1993, MOL PHYLOGENET EVOL, V2, P205, DOI 10.1006/mpev.1993.1021; Mackey LY, 1996, J MOL EVOL, V42, P552, DOI 10.1007/BF02352285; MALANYCH KM, 1995, SCIENCE, V267, P1641; MARSHALL CR, 1997, COMP SCI STAT, V29, P218; Morris SC, 1997, CURR BIOL, V7, pR71, DOI 10.1016/S0960-9822(06)00039-X; PHILIPPE H, 1994, DEVELOPMENT, P15; Siddall ME, 1995, J PARASITOL, V81, P961, DOI 10.2307/3284049; SULLIVAN J, 1995, MOL BIOL EVOL, V12, P988; TELFORD MJ, 1993, MOL BIOL EVOL, V10, P660; TURBEVILLE JM, 1994, MOL BIOL EVOL, V11, P648; VANDEPEER Y, 1993, J MOL EVOL, V37, P221, DOI 10.1007/BF02407359	21	56	58	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					505	506		10.1126/science.279.5350.505	http://dx.doi.org/10.1126/science.279.5350.505			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9454349				2022-12-28	WOS:000071616000031
J	Redinbo, MR; Stewart, L; Kuhn, P; Champoux, JJ; Hol, WGJ				Redinbo, MR; Stewart, L; Kuhn, P; Champoux, JJ; Hol, WGJ			Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA	SCIENCE			English	Article							CAMPTOTHECIN RESISTANCE; CATALYTIC ACTIVITY; ANTITUMOR-ACTIVITY; TERMINAL FRAGMENT; EUKARYOTIC TOPOISOMERASE; CLEAVABLE COMPLEXES; POINT MUTATION; BINDING-SITE; WHEAT-GERM; IDENTIFICATION	Topoisomerases I promote the relaxation of DNA superhelical tension by introducing a transient Single-stranded break in duplex DNA and are vital for the processes of replication, transcription, and recombination, The crystal structures at 2.1 and 2.5 angstrom resolution of reconstituted human topoisomerase I comprising the core and carboxyl-terminal domains in covalent and noncovalent complexes with 22-base pair DNA duplexes reveal an enzyme that "clamps" around essentially B-form DNA, The core domain and the first eight residues of the carboxyl-terminal domain of the enzyme, including the active-site nuleophile tyrosine-723, share significant structural similarity with the bacteriophage family of DNA integrases. A binding mode for the anticancer drug camptothecin is proposed on the basis of chemical and biochemical information combined with these three-dimensional structures of topoisomerase I-DNA complexes.	Univ Washington, Sch Med, Biomol Struct Ctr, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA; Stanford Univ, Stanford Synchrotron Radiat Lab, Stanford, CA 94309 USA; Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biochem, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biol Struct, Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Hol, WGJ (corresponding author), Univ Washington, Sch Med, Biomol Struct Ctr, Box 357742, Seattle, WA 98195 USA.				NATIONAL CANCER INSTITUTE [R01CA065656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049156] Funding Source: NIH RePORTER; NCI NIH HHS [CA65656] Funding Source: Medline; NIGMS NIH HHS [GM49156] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ALSNER J, 1992, J BIOL CHEM, V267, P12408; ANDERSEN AH, 1985, NUCLEIC ACIDS RES, V13, P1543, DOI 10.1093/nar/13.5.1543; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; BENDIXEN C, 1990, BIOCHEMISTRY-US, V29, P5613, DOI 10.1021/bi00475a028; BENEDETTI P, 1993, CANCER RES, V53, P4343; Berger JM, 1996, NATURE, V380, P179, DOI 10.1038/380179a0; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; BJORNSTI MA, 1989, CANCER RES, V49, P6318; Brunger A.T., 1993, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BURGIN AB, 1985, NUCLEIC ACIDS RES, V23, P2973; Caron P R, 1994, Adv Pharmacol, V29B, P271; CHAMPOUX JJ, IN PRESS PROG NUCL A; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CROW RT, 1992, J MED CHEM, V35, P4160, DOI 10.1021/jm00100a022; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; HERTZBERG RP, 1989, J MED CHEM, V32, P715, DOI 10.1021/jm00123a038; HERTZBERG RP, 1990, J BIOL CHEM, V265, P19287; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; HORWITZ SB, 1971, MOL PHARMACOL, V7, P632; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; JAXEL C, 1989, CANCER RES, V49, P1465; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSHUATOR L, 1992, J MOL BIOL, V225, P397, DOI 10.1016/0022-2836(92)90929-E; KINGSBURY WD, 1991, J MED CHEM, V34, P98, DOI 10.1021/jm00105a017; KJELDSEN E, 1988, J MOL BIOL, V202, P333, DOI 10.1016/0022-2836(88)90462-7; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KNAB AM, 1993, J BIOL CHEM, V268, P22322; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBOTA N, 1992, BIOCHEM BIOPH RES CO, V188, P571, DOI 10.1016/0006-291X(92)91094-7; LACKEY K, 1995, J MED CHEM, V38, P906, DOI 10.1021/jm00006a008; LETEURTRE F, 1994, J BIOL CHEM, V269, P28702; Li XG, 1997, BIOCHEM PHARMACOL, V53, P1019, DOI 10.1016/S0006-2952(96)00899-4; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; Lue N, 1995, STRUCTURE, V3, P1315, DOI 10.1016/S0969-2126(01)00269-6; MADDEN KR, 1992, CANCER RES, V52, P525; MCPHAIL AT, 1968, J CHEM SOC B, P923, DOI 10.1039/j29680000923; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOORE JM, 1988, BIOCHEMISTRY-US, V27, P7806, DOI 10.1021/bi00420a033; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; OTWINOWSKI Z, 1993, DATA COLLECTION PROC; POMMIER Y, 1995, P NATL ACAD SCI USA, V92, P8861, DOI 10.1073/pnas.92.19.8861; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUBIN E, 1994, J BIOL CHEM, V269, P2433; SAWADA S, 1991, CHEM PHARM BULL, V39, P3183; SHAFFER R, 1987, J BIOL CHEM, V262, P9309; SHARMA A, 1994, STRUCTURE, V2, P767, DOI 10.1016/S0969-2126(94)00077-8; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; Stewart L, 1997, J MOL BIOL, V269, P355, DOI 10.1006/jmbi.1997.1056; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; TAMURA H, 1991, NUCLEIC ACIDS RES, V19, P69, DOI 10.1093/nar/19.1.69; TANIZAWA A, 1993, J BIOL CHEM, V268, P25463; TANIZAWA A, 1995, BIOCHEMISTRY-US, V34, P7200, DOI 10.1021/bi00021a035; TANIZAWA A, 1993, NUCLEIC ACIDS RES, V21, P5157, DOI 10.1093/nar/21.22.5157; WALL ME, 1966, J AM CHEM SOC, V88, P3888, DOI 10.1021/ja00968a057; WALL ME, 1993, J MED CHEM, V36, P2689, DOI 10.1021/jm00070a013; Wang HK, 1997, MED RES REV, V17, P367, DOI 10.1002/(SICI)1098-1128(199707)17:4<367::AID-MED3>3.0.CO;2-U; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang LF, 1997, CANCER RES, V57, P1516	75	743	772	6	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1504	1513		10.1126/science.279.5356.1504	http://dx.doi.org/10.1126/science.279.5356.1504			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488644				2022-12-28	WOS:000072372900057
J	Shahab, N; Evans, ML				Shahab, N; Evans, ML			Platelet satellitism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Hosp & Clin, Columbia, MO 65203 USA	University of Missouri System; University of Missouri Columbia	Shahab, N (corresponding author), Univ Hosp & Clin, Columbia, MO 65203 USA.								0	11	11	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 26	1998	338	9					591	591		10.1056/NEJM199802263380906	http://dx.doi.org/10.1056/NEJM199802263380906			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY708	9475767				2022-12-28	WOS:000072175700006
J	Garcia, KC; Degano, M; Pease, LR; Huang, MD; Peterson, PA; Teyton, L; Wilson, IA				Garcia, KC; Degano, M; Pease, LR; Huang, MD; Peterson, PA; Teyton, L; Wilson, IA			Structural basis of plasticity in T cell receptor recognition of a self peptide MHC antigen	SCIENCE			English	Article							ELECTRON-DENSITY MAPS; POSITIVE SELECTION; CRYSTAL-STRUCTURE; LYMPHOCYTES-T; V-ALPHA; TRANSGENIC MICE; VIRAL PEPTIDES; BETA-CHAIN; COMPLEX; ANTIBODY	The T cell receptor (TCR) inherently has dual specificity, T cells must recognize self-antigens in the thymus during maturation and then discriminate between foreign pathogens in the periphery, A molecular basis for this cross-reactivity is elucidated by the crystal structure of the alloreactive 2C TCR bound to self peptide-major histocompatibility complex (pMHC) antigen H-2K(b)-dEV8 refined against anisotropic 3.0 angstrom resolution x-ray data, The interface between peptide and TCR exhibits extremely poor shape complementarity, and the TCR beta chain complementarity-determining region 3 (CDR3) has minimal interaction with the dEV8 peptide, Large conformational changes in three of the TCR CDR loops are induced upon binding, providing a mechanism of structural plasticity to accommodate a variety of different peptide antigens, Extensive TCR interaction with the pMHC alpha helices suggests a generalized orientation that is mediated by the V-alpha domain of the TCR and rationalizes how TCRs can effectively "scan" different peptides bound within a large, low-affinity MHC structural framework for those that provide the slight additional kinetic stabilization required for signaling.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Mayo Clinic; Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute	Wilson, IA (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	wilson@scripps.edu	Degano, Massimo/K-4669-2018; Huang, Mary/I-6216-2013	Degano, Massimo/0000-0002-0787-1883; Huang, Mary/0000-0001-8547-5328	NCI NIH HHS [R01 CA58896] Funding Source: Medline; NIAID NIH HHS [AI42266, AI42267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI142267, R01AI042267, R37AI042266, R01AI042266] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; ALLISON JP, 1984, IMMUNOL REV, V81, P145, DOI 10.1111/j.1600-065X.1984.tb01108.x; Ausubel LJ, 1996, P NATL ACAD SCI USA, V93, P15317, DOI 10.1073/pnas.93.26.15317; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; Bevan MJ, 1997, IMMUNITY, V7, P175, DOI 10.1016/S1074-7613(00)80520-8; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BRANDLE D, 1991, EUR J IMMUNOL, V21, P2195, DOI 10.1002/eji.1830210930; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Clark Stephen P., 1995, Immunogenetics, V42, P531; Collaborative Computational Project, 1994, ACTA CRYST D, V50, P760; CONNOLLY ML, 1993, J MOL GRAPH MODEL, V11, P139, DOI 10.1016/0263-7855(93)87010-3; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P439; COSE SC, 1995, J VIROL, V69, P5849, DOI 10.1128/JVI.69.9.5849-5852.1995; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEMBIC Z, 1986, NATURE, V320, P232, DOI 10.1038/320232a0; Fields BA, 1996, IMMUNOL TODAY, V17, P330, DOI 10.1016/0167-5699(96)10020-7; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1997, P NATL ACAD SCI USA, V94, P13838, DOI 10.1073/pnas.94.25.13838; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Germain RN, 1997, CURR BIOL, V7, pR640, DOI 10.1016/S0960-9822(06)00323-X; GERMAIN RN, 1990, NATURE, V344, P19, DOI 10.1038/344019a0; HASKINS K, 1984, ANNU REV IMMUNOL, V2, P51, DOI 10.1146/annurev.iy.02.040184.000411; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HONG SC, 1992, CELL, V69, P999, DOI 10.1016/0092-8674(92)90618-M; Housset D, 1997, EMBO J, V16, P4205, DOI 10.1093/emboj/16.14.4205; Ignatowicz L, 1996, CELL, V84, P521, DOI 10.1016/S0092-8674(00)81028-4; JAMESON SC, 1995, IMMUNITY, V2, P1, DOI 10.1016/1074-7613(95)90074-8; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; KATZ DH, 1973, P NATL ACAD SCI USA, V70, P2624, DOI 10.1073/pnas.70.9.2624; Kersh GJ, 1996, J EXP MED, V184, P1259, DOI 10.1084/jem.184.4.1259; Kersh GJ, 1996, NATURE, V380, P495, DOI 10.1038/380495a0; KLEIN J, 1996, NATURAL HIST MAJOR H; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P573, DOI 10.1073/pnas.81.2.573; KUZUSHIMA K, 1995, J IMMUNOL, V155, P594; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; Madrenas J, 1996, Semin Immunol, V8, P83, DOI 10.1006/smim.1996.0011; Madrenas J, 1997, J EXP MED, V185, P219, DOI 10.1084/jem.185.2.219; MARTIN ACR, 1992, SCITECH SOFTWARE; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; MEUER SC, 1984, ANNU REV IMMUNOL, V2, P23, DOI 10.1146/annurev.immunol.2.1.23; NANDA NK, 1995, J EXP MED, V182, P531, DOI 10.1084/jem.182.2.531; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAWLOWSKI TJ, 1996, EUR J IMMUNOL, V26, P85; PULLEN JK, 1989, J IMMUNOL, V143, P1674; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; SAITO T, 1987, NATURE, V329, P256, DOI 10.1038/329256a0; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SHERMAN LA, 1993, ANNU REV IMMUNOL, V11, P385, DOI 10.1146/annurev.immunol.11.1.385; Sim BC, 1996, SCIENCE, V273, P963, DOI 10.1126/science.273.5277.963; SPEIR JP, UNPUB; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; Tallquist MD, 1998, J IMMUNOL, V160, P802; TALLQUIST MD, 1995, J IMMUNOL, V155, P2419; Tallquist MD, 1996, J EXP MED, V184, P1017, DOI 10.1084/jem.184.3.1017; TERHORST O, 1995, T CELL RECEPTORS, P369; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; Udaka K, 1996, J IMMUNOL, V157, P670; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; Utz U, 1996, J VIROL, V70, P843, DOI 10.1128/JVI.70.2.843-851.1996; Vergelli M, 1997, J IMMUNOL, V158, P3746; Wang JH, 1998, EMBO J, V17, P10, DOI 10.1093/emboj/17.1.10; WEDEMAYER GJ, 1997, SCIENCE, V276, P16665; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; Wilson IA, 1997, CURR OPIN STRUC BIOL, V7, P839, DOI 10.1016/S0959-440X(97)80156-X; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	90	577	587	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1166	1172		10.1126/science.279.5354.1166	http://dx.doi.org/10.1126/science.279.5354.1166			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469799				2022-12-28	WOS:000072115200031
J	Braud, VM; Allan, DSJ; O'Callaghan, CA; Soderstrom, K; D'Andrea, A; Ogg, GS; Lazetic, S; Young, NT; Bell, JI; Phillips, JH; Lanier, LL; McMichael, AJ				Braud, VM; Allan, DSJ; O'Callaghan, CA; Soderstrom, K; D'Andrea, A; Ogg, GS; Lazetic, S; Young, NT; Bell, JI; Phillips, JH; Lanier, LL; McMichael, AJ			HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C	NATURE			English	Article							MONOCLONAL-ANTIBODY; CD94; ANTIGEN; RECOGNITION; PEPTIDE; IDENTIFICATION; LYMPHOCYTES; ALLELES; FORM	The protein HLA-E is a non-classical major histocompatibility complex (MHC) molecule of limited sequence variability. Its expression on the cell surface is regulated by the binding of peptides derived from the signal sequence of some other MHC class I molecules(1,2). Here we report the identification of ligands for HLA-E. We constructed tetramers(3) in which recombinant HLA-E and beta 2-microglobulin were refolded with an MHC leader-sequence peptide, biotinylated, and conjugated to phycoerythrin-labelled Extravidin. This HLA-E tetramer bound to natural killer (NK) cells and a small subset of T cells from peripheral blood. On transfectants, the tetramer bound to the CD94/NKG2A, CD94/NKGK2B and CD94/NKG2C NK cell receptors, but did not bind to the immunoglobulin family of NK cell receptors (KIR). Surface expression of HLA-E was enough to protect target cells from lysis by CD94/NKG2A(+) NK-cell clones. A subset of HLA class I alleles has been shown to inhibit killing by CD94/NKG2A(+) NK-cell clones(4-6). Only the HLA alleles that possess a leader peptide capable of upregulating HLA-E surface expression confer resistance to NK-cell-mediated lysis, implying that their action is mediated by HLA-E, the predominant ligand for the NK cell inhibitory receptor CD94/NKG2A.	John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England; DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunol, Palo Alto, CA 94304 USA; John Radcliffe Hosp, Nuffield Dept Surg, Oxford OX3 9DU, England	University of Oxford; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Oxford	Braud, VM (corresponding author), John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England.		D'Andrea, Annalisa/F-9836-2011; Lanier, Lewis L/E-2139-2014; Soderstrom, Kalle/G-5788-2011; braud, veronique M/I-4597-2013	Lanier, Lewis L/0000-0003-1308-3952; braud, veronique M/0000-0001-8213-3947; Ogg, Graham/0000-0002-3097-045X				ALDRICH CJ, 1994, CELL, V79, P649, DOI 10.1016/0092-8674(94)90550-9; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; ARAMBURU J, 1990, J IMMUNOL, V144, P3238; Braud V, 1997, EUR J IMMUNOL, V27, P1164, DOI 10.1002/eji.1830270517; Braud VM, 1998, CURR BIOL, V8, P1, DOI 10.1016/S0960-9822(98)70014-4; Brooks AG, 1997, J EXP MED, V185, P795, DOI 10.1084/jem.185.4.795; Carretero M, 1997, EUR J IMMUNOL, V27, P563, DOI 10.1002/eji.1830270230; CHANG CW, 1995, EUR J IMMUNOL, V25, P2433, DOI 10.1002/eji.1830250904; CONNOLLY DJ, 1993, J IMMUNOL, V151, P6089; Cotterill LA, 1997, EUR J IMMUNOL, V27, P2123, DOI 10.1002/eji.1830270902; DeCloux A, 1997, J IMMUNOL, V158, P2183; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Houchins JP, 1997, J IMMUNOL, V158, P3603; Lanier LL, 1997, IMMUNOL REV, V155, P145, DOI 10.1111/j.1600-065X.1997.tb00947.x; Lazetic S, 1996, J IMMUNOL, V157, P4741; LITWIN V, 1993, J EXP MED, V178, P1321, DOI 10.1084/jem.178.4.1321; OGG GS, IN PRESS SCIENCE; Pende D, 1997, EUR J IMMUNOL, V27, P1875, DOI 10.1002/eji.1830270809; Phillips JH, 1996, IMMUNITY, V5, P163, DOI 10.1016/S1074-7613(00)80492-6; Reyburn HT, 1997, NATURE, V386, P514, DOI 10.1038/386514a0; Robertson MJ, 1996, EXP HEMATOL, V24, P406; Sivori S, 1996, EUR J IMMUNOL, V26, P2487, DOI 10.1002/eji.1830261032; Sivori S, 1996, TRANSPLANT P, V28, P3199; Soderstrom K, 1997, J IMMUNOL, V159, P1072; Steven NM, 1997, J EXP MED, V185, P1605, DOI 10.1084/jem.185.9.1605; VILLAR JJP, 1997, J IMMUNOL, V158, P5736; WEI XH, 1990, HUM IMMUNOL, V29, P131, DOI 10.1016/0198-8859(90)90076-2	27	1681	1737	2	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					795	799		10.1038/35869	http://dx.doi.org/10.1038/35869			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486650				2022-12-28	WOS:000072089500054
J	Clynes, R; Dumitru, C; Ravetch, JV				Clynes, R; Dumitru, C; Ravetch, JV			Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis	SCIENCE			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; GLOMERULAR MESANGIAL CELLS; MURINE LUPUS; FC-RECEPTORS; GAMMA-CHAIN; MICE; NEPHRITIS; DISEASE; F1-MICE; INJURY	The generation of autoantibody and subsequent tissue deposition of immune complexes (IC) is thought to trigger the pathogenic consequences of systemic autoimmune disease. Modulation of the autoantibody response disrupts pathogenesis by preventing the formation of ICs; however, uncoupling IC formation from subsequent inflammatory responses seems unlikely because of the apparent complexity of the IC-triggered inflammatory cascade. However, the disruption of a single gene, which encodes the gamma chain of the Fc receptor, was found to achieve this uncoupling in a spontaneous model of lupus nephritis, the New Zealand Black/New Zealand White (NZB/NZW) mouse. Gamma chain-deficient NZB/NZW mice generated and deposited IC and activated complement, but were protected from severe nephritis, thus defining another potential pathway for therapeutic intervention in autoimmune disease.	Rockefeller Univ, Mol Genet & Immunol Lab, New York, NY 10021 USA	Rockefeller University	Ravetch, JV (corresponding author), Rockefeller Univ, Mol Genet & Immunol Lab, New York, NY 10021 USA.		Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041				Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; BELMONT HM, 1997, DUBOISS LUPUS ERYTHE, P263; Capra, 1997, IMMUNOBIOLOGY IMMUNE; Clynes R, 1998, P NATL ACAD SCI USA, V95, P652, DOI 10.1073/pnas.95.2.652; CLYNES R, 1995, IMMUNITY, V3, P21, DOI 10.1016/1074-7613(95)90155-8; CLYNES R, UNPUB; COUSER WG, 1990, J AM SOC NEPHROL, V1, P13; DAVIES KA, 1996, BR J RHEUMATOL, V35, P3; Early GS, 1996, J IMMUNOL, V157, P3159; FINCK BK, 1994, J CLIN INVEST, V94, P585, DOI 10.1172/JCI117373; FINCK BK, 1994, SCIENCE, V265, P1225, DOI 10.1126/science.7520604; FISCHER MB, 1997, NATURE, V159, P976; FRANK MM, 1987, NEW ENGL J MED, V316, P1525, DOI 10.1056/NEJM198706113162407; GAUTHIER VJ, 1997, DUBOIS LUPUS ERYTHEM, P207; Hahn BH, 1997, DUBOIS LUPUS ERYTHEM, P69; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; HEBERT LA, 1992, SEMIN NEPHROL, V12, P408; ISHIDA H, 1994, J EXP MED, V179, P305, DOI 10.1084/jem.179.1.305; JANKOVIC D, IN PRESS J EXP MED; MADAIO MP, 1987, J IMMUNOL, V138, P2883; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; MOHAN C, 1995, J IMMUNOL, V154, P1470; MORCOS M, 1994, KIDNEY INT, V46, P1627, DOI 10.1038/ki.1994.462; MOREL L, 1994, IMMUNITY, V1, P219, DOI 10.1016/1074-7613(94)90100-7; Nakajima A, 1997, J IMMUNOL, V158, P1466; RADEKE HH, 1994, J IMMUNOL, V153, P1281; RAVETCH JV, IN PRESS ANN REV IMM; REININGER L, 1992, J EXP MED, V176, P1343, DOI 10.1084/jem.176.5.1343; SCHUR PH, 1997, DUBOIS LUPUS ERYTHEM, P245; Suzuki Y., UNPUB; Sylvestre D, 1996, J EXP MED, V184, P2385, DOI 10.1084/jem.184.6.2385; SYLVESTRE DL, 1994, SCIENCE, V265, P1095, DOI 10.1126/science.8066448; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; THEOFILOPOULOS AN, 1985, ADV IMMUNOL, V37, P269, DOI 10.1016/S0065-2776(08)60342-9; TSAO BP, 1992, J IMMUNOL, V149, P350; UNANUE E, 1964, J EXP MED, V119, P965, DOI 10.1084/jem.119.6.965; Vora KA, 1997, J IMMUNOL, V159, P2116; Vyse TJ, 1996, CURR OPIN IMMUNOL, V8, P843, DOI 10.1016/S0952-7915(96)80014-8; WANG Y, 1996, P NATL ACAD SCI USA, V93, P8653; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; WOLPERT MJ, 1997, ANN NY ACAD SCI, V815, P267; YUAN R, IN PRESS J EXP MED	42	492	540	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1052	1054		10.1126/science.279.5353.1052	http://dx.doi.org/10.1126/science.279.5353.1052			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461440				2022-12-28	WOS:000072006400052
J	Kujala, UM; Kaprio, J; Sarna, S; Koskenvuo, M				Kujala, UM; Kaprio, J; Sarna, S; Koskenvuo, M			Relationship of leisure-time physical activity and mortality - The Finnish Twin Cohort	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; ALL-CAUSE MORTALITY; CARDIORESPIRATORY FITNESS; CARDIOVASCULAR-DISEASE; FOLLOW-UP; MEN; POPULATION; WOMEN; RISK; LONGEVITY	Context.-Physical activity and fitness are believed to reduce premature mortality, but whether genetic factors modify this effect is not known. Objective.-To investigate leisure physical activity and mortality with respect to familial aggregation of health habits during childhood and factors that may enable some individuals to achieve higher levels of fitness. Design.-Prospective twin cohort study. Setting.-Finland. Subjects.-In 1975, at baseline, 7925 healthy men and 7977 healthy women of the Finnish Twin Cohort aged 25 to 64 years who responded to a questionnaire on physical activity habits and known predictors of mortality. Those who reported exercising at least 6 times per month with an intensity corresponding to at least vigorous walking for a mean duration of 30 minutes were classified as conditioning exercisers, those who reported no leisure physical activity were classified as sedentary, and other subjects were classified as occasional exercisers. Main Outcome Measures.-All-cause mortality and discordant deaths among same-sex twin pairs from 1977 through 1994. Results.-Among the entire cohort, 1253 subjects died, The hazard ratio for death adjusted for age and sex was 0.71 (95% confidence interval [CI], 0.62-0.81) in occasional exercisers and 0.57 (95% CI, 0.45-0.74) in conditioning exercisers, compared with those who were sedentary (P for trend <.001). Among the twin pairs who were healthy at baseline and discordant for death (n=434), the odds ratio for death was 0.66 (95% CI, 0.46-0.94) in occasional exercisers and 0.44 (95% CI, 0.23-0.83) in conditioning exercisers compared with those who were sedentary (P for trend, .005). The beneficial effect of physical activity remained after controlling for other predictors of mortality. Conclusion.-Leisure-time physical activity is associated with reduced mortality, even after genetic and other familial factors are taken into account.	Univ Helsinki, Inst Biomed, Unit Sports & Exercise Med, FIN-00250 Helsinki, Finland; Univ Helsinki, Dept Publ Hlth, FIN-00250 Helsinki, Finland; Univ Turku, Dept Publ Hlth, Turku, Finland	University of Helsinki; University of Helsinki; University of Turku	Kujala, UM (corresponding author), Univ Helsinki, Inst Biomed, Unit Sports & Exercise Med, Mannerheimintie 17,Toolo Sports Hall, FIN-00250 Helsinki, Finland.	Urho.Kujala@helsinki.fi	Kujala, Urho/AAP-2547-2020; Kaprio, Jaakko/A-1820-2008	Kaprio, Jaakko/0000-0002-3716-2455; Kujala, Urho/0000-0002-9262-1992; Sarna, Seppo/0000-0003-3458-1627				Ainsworth B, 1993, WOMEN SPORT PHYS ACT, V2, P1; [Anonymous], 1990, Med Sci Sports Exerc, V22, P265; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; Blair SN, 1996, MED SCI SPORT EXER, V28, P9, DOI 10.1097/00005768-199601000-00004; Blair SN, 1996, JAMA-J AM MED ASSOC, V276, P205, DOI 10.1001/jama.276.3.205; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; Finland Central Statistical Office, 1972, ALPH LIST OCC CLASS; Herskind AM, 1996, HUM GENET, V97, P319, DOI 10.1007/s004390050042; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; KAPRIO J, 1987, ALCOHOL CLIN EXP RES, V11, P349, DOI 10.1111/j.1530-0277.1987.tb01324.x; KAPRIO J, 1988, J CLIN EPIDEMIOL, V41, P139, DOI 10.1016/0895-4356(88)90088-1; Kaprio J, 1978, Prog Clin Biol Res, V24 Pt B, P179; KAPRIO J, 1978, FINNISH TWIN REGISTR; Keskimaki I, 1991, INT J HLTH SCI, V2, P15, DOI DOI 10.1177/1403494812456637; KUJALA UM, 1994, MED SCI SPORT EXER, V26, P889; KUJALA UM, 1994, METABOLISM, V43, P1255, DOI 10.1016/0026-0495(94)90219-4; LAKKA TA, 1994, NEW ENGL J MED, V330, P1549, DOI 10.1056/NEJM199406023302201; Lauderdale DS, 1997, MED SCI SPORT EXER, V29, P1062, DOI 10.1097/00005768-199708000-00012; Lee I M, 1996, Exerc Sport Sci Rev, V24, P135; LEE IM, 1995, JAMA-J AM MED ASSOC, V273, P1179, DOI 10.1001/jama.273.15.1179; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; MORRIS JN, 1980, LANCET, V2, P1207; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PEKKANEN J, 1987, LANCET, V1, P1473, DOI 10.1016/S0140-6736(87)92218-5; PRESTON DL, 1993, EPICURE RELEASE 2 0; PYORALA K, 1974, PUBLICATIONS SOCIAL; ROSE G, 1968, WHO MONOGRAPH SERIES, V65; ROSE RJ, 1988, J PERS SOC PSYCHOL, V54, P161, DOI 10.1037/0022-3514.54.1.161; SARNA S, 1978, HUM HERED, V28, P241, DOI 10.1159/000152964; SHAPER AG, 1991, BRIT HEART J, V66, P384; SLATTERY ML, 1989, CIRCULATION, V79, P304, DOI 10.1161/01.CIR.79.2.304; Teppo L, 1975, Acta Pathol Microbiol Scand Suppl, VSUPPL 252, P1; *WHO, 1969, ICD8 WHO; WILSON PWF, 1986, AM HEART J, V111, P1177, DOI 10.1016/0002-8703(86)90022-0	35	429	437	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	1998	279	6					440	444		10.1001/jama.279.6.440	http://dx.doi.org/10.1001/jama.279.6.440			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV580	9466636	Bronze			2022-12-28	WOS:000071839800031
J	Alberts, B				Alberts, B			The cell as a collection of protein machines: Preparing the next generation of molecular biologists	CELL			English	Editorial Material							DNA		Natl Acad Sci, Washington, DC 20418 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	National Academies of Sciences, Engineering & Medicine; University of California System; University of California San Francisco	Alberts, B (corresponding author), Natl Acad Sci, 2101 Constitut Ave Nw, Washington, DC 20418 USA.							ALBERTS B, 1992, CELL, V68, P415, DOI 10.1016/0092-8674(92)90179-G; ALBERTS BM, 1984, COLD SPRING HARB SYM, V49, P1; ALBERTS BM, 1986, AM ZOOL, V26, P781; ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Meirovitch L., 1970, METHODS ANAL DYNAMIC; National Research Council Committee on Undergraduate Science Education, 1997, SCI TEACH REC; National Research Council (NRC), 1996, NAT SCI ED STAND; OGATA K, 1992, SYSTEM DYNAMICS; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Tjian R, 1996, PHILOS T R SOC B, V351, P491, DOI 10.1098/rstb.1996.0047; Wilson KS, 1998, CELL, V92, P337, DOI 10.1016/S0092-8674(00)80927-7; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	22	937	963	2	94	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 6	1998	92	3					291	294		10.1016/S0092-8674(00)80922-8	http://dx.doi.org/10.1016/S0092-8674(00)80922-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YX283	9476889	Bronze			2022-12-28	WOS:000072024700001
J	Kadonaga, JT				Kadonaga, JT			Eukaryotic transcription: An interlaced network of transcription factors and chromatin-modifying machines	CELL			English	Review							RNA-POLYMERASE-II; NUCLEOSOME REMODELING FACTOR; HISTONE-BINDING PROTEIN; DNA-REPLICATION INVITRO; YEAST SWI/SNF COMPLEX; ASSEMBLY FACTOR-1; HYPERSENSITIVE SITES; DROSOPHILA; ACTIVATION; DISRUPTION		Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Kadonaga, JT (corresponding author), Univ Calif San Diego, Dept Biol, 0347, La Jolla, CA 92093 USA.				NIGMS NIH HHS [GM46995] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; Gaudreau L, 1997, CELL, V89, P55, DOI 10.1016/S0092-8674(00)80182-8; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hartzog GA, 1997, CURR OPIN GENET DEV, V7, P192, DOI 10.1016/S0959-437X(97)80128-1; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Ito T, 1997, GENES CELLS, V2, P593, DOI 10.1046/j.1365-2443.1997.1500348.x; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Kamakaka RT, 1996, MOL CELL BIOL, V16, P810; Kaufman PD, 1996, CURR OPIN CELL BIOL, V8, P369, DOI 10.1016/S0955-0674(96)80012-3; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Lusser A, 1997, SCIENCE, V277, P88, DOI 10.1126/science.277.5322.88; MARTINEZBALBAS MA, 1997, IN PRESS P NATL ACAD; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pan GH, 1997, J BIOL CHEM, V272, P24563, DOI 10.1074/jbc.272.39.24563; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Pazin MJ, 1997, SCIENCE, V276, P809, DOI 10.1126/science.276.5313.809; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Roberts SM, 1997, GENETICS, V147, P451; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4	64	456	466	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 6	1998	92	3					307	313		10.1016/S0092-8674(00)80924-1	http://dx.doi.org/10.1016/S0092-8674(00)80924-1			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YX283	9476891	Bronze			2022-12-28	WOS:000072024700003
J	Kaufman, MJ; Levin, JM; Ross, MH; Lange, N; Rose, SL; Kukes, TJ; Mendelson, JH; Lukas, SE; Cohen, BM; Renshaw, PF				Kaufman, MJ; Levin, JM; Ross, MH; Lange, N; Rose, SL; Kukes, TJ; Mendelson, JH; Lukas, SE; Cohen, BM; Renshaw, PF			Cocaine-induced cerebral vasoconstriction detected in humans with magnetic resonance angiography	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY VASOCONSTRICTION; BLOOD-FLOW VELOCITY; CEREBROVASCULAR COMPLICATIONS; NEUROPSYCHOLOGICAL DEFICITS; INTRACRANIAL HEMORRHAGE; INTRAVENOUS COCAINE; ALKALOIDAL COCAINE; POLYDRUG USERS; METABOLITES; ABUSERS	Context.-Clinical observations and case reports suggest that there are important cerebrovascular complications of cocaine use, but no studies have documented a direct link. Objective.-To determine whether low-dose cocaine administration induces cerebral vasoconstriction in healthy cocaine users, Design.-Randomized controlled trial. Subjects.-Twenty-four healthy and neurologically normal men (mean age, 29 years) reporting median cocaine use of 8 lifetime exposures (range, 3 to >40). Intervention.-Double-blind intravenous administration of cocaine (0.4 or 0.2 mg/kg) or placebo, with cerebral magnetic resonance angiography performed at baseline and 20 minutes following infusion. Main Outcome Measure.-Cocaine-induced angiographic change indicative of vasoconstriction, as independently and concordantly rated by 2 reviewers blind to treatment condition. Results.-Cocaine-induced cerebral vasoconstriction in a dose-related fashion (P=.03), with angiograms indicative of vasoconstriction found in 5 of 8 and 3 of 9 subjects receiving 0.4- and 0.2-mg/kg cocaine, respectively, compared with 1 of 7 subjects administered placebo. Outcome stratification by frequency of self-reported lifetime cocaine use (3-10 times, 11-40 times, or >40 times) revealed a statistically stronger dose-related effect (P<.001), suggesting that greater lifetime cocaine use was associated with a greater likelihood of vasoconstriction. Conclusions.-Cocaine administration induced dose-related cerebral vasoconstriction on magnetic resonance angiograms. These changes occurred at low cocaine doses and in the absence of other risk factors, including polydrug abuse, hypertension, or cerebrovascular disease, Outcome stratification by prior cocaine use statistically strengthened the relationship between cocaine administration and vasoconstriction, suggesting that cocaine may have a cumulative residual effect in promoting cerebrovascular dysfunction.	Harvard Univ, McLean Hosp, Sch Med, Consolidated Dept Psychiat,Brain Imaging Ctr, Belmont, MA 02178 USA; Harvard Univ, McLean Hosp, Sch Med,Consolidated Dept Psychiat, Alcohol & Drug Abuse Res Ctr, Belmont, MA 02178 USA	Harvard University; McLean Hospital; Harvard University; McLean Hospital	Kaufman, MJ (corresponding author), Harvard Univ, McLean Hosp, Sch Med, Consolidated Dept Psychiat,Brain Imaging Ctr, 115 Mill St, Belmont, MA 02178 USA.		Leveque, Thellea/AAC-3294-2019; Renshaw, Perry/O-1384-2018; Cohen, Bruce M./AAZ-4986-2020	Kaufman, Marc/0000-0002-4383-1264	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009448] Funding Source: NIH RePORTER; NIDA NIH HHS [DA09448, DA00297, DA00329] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Aggarwal SK, 1996, NEUROLOGY, V46, P1741, DOI 10.1212/WNL.46.6.1741; Agresti A., 1990, CATEGORICAL DATA ANA, pXV; *AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P222; ARDILA A, 1991, INT J NEUROSCI, V57, P73, DOI 10.3109/00207459109150348; BERRY J, 1993, DRUG ALCOHOL DEPEN, V32, P231, DOI 10.1016/0376-8716(93)90087-7; BLACK KS, 1995, AM J NEURORADIOL, V16, P1650; BROGAN WC, 1992, ANN INTERN MED, V116, P556, DOI 10.7326/0003-4819-116-7-556; DARAS M, 1996, PUBL US DEP HHS, P43; DAVIS SM, 1992, STROKE, V23, P492, DOI 10.1161/01.STR.23.4.492; Evans SM, 1996, J PHARMACOL EXP THER, V279, P1345; FLEISS JL, 1973, EDUC PSYCHOL MEAS, V33, P613, DOI 10.1177/001316447303300309; FOLTIN RW, 1991, J PHARMACOL EXP THER, V257, P247; HE GQ, 1994, J PHARMACOL EXP THER, V268, P1532; HELLSTROM G, 1993, NEUROSURG REV, V16, P151, DOI 10.1007/BF00258249; Hoff AL, 1996, PSYCHIAT RES, V60, P167, DOI 10.1016/0165-1781(96)02758-8; HOLMAN BL, 1991, J NUCL MED, V32, P1206; Horikoshi Tohru, 1995, Neurologia Medico-Chirurgica, V35, P298, DOI 10.2176/nmc.35.298; JACOBS IG, 1989, RADIOLOGY, V170, P223, DOI 10.1148/radiology.170.1.2909100; KLONOFF DC, 1989, ARCH NEUROL-CHICAGO, V46, P989, DOI 10.1001/archneur.1989.00520450059019; KONZEN JP, 1995, STROKE, V26, P1114, DOI 10.1161/01.STR.26.6.1114; KURTH CD, 1993, J PHARMACOL EXP THER, V265, P587; LANGE RA, 1989, NEW ENGL J MED, V321, P1557, DOI 10.1056/NEJM198912073212301; LEVIN JM, 1995, J NUCL MED, V36, P1211; LEVINE SR, 1990, NEW ENGL J MED, V323, P699, DOI 10.1056/NEJM199009133231102; LEVINE SR, 1991, NEUROLOGY, V41, P1173, DOI 10.1212/WNL.41.8.1173; MADDEN JA, 1995, LIFE SCI, V56, P679, DOI 10.1016/0024-3205(94)00501-I; MADDEN JA, 1990, LIFE SCI, V47, P1109, DOI 10.1016/0024-3205(90)90169-R; MENA I, 1994, PUBLICATION US DEP H, P161; MODY CK, 1988, NEUROLOGY, V38, P1189, DOI 10.1212/WNL.38.8.1189; MOLITERNO DJ, 1994, NEW ENGL J MED, V330, P454, DOI 10.1056/NEJM199402173300702; Nolte KB, 1996, NEUROLOGY, V46, P1291, DOI 10.1212/WNL.46.5.1291; OMALLEY S, 1992, AM J DRUG ALCOHOL AB, V18, P131, DOI 10.3109/00952999208992826; Peterson P L, 1991, J Neuropsychiatry Clin Neurosci, V3, P143; SEKHON LHS, 1994, STROKE, V25, P1022, DOI 10.1161/01.STR.25.5.1022; STRICKLAND TL, 1993, J NEUROPSYCH CLIN N, V5, P419; *SUBST AB MENT HLT, 1996, 18 US DEP HHS; TEOH SK, 1993, J CLIN PSYCHOPHARM, V13, P87; VEREBEY K, 1988, PSYCHIAT ANN, V18, P513, DOI 10.3928/0048-5713-19880901-06; VOLKOW ND, 1988, BRIT J PSYCHIAT, V152, P641, DOI 10.1192/bjp.152.5.641; WAHLGREN NG, 1992, CEREBROVASC DIS, V2, P359, DOI 10.1159/000109067; WEISS RD, 1988, AM J MED, V85, P879	41	133	135	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					376	380		10.1001/jama.279.5.376	http://dx.doi.org/10.1001/jama.279.5.376			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459471	Bronze			2022-12-28	WOS:000071731300028
J	Atherton, ST				Atherton, ST			Involving clinical professionals in managing and planning services	BRITISH MEDICAL JOURNAL			English	Article									Whiston Hosp, St Helens Hosp, Prescot L35 5DR, Merseyside, England; Whiston Hosp, Knowsley Hosp, Prescot L35 5DR, Merseyside, England	Whiston Hospital; Whiston Hospital	Atherton, ST (corresponding author), Whiston Hosp, St Helens Hosp, Prescot L35 5DR, Merseyside, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 31	1998	316	7128					379	379		10.1136/bmj.316.7128.379	http://dx.doi.org/10.1136/bmj.316.7128.379			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487179	Green Published			2022-12-28	WOS:000071863900038
J	Oakeshott, P; Kerry, S; Hay, S; Hay, P				Oakeshott, P; Kerry, S; Hay, S; Hay, P			Opportunistic screening for chlamydial infection at time of cervical smear testing in general practice: prevalence study	BRITISH MEDICAL JOURNAL			English	Article									St George Hosp, Sch Med, Dept Gen Practice & Primary Care, London SW17 0RE, England; Univ London St Georges Hosp, Sch Med, Dept Genitourinary Med, London, England	St Georges University London; St Georges University London	Oakeshott, P (corresponding author), St George Hosp, Sch Med, Dept Gen Practice & Primary Care, Cranmer Terrace, London SW17 0RE, England.			Oakeshott, Pippa/0000-0003-2568-8211				[Anonymous], 1993, MMWR Recomm Rep, V42, P1; Johnson AM, 1996, BRIT MED J, V313, P1160, DOI 10.1136/bmj.313.7066.1160; PHILLIPS RS, 1987, ANN INTERN MED, V107, P188, DOI 10.7326/0003-4819-107-2-188; *PUBL HLTH LAB SER, 1995, GEN CHLAM TRACH INF; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103	5	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 31	1998	316	7128					351	352		10.1136/bmj.316.7128.351	http://dx.doi.org/10.1136/bmj.316.7128.351			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487170	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000071863900025
J	Bevan, M; Bancroft, I; Bent, E; Love, K; Goodman, H; Dean, C; Bergkamp, R; Dirkse, W; Van Staveren, M; Stiekema, W; Drost, L; Ridley, P; Hudson, SA; Patel, K; Murphy, G; Piffanelli, P; Wedler, H; Wedler, E; Wambutt, R; Weitzenegger, T; Pohl, TM; Terryn, N; Gielen, J; Villarroel, R; De Clerck, R; Van Montagu, M; Lecharny, A; Auborg, S; Gy, I; Kreis, M; Lao, N; Kavanagh, T; Hempel, S; Kotter, P; Entian, KD; Rieger, M; Schaeffer, M; Funk, B; Mueller-Auer, S; Silvey, M; James, R; Montfort, A; Pons, A; Puigdomenech, P; Douka, A; Voukelatou, E; Milioni, D; Hatzopoulos, P; Piravandi, E; Obermaier, B; Hilbert, H; Dusterhoft, A; Moores, T; Jones, JDG; Eneva, T; Palme, K; Benes, V; Rechman, S; Ansorge, W; Cooke, R; Berger, C; Delseny, M; Voet, M; Volckaert, G; Mewes, HW; Klosterman, S; Schueller, C; Chalwatzis, N				Bevan, M; Bancroft, I; Bent, E; Love, K; Goodman, H; Dean, C; Bergkamp, R; Dirkse, W; Van Staveren, M; Stiekema, W; Drost, L; Ridley, P; Hudson, SA; Patel, K; Murphy, G; Piffanelli, P; Wedler, H; Wedler, E; Wambutt, R; Weitzenegger, T; Pohl, TM; Terryn, N; Gielen, J; Villarroel, R; De Clerck, R; Van Montagu, M; Lecharny, A; Auborg, S; Gy, I; Kreis, M; Lao, N; Kavanagh, T; Hempel, S; Kotter, P; Entian, KD; Rieger, M; Schaeffer, M; Funk, B; Mueller-Auer, S; Silvey, M; James, R; Montfort, A; Pons, A; Puigdomenech, P; Douka, A; Voukelatou, E; Milioni, D; Hatzopoulos, P; Piravandi, E; Obermaier, B; Hilbert, H; Dusterhoft, A; Moores, T; Jones, JDG; Eneva, T; Palme, K; Benes, V; Rechman, S; Ansorge, W; Cooke, R; Berger, C; Delseny, M; Voet, M; Volckaert, G; Mewes, HW; Klosterman, S; Schueller, C; Chalwatzis, N		EU Arabidopsis Genome Project	Analysis of 1.9 Mb of contiguous sequence from chromosome 4 of Arabidopsis thaliana	NATURE			English	Article							PHYSICAL MAP; RETROTRANSPOSONS; ASSOCIATION; EXPRESSION; EVOLUTION; REGIONS; PROTEIN; GENOME; GENES	The plant Arabidopsis thaliana (Arabidopsis) has become an important model species for the study of many aspects of plant biology(1). The relatively small size of the nuclear genome and the availability of extensive physical maps of the five chromosomes(2-4) provide a feasible basis for initiating sequencing of the five chromosomes. The YAC (yeast artificial chromosome)-based physical map of chromosome 4 was used to construct a sequence-ready map of cosmid and BAC (bacterial artificial chromosome) clones covering a 1,9-megabase (Mb) contiguous region(5), and the sequence of this region is reported here. Analysis of the sequence revealed an average gene density of one gene every 4.8 kilobases (kb), and 54% of the predicted genes had significant similarity to known genes. Other interesting features were found, such as the sequence of a disease-resistance gene locus, the distribution of retroelements, the frequent occurrence of clustered gene families, and the sequence of several classes of genes not previously encountered in plants.	John Innes Ctr Plant Sci Res, Dept Mol Genet, Norwich NR4 7UJ, Norfolk, England; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02144 USA; DLO, Ctr Plant Breeding & Reprod Res, Dept Mol Biol, NL-6700 AA Wageningen, Netherlands; AGOWA GmbH, D-12489 Berlin, Germany; GATC GmbH, D-78467 Constance, Germany; Vlaams Interuniv Inst Biotechnol, Dept Genet, B-9000 Ghent, Belgium; Univ Paris 11, Inst Biotechnol Plantes, CNRS, ERS 569, F-91405 Orsay, France; Univ Dublin Trinity Coll, Dept Genet, Dublin 2, Ireland; SRD GmbH, D-61440 Oberursel, Germany; Genotype GmbH, D-69259 Wilhelmsfeld, Germany; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; CSIC, CID, E-08034 Barcelona, Spain; Agr Univ Athens, GR-11855 Athens, Greece; Medigene AG, D-82152 Planegg Martinsried, Germany; QIAGEN GmbH, D-4072 Hilden, Germany; John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UJ, Norfolk, England; Max Planck Gesell, Max Delbruck Lab, D-50829 Cologne, Germany; European Mol Biol Lab, D-69012 Heidelberg, Germany; Univ Perpignan, CNRS, UMR 5545, F-66860 Perpignan, France; Katholieke Univ Leuven, Lab Gene Technol, B-3001 Louvain, Belgium; Max Planck Inst Biochem, Martinsrieder Inst Prot Sequenzen, D-82152 Martinsried, Germany	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Trinity College Dublin; University of East Anglia; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion y Desarrollo Pascual Vila (CID-CSIC); Agricultural University of Athens; QIAGEN GmbH; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Max Planck Society; European Molecular Biology Laboratory (EMBL); Centre National de la Recherche Scientifique (CNRS); Universite Perpignan Via Domitia; KU Leuven; Max Planck Society	Bevan, M (corresponding author), John Innes Ctr Plant Sci Res, Dept Mol Genet, Norwich NR4 7UJ, Norfolk, England.	bevan@bbsrc.ac.uk	Ding, Cheng-Qiang/B-6287-2011; Entian, Karl-Dieter/D-3080-2011; Jones, Jonathan DG/J-5129-2012; Ansorge, Wilhelm/AAN-8780-2020; Monfort, Amparo/K-1356-2015; James, Richard/B-2252-2009; Palme, Klaus/A-9524-2013; Bancroft, Ian/AAH-3831-2020; Mewes, Hans-Werner/A-8204-2019	Jones, Jonathan DG/0000-0002-4953-261X; Monfort, Amparo/0000-0001-7106-7745; Palme, Klaus/0000-0002-2728-3835; Cooke, Richard/0000-0001-6335-1092; Mewes, Hans-Werner/0000-0002-9713-6398; Silvey, Mark/0000-0002-9096-3139; Bancroft, Ian/0000-0001-7707-1171; Benes, Vladimir/0000-0002-0352-2547				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BACK K, 1995, J BIOL CHEM, V270, P7375, DOI 10.1074/jbc.270.13.7375; Bancroft I., 1997, WEEDS WORLD, V4, P1; BENT E, IN PRESS PLANT J; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; KONIECZNY A, 1991, GENETICS, V127, P801; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Meyerowitz EM, 1997, GENETICS, V145, P5; MEYEROWITZ EM, 1994, ARABIDOPSIS; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Oppenheimer DG, 1997, P NATL ACAD SCI USA, V94, P6261, DOI 10.1073/pnas.94.12.6261; Parker JE, 1997, PLANT CELL, V9, P879, DOI 10.1105/tpc.9.6.879; Pear JR, 1996, P NATL ACAD SCI USA, V93, P12637, DOI 10.1073/pnas.93.22.12637; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; SanMiguel P, 1996, SCIENCE, V274, P765, DOI 10.1126/science.274.5288.765; Sato S, 1997, DNA Res, V4, P215, DOI 10.1093/dnares/4.3.215; Schmidt R, 1997, PLANT J, V11, P563, DOI 10.1046/j.1365-313X.1997.11030563.x; SCHMIDT R, 1995, SCIENCE, V270, P480, DOI 10.1126/science.270.5235.480; WESSLER SR, 1995, CURR OPIN GENET DEV, V5, P814, DOI 10.1016/0959-437X(95)80016-X; WHITE SE, 1994, P NATL ACAD SCI USA, V91, P11792, DOI 10.1073/pnas.91.25.11792; Zachgo EA, 1996, GENOME RES, V6, P19, DOI 10.1101/gr.6.1.19	29	458	877	3	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 29	1998	391	6666					485	488		10.1038/35140	http://dx.doi.org/10.1038/35140			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461215				2022-12-28	WOS:000071701800050
J	Li, HM; Lebedeva, MI; Llera, AS; Fields, BA; Brenner, MB; Mariuzza, RA				Li, HM; Lebedeva, MI; Llera, AS; Fields, BA; Brenner, MB; Mariuzza, RA			Structure of the V delta domain of a human gamma delta T-cell antigen receptor	NATURE			English	Article							CRYSTAL-STRUCTURE; MACROMOLECULAR CRYSTALLOGRAPHY; BETA-CHAIN; RECOGNITION; COMPLEX; ORIENTATION; HLA-A2	Antigen recognition by T lymphocytes is mediated by cell-surface glycoproteins known as T-cell antigen receptors (TCRs). These are composed of alpha and beta, or gamma and delta, polypeptide chains with variable (V) and constant (C) regions, In contrast to alpha beta TCRs, which recognize antigen only as peptide fragments bound to molecules of the major histocompatibility complex (MHC), gamma delta TCRs appear to recognize proteins directly, without antigen processing, and to recognize MHC molecules independently of the bound peptide(1-4). Moreover, small phosphate-containing non-peptide compounds have also been identified as ligands far certain gamma delta T cells(5,6). These studies indicate that antigen recognition by gamma delta TCRs may be fundamentally different from that by alpha beta TCRs. The three-dimensional structures of several ap TCRs and TCR fragments(7-10), and their complexes with peptide-MHC or superantigens(9-11), have been determined. Here we report the crystal structure of the V delta domain of a human gamma delta TCR at 1.9 Angstrom resolution. A comparison with antibody and alpha beta TCR V domains reveals that the framework structure of V delta more closely resembles that of VH than of V alpha; V beta or VL (where H and L refer to heavy and light chains), whereas the relative positions and conformations of its complementarity-determining regions (CDRs) share features of both V alpha and VH. These results provide the first direct evidence that gamma delta TCRs are structurally distinct from alpha beta TCRs and, together with the observation that thr CDR3 length distribution of TCR delta chains is similar to that of immunoglobulin heavy chains(12), are consistent with functional studies suggesting that recognition of certain antigens by gamma delta TCRs may resemble antigen recognition by antibodies(1-3).	Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Rheumatol & Immunol,Lymphocyte Biol Sect, Boston, MA 02115 USA	University of Sydney; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Mariuzza, RA (corresponding author), Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	mariuzza@indigo2.carb.nist.gov	Li, Hongmin/ABI-2439-2020; Llera, Andrea S/AAW-8116-2021	Li, Hongmin/0000-0002-8684-5308; Fields, Barry/0000-0003-0628-1328; Llera, Andrea/0000-0002-0089-0061				Arden Bernhard, 1995, Immunogenetics, V42, P455; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BIGBY M, 1993, J IMMUNOL, V151, P4465; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; Chien YH, 1996, ANNU REV IMMUNOL, V14, P511, DOI 10.1146/annurev.immunol.14.1.511; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; CORREA I, 1992, P NATL ACAD SCI USA, V89, P653, DOI 10.1073/pnas.89.2.653; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Crowley MP, 1997, J EXP MED, V185, P1223, DOI 10.1084/jem.185.7.1223; FAN ZC, 1992, J MOL BIOL, V228, P188, DOI 10.1016/0022-2836(92)90500-J; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; Fields BA, 1996, NATURE, V384, P188, DOI 10.1038/384188a0; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; HAAS W, 1993, ANNU REV IMMUNOL, V11, P637, DOI 10.1146/annurev.immunol.11.1.637; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; Kabat EA, 1991, SEQUENCES PROTEINS I; KRANGEL MS, 1990, J EXP MED, V172, P847, DOI 10.1084/jem.172.3.847; Lebedeva MI, 1996, PROTEIN SCI, V5, P2638, DOI 10.1002/pro.5560051226; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; ROCK EP, 1994, J EXP MED, V179, P323, DOI 10.1084/jem.179.1.323; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; SCIAMMAS R, 1994, J IMMUNOL, V152, P5392; SPITS H, 1990, J IMMUNOL, V144, P4156; TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0	30	110	114	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	1998	391	6666					502	506		10.1038/35172	http://dx.doi.org/10.1038/35172			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461220				2022-12-28	WOS:000071701800055
J	Lionetti, P; Battini, ML; Resti, M; Falcini, F				Lionetti, P; Battini, ML; Resti, M; Falcini, F			A 14-year-old girl with skin ulcers	LANCET			English	Article							PYODERMA-GANGRENOSUM; ULCERATIVE-COLITIS; CYCLOSPORINE		Univ Florence, Osped Meyer, Dipartimento Pediat, I-50132 Florence, Italy; Univ Florence, Osped Meyer, Dipartimento Dermatol, I-50132 Florence, Italy	University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER	Lionetti, P (corresponding author), Univ Florence, Osped Meyer, Dipartimento Pediat, I-50132 Florence, Italy.		Resti, Massimo/AAB-8756-2019; Lionetti, Paolo/AAC-2626-2019	Resti, Massimo/0000-0001-6350-1361; Lionetti, Paolo/0000-0001-8029-3904				DAS KM, 1992, J CLIN GASTROENTEROL, V15, P311, DOI 10.1097/00004836-199212000-00009; ELGART G, 1991, J AM ACAD DERMATOL, V24, P83, DOI 10.1016/0190-9622(91)70016-U; GRAHAM JA, 1994, PEDIATR DERMATOL, V11, P10, DOI 10.1111/j.1525-1470.1994.tb00065.x; LEVITT MD, 1991, BRIT J SURG, V78, P676, DOI 10.1002/bjs.1800780613; LICHTIGER S, 1994, NEW ENGL J MED, V330, P1841, DOI 10.1056/NEJM199406303302601	5	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 24	1998	351	9098					262	262		10.1016/S0140-6736(97)10416-0	http://dx.doi.org/10.1016/S0140-6736(97)10416-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU294	9457097				2022-12-28	WOS:000071702200013
J	Malviya, AN; Rogue, PJ				Malviya, AN; Rogue, PJ			"Tell me where is calcium bred": Clarifying the roles of nuclear calcium	CELL			English	Article; Proceedings Paper	1st European Conference on CA-2+ Signaling in the Cell Nucleus	OCT 04-08, 1997	BAIA PARAELLIOS, ITALY				RAT-LIVER NUCLEI; INOSITOL 1,4,5-TRISPHOSPHATE; CA2+ CONCENTRATION; CYTOSOLIC CA2+; PORE COMPLEX; DEPLETION; ENVELOPE; RECEPTOR; MEMBRANE; RELEASE		CNRS, Lab Biol Mol & Interact Cellulaires, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Malviya, AN (corresponding author), CNRS, Lab Biol Mol & Interact Cellulaires, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.							ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; Badminton MN, 1996, J BIOL CHEM, V271, P31210, DOI 10.1074/jbc.271.49.31210; BRINI M, 1993, EMBO J, V12, P4813, DOI 10.1002/j.1460-2075.1993.tb06170.x; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Fox JL, 1997, BIOCHEM J, V326, P491, DOI 10.1042/bj3260491; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Greber UF, 1997, EMBO J, V16, P5998, DOI 10.1093/emboj/16.19.5998; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HENNAGER DJ, 1995, J BIOL CHEM, V270, P4959, DOI 10.1074/jbc.270.10.4959; HIMPENS B, 1994, CELL CALCIUM, V16, P239, DOI 10.1016/0143-4160(94)90087-6; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; JONES DP, 1989, J BIOL CHEM, V264, P6398; KOPPLER P, 1993, J BIOL CHEM, V268, P26248; KULIKOVA O G, 1982, Biokhimiya, V47, P1216; LANINI L, 1992, J BIOL CHEM, V267, P11548; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; Lipp P, 1997, EMBO J, V16, P7166, DOI 10.1093/emboj/16.23.7166; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; Marin MC, 1996, ONCOGENE, V12, P2259; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; Pante N, 1996, CURR OPIN CELL BIOL, V8, P397, DOI 10.1016/S0955-0674(96)80016-0; PANTE N, 1994, CURR OPIN STRUC BIOL, V4, P187, DOI 10.1016/S0959-440X(94)90307-7; PerezTerzic C, 1996, SCIENCE, V273, P1875, DOI 10.1126/science.273.5283.1875; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROGUE P, 1990, J BIOL CHEM, V265, P4161; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; Santella L, 1997, CELL CALCIUM, V22, P11, DOI 10.1016/S0143-4160(97)90085-3; Santella L, 1997, FASEB J, V11, P1091, DOI 10.1096/fasebj.11.13.9367344; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; Subramanian K, 1997, CELL, V89, P963, DOI 10.1016/S0092-8674(00)80281-0; Vito P, 1997, J BIOL CHEM, V272, P28315, DOI 10.1074/jbc.272.45.28315	38	106	110	1	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 9	1998	92	1					17	23		10.1016/S0092-8674(00)80895-8	http://dx.doi.org/10.1016/S0092-8674(00)80895-8			7	Biochemistry & Molecular Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489696	Bronze			2022-12-28	WOS:000071473700004
J	Knudsen, EI				Knudsen, EI			Capacity for plasticity in the adult owl auditory system expanded by juvenile experience	SCIENCE			English	Article							CATS SUPERIOR COLLICULUS; OPTIC TECTUM; BARN OWL; RESPONSE PROPERTIES; GUINEA-PIG; SPACE; MAP; REPRESENTATION; DEPRIVATION; LANGUAGE	In the process of creating a multimodal map of space, auditory-visual neurons in the optic tectum establish associations between particular values of auditory spatial cues and locations in the visual field. In the barn owl, tectal neurons reveal these associations in the match between their tuning for interaural time differences (ITDs) and the locations of their visual receptive fields (VRFs). In young owls ITD-VRF associations can be adjusted by experience over a wide range, but the range of adjustment normally becomes quite restricted in adults. This normal range of adjustment in adults was greatly expanded in owls that had previously learned abnormal ITD-VRF associations as juveniles. Thus, the act of learning abnormal associations early in life leaves an enduring trace in this pathway that enables unusual functional connections to be reestablished, as needed, in adulthood, even when the associations represented by these connections have not been used for an extended period of time.	Stanford Univ, Sch Med, Dept Neurol, Stanford, CA 94305 USA	Stanford University	Knudsen, EI (corresponding author), Stanford Univ, Sch Med, Dept Neurol, 299 Campus Dr,Fairchild Bldg D259, Stanford, CA 94305 USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000155] Funding Source: NIH RePORTER; NIDCD NIH HHS [5 R01 DC0155-18] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BINNS KE, 1992, EUR J NEUROSCI, V4, P1333, DOI 10.1111/j.1460-9568.1992.tb00158.x; BRAINARD M, IN PRESS NEUROSCI; BRAINARD MS, 1995, J NEUROPHYSIOL, V73, P595, DOI 10.1152/jn.1995.73.2.595; BRAINARD MS, 1993, J NEUROSCI, V13, P4589; Feldman DE, 1997, J NEUROSCI, V17, P6820; Hess E. H., 1973, IMPRINTING EARLY EXP; HIRSCH JA, 1985, J NEUROPHYSIOL, V53, P726, DOI 10.1152/jn.1985.53.3.726; Immelmann K., 1972, Advances Study Behav, V4, P147, DOI 10.1016/S0065-3454(08)60009-1; KING AJ, 1983, J PHYSIOL-LONDON, V342, P361, DOI 10.1113/jphysiol.1983.sp014856; KING AJ, 1993, EXP PHYSIOL, V78, P559, DOI 10.1113/expphysiol.1993.sp003708; KING AJ, 1987, J NEUROPHYSIOL, V57, P596, DOI 10.1152/jn.1987.57.2.596; KNUDSEN EI, 1985, J NEUROSCI, V5, P3094; KNUDSEN EI, 1982, J NEUROSCI, V2, P1177; KNUDSEN EI, 1991, SCIENCE, V253, P85, DOI 10.1126/science.2063209; KONISHI M, 1985, ANNU REV NEUROSCI, V8, P125, DOI 10.1146/annurev.ne.08.030185.001013; KUHL PK, 1994, CURR OPIN NEUROBIOL, V4, P812, DOI 10.1016/0959-4388(94)90128-7; MIDDLEBROOKS JC, 1984, J NEUROSCI, V4, P2621; MOORE DR, 1993, PROG BRAIN RES, V97, P127; OLSEN JF, 1989, J NEUROSCI, V9, P2591; SCOTT JP, 1962, SCIENCE, V138, P949, DOI 10.1126/science.138.3544.949; TONG YC, 1988, J ACOUST SOC AM, V84, P951, DOI 10.1121/1.396664; Wallace MT, 1996, J NEUROPHYSIOL, V76, P1246, DOI 10.1152/jn.1996.76.2.1246; WISE LZ, 1985, J NEUROPHYSIOL, V54, P185, DOI 10.1152/jn.1985.54.2.185; WITHINGTONWRAY DJ, 1990, EUR J NEUROSCI, V2, P682, DOI 10.1111/j.1460-9568.1990.tb00458.x	24	122	122	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1531	1533		10.1126/science.279.5356.1531	http://dx.doi.org/10.1126/science.279.5356.1531			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488651				2022-12-28	WOS:000072372900064
J	Jablonski, D				Jablonski, D			Geographic variation in the molluscan recovery from the end-Cretaceous extinction	SCIENCE			English	Article							MARINE BIVALVE EXTINCTIONS; TERTIARY BOUNDARY; EAST TEXAS; PATTERNS; DIVERSIFICATION; RADIATION; LIFE	Biotic recovery patterns after the end-Cretaceous mass extinction differ among the molluscan faunas of the North American Gulf Coast, northern Europe, northern Africa, and Pakistan and northern India, In contrast to the Gulf Coast, the other three regions lack a rapid expansion and decline of "bloom taxa" and have lower proportions of invaders early in the recovery phase. The anomalous Gulf Coast patterns, distinct from extratropical Europe and the tropical regions, provide evidence for the biogeographic and macroevolutionary complexity of biotic recoveries and may have implications for present-day biotas.	Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA	University of Chicago	Jablonski, D (corresponding author), Univ Chicago, Dept Geophys Sci, 5734 S Ellis Ave, Chicago, IL 60637 USA.	djablons@midway.uchicago.edu						[Anonymous], 1988, GEOL JB B; BENTON MJ, 1995, SCIENCE, V268, P52, DOI 10.1126/science.7701342; Berggren W. A., 1995, GEOCHRONOLOGY TIME S, P129, DOI DOI 10.2110/PEC.95.04.0129; BERGGREN W. A., 1996, GEOLOGICAL SOC SPECI, V101, P309, DOI DOI 10.1144/GSL.SP.1996.101.01.17; BIGNOT G, 1997, NEUES JB GEOL PALAEO, V114; Butt A.A, 1992, GEOLOGIE MEDITERRANE, V19, DOI [https://doi.org/10.3406/geolm.1992.1479, DOI 10.3406/GEOLM.1992.1479]; CARLTON JT, 1993, SCIENCE, V261, P78, DOI 10.1126/science.261.5117.78; Case TJ, 1996, BIOL CONSERV, V78, P69, DOI 10.1016/0006-3207(96)00019-5; CASE TJ, 1991, BIOL J LINN SOC, V42, P239, DOI 10.1111/j.1095-8312.1991.tb00562.x; Dockery D.T. III, 1986, Palaios, V1, P582; Dockery III D. T., 1996, MISSISSIPPI GEOLOGY, V17, P1; ERWIN DH, 1987, EVOLUTION, V41, P1177, DOI 10.1111/j.1558-5646.1987.tb02459.x; FARIS M, 1997, NEUES JB GEOL PAL, P447; Fournie D., 1978, B CENT RECH EXPL, V2, P97; GIBSONTG, 1994, SOC BELGE GEOL B, V103, P237; GRADSTEIN FM, 1995, SEPM SPEC PUBL, V54, P95; GUIRAUD R, 1990, GEOL SURV ALGERIA ME, V3, P1; HANSEN TA, 1993, CRETACEOUS RES, V14, P685, DOI 10.1006/cres.1993.1047; HANSEN TA, 1988, PALEOBIOLOGY, V14, P37, DOI 10.1017/S0094837300011787; HANSEN TA, 1993, PALEOBIOLOGY, V19, P251, DOI 10.1017/S0094837300015906; Hantar G., 1990, GEOLOGY EGYPT, P293; JABLONSKI D, 1995, SCIENCE, V268, P389, DOI 10.1126/science.11536722; Jablonski David, 1995, P25; Johnson Claudia C., 1996, P231; Kassab A., 1995, Neues Jahrbuch fuer Geologie und Palaeontologie Abhandlungen, V196, P309; Keller G., 1996, CRETACEOUS TERTIARY, P63; Luger P., 1985, BERL GEOWISS ABH A, V63, P1; MACLEOD N, 1994, PALEOBIOLOGY, V20, P143, DOI 10.1017/S0094837300012653; MANCINI EA, 1991, J FORAMIN RES, V21, P48, DOI 10.2113/gsjfr.21.1.48; MEGERISI MF, 1980, B DEP GEOL RES MININ, V12, P1; Miller AI, 1996, PALEOBIOLOGY, V22, P304, DOI 10.1017/S0094837300016237; Moyle PB, 1996, ECOLOGY, V77, P1666, DOI 10.2307/2265770; Neal J. E., 1996, SPECIAL PUBLICATION, V101, P15, DOI DOI 10.1144/GSL.SP.1996.101.01.02; Ponder WF., 1988, MALACOLOGICAL REV S, V4, P288; Power ME, 1996, BIOSCIENCE, V46, P609, DOI 10.2307/1312990; RAUP DM, 1979, SCIENCE, V206, P217, DOI 10.1126/science.206.4415.217; RAUP DM, 1994, P NATL ACAD SCI USA, V91, P6758, DOI 10.1073/pnas.91.15.6758; RAUP DM, 1993, SCIENCE, V260, P971, DOI 10.1126/science.11537491; RAUP DM, 1991, ANAL PALEOBIOLOGY SH, V4, P207; Schultz PH, 1996, GEOLOGY, V24, P963, DOI 10.1130/0091-7613(1996)024<0963:CTCIAA>2.3.CO;2; Sepkoski J.J. Jr, 1986, P3; SEPKOSKI JJ, 1993, PALEOBIOLOGY, V19, P43, DOI 10.1017/S0094837300012306; Shah SMI., 1977, MEM GEOL SURV PAK, V12, P1; Sheehan P.M., 1990, MEMOIRS GEOLOGICAL S, V12, P181, DOI [DOI 10.1144/GSL.MEM.1990.012.01.16, 10.1144/GSL.MEM.1990.012.01.16]; Smith A.G., 1994, ATLAS MESOZOIC CENOZ; SOHL NF, 1987, J PALEONTOL, V61, P1085, DOI 10.1017/S0022336000029486; STROUGO A, 1995, MIDDLE E RES CTR AIN, V9, P1; STROUGO A, 1993, MIDDLE E RES CTR AIN, V7, P190; Toulmin L. D, 1977, GEOLOGICAL SURVEY AL, V13, P1; Vermeij GJ, 1996, BIOL CONSERV, V78, P3, DOI 10.1016/0006-3207(96)00013-4; VERMEIJ GJ, 1991, SCIENCE, V253, P1099, DOI 10.1126/science.253.5024.1099; Vinken R., 1988, GEOL JB A, V100, P1; Weiss Wolfgang, 1993, Zitteliana, V20, P223; Williamson MH, 1996, BIOL CONSERV, V78, P163, DOI 10.1016/0006-3207(96)00025-0; WINGARD GL, 1991, US GEOL SURV B, V1881, pD1	55	101	102	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	1998	279	5355					1327	1330		10.1126/science.279.5355.1327	http://dx.doi.org/10.1126/science.279.5355.1327			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478887				2022-12-28	WOS:000072251800042
J	Moliterno, AR; Hankins, WD; Spivak, JL				Moliterno, AR; Hankins, WD; Spivak, JL			Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							C-MPL LIGAND; COLONY-STIMULATING FACTOR; MULTIPOTENT STEM-CELL; HUMAN BLOOD-PLATELETS; TYROSINE PHOSPHORYLATION; ERYTHROPOIETIN RECEPTOR; MYELOPROLIFERATIVE DISORDERS; HEMATOPOIETIC PROGENITORS; ESSENTIAL THROMBOCYTHEMIA; GRANULOCYTE-MACROPHAGE	Background The cause of polycythemia vera, which originates from a multipotent hematopoietic progenitor cell, is unknown, Thrombopoietin is a hematopoietic growth factor that regulates the production of multipotent hematopoietic progenitor cells and platelets. To evaluate the possibility that an abnormality in thrombopoietin-mediated signal transduction might be involved in the pathogenesis of polycythemia vera, we examined thrombopoietin-induced tyrosine phosphorylation of proteins and the expression of the thrombopoietin receptor in platelets from patients with the disease. Methods Platelets were isolated from the blood of patients with polycythemia vera or other chronic myeloproliferative disorders and control subjects, The platelets were exposed to either thrombopoietin or thrombin and then lysed for analysis of tyrosine phosphorylation of platelet proteins and the expression of the proteins by means of immunoblotting, Expression of the thrombopoietin receptor (Mpl) by platelets and megakaryocytes was also assessed. Results Thrombopoietin-mediated tyrosine phosphorylation of proteins was impaired in platelets from 20 patients with polycythemia vera and 3 with idiopathic myelofibrosis, but not in 4 patients with essential thrombocytosis, 3 with chronic myelogenous leukemia, 6 with secondary erythrocytosis, 2 with iron-deficiency anemia, 4 with hemochromatosis, or 5 normal subjects. Thrombin-mediated tyrosine phosphorylation of proteins was intact in platelets from patients with polycythemia vera, and the tyrosine kinases and substrates involved in the process were present in normal amounts. However, expression of the platelet thrombopoietin receptor Mpl was markedly reduced or absent in 34 of 34 patients with polycythemia vera and in 13 of 14 patients with idiopathic myelofibrosis. Impaired thrombopoietin-induced tyrosine phosphorylation of proteins in patients with these two diseases was uniformly associated with markedly reduced expression of Mpl or the lack of its expression. In patients with polycythemia vera, reduced expression of Mpl by platelets was associated with reduced expression of Mpl by megakaryocytes. Conclusions Reduced expression of the thrombopoietin receptor Mpl is characteristic of polycythemia vera and idiopathic myelofibrosis, The abnormality appears to distinguish polycythemia vera from other forms of erythrocytosis. (C) 1998, Massachusetts Medical Society.	Johns Hopkins Univ, Sch Med, Dept Med, Div Hematol, Baltimore, MD 21205 USA	Johns Hopkins University	Spivak, JL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Hematol, Traylor 924,720 Rutland Ave, Baltimore, MD 21205 USA.				PHS HHS [R01-H158589] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMSON JW, 1976, NEW ENGL J MED, V295, P913, DOI 10.1056/NEJM197610212951702; BERGER S, 1973, CANCER RES, V33, P2683; BERK PD, 1986, SEMIN HEMATOL, V23, P132; CarverMoore K, 1996, BLOOD, V88, P803; CASHMAN J, 1983, BLOOD, V61, P876; Cocault L, 1996, BLOOD, V88, P1656; COOPER B, 1979, J CLIN INVEST, V64, P586, DOI 10.1172/JCI109497; CORREA PN, 1994, BLOOD, V83, P99; DAI CH, 1994, BRIT J HAEMATOL, V86, P12, DOI 10.1111/j.1365-2141.1994.tb03246.x; DAI CH, 1992, BLOOD, V80, P891; Damen JE, 1996, EXP HEMATOL, V24, P1455; DEBILI N, 1995, BLOOD, V85, P391, DOI 10.1182/blood.V85.2.391.bloodjournal852391; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; DEWOLF JTM, 1989, EXP HEMATOL, V17, P981; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; EMANUEL PD, 1992, BLOOD, V79, P3019; Emmons RVB, 1996, BLOOD, V87, P4068, DOI 10.1182/blood.V87.10.4068.bloodjournal87104068; EZUMI Y, 1995, FEBS LETT, V374, P48, DOI 10.1016/0014-5793(95)01072-M; FIALKOW PJ, 1980, BLOOD, V56, P70; FIALKOW PJ, 1981, BLOOD, V58, P916; HESS G, 1994, BRIT J HAEMATOL, V88, P794, DOI 10.1111/j.1365-2141.1994.tb05119.x; HOFFMAN R, 1995, HEMATOLOGY BASIC PRI; JACOBSON RJ, 1978, BLOOD, V51, P189; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; KAYWIN P, 1978, NEW ENGL J MED, V299, P505, DOI 10.1056/NEJM197809072991002; Ku H, 1996, BLOOD, V87, P4544, DOI 10.1182/blood.V87.11.4544.bloodjournal87114544; KUTER DJ, 1995, BLOOD, V85, P2720, DOI 10.1182/blood.V85.10.2720.bloodjournal85102720; LeCouedic JP, 1996, BLOOD, V87, P1502, DOI 10.1182/blood.V87.4.1502.bloodjournal8741502; Marsh JCW, 1996, BRIT J HAEMATOL, V95, P605, DOI 10.1046/j.1365-2141.1996.d01-1966.x; MEANS RT, 1989, J CLIN INVEST, V84, P1340, DOI 10.1172/JCI114303; MIYAKAWA Y, 1995, BLOOD, V86, P23, DOI 10.1182/blood.V86.1.23.bloodjournal86123; Miyakawa Y, 1996, BLOOD, V87, P439, DOI 10.1182/blood.V87.2.439.bloodjournal872439; Oda A, 1996, BLOOD, V88, P4304; PRCHAL JF, 1974, NEW ENGL J MED, V290, P1382; RAMAN BKS, 1989, AM J CLIN PATHOL, V91, P647, DOI 10.1093/ajcp/91.6.647; SCHAFER AI, 1982, NEW ENGL J MED, V306, P381, DOI 10.1056/NEJM198202183060701; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOKOL L, 1995, BLOOD, V86, P15, DOI 10.1182/blood.V86.1.15.bloodjournal86115; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TORTOLANI PJ, 1995, BLOOD, V85, P3444, DOI 10.1182/blood.V85.12.3444.bloodjournal85123444; Vignon I, 1992, P NATL ACAD SCI USA, V89, P5640; WENDLING F, 1986, VIROLOGY, V149, P242, DOI 10.1016/0042-6822(86)90125-X; YAN XQ, 1995, BLOOD, V86, P4025, DOI 10.1182/blood.V86.11.4025.bloodjournal86114025	44	237	249	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 26	1998	338	9					572	580		10.1056/NEJM199802263380903	http://dx.doi.org/10.1056/NEJM199802263380903			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY708	9475764				2022-12-28	WOS:000072175700003
J	Palermo, GD; Schlegel, PN; Sills, ES; Veeck, LL; Zaninovic, N; Menendez, S; Rosenwaks, Z				Palermo, GD; Schlegel, PN; Sills, ES; Veeck, LL; Zaninovic, N; Menendez, S; Rosenwaks, Z			Births after intracytoplasmic injection of sperm obtained by testicular extraction from men with nonmosaic Klinefelter's syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FERTILIZATION; SPERMATOZOA; PREGNANCIES		Cornell Univ, Med Ctr, New York Hosp, Dept Obstet & Gynecol,Ctr Reprod Med & Infertil, New York, NY 10021 USA; Cornell Univ, Med Ctr, New York Hosp, James Buchanan Brady Fdn,Dept Urol, New York, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital; Cornell University; NewYork-Presbyterian Hospital	Palermo, GD (corresponding author), Cornell Univ, Med Ctr, New York Hosp, Dept Obstet & Gynecol,Ctr Reprod Med & Infertil, HT-336,505 E 70th St, New York, NY 10021 USA.		Sills, E Scott/AAQ-8463-2020	Sills, E Scott/0000-0001-7334-1031				CHEVRET E, 1995, FERTIL STERIL S, V64, pS235; COZZI J, 1994, HUM GENET, V93, P32; Devroey P, 1996, HUM REPROD, V11, P1015; HARARI O, 1995, FERTIL STERIL, V63, P182, DOI 10.1016/S0015-0282(16)57315-4; HARGREAVE TB, 1994, MALE INFERTILITY, P116; Klinefelter HF, 1942, J CLIN ENDOCRINOL, V2, P615, DOI 10.1210/jcem-2-11-615; LUCIANI JM, 1970, ANN GENET-PARIS, V13, P249; PALERMO G, 1992, LANCET, V340, P17, DOI 10.1016/0140-6736(92)92425-F; Palermo GD, 1996, HUM REPROD, V11, P1023; Palermo GD, 1996, JAMA-J AM MED ASSOC, V276, P1893, DOI 10.1001/jama.276.23.1893; PALERMO GD, 1995, FERTIL STERIL, V63, P1231, DOI 10.1016/S0015-0282(16)57603-1; Paulsen C A, 1968, Recent Prog Horm Res, V24, P321; PAULSEN CA, 1992, GENETIC BASIS COMMON, P876; ROTHWELL NV, 1993, UNDERSTANDING GENETI, P101; Schlegel PN, 1997, UROLOGY, V49, P435, DOI 10.1016/S0090-4295(97)00032-0; Staessen C, 1996, HUM REPROD, V11, P1650; Tournaye H, 1996, HUM REPROD, V11, P1644	17	153	158	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 26	1998	338	9					588	590		10.1056/NEJM199802263380905	http://dx.doi.org/10.1056/NEJM199802263380905			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY708	9475766				2022-12-28	WOS:000072175700005
J	Belshe, RB				Belshe, RB			Influenza as a zoonosis: how likely is a pandemic?	LANCET			English	Editorial Material							VACCINES		St Louis Univ, Hlth Sci Ctr, Dept Internal Med, Div Infect Dis & Immunol, St Louis, MO 63110 USA	Saint Louis University	Belshe, RB (corresponding author), St Louis Univ, Hlth Sci Ctr, Dept Internal Med, Div Infect Dis & Immunol, St Louis, MO 63110 USA.							ALTMAN LK, 1998, NY TIMES        0106; *GOV HONG KONG, 1998, UPD INFL A H5N1; Gruber WC, 1996, J INFECT DIS, V173, P1313, DOI 10.1093/infdis/173.6.1313; LEE N, 1998, S CHINA MORNING 0209; POWERS DC, 1995, J INFECT DIS, V171, P1595, DOI 10.1093/infdis/171.6.1595; SCHOLTISSEK C, 1978, VIROLOGY, V89, P613, DOI 10.1016/0042-6822(78)90203-9; 1998, MORBID MORTAL WEEKLY, V46, P1245	7	14	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	1998	351	9101					460	461		10.1016/S0140-6736(98)22007-1	http://dx.doi.org/10.1016/S0140-6736(98)22007-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482431				2022-12-28	WOS:000072097700002
J	Vinkemeier, U; Moarefi, I; Darnell, JE; Kuriyan, J				Vinkemeier, U; Moarefi, I; Darnell, JE; Kuriyan, J			Structure of the amino-terminal protein interaction domain of STAT-4	SCIENCE			English	Article							DNA-BINDING; SIGNAL TRANSDUCERS; HORMONE INDUCTION; TRANSCRIPTION; INTERFERON; PROMOTER; SITES; ALPHA; GENE; ACTIVATORS	STATs (signal transducers and activators of transcription) are a family of transcription factors that are specifically activated to regulate gene transcription when cells encounter cytokines and growth factors, The crystal structure of an NH2-terminal conserved domain (N-domain) comprising the first 123 residues of STAT-4 was determined at 1.45 angstroms, The domain consists of eight helices that are assembled into a hook-like structure, The N-domain has been implicated in several protein-protein interactions affecting transcription, and it enables dimerized STAT molecules to polymerize and to bind DNA cooperatively, The structure shows that N-domains can interact through an extensive interface formed by polar interactions across one face of the hook. Mutagenesis of an invariant tryptophan residue at the heart of this interface abolished cooperative DNA binding by the full-length protein in vitro and reduced the transcriptional response after cytokine stimulation in vivo.	Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, Labs Mol Biophys, New York, NY 10021 USA; Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University; Rockefeller University; Rockefeller University	Kuriyan, J (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA.	kuriyan@rockvax.rockefeller.edu		Vinkemeier, Uwe/0000-0001-6924-1783	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI034420, R01AI032489, R01AI034420] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34420, AI32489] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; Brunger AT, 1992, XPLOR VERSION 3 1 MA; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Dajee M, 1996, MOL ENDOCRINOL, V10, P171, DOI 10.1210/me.10.2.171; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Leung S, 1996, SCIENCE, V273, P750, DOI 10.1126/science.273.5276.750; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; McKnight SL, 1996, GENE DEV, V10, P367, DOI 10.1101/gad.10.4.367; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; Mikita T, 1996, MOL CELL BIOL, V16, P5811; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shuai K, 1996, MOL CELL BIOL, V16, P4932; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; TIJAN R, 1994, CELL, V77, P5; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; VINKEMEIER U, UNPUB; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Xu D, 1997, J MOL BIOL, V265, P68, DOI 10.1006/jmbi.1996.0712; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yan RQ, 1996, P NATL ACAD SCI USA, V93, P5842, DOI 10.1073/pnas.93.12.5842; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	37	208	218	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1048	1052		10.1126/science.279.5353.1048	http://dx.doi.org/10.1126/science.279.5353.1048			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461439				2022-12-28	WOS:000072006400051
J	Omona, G; Matheson, KE				Omona, G; Matheson, KE			Uganda: stolen children, stolen lives	LANCET			English	Editorial Material									GUSCO, Gulu, Uganda; Redd Barna Norway, N-6230 Sykkylven, Norway		Omona, G (corresponding author), GUSCO, POB 216, Gulu, Uganda.							*SAV CHILDR ALL, 1996, 1 SAV CHILDR ALL INT	1	7	7	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					442	442		10.1016/S0140-6736(05)78383-5	http://dx.doi.org/10.1016/S0140-6736(05)78383-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482324				2022-12-28	WOS:000071982600048
J	Cockcroft, A; Williams, S				Cockcroft, A; Williams, S			Staff in the NHS	BRITISH MEDICAL JOURNAL			English	Article									Royal Free Hosp, Occupat Hlth & Safety Unit, London NW3 2QG, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Cockcroft, A (corresponding author), Royal Free Hosp, Occupat Hlth & Safety Unit, Pond St, London NW3 2QG, England.							Beecham L, 1997, BRIT MED J, V315, P1314; KARASEK R, 1990, J ORGAN BEHAV, V11, P171, DOI 10.1002/job.4030110302; *NHS EX, 1997, EL9773 NHS EX	3	1	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 31	1998	316	7128					381	381		10.1136/bmj.316.7128.381	http://dx.doi.org/10.1136/bmj.316.7128.381			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YV793	9487181	Green Published			2022-12-28	WOS:000071863900041
J	Gill, N				Gill, N			Promoting testing is no substitute for recognising risk - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, AIDS & Sexually Transmitted Dis Ctr, London NW9 5EQ, England	Public Health England	Gill, N (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, AIDS & Sexually Transmitted Dis Ctr, London NW9 5EQ, England.							*DEP HLTH, 1997, ANN REP UNL AN PREV; Gibb DM, 1997, AIDS, V11, pF53, DOI 10.1097/00002030-199707000-00001; Nicoll A, 1998, BRIT MED J, V316, P253, DOI 10.1136/bmj.316.7127.253	3	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					295	296		10.1136/bmj.316.7127.295	http://dx.doi.org/10.1136/bmj.316.7127.295			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472519	Green Published			2022-12-28	WOS:000071702100035
J	Ham, C				Ham, C			Financing the NHS	BRITISH MEDICAL JOURNAL			English	Article									Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England	University of Birmingham	Ham, C (corresponding author), Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England.							*SECR STAT HLTH, 1996, NAT HLTH SERV SERV A	1	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					212	213						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468692				2022-12-28	WOS:000071616400038
J	Egger, M; Schneider, M; Smith, GD				Egger, M; Schneider, M; Smith, GD			Meta-analysis - Spurious precision? Meta-analysis of observational studies	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; BETA-CAROTENE; BREAST-CANCER; BRITISH DOCTORS; BLOOD-PRESSURE; RISK; MORTALITY; SMOKING; METAANALYSIS; SUICIDE		Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ Bern, Dept Social & Prevent Med, CH-3012 Bern, Switzerland	University of Bristol; University of Bern	Egger, M (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	m.egger@bristol.ac.uk	Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Egger, Matthias/0000-0001-7462-5132				ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; Black N, 1996, BRIT MED J, V312, P1215; BLAIR A, 1990, SCAND J WORK ENV HEA, V16, P381, DOI 10.5271/sjweh.1767; BLOCK G, 1982, AM J EPIDEMIOL, V115, P492, DOI 10.1093/oxfordjournals.aje.a113331; BOYD NF, 1993, BRIT J CANCER, V68, P627, DOI 10.1038/bjc.1993.398; Brousson MA, 1996, CAN MED ASSOC J, V154, P307; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; CAPPUCCIO FP, 1995, AM J EPIDEMIOL, V142, P935, DOI 10.1093/oxfordjournals.aje.a117741; Chalmers I, 1995, SYSTEMATIC REV; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; DOLL R, 1980, BRIT MED J, V280, P967, DOI 10.1136/bmj.280.6219.967; Egger M, 1997, BMJ-BRIT MED J, V315, P1533, DOI 10.1136/bmj.315.7121.1533; Egger M, 1997, BMJ-BRIT MED J, V315, P1371, DOI 10.1136/bmj.315.7119.1371; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; EGGER M, 1997, BRIT MED J, V315, P61; FEINSTEIN AR, 1988, SCIENCE, V242, P1257, DOI 10.1126/science.3057627; Greenberg ER, 1996, JAMA-J AM MED ASSOC, V275, P699, DOI 10.1001/jama.275.9.699; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; HEMENWAY D, 1993, AM J PUBLIC HEALTH, V83, P249, DOI 10.2105/AJPH.83.2.249; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; HLATKY MA, 1991, STAT MED, V10, P647, DOI 10.1002/sim.4780100415; HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561; Hunter DJ, 1996, NEW ENGL J MED, V334, P356, DOI 10.1056/NEJM199602083340603; JHA P, 1995, ANN INTERN MED, V123, P860, DOI 10.7326/0003-4819-123-11-199512010-00009; LAZZARIN A, 1991, ARCH INTERN MED, V151, P2411, DOI 10.1001/archinte.151.12.2411; LEVEY BA, 1991, CLIN PHARMACOL THER, V50, P641, DOI 10.1038/clpt.1991.201; LEVITON A, 1994, ECOL FOOD NUTR, V31, P285, DOI 10.1080/03670244.1994.9991370; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; NELEMANS PJ, 1995, J CLIN EPIDEMIOL, V48, P1331, DOI 10.1016/0895-4356(95)00032-1; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; SHAPIRO S, 1994, AM J EPIDEMIOL, V140, P771, DOI 10.1093/oxfordjournals.aje.a117324; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; SMITH GD, 1992, LANCET, V340, P709; Smith GD, 1997, BMJ-BRIT MED J, V315, P1610, DOI 10.1136/bmj.315.7122.1610; TVERDAL A, 1993, J CLIN EPIDEMIOL, V46, P475, DOI 10.1016/0895-4356(93)90025-V; VARTIAINEN E, 1994, BRIT MED J, V309, P445, DOI 10.1136/bmj.309.6952.445; WILSON CWM, 1984, MED HYPOTHESES, V13, P99, DOI 10.1016/0306-9877(84)90133-6	42	740	753	1	34	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 10	1998	316	7125					140	144						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR408	9462324				2022-12-28	WOS:000071492300033
J	Shann, F; Duke, T				Shann, F; Duke, T			Micronutrients, measles, malaria, and mortality	LANCET			English	Article											Shann, F (corresponding author), ROYAL CHILDRENS HOSP,INTENS CARE UNIT,FLEMINGTON RD,PARKVILLE,VIC 3052,AUSTRALIA.		Shann, Frank/C-9510-2011					SAZAWAL S, 1995, NEW ENGL J MED, V333, P839, DOI 10.1056/NEJM199509283331304; SEMBA RD, 1995, LANCET, V345, P1330; THURSZ MR, 1995, NAT MED, V1, P374, DOI 10.1038/nm0495-374; WHITTLE HC, 1995, LANCET, V345, P1089, DOI 10.1016/S0140-6736(95)90822-6; 1995, B WORLD HEALTH ORGAN, V73, P735	5	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S16	S16		10.1016/0140-6736(95)90015-2	http://dx.doi.org/10.1016/0140-6736(95)90015-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454033	Bronze			2022-12-28	WOS:A1995TN12200016
J	McConnell, JD; Bruskewitz, R; Walsh, P; Andriole, G; Lieber, M; Holtgrewe, HL; Albertsen, P; Roehrborn, CG; Nickel, JC; Wang, DZ; Taylor, AM; Waldstreicher, J				McConnell, JD; Bruskewitz, R; Walsh, P; Andriole, G; Lieber, M; Holtgrewe, HL; Albertsen, P; Roehrborn, CG; Nickel, JC; Wang, DZ; Taylor, AM; Waldstreicher, J		Finasteride Long-Term Eff Saf Study Grp	The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Meeting of the Societe-Internationale-d-Urologie	SEP 08, 1997	MONTREAL, CANADA	Soc Int Urol			QUALITY-OF-LIFE; NATURAL-HISTORY; SYMPTOMS; EFFICACY; PLACEBO; TERAZOSIN; THERAPY; TRIAL	Background Finasteride is known to improve urinary symptoms in men with benign prostatic hyperplasia, but the extent to which the benefit is sustained and whether finasteride reduces the incidence of related events, including the need for surgery and the development of acute urinary retention, are not known. Methods In this double-blind, randomized, placebo-controlled trial, we studied 3040 men with moderate-to-severe urinary symptoms and enlarged prostate glands who were treated daily with 5 mg of finasteride or placebo for four years. Symptom scores (on a scale of 1 to 34), urinary flow rates, and the occurrence of outcome events were assessed every four months in 3016 men. Prostate volume was measured in a subgroup of the men. Complete data on outcomes were available for 2760 men. Results During the four-year study period, 152 of the 1503 men in the placebo group (10 percent) and 69 of the 1513 men in the finasteride group (5 percent) underwent surgery for benign prostatic hyperplasia (reduction in risk with finasteride, 55 percent; 95 percent confidence interval, 41 to 65 percent). Acute urinary retention developed in 99 men (7 percent) in the placebo group and 42 men (3 percent) in the finasteride group (reduction in risk with finasteride, 57 percent; 95 percent confidence interval, 40 to 69 percent). Among the men who completed the study, the mean decreases in the symptom score were 3.3 in the finasteride group and 1.3 in the placebo group (P<0.001). Treatment with finasteride also significantly improved urinary flow rates and reduced prostate volume (P<0.001). Conclusions Among men with symptoms of urinary obstruction and prostatic enlargement, treatment with finasteride for four years reduces symptoms and prostate volume, increases the urinary flow rate, and reduces the probability of surgery and acute urinary retention. (C) 1998, Massachusetts Medical Society.	Univ Texas, SW Med Ctr, Dept Urol J8 148, Dallas, TX 75235 USA; Univ Wisconsin, Ctr Clin Sci, Madison, WI USA; Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, Baltimore, MD 21205 USA; Washington Univ, Sch Med, St Louis, MO USA; Mayo Clin, Rochester, MN USA; Univ Connecticut, Ctr Hlth, Farmington, CT USA; Queens Univ, Kingston, ON, Canada; Merck Res Labs, Dept Biostat, Rahway, NJ USA; Merck Res Labs, Dept Clin Res Endocrinol & Metab, Rahway, NJ USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Wisconsin System; University of Wisconsin Madison; Johns Hopkins University; Johns Hopkins Medicine; Washington University (WUSTL); Mayo Clinic; University of Connecticut; Queens University - Canada; Merck & Company; Merck & Company	McConnell, JD (corresponding author), Univ Texas, SW Med Ctr, Dept Urol J8 148, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							Andersen JT, 1997, UROLOGY, V49, P839, DOI 10.1016/S0090-4295(97)00185-4; ANDERSEN JT, 1995, UROLOGY, V46, P631, DOI 10.1016/S0090-4295(99)80291-X; BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; Barry MJ, 1997, J UROLOGY, V157, P10, DOI 10.1016/S0022-5347(01)65267-4; BOLOGNESE JA, 1992, PROSTATE, V21, P247, DOI 10.1002/pros.2990210308; Boyle P, 1996, UROLOGY, V48, P398, DOI 10.1016/S0090-4295(96)00353-6; BYRNES CA, 1995, CLIN THER, V17, P956, DOI 10.1016/0149-2918(95)80073-5; DAWSON JD, 1993, BIOMETRICS, V49, P1022, DOI 10.2307/2532244; GIRMAN CJ, 1994, UROLOGY, V44, P825, DOI 10.1016/S0090-4295(94)80165-7; GORMLEY GJ, 1992, NEW ENGL J MED, V327, P1185, DOI 10.1056/NEJM199210223271701; GUESS HA, 1992, EPIDEMIOL REV, V14, P131, DOI 10.1093/oxfordjournals.epirev.a036083; HIGGINS PM, 1991, BRIT J UROL, V67, P365, DOI 10.1111/j.1464-410X.1991.tb15163.x; Jacobsen SJ, 1997, J UROLOGY, V158, P481, DOI 10.1016/S0022-5347(01)64508-7; JARDIN A, 1991, LANCET, V337, P1457, DOI 10.1016/0140-6736(91)93140-5; Lepor H, 1996, NEW ENGL J MED, V335, P533, DOI 10.1056/NEJM199608223350801; MALONE PR, 1988, BRIT J UROL, V61, P234, DOI 10.1111/j.1464-410X.1988.tb06386.x; MCCONNELL JD, 1992, J CLIN ENDOCR METAB, V74, P505, DOI 10.1210/jc.74.3.505; MCCONNELL JD, 1994, CLIN PRACT GUIDEL, V8, P7; McConnell John D., 1994, P33; MOCELLINI AI, 1993, PROSTATE, V22, P291; Nickel JC, 1996, CAN MED ASSOC J, V155, P1251; OESTERLING JE, 1995, NEW ENGL J MED, V332, P99, DOI 10.1056/NEJM199501123320207; Oesterling JE, 1996, PROSTATE, P67; POWELL PH, 1980, BRIT J UROL, V52, P520, DOI 10.1111/j.1464-410X.1980.tb03104.x; Roehrborn CG, 1997, UROLOGY, V49, P548, DOI 10.1016/S0090-4295(97)00031-9; Roehrborn CG, 1996, UROLOGY, V47, P159, DOI 10.1016/S0090-4295(99)80409-9; Somers William J., 1996, Journal of Urology, V155, p586A; WASSON JH, 1995, NEW ENGL J MED, V332, P75, DOI 10.1056/NEJM199501123320202	28	835	893	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 26	1998	338	9					557	563		10.1056/NEJM199802263380901	http://dx.doi.org/10.1056/NEJM199802263380901			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YY708	9475762	Bronze			2022-12-28	WOS:000072175700001
J	Delbanco, TL; Daley, J; Hartman, EE				Delbanco, TL; Daley, J; Hartman, EE			A 36-year-old woman recuperating from a stroke, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Alexander M, 1997, JAMA-J AM MED ASSOC, V277, P1970	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	1998	279	8					621	621		10.1001/jama.279.8.621	http://dx.doi.org/10.1001/jama.279.8.621			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX457	9486759				2022-12-28	WOS:000072041900040
J	Grignani, F; De Matteis, S; Nervi, C; Tomassoni, L; Gelmetti, V; Cioce, M; Fanelli, M; Ruthardt, M; Ferrara, FF; Zamir, I; Seiser, C; Grignani, F; Lazar, MA; Minucci, S; Pelicci, PG				Grignani, F; De Matteis, S; Nervi, C; Tomassoni, L; Gelmetti, V; Cioce, M; Fanelli, M; Ruthardt, M; Ferrara, FF; Zamir, I; Seiser, C; Grignani, F; Lazar, MA; Minucci, S; Pelicci, PG			Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia	NATURE			English	Article							RAR-ALPHA; LEUKEMIA FUSES; TRANSLOCATION; PML; DIFFERENTIATION; TRANSGLUTAMINASE; REPRESSION; T(15-17); DOMAINS; GENE	The transforming proteins of acute promyelocytic leukaemias (APL) are fusions of the promyelocytic leukaemia (PML) and the promyelocytic leukaemia zinc-finger (PLZF) proteins with retinoic acid receptor-alpha (RAR alpha)(1,2). These proteins retain the RAR alpha DNA- and retinoic acid (RA)-binding domains, and their ability to block haematopoietic differentiation depends on the RAR alpha DNA-binding domain(3-6), Thus RA-target genes are downstream effectors(7,8). However, treatment with RA induces differentiation of leukaemic blast cells and disease remission in PML-RAR alpha APLs, whereas PLZF-RAR alpha APLs are resistant to RA(1,2), Transcriptional regulation by RARs involves modifications of chromatin by histone deacetylases, which are recruited to RA-target genes by nuclear co-repressors(9,10), Here we show that both PML-RAR alpha and PLZF-RAR alpha fusion proteins recruit the nuclear co-repressor (N-CoR)-histone deacetylase complex through the RAR alpha CoR box, PLZF-RAR alpha contains a second, RA-resistant binding site in the PLZF amino-terminal region, High doses of RA release histone deacetylase activity from PML-RAR alpha, but not from PLZF-RAR alpha. Mutation of the N-CoR binding site abolishes the ability of PML-RAR alpha to block differentiation, whereas inhibition of histone deacetylase activity switches the transcriptional and biological effects of PLZF-RAR alpha from being an inhibitor to an activator of the RA signalling pathway, Therefore, recruitment of histone deacetylase is crucial to the transforming potential of APL fusion proteins, and the different effects of RA on the stability of the PML-RAR alpha and PLZF-RAR alpha co-repressor complexes determines the differential response of APLs to RA.	Univ Perugia, Ist Med Interna & Sci Oncol, I-06100 Perugia, Italy; Ist Super Sanita, Dept Haematol & Oncol, I-00161 Rome, Italy; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Vienna, Vienna Bioctr, Inst Mol Biol, Vienna, Austria; Univ Frankfurt, Dept Haematol, D-6000 Frankfurt, Germany	University of Perugia; Istituto Superiore di Sanita (ISS); IRCCS European Institute of Oncology (IEO); University of Pennsylvania; University of Pennsylvania; University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Goethe University Frankfurt	Pelicci, PG (corresponding author), Univ Perugia, Ist Med Interna & Sci Oncol, I-06100 Perugia, Italy.		Cioce, Mario/R-9734-2017; Lazar, Mitchell A/AAF-3738-2019; Grignani, Francesco/AAC-2565-2022; Fanelli, Mirco/F-2665-2011; Minucci, Saverio/J-9669-2012; Pelicci, Pier Giuseppe/AAL-6572-2020	Cioce, Mario/0000-0001-8129-6664; Fanelli, Mirco/0000-0002-9649-8661; NERVI, Clara/0000-0001-9341-0188; Ruthardt, Martin/0000-0003-1021-3811; Seiser, Christian/0000-0002-7046-9352; Grignani, Francesco/0000-0003-0563-5673				Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; Benedetti L, 1996, BLOOD, V87, P1939; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DHORDAIN P, 1997, P NATL ACAD SCI USA, V94, P10727; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Minucci S, 1996, CURR OPIN GENET DEV, V6, P567, DOI 10.1016/S0959-437X(96)80085-2; Nagy L, 1996, J BIOL CHEM, V271, P4355; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NERVI C, 1992, CANCER RES, V52, P3687; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; WARRELL RPJ, 1993, NEW ENGL J MED, V324, P177; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zamir I, 1996, MOL CELL BIOL, V16, P5458	29	884	925	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					815	818		10.1038/35901	http://dx.doi.org/10.1038/35901			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486655				2022-12-28	WOS:000072089500059
J	Claas, ECJ; Osterhaus, ADME; van Beek, R; De Jong, JC; Rimmelzwaan, GF; Senne, DA; Krauss, S; Shortridge, KF; Webster, RG				Claas, ECJ; Osterhaus, ADME; van Beek, R; De Jong, JC; Rimmelzwaan, GF; Senne, DA; Krauss, S; Shortridge, KF; Webster, RG			Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus	LANCET			English	Article							A-VIRUSES; RECEPTOR SPECIFICITY; HEMAGGLUTININ; SUBTYPES; ORIGIN; ACID; CONJUNCTIVITIS; NEURAMINIDASE; PANDEMICS; EVOLUTION	Background In May, 1997, a 3-year-old boy in Hong Kong was admitted to the hospital and subsequently died from influenza pneumonia, acute respiratory distress syndrome, Reye's syndrome, multiorgan failure, and disseminated intravascular coagulation. An influenza A H5N1 virus was isolated from a tracheal aspirate of the boy. Preceding this incident, avian influenza outbreaks of high mortality were reported from three chicken farms in Hong Kong, and the virus involved was also found to be of the H5 subtype. Methods We carried out an antigenic and molecular comparison of the influenza A H5N1 virus isolated from the boy with one of the viruses isolated from outbreaks of avian influenza by haemagglutination-inhibition and neuraminidase-inhibition assays and nucleotide sequence analysis. Findings Differences were observed in the antigenic reactivities of the viruses by the haemagglutination-inhibition assay, However, nucleotide sequence analysis of all gene segments revealed that the human virus A/Hong Kong/156/97 was genetically closely related to the avian A/chicken/Hong Kong/258/97. Interpretation Although direct contact between the sick child and affected chickens has not been established, our results suggest transmission of the virus from infected chickens to the child without intermediate mammalian host as a acting vessel". This event illustrates the intensive global influenza surveillance.	Erasmus Univ, Dept Virol, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, WHO, Natl Influenza Ctr, NL-3000 DR Rotterdam, Netherlands; Natl Inst Publ Hlth & Environm, Virol Lab, NL-3720 BA Bilthoven, Netherlands; Anim & Plant Hlth Serv, Natl Vet Serv Labs, USDA, Vet Serv, Ames, IA USA; Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Peoples R China; St Jude Childrens Res Hosp, Dept Virol & Mol Biol, Memphis, TN 38105 USA	Erasmus University Rotterdam; Erasmus University Rotterdam; World Health Organization; Netherlands National Institute for Public Health & the Environment; United States Department of Agriculture (USDA); University of Hong Kong; St Jude Children's Research Hospital	Claas, ECJ (corresponding author), Erasmus Univ, Dept Virol, POB 1738, NL-3000 DR Rotterdam, Netherlands.				NCI NIH HHS [CA-21765] Funding Source: Medline; NIAID NIH HHS [AI 08531, AI-29680] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029680] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AYMARDHENRY M, 1973, B WORLD HEALTH ORGAN, V48, P199; BEARE AS, 1991, ARCH VIROL, V119, P37, DOI 10.1007/BF01314321; BLOK J, 1982, BIOCHEMISTRY-US, V21, P4001, DOI 10.1021/bi00260a015; BOSCH FX, 1981, VIROLOGY, V113, P725, DOI 10.1016/0042-6822(81)90201-4; CASTRUCCI MR, 1993, VIROLOGY, V193, P503, DOI 10.1006/viro.1993.1155; CLAAS ECJ, 1993, J CLIN MICROBIOL, V31, P2218, DOI 10.1128/JCM.31.8.2218-2221.1993; CLAAS ECJ, 1994, VIROLOGY, V204, P453, DOI 10.1006/viro.1994.1553; CONNOR RJ, 1994, VIROLOGY, V205, P17, DOI 10.1006/viro.1994.1615; deJong JC, 1997, NATURE, V389, P554, DOI 10.1038/39218; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Garcia M, 1996, J GEN VIROL, V77, P1493, DOI 10.1099/0022-1317-77-7-1493; GORMAN OT, 1991, J VIROL, V65, P3704, DOI 10.1128/JVI.65.7.3704-3714.1991; KAWAOKA Y, 1987, VIROLOGY, V158, P218, DOI 10.1016/0042-6822(87)90256-X; KAWAOKA Y, 1989, J VIROL, V63, P4603, DOI 10.1128/JVI.63.11.4603-4608.1989; Kendal AP, 1982, CONCEPTS PROCEDURES; Kurtz J, 1996, LANCET, V348, P901, DOI 10.1016/S0140-6736(05)64783-6; MASUREL N, 1973, AM J EPIDEMIOL, V97, P44, DOI 10.1093/oxfordjournals.aje.a121483; NOBUSAWA E, 1991, VIROLOGY, V182, P475, DOI 10.1016/0042-6822(91)90588-3; ROGERS GN, 1983, VIROLOGY, V127, P361, DOI 10.1016/0042-6822(83)90150-2; Rohm C, 1996, VIROLOGY, V217, P508, DOI 10.1006/viro.1996.0145; SAITO T, 1994, VIROLOGY, V201, P277, DOI 10.1006/viro.1994.1292; SCHOLTISSEK C, 1988, NATURE, V331, P215, DOI 10.1038/331215a0; SCHOLTISSEK C, 1978, VIROLOGY, V87, P13, DOI 10.1016/0042-6822(78)90153-8; SCHOLTISSEK C, 1985, VIROLOGY, V147, P278; Senne DA, 1996, AVIAN DIS, V40, P425, DOI 10.2307/1592241; Shortridge K F, 1992, Semin Respir Infect, V7, P11; SHORTRIDGE KF, 1995, LANCET, V346, P1210, DOI 10.1016/S0140-6736(95)92906-1; Taubenberger JK, 1997, SCIENCE, V275, P1793, DOI 10.1126/science.275.5307.1793; WEBSTER RG, 1981, NEW ENGL J MED, V304, P911; WEBSTER RG, 1972, VIROLOGY, V48, P433, DOI 10.1016/0042-6822(72)90054-2; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; 1998, WKLY EPIDEMIOL REC, V73, P24	33	1087	1203	5	209	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	1998	351	9101					472	477		10.1016/S0140-6736(97)11212-0	http://dx.doi.org/10.1016/S0140-6736(97)11212-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482438				2022-12-28	WOS:000072097700010
J	Batchelor, AH; Piper, DE; de la Brousse, FC; McKnight, SL; Wolberger, C				Batchelor, AH; Piper, DE; de la Brousse, FC; McKnight, SL; Wolberger, C			The structure of GABP alpha/beta: An ETS domain ankyrin repeat heterodimer bound to DNA	SCIENCE			English	Article							CRYSTAL-STRUCTURE; MURINE ETS-1; PROTEIN; BINDING; COMPLEX; IDENTIFICATION; EXPRESSION; ACTIVATOR; ENHANCER; SUBUNITS	GA-binding protein (GABP) is a transcriptional regulator composed of two structurally dissimilar subunits. The alpha subunit contains a DNA-binding domain that is a member of the ETS family, whereas the beta subunit contains a series of ankyrin repeats. The crystal structure of a ternary complex containing a GABP alpha/beta ETS domain-ankyrin repeat heterodimer bound to DNA was determined at 2.15 angstrom resolution. The structure shows how an ETS domain protein can recruit a partner protein using both the ETS domain and a carboxyl-terminal extension and provides a view of an,extensive protein-protein interface formed by a set of ankyrin repeats. The structure also reveals how the GABP alpha ETS domain binds to its core GGA DNA-recognition motif.	Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Tularik, S San Francisco, CA 94080 USA; Univ Texas, SW Med Sch, Dept Biochem, Dallas, TX 75235 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wolberger, C (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA.	cynthia@groucho.med.jhmi.edu		Wolberger, Cynthia/0000-0001-8578-2969				BENNETT V, 1992, J BIOL CHEM, V267, P8703; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; DELABROUSSE FC, 1994, GENE DEV, V8, P1853, DOI 10.1101/gad.8.15.1853; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; GRAVES BJ, IN PRESS ADV CANC RE; GUNTHER CV, 1994, MOL CELL BIOL, V14, P7569, DOI 10.1128/MCB.14.11.7569; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WERNER MH, 1996, CELL, V87, P355	34	261	267	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	1998	279	5353					1037	1041		10.1126/science.279.5353.1037	http://dx.doi.org/10.1126/science.279.5353.1037			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461436				2022-12-28	WOS:000072006400048
J	Skoczenski, AM; Norcia, AM				Skoczenski, AM; Norcia, AM			Neural noise limitations on infant visual sensitivity	NATURE			English	Article							CONTRAST GAIN-CONTROL; EVOKED-POTENTIALS; VISION; SYSTEM; EXISTENCE; CELLS	Visual contrast sensitivity is poor in newborn human infants, but improves rapidly to approach adult levels by 8 months of age(1-5). During this period, infant sensitivity can be limited by physical factors affecting photon capture, such as eye size and photoreceptor density(6,7). Here we show that infant visual sensitivity is also limited by high levels of noise in the neural transduction process. Using a non-invasive electrophysiological measurements(8-10) and a visual noise titration technique(11), we have found that intrinsic neural noise in neonates is approximately nine times higher than in adults. As intrinsic neural noise decreases during infancy, contrast sensitivity improves proportionally, suggesting that neural noise places critical limits on contrast sensitivity throughout development. Moreover, contrast gain control(12), an inhibitory process that adjusts visual responses to changing stimulation, is in place and operating in infants as young as 6 weeks of age, in spite of high levels of neural noise and significant immaturities in contrast sensitivity, The contrast gain control that we observed in human neonates may serve as a building block for more complex forms of visual inhibition, which develop later in infancy(13).	Smith Kettlewell Eye Res Inst, San Francisco, CA 94115 USA	The Smith-Kettlewell Eye Research Institute	Skoczenski, AM (corresponding author), Smith Kettlewell Eye Res Inst, 2232 Webster St, San Francisco, CA 94115 USA.							ATKINSON J, 1974, NATURE, V247, P403, DOI 10.1038/247403a0; BANKS MS, 1988, J OPT SOC AM A, V5, P2059, DOI 10.1364/JOSAA.5.002059; BONDS AB, 1991, VISUAL NEUROSCI, V6, P239, DOI 10.1017/S0952523800006258; BURR DC, 1987, J PHYSIOL-LONDON, V389, P1; CAMPBELL FW, 1970, J PHYSIOL-LONDON, V207, P635, DOI 10.1113/jphysiol.1970.sp009085; GEISLER WS, 1992, VISION RES, V32, P1409, DOI 10.1016/0042-6989(92)90196-P; HARRIS L, 1976, NATURE, V264, P570, DOI 10.1038/264570a0; MORRONE MC, 1986, NATURE, V321, P235, DOI 10.1038/321235a0; NORCIA AM, 1989, VISION RES, V29, P627, DOI 10.1016/0042-6989(89)90048-5; NORCIA AM, 1985, IEEE ENG MED BIOL, V4, P26, DOI 10.1109/MEMB.1985.5006224; NORCIA AM, 1990, VISION RES, V30, P1475, DOI 10.1016/0042-6989(90)90028-J; NORCIA AM, 1988, INVEST OPHTH VIS SCI, V29, P44; OHZAWA I, 1985, J NEUROPHYSIOL, V54, P651, DOI 10.1152/jn.1985.54.3.651; Pelli D. G., 1990, VISION CODING EFFICI, P1; PELLI DG, 1991, VISION RES, V31, P1337, DOI 10.1016/0042-6989(91)90055-A; PIRCHIO M, 1978, BRAIN RES, V141, P179, DOI 10.1016/0006-8993(78)90628-5; Shannon E, 1996, VISION RES, V36, P67, DOI 10.1016/0042-6989(95)00053-3; SHAPLEY RM, 1978, J PHYSIOL-LONDON, V285, P275, DOI 10.1113/jphysiol.1978.sp012571; SKOCZENSKI AM, 1994, NEUR ABSTR, V20, P7; TANG Y, 1994, ELECTROENCEPHALOGR C, V96, P268; TYLER CW, 1979, INVEST OPHTH VIS SCI, V18, P703; VANNES FL, 1967, J OPT SOC AM, V57, P401, DOI 10.1364/JOSA.57.000401; VICTOR JD, 1991, ELECTROEN CLIN NEURO, V78, P378, DOI 10.1016/0013-4694(91)90099-P; WILSON HR, 1988, VISION RES, V28, P611; YUODELIS C, 1986, VISION RES, V26, P847, DOI 10.1016/0042-6989(86)90143-4	25	35	35	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 12	1998	391	6668					697	700		10.1038/35630	http://dx.doi.org/10.1038/35630			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490413				2022-12-28	WOS:000071982500053
J	Reardon, W				Reardon, W			Connexin 26 gene mutation and autosomal recessive deafness	LANCET			English	Editorial Material									Inst Child Hlth, Dept Clin Genet & Fetal Med, London WC1N 1EH, England	University of London; University College London	Reardon, W (corresponding author), Inst Child Hlth, Dept Clin Genet & Fetal Med, 30 Guilford St, London WC1N 1EH, England.			Reardon, Willie/0000-0001-7329-9179				Abdelhak S, 1997, NAT GENET, V15, P157, DOI 10.1038/ng0297-157; Carrasquillo MM, 1997, HUM MOL GENET, V6, P2163, DOI 10.1093/hmg/6.12.2163; Denoyelle F, 1997, HUM MOL GENET, V6, P2173, DOI 10.1093/hmg/6.12.2173; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Liu XZ, 1997, NAT GENET, V17, P268, DOI 10.1038/ng1197-268; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; Tyson J, 1997, HUM MOL GENET, V6, P2179, DOI 10.1093/hmg/6.12.2179; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; WILDE WR, 1853, PRACTICAL OBSERVATIO; Zelante L, 1997, HUM MOL GENET, V6, P1605, DOI 10.1093/hmg/6.9.1605	13	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					383	384		10.1016/S0140-6736(05)78347-1	http://dx.doi.org/10.1016/S0140-6736(05)78347-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482285				2022-12-28	WOS:000071982600003
J	Welsh, J				Welsh, J			The medicine that kills	LANCET			English	Editorial Material									Amnesty Int British Sect, Med Off, London WC1X 8DJ, England		Welsh, J (corresponding author), Amnesty Int British Sect, Med Off, 1 Easton St, London WC1X 8DJ, England.							*AM MED ASS, 1996, COD MED ETH CURR OP; *AMN INT, 1998, 500198 ACT AMN INT; Welsh J, 1996, LANCET, V348, P63, DOI 10.1016/S0140-6736(05)64393-0	3	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					441	441		10.1016/S0140-6736(05)78382-3	http://dx.doi.org/10.1016/S0140-6736(05)78382-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482322				2022-12-28	WOS:000071982600046
J	Solomon, AJ; Gersh, BJ				Solomon, AJ; Gersh, BJ			Management of chronic stable angina: Medical therapy, percutaneous transluminal coronary angioplasty, and coronary artery bypass graft surgery - Lessons from the randomized trials	ANNALS OF INTERNAL MEDICINE			English	Review							FOLLOW-UP; BALLOON ANGIOPLASTY; DISEASE; SURVIVAL; REVASCULARIZATION; METAANALYSIS; STENOSIS; PECTORIS; CASS; RISK	Purpose: To review the available data on the treatment of chronic stable angina and formulate a rational approach to the use of pharmacologic therapy, percutaneous transluminal coronary angioplasty (PTCA), and coronary artery bypass graft surgery (CABG). Data Sources: A MEDLINE search of the English-language literature published between 1976 and 1996 and the bibliographies of relevant articles. Study Selection: Primary research articles, meta-analyses, and meeting abstracts related to the management of chronic stable angina with an emphasis on comparisons of medical therapy, PTCA, and CABG. Data Extraction: Three trials comparing medical therapy with PTCA, seven trials comparing medical therapy with CABG, and nine trials comparing PTCA with CABG. Data Synthesis: Low-risk patients with single-vessel coronary artery disease and normal left ventricular function had greater alleviation of symptoms with PTCA than with medical treatment; mortality rates and rates of myocardial infarction were unchanged. In high-risk patients (risk was defined by severity of ischemia, number of diseased vessels, and presence of left ventricular dysfunction), improvement of survival was greater with CABG than with medical therapy. In moderate-risk patients with multivessel coronary artery disease (most had two-vessel disease and normal left ventricular function), PTCA and CABG produced equivalent mortality rates and rates of myocardial infarction. Conclusions: In low-risk patients, a strategy of initial medical therapy is reasonable. In moderate-risk patients, PTCA and CABG produce similar mortality rates and rates of myocardial infarction but PTCA-treated patients require more revascularization procedures. In high-risk patients, CABG is usually preferred.	Georgetown Univ, Med Ctr, Div Cardiol, Washington, DC 20007 USA	Georgetown University	Solomon, AJ (corresponding author), Georgetown Univ, Med Ctr, Div Cardiol, Room M4222,3800 Reservoir Rd NW, Washington, DC 20007 USA.							ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; Alderman EL, 1996, NEW ENGL J MED, V335, P217; [Anonymous], 1995, Lancet, V346, P1179; BELL MR, 1992, CIRCULATION, V86, P446, DOI 10.1161/01.CIR.86.2.446; Campeau L, 1997, NEW ENGL J MED, V336, P153; DETRE KM, 1984, NEW ENGL J MED, V311, P1333; FAXON DP, 1995, CIRCULATION S1, V92, P76; FISHER L, 1983, CIRCULATION, V68, P939, DOI 10.1161/01.CIR.68.5.939; GOLDMAN S, 1991, CIRCULATION, V84, P520, DOI 10.1161/01.CIR.84.2.520; GOY JJ, 1994, LANCET, V343, P1449, DOI 10.1016/S0140-6736(94)92579-8; GRUNTZIG AR, 1979, NEW ENGL J MED, V301, P61, DOI 10.1056/NEJM197907123010201; HAMM CW, 1994, NEW ENGL J MED, V331, P1037, DOI 10.1056/NEJM199410203311601; HAMPTON JR, 1993, LANCET, V341, P573; Hlatky MA, 1997, NEW ENGL J MED, V336, P92, DOI 10.1056/NEJM199701093360203; HUEB WA, 1995, J AM COLL CARDIOL, V26, P1600, DOI 10.1016/0735-1097(95)00384-3; KAISER GC, 1985, J THORAC CARDIOV SUR, V89, P513; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; Lytle B W, 1991, Cardiovasc Clin, V21, P265; MARK DB, 1994, CIRCULATION, V89, P2015, DOI 10.1161/01.CIR.89.5.2015; MURPHY ML, 1977, NEW ENGL J MED, V297, P621, DOI 10.1056/NEJM197709222971201; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; PEARSON T, 1994, CIRCULATION, V90, P3125, DOI 10.1161/01.CIR.90.6.3125; PEDERSEN TR, 1994, LANCET, V344, P1383; POCOCK SJ, 1995, LANCET, V346, P1184, DOI 10.1016/S0140-6736(95)92897-9; RODRIGUEZ A, 1993, J AM COLL CARDIOL, V22, P1060, DOI 10.1016/0735-1097(93)90416-X; SALOMON NW, 1983, J THORAC CARDIOV SUR, V85, P264; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SIEVERS B, 1993, CIRCULATION, V88, P297; SIM I, 1995, AM J CARDIOL, V76, P1025, DOI 10.1016/S0002-9149(99)80289-6; STRAUSS WE, 1995, CIRCULATION, V92, P1710, DOI 10.1161/01.CIR.92.7.1710; VARNAUSKAS E, 1980, LANCET, V2, P491; VARNAUSKAS E, 1988, NEW ENGL J MED, V319, P332, DOI 10.1056/NEJM198808113190603; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	35	62	62	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1998	128	3					216	223		10.7326/0003-4819-128-3-199802010-00008	http://dx.doi.org/10.7326/0003-4819-128-3-199802010-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU303	9454530				2022-12-28	WOS:000071703200007
J	Elston, T; Wang, HY; Oster, G				Elston, T; Wang, HY; Oster, G			Energy transduction in ATP synthase	NATURE			English	Article							SUBUNIT-C; MECHANISM; ROTATION; F-0; F1-ATPASE	Mitochondria, bacteria and chloroplasts use the free energy stored in transmembrane ion gradients to manufacture ATP by the action of ATP synthase. This enzyme consists of two principal domains. The asymmetric membrane-spanning F-0 portion contains the proton channel, and the soluble F-1 portion contains three catalytic sites which cooperate in the synthetic reactions(1). The Bow of protons through F-0 is thought to generate a torque which is transmitted to F-1 by an asymmetric shaft, the coiled-coil gamma-subunit. This acts as a rotating 'cam' within F-1, sequentially releasing ATPs from the three active sites(1-5). The free-energy difference across the inner membrane of mitochondria and bacteria is sufficient to produce three ATPs per twelve protons passing through the motor. It has been suggested that this protonmotive force biases the rotor's diffusion so that F-0 constitutes a rotary motor turning the gamma shaft(6). Here we show that biased diffusion, augmented by electrostatic forces, does indeed generate sufficient torque to account for ATP production. Moreover, the motor's reversibility-supplying torque from ATP hydrolysis in F-1 converts the motor into an efficient proton pump(7)-can also be explained by our model.	Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Oster, G (corresponding author), Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AssadiPorter FM, 1995, BIOCHEMISTRY-US, V34, P16186, DOI 10.1021/bi00049a034; BERG HC, 1983, MOBILITY RECOGNITION, P485; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; Dimroth P, 1997, BBA-BIOENERGETICS, V1318, P11, DOI 10.1016/S0005-2728(96)00127-2; DMITRIEV OY, 1995, EUR J BIOCHEM, V233, P478, DOI 10.1111/j.1432-1033.1995.478_2.x; Elston TC, 1997, BIOPHYS J, V73, P703, DOI 10.1016/S0006-3495(97)78104-9; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; Fillingame RH, 1995, BIOCHEM SOC T, V23, P760, DOI 10.1042/bst0230760; Fillingame RH, 1997, J EXP BIOL, V200, P217; FILLINGAME RH, 1990, BACTERIA, P345; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; Groth G, 1997, FEBS LETT, V410, P117, DOI 10.1016/S0014-5793(97)00529-2; HARRISON M, 1997, J MEMBRANE BIOL, V14, P1; Howitt SM, 1996, J BIOENERG BIOMEMBR, V28, P415, DOI 10.1007/BF02113983; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; KHAN S, 1983, CELL, V32, P913, DOI 10.1016/0092-8674(83)90076-4; MEISTER M, 1989, BIOPHYS J, V55, P905, DOI 10.1016/S0006-3495(89)82889-9; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; RISKEN H, 1989, FOKKERPLANCK EQUATIO; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; VALIYAVEETIL F, IN PRESS J BIOL CHEM; VIK SB, 1994, J BIOL CHEM, V269, P30364; Yasuda R, 1997, J BIOENERG BIOMEMBR, V29, P207, DOI 10.1023/A:1022449708449	25	431	440	4	89	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 29	1998	391	6666					510	513		10.1038/35185	http://dx.doi.org/10.1038/35185			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461222				2022-12-28	WOS:000071701800057
J	Richardson, MP; Sharland, M				Richardson, MP; Sharland, M			Late diagnosis of paediatric HIV infection in south west London	BRITISH MEDICAL JOURNAL			English	Article									St George Hosp, Paediat Infect Dis Unit, London SW17 0QT, England	St Georges University London	Richardson, MP (corresponding author), St George Hosp, Paediat Infect Dis Unit, London SW17 0QT, England.			sharland, mike/0000-0001-8626-8291				[Anonymous], 1994, MMWR Recomm Rep, V43, P1; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; *DEP HLTH, 1996, UNL AN HIV PREV MON; *DEP HLTH, 1997, GUID OFF VOL NAM HIV; GALLI L, 1995, AIDS, V9, P455, DOI 10.1097/00002030-199509050-00007	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					271	272		10.1136/bmj.316.7127.271	http://dx.doi.org/10.1136/bmj.316.7127.271			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472509	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000071702100023
J	Wyatt, JC				Wyatt, JC			Will improved clinical information help realise the new NHS?	BRITISH MEDICAL JOURNAL			English	Article									UCL, Sch Publ Policy, Hlth Knowledge Management Programme, London WC1E 7HN, England	University of London; University College London	Wyatt, JC (corresponding author), UCL, Sch Publ Policy, Hlth Knowledge Management Programme, London WC1E 7HN, England.		Wyatt, Jeremy/F-8160-2010	Wyatt, Jeremy/0000-0001-7008-1473				*AUD COMM, 1995, YOUR INF STUD INF MA; FRASER V, 1997, NHS GUIDELINES LIB I; Friedman C.P., 1997, EVALUATION METHODS M, P41; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Smith R, 1997, BRIT MED J, V314, P1495, DOI 10.1136/bmj.314.7093.1495; WYATT JC, 1994, LANCET, V344, P1682, DOI 10.1016/S0140-6736(94)90463-4	6	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					298	299		10.1136/bmj.316.7127.298	http://dx.doi.org/10.1136/bmj.316.7127.298			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472522	Green Published			2022-12-28	WOS:000071702100039
J	Kliewer, SA; Moore, JT; Wade, L; Staudinger, JL; Watson, MA; Jones, SA; McKee, DD; Oliver, BB; Willson, TM; Zetterstrom, RH; Perlmann, T; Lehmann, JM				Kliewer, SA; Moore, JT; Wade, L; Staudinger, JL; Watson, MA; Jones, SA; McKee, DD; Oliver, BB; Willson, TM; Zetterstrom, RH; Perlmann, T; Lehmann, JM			An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway	CELL			English	Article							HIGH-AFFINITY LIGAND; 9-CIS RETINOIC ACID; RAT-LIVER; THYROID-HORMONE; HEPATIC CYTOCHROME-P-450; MESSENGER-RNA; INDUCTION; PREGNENOLONE-16-ALPHA-CARBONITRILE; SUPERFAMILY; SEQUENCE	Steroid hormones exert profound effects on differentiation, development, and homeostasis in higher eukaryotes through interactions with nuclear receptors. We describe a novel orphan nuclear receptor, termed the pregnane X receptor (PXR), that is activated by naturally occurring steroids such as pregnenolone and progesterone, and synthetic glucocorticoids and antiglucocorticoids. PXR exists as two isoforms, PXR.1 and PXR.2, that are differentially activated by steroids. Notably, PXR.1 is efficaciously activated by pregnenolone 16 alpha-carbonitrile, a glucocorticoid receptor antagonist that induces the expression of the CYP3A family of steroid hydroxylases and modulates sterol and bile acid biosynthesis in vivo. Our results provide evidence for the existence of a novel steroid hormone signaling pathway with potential implications in the regulation of steroid hormone and sterol homeostasis.	Glaxo Wellcome Res & Dev Ltd, Dept Mol Endocrinol, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Res & Dev Ltd, Dept Mol Sci, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Res & Dev Ltd, Dept Med Chem, Res Triangle Pk, NC 27709 USA; Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden; Ludwig Inst Canc Res, Stockholm Branch, S-17177 Stockholm, Sweden	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Karolinska Institutet; Ludwig Institute for Cancer Research	Kliewer, SA (corresponding author), Glaxo Wellcome Res & Dev Ltd, Dept Mol Endocrinol, Res Triangle Pk, NC 27709 USA.		feinstein, doug/M-9414-2019	Zetterstrom, Rolf/0000-0002-3016-0019				BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Cadepond F, 1997, ANNU REV MED, V48, P129; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; DAGERLIND A, 1992, HISTOCHEMISTRY, V98, P39, DOI 10.1007/BF00716936; Debri K, 1995, BIOCHEM PHARMACOL, V50, P2047, DOI 10.1016/0006-2952(95)02107-8; ELSHOURBAGY NA, 1980, J BIOL CHEM, V255, P1279; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GONZALEZ FJ, 1985, J BIOL CHEM, V260, P7435; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HARDWICK JP, 1983, J BIOL CHEM, V258, P182; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HEUMAN DM, 1982, MOL PHARMACOL, V21, P753; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HUSS JM, 1996, J BIOL CHEM, V93, P4666; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JUCHAU MR, 1990, LIFE SCI, V47, P2385, DOI 10.1016/0024-3205(90)90482-7; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kourounakis P, 1977, Adv Steroid Biochem Pharmacol, V6, P35; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5790; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MASON JI, 1978, STEROIDS, V31, P849, DOI 10.1016/S0039-128X(78)80048-8; MIYATA M, 1995, ARCH BIOCHEM BIOPHYS, V318, P71, DOI 10.1006/abbi.1995.1206; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; ONATE SA, 1995, SCIENCE, V270, P1354; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PUNJABI U, 1983, J STEROID BIOCHEM, V19, P1481, DOI 10.1016/0022-4731(83)91124-X; QUATTROCHI LC, 1995, J BIOL CHEM, V270, P28917, DOI 10.1074/jbc.270.48.28917; SCHUETZ EG, 1984, J BIOL CHEM, V259, P1999; SCHUETZ EG, 1984, J BIOL CHEM, V259, P2007; SELYE H, 1971, J PHARM SCI, V60, P1, DOI 10.1002/jps.2600600102; SMITH DP, 1994, NUCLEIC ACIDS RES, V22, P66, DOI 10.1093/nar/22.1.66; STAHLBERG D, 1995, LIPIDS, V30, P361, DOI 10.1007/BF02536046; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Tietz NW, 1995, CLIN GUIDE LAB TESTS, V3rd; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TURLEY SD, 1984, GASTROENTEROLOGY, V87, P284; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; von Bergmann K, 1975, Naunyn Schmiedebergs Arch Pharmacol, V287, P33; WICHMANN U, 1984, EXP CLIN ENDOCRINOL, V83, P283, DOI 10.1055/s-0029-1210342; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909	57	1254	1319	1	45	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 9	1998	92	1					73	82		10.1016/S0092-8674(00)80900-9	http://dx.doi.org/10.1016/S0092-8674(00)80900-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489701	Bronze			2022-12-28	WOS:000071473700009
J	Skegg, DCG				Skegg, DCG			Breast cancer: Progress at last?	LANCET			English	Article											Skegg, DCG (corresponding author), UNIV OTAGO,DEPT PREVENT & SOCIAL MED,POB 913,DUNEDIN,NEW ZEALAND.							Berrino F, 1995, IARC SCI PUBLICATION, V132; BONADONNA G, 1995, NEW ENGL J MED, V332, P901, DOI 10.1056/NEJM199504063321401; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; NEWCOMB PA, 1995, JNCI-J NATL CANCER I, V87, P1067, DOI 10.1093/jnci/87.14.1067; SAINSBURY JRC, 1995, BRIT J CANCER, V71, P1275	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S15	S15						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454032				2022-12-28	WOS:A1995TN12200015
J	Parry, S; Strauss, JF				Parry, S; Strauss, JF			Mechanisms of disease - Premature rupture of the fetal membranes.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN CHORIONIC CELLS; HUMAN AMNION; MATRIX METALLOPROTEINASE-9; HORMONAL-REGULATION; TISSUE INHIBITOR; PRETERM DELIVERY; COLLAGEN CONTENT; UTERINE CERVIX; PREGNANCY; BIRTH		Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Div Maternal Fetal Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Parry, S (corresponding author), Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, Dept Obstet & Gynecol, 2000 Courtyard Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.				NICHD NIH HHS [HD-34612, HD-07305] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034612] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALGER LS, 1988, AM J OBSTET GYNECOL, V159, P397, DOI 10.1016/S0002-9378(88)80093-0; ALZAID NS, 1980, BRIT J OBSTET GYNAEC, V87, P227, DOI 10.1111/j.1471-0528.1980.tb04524.x; *AM COLL OBST GYN, 1988, ACOG TECHN B, V115; ARTAL R, 1979, OBSTET GYNECOL, V53, P608; BARABAS AP, 1966, BRIT MED J, V2, P682, DOI 10.1136/bmj.2.5515.682; BRYANTGREENWOOD GD, 1995, AM J OBSTET GYNECOL, V172, P63, DOI 10.1016/0002-9378(95)90085-3; Casey ML, 1996, BIOL REPROD, V55, P1253, DOI 10.1095/biolreprod55.6.1253; Casey ML, 1997, J CLIN ENDOCR METAB, V82, P167, DOI 10.1210/jc.82.1.167; DALE PO, 1989, EUR J OBSTET GYN R B, V30, P257, DOI 10.1016/0028-2243(89)90010-5; DIBATTISTA JA, 1995, J RHEUMATOL, V22, P123; DRAPER D, 1995, AM J OBSTET GYNECOL, V173, P1506, DOI 10.1016/0002-9378(95)90640-1; Draper D, 1995, Infect Dis Obstet Gynecol, V2, P267, DOI 10.1155/S1064744995000160; EKWO EE, 1993, INT J EPIDEMIOL, V22, P495, DOI 10.1093/ije/22.3.495; ElMaradny E, 1996, AM J OBSTET GYNECOL, V174, P843, DOI 10.1016/S0002-9378(96)70311-3; Goldenberg RL, 1996, OBSTET GYNECOL, V87, P643, DOI 10.1016/0029-7844(96)00035-X; Goldenberg RL, 1997, AM J OBSTET GYNECOL, V177, P8, DOI 10.1016/S0002-9378(97)70430-7; GULLER S, 1995, J CLIN ENDOCR METAB, V80, P2244, DOI 10.1210/jc.80.7.2244; HEDDLESTON L, 1993, AM J OBSTET GYNECOL, V169, P708, DOI 10.1016/0002-9378(93)90647-2; Jackson GM, 1996, J SOC GYNECOL INVEST, V3, P85, DOI 10.1016/1071-5576(95)00050-X; JOHNSON JWC, 1981, OBSTET GYNECOL, V57, P547; KANAYAMA N, 1985, AM J OBSTET GYNECOL, V153, P899, DOI 10.1016/0002-9378(85)90703-3; KATSURA M, 1989, FEBS LETT, V244, P315, DOI 10.1016/0014-5793(89)80553-8; LAVERY JP, 1982, OBSTET GYNECOL, V60, P87; LEI HQ, 1995, BIOL REPROD, V53, P339, DOI 10.1095/biolreprod53.2.339; Lei HQ, 1996, J CLIN INVEST, V98, P1971, DOI 10.1172/JCI119001; Leppert P. C., 1996, J SOC GYNECOL INVEST, V3, p128A; LOCKWOOD CJ, 1991, NEW ENGL J MED, V325, P669, DOI 10.1056/NEJM199109053251001; MALAK TM, 1993, PLACENTA, V14, P385, DOI 10.1016/S0143-4004(05)80460-6; MALAK TM, 1994, BRIT J OBSTET GYNAEC, V101, P375, DOI 10.1111/j.1471-0528.1994.tb11908.x; MCDONALD HM, 1994, J INFECT DIS, V170, P724, DOI 10.1093/infdis/170.3.724; MCGREGOR JA, 1987, OBSTET GYNECOL, V69, P167; MCGREGOR JA, 1990, OBSTET GYNECOL, V76, P124; MCGREGOR JA, 1995, AM J OBSTET GYNECOL, V173, P157, DOI 10.1016/0002-9378(95)90184-1; Offenbacher S, 1996, J PERIODONTOL, V67, P1103, DOI 10.1902/jop.1996.67.10s.1103; Qin XJ, 1997, BIOL REPROD, V56, P812, DOI 10.1095/biolreprod56.4.812; RAJABI M, 1991, ENDOCRINOLOGY, V128, P863, DOI 10.1210/endo-128-2-863; RAJABI MR, 1988, AM J OBSTET GYNECOL, V159, P971, DOI 10.1016/S0002-9378(88)80183-2; REGAN JA, 1981, AM J OBSTET GYNECOL, V141, P184, DOI 10.1016/S0002-9378(16)32589-3; SATO T, 1991, BIOCHEM J, V275, P645, DOI 10.1042/bj2750645; SCHECTMAN G, 1989, AM J PUBLIC HEALTH, V79, P158, DOI 10.2105/AJPH.79.2.158; Schmidt W, 1992, Adv Anat Embryol Cell Biol, V127, P1; SKINNER SJM, 1981, OBSTET GYNECOL, V57, P487; SLATER DM, 1995, AM J OBSTET GYNECOL, V172, P77, DOI 10.1016/0002-9378(95)90087-X; SO T, 1992, BIOL REPROD, V46, P772, DOI 10.1095/biolreprod46.5.772; TJUGUM J, 1985, EUR J OBSTET GYN R B, V19, P137, DOI 10.1016/0028-2243(85)90147-9; VADILLOORTEGA F, 1995, AM J PATHOL, V146, P148; VadilloOrtega F, 1996, AM J OBSTET GYNECOL, V174, P1371, DOI 10.1016/S0002-9378(96)70687-7; VADILLOORTEGA F, 1990, OBSTET GYNECOL, V75, P84; Vettraino IM, 1996, PLACENTA, V17, P557, DOI 10.1016/S0143-4004(96)80072-5; WIDEMAN GL, 1964, AM J OBSTET GYNECOL, V88, P592, DOI 10.1016/0002-9378(64)90885-3	50	536	556	0	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1998	338	10					663	670		10.1056/NEJM199803053381006	http://dx.doi.org/10.1056/NEJM199803053381006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ844	9486996				2022-12-28	WOS:000072299700006
J	Gunn, MD; Ngo, VN; Ansel, KM; Ekland, EH; Cyster, JG; Williams, LT				Gunn, MD; Ngo, VN; Ansel, KM; Ekland, EH; Cyster, JG; Williams, LT			A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1	NATURE			English	Article							FOLLICULAR DENDRITIC CELLS; MAREKS-DISEASE; CHEMOATTRACTANT; EXPRESSION; GENOME; LIGAND; SDF-1; BLR1	Secondary lymphoid organs (spleen, lymph nodes and Peyer's patches) are divided into compartments, such as B-cell zones (follicles) and T-cell zones, which provide specialized environments for specific steps of the immune response. Migration of lymphocyte subsets into these compartments is essential for normal immune function, yet the molecular cues guiding this cellular traffic are poorly defined. Chemokines constitute a family of chemotactic cytokines that have been shown to direct the migration of leukocytes during inflammation(1,2) and which may be involved in the constitutive homing of lymphocytes into follicles and T-cell zones(3-8). Here we describe a novel chemokine, B-lymphocyte chemoattractant (BLC), that is strongly expressed in the follicles of Peyer's patches, the spleen and lymph nodes. BLC strongly attracts B lymphocytes while promoting migration of only small numbers of T cells and macrophages, and therefore is the first chemokine to be identified that is selective towards B cells. An orphan chemokine receptor, Burkitt's lymphoma receptor 1 (BLR-1), has been found to be required for B-cell migration into lymphoid follicles(6). We show that BLC stimulates calcium influx into, and chemotaxis of, cells transfected with BLR-1. Our results indicate that BLC functions as a BLR-1 ligand and may guide B lymphocytes to follicles in secondary lymphoid organs.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94143 USA; Chiron Corp, Emeryville, CA 94608 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Novartis	Cyster, JG (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.			Gunn, Michael/0000-0003-4602-0667; Ngo, Vu/0000-0002-9501-6990	NATIONAL CANCER INSTITUTE [U19CA179512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM125089] Funding Source: NIH RePORTER; NCI NIH HHS [U19 CA179512] Funding Source: Medline; NIGMS NIH HHS [R01 GM125089] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bacon KB, 1996, INT ARCH ALLERGY IMM, V109, P97, DOI 10.1159/000237207; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BARELLA L, 1995, BIOCHEM J, V309, P773, DOI 10.1042/bj3090773; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CALNEK BW, 1986, CRC CR REV MICROBIOL, V12, P293; CYSTER JG, 1995, J EXP MED, V182, P581, DOI 10.1084/jem.182.2.581; FORSTER R, 1994, BLOOD, V84, P830; FORSTER R, 1996, CELL, V87, P1; Goodnow CC, 1997, CURR BIOL, V7, pR219, DOI 10.1016/S0960-9822(06)00105-9; GOODNOW CC, 1995, ADV IMMUNOL, V59, P279, DOI 10.1016/S0065-2776(08)60633-1; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; Imai Y, 1996, PATHOL INT, V46, P807, DOI 10.1111/j.1440-1827.1996.tb03555.x; ISHII K, 1993, J BIOL CHEM, V268, P9780; KAISER E, 1993, EUR J IMMUNOL, V23, P2532, DOI 10.1002/eji.1830231023; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LYONS AB, 1995, EUR J IMMUNOL, V25, P3165, DOI 10.1002/eji.1830251127; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; Nagira M, 1997, J BIOL CHEM, V272, P19518, DOI 10.1074/jbc.272.31.19518; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PENG Q, 1995, VIROLOGY, V213, P590, DOI 10.1006/viro.1995.0031; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Ueda H, 1997, J BIOL CHEM, V272, P24966, DOI 10.1074/jbc.272.40.24966; YOSHIDA K, 1994, EUR J IMMUNOL, V24, P464, DOI 10.1002/eji.1830240230	28	626	654	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					799	803		10.1038/35876	http://dx.doi.org/10.1038/35876			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486651				2022-12-28	WOS:000072089500055
J	Hodis, HN; Mack, WJ; LaBree, L; Selzer, RH; Liu, CR; Liu, CH; Azen, SP				Hodis, HN; Mack, WJ; LaBree, L; Selzer, RH; Liu, CR; Liu, CH; Azen, SP			The role of carotid arterial intima-media thickness in predicting clinical coronary events	ANNALS OF INTERNAL MEDICINE			English	Article						coronary arteriosclerosis; carotid artery diseases; ultrasonography; tunica intima; tunica media	COLESTIPOL-NIACIN THERAPY; CHOLESTEROL-LOWERING ATHEROSCLEROSIS; FOLLOW-UP; BYPASS GRAFTS; DISEASE; ULTRASOUND; RISK; PROGRESSION; LOVASTATIN; REDUCTION	Background: Carotid arterial intima-media thickness is used as a noninvasive surrogate end point to measure progression of atherosclerosis, but its relation to coronary events has not been fully explored. Objective: To determine whether carotid arterial intimamedia thickness predicts coronary events. Design: Long-term follow-up (average, 8.8 years) of a previously assembled cohort of persons who completed the 2-year Cholesterol Lowering Atherosclerosis Study, a randomized arterial imaging trial designed to study the effects of lipid lowering on progression of atherosclerosis. Setting: University-based ultrasonography laboratory. Patients: 146 men 40 to 59 years of age who had previously had coronary artery bypass graft surgery. Measurements: Preintrusive atherosclerosis in the common carotid artery was evaluated every 6 months with B-mode ultrasonography, and intrusive atherosclerosis in the coronary arteries was evaluated at baseline and at 2 years with quantitative coronary angiography. After the trial, the incidences of coronary events (nonfatal acute myocardial infarction, coronary death, and coronary artery revascularization) were documented. Results: For each 0.03-mm increase per year in carotid arterial intima-media thickness, the relative risk for non-fatal myocardial infarction or coronary death was 2.2 (95 % Cl, 1.4 to 3.6) and the relative risk for any coronary event was 3.1 (Cl, 2.1 to 4.5) (P < 0.001). Absolute intima-media thickness was also related to risk for clinical coronary events (P < 0.02). Absolute thickness and progression in thickness predicted risk for coronary events beyond that predicted by coronary arterial measures of atherosclerosis and lipid measurements (P < 0.001). Conclusion: Noninvasive B-mode ultrasonographic measurement of progression of intima-media thickness in the distal common carotid artery is a useful surrogate end point for clinical coronary events.	Univ So Calif, Sch Med, Div Cardiol, Atherosclerosis Res Unit, Los Angeles, CA 90033 USA; CALTECH, Pasadena, CA 91125 USA; Univ So Calif, Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA	University of Southern California; California Institute of Technology; University of Southern California	Hodis, HN (corresponding author), Univ So Calif, Sch Med, Div Cardiol, Atherosclerosis Res Unit, 2250 Alcazar St,CSC 132, Los Angeles, CA 90033 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL054532, R01HL049885] Funding Source: NIH RePORTER; NHLBI NIH HHS [R03-HL-54532, R01-HL-49885] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Azen SP, 1996, CIRCULATION, V93, P34, DOI 10.1161/01.CIR.93.1.34; Belcaro G, 1996, ARTERIOSCL THROM VAS, V16, P851, DOI 10.1161/01.ATV.16.7.851; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; BLANKENHORN DH, 1990, CIRCULATION, V81, P470, DOI 10.1161/01.CIR.81.2.470; BLANKENHORN DH, 1994, ARTERIOSCLER THROMB, V14, P177, DOI 10.1161/01.ATV.14.2.177; BLANKENHORN DH, 1993, CIRCULATION, V88, P20, DOI 10.1161/01.CIR.88.1.20; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BLANKENHORN DH, 1991, CIRCULATION, V83, P438, DOI 10.1161/01.CIR.83.2.438; BLANKENHORN DH, 1987, CONTROL CLIN TRIALS, V8, P354, DOI 10.1016/0197-2456(87)90156-5; BUCHWALD H, 1992, JAMA-J AM MED ASSOC, V268, P1429, DOI 10.1001/jama.268.11.1429; CASHINHEMPHILL L, 1990, JAMA-J AM MED ASSOC, V264, P3013, DOI 10.1001/jama.264.23.3013; CASTEILL WP, 1993, BRIT HEART J, V59, pS70; CROUSE JR, 1995, CIRCULATION, V92, P1141, DOI 10.1161/01.CIR.92.5.1141; GEROULAKOS G, 1994, J INTERN MED, V235, P431, DOI 10.1111/j.1365-2796.1994.tb01099.x; GEROULAKOS G, 1994, EUR HEART J, V15, P781, DOI 10.1093/oxfordjournals.eurheartj.a060585; HODIS HN, 1994, CIRCULATION, V90, P42, DOI 10.1161/01.CIR.90.1.42; Hodis HN, 1996, ANN INTERN MED, V124, P548, DOI 10.7326/0003-4819-124-6-199603150-00002; HODIS HN, 1994, J INTERN MED, V236, P111, DOI 10.1111/j.1365-2796.1994.tb01272.x; MACK WJ, 1993, STROKE, V24, P1779, DOI 10.1161/01.STR.24.12.1779; MCISAAC WJ, 1991, J GEN INTERN MED, V6, P518, DOI 10.1007/BF02598220; MITCHELL JR, 1962, BRIT MED J, P1293; PERSSON J, 1994, ARTERIOSCLER THROMB, V14, P261, DOI 10.1161/01.ATV.14.2.261; SALONEN JT, 1991, ARTERIOSCLER THROMB, V11, P1245, DOI 10.1161/01.ATV.11.5.1245; SELZER RH, 1989, J CLIN INVEST, V83, P520, DOI 10.1172/JCI113913; SELZER RH, 1994, ATHEROSCLEROSIS, V111, P1, DOI 10.1016/0021-9150(94)90186-4; WATERS D, 1993, CIRCULATION, V87, P1067, DOI 10.1161/01.CIR.87.4.1067; WISSLER RW, 1993, ARTERIOSCLER THROMB, V13, P1291	27	999	1034	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1998	128	4					262	+		10.7326/0003-4819-128-4-199802150-00002	http://dx.doi.org/10.7326/0003-4819-128-4-199802150-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX170	9471928				2022-12-28	WOS:000072013400002
J	Rosler, A; Witztum, E				Rosler, A; Witztum, E			Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CYPROTERONE-ACETATE; LHRH AGONIST; TESTOSTERONE REPLACEMENT; CHILD MOLESTERS; SEXUAL-BEHAVIOR; HYPOGONADAL MEN; BONE-DENSITY; OFFENDERS; DISORDERS; ANDROGENS	Background Men with deviant sexual behavior, or paraphilia, are usually treated with psychotherapy, antidepressant drugs, progestins, and antiandrogens, but these treatments are often ineffective. Selective inhibition of pituitary-gonadal function with a long-acting agonist analogue of gonadotropin-releasing hormone may abolish the deviant sexual behavior by reducing testosterone secretion. Methods In an uncontrolled observational study, we treated 30 men (mean age, 32 years) with severe long-standing paraphilia (25 with pedophilia and 5 with other types of abnormal behavior) with monthly injections of 3.75 mg of triptorelin and supportive psychotherapy for 8 to 42 months. The efficacy of therapy was evaluated monthly by the Intensity of Sexual Desire and Symptoms Scale and yearly by the Three Main Complaints questionnaire. Results All the men had a decrease in the number of deviant sexual fantasies and desires, from a mean (+/- SD) of 48 +/- 10 per week before therapy to zero during therapy (P<0.001), and a decrease in the number of incidents of abnormal sexual behavior (from 5 +/- 2 per month to zero, P<0.001) while receiving triptorelin. These effects were evident after 3 to 10 months of therapy (P<0.001) and persisted in all 24 men who continued therapy for at least 1 year. The men's mean serum testosterone concentration fell from 545 +/- 196 ng per deciliter (18.9 +/- 6.8 nmol per liter) before therapy to 23 +/- 14 ng per deciliter (0.8 +/- 0.5 nmol per liter, P<0.001) after 42 months of triptorelin. The main side effects were erectile failure, hot flashes, and decrease in bone mineral density in some men. Conclusions Continuous administration of triptorelin, a long-acting agonist analogue of gonadotropin-releasing hormone, together with supportive psychotherapy, may be an effective treatment for men with severe paraphilia. (C) 1998, Massachusetts Medical Society.	Hadassah Hebrew Univ Med Ctr, Dept Endocrinol & Metab, Jerusalem, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, Mental Hlth Ctr Beer Sheva, Beer Sheva, Israel	Hebrew University of Jerusalem; Ben Gurion University	Rosler, A (corresponding author), Hadassah Univ Hosp, Dept Endocrinol & Metab, POB 12000, IL-91120 Jerusalem, Israel.							Abel G. G., 1989, COMPREHENSIVE TXB PS, P1069; *ADV BOARD CHILD A, 1990, CHILD AB NEGL CRIT 1; ALLOLIO B, 1985, DEUT MED WOCHENSCHR, V110, P1952; AM. PSYCHIATRIC ASS'N, 1994, DIAGN STAT MAN MENT, P527; BAKER AW, 1985, CHILD ABUSE NEGLECT, V9, P457, DOI 10.1016/0145-2134(85)90054-7; BANCROFT J, 1974, BRIT J PSYCHIAT, V125, P310, DOI 10.1192/bjp.125.3.310; BANCROFT J, 1989, HUMAN SEXUALITY ITS, P664; BATTLE CC, 1966, AM J PSYCHOTHER, V20, P184, DOI 10.1176/appi.psychotherapy.1966.20.1.184; BRADFORD JMW, 1993, ARCH SEX BEHAV, V22, P383, DOI 10.1007/BF01542555; COHEN J, 1983, APPL MULTIPLE REGRES, P172; CONN PM, 1991, NEW ENGL J MED, V324, P93; COOPER AJ, 1994, BIOL PSYCHIAT, V36, P269, DOI 10.1016/0006-3223(94)90609-2; Cundy T, 1996, J CLIN ENDOCR METAB, V81, P1014, DOI 10.1210/jc.81.3.1014; CUNNINGHAM GR, 1990, J CLIN ENDOCR METAB, V70, P792, DOI 10.1210/jcem-70-3-792; DICKEY R, 1992, CAN J PSYCHIAT, V37, P567, DOI 10.1177/070674379203700808; Finkelhor David, 1986, J SEX RES, V22, P145, DOI [10.1080/00224498609551297, DOI 10.1080/00224498609551297]; GLASER B, 1997, RES PUBLIC POLICY SE, V12, P4; GOLDRAY D, 1993, J CLIN ENDOCR METAB, V76, P288, DOI 10.1210/jc.76.2.288; HEIM N, 1979, ARCH SEX BEHAV, V8, P281, DOI 10.1007/BF01541244; HIRSCH D, 1994, ISRAEL J MED SCI, V30, P238; KADAR T, 1992, PHYSIOL BEHAV, V51, P601, DOI 10.1016/0031-9384(92)90186-6; KUTCHINSKY B, 1985, COMP SOCIAL RES, V8, P301; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; LOOSEN PT, 1994, AM J PSYCHIAT, V151, P271; MARSHALL WL, 1988, BEHAV RES THER, V26, P499, DOI 10.1016/0005-7967(88)90146-5; Meyer W J 3rd, 1992, Bull Am Acad Psychiatry Law, V20, P249; *MIN SUPPL SERV CA, 1984, COMM SEX OFF CHILDR; MONEY J, 1984, AM J PSYCHOTHER, V38, P164, DOI 10.1176/appi.psychotherapy.1984.38.2.164; MONEY J, 1987, J SEX MARITAL THER, V13, P219; MOSS RL, 1989, NEUROL NEUROBIOL, V50, P485; NEUMANN F, 1991, EXP CLIN ENDOCRINOL, V98, P71, DOI 10.1055/s-0029-1211103; PRENTKY R, 1990, AM J ORTHOPSYCHIAT, V60, P108, DOI 10.1037/h0079197; RICHER M, 1993, ANN PHARMACOTHER, V27, P316, DOI 10.1177/106002809302700314; ROSLER A, 1992, J STEROID BIOCHEM, V43, P989, DOI 10.1016/0960-0760(92)90327-F; ROUSSEAU L, 1990, CAN J PSYCHIAT, V35, P338, DOI 10.1177/070674379003500412; Rubinow DR, 1996, AM J PSYCHIAT, V153, P974; SALMIMIES P, 1982, ARCH SEX BEHAV, V11, P345, DOI 10.1007/BF01541595; STEIN DJ, 1992, J CLIN PSYCHIAT, V53, P267; Thibaut F, 1996, PSYCHONEUROENDOCRINO, V21, P411, DOI 10.1016/0306-4530(96)00004-2; THIBAUT F, 1993, ACTA PSYCHIAT SCAND, V87, P445, DOI 10.1111/j.1600-0447.1993.tb03402.x; VANDEMEULEBROUC.M, 1995, SOIR            0114, P27; vanderZwaan M, 1995, SPRING COMP SCI, P1; ZACHMANN M, 1974, HELV PAEDIATR ACTA, V29, P61	43	137	138	0	27	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 12	1998	338	7					416	422		10.1056/nejm199802123380702	http://dx.doi.org/10.1056/nejm199802123380702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YW122	9459644				2022-12-28	WOS:000071900100002
J	Bradshaw, A				Bradshaw, A			Charting some challenges in the art and science of nursing	LANCET			English	Article									Radcliffe Infirm, Royal Coll, Nursing Inst, Oxford Ctr, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Bradshaw, A (corresponding author), Radcliffe Infirm, Royal Coll, Nursing Inst, Oxford Ctr, Oxford OX2 6HE, England.							ABELSMITH B, 1960, HIST NURISNG PROFESS; Alderman C, 1997, Nurs Stand, V11, P23; Bradshaw A, 1997, J CLIN NURS, V6, P347, DOI 10.1046/j.1365-2702.1997.00129.x; Bradshaw A, 1994, LIGHTING LAMP; BreeWilliams FJ, 1996, J ADV NURS, V23, P48, DOI 10.1111/j.1365-2648.1996.tb03134.x; CLINTON HR, 1994, AM NURS ASS CONV SAN; COX C, 1993, NURSING ITS HIDDEN A; DAVIS F, 1975, SOCIOLOGY MED PRACTI; GULLAND A, 1997, NURS TIMES, V93, P9; *HLTH SERV MAN UN, 1996, FUT HEALTHC WORKF ST, P14; HORTON R, 1997, OBSERVER LIFE   0330, P53; Kitson AL, 1996, BRIT MED J, V313, P1647, DOI 10.1136/bmj.313.7072.1647; Lawson Nigella, 1996, TIMES           1113, P17; MACGUIRE J, 1961, STUDENT NURSE; MacGuire JM, 1966, STUDENT NURSE; MACKAY L, 1989, NURISNG PROBLEM, P134; MORTONWILLIAMS J, 1971, NURSES ATTITUDE SURV; NESSLING RC, 1989, PROFESSIONAL NURSING; Raatikainen R, 1997, J ADV NURS, V25, P1111, DOI 10.1046/j.1365-2648.1997.19970251111.x; Ridge K W, 1995, Qual Health Care, V4, P240, DOI 10.1136/qshc.4.4.240; *ROYAL COLL NURS, 1985, ED NURS NEW DISP, P7; SMITH JP, 1989, V HENDERSON 1 90 YEA; TODD CJ, 1995, BRIT MED J, V310, P904, DOI 10.1136/bmj.310.6984.904; *UK CENTR COUNC NU, 1996, MIDW HLTH VIS, V17, P9; *UK CENTR COUNC NU, 1997, MIDW HLTH VIS REP PO, V20, P8; *UK CENTR COUNC NU, 1990, MIDW HLTH VIS REP PO; *UK CENTR COUNC NU, 1996, MIDW HLTH VIS ISS AR; *UKCC, 1997, NURS STAND, V26, P9; WILKOSKI L, 1996, CONTEMP TOP LAB ANIM, V35, P35; 1997, HEALTHCARE PARLIAMEN, V184, P9; 1972, CMND5115	31	11	12	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					438	440		10.1016/S0140-6736(97)09044-2	http://dx.doi.org/10.1016/S0140-6736(97)09044-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482321				2022-12-28	WOS:000071982600045
J	Staley, JP; Guthrie, C				Staley, JP; Guthrie, C			Mechanical devices of the spliceosome: Motors, clocks, springs, and things	CELL			English	Review							PRE-MESSENGER-RNA; HELICASE-LIKE PROTEIN; BOX PROTEIN; SPLICING FACTOR; COMPLEX; IDENTIFICATION; ELONGATION; MUTATIONS; BINDING; FAMILY		Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Guthrie, C (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.				NIGMS NIH HHS [GM21119] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021119, R37GM021119] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abel K, 1996, STRUCTURE, V4, P229, DOI 10.1016/S0969-2126(96)00027-5; ABOVICH N, 1994, GENE DEV, V8, P843, DOI 10.1101/gad.8.7.843; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; Arenas JE, 1997, P NATL ACAD SCI USA, V94, P11798, DOI 10.1073/pnas.94.22.11798; Auble DT, 1997, MOL CELL BIOL, V17, P4842, DOI 10.1128/MCB.17.8.4842; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BERGET SM, 1977, P NATL ACAD SCI USA, V74, P3171, DOI 10.1073/pnas.74.8.3171; Berglund JA, 1997, CELL, V89, P781, DOI 10.1016/S0092-8674(00)80261-5; BOURNE HR, 1995, PHILOS T R SOC B, V349, P283, DOI 10.1098/rstb.1995.0114; BRODY E, 1985, SCIENCE, V228, P963, DOI 10.1126/science.3890181; BURGESS SM, 1993, TRENDS BIOCHEM SCI, V18, P381, DOI 10.1016/0968-0004(93)90094-4; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; CHOW LT, 1977, CELL, V12, P1, DOI 10.1016/0092-8674(77)90180-5; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; Fabrizio P, 1997, EMBO J, V16, P4092, DOI 10.1093/emboj/16.13.4092; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; FU XD, 1995, RNA, V1, P663; Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0; Gee S, 1997, P NATL ACAD SCI USA, V94, P11803, DOI 10.1073/pnas.94.22.11803; GESTELAND RF, 1993, RNA WORLD; GHETTI A, 1995, RNA, V1, P132; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; Hertel KJ, 1997, CURR OPIN CELL BIOL, V9, P350, DOI 10.1016/S0955-0674(97)80007-5; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KIM SH, 1992, EMBO J, V11, P2319, DOI 10.1002/j.1460-2075.1992.tb05291.x; Kim SH, 1996, MOL CELL BIOL, V16, P6810; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; KOROLEV S, 1997, IN PRESS PROTEIN SCI; LAGGERBAUER B, 1998, IN PRESS P NATL ACAD; Lauber J, 1996, EMBO J, V15, P4001, DOI 10.1002/j.1460-2075.1996.tb00774.x; Lin J, 1996, RNA, V2, P835; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LORSCH JR, 1998, IN PRESS BIOCHEMISTR; Marians KJ, 1997, STRUCTURE, V5, P1129, DOI 10.1016/S0969-2126(97)00263-3; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; Moore M., 1993, RNA WORLD, P303; MOUNT SM, 1983, CELL, V33, P509, DOI 10.1016/0092-8674(83)90432-4; Newman AJ, 1997, EMBO J, V16, P5797, DOI 10.1093/emboj/16.19.5797; Nilsen TW, 1998, COLD SPRING HARBOR M, P279; Noble SM, 1996, GENETICS, V143, P67; NOBLE SM, 1995, THESIS U CALIFORNIA; ODay CL, 1996, J BIOL CHEM, V271, P33261, DOI 10.1074/jbc.271.52.33261; Ohno M, 1996, GENE DEV, V10, P997, DOI 10.1101/gad.10.8.997; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; ONO W, 1994, MOL CELL BIOL, V14, P7611, DOI 10.1128/MCB.14.11.7611; RAGHUNATHAN PL, 1998, IN PRESS SCIENCE; RAGHUNATHAN PL, 1997, THESIS U CALIFORNIA; Rodnina MV, 1995, BIOCHEM CELL BIOL, V73, P1221, DOI 10.1139/o95-132; ROY J, 1995, RNA, V1, P375; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; SCHWER B, 1992, EMBO J, V11, P5033, DOI 10.1002/j.1460-2075.1992.tb05610.x; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; SHAMOO Y, 1995, NUCLEIC ACIDS RES, V23, P725, DOI 10.1093/nar/23.5.725; SONTHEIMER EJ, 1997, ANNU REV BIOCHEM, V66, P639; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; STRAUSS EJ, 1994, NUCLEIC ACIDS RES, V22, P3187, DOI 10.1093/nar/22.15.3187; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; Tarn WY, 1997, TRENDS BIOCHEM SCI, V22, P132, DOI 10.1016/S0968-0004(97)01018-9; Teigelkamp S, 1997, RNA, V3, P1313; Umen JG, 1995, RNA, V1, P869; UTANS U, 1992, GENE DEV, V6, P631, DOI 10.1101/gad.6.4.631; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; Wang J, 1997, CURR OPIN GENET DEV, V7, P205, DOI 10.1016/S0959-437X(97)80130-X; Wiest DK, 1996, J BIOL CHEM, V271, P33268, DOI 10.1074/jbc.271.52.33268; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8; Wilson KS, 1998, CELL, V92, P337, DOI 10.1016/S0092-8674(00)80927-7; Xu DM, 1996, NATURE, V381, P709, DOI 10.1038/381709a0; Xu RM, 1997, STRUCTURE, V5, P559, DOI 10.1016/S0969-2126(97)00211-6; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; YEAN SL, 1991, MOL CELL BIOL, V11, P5571, DOI 10.1128/MCB.11.11.5571; Yean SL, 1996, GENE EXPRESSION, V5, P301; ZAVANELLI MI, 1994, MOL CELL BIOL, V14, P1689, DOI 10.1128/MCB.14.3.1689	75	892	931	1	56	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 6	1998	92	3					315	326		10.1016/S0092-8674(00)80925-3	http://dx.doi.org/10.1016/S0092-8674(00)80925-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YX283	9476892	Bronze			2022-12-28	WOS:000072024700004
J	Andersen, B; Ostergaard, L; Moller, JK; Olesen, F				Andersen, B; Ostergaard, L; Moller, JK; Olesen, F			Home sampling versus conventional contact tracing for detecting Chlamydia trachomatis infection in male partners of infected women: randomised study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Aarhus Univ, Res Unit, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Gen Practice, DK-8000 Aarhus C, Denmark; Aarhus Univ Hosp, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University; Aarhus University	Andersen, B (corresponding author), Aarhus Univ, Res Unit, DK-8000 Aarhus C, Denmark.	ba@alm.aau.dk	Andersen, Berit/J-3402-2017; Ostergaard, Lars/AAA-3020-2020	Andersen, Berit/0000-0003-4074-6504; Ostergaard, Lars/0000-0003-2459-0511; Moller, Jens Kjolseth/0000-0002-5547-5498; Ostergaard, Lars/0000-0002-7619-605X				CATES W, 1991, AM J OBSTET GYNECOL, V164, P1771, DOI 10.1016/0002-9378(91)90559-A; JASCHEK G, 1993, J CLIN MICROBIOL, V31, P1209, DOI 10.1128/JCM.31.5.1209-1212.1993; OSTERGAARD L, 1995, J CLIN MICROBIOL, V33, P2620, DOI 10.1128/JCM.33.10.2620-2623.1995; Ostergaard L, 1996, BRIT MED J, V313, P1186, DOI 10.1136/bmj.313.7066.1186; RIPA T, 1990, SCAND J INFECT DIS, P157	5	47	47	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 31	1998	316	7128					350	351		10.1136/bmj.316.7128.350	http://dx.doi.org/10.1136/bmj.316.7128.350			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487169	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000071863900024
J	Carr, A; Marriott, D; Field, A; Vasak, E; Cooper, DA				Carr, A; Marriott, D; Field, A; Vasak, E; Cooper, DA			Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; PARVUM; AIDS; GAMMA; INTERFERON; RITONAVIR; INHIBITOR; DIARRHEA; PROTEASE	Background Enterocytozoon bieneusi and Cryptosporidium parvum? cause chronic antimicrobial-resistant gastrointestinal infections in HIV-1-infected individuals. HIV-1 reverse transcriptase inhibitors delay the onset of opportunistic infections, but are not known to reverse: established infections. HIV-1 protease inhibitors are more effective across a broader range of HIV-l-infected immune cells. Combination antiretroviral[ therapy that includes a protease inhibitor could improve immunity to E bieneusi and C:parvum, Methods HIV-1 infected patients with chronic microsporidiosis (five), cryptosporidiosis (three), or dual infection lane), were treated with combination therapy that included at least one HIV-1 protease inhibitor, Outcome measures were symptoms weight, use of antidiarrhoeal and antimicrobial drugs, T-lymphocyte subsets, HIV-1 viraemia! stool microscopy, and biopsy by endoscopy. Findings Ail patients had complete clinical responses, gained a median 15 hg in weight, and ceased ail antidiarrhoeal and antimicrobial therapies, Biliary cryptosporidiosis responded in both affected patients, Neither pathogen was detected in follow-up stool microscopy (eight of eight patients) or in biopsy samples by endoscopy (five of five), Intestinal architecture returned to normal in three patients, There was a dense CD8 lymphocyte and macrophage infiltrate and staining of intraepithelial E bieneusi with interferon-gamma before and after treatment, but little staining for CD4 or B lymphocytes, interleukin 10, or HIV-1 gp41., Five patients remained symptom-free after a median 13 months' follow-up, Four patients had recurrent diarrhoea at 7-13 months (one with positive stool microscopy), associated with declining CD4 counts. Interpretation Combination antiretroviral therapy that includes a protease inhibitor can restore immunity to E bieneusi or C parvum in HIV-1 infected individuals, and result in complete clinical, microbiological, and histological responses, The persistent CD8 cell and macrophage infiltrate, and the rapid time to relapse in patients with declining CD4 lymphocyte counts, suggest that neither infection was eradicated.	St Vincents Hosp, HIV Med Unit, Sydney, NSW 2010, Australia; St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia; St Vincents Hosp, Dept Anat Pathol, Sydney, NSW 2010, Australia; Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia	St Vincents Hospital Sydney; St Vincents Hospital Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney; Kirby Institute	Carr, A (corresponding author), St Vincents Hosp, HIV Med Unit, Sydney, NSW 2010, Australia.	acarr@stvincents.com.au						AnwarBruni DM, 1996, AIDS, V10, P619, DOI 10.1097/00002030-199606000-00007; BIGGS BA, 1995, J IMMUNOL, V154, P6132; BISSUEL F, 1994, CLIN INFECT DIS, V18, P447, DOI 10.1093/clinids/18.3.447; CAMERON B, 1996, 11 INT C AIDS VANC C; Carr A, 1996, J ACQ IMMUN DEF SYND, V13, P320, DOI 10.1097/00042560-199612010-00004; CARR A, 1996, AIDS SA, V10, P151; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; COZON G, 1994, J INFECT DIS, V169, P696, DOI 10.1093/infdis/169.3.696; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; DUPONT HL, 1995, NEW ENGL J MED, V332, P855, DOI 10.1056/NEJM199503303321304; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FIELD AS, 1993, AIDS S, V7, P27; FLANIGAN T, 1992, ANN INTERN MED, V116, P840, DOI 10.7326/0003-4819-116-10-840; HARP JA, 1994, J PARASITOL, V80, P67, DOI 10.2307/3283347; HARRIS M, 1994, AIDS, V8, P1109, DOI 10.1097/00002030-199408000-00011; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; KOTLER DP, 1990, ANN INTERN MED, V113, P444; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; MACDONALD TT, 1988, J EXP MED, V167, P1341, DOI 10.1084/jem.167.4.1341; MCGOWAN I, 1994, AIDS, V8, P1569, DOI 10.1097/00002030-199411000-00008; MEISEL JL, 1976, GASTROENTEROLOGY, V70, P1156; MONTAGNINO G, 1994, AM J NEPHROL, V14, P121, DOI 10.1159/000168700; Orenstein JM, 1997, SCIENCE, V276, P1857, DOI 10.1126/science.276.5320.1857; POL S, 1993, NEW ENGL J MED, V328, P95, DOI 10.1056/NEJM199301143280204; Rehg JE, 1996, J INFECT DIS, V174, P229, DOI 10.1093/infdis/174.1.229; SAXON A, 1987, J PARASITOL, V73, P413, DOI 10.2307/3282099; SLOPER KS, 1982, GUT, V23, P80, DOI 10.1136/gut.23.1.80; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; UNGAR BLP, 1991, J IMMUNOL, V147, P1014; Vakil NB, 1996, NEW ENGL J MED, V334, P19, DOI 10.1056/NEJM199601043340104; WHITE AC, 1994, J INFECT DIS, V170, P419, DOI 10.1093/infdis/170.2.419	33	233	238	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 24	1998	351	9098					256	261		10.1016/S0140-6736(97)07529-6	http://dx.doi.org/10.1016/S0140-6736(97)07529-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU294	9457096				2022-12-28	WOS:000071702200012
J	Huppa, JB; Ploegh, HL				Huppa, JB; Ploegh, HL			The eS-Sence of -SH in the ER	CELL			English	Review							ENDOPLASMIC-RETICULUM		Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Huppa, JB (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.			Huppa, Johannes/0000-0003-2634-8198				BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; Carelli S, 1997, SCIENCE, V277, P1681, DOI 10.1126/science.277.5332.1681; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Creighton TE, 1997, BIOL CHEM, V378, P731; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0	14	59	59	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					145	148		10.1016/S0092-8674(00)80907-1	http://dx.doi.org/10.1016/S0092-8674(00)80907-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458037	Bronze			2022-12-28	WOS:000071672600002
J	Podrebarac, T; McKendry, R				Podrebarac, T; McKendry, R			Cellular suicide: Critical concept or fleeting fad?	LANCET			English	Article											Podrebarac, T (corresponding author), UNIV OTTAWA,OTTAWA GEN HOSP,RHEUMAT DIS UNIT,LM 10,501 SMYTH,OTTAWA,ON K1H 8L6,CANADA.							BLEASEL JF, 1995, J RHEUMATOL, V22, P34; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504; KLOPPENBURG M, 1994, ARTHRITIS RHEUM, V37, P629, DOI 10.1002/art.1780370505; TILLEY BC, 1995, ANN INTERN MED, V122, P81, DOI 10.7326/0003-4819-122-2-199501150-00001	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S22	S22		10.1016/0140-6736(95)90021-7	http://dx.doi.org/10.1016/0140-6736(95)90021-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454040				2022-12-28	WOS:A1995TN12200022
J	vanGijn, J; Wokke, JHJ				vanGijn, J; Wokke, JHJ			At snail's pace from description to intervention	LANCET			English	Article											vanGijn, J (corresponding author), UNIV UTRECHT,DEPT NEUROL,POB 85500,3508 GA UTRECHT,NETHERLANDS.		van Gijn, Jan/A-9444-2008					TFELTHANSEN P, 1995, LANCET, V346, P923, DOI 10.1016/S0140-6736(95)91554-0; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; 1995, LANCET, V345, P1455; 1995, JAMA-J AM MED ASSOC, V273, P1421; 1995, COCHRANE DATABASE SY	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S14	S14		10.1016/0140-6736(95)90013-6	http://dx.doi.org/10.1016/0140-6736(95)90013-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454031				2022-12-28	WOS:A1995TN12200014
J	Daley, J; McDaniel, MD; Parker, RA				Daley, J; McDaniel, MD; Parker, RA			A 52-year-old woman with diabetes and claudication	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PERIPHERAL ARTERIAL-DISEASE; STAGE RENAL-DISEASE; COOPERATIVE INFORMATION PROJECT; INTERMITTENT CLAUDICATION; PLASMA HOMOCYSTEINE; SURGICAL REVASCULARIZATION; DEFINED POPULATION; COST-EFFECTIVENESS; VASCULAR-DISEASE; RISK-FACTORS		Dartmouth Coll, Sch Med, Hanover, NH 03755 USA; Vet Affairs Med Ctr, Surg Serv, White River Junction, VT USA	Dartmouth College; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Daley, J (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave,LY318, Boston, MA 02215 USA.							ADAR R, 1989, J VASC SURG, V10, P57, DOI 10.1067/mva.1989.vs0100057; Austin MA, 1996, ANN MED, V28, P459, DOI 10.3109/07853899608999108; Bosch JL, 1997, RADIOLOGY, V204, P87, DOI 10.1148/radiology.204.1.9205227; Bostom AG, 1996, ATHEROSCLEROSIS, V123, P193, DOI 10.1016/0021-9150(96)05809-1; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BOYD A. M., 1960, ANGIOLOGY, V11, P10, DOI 10.1177/000331976001100103; CAMERON JL, 1995, CURRENT SURG THERAPY, P658; Chauveau P, 1996, MINER ELECTROL METAB, V22, P106; CHAUVEAU P, 1993, KIDNEY INT S, V41, pS72; CRANLEY JJ, 1969, ARCH SURG-CHICAGO, V98, P187; CRIQUI MH, 1985, CIRCULATION, V72, P768, DOI 10.1161/01.CIR.72.4.768; CRIQUI MH, 1985, CIRCULATION, V71, P516, DOI 10.1161/01.CIR.71.3.516; CRIQUI MH, 1985, CIRCULATION, V71, P510, DOI 10.1161/01.CIR.71.3.510; DAVEYSMITH G, 1990, CIRCULATION, V82, P1925; DAWSON I, 1993, J VASC SURG, V18, P249, DOI 10.1016/0741-5214(93)90605-L; DONALDSON MC, 1990, J VASC SURG, V11, P25; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; GREEN RM, 1988, J VASC SURG, V7, P356, DOI 10.1067/mva.1988.avs0070356; Hennekens CH, 1997, ANNU REV PUBL HEALTH, V18, P37, DOI 10.1146/annurev.publhealth.18.1.37; HUGHSON WG, 1978, BRIT MED J, V1, P1377, DOI 10.1136/bmj.1.6124.1377; HUNINK MGM, 1995, JAMA-J AM MED ASSOC, V274, P165, DOI 10.1001/jama.274.2.165; HUNINK MGM, 1994, MED DECIS MAKING, V14, P71, DOI 10.1177/0272989X9401400109; JOHNSON BL, 1995, J VASC SURG, V22, P280, DOI 10.1016/S0741-5214(95)70142-7; JONASON T, 1985, ACTA MED SCAND, V218, P27; JONASON T, 1985, ACTA MED SCAND, V218, P217; Levy PJ, 1996, J VASC SURG, V23, P36, DOI 10.1016/S0741-5214(05)80033-3; Mailloux LU, 1996, ASAIO J, V42, P164, DOI 10.1097/00002480-199605000-00008; Marcelli D, 1996, KIDNEY INT, V50, P1013, DOI 10.1038/ki.1996.403; MCCREADY RA, 1984, SURGERY, V96, P863; McDaniel MD, 1997, ANN VASC SURG, V11, P425, DOI 10.1007/s100169900073; MCDANIEL MD, 1989, ANN VASC SURG, V3, P374; NELSON E, 1983, JAMA-J AM MED ASSOC, V249, P3331, DOI 10.1001/jama.249.24.3331; NELSON E, 1987, J CHRON DIS, V40, pS55, DOI 10.1016/S0021-9681(87)80033-4; NELSON EC, 1981, J FAM PRACTICE, V13, P867; NELSON EC, 1981, J FAM PRACTICE, V13, P641; Ouriel K, 1996, J VASC SURG, V23, P46, DOI 10.1016/S0741-5214(05)80034-5; Owen WF, 1996, AM J KIDNEY DIS, V28, P931, DOI 10.1016/S0272-6386(96)90397-2; Patterson RB, 1997, J VASC SURG, V25, P312, DOI 10.1016/S0741-5214(97)70352-5; RICHARD JL, 1972, REV EPIDEMIOL SANTE, V20, P735; Robinson K, 1996, CIRCULATION, V94, P2743, DOI 10.1161/01.CIR.94.11.2743; ROESSNER M, 1987, Journal of Medicine (Westbury), V18, P1; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; Rutherford RB, 1997, J VASC SURG, V26, P517, DOI 10.1016/S0741-5214(97)70045-4; SCHOENHARTING M, 1988, Pharmatherapeutica, V5, P159; Ubbink JB, 1997, J INHERIT METAB DIS, V20, P316, DOI 10.1023/A:1005329427711; Valentine RJ, 1996, J VASC SURG, V23, P53, DOI 10.1016/S0741-5214(05)80035-7; VROEGINDEWEIJ D, 1995, EUR J VASC ENDOVASC, V10, P40, DOI 10.1016/S1078-5884(05)80197-2; Whyman MR, 1997, J VASC SURG, V26, P551, DOI 10.1016/S0741-5214(97)70052-1; Zannetti S, 1996, J VASC SURG, V24, P65, DOI 10.1016/S0741-5214(96)70146-5	49	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	1998	279	8					615	621		10.1001/jama.279.8.615	http://dx.doi.org/10.1001/jama.279.8.615			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX457	9486758				2022-12-28	WOS:000072041900039
J	Pincus, HA; Tanielian, TL; Marcus, SC; Olfson, M; Zarin, DA; Thompson, J; Zito, JM				Pincus, HA; Tanielian, TL; Marcus, SC; Olfson, M; Zarin, DA; Thompson, J; Zito, JM			Prescribing trends in psychotropic medications - Primary care, psychiatry, and other medical specialties	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEFICIT-HYPERACTIVITY DISORDER; DEPRESSION; PRESCRIPTION; HALOPERIDOL; PHYSICIANS; OUTCOMES	Context.-Psychotropic medications are widely prescribed, but how new classes of psychotropic medications have affected prescribing patterns has not been well documented. Objective.-To examine changes between 1985 and 1994 (data from 1993 and 1994 were combined) in the prescribing patterns of psychotropic: medications by office-based primary care physicians, psychiatrists, and other medical specialists. Design.-National estimates for the number of visits during which a physician prescribed a psychotropic medication based on the National Ambulatory Medical Care Surveys conducted in 1985, 1993, and 1994. Setting.-Office-based physician practices in the United Stales. Participants.-A systematically sampled group of office-based physicians. Main Outcome Measures.-National estimates of visits that included a psychotropic medication. Results.-The number of visits during which a psychotropic medication was prescribed increased from 32.73 million to 45.64 million; the proportion of such visits, as a proportion of all visits, increased from 5.1% to 6.5% (P less than or equal to.01). Antianxiety or hypnotic drug visits, previously the largest category, decreased as a proportion of psychotropic drug visits (P less than or equal to.01) and are now surpassed by antidepressant visits, Visits for depression increased from 10.99 million in 1988 to 20.43 million in 1993 and 1994 (P less than or equal to.01). Stimulant drug visits increased from 0.57 million to 2.86 million (P less than or equal to.01). Although visits for depression doubled for both primary care physicians and psychiatrists, the proportion of visits for depression during which an antidepressant was prescribed increased for psychiatrists but not for primary care physicians. Conclusions.-The patterns of psychotropic medication use in outpatient medical practice changed dramatically during the study period, especially in psychiatric practice.	Amer Psychiat Assoc, Res Off, Washington, DC 20005 USA; Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA USA; Columbia Univ, Dept Psychiat, New York, NY USA; New York State Psychiat Inst & Hosp, New York, NY 10032 USA; Univ Maryland, Dept Psychiat, Baltimore, MD 21201 USA; Univ Maryland, Dept Phrm Practice & Sci, Baltimore, MD 21201 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC; Columbia University; New York State Psychiatry Institute; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Pincus, HA (corresponding author), Amer Psychiat Assoc, Res Off, 1400 K St NW, Washington, DC 20005 USA.	hpincus@psych.org	Olfson, Mark/AAA-8547-2021					AANA GW, 1991, HDB PSYCHIAT DRUG TH; *AM MED ASS, 1994, DRUG EV ANN 1994; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; American Psychiatric Association, 1996, PRACT GUID; AMSTERDAM JD, 1994, J CLIN PSYCHIAT, V55, P394; [Anonymous], 1994, Am J Psychiatry, V151, P1; BEARDSLEY RS, 1988, ARCH GEN PSYCHIAT, V45, P1117; GLASER M, 1995, DRUG TOPICS, V139, P43; GLASS RM, 1991, JAMA-J AM MED ASSOC, V266, P2431, DOI 10.1001/jama.266.17.2431; GREENHILL LL, 1992, PSYCHIAT CLIN N AM, V15, P1; Herz MI, 1997, AM J PSYCHIAT, V154, P1; Hirschfield RMA, 1997, JAMA-J AM MED ASSOC, V277, P333, DOI 10.1001/jama.277.4.333; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kramer P. D., 1993, LISTENING PROZAC; Kroenke K, 1997, ANN INTERN MED, V126, P463, DOI 10.7326/0003-4819-126-6-199703150-00008; LENOX RH, 1992, J CLIN PSYCHIAT, V53, P47; MCLEMORE T, 1987, NATL AMBULATORY MED; *MED EC CO INC, 1994, PHYS DESK REF; *MED EC CO INC, 1997, PHYS DESK REF; OLFSON M, 1992, J FAM PRACTICE, V35, P627; OLFSON M, 1993, MED CARE, V31, P559, DOI 10.1097/00005650-199306000-00010; PINCUS HA, 1990, GEN HOSP PSYCHIAT, V12, P23, DOI 10.1016/0163-8343(90)90034-A; Pincus HA, 1996, ARCH GEN PSYCHIAT, V53, P870; REGIER DA, 1988, AM J PSYCHIAT, V145, P1351; ROGERS WH, 1993, ARCH GEN PSYCHIAT, V50, P517; SAFER DJ, 1988, JAMA-J AM MED ASSOC, V260, P2256, DOI 10.1001/jama.260.15.2256; SCHAPPERT S, 1995, NATL AMBULATORY MED; SHOPSIN B, 1975, ARCH GEN PSYCHIAT, V32, P34; SWANSON JM, 1995, NEW ENGL J MED, V333, P944, DOI 10.1056/NEJM199510053331419; SWANSON JM, 1995, ADV CLIN CHILD PSYCH, V17, P265; *US DHHS, 1988, INT CLASS DIS 9 REV; *US DHHS, 1993, DEPR PRIM CAR; WALLIS C, 1994, TIME            0718, V144, P42; WEINTRAUB M, 1991, JAMA-J AM MED ASSOC, V266, P2392, DOI 10.1001/jama.266.17.2392; WOLKOWITZ OM, 1991, AM J PSYCHIAT, V148, P714; WOODWELL DW, 1995, NATL AMBULATORY MED; ZARIN DA, 1993, AM J PSYCHIAT, V150, P175	37	312	317	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	1998	279	7					526	531		10.1001/jama.279.7.526	http://dx.doi.org/10.1001/jama.279.7.526			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YW470	9480363				2022-12-28	WOS:000071938900034
J	Howell, MR; Quinn, TC; Gaydos, CA				Howell, MR; Quinn, TC; Gaydos, CA			Screening for Chlamydia trachomatis in asymptomatic women attending family planning clinics - A cost-effectiveness analysis of three strategies	ANNALS OF INTERNAL MEDICINE			English	Article						cost-benefit analysis; Chlamydia trachomatis; mass screening; adnexitis	POLYMERASE CHAIN-REACTION; PELVIC INFLAMMATORY DISEASE; AMPLICOR-PCR; ENDOCERVICAL SPECIMENS; INCREMENTAL COST; REACTION ASSAY; LOW-PREVALENCE; INFECTION; URINE; DIAGNOSIS	Background: Screening women for Chlamydia trachomatis in family planning clinics is associated with a reduced incidence of chlamydial sequelae. However, the question of whom to screen to maintain efficient use of resources remains controversial. Objective: To assess the cost-effectiveness of chlamydial screening done according to three sets of criteria in asymptomatic women attending family planning clinics. Design: Cost-effectiveness analysis done by using a decision model with the perspective of a health care system. Model estimates were based on analysis of cohort data, clinic costs, laboratory costs, and published data. Setting: Two family planning clinics in Baltimore, Mary land. Patients: 7699 asymptomatic women who presented between April 1994 and August 1996. Intervention: Three screening strategies-screening according to the criteria of the Centers for Disease Control and Prevention (CDC), screening all women younger than 30 years of age, and universal screening-were retrospectively applied and compared. All women were tested with polymerase chain reaction. Measurements: Medical outcomes included sequelae prevented in women, men, and infants. Total costs included screening program costs and future medical costs of all sequelae. The incremental cost-effectiveness ratios of each strategy were calculated. Results: Without screening, 152 cases of pelvic inflammatory disease would occur at a cost of $676 000. Screening done by using the CDC criteria would prevent 64 cases of pelvic inflammatory disease at a cost savings of $231 000. Screening all women younger than 30 years of age would prevent an additional 21 cases of pelvic inflammatory disease and save $74 000. Universal screening would prevent an additional 6 cases of pelvic inflammatory disease but would cost $19 000 more than age-based screening, or approximately $3000 more per case of pelvic inflammatory disease prevented. If the prevalence of C. trachomatis is more than 10.2% or if less than 88.5% of infections occur in women younger than 30 years of age, universal screening provides the greatest cost savings. Conclusions: These results suggest that age-based screening provides the greatest cost savings of the three strategies examined. However, universal screening is desirable in some situations. In general, screening done by using any criteria and a highly sensitive diagnostic assay should be part of any chlamydial prevention and control program or health plan.	Johns Hopkins Univ, Div Infect Dis, Baltimore, MD 21205 USA; NIAID, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Howell, MR (corresponding author), Johns Hopkins Univ, Div Infect Dis, Ross Res Bldg,Room 1159,720 Rutland Ave, Baltimore, MD 21205 USA.		Gaydos, Charlotte A./E-9937-2010; Quinn, Thomas/A-2494-2010					BASS CA, 1993, J CLIN MICROBIOL, V31, P2648, DOI 10.1128/JCM.31.10.2648-2653.1993; BAUWENS JE, 1993, J CLIN MICROBIOL, V31, P3023, DOI 10.1128/JCM.31.11.3023-3027.1993; BEGLEY CE, 1989, SEX TRANSM DIS, V16, P63, DOI 10.1097/00007435-198904000-00004; BIANCHI A, 1994, SEX TRANSM DIS, V21, P196, DOI 10.1097/00007435-199407000-00003; CATRY MA, 1995, GENITOURIN MED, V71, P247; Genc M, 1996, ANN INTERN MED, V124, P1, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00001; Gold MR, 1996, COST EFFECTIVENESS H, P232; HADDIX AC, 1995, SEX TRANSM DIS, V22, P274, DOI 10.1097/00007435-199509000-00002; HAMMERSCHLAG MR, 1979, PEDIATRICS, V64, P142; HILLIS S, 1995, SEX TRANSM DIS, V22, P197, DOI 10.1097/00007435-199505000-00011; HILLIS SD, 1995, 11 M INT SOC STD RES, V267, P156; JONES RB, 1986, AM J OBSTET GYNECOL, V155, P35, DOI 10.1016/0002-9378(86)90073-6; Magid D, 1996, ANN INTERN MED, V124, P389, DOI 10.7326/0003-4819-124-4-199602150-00002; MAHONY JB, 1994, J CLIN MICROBIOL, V32, P2490, DOI 10.1128/JCM.32.10.2490-2493.1994; Marrazzo JM, 1997, SEX TRANSM DIS, V24, P131, DOI 10.1097/00007435-199703000-00003; Pasternack R, 1996, J CLIN MICROBIOL, V34, P995, DOI 10.1128/JCM.34.4.995-998.1996; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; Quinn TC, 1996, JAMA-J AM MED ASSOC, V276, P1737, DOI 10.1001/jama.276.21.1737; Quinn TC, 1996, J CLIN MICROBIOL, V34, P1401, DOI 10.1128/JCM.34.6.1401-1406.1996; REES E, 1980, AM J OBSTET GYNECOL, V138, P1042, DOI 10.1016/0002-9378(80)91105-9; SCHACHTER J, 1986, JAMA-J AM MED ASSOC, V255, P3374, DOI 10.1001/jama.255.24.3374; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103; SKULNICK M, 1994, DIAGN MICR INFEC DIS, V20, P195, DOI 10.1016/0732-8893(94)90003-5; STAMM WE, 1984, NEW ENGL J MED, V310, P545, DOI 10.1056/NEJM198403013100901; STAMM WE, 1986, SEX TRANSM DIS, V13, P163, DOI 10.1097/00007435-198607000-00010; STERGACHIS A, 1993, AM J EPIDEMIOL, V138, P143, DOI 10.1093/oxfordjournals.aje.a116840; Stika CS, 1996, AM J OBSTET GYNECOL, V174, P1840, DOI 10.1016/S0002-9378(96)70219-3; TENGS TO, 1995, RISK ANAL, V15, P369, DOI 10.1111/j.1539-6924.1995.tb00330.x; WASHINGTON AE, 1991, JAMA-J AM MED ASSOC, V266, P2565, DOI 10.1001/jama.266.18.2565; WASHINGTON AE, 1987, JAMA-J AM MED ASSOC, V257, P2070, DOI 10.1001/jama.257.15.2070; WEINSTOCK HS, 1992, AM J EPIDEMIOL, V135, P41, DOI 10.1093/oxfordjournals.aje.a116200; WESTROM L, 1992, SEX TRANSM DIS, V19, P185, DOI 10.1097/00007435-199207000-00001; ZENILMAN JM, 1995, SEX TRANSM DIS, V22, P15, DOI 10.1097/00007435-199501000-00003; 1993, MMWR MORB MORTAL WKL, V42, P1	34	113	114	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1998	128	4					277	+		10.7326/0003-4819-128-4-199802150-00005	http://dx.doi.org/10.7326/0003-4819-128-4-199802150-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX170	9471930				2022-12-28	WOS:000072013400004
J	Katz, MH; Gerberding, JL				Katz, MH; Gerberding, JL			The care of persons with recent sexual exposure to HIV	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; RISK-REDUCTION INTERVENTION; PRIMARY INFECTION; CONTROLLED TRIAL; HOMOSEXUAL MEN; VACCINE TRIALS; AIDS; PREVENTION; ANTIBODY; TYPE-1	Until recently, patients had little motivation to seek medical care soon after sexual exposure to HIV. However, evidence that antiretroviral treatment prevents HIV infection after occupational exposure has led to the recommendation that prophylaxis be considered after sexual exposure. This recommendation will result in an increased number of recently exposed patients presenting for care. Clinicians should seize this opportunity to reach persons who are at high risk for HIV seroconversion and provide them with evaluation, treatment, and counseling. A comprehensive approach to the care of persons recently exposed to HIV is proposed. Candidates for postexposure prophylaxis should be identified and given appropriate antiretroviral treatment. Physicians must perform HIV antibody testing to determine which persons are already infected with HIV and must do baseline laboratory studies. Follow-up care includes assessment of side effects from postexposure treatment and surveillance for development of primary HIV infection. Most important, clinicians must provide risk-reduction counseling to decrease the chance of future exposures. Public health messages must emphasize that postexposure treatment should be used only as a backup for failure of primary prevention methods, such as avoidance of high-risk sexual exposures or use of condoms.	Univ Calif San Francisco, San Francisco, CA 94143 USA; San Francisco Dept Publ Hlth, San Francisco, CA USA	University of California System; University of California San Francisco; San Francisco Department of Public Health	Katz, MH (corresponding author), 101 Grove St,Room 308, San Francisco, CA 94102 USA.							ALBERT J, 1994, J VIROL, V68, P5918, DOI 10.1128/JVI.68.9.5918-5924.1994; *AM MED ASS, 1996, PHYS GUID HIV PREV; BERRIOS DC, 1993, JAMA-J AM MED ASSOC, V270, P1576, DOI 10.1001/jama.270.13.1576; BLAUVELT A, 1995, J INVEST DERMATOL, V105, pS122, DOI 10.1111/1523-1747.ep12316662; Buchbinder SP, 1996, J INFECT DIS, V174, P954, DOI 10.1093/infdis/174.5.954; Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Cates W, 1995, NEW ENGL J MED, V333, P1783; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P574; CHESNEY MA, 1995, J ACQ IMMUN DEF SYND, V9, P30; CHMIEL JS, 1987, AM J EPIDEMIOL, V126, P568, DOI 10.1093/oxfordjournals.aje.a114696; CHOI KH, 1994, AIDS, V8, P1371, DOI 10.1097/00002030-199410000-00003; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; Claydon E, 1991, Int J STD AIDS, V2, P200; CONWAY B, 1995, P INT WORKSH HIV DRU, V4, P8; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DEGRUTTOLA V, 1989, J CLIN EPIDEMIOL, V42, P849, DOI 10.1016/0895-4356(89)90098-X; DESJARLAIS DC, 1995, JAMA-J AM MED ASSOC, V274, P1226, DOI 10.1001/jama.274.15.1226; DIAZ T, 1994, AM J PUBLIC HEALTH, V84, P1015, DOI 10.2105/AJPH.84.6.1015; DICLEMENTE RJ, 1995, JAMA-J AM MED ASSOC, V274, P1271, DOI 10.1001/jama.274.16.1271; Downs AM, 1996, J ACQ IMMUN DEF SYND, V11, P388, DOI 10.1097/00042560-199604010-00010; ENG TR, 1996, HIDEN EPIDEMIC CONFR; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; Feder HM, 1997, NEW ENGL J MED, V336, P959; FLEISHMAN JA, 1993, INQUIRY-J HEALTH CAR, V30, P180; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; Gerberding JL, 1996, ANN INTERN MED, V125, P497, DOI 10.7326/0003-4819-125-6-199609150-00011; GOSTIN LO, 1994, JAMA-J AM MED ASSOC, V271, P1436, DOI 10.1001/jama.271.18.1436; Hearst N, 1994, J Am Board Fam Pract, V7, P44; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; Holmberg SD, 1996, AM J PUBLIC HEALTH, V86, P642, DOI 10.2105/AJPH.86.5.642; HORSBURGH CR, 1989, LANCET, V2, P637; Irwin K, 1996, ANN INTERN MED, V125, P471, DOI 10.7326/0003-4819-125-6-199609150-00007; JACQUEZ JA, 1994, J ACQ IMMUN DEF SYND, V7, P1169; Janz NK, 1996, HEALTH EDUC QUART, V23, P80, DOI 10.1177/109019819602300106; KAMB ML, 1996, P 1996 NAT STD PREV; Katz MH, 1997, NEW ENGL J MED, V336, P1097, DOI 10.1056/NEJM199704103361512; KELLY JA, 1993, AM PSYCHOL, V48, P1023, DOI 10.1037/0003-066X.48.10.1023; KELLY JA, 1994, AM J PUBLIC HEALTH, V84, P1918, DOI 10.2105/AJPH.84.12.1918; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P408, DOI 10.1056/NEJM199508173330702; Kopp JB, 1997, ANN INTERN MED, V127, P119, DOI 10.7326/0003-4819-127-2-199707150-00004; Li RW, 1997, NEW ENGL J MED, V337, P499, DOI 10.1056/NEJM199708143370714; LIFSON AR, 1990, AM J PUBLIC HEALTH, V80, P1509, DOI 10.2105/AJPH.80.12.1509; Liuzzi G, 1996, AIDS, V10, pF51, DOI 10.1097/00002030-199612000-00001; MAKADON HJ, 1995, ANN INTERN MED, V123, P715, DOI 10.7326/0003-4819-123-9-199511010-00010; MANLEY M, 1991, JAMA-J AM MED ASSOC, V266, P3172, DOI 10.1001/jama.266.22.3172; Mayers Douglas L., 1997, American Journal of Medicine, V102, P70, DOI 10.1016/S0002-9343(97)00067-3; MCCUSKER J, 1992, AIDS, V6, P861, DOI 10.1097/00002030-199208000-00015; Messiah A, 1997, AM J PUBLIC HEALTH, V87, P421, DOI 10.2105/AJPH.87.3.421; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; Peterson JL, 1996, AIDS, V10, P319, DOI 10.1097/00002030-199603000-00011; *PHS, IN PRESS MMWR MORB M; Pinkerton SD, 1997, ARCH INTERN MED, V157, P1972, DOI 10.1001/archinte.157.17.1972; Pinkerton SD, 1997, NEW ENGL J MED, V337, P500; Pinto Ligia A., 1997, American Journal of Medicine, V102, P21, DOI 10.1016/S0002-9343(97)00056-9; Rasheed S, 1996, AM J OBSTET GYNECOL, V175, P122, DOI 10.1016/S0002-9378(96)70261-2; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; Rubio A, 1997, AIDS, V11, P1184, DOI 10.1097/00002030-199709000-00016; SAMUEL MC, 1994, MODELING THE AIDS EPIDEMIC: PLANNING, POLICY, AND PREDICTION, P423; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; Spielberg F, 1996, ANN INTERN MED, V125, P509, DOI 10.7326/0003-4819-125-6-199609150-00014; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; STALL R, 1990, J ACQ IMMUN DEF SYND, V3, P1181; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; THOMPSON JLP, 1993, AM J PUBLIC HEALTH, V83, P1409, DOI 10.2105/AJPH.83.10.1409; TRUSSELL J, 1995, FERTILITY CONTROL RE, V4, P8; Vernazza PL, 1997, AIDS, V11, P987, DOI 10.1097/00002030-199708000-00006; Voelker R, 1996, JAMA-J AM MED ASSOC, V276, P585, DOI 10.1001/jama.276.8.585; WILEY JA, 1989, STAT MED, V8, P93, DOI 10.1002/sim.4780080110; WORTLEY PM, 1995, AIDS, V9, P487, DOI 10.1097/00002030-199509050-00011; 1998, IN PRESS MMWR MORB M; 1995, MMWR MORB MORTAL WKL, V44, P929; 1993, MMWR MORB MORTAL WKL, V42, P97; 1996, MMWR MORB MORTAL WKL, V45, P468; 1993, MMWR MORB MORTAL WKL, V42, P11	77	72	72	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1998	128	4					306	312		10.7326/0003-4819-128-4-199802150-00012	http://dx.doi.org/10.7326/0003-4819-128-4-199802150-00012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YX170	9471935				2022-12-28	WOS:000072013400009
J	Knutson, TR; Tuleya, RE; Kurihara, Y				Knutson, TR; Tuleya, RE; Kurihara, Y			Simulated increase of hurricane intensities in a CO2-warmed climate	SCIENCE			English	Article							TROPICAL CYCLONE CLIMATE; ANTHROPOGENIC CHANGES; MODELS	Hurricanes can inflict catastrophic property damage and loss of human life. Thus, it is important to determine how the character of these powerful storms could change in response to greenhouse gas-induced global warming. The impact of climate warming on hurricane intensities was investigated with a regional, high-resolution, hurricane prediction model. In a case study, 51 western Pacific storm cases under present-day climate conditions were compared with 51 storm cases under high-CO2 conditions, More idealized experiments were also performed. The large-scale initial conditions were derived from a global climate model. For a sea surface temperature warming of about 2.2 degrees C, the simulations yielded hurricanes that were more intense by 3 to 7 meters per second (5 to 12 percent) for wind speed and 7 to 20 millibars for central surface pressure.	NOAA, Geophys Fluid Dynam Lab, Princeton, NJ 08542 USA	National Oceanic Atmospheric Admin (NOAA) - USA	Knutson, TR (corresponding author), NOAA, Geophys Fluid Dynam Lab, POB 308, Princeton, NJ 08542 USA.		Knutson, Thomas/P-7225-2019; Knutson, Thomas/G-7457-2019	Knutson, Thomas/0000-0003-4541-519X; Knutson, Thomas/0000-0003-4541-519X				BENDER MA, 1993, MON WEATHER REV, V121, P2046, DOI 10.1175/1520-0493(1993)121<2046:IITCTA>2.0.CO;2; Bengtsson L, 1996, TELLUS A, V48, P57, DOI 10.1034/j.1600-0870.1996.00004.x; BROCCOLI AJ, 1990, GEOPHYS RES LETT, V17, P1917, DOI 10.1029/GL017i011p01917; BROCCOLI AJ, 1992, GEOPHYS RES LETT, V19, P1525, DOI 10.1029/92GL01670; EFRON B, 1991, SCIENCE, V253, P390, DOI 10.1126/science.253.5018.390; EMANUEL KA, 1988, J ATMOS SCI, V45, P1143, DOI 10.1175/1520-0469(1988)045<1143:TMIOH>2.0.CO;2; EMANUEL KA, 1986, J ATMOS SCI, V43, P585, DOI 10.1175/1520-0469(1986)043<0585:AASITF>2.0.CO;2; EMANUEL KA, 1987, NATURE, V326, P483, DOI 10.1038/326483a0; EMANUEL KA, 1995, J ATMOS SCI, V52, P3969, DOI 10.1175/1520-0469(1995)052<3969:SOTCTS>2.0.CO;2; HAARSMA RJ, 1993, CLIM DYNAM, V8, P247, DOI 10.1007/BF00198619; Holland GJ, 1997, J ATMOS SCI, V54, P2519, DOI 10.1175/1520-0469(1997)054<2519:TMPIOT>2.0.CO;2; LIGHTHILL J, 1994, B AM METEOROL SOC, V75, P2147; MANABE S, 1991, J CLIMATE, V4, P785, DOI 10.1175/1520-0442(1991)004<0785:TROACO>2.0.CO;2	13	203	222	3	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1018	1020		10.1126/science.279.5353.1018	http://dx.doi.org/10.1126/science.279.5353.1018			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461431				2022-12-28	WOS:000072006400043
J	Gazelle, G				Gazelle, G			The slow code - Should anyone rush to its defense?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ADVANCE DIRECTIVES; CARDIOPULMONARY-RESUSCITATION; PHYSICIANS ATTITUDES; CARE; FUTILITY; PATIENT		Brigham & Womens Hosp, Harvard Vanguard Med Associates Div Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Vanguard Medical Associates	Gazelle, G (corresponding author), Brigham & Womens Hosp, Harvard Vanguard Med Associates Div Med, 75 Francis St, Boston, MA 02115 USA.							[Anonymous], 1992, ANN INTERN MED, V117, P947; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; DAVIDSON KW, 1989, JAMA-J AM MED ASSOC, V262, P2415, DOI 10.1001/jama.262.17.2415; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FOWLER MDM, 1989, HEART LUNG, V18, P533; GOLDENRING J, 1979, NEW ENGL J MED, V300, P1058; Jonsen A., 1986, CLIN ETHICS PRACTICA; LANDRY FJ, 1992, ARCH INTERN MED, V152, P2305, DOI 10.1001/archinte.152.11.2305; MARKSON LJ, 1994, ARCH INTERN MED, V154, P2321, DOI 10.1001/archinte.154.20.2321; MCCUE JD, 1995, JAMA-J AM MED ASSOC, V273, P1039, DOI 10.1001/jama.273.13.1039; MORRISON RS, 1994, ARCH INTERN MED, V154, P2311, DOI 10.1001/archinte.154.20.2311; MULLER JH, 1992, SOC SCI MED, V34, P885, DOI 10.1016/0277-9536(92)90257-Q; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; NEHER JO, 1988, J FAM PRACTICE, V27, P429; Nuland S.B., 1994, HOW WE DIE; *PC STUD ETH PROBL, 1983, DEC FOR LIF SUST TRE; REILLY BM, 1994, ARCH INTERN MED, V154, P2299, DOI 10.1001/archinte.154.20.2299; SACHS GA, 1992, J AM GERIATR SOC, V40, P269, DOI 10.1111/j.1532-5415.1992.tb02081.x; SAKLAYEN M, 1995, MEDICINE, V74, P163, DOI 10.1097/00005792-199507000-00001; Schneider A P 2nd, 1993, J Am Board Fam Pract, V6, P91; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; THOMASMA DC, 1983, ANN INTERN MED, V98, P243, DOI 10.7326/0003-4819-98-2-243; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; ZUGER A, 1989, JAMA-J AM MED ASSOC, V262, P2988	25	33	33	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 12	1998	338	7					467	469		10.1056/NEJM199802123380712	http://dx.doi.org/10.1056/NEJM199802123380712			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW122	9459653				2022-12-28	WOS:000071900100011
J	Avins, AL; Browner, WS				Avins, AL; Browner, WS			Improving the prediction of coronary heart disease to aid in the management of high cholesterol levels - What a difference a decade makes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK; HEALTH; PRAVASTATIN; ADULTS; MEN	Context.-A patients coronary heart disease (CHD) risk must be correctly classified to successfully apply risk-based guidelines for treatment of hypercholesterolemia. Objective.-To determine the classification accuracy of the National Cholesterol Education Program (NCEP) CHD risk-stratification system and compare it with a simple revised system that gives greater weight to age as a CHD risk factor. Design.-Modeling of 10-year CHD risk, using equations from the Framingham Heart Study applied to a cross-sectional survey of the US population. Subjects.-The 3284 subjects aged 20 to 74 years surveyed in the Second National Health and Nutrition Examination Survey (1978-1982) who had fasting lipid levels measured. Main Outcome Measures.-The area under the receiver operating characteristic curve (AUC) for 10-year CHD risk for the NCEP and revised scales. Results.-Among all adults with a low-density lipoprotein cholesterol value of at least 4.1 mmol/L (160 mg/dL), the NCEP system showed fairly good discrimination (AUC=0.90), though there was a substantial decline among men 35 to 74 years old and women 55 to 74 years old (AUC=0.81). By contrast, the revised system showed superior performance in all hypercholesterolemic adults (AUC=0.94-0.97) as well as in the subgroup of men 35 to 74 years old and women 55 to 74 years old (AUC=0.94-0.96). Conclusions.-Simple modifications of the NCEP treatment criteria result in a substantially improved ability to discriminate between higher and lower CHD risk groups. Unlike the NCEP system, this revised system retains its classification ability in all age groups studied.	Vet Affairs Med Ctr, Gen Internal Med Sect 111A1, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Avins, AL (corresponding author), Vet Affairs Med Ctr, Gen Internal Med Sect 111A1, 4150 Clement St, San Francisco, CA 94121 USA.	andy_avins@quickmail.ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL051024] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51024] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; Avins AL, 1996, ANN INTERN MED, V125, P502, DOI 10.7326/0003-4819-125-6-199609150-00012; DAVEYSMITH G, 1994, BRIT MED J, V308, P72; Forrester JS, 1997, AM J CARDIOL, V79, P790; Garber AM, 1996, ANN INTERN MED, V124, P518, DOI 10.7326/0003-4819-124-5-199603010-00013; Glick H, 1992, Int J Technol Assess Health Care, V8, P719; GOLDMAN L, 1992, CIRCULATION, V85, P1960, DOI 10.1161/01.CIR.85.5.1960; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; Manolio T A, 1992, Ann Epidemiol, V2, P161, DOI 10.1016/1047-2797(92)90051-Q; MCDOWELL A, 1981, PLAN OPERATION 2 NAT; MCISAAC WJ, 1991, J GEN INTERN MED, V6, P518, DOI 10.1007/BF02598220; MOSSMAN D, 1995, MED DECIS MAKING, V15, P358, DOI 10.1177/0272989X9501500406; PEDERSEN TR, 1994, LANCET, V344, P1765; PERKINS KA, 1986, AM J EPIDEMIOL, V124, P182, DOI 10.1093/oxfordjournals.aje.a114377; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; *STAT, 1996, STAT STAT SOFTW REL; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; *US BUR CENS, 1996, US POP EST AG SEX RA; ZWEIG MH, 1993, CLIN CHEM, V39, P561	23	28	29	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	1998	279	6					445	449		10.1001/jama.279.6.445	http://dx.doi.org/10.1001/jama.279.6.445			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV580	9466637				2022-12-28	WOS:000071839800032
J	Polat, U; Mizobe, K; Pettet, MW; Kasamatsu, T; Norcia, AM				Polat, U; Mizobe, K; Pettet, MW; Kasamatsu, T; Norcia, AM			Collinear stimuli regulate visual responses depending on cell's contrast threshold	NATURE			English	Article							CAT STRIATE CORTEX; SPATIAL INTERACTIONS; LATERAL INTERACTIONS; APPARENT CONTRAST; FACILITATION; SUPPRESSION; NEURONS; CONNECTIONS; PHYSIOLOGY; POTENTIALS	Neurons in the primary visual cortex are selective for the size, orientation and direction of motion of patterns falling within a restricted region of visual space known as the receptive field(1). The response to stimuli presented within the receptive field can be facilitated or suppressed by other stimuli falling outside the receptive field which, when presented in isolation, fail to activate the cell(2-8). Whether this interaction is facilitative(3,4,7,9-12) or suppressive(2,3,5,6,8-14) depends on the relative orientation of pattern elements inside and outside the receptive field. Here we show that neuronal facilitation preferentially occurs when a near-threshold stimulus inside the receptive field is flanked by higher-contrast, collinear elements located in surrounding regions of visual space. Collinear flanks and orthogonally oriented flanks, however, both act to reduce the response to high-contrast stimuli presented within the receptive field. The observed pattern of facilitation and suppression may be the cellular basis for the observation in humans that the detectability of an oriented pattern is enhanced by collinear flanking elements(15-17). Modulation of neuronal responses by stimuli falling outside their receptive fields may thus represent an early neural mechanism for encoding objects and enhancing-their perceptual saliency.	Smith Kettlewell Eye Res Inst, San Francisco, CA 94115 USA	The Smith-Kettlewell Eye Research Institute	Kasamatsu, T (corresponding author), Smith Kettlewell Eye Res Inst, 2232 Webster St, San Francisco, CA 94115 USA.							ALBRECHT DG, 1982, J NEUROPHYSIOL, V48, P217, DOI 10.1152/jn.1982.48.1.217; BLAKEMORE C, 1972, EXP BRAIN RES, V15, P439; CANNON MW, 1993, VISION RES, V33, P1685, DOI 10.1016/0042-6989(93)90034-T; CANNON MW, 1991, VISION RES, V31, P1985, DOI 10.1016/0042-6989(91)90193-9; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P659, DOI 10.1113/jphysiol.1991.sp018730; Douglas RJ, 1989, NEURAL COMPUT, V1, P480, DOI 10.1162/neco.1989.1.4.480; Fitzpatrick D, 1996, CEREB CORTEX, V6, P329, DOI 10.1093/cercor/6.3.329; GILBERT CD, 1989, J NEUROSCI, V9, P2432; HEEGER DJ, 1992, VISUAL NEUROSCI, V9, P181, DOI 10.1017/S0952523800009640; HIRSCH JA, 1991, J NEUROSCI, V11, P1800; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; KAPADIA MK, 1995, NEURON, V15, P843, DOI 10.1016/0896-6273(95)90175-2; KITANO M, 1994, VISUAL NEUROSCI, V11, P953, DOI 10.1017/S0952523800003904; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; Levitt JB, 1997, NATURE, V387, P73, DOI 10.1038/387073a0; LI CY, 1994, VISION RES, V34, P2337, DOI 10.1016/0042-6989(94)90280-1; MAFFEI L, 1976, VISION RES, V16, P1131, DOI 10.1016/0042-6989(76)90253-4; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MIZOBE K, 1996, ASS RES OPHTH ABSTR, V37, pS493; NELSON JI, 1985, EXP BRAIN RES, V61, P54; NORCIA AM, 1985, IEEE ENG MED BIOL, V4, P26, DOI 10.1109/MEMB.1985.5006224; Polat U, 1996, VISION RES, V36, P2099, DOI 10.1016/0042-6989(95)00281-2; POLAT U, 1993, VISION RES, V33, P993, DOI 10.1016/0042-6989(93)90081-7; POLAT U, 1994, VISION RES, V34, P73, DOI 10.1016/0042-6989(94)90258-5; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; Somers D., 1994, Society for Neuroscience Abstracts, V20, P1577; SOMERS DC, IN PRESS CEREBR CORT; STEMMLER M, 1995, SCIENCE, V269, P1877, DOI 10.1126/science.7569930; Toth LJ, 1996, P NATL ACAD SCI USA, V93, P9869, DOI 10.1073/pnas.93.18.9869; VICTOR JD, 1991, ELECTROEN CLIN NEURO, V78, P378, DOI 10.1016/0013-4694(91)90099-P	30	464	471	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 5	1998	391	6667					580	584		10.1038/35372	http://dx.doi.org/10.1038/35372			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468134				2022-12-28	WOS:000071842300050
J	Mons, B; Klasen, E; van Kessel, R; Nchinda, T				Mons, B; Klasen, E; van Kessel, R; Nchinda, T			Policy: Biomedicine - Partnership between south and north crystallizes around malaria	SCIENCE			English	Article									Netherlands Org Sci Res, NL-2593 BM The Hague, Netherlands; WHO, TDR, Geneva, Switzerland	World Health Organization	Mons, B (corresponding author), Netherlands Org Sci Res, NL-2593 BM The Hague, Netherlands.			Mons, Barend/0000-0003-3934-0072				Butler D, 1997, NATURE, V386, P535, DOI 10.1038/42306; *WELC TRUST, 1996, 7 PRISM WELC TRUST; 1997, COUNCIL RESOLUTION R	3	13	13	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					498	499		10.1126/science.279.5350.498	http://dx.doi.org/10.1126/science.279.5350.498			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9454348				2022-12-28	WOS:000071616000026
J	Nielsen, LLW; Nielsen, NM; Melbye, M; Sodermann, M; Jacobsen, M; Aaby, P				Nielsen, LLW; Nielsen, NM; Melbye, M; Sodermann, M; Jacobsen, M; Aaby, P			Exposure to measles in utero and Crohn's disease: Danish register study	BRITISH MEDICAL JOURNAL			English	Article							VIRUS INFECTION		Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark; Danish Epidemiol Sci Ctr, Inst Epidemiol & Social Med, Aarhus, Denmark	Aarhus University; Statens Serum Institut; Aarhus University	Nielsen, LLW (corresponding author), Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark.			melbye, mads/0000-0001-8264-6785; Aaby, Peter/0000-0001-8331-1389				Ekbom A, 1996, LANCET, V348, P515, DOI 10.1016/S0140-6736(96)04429-7; EKBOM A, 1994, LANCET, V344, P508, DOI 10.1016/S0140-6736(94)91898-8; Jones P, 1997, LANCET, V349, P473, DOI 10.1016/S0140-6736(05)61184-1; WAKEFIELD AJ, 1993, J MED VIROL, V39, P345, DOI 10.1002/jmv.1890390415; WAKEFIELD AJ, 1995, GASTROENTEROLOGY, V108, P911, DOI 10.1016/0016-5085(95)90467-0	5	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					196	197						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468686	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000071616400027
J	Casscells, W				Casscells, W			Prevention works; So does treatment (if you make it to the doctor)	LANCET			English	Article									ST LUKES EPISCOPAL HOSP,TEXAS HEART INST,HOUSTON,TX 77225	Saint Lukes Episcopal Hospital; Texas Heart Institute	Casscells, W (corresponding author), UNIV TEXAS,HERMANN HOSP,6431 FANNIN,POB 20708,HOUSTON,TX 77225, USA.							[Anonymous], 1995, LANCET, V346, P1179; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; PACKER M, 1995, CIRCULATION S1, V92, P142; SERRUYS PW, 1995, CIRCULATION S1, V92, P542; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S2	S2		10.1016/0140-6736(95)90001-2	http://dx.doi.org/10.1016/0140-6736(95)90001-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454037				2022-12-28	WOS:A1995TN12200002
J	Nitti, VW; Lepor, H				Nitti, VW; Lepor, H			Controversies old and new	LANCET			English	Article											Nitti, VW (corresponding author), NYU,MED CTR,DEPT UROL,NEW YORK,NY 10016, USA.			Nitti, Victor/0000-0002-1390-7053				AUS G, 1995, J UROLOGY, V154, P460, DOI 10.1016/S0022-5347(01)67074-5; GRASSO M, 1995, UROLOGY, V45, P372, DOI 10.1016/S0090-4295(99)80003-X; HOLTGREWE HL, 1995, UROLOGY, V46, P23; TROTMAN BA, 1995, J UROLOGY, V154, P1841; YALLA SV, 1995, J UROLOGY, V153, P674, DOI 10.1016/S0022-5347(01)67682-1	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S26	S26		10.1016/0140-6736(95)90025-X	http://dx.doi.org/10.1016/0140-6736(95)90025-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454044	hybrid			2022-12-28	WOS:A1995TN12200026
J	Treacy, PJ; Johnson, AG				Treacy, PJ; Johnson, AG			Is the laparoscopic bubble bursting?	LANCET			English	Article											Treacy, PJ (corresponding author), ROYAL HALLAMSHIRE HOSP,DEPT SURG & ANAESTHET SCI,GLOSSOP RD,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND.							Macintyre I M, 1995, J R Coll Surg Edinb, V40, P331; MAJEED AW, 1994, P ANN SCI M HARR, P27; MARTIN LC, 1995, ANN SURG, V222, P256, DOI 10.1097/00000658-199509000-00004; MCGINN FP, 1995, BRIT J SURG, V82, P1374, DOI 10.1002/bjs.1800821027; MCMAHON AJ, 1994, LANCET, V343, P135, DOI 10.1016/S0140-6736(94)90932-6	5	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S23	S23		10.1016/0140-6736(95)90022-5	http://dx.doi.org/10.1016/0140-6736(95)90022-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454041				2022-12-28	WOS:A1995TN12200023
J	Gastel, JA; Roseboom, PH; Rinaldi, PA; Weller, JL; Klein, DC				Gastel, JA; Roseboom, PH; Rinaldi, PA; Weller, JL; Klein, DC			Melatonin production: Proteasomal proteolysis in serotonin N-acetyltransferase regulation	SCIENCE			English	Article							LIGHT-INDUCED DECREASE; PINEAL-GLAND; PROTEIN; UBIQUITIN; SECRETION; PATHWAY; TURNOVER; RHYTHM; ORGAN	The nocturnal increase in circulating melatonin in vertebrates is regulated bg, 10- to 100-fold increases in pineal serotonin N-acetyltransferase (AA-NAT) activity. Changes in the amount of AA-NAT protein were shown to parallel changes in AA-NAT activity. When neural stimulation was switched off by either light exposure or L-propranalol-induced beta-adrenergic blockade, both AA-NAT activity and protein decreased rapidly. Effects of L-propranolol were blocked in vitro by dibutyryl adenosine 3',5'-monophasphate (cAMP) or inhibitors of proteasomal proteolysis. This result indicates that adrenergic-cAMP regulation of AA-NAT is mediated by rapid reversible control af selective proteasomal proteolysis. Similar proteasome-based mechanisms may function widely as selective molecular switches in vertebrate neural systems.	NICHHD, Sect Neuroendocrinol, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Klein, DC (corresponding author), NICHHD, Sect Neuroendocrinol, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA.	klein@helix.nih.gov		Klein, David/0000-0002-1792-5806				Arendt J., 1995, MELATONIN MAMMALIAN, P1; AXELROD J, 1974, SCIENCE, V184, P1341, DOI 10.1126/science.184.4144.1341; Baler R, 1997, J BIOL CHEM, V272, P6979, DOI 10.1074/jbc.272.11.6979; Bernard M, 1997, J NEUROCHEM, V68, P213; BINKLEY S, 1975, ENDOCRINOLOGY, V96, P848, DOI 10.1210/endo-96-4-848; BITTMAN EL, 1983, ENDOCRINOLOGY, V113, P2276, DOI 10.1210/endo-113-6-2276; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; BROWNSTEIN M, 1974, SCIENCE, V184, P163, DOI 10.1126/science.184.4133.163; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; COSTELLI P, 1995, J CLIN INVEST, V95, P2367, DOI 10.1172/JCI117929; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DECKER RS, 1993, AM J PHYSIOL, V265, pH329, DOI 10.1152/ajpheart.1993.265.1.H329; DEGUCHI T, 1972, P NATL ACAD SCI USA, V69, P2547, DOI 10.1073/pnas.69.9.2547; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; FALCON J, 1989, J NEUROSCI, V9, P1943; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GASTEL JA, UNPUB; HAMM HE, 1983, BRAIN RES, V266, P287, DOI 10.1016/0006-8993(83)90660-1; Hegde AN, 1997, CELL, V89, P115, DOI 10.1016/S0092-8674(00)80188-9; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; ILLNEROVA H, 1979, J NEUROCHEM, V32, P673, DOI 10.1111/j.1471-4159.1979.tb00407.x; ILLNEROVA H, 1971, LIFE SCI, V10, P955, DOI 10.1016/0024-3205(71)90360-2; KARSCH FJ, 1991, SUPRACHIASMATIC NUCL, P217; KLEIN DC, 1970, SCIENCE, V169, P1093, DOI 10.1126/science.169.3950.1093; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; KLEIN DC, 1972, SCIENCE, V177, P532, DOI 10.1126/science.177.4048.532; KLEIN DC, 1992, BIOCHEM SOC T, V20, P299, DOI 10.1042/bst0200299; KLEIN DC, 1978, SCIENCE, V199, P309, DOI 10.1126/science.202027; KLEIN DC, 1970, SCIENCE, V167, P1738, DOI 10.1126/science.167.3926.1738; LERNER AB, 1960, J BIOL CHEM, V235, P1992; LEWY AJ, 1980, SCIENCE, V210, P1267, DOI 10.1126/science.7434030; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; NAMBOODIRI MAA, 1987, METHOD ENZYMOL, V142, P583; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROLLAG MD, 1976, ENDOCRINOLOGY, V98, P482, DOI 10.1210/endo-98-2-482; ROMERO JA, 1975, P NATL ACAD SCI USA, V72, P2107, DOI 10.1073/pnas.72.6.2107; Roseboom PH, 1996, ENDOCRINOLOGY, V137, P3033, DOI 10.1210/en.137.7.3033; TAMARKIN L, 1977, SCIENCE, V198, P953, DOI 10.1126/science.563102; WAYNE DW, 1995, BIOSTATISTICS, P210; WELLER J, 1996, BRAIN RES, V25, P713	43	244	249	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	1998	279	5355					1358	1360		10.1126/science.279.5355.1358	http://dx.doi.org/10.1126/science.279.5355.1358			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478897				2022-12-28	WOS:000072251800052
J	Moreira, M; Kunz, J; Allegre, C				Moreira, M; Kunz, J; Allegre, C			Rare gas systematics in popping rock: Isotopic and elemental compositions in the upper mantle	SCIENCE			English	Article							MID-ATLANTIC RIDGE; NOBLE-GASES; ULTRAMAFIC XENOLITHS; BASALT GLASSES; NEON; HELIUM; EVOLUTION; XENON; 14-DEGREES-N; ORIGIN	New experimental data on the isotopic variations of neon, argon, and xenon in a popping rock imply that the Ar-40/Ar-36 ratio of the upper mantle is less than 44,000 and that the Xe-129/Xe-130 ratio is less than 8.2. The elemental abundance pattern of rare gases is chondritic-like and is quite distinct from the solar pattern. These data imply that Earth accreted from planetesimals that probably underwent a transformation of their rare gas budget from solar- to chondritic-like, leaving the isotopic composition unchanged from the solar pattern.	Univ Paris 07, Lab Geochim & Cosmochim, Inst Phys Globe, CNRS,URA 1758, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Moreira, M (corresponding author), Univ Paris 07, Lab Geochim & Cosmochim, Inst Phys Globe, CNRS,URA 1758, 4 Pl Jussieu, F-75252 Paris 05, France.		moreira, manuel/H-5329-2017	moreira, manuel/0000-0001-5845-4660				Allegre C.J., 1986, EARTH PLANET SC LETT, V81, P127; ALLEGRE CJ, 1995, GEOPHYS RES LETT, V22, P2325, DOI 10.1029/95GL02307; ALLEGRE CJ, 1983, NATURE, V303, P762, DOI 10.1038/303762a0; AZBEL IYA, 1993, METEORITICS, V28, P609, DOI 10.1111/j.1945-5100.1993.tb00631.x; BENKERT JP, 1993, J GEOPHYS RES-PLANET, V98, P13147, DOI 10.1029/93JE01460; Burnard P, 1997, SCIENCE, V276, P568, DOI 10.1126/science.276.5312.568; CRAIG H, 1976, EARTH PLANET SC LETT, V31, P369, DOI 10.1016/0012-821X(76)90118-7; CZIMA M, 1983, NOBLE GAS GEOCHEMIST, P1; DYMOND J, 1973, EARTH PLANET SC LETT, V20, P131, DOI 10.1016/0012-821X(73)90150-7; FANALE F, 1971, EARTH PLANET SC LETT, V11, P361; Harper CL, 1996, SCIENCE, V273, P1814, DOI 10.1126/science.273.5283.1814; HONDA M, 1991, NATURE, V349, P149, DOI 10.1038/349149a0; Hunten D.M., 1987, ICARUS, V43, P22; JAVOY M, 1991, EARTH PLANET SC LETT, V107, P598, DOI 10.1016/0012-821X(91)90104-P; KANEOKA I, 1978, EARTH PLANET SC LETT, V39, P382, DOI 10.1016/0012-821X(78)90026-2; KELLOGG LH, 1990, EARTH PLANET SC LETT, V99, P276, DOI 10.1016/0012-821X(90)90116-F; KURZ MD, 1982, NATURE, V297, P43, DOI 10.1038/297043a0; KYSER TK, 1982, J GEOPHYS RES, V87, P5611, DOI 10.1029/JB087iB07p05611; MARTY B, 1989, EARTH PLANET SC LETT, V94, P45, DOI 10.1016/0012-821X(89)90082-4; Marty B., 1994, NOBLE GAS GEOCHEMIST, P191; MAZOR E, 1970, GEOCHIM COSMOCHIM AC, V34, P781, DOI 10.1016/0016-7037(70)90031-1; MOREIRA M, 1995, EARTH PLANET SC LETT, V133, P367, DOI 10.1016/0012-821X(95)00080-V; Moreira M, 1996, GEOPHYS RES LETT, V23, P2453, DOI 10.1029/96GL02301; MOREIRA M, IN PRESS CHEM GEOL; Niedermann S, 1997, GEOCHIM COSMOCHIM AC, V61, P2697, DOI 10.1016/S0016-7037(97)00102-6; ONIONS RK, 1994, EARTH PLANET SC LETT, V124, P131, DOI 10.1016/0012-821X(94)00070-0; OWEN T, 1992, NATURE, V358, P43, DOI 10.1038/358043a0; OZIMA M, 1993, GEOCHEM J, V27, P185, DOI 10.2343/geochemj.27.185; OZIMA M, 1994, REV GEOPHYS, V32, P405, DOI 10.1029/94RG01875; PEPIN RO, 1991, ICARUS, V92, P2, DOI 10.1016/0019-1035(91)90036-S; PINEAU F, 1994, EARTH PLANET SC LETT, V123, P179, DOI 10.1016/0012-821X(94)90266-6; PODOSEK FA, 1981, GEOCHIM COSMOCHIM AC, V45, P2401, DOI 10.1016/0016-7037(81)90094-6; PORCELLI D, 1995, GEOCHIM COSMOCHIM AC, V59, P4921, DOI 10.1016/0016-7037(95)00336-3; POREDA RJ, 1992, EARTH PLANET SC LETT, V113, P129, DOI 10.1016/0012-821X(92)90215-H; SARDA P, 1990, EARTH PLANET SC LETT, V97, P268, DOI 10.1016/0012-821X(90)90047-2; SARDA P, 1988, EARTH PLANET SC LETT, V91, P73, DOI 10.1016/0012-821X(88)90152-5; STAUDACHER T, 1989, EARTH PLANET SC LETT, V96, P119, DOI 10.1016/0012-821X(89)90127-1; STAUDACHER T, 1986, CHEM GEOL, V56, P193, DOI 10.1016/0009-2541(86)90003-3; STAUDACHER T, 1994, MINERAL MAG A, V58, P874; STAUDACHER T, 1990, CHEM GEOL, V59, P35; Valbracht PJ, 1996, EARTH PLANET SC LETT, V138, P29, DOI 10.1016/0012-821X(95)00226-3; Valbracht PJ, 1997, EARTH PLANET SC LETT, V150, P399, DOI 10.1016/S0012-821X(97)00094-0; WACKER JF, 1989, GEOCHIM COSMOCHIM AC, V53, P1421; WIELER R, 1991, GEOCHIM COSMOCHIM AC, V55, P1709, DOI 10.1016/0016-7037(91)90141-Q; YANG J, 1982, GEOCHIM COSMOCHIM AC, V46, P877, DOI 10.1016/0016-7037(82)90044-8; Yatsevich I, 1997, J GEOPHYS RES-SOL EA, V102, P10291, DOI 10.1029/97JB00395	46	311	320	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1178	1181		10.1126/science.279.5354.1178	http://dx.doi.org/10.1126/science.279.5354.1178			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469801				2022-12-28	WOS:000072115200033
J	Newacheck, PW; Stoddard, JJ; Hughes, DC; Pearl, M				Newacheck, PW; Stoddard, JJ; Hughes, DC; Pearl, M			Health insurance and access to primary care for children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; AMBULATORY CARE; MEDICAL-CARE; ADOLESCENTS; SERVICES; RACE	Background Numerous studies have demonstrated that insurance status influences the amount of ambulatory care received by children, but few have assessed the role of insurance as a determinant of children's access to primary care. We studied the effect of health insurance on children's access to primary care. Methods We analyzed a sample of 49,367 children under 18 years of, age from the 1993-1994 National Health Interview Survey, a nationwide household survey. The overall rate of response was 86.5 percent. The survey included questions on insurance coverage and access to primary care. Results An estimated 13 percent of U.S. children did not have health insurance in 1993-1994. Uninsured children were less likely than insured children to have a usual source of care (75.9 percent vs. 96.2 percent, P<0.001). Among those with a usual source of care, uninsured children were more likely than insured children to have no regular physician (24.3 percent vs. 13.8 percent, P<0.001), to be without ac cess to medical care after normal business hours (11.8 percent vs. 7.0 percent, P<0.001), and to have families that were dissatisfied with at least one aspect of their care (19.6 percent vs. 14.0 percent, P=0.01). Uninsured children were more likely than insured children to have gone without needed medical, dental, or other health care (22.2 percent vs. 6.1 percent, P<0.001). Uninsured children were also less likely than insured children to have had contact with a physician during the previous year (67.4 percent vs. 83.8 percent, P<0.001). All differences remained significant after we controlled for potential confounders using linear and logistic regression. Conclusions Among children, having health insurance is strongly associated with access to primary care. The new children's health insurance program enacted as part of the Balanced Budget Act of 1997 may substantially improve access to and use of primary care by children. (C) 1998, Massachusetts Medical Society.	Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94109 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94109 USA; Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94109 USA; Univ Wisconsin, Dept Pediat, Madison, WI USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Wisconsin System; University of Wisconsin Madison	Newacheck, PW (corresponding author), Univ Calif San Francisco, Inst Hlth Policy Studies, 1388 Sutter St,Suite 1100, San Francisco, CA 94109 USA.							ADAY LA, 1993, MED CARE, V31, P1013, DOI 10.1097/00005650-199311000-00004; *AM AC PED, 1993, AM ACAD PEDIAT NEWS, V9, P7; BENSON V, 1994, VITAL HLTH STAT 10, V190; Currie J, 1996, Q J ECON, V111, P431, DOI 10.2307/2946684; Ettner SL, 1996, AM J PUBLIC HEALTH, V86, P1748, DOI 10.2105/AJPH.86.12.1748; *GEN ACC OFF, 1996, PUBL GAO; *GOV ACC OFF, 1997, PUBL GAO; HOLL JL, 1995, ARCH PEDIAT ADOL MED, V149, P398, DOI 10.1001/archpedi.1995.02170160052008; KOGAN MD, 1995, JAMA-J AM MED ASSOC, V274, P1429, DOI 10.1001/jama.274.18.1429; LEIBOWITZ A, 1985, PEDIATRICS, V75, P942; LIEU TA, 1993, AM J PUBLIC HEALTH, V83, P960, DOI 10.2105/AJPH.83.7.960; MUSTIN HD, 1994, JAMA-J AM MED ASSOC, V272, P111; NEWACHECK PW, 1992, MED CARE, V30, P30, DOI 10.1097/00005650-199201000-00003; Newacheck PW, 1996, PEDIATRICS, V97, P26; NEWACHECK PW, 1997, HLTH CARE CHILDREN W, P53; Shah BV, 1996, SUDAAN USERS MANUAL; Starfield B., 1992, PRIMARY CARE CONCEPT; STODDARD JJ, 1994, NEW ENGL J MED, V330, P1421, DOI 10.1056/NEJM199405193302006; VALDEZ RB, 1985, PEDIATRICS, V75, P952; Wehr E, 1994, Future Child, V4, P115, DOI 10.2307/1602437; WOOD DL, 1990, PEDIATRICS, V86, P666	21	322	323	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 19	1998	338	8					513	519		10.1056/NEJM199802193380806	http://dx.doi.org/10.1056/NEJM199802193380806			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YX639	9468469				2022-12-28	WOS:000072061400006
J	Best, PJM; Berger, PB; Miller, VM; Lerman, A				Best, PJM; Berger, PB; Miller, VM; Lerman, A			The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women	ANNALS OF INTERNAL MEDICINE			English	Article							SMOOTH-MUSCLE CELLS; FOLLOW-UP; CORONARY ATHEROSCLEROSIS; 17-BETA-ESTRADIOL; DISEASE; GROWTH; AORTA	Background: Estrogen replacement therapy (ERT) in postmenopausal women decreases cardiac mortality and improves endothelial function. The endothelium regulates vascular tone and growth by releasing such factors as nitric oxide and endothelin-l. Objective: To determine whether ERT alters the balance between the total oxidized products of nitric oxide and endothelin-l. Design: Single-arm, before-after clinical trial. Setting: Outpatient clinical research center of an academic medical center. Patients: 15 postmenopausal women. Intervention: Treatment with 17 beta-estradiol for 6 months and a 10-day course of methoxyprogesterone every 3 months. Measurements: Plasma nitric oxide and endothelin-l levels were measured at baseline and after 6 months of ERT. Results: The mean baseline nitric oxide level was 27.5 nmol/mL (range, 20.3 to 34.8 nmol/mL) and increased by a mean of 7.2 nmol/ml (range, 0.2 to 14.1 nmol/ml) (P = 0.04). The mean baseline plasma endothelin-l level was 16.4 pg/mL (range, 12.0 to 20.8 pg/mL) and decreased by a mean of 3.9 pg/mL (range, 0.4 to 7.8 pg/mL) (P = 0.04). The mean baseline ratio of nitric oxide to endothelin-l was 2.0 (range, 1.3 to 2.8) and increased by 1.2 (range, 0.1 to 2.2) (P = 0.03). Conclusion: ERT results in an increased ratio of nitric oxide to endothelin-l. This may be one mechanism by which ERT provides cardiovascular benefit.	Mayo Clin & Mayo Fdn, Dept Internal Med & Cardiovasc Dis, Rochester, MN 55905 USA	Mayo Clinic	Lerman, A (corresponding author), Mayo Clin & Mayo Fdn, Dept Internal Med & Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051736] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07111-21D, HL51736] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; BRAMAN RS, 1989, ANAL CHEM, V61, P2715, DOI 10.1021/ac00199a007; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; Busse R, 1996, J VASC RES, V33, P181, DOI 10.1159/000159147; COLLINS P, 1995, CIRCULATION, V92, P24, DOI 10.1161/01.CIR.92.1.24; DUBEY RK, 1994, J PHARMACOL EXP THER, V269, P402; Duckles SP, 1996, J PHARMACOL EXP THER, V279, P1; GISCLARD V, 1988, J PHARMACOL EXP THER, V244, P19; GOETZ RM, 1994, BIOCHEM BIOPH RES CO, V205, P905, DOI 10.1006/bbrc.1994.2750; LERMAN A, 1995, CIRCULATION, V92, P2426, DOI 10.1161/01.CIR.92.9.2426; LOSCALZO J, 1995, PROG CARDIOVASC DIS, V38, P87, DOI 10.1016/S0033-0620(05)80001-5; Mathew V, 1996, MAYO CLIN PROC, V71, P769; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; POLDERMAN KH, 1993, ANN INTERN MED, V118, P429, DOI 10.7326/0003-4819-118-6-199303150-00006; QUYYUMI AA, 1995, J CLIN INVEST, V95, P1747, DOI 10.1172/JCI117852; RODEHEFFER RJ, 1992, MAYO CLIN PROC, V67, P719, DOI 10.1016/S0025-6196(12)60795-2; ROSSELLI M, 1995, HYPERTENSION, V25, P848, DOI 10.1161/01.HYP.25.4.848; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; WEISSBERG PL, 1990, ATHEROSCLEROSIS, V85, P257, DOI 10.1016/0021-9150(90)90118-3; YLIKORKALA O, 1995, J CLIN ENDOCR METAB, V80, P3384, DOI 10.1210/jc.80.11.3384	20	174	178	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1998	128	4					285	288		10.7326/0003-4819-128-4-199802150-00006	http://dx.doi.org/10.7326/0003-4819-128-4-199802150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX170	9471931				2022-12-28	WOS:000072013400005
J	McClung, M; Clemmesen, B; Daifotis, A; Gilchrist, NL; Eisman, J; Weinstein, RS; El-Hajj Fuleihan, G; Reda, C; Yates, AJ; Ravn, P				McClung, M; Clemmesen, B; Daifotis, A; Gilchrist, NL; Eisman, J; Weinstein, RS; El-Hajj Fuleihan, G; Reda, C; Yates, AJ; Ravn, P		Alendronate Osteoporosis Prevention Study Grp	Alendronate prevents postmenopausal bone loss in women without osteoporosis - A double-blind, randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						osteoporosis, postmenopausal; alendronate; menopause; bone density; fractures	HORMONE-REPLACEMENT THERAPY; CALCIUM SUPPLEMENTATION; HIP-FRACTURES; DENSITY; PREDICTION; ETIDRONATE; ESTROGENS; MENOPAUSE; DRUG; RISK	Background: Preventing bone loss associated with menopause and aging and maintaining the normal microarchitecture of bone provide important opportunities for the prevention of osteoporosis and fractures. Objective: To determine the safety and efficacy of alendronate, an aminobisphosphonate, for preventing postmenopausal bone loss. Design: 3-year double-blind, randomized, placebo-controlled trial. Setting: 15 osteoporosis centers throughout the world. Participants: 447 women who had recently experienced menopause (6 to 36 months before study entry). Intervention: Participants were randomly assigned to one of five regimens: oral placebo; oral alendronate, 1, 5, or 10 mg/d; or oral alendronate, 20 mg/d for 2 years followed by placebo during the third year (20/0 mg/d). Measurements: Bone mineral density was measured by dual-energy x-ray absorptiometry. Bone turnover and bone quality were assessed with biochemical markers and bone histomorphometry. Results: Alendronate at 5, 10, and 20/0 mg/d increased bone mineral density from baseline at the lumbar spine, femoral neck, and trochanter by 1% to 4% and in the total body by 0.3% to 1.0%; placebo led to losses of 2% to 4% at these sites. Alendronate, 1 mg/d, attenuated losses relative to those seen with placebo. Alendronate decreased markers of bone resorption to a new steady state by 3 months and decreased markers of bone formation by 6 to 12 months. Bone quality remained normal. At all dosages studied, alendronate had a safety and tolerability profile similar to that of placebo. Conclusions: In early postmenopausal women, alendronate given for 3 years at dosages of 5 mg/d or greater prevented the loss of bone mineral density at the spine and hip and in the total body. Alendronate seems to be a safe and effective nonhormonal option for prevention of postmenopausal bone loss.	Oregon Osteoporosis Ctr, Providence Hlth Syst, Portland, OR 97213 USA; Ctr Clin & Basic Res, Ballerup 2750, Denmark; Merck & Co Inc, Rahway, NJ 07065 USA; Princess Margaret Hosp, Christchurch 8002, New Zealand; St Vincents Hosp, Sydney, NSW 2010, Australia; Univ Arkansas Med Sci, Little Rock, AR 72205 USA; Brigham & Womens Hosp, Boston, MA 02215 USA	Oregon Osteoporosis Center; Center Clinical & Basic Research; Merck & Company; St Vincents Hospital Sydney; University of Arkansas System; University of Arkansas Medical Sciences; Harvard University; Brigham & Women's Hospital	McClung, M (corresponding author), Oregon Osteoporosis Ctr, Providence Hlth Syst, 5050 NE Hoyt St,Suite 651, Portland, OR 97213 USA.		McClung, Michael/ABA-4100-2021; Eisman, John A/C-2886-2014; Ravn, Pernillle/AAT-9761-2020	McClung, Michael/0000-0002-7827-0778; Ravn, Pernillle/0000-0001-8752-1121				ALOIA JF, 1994, ANN INTERN MED, V120, P97, DOI 10.7326/0003-4819-120-2-199401150-00001; ARLOT MC, 1995, J BONE MINER RES, V10, pS199; BALENA R, 1993, J CLIN INVEST, V92, P2577, DOI 10.1172/JCI116872; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; BOYCE WJ, 1985, LANCET, V1, P150; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; CAPIZZI T, 1992, BIOMETRICAL J, V34, P275, DOI 10.1002/bimj.4710340303; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Chesnut CH, 1997, AM J MED, V102, P29, DOI 10.1016/S0002-9343(96)00387-7; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; ELDERS PJM, 1988, BONE MINER, V5, P11, DOI 10.1016/0169-6009(88)90003-7; ENSRUD KE, 1995, J BONE MINER RES, V10, P1778; FAULKNER KG, 1995, OSTEOPOROSIS INT, V5, P218, DOI 10.1007/BF01774010; FIELD CS, 1993, AM J OBSTET GYNECOL, V168, P114, DOI 10.1016/S0002-9378(12)90897-2; HANSEN MA, 1995, J BONE MINER RES, V10, P205; HARRIS RB, 1990, AM J PUBLIC HEALTH, V80, P1266, DOI 10.2105/AJPH.80.10.1266; JONES G, 1994, BRIT MED J, V309, P691, DOI 10.1136/bmj.309.6956.691; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756-3282(96)00182-2; MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902; NGUYEN T, 1993, BRIT MED J, V307, P1111, DOI 10.1136/bmj.307.6912.1111; PRINCE RL, 1991, NEW ENGL J MED, V325, P1189, DOI 10.1056/NEJM199110243251701; Raisz LG, 1996, J CLIN ENDOCR METAB, V81, P37, DOI 10.1210/jc.81.1.37; REGINSTER JY, 1987, LANCET, V2, P1481; REGINSTER JY, 1989, LANCET, V2, P1469; Reid IR, 1996, AM J MED, V101, P341, DOI 10.1016/S0002-9343(96)00227-6; REID IR, 1993, NEW ENGL J MED, V328, P460, DOI 10.1056/NEJM199302183280702; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; RYAN PJ, 1992, BRIT J OBSTET GYNAEC, V99, P325, DOI 10.1111/j.1471-0528.1992.tb13732.x; Siris E, 1996, J CLIN ENDOCR METAB, V81, P961, DOI 10.1210/jc.81.3.961; Speroff L, 1996, JAMA-J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397; TUKEY JW, 1985, BIOMETRICS, V41, P295, DOI 10.2307/2530666; World Health Organization, 1994, WHO TECHN REP SER, V843	37	213	225	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1998	128	4					253	+		10.7326/0003-4819-128-4-199802150-00001	http://dx.doi.org/10.7326/0003-4819-128-4-199802150-00001			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX170	9471927				2022-12-28	WOS:000072013400001
J	Giroir, BP				Giroir, BP			Bactericidal/permeability-increasing protein for severe meningococcal sepsis - Reply	LANCET			English	Letter									Univ Texas, SW Med Sch, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Giroir, BP (corresponding author), Univ Texas, SW Med Sch, Dallas, TX 75235 USA.								0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	1998	351	9101					526	526						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482481				2022-12-28	WOS:000072097700060
J	Kadir, RA; Economides, DL; Sabin, CA; Owens, D; Lee, CA				Kadir, RA; Economides, DL; Sabin, CA; Owens, D; Lee, CA			Frequency of inherited bleeding disorders in women with menorrhagia	LANCET			English	Article							FACTOR-XI DEFICIENCY; MENSTRUAL BLOOD-LOSS; VON-WILLEBRAND DISEASE; VONWILLEBRANDS DISEASE; COAGULATION DISORDERS; FACTOR-VIII; DEFINITION; PREVALENCE; DIAGNOSIS; ANTIGEN	Background Although menorrhagia is a common gynaecological symptom, a specific cause is identified in less than 50% of affected women. We investigated the frequency of inherited bleeding disorders in women with menorrhagia. Methods Women referred for investigation of menorrhagia whose pelvis was normal on clinical examination and who had an estimated menstrual blood loss of more than 80 mL were studied. A detailed menstrual history and history about other bleeding symptoms was taken. The activated partial thromboplastin time, factor VIII activity, von-Willebrand-factor antigen and activity, and factor XI (FXI) were measured in all patients; further tests were done when results were at or outside the limits of the assays. Findings 150 women were screened. An inherited bleeding disorder was diagnosed in 26 (17%) patients: the disorders were von Willebrand's disease of mild (15) or moderate severity (three), mild FXI deficiency (four), mild von Willebrand's disease and FXI deficiency (one), combined von Willebrand's disease, FXI deficiency, and factor X deficiency (one), carriage of haemophilia-A gene (one), and platelet dysfunction (one). The frequency of von Willebrand's disease and FXI deficiency were 13% (95% CI 7.9-18.8%) and 4% (1.5-8.5%), respectively. Menorrhagia since menarche was noted in 11 (8.9%) of 123 women without a bleeding disorder compared with 13 (65%) of 20 women with von Willebrand's disease (p=0.001) and four (66.7%) of six women with FXI deficiency (p<0.001). Interpretation Inherited bleeding disorders are found in a substantial proportion of women with menorrhagia and a normal pelvis examination. We suggest that such patients should be investigated for these disorders-especially von Willebrand's disease-before invasive procedures are done.	Univ London Royal Free Hosp, Sch Med, Dept Obstet & Gynaecol, London NW3 2QG, England; Royal Free Hosp, Sch Med, Dept Primary Care & Populat Sci, London NW3 2QG, England; Royal Free Hosp, Sch Med, Haemophilia Ctr, London NW3 2QG, England; Royal Free Hosp, Sch Med, Haemostasis Unit, London NW3 2QG, England	University of London; University College London; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Economides, DL (corresponding author), Univ London Royal Free Hosp, Sch Med, Dept Obstet & Gynaecol, Pond St, London NW3 2QG, England.		Abdulkadir, Rezan/C-5589-2008; Sabin, Caroline/C-2464-2008	Sabin, Caroline/0000-0001-5173-2760				ABILDGAARD CF, 1980, BLOOD, V56, P712; BOLTONMAGGS PHB, 1995, THROMB HAEMOSTASIS, V73, P194; BOLTONMAGGS PHB, 1988, BRIT J HAEMATOL, V69, P521, DOI 10.1111/j.1365-2141.1988.tb02409.x; BRADLOW J, 1992, PATTERNS REFERRAL; CEJKA J, 1982, CLIN CHEM, V28, P1356; CHEDIAK J, 1980, AM J CLIN PATHOL, V74, P108; Edlund M, 1996, AM J HEMATOL, V53, P234, DOI 10.1002/(SICI)1096-8652(199612)53:4<234::AID-AJH4>3.0.CO;2-Z; EVANS PC, 1971, OBSTET GYNECOL, V38, P37; FRASER IS, 1984, AM J OBSTET GYNECOL, V149, P788, DOI 10.1016/0002-9378(84)90123-6; FRASER IS, 1986, OBSTET GYNECOL, V68, P630; GREER IA, 1991, BRIT J OBSTET GYNAEC, V98, P909, DOI 10.1111/j.1471-0528.1991.tb13514.x; HALLBERG L, 1966, ACTA OBSTET GYN SCAN, V45, P320, DOI 10.3109/00016346609158455; HALLBERG L, 1964, SCAND J CLIN LAB INV, V16, P244, DOI 10.3109/00365516409060511; HAYNES PJ, 1977, BRIT J OBSTET GYNAEC, V84, P763, DOI 10.1111/j.1471-0528.1977.tb12490.x; HIGHAM JM, 1990, BRIT J OBSTET GYNAEC, V97, P734, DOI 10.1111/j.1471-0528.1990.tb16249.x; LEIBA H, 1965, BRIT J HAEMATOL, V11, P654, DOI 10.1111/j.1365-2141.1965.tb00114.x; LIAN ECY, 1976, AM J HEMATOL, V1, P319, DOI 10.1002/ajh.2830010306; LUSHER JM, 1978, AM J MED, V65, P637, DOI 10.1016/0002-9343(78)90852-5; Lusher JM, 1996, AM J OBSTET GYNECOL, V175, P778, DOI 10.1016/S0002-9378(96)80084-6; Murdock PJ, 1997, THROMB HAEMOSTASIS, V78, P1272; NILSSON IM, 1977, ACTA MED SCAND, V201, P497; REES M, 1987, BRIT MED J, V294, P759, DOI 10.1136/bmj.294.6574.759; RODEGHIERO F, 1990, THROMB HAEMOSTASIS, V64, P349; RODEGHIERO F, 1987, BLOOD, V69, P454; *ROYAL COLL GEN PR, 1986, SER MBS, V1; RUGGI ZM, 1987, J CLIN LAB ANAL, V1, P535; SADLER JE, 1994, THROMB HAEMOSTASIS, V71, P520; SELIGSOHN U, 1978, BLOOD, V51, P1223; SELIGSOHN U, 1981, ISRAEL J MED SCI, V17, P413; SELIGSOHN U, 1979, GENETIC DISEASES ASH, P141; Smith JK, 1996, HAEMOPHILIA, V2, P128, DOI 10.1111/j.1365-2516.1996.tb00155.x; TAVORI S, 1990, THROMB HAEMOSTASIS, V63, P36; WERNER EJ, 1993, J PEDIATR-US, V123, P893, DOI 10.1016/S0022-3476(05)80384-1; WERNER EJ, 1992, J PEDIATR-US, V121, P34, DOI 10.1016/S0022-3476(05)82537-5; ZHANG ZP, 1995, HUM GENET, V96, P388	35	303	307	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	1998	351	9101					485	489		10.1016/S0140-6736(97)08248-2	http://dx.doi.org/10.1016/S0140-6736(97)08248-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482440				2022-12-28	WOS:000072097700012
J	Kim, SH; Lin, DP; Matsumoto, S; Kitazono, A; Matsumoto, T				Kim, SH; Lin, DP; Matsumoto, S; Kitazono, A; Matsumoto, T			Fission yeast Slp1: An effector of the Mad2-dependent spindle checkpoint	SCIENCE			English	Article							SISTER-CHROMATID SEPARATION; SACCHAROMYCES-CEREVISIAE; CYCLIN-B; ASSEMBLY CHECKPOINT; BUDDING YEAST; CDC20 GENE; CELL-CYCLE; MITOSIS; PROTEIN; PROTEOLYSIS	Mad2 is a component of the spindle checkpoint, which delays the onset of anaphase until all chromosomes are attached to the spindle. Mad2 formed a complex with Slp1, a WD (tryptophan-aspartic acid)-repeat protein essential for the onset of anaphase. When the physical interaction between the two proteins was disrupted, the spindle checkpoint was no longer functional. Post-anaphase events such as chromosome decondensation and the next round of DNA replication were not delayed even when the spindle assembly was incomplete. This relief of dependence appears to be a result of deregulation of ubiquitin-dependent proteolysis mediated by the anaphase-promoting complex.	Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Matsumoto, T (corresponding author), Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10461 USA.			Kitazono, Ana/0000-0002-6924-1799; Kim, Sanghoon/0000-0002-4078-6269	NIGMS NIH HHS [5T32GM07491, R01GM56305] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056305, T32GM007491] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; HERSHKO A, 1991, J BIOL CHEM, V266, P4940; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Matsumoto T, 1997, MOL CELL BIOL, V17, P742, DOI 10.1128/MCB.17.2.742; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; ROSE M, 1983, METHOD ENZYMOL, V101, P167; SAMEJIMA I, 1994, J CELL BIOL, V127, P1655, DOI 10.1083/jcb.127.6.1655; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; Yamashita YM, 1996, NATURE, V384, P276, DOI 10.1038/384276a0; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	31	311	318	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1045	1047		10.1126/science.279.5353.1045	http://dx.doi.org/10.1126/science.279.5353.1045			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461438				2022-12-28	WOS:000072006400050
J	Gammage, M				Gammage, M			Treatment of acute pulmonary oedema: diuresis or vasodilatation?	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; ACUTE HEART-FAILURE; ISOSORBIDE DINITRATE; FRUSEMIDE; FUROSEMIDE		Univ Birmingham, Dept Cardiovasc Med, Birmingham, W Midlands, England; Univ Hosp Birmingham, NHS Trust, Birmingham B15 2TH, W Midlands, England	University of Birmingham; University of Birmingham	Gammage, M (corresponding author), Univ Birmingham, Dept Cardiovasc Med, Birmingham, W Midlands, England.							BIDDLE TL, 1979, AM J CARDIOL, V43, P86, DOI 10.1016/0002-9149(79)90049-3; BOSC E, 1982, ANN CARDIOL ANGEIOL, V31, P477; CHATTERJEE K, 1973, CIRCULATION, V48, P1183, DOI 10.1161/01.CIR.48.6.1183; DOWN WH, 1974, J PHARM SCI-US, V63, P1147, DOI 10.1002/jps.2600630728; GAMMAGE MD, 1986, EUR J CLIN PHARMACOL, V29, P639, DOI 10.1007/BF00615952; LAL S, 1969, BRIT HEART J, V31, P711; MORRISON RA, 1983, CLIN PHARMACOL THER, V33, P747, DOI 10.1038/clpt.1983.102; MUKHERJEE SK, 1981, AM HEART J, V101, P313, DOI 10.1016/0002-8703(81)90196-4; NELSON GIC, 1983, LANCET, V1, P730; Northridge D, 1996, LANCET, V347, P667, DOI 10.1016/S0140-6736(96)91209-X; Pickkers P, 1996, LANCET, V347, P1338, DOI 10.1016/S0140-6736(96)90990-3; SPORLRADUN S, 1980, EUR J CLIN PHARMACOL, V18, P237, DOI 10.1007/BF00563005; TAYLOR T, 1980, BIOPHARM DRUG DISPOS, V1, P149, DOI 10.1002/bdd.2510010310	13	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					382	383		10.1016/S0140-6736(98)22006-X	http://dx.doi.org/10.1016/S0140-6736(98)22006-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482284				2022-12-28	WOS:000071982600002
J	Baker, TA; Bell, SP				Baker, TA; Bell, SP			Polymerases and the replisome: Machines within machines	CELL			English	Review							DNA-REPLICATION FORK; ORIGIN RECOGNITION COMPLEX; LAGGING-STRAND REPLICATION; PRIMER-TEMPLATE JUNCTION; CELL NUCLEAR ANTIGEN; HEAT-SHOCK PROTEIN; ESCHERICHIA-COLI; SLIDING CLAMPS; ACCESSORY PROTEINS; ALPHA-PRIMASE		MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Baker, TA (corresponding author), MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA.			Bell, Stephen/0000-0002-2876-610X	NIGMS NIH HHS [GM-52339, GM-499224] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; ALFANO C, 1989, J BIOL CHEM, V264, P10709; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BAKER TA, 1995, CELL, V80, P521, DOI 10.1016/0092-8674(95)90504-9; BAKER TA, 1992, ANNU REV GENET, V26, P447; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; CASSLER MR, 1995, EMBO J, V14, P5833, DOI 10.1002/j.1460-2075.1995.tb00271.x; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COLLINS KL, 1993, EMBO J, V12, P4555, DOI 10.1002/j.1460-2075.1993.tb06144.x; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Dong F, 1996, P NATL ACAD SCI USA, V93, P14456, DOI 10.1073/pnas.93.25.14456; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Egelman EH, 1996, STRUCTURE, V4, P759, DOI 10.1016/S0969-2126(96)00081-0; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; HWANG DS, 1992, J BIOL CHEM, V267, P23083; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Joyce CM, 1997, P NATL ACAD SCI USA, V94, P1619, DOI 10.1073/pnas.94.5.1619; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KIEFER JR, 1998, IN PRESS NATURE; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; KREUZER KN, 1994, MOL BIOL BACTERIOPHA, P82; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; Kusakabe T, 1996, J BIOL CHEM, V271, P19563, DOI 10.1074/jbc.271.32.19563; Learn BA, 1997, P NATL ACAD SCI USA, V94, P1154, DOI 10.1073/pnas.94.4.1154; Lee DG, 1997, MOL CELL BIOL, V17, P7159, DOI 10.1128/MCB.17.12.7159; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Marians KJ, 1997, STRUCTURE, V5, P1129, DOI 10.1016/S0969-2126(97)00263-3; Messer W, 1997, MOL MICROBIOL, V24, P1, DOI 10.1046/j.1365-2958.1997.3171678.x; MUNN MM, 1991, J BIOL CHEM, V266, P20024; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; PARK P, 1994, P NATL ACAD SCI USA, V91, P8700, DOI 10.1073/pnas.91.18.8700; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; SANMARTIN MC, 1995, J STRUCT BIOL, V114, P167, DOI 10.1006/jsbi.1995.1016; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SENGUPTA DJ, 1994, EMBO J, V13, P982, DOI 10.1002/j.1460-2075.1994.tb06343.x; Shcherbakova PV, 1996, GENETICS, V142, P717; Sousa R, 1996, TRENDS BIOCHEM SCI, V21, P186, DOI 10.1016/S0968-0004(96)10023-2; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WAHLE E, 1989, J BIOL CHEM, V264, P2469; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; WYMAN C, 1993, J BIOL CHEM, V268, P25192; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; Young MC, 1996, J MOL BIOL, V264, P440, DOI 10.1006/jmbi.1996.0652; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351	88	272	278	6	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 6	1998	92	3					295	305		10.1016/S0092-8674(00)80923-X	http://dx.doi.org/10.1016/S0092-8674(00)80923-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YX283	9476890	Bronze			2022-12-28	WOS:000072024700002
J	Wilson, KS; Noller, HF				Wilson, KS; Noller, HF			Molecular movement inside the translational engine	CELL			English	Review							16S RIBOSOMAL-RNA; ESCHERICHIA-COLI RIBOSOME; ELONGATION-FACTOR-G; PEPTIDYL-TRANSFER-RNA; ALLOSTERIC 3-SITE MODEL; P-SITE; CRYSTAL-STRUCTURE; PROTEIN L7/L12; EF-TU; 3-DIMENSIONAL STRUCTURE		Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Wilson, KS (corresponding author), Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA.							Abel K, 1996, STRUCTURE, V4, P229, DOI 10.1016/S0969-2126(96)00027-5; AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; ALLEN PN, 1989, J MOL BIOL, V208, P457, DOI 10.1016/0022-2836(89)90509-3; ALLEN PN, 1991, CELL, V66, P141, DOI 10.1016/0092-8674(91)90146-P; BELITSINA NV, 1981, FEBS LETT, V131, P289, DOI 10.1016/0014-5793(81)80387-0; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BOLLEN A, 1969, SCIENCE, V165, P85, DOI 10.1126/science.165.3888.85; Borowski C, 1996, P NATL ACAD SCI USA, V93, P4202, DOI 10.1073/pnas.93.9.4202; BRETSCHER MS, 1968, NATURE, V218, P675, DOI 10.1038/218675a0; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; BRIMACOMBE R, 1991, BIOCHIMIE, V73, P927, DOI 10.1016/0300-9084(91)90134-M; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; CUNDLIFF.E, 1972, BIOCHEM BIOPH RES CO, V46, P1794, DOI 10.1016/0006-291X(72)90053-8; CUNDLIFFE E, 1990, RIBOSOME, P479; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; Czworkowski J, 1996, PROG NUCLEIC ACID RE, V54, P293, DOI 10.1016/S0079-6603(08)60366-9; ENDO Y, 1982, J BIOL CHEM, V257, P9054; FERNANDEZPUENTES C, 1977, FEBS LETT, V78, P143, DOI 10.1016/0014-5793(77)80292-5; Fink DL, 1996, RNA, V2, P851; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GAVRILOV.LP, 1971, FEBS LETT, V17, P324, DOI 10.1016/0014-5793(71)80177-1; GIRSHOVICH AS, 1981, FEBS LETT, V130, P54, DOI 10.1016/0014-5793(81)80664-3; GORINI L, 1971, NATURE-NEW BIOL, V234, P261, DOI 10.1038/newbio234261a0; GROSJEAN H, 1976, J MOL BIOL, V103, P499, DOI 10.1016/0022-2836(76)90214-X; HAUSNER TP, 1987, BIOCHIMIE, V69, P911, DOI 10.1016/0300-9084(87)90225-2; Hill WE., 1990, RIBOSOME STRUCTURE F; HUTTENHOFER A, 1992, P NATL ACAD SCI USA, V89, P7851, DOI 10.1073/pnas.89.17.7851; INOUEYOKOSAWA N, 1974, J BIOL CHEM, V249, P4321; Joseph S, 1997, SCIENCE, V278, P1093, DOI 10.1126/science.278.5340.1093; Karimi R, 1996, EMBO J, V15, P1149, DOI 10.1002/j.1460-2075.1996.tb00453.x; KARIMI R, 1994, EUR J BIOCHEM, V226, P355, DOI 10.1111/j.1432-1033.1994.tb20059.x; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KIRILLOV SV, 1983, FEBS LETT, V157, P91, DOI 10.1016/0014-5793(83)81122-3; LILJAS A, 1987, BIOCHIMIE, V69, P1043, DOI 10.1016/0300-9084(87)90004-6; LILL R, 1987, J MOL BIOL, V196, P137, DOI 10.1016/0022-2836(87)90516-X; Lodmell JS, 1997, SCIENCE, V277, P1262, DOI 10.1126/science.277.5330.1262; LUCASLENARD J, 1969, P NATL ACAD SCI USA, V63, P93, DOI 10.1073/pnas.63.1.93; MALHOTRA A, 1994, J MOL BIOL, V240, P308, DOI 10.1006/jmbi.1994.1448; MATHESON AT, 1995, FRONTIERS TRANSLATIO; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MODOLELL J, 1977, EUR J BIOCHEM, V81, P491, DOI 10.1111/j.1432-1033.1977.tb11974.x; MOLLER W, 1990, RIBOSOME, P380; Mueller F, 1997, J MOL BIOL, V271, P524, DOI 10.1006/jmbi.1997.1210; Munishkin A, 1997, P NATL ACAD SCI USA, V94, P12280, DOI 10.1073/pnas.94.23.12280; NIERHAUS KH, 1990, BIOCHEMISTRY-US, V29, P4997, DOI 10.1021/bi00473a001; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; NOLLER HF, 1984, ANNU REV BIOCHEM, V53, P119, DOI 10.1146/annurev.bi.53.070184.001003; NOLLER HF, 1990, RIBOSOME, P73; Noller HF, 1995, BIOCHEM CELL BIOL, V73, P997, DOI 10.1139/o95-107; ODOM OW, 1990, BIOCHEMISTRY-US, V29, P10734, DOI 10.1021/bi00500a004; OFVERSTEDT LG, 1994, CELL, V79, P629, DOI 10.1016/0092-8674(94)90548-7; OLSON HM, 1986, J BIOL CHEM, V261, P6924; PAULSEN H, 1983, J MOL BIOL, V167, P411, DOI 10.1016/S0022-2836(83)80342-8; PESTKA S, 1969, J BIOL CHEM, V244, P1533; POWERS T, 1995, RNA, V1, P194; POWERS T, 1994, TRENDS GENET, V10, P27, DOI 10.1016/0168-9525(94)90016-7; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; RICHMAN N, 1972, P NATL ACAD SCI USA, V69, P686, DOI 10.1073/pnas.69.3.686; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; Rodnina MV, 1995, BIOCHEM CELL BIOL, V73, P1221, DOI 10.1139/o95-132; ROSE SJ, 1983, J MOL BIOL, V167, P103, DOI 10.1016/S0022-2836(83)80036-9; ROSING J, 1972, BIOCHIM BIOPHYS ACTA, V267, P275, DOI 10.1016/0005-2728(72)90116-8; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; SCHILLINGBARTETZKO S, 1992, J BIOL CHEM, V267, P4703; Semenkov YP, 1996, P NATL ACAD SCI USA, V93, P12183, DOI 10.1073/pnas.93.22.12183; SERDYUK I, 1992, BIOCHIMIE, V74, P299, DOI 10.1016/0300-9084(92)90107-P; SIGMUND CD, 1984, NUCLEIC ACIDS RES, V12, P4653, DOI 10.1093/nar/12.11.4653; SPIRIN AS, 1968, DOKL AKAD NAUK SSSR+, V179, P1467; SPIRIN AS, 1985, PROG NUCLEIC ACID RE, V32, P75, DOI 10.1016/S0079-6603(08)60346-3; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; Traut RR, 1995, BIOCHEM CELL BIOL, V73, P949, DOI 10.1139/o95-102; TRAUT RR, 1983, J BIOL CHEM, V258, P4592; VONAHSEN U, 1995, SCIENCE, V267, P234, DOI 10.1126/science.7528943; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232; YONATH A, 1992, ANNU REV BIOPH BIOM, V21, P77, DOI 10.1146/annurev.biophys.21.1.77	85	164	167	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 6	1998	92	3					337	349		10.1016/S0092-8674(00)80927-7	http://dx.doi.org/10.1016/S0092-8674(00)80927-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YX283	9476894	Bronze			2022-12-28	WOS:000072024700006
J	Maggs, DG; Buchanan, TA; Burant, CF; Cline, G; Gumbiner, B; Hsueh, WA; Inzucchi, S; Kelley, D; Nolan, J; Olefsky, JM; Polonsky, KS; Silver, D; Valiquett, TR; Shulman, GI				Maggs, DG; Buchanan, TA; Burant, CF; Cline, G; Gumbiner, B; Hsueh, WA; Inzucchi, S; Kelley, D; Nolan, J; Olefsky, JM; Polonsky, KS; Silver, D; Valiquett, TR; Shulman, GI			Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							INDUCED INSULIN-RESISTANCE; PLASMA-GLUCOSE CONCENTRATION; ORAL ANTIDIABETIC AGENT; C57BL/KSJ-DB/DB MICE; FATTY RATS; CS-045; NIDDM; FRUCTOSE; SECRETION; RECEPTOR	Background: Troglitazone is a new insulin-sensitizing agent used to treat type 2 diabetes mellitus. The mechanism by which troglitazone exerts its effect on systemic glucose metabolism is unknown. Objective: To determine the effects of 6 months of troglitazone monotherapy on glucose metabolism in patients with type Z diabetes mellitus. Design: Randomized, double-blind, placebo-controlled trial. Setting: Six general clinical research centers at university hospitals. Patients: 93 patients (mean age, 52 years) with type 2 diabetes mellitus (mean fasting plasma glucose level, 11.2 mmol/L) who were being treated with diet alone or who had discontinued oral antidiabetic medication therapy. Intervention: Patients were randomly assigned to one of five treatment groups (100, 200, 400, or 600 mg of troglitazone daily or placebo) and had metabolic assessment before and after 6 months of treatment. Measurements: Plasma glucose and insulin profiles during a meal tolerance test; basal hepatic glucose production and insulin-stimulated glucose disposal rate during a hyperinsulinemic-euglycemic clamp procedure. Results: Troglitazone at 400 and 600 mg/d decreased both fasting (P < 0.001) and postprandial (P = 0.016) plasma glucose levels by approximately 20%. All four troglitazone dosages also decreased fasting (P = 0.012) and postprandial (P < 0.001) triglyceride levels; 600 mg of the drug per day decreased fasting free fatty acid levels (P = 0.018). Plasma insulin levels decreased in the 200-, 400-, and 600-mg/d groups (P < 0.001), and C-peptide levels decreased in all five study groups (P < 0.001). Basal hepatic glucose production was suppressed in the 600-mg/d group compared with the placebo group (P = 0.02). Troglitazone at 400 and 600 mg/d increased glucose disposal rate by approximately 45% above pretreatment levels (P = 0.003). Stepwise regression analysis showed that troglitazone therapy was the strongest predictor of a decrease in fasting (P < 0.001) or postprandial (P = 0.01) glucose levels. Fasting C-peptide level was the next strongest predictor (higher C-peptide level equaled greater glucose-lowering effect). Conclusion: Troglitazone monotherapy decreased fasting and postprandial glucose levels in patients with type 2 diabetes, primarily by augmenting insulin-mediated glucose disposal.	Yale Univ, Sch Med, New Haven, CT 06520 USA; Univ Chicago, Med Ctr, Dept Med, Endocrinol Sect, Chicago, IL 60637 USA; Univ So Calif, Los Angeles Cty Med Ctr, Sch Med, Los Angeles, CA 90033 USA; Univ Rochester, Rochester, NY USA; Univ Pittsburgh, Dept Endocrinol, Pittsburgh, PA 15261 USA; Univ Calif San Diego, Endocrine Metab Div, Vet Affairs Med Ctr 111G, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Endocrinol, La Jolla, CA 92093 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Ann Arbor, MI 48105 USA	Yale University; University of Chicago; University of Chicago Medical Center; University of Southern California; University of Rochester; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Diego; University of California System; University of California San Diego; Pfizer	Maggs, DG (corresponding author), Yale Univ, Sch Med, Box 208020, New Haven, CT 06520 USA.		Shulman, Gerald I./P-7176-2019; Inzucchi, Silvio/ABF-4121-2021; Burant, Charles/GPC-5690-2022	Shulman, Gerald I./0000-0003-1529-5668; Burant, Charles/0000-0001-9189-5003	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033649, R01DK049230] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00827] Funding Source: Medline; NIDDK NIH HHS [R01-DK 49230, R01-DK 33649] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKANUMA Y, 1993, J CLIN THER MED S3, V9, P127; BADER S, 1993, DIABETES STOFFWECH H, V2, P56; BODEN G, 1991, J CLIN INVEST, V88, P960, DOI 10.1172/JCI115399; BOGARDUS C, 1984, J CLIN INVEST, V74, P1238, DOI 10.1172/JCI111533; BOWEN L, 1991, METABOLISM, V40, P1025, DOI 10.1016/0026-0495(91)90124-F; CHEN YDI, 1988, J CLIN ENDOCR METAB, V67, P1084, DOI 10.1210/jcem-67-5-1084; CIARALDI TP, 1990, METABOLISM, V39, P1056, DOI 10.1016/0026-0495(90)90166-A; CLISSOLD SP, 1988, DRUGS, V35, P214, DOI 10.2165/00003495-198835030-00003; DEFRONZO RA, 1982, DIABETOLOGIA, V23, P313; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DEFRONZO RA, 1992, DIABETOLOGIA, V35, P389, DOI 10.1007/BF00401208; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; FERRANNINI E, 1983, J CLIN INVEST, V72, P1737, DOI 10.1172/JCI111133; FUJIWARA T, 1991, METABOLISM, V40, P1213, DOI 10.1016/0026-0495(91)90218-L; FUJIWARA T, 1995, METABOLISM, V44, P486, DOI 10.1016/0026-0495(95)90056-X; FUJIWARA T, 1988, DIABETES, V37, P1549, DOI 10.2337/diabetes.37.11.1549; HARRIS JA, 1919, CARNEGIE I WASHINGTO, V279; HARRIS M, 1979, DIABETES, V28, P1039; HOTHERNIELSEN O, 1990, DIABETOLOGIA, V33, P603, DOI 10.1007/BF00400204; Inoue I, 1995, METABOLISM, V44, P1626, DOI 10.1016/0026-0495(95)90085-3; Iwamoto Y, 1996, DIABETIC MED, V13, P365, DOI 10.1002/(SICI)1096-9136(199604)13:4<365::AID-DIA19>3.0.CO;2-M; Iwamoto Y, 1996, DIABETES CARE, V19, P151, DOI 10.2337/diacare.19.2.151; JENG CY, 1994, DIABETES, V43, P1440, DOI 10.2337/diabetes.43.12.1440; Kazumi T, 1996, DIABETES, V45, P806, DOI 10.2337/diab.45.6.806; KELLERER M, 1994, DIABETES, V43, P447, DOI 10.2337/diabetes.43.3.447; KOLTERMAN OG, 1981, J CLIN INVEST, V68, P957, DOI 10.1172/JCI110350; KOSAKA K, 1993, J CLIN THER MED S3, V9, P61; KOSAKA K, 1993, J CLIN THER MED S3, V9, P95; Kumar S, 1996, DIABETOLOGIA, V39, P701; LEE MK, 1994, DIABETES, V43, P1435, DOI 10.2337/diabetes.43.12.1435; RANDLE PJ, 1963, LANCET, V1, P785; REAVEN GM, 1993, DIABETES METAB REV, V9, pS5, DOI 10.1002/dmr.5610090503; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; ROSSETTI L, 1987, J CLIN INVEST, V80, P1037, DOI 10.1172/JCI113157; STUMVOLL M, 1995, NEW ENGL J MED, V333, P550, DOI 10.1056/NEJM199508313330903; SUTER SL, 1992, DIABETES CARE, V15, P193, DOI 10.2337/diacare.15.2.193; TOMINAGA M, 1993, ENDOCR J, V40, P343, DOI 10.1507/endocrj.40.343; WOLFE RR, 1992, PRINCIPLES PRACTICE, P283	38	262	268	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1998	128	3					176	185		10.7326/0003-4819-128-3-199802010-00002	http://dx.doi.org/10.7326/0003-4819-128-3-199802010-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU303	9454525				2022-12-28	WOS:000071703200002
J	Sha, BD; Phillips, SE; Bankaitis, VA; Luo, M				Sha, BD; Phillips, SE; Bankaitis, VA; Luo, M			Crystal structure of the Saccharomyces cerevisiae phosphatidylinositol-transfer protein	NATURE			English	Article							PHOSPHOLIPID TRANSFER PROTEIN; YEAST GOLGI; GENE; SEC14; MUTATIONS; MEMBRANES; PRODUCT; PATHWAY	The yeast phosphatidylinositol-transfer protein (Sec14) catalyses exchange of phosphatidylinositol and phosphatidylcholine between membrane bilayers in vitro(1,2). In vivo, Sec14 activity is essential for vesicle budding from the Golgi complex(3). Hero we report a three-dimensional structure for Sec14 at 2.5 A resolution. Sec14 consists of twelve alpha-helices, six beta-strands, eight 3(10)-helices and has two distinct domains. The carboxy-terminal domain forms a hydrophobic pocket which, in the crystal structure, is occupied by two molecules of N-octyl-beta-D-glucopyranoside and represents the phospholipid-binding domain. This pocket is reinforced by a string motif whose disruption in a sec14 temperature-sensitive mutant results in destabilization of the phospholipid-binding domain. Finally, we have identified an unusual surface helix that may play a critical role in driving Sec14-mediated phospholipid exchange. From this structure, we derive the first molecular clues into how a phosphatidylinositol-transfer protein functions.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Macromol Crystallog, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Bankaitis, VA (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA.	vabankaitis@tmg.bhs.uab.edu; ming@orion.cmc.vab.edu		PHILLIPS, SCOTT/0000-0002-5451-0984				Alb JG, 1996, CURR OPIN CELL BIOL, V8, P534, DOI 10.1016/S0955-0674(96)80032-9; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BANKAITIS VA, 1996, PHOSPHOLIPID TRANSFE; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chinen K, 1996, CYTOGENET CELL GENET, V73, P218, DOI 10.1159/000134342; Cleves A, 1991, Trends Cell Biol, V1, P30, DOI 10.1016/0962-8924(91)90067-J; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; DICKESON SK, 1989, J BIOL CHEM, V264, P16557; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Minor W., 1993, XDISPLAYF PROGRAM; NICHOOS A, 1992, GRASP GRAPHICAL REPR; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; SALAMA SR, 1990, J BACTERIOL, V172, P4510, DOI 10.1128/jb.172.8.4510-4521.1990; SATO Y, 1993, J BIOL CHEM, V268, P17705; Sha BD, 1997, ACTA CRYSTALLOGR D, V53, P784, DOI 10.1107/S0907444997006872; SKINNER HB, 1993, EMBO J, V12, P4775, DOI 10.1002/j.1460-2075.1993.tb06166.x; VAZ WLC, 1984, FEBS LETT, V174, P199, DOI 10.1016/0014-5793(84)81157-6	29	222	232	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	1998	391	6666					506	510		10.1038/35179	http://dx.doi.org/10.1038/35179			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461221				2022-12-28	WOS:000071701800056
J	Griffiths, S				Griffiths, S			From health care to health	BRITISH MEDICAL JOURNAL			English	Article									Oxfordshire Hlth Author, Oxford OX3 7LG, England		Griffiths, S (corresponding author), Oxfordshire Hlth Author, Oxford OX3 7LG, England.							Jacobson B, 1998, BRIT MED J, V316, P164; *SECR STAT SCOTL, 1997, DES CAR REN NAT HLTH; *WHO, 1978, ALM AT 1978 PRIM HLT; 1991, HLTH NAT STRAT HLTH	4	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					300	301		10.1136/bmj.316.7127.300	http://dx.doi.org/10.1136/bmj.316.7127.300			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472524	Green Published			2022-12-28	WOS:000071702100041
J	Groigno, L; Whitaker, M				Groigno, L; Whitaker, M			An anaphase calcium signal controls chromosome disjunction in early sea urchin embryos	CELL			English	Article							SISTER-CHROMATID SEPARATION; NUCLEAR-ENVELOPE BREAKDOWN; DNA TOPOISOMERASE-II; STAMEN HAIR-CELLS; INTRACELLULAR FREE CALCIUM; PROTEIN-KINASE; SPINDLE MICROTUBULES; CYCLIN DEGRADATION; BUDDING YEAST; EGG EXTRACTS	A transient increase in intracellular calcium concentration [Ca2+](i) occurs throughout the cell as sea urchin embryos enter anaphase of the first cell cycle. The transient just precedes chromatid disjunction and spindle elongation. Microinjection of calcium chelators or heparin, an InsP(3), receptor antagonist, blocks chromosome separation. Photorelease of calcium or InsP, can reverse the block. Nuclear reformation is merely delayed by calcium antagonists at concentrations that block chromatid separation. Thus, the calcium signal triggers the separation of chromatids, while calcium-independent pathways can bring about the alterations in microtubule dynamics and nuclear events associated with anaphase progression. That calcium triggers chromosome disjunction alone is unexpected. It helps explain previous conflicting results and allows the prediction that calcium plays a similar role at anaphase in other cell types.	Univ Newcastle Upon Tyne, Sch Med, Dept Physiol Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Whitaker, M (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Dept Physiol Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; Becchetti A, 1997, DEVELOPMENT, V124, P1099; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; CIAPA B, 1994, NATURE, V368, P875, DOI 10.1038/368875a0; DINSMORE JH, 1988, CELL, V53, P769, DOI 10.1016/0092-8674(88)90094-3; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ELLISDAVIES GCR, 1994, P NATL ACAD SCI USA, V91, P187, DOI 10.1073/pnas.91.1.187; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GILLOT I, 1994, CELL CALCIUM, V16, P269, DOI 10.1016/0143-4160(94)90090-6; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HEPLER PK, 1985, J CELL BIOL, V100, P1363, DOI 10.1083/jcb.100.5.1363; HEPLER PK, 1994, CELL CALCIUM, V16, P322, DOI 10.1016/0143-4160(94)90096-5; HEPLER PK, 1987, J CELL BIOL, V105, P2137, DOI 10.1083/jcb.105.5.2137; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; IZANT JG, 1983, CHROMOSOMA, V88, P1, DOI 10.1007/BF00329497; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; KAWAHARA H, 1994, DEV BIOL, V166, P623, DOI 10.1006/dbio.1994.1342; KEITH C, 1983, J CELL BIOL, V97, P1918, DOI 10.1083/jcb.97.6.1918; Khodjakov A, 1996, J CELL BIOL, V132, P1093, DOI 10.1083/jcb.132.6.1093; KIEHART DP, 1981, J CELL BIOL, V88, P604, DOI 10.1083/jcb.88.3.604; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; LINDSAY HD, 1995, J CELL SCI, V108, P3557; LORCA T, 1991, EMBO J, V10, P2087, DOI 10.1002/j.1460-2075.1991.tb07741.x; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MCINTOSH JR, 1991, ANNU REV CELL BIOL, V7, P403, DOI 10.1146/annurev.cellbio.7.1.403; MORIN N, 1994, EMBO J, V13, P4343, DOI 10.1002/j.1460-2075.1994.tb06754.x; Murray AW, 1996, P NATL ACAD SCI USA, V93, P12327, DOI 10.1073/pnas.93.22.12327; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PETZELT C, 1987, European Journal of Cell Biology, V45, P268; POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; RATTAN RR, 1986, P NATL ACAD SCI USA, V83, P5136; RATTAN RR, 1988, J CELL BIOL, V107, P993; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SILVER RB, 1980, CELL, V19, P505, DOI 10.1016/0092-8674(80)90525-5; SILVER RB, 1989, DEV BIOL, V131, P11; SLUDER G, 1994, J CELL BIOL, V126, P189, DOI 10.1083/jcb.126.1.189; SLUDER G, 1979, J CELL BIOL, V80, P674, DOI 10.1083/jcb.80.3.674; SLUDER G, 1988, ZOOL SCI, V5, P653; SPEKSNIJDER JE, 1989, P NATL ACAD SCI USA, V86, P6607, DOI 10.1073/pnas.86.17.6607; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; Stratmann R, 1996, CELL, V84, P25, DOI 10.1016/S0092-8674(00)80990-3; SUPRYNOWICZ FA, 1994, P NATL ACAD SCI USA, V91, P6176, DOI 10.1073/pnas.91.13.6176; SUPRYNOWICZ FA, 1985, P NATL ACAD SCI USA, V82, P2389, DOI 10.1073/pnas.82.8.2389; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; SWEET SC, 1988, J CELL BIOL, V107, P2243, DOI 10.1083/jcb.107.6.2243; TERASAKI M, 1991, J CELL BIOL, V114, P929, DOI 10.1083/jcb.114.5.929; TOMBES RM, 1989, J CELL BIOL, V109, P627, DOI 10.1083/jcb.109.2.627; TWIGG J, 1988, NATURE, V332, P366, DOI 10.1038/332366a0; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WHITAKER M, 1993, NATURE, V366, P211, DOI 10.1038/366211a0; WHITAKER M, 1990, DEVELOPMENT, V108, P525; Wilding M, 1996, J CELL BIOL, V135, P191, DOI 10.1083/jcb.135.1.191; Yamano H, 1996, EMBO J, V15, P5268, DOI 10.1002/j.1460-2075.1996.tb00912.x; ZHANG DH, 1992, J CELL SCI, V102, P79	69	110	112	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					193	204		10.1016/S0092-8674(00)80914-9	http://dx.doi.org/10.1016/S0092-8674(00)80914-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458044	Bronze			2022-12-28	WOS:000071672600009
J	Sprengel, R; Suchanek, B; Amico, C; Brusa, R; Burnashev, N; Rozov, A; Hvalby, O; Jensen, V; Paulsen, O; Andersen, P; Kim, JJ; Thompson, RF; Sun, W; Webster, LC; Grant, SGN; Eilers, J; Konnerth, A; Li, JY; McNamara, JO; Seeburg, PH				Sprengel, R; Suchanek, B; Amico, C; Brusa, R; Burnashev, N; Rozov, A; Hvalby, O; Jensen, V; Paulsen, O; Andersen, P; Kim, JJ; Thompson, RF; Sun, W; Webster, LC; Grant, SGN; Eilers, J; Konnerth, A; Li, JY; McNamara, JO; Seeburg, PH			Importance of the intracellular domain of NR2 subunits for NMDA receptor function in vivo	CELL			English	Article							D-ASPARTATE RECEPTOR; SIGNAL-TRANSDUCTION; TARGETED DISRUPTION; EPSILON-1 SUBUNIT; HIPPOCAMPAL LTP; MESSENGER-RNAS; MUTANT MICE; RAT-BRAIN; EXPRESSION; GENE	NMDA receptors, a class of glutamate-gated cation channels with high Ca2+ conductance, mediate fast transmission and plasticity of central excitatory synapses. We show here that gene-targeted mice expressing NMDA receptors without the large intracellular C-terminal domain of any one of three NR2 subunits phenotypically resemble mice made deficient in that particular subunit. Mice expressing the NR2B subunit in a C-terminally truncated form (NR2B(Delta C/Delta C) mice) die perinatally. NR2A(Delta C Delta C) mice are viable but exhibit impaired synaptic plasticity and contextual memory. These and NR2C(Delta C Delta C) mice display deficits in motor coordination. C-terminal truncation of NR2 subunits does not interfere with the formation of gateable receptor channels that can be synaptically activated. Thus, the phenotypes of our mutants appear to reflect defective intracellular signaling.	Max Planck Inst Med Res, Dept Mol Neurosci, D-69120 Heidelberg, Germany; Max Planck Inst Med Res, Dept Cell Physiol, D-69120 Heidelberg, Germany; Univ Oslo, Inst Neurophysiol, N-0317 Oslo, Norway; Univ So Calif, Los Angeles, CA 90089 USA; Univ Edinburgh, Ctr Genome Res & Neurosci, Edinburgh EH9 3JQ, Midlothian, Scotland; Univ Saarland, Inst Physiol, D-66421 Homburg, Germany; Duke Univ, Dept Med, Durham, NC 27710 USA	Max Planck Society; Max Planck Society; University of Oslo; University of Southern California; University of Edinburgh; Saarland University; Duke University	Sprengel, R (corresponding author), Max Planck Inst Med Res, Dept Mol Neurosci, Jahnstr 29, D-69120 Heidelberg, Germany.		Paulsen, Ole/ABB-4843-2020; Rozov, Andrei/C-1997-2015; Burnashev, Nail/G-4056-2013; Eilers, Jens/E-6251-2012; Sun, William/B-9092-2014	Paulsen, Ole/0000-0002-2258-5455; Eilers, Jens/0000-0003-0497-5625; Sun, William/0000-0003-3279-7408; Grant, Seth/0000-0001-8732-8735; Kim, Jeansok/0000-0001-7964-106X	NIA NIH HHS [AG0093] Funding Source: Medline; Wellcome Trust Funding Source: Medline; ACF HHS [AF05142] Funding Source: Medline; OMHHE CDC HHS [IF32MN10521-01] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Wellcome Trust(Wellcome TrustEuropean Commission); ACF HHS; OMHHE CDC HHS		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; AKAZAWA C, 1994, J COMP NEUROL, V347, P150, DOI 10.1002/cne.903470112; AMMASSARITEULE M, 1991, BRAIN RES, V551, P104, DOI 10.1016/0006-8993(91)90919-M; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; Chen C, 1995, CELL, V83, P1233, DOI 10.1016/0092-8674(95)90148-5; Chen C, 1996, BEHAV NEUROSCI, V110, P1177; COLLINGRIDGE GL, 1995, TRENDS NEUROSCI, V18, P54, DOI 10.1016/0166-2236(95)93868-X; Ebralidze AK, 1996, J NEUROSCI, V16, P5014; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Eilers Jens, 1995, P213; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; GODDARD GV, 1969, EXP NEUROL, V25, P295, DOI 10.1016/0014-4886(69)90128-9; HARTVEIT E, 1994, J COMP NEUROL, V348, P570, DOI 10.1002/cne.903480407; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; IKEDA K, 1995, MOL BRAIN RES, V33, P61, DOI 10.1016/0169-328X(95)00107-4; Ito I, 1996, NEUROSCI LETT, V203, P69, DOI 10.1016/0304-3940(95)12258-3; Kadotani H, 1996, J NEUROSCI, V16, P7859; Klingauf J, 1997, BIOPHYS J, V72, P674, DOI 10.1016/S0006-3495(97)78704-6; KOH DS, 1995, J PHYSIOL-LONDON, V485, P383, DOI 10.1113/jphysiol.1995.sp020737; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kutsuwada T, 1996, NEURON, V16, P333, DOI 10.1016/S0896-6273(00)80051-3; LAURIE DJ, 1995, MOL BRAIN RES, V32, P94, DOI 10.1016/0169-328X(95)00067-3; LAURIE DJ, 1997, IN PRESS MOL BRAIN R; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MCNAMARA JO, 1993, CURR OPIN NEUROL NEU, V6, P583; MCNAMARA JO, 1988, TRENDS NEUROSCI, V11, P33, DOI 10.1016/0166-2236(88)90047-1; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; Niethammer M, 1996, J NEUROSCI, V16, P2157; NITSCHKE L, 1993, BIOTECHNIQUES, V14, P914; Omkumar RV, 1996, J BIOL CHEM, V271, P31670, DOI 10.1074/jbc.271.49.31670; PETRALIA RS, 1994, J NEUROSCI, V14, P6102; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; SATHER W, 1992, J PHYSIOL-LONDON, V450, P643, DOI 10.1113/jphysiol.1992.sp019148; Smart TG, 1997, CURR OPIN NEUROBIOL, V7, P358, DOI 10.1016/S0959-4388(97)80063-3; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; SUCHANEK B, 1995, J BIOL CHEM, V270, P41, DOI 10.1074/jbc.270.1.41; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; Sutula T, 1996, J NEUROSCI, V16, P7398; Takahashi T, 1996, J NEUROSCI, V16, P4376; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; WATANABE M, 1993, J COMP NEUROL, V338, P377, DOI 10.1002/cne.903380305; Watanabe Y, 1996, J NEUROSCI, V16, P3827; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	53	372	388	1	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 23	1998	92	2					279	289		10.1016/S0092-8674(00)80921-6	http://dx.doi.org/10.1016/S0092-8674(00)80921-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458051	hybrid			2022-12-28	WOS:000071672600016
J	Boyce, J; Lamont, T				Boyce, J; Lamont, T			The new health authorities: moving forward, moving back?	BRITISH MEDICAL JOURNAL			English	Article									Audit Commiss, London SW1P 2PN, England		Boyce, J (corresponding author), Audit Commiss, London SW1P 2PN, England.							*AUD COMM, 1997, HIGH PURCH COMM SPEC; Audit Commission, 1997, COM AG IMPR CAR SERV	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					215	215						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468695				2022-12-28	WOS:000071616400042
J	Barbezat, GO				Barbezat, GO			Recent advances - Gastroenterology	BRITISH MEDICAL JOURNAL			English	Review							FECAL-OCCULT-BLOOD; CROHNS-DISEASE; HELICOBACTER-PYLORI; BARRETTS-ESOPHAGUS; COLORECTAL-CANCER; MYCOBACTERIUM-PARATUBERCULOSIS; PHOTODYNAMIC THERAPY; GASTRIC METAPLASIA; PROTOPORPHYRIN-IX; ORAL IMMUNIZATION		Univ Otago, Dunedin Sch Med, Dunedin, New Zealand	University of Otago	Barbezat, GO (corresponding author), Univ Otago, Dunedin Sch Med, POB 913, Dunedin, New Zealand.	gil.barbezat@stonebow.otago.ac.nz						Atherton JC, 1997, GASTROENTEROLOGY, V112, P92, DOI 10.1016/S0016-5085(97)70223-3; Axon ATR, 1997, ALIMENT PHARM THERAP, V11, P81, DOI 10.1046/j.1365-2036.1997.116287000.x; Barr H, 1996, LANCET, V348, P584, DOI 10.1016/S0140-6736(96)03054-1; Bazzoli F., 1996, Gut, V39, pA33; BERENSON MM, 1993, GASTROENTEROLOGY, V104, P1686, DOI 10.1016/0016-5085(93)90646-T; Burt MJ, 1996, GENOMICS, V33, P153, DOI 10.1006/geno.1996.0178; Chadwick N, 1997, GASTROENTEROLOGY, V112, pA946; CORTHESYTHEULAZ I, 1995, GASTROENTEROLOGY, V109, P115, DOI 10.1016/0016-5085(95)90275-9; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Fossati D., 1996, Gut, V39, pA104; Franzin G, 1996, GASTROENTEROLOGY, V110, pA109; GRAHAM DY, 1995, GASTROENTEROLOGY, V108, pA826; GUI GPH, 1997, BR SOC ANTIMICROB CH, V39, P393; Harris AW, 1996, GUT, V39, P513, DOI 10.1136/gut.39.4.513; Kreiss C, 1996, GASTROENTEROLOGY, V110, pA162; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; LIU Y, 1995, GASTROENTEROLOGY, V108, P1396, DOI 10.1016/0016-5085(95)90687-8; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; Millar D, 1996, APPL ENVIRON MICROB, V62, P3446, DOI 10.1128/AEM.62.9.3446-3452.1996; Mishina D, 1996, P NATL ACAD SCI USA, V93, P9816, DOI 10.1073/pnas.93.18.9816; Misiewicz J. J., 1996, Gut, V39, pA34; MORGAN KL, 1987, LANCET, V1, P1017; Mulcahy HE, 1997, BRIT MED J, V314, P285, DOI 10.1136/bmj.314.7076.285; NOACH LA, 1993, GUT, V34, P1510, DOI 10.1136/gut.34.11.1510; OVERHOLT BF, 1995, GASTROINTEST ENDOSC, V42, P64, DOI 10.1016/S0016-5107(95)70246-6; PROVENZALE D, 1994, AM J GASTROENTEROL, V89, P670; REGULA J, 1995, GUT, V36, P67, DOI 10.1136/gut.36.1.67; ROWBOTHAM DS, 1995, GUT, V37, P660, DOI 10.1136/gut.37.5.660; RUBIN PH, 1996, GASTROENTEROLOGY, V110, pA1005, DOI DOI 10.1136/gut.2006.111872; SIMON M, 1976, GUT, V17, P332, DOI 10.1136/gut.17.5.332; Spechler SJ, 1996, GASTROENTEROLOGY, V110, P614, DOI 10.1053/gast.1996.v110.agast960614; SPECHLER SJ, 1993, GASTROENTEROLOGY, V104, P1855, DOI 10.1016/0016-5085(93)90670-8; SUENAGA K, 1995, AM J GASTROENTEROL, V90, P76; SWIFT GL, 1994, GUT, V35, P363, DOI 10.1136/gut.35.3.363; vanderBurgh A, 1996, GUT, V39, P5, DOI 10.1136/gut.39.1.5; WAKEFIELD AJ, 1995, GASTROENTEROLOGY, V108, P911, DOI 10.1016/0016-5085(95)90467-0; 1995, NATURE GENETICS, V13, P375	39	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 10	1998	316	7125					125	128						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR408	9462319				2022-12-28	WOS:000071492300026
J	Macpherson, AJS; Bjarnason, I				Macpherson, AJS; Bjarnason, I			Basic science 1, clinical gastroenterology 0	LANCET			English	Article											Macpherson, AJS (corresponding author), UNIV LONDON KINGS COLL,SCH MED,DEPT MED,BESSEMER RD,LONDON SE5 9PJ,ENGLAND.							HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; LIU Y, 1995, GASTROENTEROLOGY, V108, P1396, DOI 10.1016/0016-5085(95)90687-8; SUAREZ FL, 1995, NEW ENGL J MED, V333, P1, DOI 10.1056/NEJM199507063330101	4	0	0	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S6	S6						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454049				2022-12-28	WOS:A1995TN12200006
J	Bush, ABG; Philander, SGH				Bush, ABG; Philander, SGH			The role of ocean-atmosphere interactions in tropical cooling during the last glacial maximum	SCIENCE			English	Article							EQUATORIAL PACIFIC; ICE SHEETS; TEMPERATURE; CLIMATE; PRODUCTIVITY; CONSTRAINTS; CIRCULATION; RECORD; AGE	A simulation with a coupled atmosphere-ocean general circulation model configured for the Last Glacial Maximum delivered a tropical climate that is much cooler than that produced by atmosphere-only models. The main reason is a decrease in tropical sea surface temperatures, up to 6 degrees C in the western tropical Pacific, which occurs because of two processes. The trade winds induce equatorial upwelling and zonal advection of cold water that further intensify the trade winds, and an exchange of water occurs between the tropical and extratropical Pacific in which the poleward surface flow is balanced by equatorward flow of cold water in the thermocline. Simulated tropical temperature depressions are of the same magnitude as those that have been proposed from recent proxy data.	Univ Alberta, Dept Earth & Atmospher Sci, Edmonton, AB T6G 2E3, Canada; Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA	University of Alberta; Princeton University	Bush, ABG (corresponding author), Univ Alberta, Dept Earth & Atmospher Sci, 126 Earth Sci Bldg, Edmonton, AB T6G 2E3, Canada.							Andreasen DJ, 1997, PALEOCEANOGRAPHY, V12, P395, DOI 10.1029/97PA00822; BROCCOLI AJ, 1987, CLIM DYNAM, V1, P87; BROECKER WS, 1986, QUATERNARY RES, V26, P121, DOI 10.1016/0033-5894(86)90087-6; BUSH ABG, 1994, J ATMOS SCI, V51, P1581, DOI 10.1175/1520-0469(1994)051<1581:TFASSB>2.0.CO;2; CROWLEY TJ, 1991, OXFORD MONOGRAPH GEO, V18, P56; FAIRBANKS RG, 1989, NATURE, V342, P637, DOI 10.1038/342637a0; *GEOL SOC AM, 1981, MAP CHART SER; GILL AE, 1980, Q J ROY METEOR SOC, V106, P447, DOI 10.1002/qj.49710644905; GORDON CT, 1982, MON WEATHER REV, V110, P625, DOI 10.1175/1520-0493(1982)110<0625:ADOTGG>2.0.CO;2; Gu DF, 1997, SCIENCE, V275, P805, DOI 10.1126/science.275.5301.805; GUILDERSON TP, 1994, SCIENCE, V263, P663, DOI 10.1126/science.263.5147.663; Hall NMJ, 1996, J CLIMATE, V9, P1004, DOI 10.1175/1520-0442(1996)009<1004:TMOTLG>2.0.CO;2; Hyde WT, 1989, J CLIMATE, V2, P864, DOI 10.1175/1520-0442(1989)002<0864:COGAEB>2.0.CO;2; KUTZBACH JE, 1986, J ATMOS SCI, V43, P1726, DOI 10.1175/1520-0469(1986)043<1726:TIOCOP>2.0.CO;2; Levitus S., 1982, 13 NOAA; LIU ZY, 1995, J PHYS OCEANOGR, V25, P449, DOI 10.1175/1520-0485(1995)025<0449:HDWSPA>2.0.CO;2; LYLE MW, 1992, NATURE, V355, P812, DOI 10.1038/355812a0; MANABE S, 1985, J GEOPHYS RES-ATMOS, V90, P2167, DOI 10.1029/JD090iD01p02167; NEELIN JD, 1994, ANNU REV FLUID MECH, V26, P617, DOI 10.1146/annurev.fl.26.010194.003153; PACANOWSKI RC, 1991, 2 GFDL OC GRP; PEDERSEN TF, 1983, GEOLOGY, V11, P16, DOI 10.1130/0091-7613(1983)11<16:IPITEE>2.0.CO;2; PELTIER WR, 1994, SCIENCE, V265, P195, DOI 10.1126/science.265.5169.195; Philander SGH, 1996, J CLIMATE, V9, P2958, DOI 10.1175/1520-0442(1996)009<2958:WTIIMN>2.0.CO;2; PHILANDER SGH, 1990, INT GEOPHYSICS SERIE, V46; RIND D, 1985, QUATERNARY RES, V24, P1, DOI 10.1016/0033-5894(85)90080-8; Schrag DP, 1996, SCIENCE, V272, P1930, DOI 10.1126/science.272.5270.1930; STUTE M, 1995, SCIENCE, V269, P379, DOI 10.1126/science.269.5222.379; THOMPSON LG, 1995, SCIENCE, V269, P46, DOI 10.1126/science.269.5220.46	28	124	131	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	1998	279	5355					1341	1344		10.1126/science.279.5355.1341	http://dx.doi.org/10.1126/science.279.5355.1341			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478892				2022-12-28	WOS:000072251800047
J	Luster, AD				Luster, AD			Chemokines - Chemotactic cytokines that mediate inflammation	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MONOCYTE-CHEMOATTRACTANT PROTEIN-1; BOWEL-DISEASE MUCOSA; T-CELL; HIV-1 INFECTION; LYMPHOCYTE CHEMOATTRACTANT; NH2-TERMINAL RESIDUES; PLATELET FACTOR-4; MESSENGER-RNA; CC CHEMOKINE; IN-VIVO		Massachusetts Gen Hosp E, Infect Dis Unit, Partners AIDS Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA	Harvard University; Harvard Medical School	Luster, AD (corresponding author), Massachusetts Gen Hosp E, Infect Dis Unit, Partners AIDS Res Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.		Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912	NCI NIH HHS [R01-CA69212] Funding Source: Medline; NIAID NIH HHS [R01-AI40618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040618] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; BISCHOFF SC, 1990, J EXP MED, V172, P1577, DOI 10.1084/jem.172.6.1577; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CHOLLETMARTIN S, 1993, INFECT IMMUN, V61, P4553, DOI 10.1128/IAI.61.11.4553-4559.1993; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DEUEL TF, 1977, P NATL ACAD SCI USA, V74, P2256, DOI 10.1073/pnas.74.6.2256; Dilloo D, 1996, NAT MED, V2, P1090, DOI 10.1038/nm1096-1090; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; GILLITZER R, 1993, J INVEST DERMATOL, V101, P127, DOI 10.1111/1523-1747.ep12363613; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; GOTTLIEB AB, 1988, J EXP MED, V168, P941, DOI 10.1084/jem.168.3.941; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; Grimm MC, 1996, INFLAMM BOWEL DIS, V2, P88, DOI 10.1002/ibd.3780020204; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; Humbert M, 1997, AM J RESP CELL MOL, V16, P1; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Lahrtz F, 1997, EUR J IMMUNOL, V27, P2484, DOI 10.1002/eji.1830271004; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; Lukacs NW, 1997, J IMMUNOL, V158, P4398; LUSTER AD, 1993, J EXP MED, V178, P1057, DOI 10.1084/jem.178.3.1057; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; Luster AD, 1997, J LEUKOCYTE BIOL, V62, P620, DOI 10.1002/jlb.62.5.620; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MacLean JA, 1996, J EXP MED, V184, P1461, DOI 10.1084/jem.184.4.1461; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; REINECKER HC, 1995, GASTROENTEROLOGY, V108, P40, DOI 10.1016/0016-5085(95)90006-3; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Sarafi MN, 1997, J EXP MED, V185, P99, DOI 10.1084/jem.185.1.99; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; SHARPE RJ, 1990, JNCI-J NATL CANCER I, V82, P848, DOI 10.1093/jnci/82.10.848; Sica A, 1997, J EXP MED, V185, P969, DOI 10.1084/jem.185.5.969; SOUSA AR, 1994, AM J RESP CELL MOL, V10, P142, DOI 10.1165/ajrcmb.10.2.8110469; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stafford S, 1997, J IMMUNOL, V158, P4953; STREITER RM, 1996, J IMMUNOL, V156, P3583; STRIETER RM, 1995, J LEUKOCYTE BIOL, V57, P752, DOI 10.1002/jlb.57.5.752; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; WADA T, 1994, J EXP MED, V180, P1135, DOI 10.1084/jem.180.3.1135; WALZ A, 1989, J EXP MED, V170, P1745, DOI 10.1084/jem.170.5.1745; Weber M, 1996, J EXP MED, V183, P681, DOI 10.1084/jem.183.2.681; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; YING S, 1995, J EXP MED, V181, P2153, DOI 10.1084/jem.181.6.2153; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; YOSHIMURA T, 1989, J EXP MED, V169, P1449, DOI 10.1084/jem.169.4.1449	84	3028	3189	7	235	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 12	1998	338	7					436	445		10.1056/NEJM199802123380706	http://dx.doi.org/10.1056/NEJM199802123380706			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW122	9459648				2022-12-28	WOS:000071900100006
J	Douketis, JD; Kearon, C; Bates, S; Duku, EK; Ginsberg, JS				Douketis, JD; Kearon, C; Bates, S; Duku, EK; Ginsberg, JS			Risk of fatal pulmonary embolism in patients with treated venous thromboembolism	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; INTRAVENOUS UNFRACTIONATED HEPARIN; ORAL ANTICOAGULANT-THERAPY; LONG-TERM TREATMENT; INITIAL TREATMENT; IMPEDANCE PLETHYSMOGRAPHY; SUBCUTANEOUS HEPARIN; STANDARD HEPARIN; RANDOMIZED TRIAL	Context.-The most serious complication of deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE) is fatal PE, However, reliable estimates as to the risk of fatal PE in patients with treated DVT or PE are lacking. Objective.-To provide reliable estimates of the risk of fatal PE and the case-fatality rate of recurrent DVT or PE among patients presenting with symptomatic DVT or PE, during and following 3 months of anticoagulant therapy. Data Sources.-A MEDLINE literature search was performed to identify prospective studies in which patients with symptomatic DVT or PE were treated with 5 to 10 days of heparin and 3 months of oral anticoagulants. We searched the years 1966 to September 1997 using the search terms thrombophlebitis, diagnosis, drug therapy, and prognosis. Current Contents and bibliographies were also scanned. Data Extraction.-Of 137 retrieved studies, 25 studies satisfied predetermined methodologic criteria and were included in the analysis. Data Synthesis.-Among patients presenting with DVT, the rate of fatal PE during anticoagulant therapy was 0.4% (95% confidence interval [CI], 0.2%-0.6%); following anticoagulant therapy it was 0.3 per 100 patient-years (95% CI, 0.1-0.8). The case-fatality rate of recurrent DVT or PE during anticoagulant therapy was 8.8% (95% CI, 5.0%-14.1%); following anticoagulant therapy it was 5.1% (95% CI, 1.4%-12.5%), Among patients presenting with PE, the rate of fatal PE during anticoagulant therapy was 1.5% (95% CI, 0.9%-2.2%); following anticoagulant therapy it was 0 per 265 patient-years (95% CI, 0-3.6), The case-fatality rate of recurrent DVT or PE among patients presenting with PE was 26.4% (95% CI, 16.7%-38.1%). Conclusion.-Among patients with symptomatic PE or DVT who are treated with anticoagulants for 3 months, fatal PE is rare during and following anticoagulant therapy. Patients presenting with PE are more likely to die of recurrent PE or DVT than are patients presenting with DVT.	McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada	McMaster University; McMaster University	Douketis, JD (corresponding author), St Josephs Hosp, Room L-208,50 Charlton Ave, Hamilton, ON L8N 4A6, Canada.		ginsberg, jeffrey s/ABC-1065-2020; Douketis, James/AAO-5659-2021; Duku, Eric/C-6552-2008	Duku, Eric/0000-0003-3599-3527				ALPERT JS, 1976, JAMA-J AM MED ASSOC, V236, P1477, DOI 10.1001/jama.236.13.1477; ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; BRANDJES DPM, 1992, NEW ENGL J MED, V327, P1485, DOI 10.1056/NEJM199211193272103; BRATT G, 1990, THROMB HAEMOSTASIS, V64, P506; CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; DALEN JE, 1975, PROG CARDIOVASC DIS, V17, P259, DOI 10.1016/S0033-0620(75)80017-X; Dolovich L, 1997, VESSELS, V3, P4; DUROUX P, 1991, THROMB HAEMOSTASIS, V65, P251; FLEISS JL, 1973, STAT METHODS RATES P, V1, P43; GALLUS A, 1986, LANCET, V2, P1293; HOMMES DW, 1992, ANN INTERN MED, V116, P279, DOI 10.7326/0003-4819-116-4-279; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; HUISMAN MV, 1988, ARCH INTERN MED, V148, P681, DOI 10.1001/archinte.148.3.681; HULL R, 1979, NEW ENGL J MED, V301, P855, DOI 10.1056/NEJM197910183011602; HULL R, 1982, NEW ENGL J MED, V306, P189, DOI 10.1056/NEJM198201283060401; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; HULL RD, 1994, ARCH INTERN MED, V154, P289, DOI 10.1001/archinte.154.3.289; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; HULL RD, 1983, CIRCULATION, V67, P901, DOI 10.1161/01.CIR.67.4.901; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; KEARON C, 1997, THROMB HAEMOSTASIS, V78, P767; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; LAGERSTEDT CI, 1985, LANCET, V2, P515; LENSING AWA, 1992, THROMB HAEMOSTASIS, V67, P8; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; LEVINE MN, 1995, THROMB HAEMOSTASIS, V74, P606; LINDMARKER P, 1994, THROMB HAEMOSTASIS, V72, P186; LOPACIUK S, 1992, THROMB HAEMOSTASIS, V68, P14; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; PRANDONI P, 1993, CIRCULATION, V88, P1730, DOI 10.1161/01.CIR.88.4.1730; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; SALZMAN EW, 1994, HEMOSTASIS THROMBOSI, P1275; SCHULMAN S, 1985, ACTA MED SCAND, V217, P547; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; Simonneau G, 1997, NEW ENGL J MED, V337, P663, DOI 10.1056/NEJM199709043371002; SIMONNEAU G, 1993, ARCH INTERN MED, V153, P1541, DOI 10.1001/archinte.153.13.1541; tenCate JW, 1997, NEW ENGL J MED, V337, P657; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WHITE RH, 1989, ANN INTERN MED, V111, P297, DOI 10.7326/0003-4819-111-4-297	43	468	481	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	1998	279	6					458	462		10.1001/jama.279.6.458	http://dx.doi.org/10.1001/jama.279.6.458			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV580	9466640				2022-12-28	WOS:000071839800035
J	Baptista, MV; Maeder, P; Dewarrat, A; Bogousslavsky, J				Baptista, MV; Maeder, P; Dewarrat, A; Bogousslavsky, J			Conflicting images	LANCET			English	Article							CAROTID ENDARTERECTOMY; SURGERY		CHU Vaudois, Dept Neurol, CH-1011 Lausanne, Switzerland; CHU Vaudois, Dept Neuroradiol, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Bogousslavsky, J (corresponding author), CHU Vaudois, Dept Neurol, CH-1011 Lausanne, Switzerland.		Viana-Baptista, Miguel/AAW-6791-2020	Viana-Baptista, Miguel/0000-0001-6166-2073				Breen JC, 1996, NEUROLOGY, V46, P175, DOI 10.1212/WNL.46.1.175; POWERS AD, 1990, NEUROSURGERY, V26, P56, DOI 10.1227/00006123-199001000-00008; REGLI L, IN PRESS CEREBRAVASC; SCHAEFER PW, 1997, STROKE, V28, P1002; SUNDT TM, 1981, MAYO CLIN PROC, V56, P533	5	12	12	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					414	414		10.1016/S0140-6736(97)10180-5	http://dx.doi.org/10.1016/S0140-6736(97)10180-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482296				2022-12-28	WOS:000071982600014
J	Sharp, D				Sharp, D			Another tropical-drug donation	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Sharp, D (corresponding author), Lancet, London WC1B 3SL, England.							Addiss DG, 1997, LANCET, V350, P480, DOI 10.1016/S0140-6736(97)02231-9; Bloland PB, 1997, LANCET, V350, P1624, DOI 10.1016/S0140-6736(97)06082-0; Brown KR, 1997, LANCET, V349, P5	3	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					388	388		10.1016/S0140-6736(05)78352-5	http://dx.doi.org/10.1016/S0140-6736(05)78352-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482290				2022-12-28	WOS:000071982600008
J	Walt, G				Walt, G			Globalisation of international health	LANCET			English	Article								40 years ago, activities; in international health were the domain of WHO, governments (based on bilateral agreements), and non-governmental organisations. this has changed. Today, new players (such as the World Bank and, increasingly, the World Trade Organisation) Rave an influence on international health. As globalisation of trade and markets takes hold, new coalitions and alliances are forming to examine and deal with the direct and Indirect consequences on health., This paper examines the changing context of cooperation in international health, and voices concerns about rising potential inequalities in health, both within and between countries. The question of how suck changes will affect the? actions of organisations working in international health is also addressed.	Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Policy Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Walt, G (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Policy Unit, London WC1E 7HT, England.							Cornia A., 1987, ADJUSTMENT HUMAN FAC; Department for International Development, 1997, EL WORLD POV CHALL 2; GOLDSTEIN E, 1997, 341 WORLD BANK, V1; Hutton W., 1995, STATE WERE; Institute of Medicine, 1997, AM VIT INT GLOB HLTH; Krut Riva, 1997, GLOBALIZATION CIVIL; Lee K, 1996, BRIT MED J, V312, P302; Leon DA, 1997, LANCET, V350, P383, DOI 10.1016/S0140-6736(97)03360-6; Lucas A, 1997, COOPERATION HLTH DEV; MACKINTOSH M, 1997, C PUBL MAN NEXT CENT; McKee M, 1996, J EUROPEAN SOCIAL PO, V6, P263, DOI DOI 10.1177/095892879600600401; MCMICHAEL J, 1997, BRIT MED J, V315, P805; MORAN M, 1995, GLOBALIZATION PUBLIC; *ORG EC COOP DEV, 1997, DEV ASS COMM REP AID; RAYMOND SU, 1997, GLOBAL PUBLIC HLTH C; Rifkin J., 1995, END WORK; SiegelItzkovich J, 1997, BRIT MED J, V314, P1504; *UN C TRAD DEV, 1997, TDBCOM1EM12 UN C TRA; United Nations Development Programme, 1997, HUM DEV REP; VIDAL J, 1997, GUARDIAN        0927, P3; WARNOCK B, 1994, HEALTH ECON, V3, P297, DOI 10.1002/hec.4730030502; *WHO, 1997, THINK ACT GLOB INT P; Wilkinson R, 1996, UNHEALTHY SOC; WILKINSON RG, 1996, E W LIFE EXPECTANCY; *WORLD BANK, 1997, HUM DEV NETW SECT ST; YACH D, 1998, IN PRESS AM J PUBLIC; 1997, SOC SCI MED, V44, P6; 1997, ECONOMIST       0927, P82; 1996, NORDIC UN REFORM REP	29	57	61	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					434	437		10.1016/S0140-6736(97)05546-3	http://dx.doi.org/10.1016/S0140-6736(97)05546-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YW873	9482320				2022-12-28	WOS:000071982600044
J	Haber, JE				Haber, JE			Meiosis - Searching for a partner	SCIENCE			English	Editorial Material							MEIOTIC CHROMOSOME SYNAPSIS; RECOMBINATION; YEAST		Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Dept Biol, Waltham, MA 02254 USA; Brandeis Univ, Keck Inst Cellular Visualizat, Waltham, MA 02254 USA	Brandeis University; Brandeis University	Haber, JE (corresponding author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Dept Biol, Waltham, MA 02254 USA.			Haber, James/0000-0002-1878-0610				Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Goldman ASH, 1996, GENETICS, V144, P43; HAWLEY RS, 1980, GENETICS, V94, P625; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; LOIDL J, 1991, CHROMOSOMA, V100, P221, DOI 10.1007/BF00344155; McKim KS, 1998, SCIENCE, V279, P876, DOI 10.1126/science.279.5352.876; MOSES MJ, 1982, CHROMOSOMA, V84, P457, DOI 10.1007/BF00292848; Rocco V, 1996, GENES CELLS, V1, P645, DOI 10.1046/j.1365-2443.1996.00256.x; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; ZETKA M, 1995, TRENDS GENET, V11, P27, DOI 10.1016/S0168-9525(00)88983-0	13	11	11	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					823	824		10.1126/science.279.5352.823	http://dx.doi.org/10.1126/science.279.5352.823			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9480551				2022-12-28	WOS:000071923500031
J	Javaheri, S; Corbett, WS				Javaheri, S; Corbett, WS			Association of low PaCO2 with central sleep apnea and ventricular arrhythmias in ambulatory patients with stable heart failure	ANNALS OF INTERNAL MEDICINE			English	Article							PATHOGENESIS; RESPIRATION	Background: Central sleep apnea frequently occurs in patients with heart failure. Because it is not practical to perform sleep studies on all patients, readily available laboratory tests that predict sleep apnea would be clinically useful. Arterial PCO2 has a profound influence on breathing during sleep: When it decreases below a certain threshold, apnea occurs. Objective: To study the value of a low PaCO2 while patients are awake in predicting central sleep apnea in patients with stable, treated heart failure. Design: Prospective study. Setting: Referral sleep laboratory of a Department of Veterans Affairs Medical Center. Participants: 59 patients with left ventricular ejection fractions of 45% or less. Measurements: Arterial blood gases and hydrogen ion concentrations were measured, and cardiac radionuclide ventriculography, Holter monitoring, and polysomnography were done. Results: Patients were classified as eucapnic (PaCO2 > 35 and < 44 mm Hg [n = 41]) or hypocapnic (PaCO2 less than or equal to 35 mm Hg [n = 18]). The mean (+/- SD) hourly episodes of apnea or hypopnea (36 +/- 25 and 20 +/- 27; P = 0.015), the prevalence of central sleep apnea (78% and 39%; P = 0.01), and the mean hourly occurrences of ventricular tachycardia (Z +/- 3 and 0.1 +/- 0.1; P = 0.003) were significantly greater in hypocapnic patients than in eucapnic patients. Conclusion: Data on patients with heart failure in this study are consistent with the physiologic notion that a low PaCO2 results in ventilatory instability and central apnea during sleep. The positive predictive value of a low PaCO2 for central sleep apnea is 78%. The prevalence of ventricular tachycardia was 20 times greater in hypocapnic patients than in eucapnic patients.	Vet Affairs Med Ctr, Pulm Sect 111F, Cincinnati, OH 45220 USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati	Javaheri, S (corresponding author), Vet Affairs Med Ctr, Pulm Sect 111F, 3200 Vine St, Cincinnati, OH 45220 USA.							AYRES SM, 1969, AM J MED, V46, P495, DOI 10.1016/0002-9343(69)90069-2; CHERNIACK NS, 1984, J CLIN INVEST, V73, P1501, DOI 10.1172/JCI111355; *EEG, 1992, SLEEP, V15, P174; Gennari FJ, 1982, ACID BASE, P349; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; HANLY P, 1993, CHEST, V104, P1079, DOI 10.1378/chest.104.4.1079; HANLY PJ, 1989, ANN INTERN MED, V111, P777, DOI 10.7326/0003-4819-111-10-777; JAVAHERI S, 1987, AM REV RESPIR DIS, V135, P597; Javaheri S, 1996, NEW ENGL J MED, V335, P562, DOI 10.1056/NEJM199608223350805; Javaheri S, 1996, SLEEP, V19, pS229; JAVAHERI S, 1995, ANN INTERN MED, V122, P487, DOI 10.7326/0003-4819-122-7-199504010-00002; JAVAHERI S, 1994, SLEEP, V17, P416, DOI 10.1093/sleep/17.5.416; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; NAUGHTON M, 1993, AM REV RESPIR DIS, V148, P330, DOI 10.1164/ajrccm/148.2.330; *SAS I INC, 1998, SAS STAT US GUID VER; SKATRUD JB, 1983, J APPL PHYSIOL, V55, P813, DOI 10.1152/jappl.1983.55.3.813; TAKASAKI Y, 1989, AM REV RESPIR DIS, V140, P1578, DOI 10.1164/ajrccm/140.6.1578; YAMASHIRO Y, 1993, SLEEP, V16, P513, DOI 10.1093/sleep/16.6.513	18	107	112	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1998	128	3					204	207		10.7326/0003-4819-128-3-199802010-00006	http://dx.doi.org/10.7326/0003-4819-128-3-199802010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU303	9454528				2022-12-28	WOS:000071703200005
J	Mangano, CM; Diamondstone, LS; Ramsay, JG; Aggarwal, A; Herskowitz, A; Mangano, DT				Mangano, CM; Diamondstone, LS; Ramsay, JG; Aggarwal, A; Herskowitz, A; Mangano, DT		Multictr Study Perioperative Ischemia Res Grp	Renal dysfunction after myocardial revascularization: Risk factors, adverse outcomes, and hospital resource utilization	ANNALS OF INTERNAL MEDICINE			English	Article							OPEN-HEART SURGERY; CARDIOPULMONARY BYPASS; CARDIAC OPERATIONS; FAILURE; MORBIDITY; PROGNOSIS; PERFUSION	Background: Acute changes in renal function after elective coronary bypass surgery are incompletely characterized and represent a challenging clinical problem. Objective: To determine the incidence and characteristics of postoperative renal dysfunction and failure, perioperative predictors of dysfunction, and the effect of renal dysfunction and failure on in-hospital resource utilization and patient disposition after discharge. Design: Prospective, observational, multicenter study. Setting: 24 university hospitals. Patients: 2222 patients having myocardial revascularization with or without concurrent valvular surgery. Measurements: Prospective histories, physical examinations, and electrocardiographic and laboratory studies. The main outcome measure was renal dysfunction (defined as a postoperative serum creatinine level greater than or equal to 177 mu mol/L with a preoperative-to-postoperative increase greater than or equal to 62 mu mol/L). Results: 171 patients (7.7%) had postoperative renal dysfunction; 30 of these (1.4% overall) had oliguric renal failure that required dialysis. In-hospital mortality, length of stay in the intensive care unit, and hospitalization were significantly increased in patients who had renal failure and those who had renal dysfunction compared with those who had neither (mortality: 63%, 19%, and 0.9%; intensive care unit stay: 14.9 days, 6.5 days, and 3.1 days; hospitalization: 28.8 days, 18.2 days, and 10.6 days, respectively). Patients with renal dysfunction were three times as likely to be discharged to an extended-care facility. Multivariable analysis identified five independent preoperative predictors of renal dysfunction: age 70 to 79 years (relative risk [RR], 1.6 [95% CI, 1.1 to 2.3]) or age 80 to 95 years (RR 3.5 [CI, 1.9 to 6.3]); congestive heart failure (RR, 1.8 [CI, 1.3 to 2.6]); previous myocardial revascularization (RR, 1.8 [CI, 1.2 to 2.7]); type 1 diabetes mellitus (RR, 1.8 [CI, 1.1 to 3.0]) or preoperative serum glucose levels exceeding 16.6 mmol/L (RR, 3.7 [CI, 1.7 to 7.8]); and preoperative serum creatinine levels of 124 to 177 mu mol/L (RR, 2.3 [CI, 1.6 to 3.4]). Independent perioperative factors that exacerbated risk were cardiopulmonary bypass lasting 3 or more hours and three measures of ventricular dysfunction. Conclusions: Many patients having elective myocardial revascularization develop postoperative renal dysfunction and failure, which are associated with prolonged intensive care unit and hospital stays, significant increases in mortality, and greater need for specialized long-term care. Resources should be redirected to mitigate renal injury in high-risk patients.	Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA 94305 USA; Ischemia Res & Educ Fdn, San Francisco, CA 94134 USA; Emory Univ, Sch Med, Atlanta, GA USA; Med Coll Wisconsin, Madison, WI USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA	Stanford University; Emory University; Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Mangano, CM (corresponding author), Stanford Univ, Sch Med, Dept Anesthesia, 300 Pasteur Dr,Room H3084, Stanford, CA 94305 USA.							ABEL RM, 1976, J THORAC CARDIOV SUR, V71, P323; BHAT JG, 1976, ANN INTERN MED, V84, P677, DOI 10.7326/0003-4819-84-6-677; CORWIN HL, 1989, J THORAC CARDIOV SUR, V98, P1107; DONOHOE JF, 1978, KIDNEY INT, V13, P208, DOI 10.1038/ki.1978.31; GAILIUNAS P, 1980, J THORAC CARDIOV SUR, V79, P241; HILBERMAN M, 1980, J THORAC CARDIOV SUR, V79, P838; HILBERMAN M, 1979, J THORAC CARDIOV SUR, V77, P880; IPYAM PC, 1994, ANESTH ANALG, V78, P842; JONES EL, 1991, J THORAC CARDIOV SUR, V101, P108; KONING HM, 1987, SCAND J THORAC CARD, V21, P207, DOI 10.3109/14017438709106026; LANGE HW, 1987, AM HEART J, V113, P1138, DOI 10.1016/0002-8703(87)90925-2; LOWE MB, 1966, J PATHOL BACTERIOL, V92, P319, DOI 10.1002/path.1700920208; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MAZZARELLA V, 1992, J THORAC CARDIOV SUR, V104, P1625, DOI 10.1016/S0022-5223(19)33893-0; MCLEISH KR, 1977, SURG GYNECOL OBSTET, V145, P28; MORI A, 1988, ARCH SURG-CHICAGO, V124, P458; MYERS BD, 1986, NEW ENGL J MED, V314, P97; PRICE RG, 1992, EUR J CLIN CHEM CLIN, V30, P693; RAMSAY JG, 1995, CARDIOPULMONARY BYPA, P147; REVES JG, 1982, CIRCULATION, V66, P49, DOI 10.1161/01.CIR.66.1.49; SHAW PJ, 1987, STROKE, V18, P700, DOI 10.1161/01.STR.18.4.700; SLOGOFF S, 1990, ANN THORAC SURG, V50, P911, DOI 10.1016/0003-4975(90)91118-U; YEBOAH ED, 1972, BRIT MED J, V1, P415, DOI 10.1136/bmj.1.5797.415; ZANARDO G, 1994, J THORAC CARDIOV SUR, V107, P1489, DOI 10.1016/S0022-5223(94)70429-5	24	803	849	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1998	128	3					194	203		10.7326/0003-4819-128-3-199802010-00005	http://dx.doi.org/10.7326/0003-4819-128-3-199802010-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU303	9454527				2022-12-28	WOS:000071703200004
J	Schmid, ML; Kudesia, G; Wake, S; Read, RC				Schmid, ML; Kudesia, G; Wake, S; Read, RC			Prospective comparative study of culture specimens and methods in diagnosing influenza in adults	BRITISH MEDICAL JOURNAL			English	Article									Univ Sheffield, Sch Med, Div Mol & Genet Med, Sheffield S10 2RX, S Yorkshire, England; Royal Hallamshire Hosp, N Trent Dept Infect & Trop Med, Sheffield S10 2JF, S Yorkshire, England; No Gen Hosp, Publ Hlth Lab, Sheffield S5 7AU, S Yorkshire, England	University of Sheffield; University of Sheffield; Northern General Hospital	Read, RC (corresponding author), Univ Sheffield, Sch Med, Div Mol & Genet Med, Sheffield S10 2RX, S Yorkshire, England.		Schmid, Matthias/B-7750-2008	Read, Robert/0000-0002-4297-6728				BETTS RF, 1995, PRINCIPLES PRACTICE, P1546; HUTCHINSON EJ, 1996, COMMUN DIS REP CDR W, V6, P163; SCHIRM J, 1992, J MED VIROL, V38, P147, DOI 10.1002/jmv.1890380214; WISELKA M, 1994, BRIT MED J, V308, P1341, DOI 10.1136/bmj.308.6940.1341	4	25	29	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					275	275		10.1136/bmj.316.7127.275	http://dx.doi.org/10.1136/bmj.316.7127.275			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472512	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000071702100026
J	Parker, L; Cole, M; Craft, AW; Hey, EN				Parker, L; Cole, M; Craft, AW; Hey, EN			Neonatal vitamin K administration and childhood cancer in the north of England: retrospective case-control study	BRITISH MEDICAL JOURNAL			English	Article							NEWBORN-INFANTS; PROPHYLAXIS; LEUKEMIA; DENMARK; GERMANY; DISEASE; BIRTH; RISK	Objective: To explore the possible association between intramuscular vitamin K given to neonates and the subsequent development of childhood cancer. Design: Retrospective case-control study on the basis of hospital records. Setting: The former Northern Health region of England. Subjects: 685 children who were born and lived in the region and who developed cancer before their 15th birthday, and 3442 controls also born between 1960 and 1991 and matched only for date and hospital of birth. The notes of a further 701 index cases were untraceable. Main exposure measure: Administration of intramuscular vitamin K versus no exposure to vitamin K. Results: There was no association between the administration of vitamin K and the development of all childhood cancers (unadjusted odds ratio 0.89; 95% confidence interval 0.69 to 1.15) or for all acute lymphoblastic leukaemia (1.20; 0.75 to 1.92), but there was a raised odds ratio for acute lymphoblastic leukaemia developing 1-6 years after birth (1.79; 1.02 to 3.15). No such association was seen in a separate cohort-based study not dependent on case note retrieval in which the rates of acute lymphoblastic leukaemia in children born in hospital units where all babies received vitamin K were compared with those born in units where less than a third received prophylaxis. Conclusions: It is not possible, on the basis of currently published evidence, to refute the suggestion that neonatal intramuscular vitamin K administration increases the risk of early childhood leukaemia. Any association may have been masked in earlier studies that did not use controls matched for time and locality by other unidentified factors affecting the spatiotemporal variations in incidence of leukaemia.	Univ Newcastle Upon Tyne, Royal Victoria Infirm, Sir James Spence Inst Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK	Parker, L (corresponding author), Univ Newcastle Upon Tyne, Royal Victoria Infirm, Sir James Spence Inst Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.			PARKER, LOUISE/0000-0002-5188-8113				Ansell P, 1996, BRIT MED J, V313, P204, DOI 10.1136/bmj.313.7051.204; Baenziger O, 1996, LANCET, V348, P1456, DOI 10.1016/S0140-6736(04)70106-3; BRESLOW NE, 1987, IARC SCI PUBL, V82, P135; Breslow NE, 1980, IARC SCI PUBL, V32, P248; CORNELISSEN M, 1994, BMJ-BRIT MED J, V309, P1441, DOI 10.1136/bmj.309.6966.1441c; Cornelissen M, 1997, EUR J PEDIATR, V156, P126, DOI 10.1007/s004310050570; CRAFT AW, 1987, BRIT J CANCER, V56, P853, DOI 10.1038/bjc.1987.305; *DEP HLTH SOC SERV, 1988, REP HLTH SOC SUBJ, V32, P35; DRAPER G, 1995, OPCS SERIES DS, V11, P140; DRAPER GJ, 1991, GEOGRAPHICAL EPIDEMI; EKELUND H, 1993, BRIT MED J, V307, P89, DOI 10.1136/bmj.307.6896.89; GOLDING J, 1990, BRIT J CANCER, V62, P304, DOI 10.1038/bjc.1990.283; GOLDING J, 1992, BRIT MED J, V305, P241; Greaves MF, 1997, LANCET, V349, P344, DOI 10.1016/S0140-6736(96)09412-3; GREER FR, 1997, PEDIATRICS, V99, P8; Hansen KN, 1996, ACTA PAEDIATR, V85, P1137, DOI 10.1111/j.1651-2227.1996.tb18216.x; KLEBANOFF MA, 1993, NEW ENGL J MED, V329, P905, DOI 10.1056/NEJM199309233291301; LAUGHNAN PM, 1996, J PAEDIAT CHILD HLTH, V32, P251; MCNINCH A, 1996, VITAMIN K DEFICIENCY; MCNINCH AW, 1985, ARCH DIS CHILD, V60, P814, DOI 10.1136/adc.60.9.814; Nishiguchi T, 1996, BRIT J OBSTET GYNAEC, V103, P1078, DOI 10.1111/j.1471-0528.1996.tb09586.x; OLSEN JH, 1994, BRIT MED J, V308, P895, DOI 10.1136/bmj.308.6933.895; Roman E, 1997, BRIT J CANCER, V76, P406, DOI 10.1038/bjc.1997.399; SCHUBIGER G, 1993, J PEDIATR GASTR NUTR, V16, P435, DOI 10.1097/00005176-199305000-00016; VONKRIES R, 1995, BMJ-BRIT MED J, V310, P1097, DOI 10.1136/bmj.310.6987.1097; vonKries R, 1996, BRIT MED J, V313, P199, DOI 10.1136/bmj.313.7051.199; Zipursky A, 1996, BMJ-BRIT MED J, V313, P179, DOI 10.1136/bmj.313.7051.179	27	34	40	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					189	193						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468683	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000071616400023
J	Oren, DA; Terman, M				Oren, DA; Terman, M			Tweaking the human circadian clock with light	SCIENCE			English	Article							RHYTHMS		US Dept Vet Affairs, W Haven, CT 06516 USA; Yale Univ, Sch Med, W Haven, CT 06516 USA; New York State Psychiat Inst, New York, NY 10032 USA; Columbia Univ, New York, NY 10032 USA	US Department of Veterans Affairs; Yale University; New York State Psychiatry Institute; Columbia University	Oren, DA (corresponding author), US Dept Vet Affairs, W Haven, CT 06516 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH042931] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-42931] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Arendt J, 1997, J BIOL RHYTHM, V12, P604, DOI 10.1177/074873049701200616; AVERY DH, 1993, AM J PSYCHIAT, V150, P113; Bunning E, 1973, PHYSL CLOCK; Campbell SS, 1998, SCIENCE, V279, P396, DOI 10.1126/science.279.5349.396; CZELSLR A, 1997, J BIOL RHYTHM, V12, P618; LEWY AJ, 1992, CHRONOBIOL INT, V9, P380, DOI 10.3109/07420529209064550; LEWY AJ, 1987, SCIENCE, V235, P352, DOI 10.1126/science.3798117; Oren DA, 1996, NEUROSCIENTIST, V2, P207, DOI 10.1177/107385849600200408; Oren DA, 1997, CHRONOBIOL INT, V14, P319, DOI 10.3109/07420529709001423; Oren DA, 1993, DEPRESSION, V1, P29; PITTENDRIGH CS, 1989, SEASONAL AFFECTIVE D, P87; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; PROVENCIO I, 1994, VISION RES, V34, P1799, DOI 10.1016/0042-6989(94)90304-2; RICHTER CP, 1967, P ASS RES NERV MENT, V45, P8; TAKAHASHI JS, 1984, NATURE, V308, P186, DOI 10.1038/308186a0; TERMAN M, 1990, SLEEP BIOL RHYTHMS, P113; TERMAN M, 1998, IN PRESS SEASONAL AF; TERMAN M, IN PRESS SLEEP; TERMAN M, 1997, SLEEP SCI INTEGRATIN, P230; Thompson C, 1997, BRIT J PSYCHIAT, V170, P431, DOI 10.1192/bjp.170.5.431; 1729, HIST ACAD ROYALE SCI, P47	21	39	40	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					333	334		10.1126/science.279.5349.333	http://dx.doi.org/10.1126/science.279.5349.333			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9454328				2022-12-28	WOS:000071570800030
J	Tyrer, P; Evans, K; Gandhi, N; Lamont, A; Harrison-Read, P; Johnson, T				Tyrer, P; Evans, K; Gandhi, N; Lamont, A; Harrison-Read, P; Johnson, T			Randomised controlled trial of two models of care for discharged psychiatric patients	BRITISH MEDICAL JOURNAL			English	Article							MENTAL-ILLNESS; SCALE	Objective: To compare the clinical outcome and costs of care of psychiatric patients allocated to community multidisciplinary teams or to hospital based care programmes after discharge from inpatient care. Design: Randomised controlled trial. Setting: Inner London (Paddington and North Kensington) and outer London (Brent) psychiatric services. Subjects: 155 patients with severe mental illness with a previous admission within the past 2 years. Main outcome measures: Ratings of clinical psychopathology, depression, anxiety, and social functioning; comprehensive costs of health care. Results: Clinical outcomes were available for 133 patients and cost data for 144 patients after 1 year. The clinical outcomes of the two models of care were essentially similar, but admission to hospital was more likely in the hospital based care group and the costs of health care were 14% greater per patient than in the community group. This difference, however, was dwarfed by a twofold difference in the costs of care in the outer London services compared with those in inner London. This was explained largely by greater inpatient care for outer London patients (58 median bed days v 18 for inner London patients), more of which was provided by extracontractual referrals to other psychiatric hospitals as Brent had only 0.28/1000 beds available for acute adult patients compared with 0.82/1000 in Paddington and North Kensington over the period of the study. Conclusion: Aftercare by community teams for psychiatric patients with severe mental illness has a similar outcome to hospital based aftercare but with fewer admissions to hospital. When psychiatric bed requirements are insufficient for a population, however, neither form of aftercare is effective as greater use of hospital beds elsewhere swamps any advantage of community care programmes, with disintegration and discontinuity of psychiatric services leading to escalating costs.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Paterson Ctr, Div Neurosci & Psychol Med, London W2 1PD, England; Cent Middlesex Hosp, Pk Royal Ctr Mental Hlth, London NW10 7NS, England; Univ Forvie Site, Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England	Imperial College London; Imperial College London; MRC Biostatistics Unit; University of Cambridge	Tyrer, P (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Paterson Ctr, Div Neurosci & Psychol Med, London W2 1PD, England.	p.tyrer@ic.ac.uk						ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5; BURNS T, 1993, BRIT J PSYCHIAT, V163, P49, DOI 10.1192/bjp.163.1.49; CREED F, 1995, COMMUNITY PSYCHIAT A, P11; Department of Health, 1996, BUILD BRIDG GUID ARR; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; HOLLANDER D, 1994, PSYCHIAT B, V18, P532; HOULT J, 1984, ACTA PSYCHIAT SCAND, V69, P359, DOI 10.1111/j.1600-0447.1984.tb02506.x; KINGDON D.G, 1994, PSYCHIATRIC B, V18, P68; KNAPP M, 1994, BRIT J PSYCHIAT, V165, P195, DOI 10.1192/bjp.165.2.195; MARSHALL M, 1996, SCHIZOPHRENIA MODULE; MCGUFFIN P, 1993, OPCRIT VERSION 3 3 P; *MILMIS PROJ GROUP, 1995, PSYCHIAT B, V19, P276; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; MUIJEN M, 1992, BRIT MED J, V304, P749, DOI 10.1136/bmj.304.6829.749; SPITZER RL, 1987, STRUCTURAL CLIN INTE; Stein LI, 1980, ARCH GEN PSYCHIAT, V36, P1073; TYRER P, 1995, LANCET, V345, P756, DOI 10.1016/S0140-6736(95)90640-1; TYRER P, 1984, J NEUROL NEUROSUR PS, V47, P970, DOI 10.1136/jnnp.47.9.970; TYRER P, 1995, COMMUNITY PSYCHIAT A; TYRER P, 1995, EMERGENCY MENTAL HLT, P197; Tyrer P, 1990, MEASURING HUMAN PROB, P119; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	22	61	63	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 10	1998	316	7125					106	109						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YR408	9462315				2022-12-28	WOS:000071492300018
J	Harrison, PJ; Geddes, JR				Harrison, PJ; Geddes, JR			Molecules, mice, and meta-analyses	LANCET			English	Article											Harrison, PJ (corresponding author), WARNEFORD HOSP,UNIV DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND.			Geddes, John/0000-0002-5281-5960; Harrison, Paul/0000-0002-6719-1126				GAMES D, 1995, NATURE, V375, P754; JICK SS, 1995, BRIT MED J, V310, P215, DOI 10.1136/bmj.310.6974.215; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; TYRER P, 1995, LANCET, V345, P756, DOI 10.1016/S0140-6736(95)90640-1; WANG SB, 1995, NAT GENET, V10, P41, DOI 10.1038/ng0595-41	5	0	0	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S19	S19		10.1016/0140-6736(95)90018-7	http://dx.doi.org/10.1016/0140-6736(95)90018-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454036				2022-12-28	WOS:A1995TN12200019
J	McMichael, AJ; Woodward, A				McMichael, AJ; Woodward, A			Hazardous environments: Local and global	LANCET			English	Article									WELLINGTON SCH MED,DEPT PUBL HLTH,WELLINGTON,NEW ZEALAND	University of Otago	McMichael, AJ (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.			Woodward, Alistair/0000-0001-5425-6018				Hertzman C, 1995, ENV HLTH CENTRAL E E; PATZ JA, IN PRESS JAMA; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669, DOI 10.1164/ajrccm/151.3_Pt_1.669; STEPHENS C, 1995, HEALTH POLICY PLANN, V10, P109, DOI 10.1093/heapol/10.2.109; WATSON RT, 1995, IN PRESS INTERGOVERN, V2	5	1	1	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S5	S5		10.1016/0140-6736(95)90004-7	http://dx.doi.org/10.1016/0140-6736(95)90004-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454048				2022-12-28	WOS:A1995TN12200005
J	Lu, YM; Roder, JC; Davidow, J; Salter, MW				Lu, YM; Roder, JC; Davidow, J; Salter, MW			Src activation in the induction of long-term potentiation in CA1 hippocampal neurons	SCIENCE			English	Article							D-ASPARTATE RECEPTOR; PROTEIN-TYROSINE KINASES; POSTSYNAPTIC CALCIUM; SYNAPTIC PLASTICITY; MUTANT MICE; SUBUNIT 2B; PHOSPHORYLATION; FYN; PHOSPHATASES; MECHANISMS	Long-term potentiation (LTP) is an activity-dependent strengthening of synaptic efficacy that is considered to be a model of learning and memory. Protein tyrosine phosphorylation is necessary io induce LTP. Here, induction of LTP in CA1 pyramidal cells of rats was prevented by blocking the tyrosine kinase Src, and Src activity was increased by stimulation producing LTP. Directly activating Sre in the postsynaptic neuron enhanced excitatory synaptic responses, occluding LTP. Src-induced enhancement of alpha-amino-3-hydroxy-5-methylisoxazolepropionic acid (AMPA) receptor-mediated synaptic responses required raised intracellular Ca2+ and N-methyl-D-aspartate (NMDA) receptors. Thus, Sre activation is necessary and sufficient for inducing LTP and may function by up-regulating NMDA receptors.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Hosp Sick Children, Div Neurosci, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Roder, JC (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5S 1A8, Canada.		Roder, John/G-6468-2013					Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; BURKHARDT AL, 1993, CURRENT PROTOCOLS IM, P1; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GUSTAFSSON B, 1988, TRENDS NEUROSCI, V11, P156, DOI 10.1016/0166-2236(88)90142-7; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; Kojima N, 1997, P NATL ACAD SCI USA, V94, P4761, DOI 10.1073/pnas.94.9.4761; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LIU XQ, 1993, ONCOGENE, V8, P1119; Lu YM, 1997, J NEUROSCI, V17, P5196; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MALENKA RC, 1992, NEURON, V9, P121, DOI 10.1016/0896-6273(92)90227-5; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Rosenblum K, 1996, P NATL ACAD SCI USA, V93, P10457, DOI 10.1073/pnas.93.19.10457; Rostas JAP, 1996, P NATL ACAD SCI USA, V93, P10452, DOI 10.1073/pnas.93.19.10452; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WYLLIE DJA, 1994, NEURON, V12, P127, DOI 10.1016/0896-6273(94)90158-9; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	32	268	279	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	1998	279	5355					1363	1367		10.1126/science.279.5355.1363	http://dx.doi.org/10.1126/science.279.5355.1363			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478899				2022-12-28	WOS:000072251800054
J	Kulin, NA; Pastuszak, A; Sage, SR; Schick-Boschetto, B; Spivey, G; Feldkamp, M; Ormond, K; Matsui, D; Stein-Schechman, AK; Cook, L; Brochu, J; Rieder, M; Koren, G				Kulin, NA; Pastuszak, A; Sage, SR; Schick-Boschetto, B; Spivey, G; Feldkamp, M; Ormond, K; Matsui, D; Stein-Schechman, AK; Cook, L; Brochu, J; Rieder, M; Koren, G			Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors - A prospective controlled multicenter study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FLUOXETINE	Context.-Although a large number of women of reproductive age use new selective serotonin reuptake inhibitors (SSRIs) and half of all pregnancies are unplanned, no data exist on the safety of these agents for the human fetus. Objective.-To assess fetal safety and risk of fluvoxamine, paroxetine, and sertraline. Design.-A prospective, multicenter, controlled cohort study. Setting.-Nine Teratology Information Service centers in the United States and Canada. Patients.-All women who were counseled during pregnancy following exposure to a new SSRI and followed up by the participating centers. Controls were randomly selected from women counseled after exposure to nonteratogenic agents. Main Outcome Measures.-Rates of major congenital malformations. Results.-A total of 267 women exposed to an SSRI and 267 controls were studied. Exposure to SSRIs was not associated with either increased risk for major malformations (9/222 live births [4.1%] vs 9/235 live births [3.8%] in the controls, relative risk, 1.06, 95% confidence interval, 0.43-2.62) or higher rates of miscarriage, stillbirth, or prematurity. Mean (SD) birth weights among SSRI users (3439 [505] g) were similar to the controls (3445 [610] g) as were the gestational ages (39.4 [1.7] weeks vs 39.4 [1.9] weeks). Conclusion.-The new SSRIs, fluvoxamine, paroxetine, and sertraline, do not appear to increase the teratogenic risk when used in their recommended doses.	Hosp Sick Children, Motherisk Program, Toronto, ON M5G 1X8, Canada; Teratogen Informat Serv, Tampa, FL USA; Penn Hosp, Philadelphia, PA 19107 USA; Connecticut Pregnancy Exposure Informat Serv, Farmington, CT USA; Pregnancy Riskline, Salt Lake City, UT USA; Univ Vermont, Coll Med, Dept Pediat, Burlington, VT USA; FRAME Program, London, ON, Canada; Illinois Teratogen Informat Serv, Chicago, IL USA; Indiana Teratogen Informat Serv, Indianapolis, IN USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Pennsylvania; Pennsylvania Medicine; University of Vermont	Koren, G (corresponding author), Hosp Sick Children, Div Clin Pharmacol Toxicol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Rieder, Michael J/L-2397-2013; Ormond, Kelly E/I-5676-2019	Ormond, Kelly E/0000-0002-1033-0818				Carpenter LL, 1996, DRUG SAFETY, V15, P116, DOI 10.2165/00002018-199615020-00004; Chambers CD, 1996, NEW ENGL J MED, V335, P1010, DOI 10.1056/NEJM199610033351402; KESSLER RC, 1993, J AFFECT DISORDERS, V29, P85, DOI 10.1016/0165-0327(93)90026-G; KOREN G, 1994, MATERNAL FETAL TOXIC, P707; Nulman I, 1997, NEW ENGL J MED, V336, P258, DOI 10.1056/NEJM199701233360404; PASTUSZAK A, 1993, JAMA-J AM MED ASSOC, V269, P2246, DOI 10.1001/jama.269.17.2246; Sclar DA, 1995, J INT MED RES, V23, P395, DOI 10.1177/030006059502300601; 1992, LANCET, V339, P1600	8	320	324	1	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	1998	279	8					609	610		10.1001/jama.279.8.609	http://dx.doi.org/10.1001/jama.279.8.609			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX457	9486756	Bronze			2022-12-28	WOS:000072041900037
J	Kitagawa, H; van der Plicht, J				Kitagawa, H; van der Plicht, J			Atmospheric radiocarbon calibration to 45,000 yr BP: Late glacial fluctuations and cosmogenic isotope production	SCIENCE			English	Article							ENHANCED BE-10 DEPOSITION; NORTH-ATLANTIC; MELTWATER DISCHARGE; YOUNGER DRYAS; CO2 RECORD; C-14; CIRCULATION; CORALS; SEDIMENTS; LAKE	More than 250 carbon-14 accelerator mass spectrometry dates of terrestrial macrofossils from annually laminated sediments from Lake Suigetsu (Japan) provide a first atmospheric calibration for almost the total range of the radiocarbon method (45,000 years before the present), The results confirm the (recently revised) floating German pine chronology and are consistent with data from European and marine varved sediments, and combined uranium-thorium and carbon-14 dating of corals up to the Last Glacial Maximum, The data during the Glacial show large fluctuations in the atmospheric carbon-14 content, related to changes in global environment and in cosmogenic isotope production.	Int Res Ctr Japanese Studies, Nishikyo Ku, Kyoto 6101192, Japan; Ctr Isotope Res, NL-9747 AG Groningen, Netherlands	University of Groningen	Kitagawa, H (corresponding author), Int Res Ctr Japanese Studies, Nishikyo Ku, 3-2 Goryo Oeyama Cho, Kyoto 6101192, Japan.		van der Plicht, Johannes/B-9994-2013					Adkins JF, 1997, PALEOCEANOGRAPHY, V12, P337, DOI 10.1029/97PA00379; AMMANN B, 1989, BOREAS, V18, P109, DOI 10.1111/j.1502-3885.1989.tb00381.x; BARD E, 1990, NATURE, V345, P405, DOI 10.1038/345405a0; Bard E, 1996, NATURE, V382, P241, DOI 10.1038/382241a0; BARD E, 1993, RADIOCARBON, V35, P191, DOI 10.1017/S0033822200013886; Bard E, 1997, SCIENCE, V277, P532, DOI 10.1126/science.277.5325.532; BARNOLA JM, 1987, NATURE, V329, P408, DOI 10.1038/329408a0; BEER J, 1992, NATO ASI SER, P141; Bjorck S, 1996, SCIENCE, V274, P1155, DOI 10.1126/science.274.5290.1155; CASTAGNOLI GC, 1995, GEOPHYS RES LETT, V22, P707, DOI 10.1029/95GL00298; CHALES CD, 1992, NATURE, V355, P416; EDWARDS RL, 1993, SCIENCE, V260, P962, DOI 10.1126/science.260.5110.962; FIGGE RA, 1995, GLOBAL BIOGEOCHEM CY, V9, P391, DOI 10.1029/95GB01458; Finkel RC, 1997, J GEOPHYS RES-OCEANS, V102, P26699, DOI 10.1029/97JC01282; Frank M, 1997, EARTH PLANET SC LETT, V149, P121, DOI 10.1016/S0012-821X(97)00070-8; GOSLAR T, 1995, NATURE, V377, P414, DOI 10.1038/377414a0; Gottdang A, 1995, RADIOCARBON, V37, P649, DOI 10.1017/S0033822200031167; Guyodo Y, 1996, EARTH PLANET SC LETT, V143, P23, DOI 10.1016/0012-821X(96)00121-5; HADJAS I, 1995, QUATERNARY SCI REV, V14, P137; HAJDAS I, 1993, CLIM DYNAM, V9, P107, DOI 10.1007/BF00209748; Haske BJ, 1991, PALEOCEANOGRAPHY, V6, P21, DOI 10.1029/90PA01939; Hughen KA, 1998, NATURE, V391, P65, DOI 10.1038/34150; KEIGWIN LD, 1991, J GEOPHYS RES-OCEANS, V96, P16811, DOI 10.1029/91JC01624; Kitagawa H, 1995, RADIOCARBON, V37, P371, DOI 10.1017/S0033822200030848; KITAGAWA H, 1997, 16 INT RAD C GRON NE; Kromer B, 1996, RADIOCARBON, V38, P607, DOI 10.1017/S0033822200030149; LAO Y, 1992, NATURE, V357, P576, DOI 10.1038/357576a0; LEHMAN SJ, 1992, NATURE, V356, P757, DOI 10.1038/356757a0; LIDDICOAT JC, 1992, GEOPHYS J INT, V108, P422; MCHARGUE LR, 1995, GEOPHYS RES LETT, V22, P659, DOI 10.1029/95GL00169; Mook W.G., 1981, P 1 INT S 14 C ARCH, V8, P31; NEFTEL A, 1988, NATURE, V331, P609, DOI 10.1038/331609a0; OESCHGER H, 1982, NUCL CHEM DATING TEC, P5; PEARSON GW, 1986, RADIOCARBON, V28, P292, DOI 10.1017/S0033822200007396; RAISBECK GM, 1987, NATURE, V326, P273, DOI 10.1038/326273a0; RAISBECK GM, 1992, NATO ASI SERIES I, V2, P127; SONNETT CP, 1987, NATURE, V330, P458; Stocker TF, 1996, PALEOCEANOGRAPHY, V11, P773, DOI 10.1029/96PA02640; STUIVER M, 1977, RADIOCARBON, V19, P355, DOI 10.1017/S0033822200003672; STUIVERM, 1993, RADIOCARBON, V35; VanderPlicht J, 1995, RADIOCARBON, V37, P657, DOI 10.1017/S0033822200031179; Vlag P, 1996, J GEOPHYS RES-SOL EA, V101, P28211, DOI 10.1029/96JB02096; Vogel JC, 1997, RADIOCARBON, V39, P27, DOI 10.1017/S003382220004087X; VOGEL JC, 1983, RADIOCARBON, V25, P213, DOI 10.1017/S0033822200005506; WINK T, 1985, GEOPHYS MONOGR, V32, P185; Wohlfarth B, 1996, QUATERNARY SCI REV, V15, P267, DOI 10.1016/0277-3791(96)00001-7; Yiou F, 1997, J GEOPHYS RES-OCEANS, V102, P26783, DOI 10.1029/97JC01265	47	296	308	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1187	1190		10.1126/science.279.5354.1187	http://dx.doi.org/10.1126/science.279.5354.1187			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469804	Green Submitted			2022-12-28	WOS:000072115200036
J	VanWiggeren, GD; Roy, R				VanWiggeren, GD; Roy, R			Communication with chaotic lasers	SCIENCE			English	Article							STOCHASTIC RESONANCE; RING LASER; SYNCHRONIZATION	Recent experiments with chaotic electronic circuits have shown the possibility of communication with chaos, The experimental demonstration of chaotic communication with an optical system is described. An erbium-doped fiber ring laser (EDFRL) was used io produce chaotic light with a wavelength of 1.53 micrometers, A smalt 10-megahertz message was embedded in the larger chaotic carrier and transmitted to a receiver system where the message was recovered from the chaos. Chaotic optical waveforms can thus be used to communicate masked information at high bandwidths.	Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology	Roy, R (corresponding author), Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA.	rajarshi.roy@physics.gatech.edu						ABARBANEL HDI, IN PRESS PHYS REV LE; Alsing PM, 1997, PHYS REV E, V56, P6302, DOI 10.1103/PhysRevE.56.6302; COLET P, 1994, OPT LETT, V19, P2056, DOI 10.1364/OL.19.002056; CUOMO KM, 1993, PHYS REV LETT, V71, P65, DOI 10.1103/PhysRevLett.71.65; CUOMO KM, 1993, IEEE T CIRCUITS-II, V40, P626, DOI 10.1109/82.246163; DITTO WL, 1993, SCI AM, V269, P78, DOI 10.1038/scientificamerican0893-78; GarciaOjalvo J, 1997, PHYS LETT A, V229, P362, DOI 10.1016/S0375-9601(97)00198-9; Kocarev L., 1992, INT J BIFURCAT CHAOS, V2, P709; MCNAMARA B, 1988, PHYS REV LETT, V60, P2626, DOI 10.1103/PhysRevLett.60.2626; Mirasso CR, 1996, IEEE PHOTONIC TECH L, V8, P299, DOI 10.1109/68.484273; Parlitz U, 1996, PHYS REV E, V53, P4351, DOI 10.1103/PhysRevE.53.4351; PECORA LM, 1991, PHYS REV A, V44, P2374, DOI 10.1103/PhysRevA.44.2374; SUGAWARA T, 1994, PHYS REV LETT, V72, P3502, DOI 10.1103/PhysRevLett.72.3502; Volkovskii A. R., 1993, Technical Physics Letters, V19, P97; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0; Williams QL, 1997, PHYS REV A, V55, P2376, DOI 10.1103/PhysRevA.55.2376; Williams QL, 1996, OPT LETT, V21, P1478, DOI 10.1364/OL.21.001478	18	769	782	8	116	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	1998	279	5354					1198	1200		10.1126/science.279.5354.1198	http://dx.doi.org/10.1126/science.279.5354.1198			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469808				2022-12-28	WOS:000072115200040
J	Hwang, LH; Lau, LF; Smith, DL; Mistrot, CA; Hardwick, KG; Hwang, ES; Amon, A; Murray, AW				Hwang, LH; Lau, LF; Smith, DL; Mistrot, CA; Hardwick, KG; Hwang, ES; Amon, A; Murray, AW			Budding yeast Cdc20: A target of the spindle checkpoint	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; ASSEMBLY CHECKPOINT; MITOSIS; ANAPHASE; COMPLEX; UBIQUITIN; PDS1P	The spindle checkpoint regulates the cell division cycle by keeping cells with defective spindles from leaving mitosis. In the two-hybrid system, three proteins that are components of the checkpoint, Mad1, Mad2, and Mad3, were shown to interact with Cdc20, a protein required for exit from mitosis. Mad2 and Mad3 coprecipitated with Cdc20 at all stages of the cell cycle. The binding of Mad2 depended on Mad1 and that of Mad3 on Mad1 and Mad2. Overexpression of Cdc20 allowed cells with a depolymerized spindle or damaged DNA to leave mitosis but did not overcome the arrest caused by unreplicated DNA. Mutants in Cdc20 that were resistant to the spindle checkpoint no longer bound Mad proteins, suggesting that Cdc20 is the target of the spindle checkpoint.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Massachusetts Institute of Technology (MIT); Whitehead Institute	Murray, AW (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.		Holt, Janet E/B-2415-2013	Hardwick, Kevin/0000-0002-6462-1047; Amon, Angelika/0000-0001-9837-0314				AMON A, UNPUB; Cohen-Fix O, 1997, P NATL ACAD SCI USA, V94, P14361, DOI 10.1073/pnas.94.26.14361; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; HARDWICK KG, UNPUB; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HWANG LC, UNPUB; Hwang LH, 1997, MOL BIOL CELL, V8, P1877, DOI 10.1091/mbc.8.10.1877; IRNIGER S, 1995, CELL, V77, P1037; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Lim HH, 1996, MOL GEN GENET, V253, P138, DOI 10.1007/s004380050306; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SCHOTT EJ, IN PRESS GENETICS; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Sherman F., 1974, METHODS YEAST GENETI; STAUDINGER J, 1993, J BIOL CHEM, V268, P4608; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	29	453	466	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1041	1044		10.1126/science.279.5353.1041	http://dx.doi.org/10.1126/science.279.5353.1041			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461437				2022-12-28	WOS:000072006400049
J	Raymond, CS; Shamu, CE; Shen, MM; Seifert, KJ; Hirsch, B; Hodgkin, J; Zarkower, D				Raymond, CS; Shamu, CE; Shen, MM; Seifert, KJ; Hirsch, B; Hodgkin, J; Zarkower, D			Evidence for evolutionary conservation of sex-determining genes	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; C-ELEGANS; DROSOPHILA; TRA-1; ORIENTATION; FRUITLESS; PROTEINS; REGIONS; DOMAIN; MICE	Most metazoans occur as two sexes. Surprisingly, molecular analyses have hitherto indicated that sex-determining mechanisms differ completely between phyla. Here we present evidence to the contrary, We have isolated the male sexual regulatory gene mab-3 (ref. 1) from the nematode Caenorhabditis elegans and found that it is related to the Drosophila melanogaster sexual regulatory gene doublesex (dsx)(2). Both genes encode proteins with a DNA-binding motif(3) that we have named the 'DM domain'. Both genes control sex-specific neuroblast differentiation and yolk protein gene transcription; dsx controls other sexually dimorphic features as well, The form of DSX that is found in males can direct male-specific neuroblast differentiation in C. elegans. This structural and functional similarity between phyla suggests a common evolutionary origin of at least some aspects of sexual regulation. We have identified a human gene, DMT1, that encodes a protein with a DM domain and find that DMT1 is expressed only in testis. DMT1 maps to the distal short arm of chromosome 9, a location implicated in human XY sex reversal(4). Proteins with DM domains may therefore also regulate sexual development in mammals.	Univ Minnesota, Sch Med, Inst Human Genet, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Biochem, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; MRC Laboratory Molecular Biology	Zarkower, D (corresponding author), Univ Minnesota, Sch Med, Inst Human Genet, Minneapolis, MN 55455 USA.		Shen, Michael M/C-7546-2009	Shen, Michael M/0000-0002-4042-1657; Raymond, Christopher/0000-0003-1128-8524				BAKER BS, 1980, GENETICS, V94, P383; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; deBono M, 1996, GENETICS, V144, P587; Eicher EM, 1996, NAT GENET, V14, P206, DOI 10.1038/ng1096-206; Erdman SE, 1996, GENETICS, V144, P1639; ERDMAN SE, 1993, EMBO J, V12, P527, DOI 10.1002/j.1460-2075.1993.tb05684.x; Finley KD, 1997, P NATL ACAD SCI USA, V94, P913, DOI 10.1073/pnas.94.3.913; HODGKIN J, 1987, GENE DEV, V1, P731, DOI 10.1101/gad.1.7.731; HODGKIN J, 1980, GENETICS, V96, P649; HODGKIN J, 1983, GENETICS, V103, P43; Hodgkin J., 1988, NEMATODE CAENORHABDI, P243; HODGKIN JA, 1977, GENETICS, V86, P275; Ito H, 1996, P NATL ACAD SCI USA, V93, P9687, DOI 10.1073/pnas.93.18.9687; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; Kuwabara PE, 1996, GENETICS, V144, P597; McDonald MT, 1997, AM J MED GENET, V73, P321; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Ryner LC, 1996, CELL, V87, P1079, DOI 10.1016/S0092-8674(00)81802-4; SCHEDL T, 1989, GENETICS, V123, P755; SHEN MM, 1988, CELL, V54, P1019, DOI 10.1016/0092-8674(88)90117-1; SIGURDSON DC, 1984, GENETICS, V108, P331; SPIETH J, 1985, NUCLEIC ACIDS RES, V13, P5283, DOI 10.1093/nar/13.14.5283; SPIETH J, 1991, MOL CELL BIOL, V11, P4651, DOI 10.1128/MCB.11.9.4651; Sulston J., 1988, NEMATODE CAENORHABDI, P587; TRASK B, GENOME ANAL LAB MANU; TUCKER PK, 1993, NATURE, V364, P715, DOI 10.1038/364715a0; Veitia R, 1997, GENOMICS, V41, P271, DOI 10.1006/geno.1997.4648; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; WILKINS AS, 1995, BIOESSAYS, V17, P71, DOI 10.1002/bies.950170113; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X	30	615	683	3	131	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 12	1998	391	6668					691	695		10.1038/35618	http://dx.doi.org/10.1038/35618			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490411				2022-12-28	WOS:000071982500051
J	Moore, RA; Tramer, MR; Carroll, D; Wiffen, PJ; McQuay, HJ				Moore, RA; Tramer, MR; Carroll, D; Wiffen, PJ; McQuay, HJ			Quantitive systematic review of topically applied non-steroidal anti-inflammatory drugs	BRITISH MEDICAL JOURNAL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RANDOMIZED CLINICAL-TRIALS; ELDERLY PATIENTS; META-ANALYSIS; QUALITY; IBUPROFEN; GEL	Objective: To review the effectiveness and safety of topical non-steroidal anti-inflammatory drugs in acute and chronic pain conditions. Design: Quantitive systematic review of randomised controlled trials. Data sources: 86 trials involving 10 160 patients. Main outcome measures: Measures of treatment success approximating at least 50% reduction in pain, local and systemic adverse effects. Analysis at 1 week for acute and 2 weeks for chronic conditions with relative benefit and number needed to treat. Results: In acute pain conditions (soft tissue trauma, strains, and sprains) placebo controlled trials had a relative benefit of 1.7 (1.5 to 1.9), the number needed to treat was 3.9 (3.4 to 4.4). With analysis by drug (at least three trials), ketoprofen (number needed to treat 2.6), felbinac (3.0), ibuprofen (3.5), and piroxicam (4.2) had significant efficacy. Benzydamine and indomethacin were no different from placebo. In chronic pain conditions (osteoarthritis, tendinitis) placebo controlled trials had a relative benefit of 2.0 (1.5 to 2.7); the number needed to treat was 3.1 (2.7 to 3.8). Small trials (<40 treated patients) exaggerated effectiveness of topical non-steroidals by 33% in acute conditions but not in chronic conditions. There was no relation between trial quality and treatment effect In both acute and chronic pain local and systemic adverse events and withdrawal from the study related to the drug had a low incidence and were no different from placebo. Conclusion: Topical non-steroidal anti-inflammatory drugs are effective in relieving pain in acute and chronic conditions.	Univ Oxford, Nuffield Dept Anaesthet, Oxford Radcliffe Hosp, Oxford OX3 7LJ, England	University of Oxford	Moore, RA (corresponding author), Univ Oxford, Nuffield Dept Anaesthet, Oxford Radcliffe Hosp, S Parks Rd, Oxford OX3 7LJ, England.		Wiffen, Philip/GNP-1768-2022					AKERMARK C, 1990, INT J SPORTS MED, V11, P393, DOI 10.1055/s-2007-1024825; BATEMAN DN, 1995, BRIT MED J, V310, P817, DOI 10.1136/bmj.310.6983.817; BERNER G, 1989, DRUG EXP CLIN RES, V15, P559; BROWNING RC, 1994, ADV THER, V11, P198; Carroll D, 1996, BRIT J ANAESTH, V77, P798, DOI 10.1093/bja/77.6.798; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; EVANS JMM, 1995, BMJ-BRIT MED J, V311, P22, DOI 10.1136/bmj.311.6996.22; GOLDEN EL, 1978, CURR THER RES CLIN E, V24, P524; HOSIE GAC, 1993, BR J CLIN RES, V4, P5; Jadad AR, 1996, PAIN, V66, P239, DOI 10.1016/0304-3959(96)03033-3; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Khan KS, 1996, ARCH INTERN MED, V156, P661, DOI 10.1001/archinte.156.6.661; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; McQuay H, 1997, BMJ-BRIT MED J, V314, P1531, DOI 10.1136/bmj.314.7093.1531; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; TREFFEL P, 1993, SKIN PHARMACOL, V6, P268; Vanderstraeten G, 1990, Acta Belg Med Phys, V13, P139; Wynne H A, 1993, Pharmacoeconomics, V3, P107, DOI 10.2165/00019053-199303020-00004; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1994, DRUG THER B, V32, P91	24	296	317	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 31	1998	316	7128					333	338		10.1136/bmj.316.7128.333	http://dx.doi.org/10.1136/bmj.316.7128.333			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487165	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000071863900019
J	Gleeson, JG; Allen, KM; Fox, JW; Lamperti, ED; Berkovic, S; Scheffer, I; Cooper, EC; Dobyns, WB; Minnerath, SR; Ross, ME; Walsh, CA				Gleeson, JG; Allen, KM; Fox, JW; Lamperti, ED; Berkovic, S; Scheffer, I; Cooper, EC; Dobyns, WB; Minnerath, SR; Ross, ME; Walsh, CA			doublecortin, a brain-specific gene mutated in human X-linked lissencephaly and double cortex syndrome, encodes a putative signaling protein	CELL			English	Article							CORTICAL DEVELOPMENT; KINASE; MICE; MALFORMATIONS; OUTGROWTH; SUBUNIT	X-linked lissencephaly and "double cortex" are allelic human disorders mapping to Xq22.3-Xq23 associated with arrest of migrating cerebral cortical neurons. We identified a novel 10 kb brain-specific cDNA interrupted by a balanced translocation in an XLIS patient that encodes a novel 40 kDa predicted protein named Doublecortin. Four double cortex/X-linked lissencephaly families and three sporadic double cortex patients show independent doublecortin mutations, at least one of them a de novo mutation. Doublecortin contains a consensus Abl phosphorylation site and other sites of potential phosphorylation. Although Doublecortin does not contain a kinase domain, it is homologous to the amino terminus of a predicted kinase protein, indicating a likely role in signal transduction. Doublecortin, along with the newly characterized mDab1, may define an Abl-dependent pathway regulating neuronal migration.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol,Div Neurogenet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Biol & Biomed Sci, Boston, MA 02115 USA; Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; Austin Hosp, Heidelberg, Vic 3084, Australia; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA; Univ Minnesota, Lab Mol Neurobiol & Dev, Minneapolis, MN 55455 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Walsh, CA (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol,Div Neurogenet, Boston, MA 02115 USA.		Dobyns, William Brian/ABC-6525-2021; Cooper, Edward/A-1036-2009; Dobyns, William/AAI-2768-2020; jiang, yu/HGU-0029-2022; Cooper, Edward/X-6659-2019; Scheffer, Ingrid E/G-1668-2013	Dobyns, William/0000-0002-7681-2844; Cooper, Edward/0000-0003-3672-8442; Scheffer, Ingrid E/0000-0002-2311-2174; Walsh, Christopher/0000-0002-0156-2238; Berkovic, Samuel/0000-0003-4580-841X	NIMH NIH HHS [MH10691] Funding Source: Medline; NINDS NIH HHS [5K12NS01701-04, R01 NS041537, KO8-NS01520] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041537, K12NS001701, K08NS001520] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BEGGS HE, 1994, J CELL BIOL, V127, P825, DOI 10.1083/jcb.127.3.825; Beggs HE, 1997, J BIOL CHEM, V272, P8310, DOI 10.1074/jbc.272.13.8310; BERG M, 1997, IN PRESS NEUROLOGY; Brunati AM, 1996, EUR J BIOCHEM, V240, P400, DOI 10.1111/j.1432-1033.1996.0400h.x; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; des Portes V, 1998, CELL, V92, P51; desPortes V, 1997, J MED GENET, V34, P177, DOI 10.1136/jmg.34.3.177; Dobyns WB, 1996, NEUROLOGY, V47, P331, DOI 10.1212/WNL.47.2.331; DOBYNS WB, 1992, NEUROLOGY, V42, P1375, DOI 10.1212/WNL.42.7.1375; DOBYNS WB, 1995, NEUROPEDIATRICS, V26, P132, DOI 10.1055/s-2007-979744; DOBYNS WB, 1993, JAMA-J AM MED ASSOC, V270, P2838, DOI 10.1001/jama.270.23.2838; Eksioglu YZ, 1996, NEURON, V16, P77, DOI 10.1016/S0896-6273(00)80025-2; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; Gonzalez JL, 1997, J NEUROSCI, V17, P9204; Harding B, 1996, DYSPLASIAS OF CEREBRAL CORTEX AND EPILEPSY, P81; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; INGEIZI MA, 1994, NEURON, V12, P873; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; OGILVIE DJ, 1996, YAC PROTOCOLS, V54; RAYMOND AA, 1995, BRAIN, V118, P829; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; ROSS ME, 1997, HUM MOL GENET, V6, P553; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SRIVASTAVA A, 1995, CYTOGENET CELL GENET, V31, P430; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WARE ML, 1997, NEURON, V19, P1	36	812	836	2	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 9	1998	92	1					63	72		10.1016/S0092-8674(00)80899-5	http://dx.doi.org/10.1016/S0092-8674(00)80899-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489700	Bronze			2022-12-28	WOS:000071473700008
J	Karlawish, J				Karlawish, J			A personal choice	LANCET			English	Editorial Material									Univ Penn, Inst Aging, Hlth Syst, Philadelphia, PA 19104 USA; Univ Penn, Ctr Bioeth, Hlth Syst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Karlawish, J (corresponding author), Univ Penn, Inst Aging, Hlth Syst, 3615 Chestnut St, Philadelphia, PA 19104 USA.								0	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	1997	350	9094					1833	1834		10.1016/S0140-6736(97)11309-5	http://dx.doi.org/10.1016/S0140-6736(97)11309-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM803	9454054				2022-12-28	WOS:000071102500043
J	Wang, PH; Korc, M				Wang, PH; Korc, M			Searching for the Holy Grail: The cause of diabetes	LANCET			English	Article											Wang, PH (corresponding author), UNIV CALIF IRVINE,DEPT MED,DIV ENDOCRINOL DIABET & METAB,IRVINE,CA 92717, USA.							CLAUSEN JO, 1995, LANCET, V346, P397, DOI 10.1016/S0140-6736(95)92779-4; MADDUX BA, 1995, NATURE, V373, P448, DOI 10.1038/373448a0; WALSTON J, 1995, NEW ENGL J MED, V333, P343, DOI 10.1056/NEJM199508103330603; WIDEN E, 1995, NEW ENGL J MED, V333, P348, DOI 10.1056/NEJM199508103330604; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	5	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S4	S4		10.1016/0140-6736(95)90003-9	http://dx.doi.org/10.1016/0140-6736(95)90003-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454047				2022-12-28	WOS:A1995TN12200004
J	Berga, SL				Berga, SL			Understanding premenstrual syndrome	LANCET			English	Editorial Material							PROGESTERONE		Univ Pittsburgh, Magee Womens Hosp, Sch Med,Dept Obstet Gynecol & Reprod Sci, Div Reprod Endocrinol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Magee Womens Hosp, Dept Psychiat, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Berga, SL (corresponding author), Univ Pittsburgh, Magee Womens Hosp, Sch Med,Dept Obstet Gynecol & Reprod Sci, Div Reprod Endocrinol, Pittsburgh, PA 15213 USA.							FREEMAN E, 1990, JAMA-J AM MED ASSOC, V264, P349; FREEMAN EW, 1995, JAMA-J AM MED ASSOC, V274, P51, DOI 10.1001/jama.274.1.51; Rapkin AJ, 1997, OBSTET GYNECOL, V90, P709, DOI 10.1016/S0029-7844(97)00417-1; Reddy DS, 1997, BRAIN RES, V752, P61, DOI 10.1016/S0006-8993(96)01447-3; Rupprecht R, 1997, J PSYCHIATR RES, V31, P297, DOI 10.1016/S0022-3956(96)00060-X; Schmidt PJ, 1998, NEW ENGL J MED, V338, P209, DOI 10.1056/NEJM199801223380401; STEINER M, 1995, NEW ENGL J MED, V332, P1529, DOI 10.1056/NEJM199506083322301; YONKERS KA, 1997, JAMA-J AM MED ASSOC, V278, P1024	8	13	14	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	1998	351	9101					465	466		10.1016/S0140-6736(05)78679-7	http://dx.doi.org/10.1016/S0140-6736(05)78679-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482435				2022-12-28	WOS:000072097700006
J	Jamison, DT; Frenk, J; Knaul, F				Jamison, DT; Frenk, J; Knaul, F			International collective action in health: objectives, functions, and rationale	LANCET			English	Article; Proceedings Paper	International Meeting of the Future of International Health	FEB 03-04, 1997	NATL INST PUBLIC HLTH, CUERNAVACA, MEXICO		NATL INST PUBLIC HLTH			To improve the performance of international health organisations, their essential functions must be agreed. This paper develops a framework to discuss these essential functions. Two groups are identified: core functions and supportive functions. Core functions transcend the sovereignty of any one nation state, and include promotion of International public goods (eg, research and development), and surveillance and control of International externalities (eg environmental risks and spread of pathogens). Supportive functions deal with problems that take place within individual countries, but which may justify collective action at international level owing to shortcomings in national health system-such as helping the dispossessed (eg, victims of human rights violations) and technical cooperation and development financing. Core functions serve all countries, whereas supportive functions assist countries with greater needs. Focus on essential functions appropriate to their mandate will better prepare international health organisations to define their roles, eg for WHO to focus on core functions and for the World Bank to focus on supportive ones.	Univ Calif Los Angeles, Ctr Pacific Rim Studies, Los Angeles, CA 90095 USA; Ctr Econ Res & Educ, Mexico City, DF, Mexico; Mexican Hlth Fdn, Ctr Hlth & Econ, Mexico City, DF, Mexico	University of California System; University of California Los Angeles	Jamison, DT (corresponding author), Univ Calif Los Angeles, Ctr Pacific Rim Studies, 11292 Bunche Hall, Los Angeles, CA 90095 USA.			Knaul, Felicia/0000-0002-0512-4788				[Anonymous], 1992, BAS DOC; Chen L, 1996, POCANTICO RETREAT EN, P9; CORREA H, 1997, WHOTFHE971, P33; EBBAN A, 1995, FOREIGN AFF, V74, P39; Frenk J, 1997, BRIT MED J, V314, P1404; Graham C, 1997, FOREIGN AFF, V76, P96, DOI 10.2307/20048124; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; Institute of Medicine and Board on International Health, 1997, AM VIT INT GLOB HLTH; Lucas A, 1997, COOPERATION HLTH DEV; NIGHTINGALE S, 1994, SWISS PHARM, V116, P59; RAYMOND SU, 1997, GLOBAL PUBLIC HLTH C; *ROCK FDN NAT I PU, 1997, CUERN RETR FUT INT H; *ROCK FDN SOC SCI, 1996, POC RETR ENH PERF IN; Slaughter AM, 1997, FOREIGN AFF, V76, P183, DOI 10.2307/20048208; STERKY G, 1996, TOMORROWS GLOBAL HLT; *WHO AD HOC COMM, 1996, WHO AD HOC COMM HLTH; World Bank, 1997, WORLD DEV REP STAT C; *WORLD BANK GROUP, 1997, HUM DEV NETW SECT ST	18	53	54	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	1998	351	9101					514	517		10.1016/S0140-6736(97)11451-9	http://dx.doi.org/10.1016/S0140-6736(97)11451-9			4	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YX958	9482466				2022-12-28	WOS:000072097700045
J	Melzer, D				Melzer, D			Patent protection for medical technologies: why some and not others?	LANCET			English	Article									Univ Cambridge, Inst Publ Hlth, Cambridge CB2 2SR, England	University of Cambridge	Melzer, D (corresponding author), Univ Cambridge, Inst Publ Hlth, Forvie Site, Cambridge CB2 2SR, England.			Melzer, David/0000-0002-0170-3838				ABELSMITH B, 1995, CHOICES HLTH POLICY, P55; BERNSTEIN RSR, 1995, PERSPECT BIOL MED, V39, P110; Blumenthal D, 1997, JAMA-J AM MED ASSOC, V277, P1224, DOI 10.1001/jama.277.15.1224; Caplan AL, 1996, BRIT MED J, V312, P926; Culyer A., 1994, SUPPORTING RES DEV N; DAM KW, 1994, J LEGAL STUD, V23, P247, DOI 10.1086/467923; DAVIS P, 1997, MANAGING MED PUBLIC; EDDY DM, 1993, JAMA-J AM MED ASSOC, V270, P520; GARATTINI S, 1991, LANCET, V337, P494, DOI 10.1016/0140-6736(91)93430-H; KO YS, 1992, YALE LAW J, V102, P777, DOI 10.2307/796918; LOUGHLAN PL, 1995, MED J AUSTRALIA, V162, P376, DOI 10.5694/j.1326-5377.1995.tb139944.x; MCDANIEL CG, 1995, BRIT MED J, V311, P12, DOI 10.1136/bmj.311.6996.12; *NHSE, 1996, NHS EX REP NHS HLTH; NISSELLE P, 1995, MED J AUSTRALIA, V162, P341, DOI 10.5694/j.1326-5377.1995.tb139930.x; PETO R, 1995, J CLIN EPIDEMIOL, V48, P23, DOI 10.1016/0895-4356(94)00150-O; ROGERS A, 1995, LANCET, V345, P916, DOI 10.1016/S0140-6736(95)90024-1; Rovner J, 1996, LANCET, V348, P1025, DOI 10.1016/S0140-6736(05)64942-2; Sackett D. L., 1995, EVIDENCE BASED MED, V1, P5; SMITHERS R, 1991, PATENT PROTECTION IN; Thompson JN, 1997, JAMA-J AM MED ASSOC, V278, P241, DOI 10.1001/jama.278.3.241	20	3	4	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	1998	351	9101					518	519		10.1016/S0140-6736(97)02432-X	http://dx.doi.org/10.1016/S0140-6736(97)02432-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482467				2022-12-28	WOS:000072097700046
J	Yuen, KY; Chan, PKS; Peiris, M; Tsang, DNC; Que, TL; Shortridge, KF; Cheung, PT; To, WK; Ho, ETF; Sung, R; Cheng, AFB				Yuen, KY; Chan, PKS; Peiris, M; Tsang, DNC; Que, TL; Shortridge, KF; Cheung, PT; To, WK; Ho, ETF; Sung, R; Cheng, AFB		H5N1 study grp	Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus	LANCET			English	Article							IMMUNOGLOBULIN	Background Human infection with an avian influenza A virus (subtype H5N1) was reported recently in Hong Kong. We describe the clinical presentation of the first 12 patients and options for rapid viral diagnosis. Methods Case notes of 12 patients with virus-culture-confirmed influenza A H5N1 infection were analysed. The clinical presentation and risk factors associated with severe disease were defined and the results of methods for rapid virus diagnosis were compared. Findings Patients ranged from 1 to 60 years of age. Clinical presentation was that of an influenza-like illness with evidence of pneumonia in seven patients. All seven patients older than 13 years had severe disease (four deaths), whereas children 5 years or younger had mild symptoms with the exception of one who died with Reye's syndrome associated with intake of aspirin. Gastrointestinal manifestations, raised liver enzymes, renal failure unrelated to rhabdomyolysis, and pancytopenia were unusually prominent. Factors associated with severe disease included older age, delay in hospitalisation, lower-respiratory-tract involvement, and a low total peripheral white blood cell count or lymphopenia at admission. An H5-specific reverse-transcription PCR assay (RT-PCR) was useful for rapid detection of virus directly in respiratory specimens. A commercially available enzyme immunoassay was more sensitive than direct immunofluorescence for rapid viral diagnosis. Direct immunofluorescence with an H5-specific monoclonal antibody pool was useful for rapid exclusion of H5-subtype infection. Interpretation Avian Influenza A H5N1 virus causes human influenza-like illness with a high rate of complications in adults admitted to hospital. Rapid H5-subtype-specific laboratory diagnosis can be made by RT-PCR applied directly to clinical specimens.	Univ Hong Kong, Dept Microbiol, Hong Kong, Peoples R China; Univ Hong Kong, Dept Paediat, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Microbiol, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Paediat, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Microbiol, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Paediat, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Anaesthesia, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Intens Care, Hong Kong, Peoples R China; Yan Chai Hosp, Dept Microbiol, Hong Kong, Peoples R China; Yan Chai Hosp, Dept Paediat, Hong Kong, Peoples R China; Yan Chai Hosp, Dept Anaesthesia, Hong Kong, Peoples R China; Yan Chai Hosp, Dept Intens Care, Hong Kong, Peoples R China; Tuen Mun Hosp, Dept Microbiol, Hong Kong, Peoples R China; Tuen Mun Hosp, Dept Paediat, Hong Kong, Peoples R China; Tuen Mun Hosp, Dept Anaesthesia, Hong Kong, Peoples R China; Tuen Mun Hosp, Dept Intens Care, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Tuen Mun Hospital; Tuen Mun Hospital; Tuen Mun Hospital; Tuen Mun Hospital	Peiris, M (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Pokfulam Rd, Hong Kong, Peoples R China.	malik@hkuce-htcu.hk	Yuen, Kwok Yung/C-4465-2009; Chan, Paul KS/J-9360-2013; Peiris, Joseph Sriyal Malik/C-4380-2009	Chan, Paul KS/0000-0002-6360-4608; Peiris, Joseph Sriyal Malik/0000-0001-8217-5995; Yuen, Kwok-yung/0000-0002-2083-1552				ALEXANDER DJ, 1993, VET REC, V132, P535, DOI 10.1136/vr.132.21.535; Claas ECJ, 1998, LANCET, V351, P472, DOI 10.1016/S0140-6736(97)11212-0; deJong JC, 1997, NATURE, V389, P554, DOI 10.1038/39218; DOUGLAS RG, 1995, INFLUENZA VIRUSES IN, P395; Easterday B. C., 1991, Diseases of poultry., P532; GAMMELIN M, 1990, MOL BIOL EVOL, V7, P194; GORMAN OT, 1991, J VIROL, V65, P3704, DOI 10.1128/JVI.65.7.3704-3714.1991; ITO T, 1996, OPTIONS CONTROL INFL, V3, P516; KAPILA CC, 1958, BRIT MED J, V4, P1311; KILBOURNE ED, 1995, INFLUENZA VIRUSES IN, P483; Kurtz J, 1996, LANCET, V348, P901, DOI 10.1016/S0140-6736(05)64783-6; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; Madeley C. R., 1992, P33; PALLADINO G, 1995, J VIROL, V69, P2075, DOI 10.1128/JVI.69.4.2075-2081.1995; PORTERFIELD JS, 1986, ADV VIRUS RES, V31, P335, DOI 10.1016/S0065-3527(08)60268-7; Senne DA, 1996, AVIAN DIS, V40, P425, DOI 10.2307/1592241; SHENOUDA A, 1976, AM J MED, V61, P697, DOI 10.1016/0002-9343(76)90148-0; Shortridge K F, 1992, Semin Respir Infect, V7, P11; SHORTRIDGE KF, 1995, LANCET, V346, P1210, DOI 10.1016/S0140-6736(95)92906-1; Webster Robert G., 1997, Journal of Infectious Diseases, V176, pS14, DOI 10.1086/514168; WHIMBEY E, 1995, BONE MARROW TRANSPL, V16, P393; Woo PCY, 1997, J CLIN MICROBIOL, V35, P1579, DOI 10.1128/JCM.35.6.1579-1581.1997; Ziegler Thedi, 1995, P918	23	782	875	0	109	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 14	1998	351	9101					467	471		10.1016/S0140-6736(98)01182-9	http://dx.doi.org/10.1016/S0140-6736(98)01182-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482437				2022-12-28	WOS:000072097700009
J	Hilton, GC; Martinis, JM; Wollman, DA; Irwin, KD; Dulcie, LL; Gerber, D; Gillevet, PM; Twerenbold, D				Hilton, GC; Martinis, JM; Wollman, DA; Irwin, KD; Dulcie, LL; Gerber, D; Gillevet, PM; Twerenbold, D			Impact energy measurement in time-of-flight mass spectrometry with cryogenic microcalorimeters	NATURE			English	Article							SUPERCONDUCTING TUNNEL JUNCTION; HOT-ELECTRON-MICROCALORIMETERS; DETECTORS	Time-of-flight mass spectrometry-most notably matrix-assisted laser-desorption-ionization time-of-flight (MALDI-TOF) spectrometry(1)-is an important class of techniques for the study of proteins and other biomolecules(2). Although these techniques provide excellent performance for masses up to about 20,000 daltons, there has been Limited success in achieving good mass resolution at higher masses, This is because the sensitivity of the microchannel plate (MCP) detectors used in most systems decreases rapidly with increasing particle mass, limiting the utility of MCP detectors for very large masses, It has recently been proposed that cryogenic particle detectors may provide a solution to these difficulties(3). Cryogenic detectors measure the thermal energy deposited by the particle impact, and thus have a sensitivity that is largely independent of particle mass, Recent experiments(4-6) have demonstrated the sensitivity of cryogenic particle detectors to single biomolecules, a quantum efficiency several orders of magnitude larger than the MCP detectors, and sensitivity to masses as large as 750,000 daltons, Here we present results demonstrating an order of magnitude better energy resolution than previous measurements, allowing direct determination of particle charge state during acceleration(7). Although application of these detectors to practical mass spectrometry will require further development of the detectors and cryogenics, these detectors can be used to elucidate the performance-limiting processes that occur in such systems.	Natl Inst Stand & Technol, Boulder, CO 80303 USA; Univ Neuchatel, Inst Phys, CH-2000 Neuchatel, Switzerland; GenSpec SA, CH-2017 Boudry, Switzerland; George Mason Univ, Inst Biosci Bioinformat & Biotechnol, Manassas, VA 22210 USA	National Institute of Standards & Technology (NIST) - USA; University of Neuchatel; George Mason University	Hilton, GC (corresponding author), Natl Inst Stand & Technol, 325 Broadway, Boulder, CO 80303 USA.	hilton@boulder.nist.gov		Wollman, David/0000-0002-6843-3692; Irwin, Kent/0000-0002-2998-9743				Benner WH, 1997, J AM SOC MASS SPECTR, V8, P1094; Frank M, 1996, RAPID COMMUN MASS SP, V10, P1946, DOI 10.1002/(SICI)1097-0231(199612)10:15<1946::AID-RCM774>3.3.CO;2-V; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; Irwin KD, 1996, APPL PHYS LETT, V69, P1945, DOI 10.1063/1.117630; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; LABOV SE, 1997, P 7 INT WORKSH LOW T, P82; Martinis JM, 1996, NUCL INSTRUM METH A, V370, P171, DOI 10.1016/0168-9002(95)01073-4; MCCAMMON D, 1993, NUCL INSTRUM METH A, V326, P157, DOI 10.1016/0168-9002(93)90346-J; Mears CA, 1996, NUCL INSTRUM METH A, V370, P53, DOI 10.1016/0168-9002(95)01047-5; NAHUM M, 1995, APPL PHYS LETT, V66, P3203, DOI 10.1063/1.113723; Peacock A, 1996, NATURE, V381, P135, DOI 10.1038/381135a0; Schreiner M, 1996, ELECTROPHORESIS, V17, P954, DOI 10.1002/elps.1150170518; SIUZDAK G, 1994, P NATL ACAD SCI USA, V91, P11290, DOI 10.1073/pnas.91.24.11290; SPENGLER B, 1992, J PHYS CHEM-US, V96, P9678, DOI 10.1021/j100203a022; Twerenbold D, 1996, APPL PHYS LETT, V68, P3503, DOI 10.1063/1.115772; Twerenbold D, 1996, NUCL INSTRUM METH A, V370, P253, DOI 10.1016/0168-9002(95)01102-1; VANEY MC, 1995, 1931 BROOKH NAT LAB; WELTY RP, 1991, IEEE T MAGN, V27, P2924, DOI 10.1109/20.133821	18	104	110	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 12	1998	391	6668					672	675		10.1038/35582	http://dx.doi.org/10.1038/35582			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490410				2022-12-28	WOS:000071982500045
J	Wechsler, ME; Garpestad, E; Flier, SR; Kocher, O; Weiland, DA; Polito, AJ; Klinek, MM; Bigby, TD; Wong, GA; Helmers, RA; Drazen, JM				Wechsler, ME; Garpestad, E; Flier, SR; Kocher, O; Weiland, DA; Polito, AJ; Klinek, MM; Bigby, TD; Wong, GA; Helmers, RA; Drazen, JM			Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHURG-STRAUSS-SYNDROME; ALLERGIC GRANULOMATOSIS; VASCULITIS; THERAPY; ANGIITIS	Context.-Zafirlukast is a potent leukotriene antagonist that recently was approved for the treatment of asthma, As use of this drug increases, adverse events that occur at low frequency or in populations not studied in premarketing clinical trials may become evident. Objective.-To describe a clinical syndrome associated with zafirlukast therapy. Design.-Case series. Patients.-Eight adults (7 women and 1 man) with steroid-dependent asthma who received zafirlukast. Main Outcome Measures.-Development of a clinical syndrome characterized by pulmonary infiltrates, cardiomyopathy, and eosinophilia following the withdrawal of corticosteroid treatment. Results.-The clinical syndrome developed while patients were receiving zafirlukast from 3 days to 4 months and from 3 days to 3 months after corticosteroid withdrawal, All 8 patients developed leukocytosis (range, 14.5-27.6x10(9)/L) with eosinophilia (range, 0.19-0.71). Six patients had fever (temperature >38.5 degrees C), 7 had muscle pain, 6 had sinusitis, and 6 had biopsy evidence of eosinophilic tissue infiltration. The clinical syndrome improved with discontinuation of zafirlukast treatment and reinitiation of corticosteroid treatment or addition of cyclophosphamide treatment. Comment.-Development of pulmonary infiltrates, cardiomyopathy, and eosinophilia may have occurred independent of zafirlukast use or may have resulted from an allergic response to this medication. We suspect that these patients may have had a primary eosinophilic infiltrative disorder that had been clinically recognized as asthma, was quelled by steroid treatment, and was unmasked following corticosteroid withdrawal facilitated by zafirlukast.	Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA USA; Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA USA; Bayfront Med Ctr, St Petersburg, FL USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Allergy & Asthma Consultants, York, PA USA; Dept Vet Affairs Med Ctr, San Diego, CA USA; Univ Calif San Diego, San Diego, CA 92103 USA; Mercy Gen Hosp, Dept Med, Sacramento, CA USA; Mayo Clin Scottsdale, Dept Med, Scottsdale, AZ USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Johns Hopkins University; University of California System; University of California San Diego; Mayo Clinic; Mayo Clinic Phoenix	Drazen, JM (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care, 75 Francis St, Boston, MA 02115 USA.		Wechsler, Michael/B-3979-2013; Wechsler, Michael/AAC-5506-2019	Wechsler, Michael/0000-0003-3505-2946; 				CHURG A, 1995, CHEST, V108, P320, DOI 10.1378/chest.108.2.320; CLARKE BF, 1974, DIABETES, V23, P739, DOI 10.2337/diab.23.9.739; GAFFEY CM, 1986, ARCH PATHOL LAB MED, V110, P131; GUILLEVIN L, 1988, BRIT J RHEUMATOL, V27, P258; Holgate ST, 1996, J ALLERGY CLIN IMMUN, V98, P1, DOI 10.1016/S0091-6749(96)70220-8; IMAI H, 1989, NEPHRON, V51, P405, DOI 10.1159/000185332; *IMS AM LTD, 1997, NAT PRESCR AUD NPAPL; JARZOBSKI J, 1970, AM HEART J, V79, P116, DOI 10.1016/0002-8703(70)90401-1; KJELLBO H, 1965, LANCET, V1, P1034; MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094, DOI 10.1002/art.1780330806; MATHUR S, 1990, BRIT MED J, V300, P613, DOI 10.1136/bmj.300.6724.613-b; SPECTOR SL, 1994, AM J RESP CRIT CARE, V150, P618, DOI 10.1164/ajrccm.150.3.8087328; Suissa S, 1997, ANN INTERN MED, V126, P177, DOI 10.7326/0003-4819-126-3-199702010-00001; TAI PC, 1984, BRIT MED J, V289, P400, DOI 10.1136/bmj.289.6442.400; WATTS RA, 1995, SEMIN ARTHRITIS RHEU, V25, P28, DOI 10.1016/S0049-0172(95)80015-8; WELLER PF, 1994, BLOOD, V83, P2759, DOI 10.1182/blood.V83.10.2759.2759; YERMAKOV VM, 1983, HUM PATHOL, V14, P182, DOI 10.1016/S0046-8177(83)80248-2; *ZEN PHARM, 1996, ACC CLIN TRIALS DAT	18	233	236	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	1998	279	6					455	457		10.1001/jama.279.6.455	http://dx.doi.org/10.1001/jama.279.6.455			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV580	9466639	Bronze			2022-12-28	WOS:000071839800034
J	Swanson, JM; Sergeant, JA; Taylor, E; Sonuga-Barke, EJS; Jensen, PS; Cantwell, DP				Swanson, JM; Sergeant, JA; Taylor, E; Sonuga-Barke, EJS; Jensen, PS; Cantwell, DP			Attention-deficit hyperactivity disorder and hyperkinetic disorder	LANCET			English	Article							CORPUS-CALLOSUM MORPHOLOGY; ONTARIO CHILD HEALTH; GENERAL-POPULATION; MORPHOMETRIC ANALYSIS; CAUDATE-NUCLEUS; RISK-FACTORS; DSM-III; PREVALENCE; SAMPLE; BOYS		Univ Calif Irvine, UCI Child Dev Ctr, Irvine, CA 92715 USA; Univ Amsterdam, Amsterdam, Netherlands; Inst Psychiat, Unit Child Psychiat, London, England; Univ Southampton, Dept Psychol, Southampton SO9 5NH, Hants, England; NIMH, Child & Adolescent Disorders Res Branch, Rockville, MD 20857 USA; Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA	University of California System; University of California Irvine; University of Amsterdam; University of London; King's College London; University of Southampton; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of California System; University of California Los Angeles	Swanson, JM (corresponding author), Univ Calif Irvine, UCI Child Dev Ctr, 19262 Jamboree, Irvine, CA 92715 USA.		Sonuga-Barke, Edmund j/D-9137-2011	Jensen, Peter/0000-0003-2387-0650				American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDERSON JC, 1987, ARCH GEN PSYCHIAT, V44, P69; AUGUST GJ, 1989, J AM ACAD CHILD PSY, V28, P739, DOI 10.1097/00004583-198909000-00016; Aylward EH, 1996, J CHILD NEUROL, V11, P112, DOI 10.1177/088307389601100210; BAREN M, 1996, CONT PEDIAT, V13, P53; BARKLEY RA, 1991, J ABNORM CHILD PSYCH, V19, P149, DOI 10.1007/BF00909976; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Baumgardner TL, 1996, NEUROLOGY, V47, P477, DOI 10.1212/WNL.47.2.477; BHATIA MS, 1991, J CHILD PSYCHOL PSYC, V32, P297, DOI 10.1111/j.1469-7610.1991.tb00308.x; Bird HR, 1996, J CHILD PSYCHOL PSYC, V37, P35, DOI 10.1111/j.1469-7610.1996.tb01379.x; Bradley C, 1937, AM J PSYCHIAT, V94, P577, DOI 10.1176/ajp.94.3.577; Cantwell DP, 1996, J AM ACAD CHILD PSY, V35, P978, DOI 10.1097/00004583-199608000-00008; Cantwell DP, 1997, J AM ACAD CHILD PSY, V36, P539, DOI 10.1097/00004583-199704000-00017; Casey BJ, 1997, J AM ACAD CHILD PSY, V36, P374, DOI 10.1097/00004583-199703000-00016; CASTELLANOS FX, 1994, AM J PSYCHIAT, V151, P1791; Castellanos FX, 1997, CLIN PEDIATR, V36, P381, DOI 10.1177/000992289703600702; Castellanos FX, 1996, ARCH GEN PSYCHIAT, V53, P607; CONNERS CK, 1985, PSYCHOPHARMACOL BULL, V21, P809; Denckla M. B., 1996, THEORY MODEL EXECUTI, V278., P263; Filipek PA, 1997, NEUROLOGY, V48, P589, DOI 10.1212/WNL.48.3.589; Gaub M, 1997, J AM ACAD CHILD PSY, V36, P1036, DOI 10.1097/00004583-199708000-00011; Gill M, 1997, MOL PSYCHIATR, V2, P311, DOI 10.1038/sj.mp.4000290; GILLBERG C, 1983, J CHILD PSYCHOL PSYC, V24, P233, DOI 10.1111/j.1469-7610.1983.tb00572.x; Gillberg C, 1997, ARCH GEN PSYCHIAT, V54, P857; Gjone H, 1996, J AM ACAD CHILD PSY, V35, P588, DOI 10.1097/00004583-199605000-00013; GREENHILL L, 1992, RITALIN THEORY PATIE; Greenhill LL, 1996, J AM ACAD CHILD PSY, V35, P1304, DOI 10.1097/00004583-199610000-00017; HEILMAN KM, 1991, J CHILD NEUROL, V6, pS76, DOI 10.1177/0883073891006001S09; Hinshaw S.P., 1997, J ATTEN DISORD, V1, P217, DOI DOI 10.1177/108705479700100403; HYND GW, 1991, J LEARN DISABIL, V24, P141, DOI 10.1177/002221949102400302; HYND GW, 1990, ARCH NEUROL-CHICAGO, V47, P919, DOI 10.1001/archneur.1990.00530080107018; HYND GW, 1993, J CHILD NEUROL, V8, P339, DOI 10.1177/088307389300800409; Jensen PS, 1997, J AM ACAD CHILD PSY, V36, P1065, DOI 10.1097/00004583-199708000-00014; Leung PW, 1996, BRIT J PSYCHIAT, V168, P486, DOI 10.1192/bjp.168.4.486; Levy F, 1997, J AM ACAD CHILD PSY, V36, P737, DOI 10.1097/00004583-199706000-00009; LOU HC, 1990, LANCET, V335, P8, DOI 10.1016/0140-6736(90)90136-S; Lou HC, 1996, ACTA PAEDIATR, V85, P1266, DOI 10.1111/j.1651-2227.1996.tb13909.x; Lyon G., 1996, ATTENTION MEMORY EXE; MANNUZZA S, 1993, ARCH GEN PSYCHIAT, V50, P565; OFFORD DR, 1987, ARCH GEN PSYCHIAT, V44, P832; PELHAM WE, IN PRESS J CHILD CLI; PENNINGTON BF, 1993, DEV PSYCHOL, V29, P511, DOI 10.1037/0012-1649.29.3.511; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; Perrin J, 1996, PEDIATRICS, V98, P301; Pliszka SR, 1996, J AM ACAD CHILD PSY, V35, P264, DOI 10.1097/00004583-199603000-00006; Posner M. I., 1994, IMAGES MIND; PRENDERGAST M, 1988, J CHILD PSYCHOL PSYC, V29, P289, DOI 10.1111/j.1469-7610.1988.tb00717.x; RAPOPORT JL, 1978, SCIENCE, V199, P560, DOI 10.1126/science.341313; SANDBERG S, 1996, HYPERACTIVITY DISORD; SATIN MS, 1985, J AM ACAD CHILD PSY, V24, P756, DOI 10.1016/S0002-7138(10)60120-3; SATTERFIELD JH, 1981, J PEDIATR-US, V98, P650, DOI 10.1016/S0022-3476(81)80788-3; SATTERFIELD JH, 1990, BIOL PSYCHIAT, V28, P879, DOI 10.1016/0006-3223(90)90569-N; SEMRUDCLIKEMAN M, 1994, J AM ACAD CHILD PSY, V33, P875, DOI 10.1097/00004583-199407000-00014; SERGEANT J, 1990, ADV CLIN CHILD PSYCH, V13, P207; SERGEANT J, 1992, EUROPEAN CHILD ADOLE, V1, P34; Shaffer D, 1996, J AM ACAD CHILD PSY, V35, P865, DOI 10.1097/00004583-199607000-00012; SHAYWITZ BA, 1991, J CHILD NEUROL, V6, pS13, DOI 10.1177/0883073891006001S03; SHEKIM WO, 1985, J AM ACAD CHILD PSY, V24, P765, DOI 10.1016/S0002-7138(10)60121-5; Still GF, 1902, LANCET, V1, P1163; Still GF, 1902, LANCET, V1, P1077; Still GF, 1902, LANCET, V1, P1008; SWANSON J, IN PRESS CUR OPIN CO; Swanson J.M., 1992, SCH BASED ASSESSMENT; SWANSON JM, 1995, NEW ENGL J MED, V333, P944, DOI 10.1056/NEJM199510053331419; SWANSON JM, 1993, EXCEPT CHILDREN, V60, P154, DOI 10.1177/001440299306000209; SWANSON JM, IN PRESS MOL PSYCHIA; SWANSON JM, 1997, ATTENTIVE BRAIN; SZATMARI P, 1989, J CHILD PSYCHOL PSYC, V30, P219, DOI 10.1111/j.1469-7610.1989.tb00236.x; Taylor E, 1996, J AM ACAD CHILD PSY, V35, P1213, DOI 10.1097/00004583-199609000-00019; Taylor E, 1991, EPIDEMIOLOGY CHILDHO; Taylor E., 1994, CHILD ADOLESCENT PSY, P285; VELEZ CN, 1989, J AM ACAD CHILD PSY, V28, P861, DOI 10.1097/00004583-198911000-00009; Wender P. H., 1995, ATTENTION DEFICIT HY; WHO, 2012, ICD 10 CLASS MENT BE; WILENS TE, 1992, PSYCHIAT CLIN N AM, V15, P191; Wolraich ML, 1996, J AM ACAD CHILD PSY, V35, P319, DOI 10.1097/00004583-199603000-00013; ZAMETKIN AJ, 1993, ARCH GEN PSYCHIAT, V50, P333; ZAMETKIN AJ, 1990, NEW ENGL J MED, V323, P1361, DOI 10.1056/NEJM199011153232001	78	517	524	2	24	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 7	1998	351	9100					429	433		10.1016/S0140-6736(97)11450-7	http://dx.doi.org/10.1016/S0140-6736(97)11450-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YW873	9482319				2022-12-28	WOS:000071982600043
J	van Steensel, B; Smogorzewska, A; de Lange, T				van Steensel, B; Smogorzewska, A; de Lange, T			TRF2 protects human telomeres from end-to-end fusions	CELL			English	Article							DNA-BINDING PROTEIN; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; IMMORTAL CELLS; IN-VIVO; SENESCENCE; LENGTH	The mechanism by which telomeres prevent end-to-end fusion has remained elusive. Here, we show that the human telomeric protein TRF2 plays a key role in the protective activity of telomeres. A dominant negative allele of TRF2 induced end-to-end chromosome fusions detectable in metaphase and anaphase cells. Telomeric DNA persisted at the fusions, demonstrating that TTAGGG repeats per se are not sufficient for telomere integrity. Molecular analysis suggested that the fusions represented ligation of telomeres that have lost their single-stranded G-tails. Therefore, TRF2 may protect chromosome ends by maintaining the correct structure at telomere termini. In addition, expression of mutant forms of TRF2 induced a growth arrest with characteristics of senescence. The results raise the possibility that chromosome end fusions and senescence in primary human cells may be caused by loss by TRF2 from shortened telomeres.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	de Lange, T (corresponding author), Rockefeller Univ, New York, NY 10021 USA.		Smogorzewska, Agata/B-8891-2011; de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X	NIGMS NIH HHS [GM07739] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; BODMAR AG, 1998, IN PRESS SCIENCE; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; de Lange T, 1998, SCIENCE, V279, P334, DOI 10.1126/science.279.5349.334; DELANGE T, 1995, TELOMERES, P265; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dionne I, 1996, P NATL ACAD SCI USA, V93, P13902, DOI 10.1073/pnas.93.24.13902; FARR C, 1991, P NATL ACAD SCI USA, V88, P7006, DOI 10.1073/pnas.88.16.7006; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1995, TELOMERES, P247; Harlow E., 1988, ANTIBODIES LAB MANUA; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HENDERSON E, 1995, TELOMERES, P11; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; Konig P, 1997, TRENDS BIOCHEM SCI, V22, P43, DOI 10.1016/S0968-0004(97)01008-6; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; Linn S.M., 1982, NUCLEASES; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Marusic L, 1997, MOL CELL BIOL, V17, P6394, DOI 10.1128/MCB.17.11.6394; McClintock B, 1942, P NATL ACAD SCI USA, V28, P458, DOI 10.1073/pnas.28.11.458; McClintock B, 1941, GENETICS, V26, P234; McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Morin GB, 1996, SEMIN CELL DEV BIOL, V7, P5, DOI 10.1006/scdb.1996.0003; Muller H.J., 1938, COLLECTING NET, V13, P181; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; PRICE CM, 1990, MOL CELL BIOL, V10, P3241; SALTMAN D, 1993, CHROMOSOMA, V102, P121, DOI 10.1007/BF00356029; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; Smith S, 1997, TRENDS GENET, V13, P21, DOI 10.1016/S0168-9525(96)10052-4; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Wellinger RJ, 1997, EUR J CANCER, V33, P735, DOI 10.1016/S0959-8049(97)00067-1; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	51	1378	1412	2	73	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 6	1998	92	3					401	413		10.1016/S0092-8674(00)80932-0	http://dx.doi.org/10.1016/S0092-8674(00)80932-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YX283	9476899	Bronze			2022-12-28	WOS:000072024700011
J	Aris, RM; Renner, JB; Winders, AD; Buell, HE; Riggs, DB; Lester, GE; Ontjes, DA				Aris, RM; Renner, JB; Winders, AD; Buell, HE; Riggs, DB; Lester, GE; Ontjes, DA			Increased rate of fractures and severe kyphosis: Sequelae of living into adulthood with cystic fibrosis	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-MINERAL DENSITY; LUNG TRANSPLANTATION; BODY-COMPOSITION; OSTEOPOROSIS; ABSORPTIOMETRY; EPIDEMIOLOGY; OSTEOPENIA; CHILDREN; WOMEN	Background: Osteoporosis occurs in patients with cystic fibrosis as they age, but its clinical implications are not well defined. Objective: To determine the clinical effect of decreased bone mineral density in adults with cystic fibrosis and to assess possible clinical predictors of osteoporosis. Design: Retrospective cohort study. Setting: Academic cystic fibrosis center. Patients: 70 adults with late-stage cystic fibrosis who were referred for lung transplantation. Measurements: Bone mineral density was measured with dual-energy x-ray absorptiometry, patient-reported fracture events were confirmed by radiography, and kyphosis angles were measured by using the Cobb method. Results: Mean bone mineral densities for the spine, femur, and total body were severely depressed in patients with cystic fibrosis, averaging 2 SDs below those of age-matched normal controls (P < 0.001). Patient interviews showed that 54 fractures had occurred over 1410 patient-years, and chest radiographs showed evidence of 14 additional rib and 62 additional vertebral compression fractures. The database (which covered 1410 patient-years) showed that fracture rates were approximately twofold greater in women with cystic fibrosis aged 16 to 34 years (P = 0.015) and men with cystic fibrosis aged 25 to 45 years (P = 0.04) than in the general population. Vertebral compression and rib fractures were 100- and 10-fold more common than expected, respectively (P < 0.001 for both comparisons). The mean kyphosis angle (+/-SD) for this group was markedly abnormal (44 +/- 14 degrees; 62% greater than or equal to 40 degrees) and probably contributed to diminished stature (mean height loss, 5.8 cm in men with cystic fibrosis and 5.9 cm in women with cystic fibrosis). Cumulative prednisone dose, body mass index, and age at puberty were the strongest predictors of bone mineral density. Conclusions: Osteoporosis is universal in adults with late-stage cystic fibrosis, and its complications include increased fracture rates and severe kyphosis.	Univ N Carolina, Div Pulm Med, Chapel Hill, NC 27599 USA; Duke Univ, Duke Res Inst, Med Ctr, Durham, NC 27710 USA; Univ N Carolina, Dept Orthopaed, Chapel Hill, NC 27599 USA; Univ N Carolina, Div Endocrinol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Aris, RM (corresponding author), Univ N Carolina, Div Pulm Med, CB 7020,724 Burnett Womack Bldg, Chapel Hill, NC 27599 USA.				NCRR NIH HHS [RR00046] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aris RM, 1996, CHEST, V109, P1176, DOI 10.1378/chest.109.5.1176; BACHRACH LK, 1994, AM J MED, V96, P27, DOI 10.1016/0002-9343(94)90112-0; Bhudhikanok GS, 1996, PEDIATRICS, V97, P103; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; Cobb J., 1948, AM ACADEMY ORTHOPAED, V5, P261; *CYST FIBR FDN, 1996, REP PAT REG, P1; DENTON JR, 1981, CLIN ORTHOP RELAT R, P71; DESCHEPPER J, 1993, HORM RES, V39, P197, DOI 10.1159/000182735; ERKKILA JC, 1978, CLIN ORTHOP RELAT R, V131, P146; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; FLUME PA, 1994, AM J RESP CRIT CARE, V149, P1601, DOI 10.1164/ajrccm.149.6.7516251; FON GT, 1980, AM J ROENTGENOL, V134, P979, DOI 10.2214/ajr.134.5.979; FULWOOD R, 1981, SERIES US DEP HHS PU, V11, P31; GIBBENS DT, 1988, J PEDIATR-US, V113, P295, DOI 10.1016/S0022-3476(88)80268-3; GRAZIER KL, 1984, FREQUENCY OCCURRENCE, P72; GREY AB, 1993, THORAX, V48, P589, DOI 10.1136/thx.48.6.589; HAHN TJ, 1979, J PEDIATR-US, V94, P38, DOI 10.1016/S0022-3476(79)80346-7; HENDERSON RC, 1994, J PEDIATR-US, V125, P208, DOI 10.1016/S0022-3476(94)70194-6; Henderson RC, 1996, J PEDIATR-US, V128, P28, DOI 10.1016/S0022-3476(96)70424-9; HIGHSMITH WE, 1993, MOL BIOL PATHOLOGY G, P159; Hollander M., 1973, NONPARAMETRIC STAT, P68; JOHNSTON CC, 1991, NEW ENGL J MED, V324, P1105; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; KOCH G, 1995, CATEGORICAL DATA ANA, P472; LOGVINOFF MM, 1984, CLIN PEDIATR, V23, P389, DOI 10.1177/000992288402300705; MELTON LJ, 1995, J BONE MINER RES, V10, P175; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; MISCHLER EH, 1979, AM J DIS CHILD, V133, P632, DOI 10.1001/archpedi.1979.02130060072016; NETER J, 1990, APPL LINEAR STAT MOD, P13; ROBBINS MK, IN PRESS CYSTIC FIBR; ROCHAT T, 1994, CHEST, V106, P800, DOI 10.1378/chest.106.3.800; ROSE J, 1987, AM J DIS CHILD, V141, P1313, DOI 10.1001/archpedi.1987.04460120079039; Salamoni F, 1996, ARCH DIS CHILD, V74, P314, DOI 10.1136/adc.74.4.314; Shane E, 1996, AM J MED, V101, P262, DOI 10.1016/S0002-9343(96)00155-6; SHAW N, 1995, AM J MED, V99, P690, DOI 10.1016/S0002-9343(99)80262-9; STAMP TCB, 1993, THORAX, V48, P585, DOI 10.1136/thx.48.6.585; VAANANEN HK, 1993, ANN MED, V25, P353, DOI 10.3109/07853899309147297	37	219	224	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1998	128	3					186	193		10.7326/0003-4819-128-3-199802010-00004	http://dx.doi.org/10.7326/0003-4819-128-3-199802010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU303	9454526				2022-12-28	WOS:000071703200003
J	Jones, S; Sadler, T; Low, N; Blott, M; Welch, J				Jones, S; Sadler, T; Low, N; Blott, M; Welch, J			Does uptake of antenatal HIV testing depend on the individual midwife? Cross sectional study	BRITISH MEDICAL JOURNAL			English	Article									Kings Healthcare, Dept Sexual Hlth, London SE5 9RS, England; Univ London Kings Coll, Sch Med & Dent, Dept Genitourinary Med, Acad Univ, London SE5 9RS, England; Kings Healthcare, Dept Womens Hlth, London SE5 9RS, England	University of London; King's College London	Welch, J (corresponding author), Kings Healthcare, Dept Sexual Hlth, London SE5 9RS, England.							*DEP HLTH, 1994, GUID OFF VOL HIV ANT; Gibb DM, 1998, BRIT MED J, V316, P259, DOI 10.1136/bmj.316.7127.259; MEADOWS J, 1990, AIDS Care, V2, P229, DOI 10.1080/09540129008257735; PECKHAM C, 1995, NEW ENGL J MED, V333, P298, DOI 10.1056/NEJM199508033330507; *UNL AN SURV STEER, 1996, UNL AN PREV MON PROG	5	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					272	273		10.1136/bmj.316.7127.272	http://dx.doi.org/10.1136/bmj.316.7127.272			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472510	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000071702100024
J	O'Brien, T; Welsh, J; Dunn, FG				O'Brien, T; Welsh, J; Dunn, FG			ABC of palliative care - Non-malignant conditions	BRITISH MEDICAL JOURNAL			English	Review									Marymount Hospice, Cork, Ireland; Cork Univ Hosp, Cork, Ireland; Univ Glasgow, Olav Kerr Chair Palliat Med, Glasgow G12 8QQ, Lanark, Scotland; Stobhill Gen Hosp, Glasgow G21 3UW, Lanark, Scotland	University College Cork; University of Glasgow	O'Brien, T (corresponding author), Marymount Hospice, Cork, Ireland.								0	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					286	289		10.1136/bmj.316.7127.286	http://dx.doi.org/10.1136/bmj.316.7127.286			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472516	Green Published			2022-12-28	WOS:000071702100032
J	Wilson, RD; Johnson, JM; Dansereau, J; Singer, J; Drinnan, SL; Winsor, EJT; Soanes, S; Kalousek, D; Hillier, J; Ho, MF; Brown, J; Wyatt, P; Farrell, S; O'Farrell, J; Chadwick, D; Natale, R; Mitchell, C; Fan, YS; Mohide, P; Beecroft, ML; Tomkins, DJ; Carter, R; Benzie, R; MacLean, B; Wang, HS; Dallaire, L; DesRochers, M; Tihy, F; Eydoux, P; Provencher, S; Cartier, L; Armson, BA; Hogg, H; Welch, JP; Harman, C; Babaian, K; Dawson, A; Okun, N; Park, M; Lin, JCC; Robinson, G; Summers, A				Wilson, RD; Johnson, JM; Dansereau, J; Singer, J; Drinnan, SL; Winsor, EJT; Soanes, S; Kalousek, D; Hillier, J; Ho, MF; Brown, J; Wyatt, P; Farrell, S; O'Farrell, J; Chadwick, D; Natale, R; Mitchell, C; Fan, YS; Mohide, P; Beecroft, ML; Tomkins, DJ; Carter, R; Benzie, R; MacLean, B; Wang, HS; Dallaire, L; DesRochers, M; Tihy, F; Eydoux, P; Provencher, S; Cartier, L; Armson, BA; Hogg, H; Welch, JP; Harman, C; Babaian, K; Dawson, A; Okun, N; Park, M; Lin, JCC; Robinson, G; Summers, A		CEMAT Grp	Randomised trial to assess safety and fetal outcome of early and midtrimester amniocentesis	LANCET			English	Article							GENETIC AMNIOCENTESIS; AGE	Background Most published reports on early amniocentesis are of cohort studies rather than randomised trials, This study was designed to assess the safely and cytogenetic accuracy of early amniocentesis in contrast to midtrimester amniocentesis in a randomised multicentre setting, Methods Pregnant women were randomly allocated early amniocentesis (between 11(+0) and 12(+6) gestational weeks(days)) or midtrimester (between 15(+0) and 16(+6) amniocentesis. A detailed fetal ultrasound examination was done between 15 and 20 gestational weeks in ail women. All amniocenteses were done under continuous ultrasound guidance: 11 mt (early amniocentesis) or 20 mt (midtrimester amniocentesis) of amniotic fluid were removed for cytogenic analysis, No more than two needle insertions were done on the same day, All fetal losses (spontaneous or induced abortions) were counted as outcome events and post-procedural losses had cytogenic analysis, Maternal and fetal health were assessed at 20-22 weeks and 5 weeks after delivery, Logistic regression analysis was used to assess the significance of the differences between the early amniocentesis and midtrimester amniocentesis groups. Findings 4374 pregnant women took part in the study, 1916 (87.8%) of 2183 women in the early amniocentesis group had their amniocentesis before 13 gestational weeks. 1775 (81.2%)) of 2185 women in the midtrimester group had their amniocentesis after 15 gestational weeks, There was a significant difference in total fetal losses for early amniocentesis compared with midtrimester amniocentesis (7.6% vs 5.9%; difference 1.7%, one-sided CI 2.98%, p=0.012). There was a significant increase in talipes equinovarus in the early amniocentesis group compared with the midtrimester amniocentesis group (1.3% vs 0.1%, p=0.0001). There was a significant difference in postprocedural amniotic-fluid leakage (early amniocentesis 3.5% vs midtrimester aminocentesis 1.7%, p=0.0007). Interpretation Our study shows that early amniocentesis is associated with an increased risk of fetal loss and talipes equinovarus, Our results should be taken into consideration when invasive prenatal diagnosis is being offered.	Univ British Columbia, BC Womens Hosp, Dept Maternal & Fetal Med, Vancouver, BC V6H 3N1, Canada; Univ Toronto, Toronto, ON, Canada; Credit Valley Hosp, Toronto, ON, Canada; Univ Western Ontario, London, ON N6A 3K7, Canada; McMaster Univ, Hamilton, ON L8S 4L8, Canada; Univ Ottawa, Ottawa, ON K1N 6N5, Canada; Univ Montreal, Montreal, PQ H3C 3J7, Canada; McGill Univ, Montreal, PQ H3A 2T5, Canada; Dalhousie Univ, Halifax, NS B3H 3J5, Canada; Univ Alberta, Edmonton, AB T6G 2M7, Canada	University of British Columbia; University of Toronto; University of Toronto; Trillium Health Partners; Credit Valley Hospital; Western University (University of Western Ontario); McMaster University; University of Ottawa; Universite de Montreal; McGill University; Dalhousie University; University of Alberta	Wilson, RD (corresponding author), Univ British Columbia, BC Womens Hosp, Dept Maternal & Fetal Med, 2H30-4500 Oak St, Vancouver, BC V6H 3N1, Canada.							[Anonymous], 1976, JAMA-J AM MED ASSOC, V236, P1471; BAIRD PA, 1994, LANCET, V344, P1134, DOI 10.1016/S0140-6736(94)90635-1; CALHOUN BC, 1994, PRENATAL DIAG, V14, P209, DOI 10.1002/pd.1970140312; COWELL HR, 1980, J BONE JOINT SURG AM, V62, P1381, DOI 10.2106/00004623-198062080-00023; CRANDALL BF, 1994, PRENATAL DIAG, V14, P913, DOI 10.1002/pd.1970141004; FEDRICK J, 1978, BRIT J OBSTET GYNAEC, V85, P1, DOI 10.1111/j.1471-0528.1978.tb15816.x; Finegan JAK, 1996, BRIT J OBSTET GYNAEC, V103, P214, DOI 10.1111/j.1471-0528.1996.tb09708.x; FINEGAN JAK, 1990, BRIT J OBSTET GYNAEC, V97, P32, DOI 10.1111/j.1471-0528.1990.tb01713.x; Greenough A, 1997, EUR J PEDIATR, V156, P550, DOI 10.1007/s004310050660; HACKETT GA, 1991, PRENATAL DIAG, V11, P311, DOI 10.1002/pd.1970110506; HAMERTON JL, 1989, LANCET, V1, P1; HISLOP A, 1982, LANCET, V2, P1271; Johnson JAM, 1996, FETAL DIAGN THER, V11, P85, DOI 10.1159/000264285; *MED RES COUNC CAN, 1977, 5 MED RES COUNC CAN; MILNER AD, 1992, EUR J PEDIATR, V151, P458, DOI 10.1007/BF01959364; Nicolaides KH, 1996, FETAL DIAGN THER, V11, P9, DOI 10.1159/000264272; Sundberg K, 1997, LANCET, V350, P697, DOI 10.1016/S0140-6736(97)02449-5; TABOR A, 1986, LANCET, V1, P1287; THOMPSON P J, 1991, Fetal Diagnosis and Therapy, V6, P148; Wilson RD, 1997, FETAL DIAGN THER, V12, P97, DOI 10.1159/000264440; Yuksel B, 1997, THORAX, V52, P181, DOI 10.1136/thx.52.2.181	21	187	191	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 24	1998	351	9098					242	247						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU294	9457093				2022-12-28	WOS:000071702200009
J	Acharya, U; Mallabiabarrena, A; Acharya, JK; Malhotra, V				Acharya, U; Mallabiabarrena, A; Acharya, JK; Malhotra, V			Signaling via mitogen-activated protein kinase kinase (MEK1) is required for Golgi fragmentation during mitosis	CELL			English	Article							MAP KINASE; CELL-CYCLE; NUCLEAR LAMINA; A431 CELLS; HELA-CELLS; M-PHASE; INVITRO; PHOSPHORYLATION; APPARATUS; CASCADE	We have developed an assay using permeabilized cells to monitor fragmentation of the Golgi complex that occurs during mitosis. Golgi stacks, in permeabilized interphase normal rat kidney (NRK) cells, upon incubation with mitotic extracts undergo extensive fragmentation, and the fragmented Golgi membranes are dispersed throughout the cytoplasm. We find that the continued presence of p34(cdc2), the mitosis initiation kinase, is not necessary for Golgi fragmentation. Instead, fragmentation depends on cytosolic mitogen-activated protein kinase kinase 1 (MEK1 or MAPKK1). However, the known cytoplasmic substrates for MEK1, ERK1, and ERK2 are not required for this process. Interestingly, we find a Golgi-associated ERK, which we propose as the likely target for MEK1 in Golgi fragmentation.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Acharya, U (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.		Malhotra, Vivek/O-9811-2014	Malhotra, Vivek/0000-0001-6198-7943; Acharya, Jairaj/0000-0001-7366-4228	NIGMS NIH HHS [GM46224] Funding Source: Medline; CSR NIH HHS [NA66RG0477] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); CSR NIH HHS		ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; ACHARYA U, 1995, J CELL BIOL, V129, P577, DOI 10.1083/jcb.129.3.577; AHN NG, 1993, P NATL ACAD SCI USA, V90, P5143, DOI 10.1073/pnas.90.11.5143; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EILENBERG H, 1989, J LIPID RES, V30, P1127; FAURE M, 1994, J BIOL CHEM, V269, P7851; GOTOH Y, 1991, EMBO J, V10, P2261; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HIROSE S, 1989, NEW PHYTOL, V111, P599, DOI 10.1111/j.1469-8137.1989.tb02353.x; Jamora C, 1997, CELL, V91, P617, DOI 10.1016/S0092-8674(00)80449-3; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LUCOCQ JM, 1987, J CELL BIOL, V104, P865, DOI 10.1083/jcb.104.4.865; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MorishimaKawashima M, 1996, MOL BIOL CELL, V7, P893, DOI 10.1091/mbc.7.6.893; NAKAGAWA J, 1989, J CELL SCI, V94, P449; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PREUSS D, 1992, MOL BIOL CELL, V3, P789, DOI 10.1091/mbc.3.7.789; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P881; ROGALSKI AA, 1984, J CELL BIOL, V99, P1092, DOI 10.1083/jcb.99.3.1092; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; Stanley H, 1997, P NATL ACAD SCI USA, V94, P14467, DOI 10.1073/pnas.94.26.14467; STUART RA, 1993, J BIOL CHEM, V268, P4050; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	41	163	165	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					183	192		10.1016/S0092-8674(00)80913-7	http://dx.doi.org/10.1016/S0092-8674(00)80913-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458043	Bronze			2022-12-28	WOS:000071672600008
J	Zhao, ZS; Granucci, F; Yeh, L; Schaffer, PA; Cantor, H				Zhao, ZS; Granucci, F; Yeh, L; Schaffer, PA; Cantor, H			Molecular mimicry by herpes simplex virus type 1: autoimmune disease after viral infection	SCIENCE			English	Article							DEPENDENT DIABETES-MELLITUS; STROMAL KERATITIS; TRANSGENIC MODEL; UL6 GENE; MUTANTS; DETERMINANTS; PATHOGENESIS; EXPRESSION; MICE; EYE	Viral infection is sometimes associated with the initiation or exacerbation of autoimmune disease, although the underlying mechanisms remain unclear. One proposed mechanism is that viral determinants that mimic host antigens trigger self-reactive T cell clones to destroy host tissue. An epitope expressed by a coat protein of herpes simplex virus-type 1 (HSV-1) KOS strain has now been shown to be recognized by autoreactive T cells that target corneal antigens in a murine model of autoimmune herpes stromal keratitis. Mutant HSV-1 viruses that lacked this epitope did not induce autoimmune disease. Thus, expression of molecular mimics can influence the development of autoimmune disease after viral infection.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute	Zhao, ZS (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.		GRANUCCI, Francesca/K-6150-2019	granucci, francesca/0000-0002-7046-4914	NIAID NIH HHS [AI 37562] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKOVA YA, 1993, CURR EYE RES, V12, P1093, DOI 10.3109/02713689309033507; AVERY AC, 1995, NATURE, V376, P431, DOI 10.1038/376431a0; CAI WH, 1987, J VIROL, V61, P714, DOI 10.1128/JVI.61.3.714-721.1987; CAI WZ, 1992, J VIROL, V66, P2904, DOI 10.1128/JVI.66.5.2904-2915.1992; CHALLONER PB, 1995, P NATL ACAD SCI USA, V92, P7440, DOI 10.1073/pnas.92.16.7440; DAHLQUIST G, 1995, DIABETOLOGIA, V38, P1371; FOSTER CS, 1990, INT CONGR SER, V918, P111; FRIEDMAN S, 1987, IMMUNOGENETICS, V26, P193, DOI 10.1007/BF00346512; GOLDIN AL, 1981, J VIROL, V38, P50, DOI 10.1128/JVI.38.1.50-58.1981; HAY J, 1992, CURR TOP MICROBIOL, V179, P1; Hemmer B, 1997, J EXP MED, V185, P1651, DOI 10.1084/jem.185.9.1651; MCCARTHY AM, 1989, J VIROL, V63, P18, DOI 10.1128/JVI.63.1.18-27.1989; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MERCADAL CM, 1993, J VIROL, V67, P3404, DOI 10.1128/JVI.67.6.3404-3408.1993; MORRISON LA, 1994, J VIROL, V68, P689, DOI 10.1128/JVI.68.2.689-696.1994; NIEMIALTOWSKI MG, 1992, J IMMUNOL, V148, P1864; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; OPREMCAK EM, 1988, INVEST OPHTH VIS SCI, V29, P749; PATEL AH, 1995, VIROLOGY, V206, P465, DOI 10.1016/S0042-6822(95)80062-X; Patel AH, 1996, VIROLOGY, V217, P111, DOI 10.1006/viro.1996.0098; RAIZMAN MB, 1988, CURR EYE RES, V7, P823, DOI 10.3109/02713688809033214; RIDGWAY WM, 1994, CURR OPIN IMMUNOL, V6, P946, DOI 10.1016/0952-7915(94)90018-3; Rouse BT, 1996, ADV VIRUS RES, V47, P353, DOI 10.1016/S0065-3527(08)60739-3; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; STREILEIN JW, 1992, J NEUROIMMUNOL, V39, P185, DOI 10.1016/0165-5728(92)90253-H; Streilein JW, 1997, IMMUNOL TODAY, V18, P443, DOI 10.1016/S0167-5699(97)01114-6; VENTO S, 1995, LANCET, V346, P608, DOI 10.1016/S0140-6736(95)91438-2; vonHerrath MG, 1996, CURR OPIN IMMUNOL, V8, P878, DOI 10.1016/S0952-7915(96)80019-7; VONHERRATH MG, 1994, IMMUNITY, V1, P231, DOI 10.1016/1074-7613(94)90101-5; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8	32	404	414	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	1998	279	5355					1344	1347		10.1126/science.279.5355.1344	http://dx.doi.org/10.1126/science.279.5355.1344			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478893				2022-12-28	WOS:000072251800048
J	Anderson, PW				Anderson, PW			c-axis electrodynamics as evidence for the interlayer theory of high-temperature superconductivity	SCIENCE			English	Article							LA2-XSRXCUO4; MECHANISM; HEAT	In the interlayer theory of high-temperature superconductivity, the interlayer pair tunneling energy (similar to the Josephson or Lawrence-Doniach energy) is the motivation for superconductivity. This connection requires two experimentally verifiable identities the coherent normal-state conductance must be smaller than the "Josephson" coupling energy, and the Josephson coupling energy must be equal to the condensation energy of the superconductor. The first condition is well satisfied in the only case that is relevant, (La,Sr)(2)CuO4, but the second condition has been questioned. It is satisfied for all dopings in (La,Sr)(2)CuO4 and also in optimally doped Hg(Ba)(2)CuO5, which was measured recently, but seems to be strongly violated in measurements on single crystals of Tl2Ba2CuO6.	Princeton Univ, Joseph Henry Labs Phys, Princeton, NJ 08544 USA	Princeton University	Anderson, PW (corresponding author), Princeton Univ, Joseph Henry Labs Phys, Princeton, NJ 08544 USA.							Anderson P. R., UNPUB; Anderson P. W., 1997, THEORY SUPERCONDUCTI; ANDERSON PW, 1995, SCIENCE, V268, P1154, DOI 10.1126/science.268.5214.1154; ANDERSON PW, IN PRESS J PHYS CHEM; Bourges P, 1997, PHYS REV B, V56, P11439, DOI 10.1103/PhysRevB.56.R11439; FONG HF, 1995, PHYS REV LETT, V75, P316, DOI 10.1103/PhysRevLett.75.316; Kim DH, 1997, PHYS REV LETT, V79, P2109, DOI 10.1103/PhysRevLett.79.2109; Leggett AJ, 1996, SCIENCE, V274, P587, DOI 10.1126/science.274.5287.587; LORAM JW, 1989, PHYSICA C, V162, P498, DOI 10.1016/0921-4534(89)91124-6; LORAM JW, 1994, PHYSICA C, V235, P134, DOI 10.1016/0921-4534(94)91331-5; MILLIS AJ, PREPRINT; Moler KA, 1998, SCIENCE, V279, P1193, DOI 10.1126/science.279.5354.1193; Panagopoulos C, 1997, PHYS REV LETT, V79, P2320, DOI 10.1103/PhysRevLett.79.2320; PUZNIAK R, 1995, PHYS REV B, V52, P3756, DOI 10.1103/PhysRevB.52.3756; SHIBAUCHI T, 1994, PHYS REV LETT, V72, P2263, DOI 10.1103/PhysRevLett.72.2263; TIMUSK T, 1995, J PHYS CHEM SOLIDS, V50, P1821; Uchida S, 1996, PHYS REV B, V53, P14558, DOI 10.1103/PhysRevB.53.14558; VANDERMAREL D, 1994, PHYSICA C, V235, P1145, DOI 10.1016/0921-4534(94)91797-3	18	137	139	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1196	1198		10.1126/science.279.5354.1196	http://dx.doi.org/10.1126/science.279.5354.1196			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469807				2022-12-28	WOS:000072115200039
J	Rivera, JM; Martin, T; Rebek, J				Rivera, JM; Martin, T; Rebek, J			Chiral spaces: Dissymmetric capsules through self-assembly	SCIENCE			English	Article							RESOLUTION; MOLECULES	Molecules with self-complementary surfaces interact through weak intermolecular forces to form assemblies, and the assembled states frequently exhibit distinctive properties. Described here are systems in which symmetrical molecules assemble through hydrogen bonding to produce capsules with dissymmetric cavities. The capsules form and dissipate on a time scale that permits their direct observation by nuclear magnetic resonance measurements, and they act as hosts for smaller molecular guests, Molecular recognition of chiral guests, such as naturally occurring terpenes, determines which dissymmetric cavities are preferentially formed in the assembly process.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; MIT, Dept Chem, Cambridge, MA 02139 USA	Scripps Research Institute; Scripps Research Institute; Massachusetts Institute of Technology (MIT)	Rebek, J (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.		Rivera, Jose/B-5657-2008; Martin, Tomas/J-9222-2014	Martin, Tomas/0000-0002-9504-7287				BILYK A, 1995, J CHEM SOC CHEM COMM, P1697, DOI 10.1039/c39950001697; BRIENNE MJ, 1994, TETRAHEDRON LETT, V35, P8157, DOI 10.1016/0040-4039(94)88270-3; CANCEILL J, 1985, J AM CHEM SOC, V107, P6993, DOI 10.1021/ja00310a041; Castellano RK, 1997, J AM CHEM SOC, V119, P12671, DOI 10.1021/ja973132+; CostanteCrassous J, 1997, J AM CHEM SOC, V119, P3818, DOI 10.1021/ja9701164; CRAM DJ, 1991, ANGEW CHEM INT EDIT, V30, P1024, DOI 10.1002/anie.199110241; JUDICE JK, 1991, J AM CHEM SOC, V113, P2790, DOI 10.1021/ja00007a085; Kang JM, 1997, NATURE, V385, P50, DOI 10.1038/385050a0; Lee SB, 1996, TETRAHEDRON LETT, V37, P8501, DOI 10.1016/0040-4039(96)01950-8; MacGillivray LR, 1997, NATURE, V389, P469, DOI 10.1038/38985; MECOZZI S, IN PRESS CHEM EUR J; Meissner R, 1997, J AM CHEM SOC, V119, P77, DOI 10.1021/ja962991f; MEISSNER RS, 1995, SCIENCE, V270, P1485, DOI 10.1126/science.270.5241.1485; Mizutani T, 1996, J AM CHEM SOC, V118, P5318, DOI 10.1021/ja953932p; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; RIVERAORTIZ JM, IN PRESS J AM CHEM S; SanchezQuesada J, 1996, J AM CHEM SOC, V118, P277, DOI 10.1021/ja953243d; Simanek EE, 1997, J ORG CHEM, V62, P2619, DOI 10.1021/jo9615460; TIMMERMAN P, 1994, ANGEW CHEM INT EDIT, V33, P2345, DOI 10.1002/anie.199423451; Tokunaga Y, 1998, J AM CHEM SOC, V120, P66, DOI 10.1021/ja972885t; Warmuth R, 1997, ANGEW CHEM INT EDIT, V36, P1347, DOI 10.1002/anie.199713471; Yoon JY, 1997, J AM CHEM SOC, V119, P11796, DOI 10.1021/ja972719l	23	181	184	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1021	1023		10.1126/science.279.5353.1021	http://dx.doi.org/10.1126/science.279.5353.1021			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461432				2022-12-28	WOS:000072006400044
J	Brooks, PC; Silletti, S; von Schalscha, TL; Friedlander, M; Cheresh, DA				Brooks, PC; Silletti, S; von Schalscha, TL; Friedlander, M; Cheresh, DA			Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity	CELL			English	Article							HUMAN-ENDOTHELIAL CELLS; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR; IV COLLAGENASE; EXTRACELLULAR-MATRIX; ADHESION RECEPTOR; PROGELATINASE-A; ACTIVATION; ALPHA(V)BETA(3); SURFACE	Angiogenesis depends on both cell adhesion and proteolytic mechanisms. In fact, matrix metalloproteinase 2 (MMP-2) and integrin alpha v beta 3 are functionally associated on the surface of angiogenic blood vessels. A fragment of MMP-2, which comprises the C-terminal hemopexin-like domain, termed PEX, prevents this enzyme binding to alpha v beta 3 and blocks cell surface collagenolytic activity. PEX blocks MMP-2 activity on the chick chorioallantoic membrane where it disrupts angiogenesis and tumor growth. Importantly, a naturally occurring form of PEX can be detected in vivo in conjunction with alpha v beta 3 expression in tumors and during developmental retinal neovascularization. Levels of PEX in these vascularized tissues suggest that it interacts with endothelial cell alpha v beta 3 where it serves as a natural inhibitor of MMP-2 activity, thereby regulating the invasive behavior of new blood vessels.	Scripps Res Inst, Dept Immunol & Vasc Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Cheresh, DA (corresponding author), Scripps Res Inst, Dept Immunol & Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R37CA050286, R01CA050286, R01CA045726] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054444] Funding Source: NIH RePORTER; NCI NIH HHS [CA45726, CA50286] Funding Source: Medline; NHLBI NIH HHS [HL54444] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIMES RT, 1994, BIOCHEM J, V200, P729; AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817; AUERBACH W, 1994, PHARMACOL THERAPEUT, V63, P265, DOI 10.1016/0163-7258(94)90027-2; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; DAMORE PA, 1987, ANNU REV PHYSIOL, V49, P453; DeClerck YA, 1996, ENZYME PROTEIN, V49, P72, DOI 10.1159/000468617; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; Foda HD, 1996, LAB INVEST, V74, P538; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; GALARDY RE, 1994, CANCER RES, V54, P4715; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Senger DR, 1996, AM J PATHOL, V149, P1; SMITH JW, 1990, J BIOL CHEM, V265, P11008; StetlerStevenson WG, 1996, AM J PATHOL, V148, P1345; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; VOLPERT OV, 1995, BIOCHEM BIOPH RES CO, V217, P326, DOI 10.1006/bbrc.1995.2780; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730	41	515	566	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 6	1998	92	3					391	400		10.1016/S0092-8674(00)80931-9	http://dx.doi.org/10.1016/S0092-8674(00)80931-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YX283	9476898	Bronze			2022-12-28	WOS:000072024700010
J	Ohno, M; Fornerod, M; Mattaj, IW				Ohno, M; Fornerod, M; Mattaj, IW			Nucleocytoplasmic transport: The last 200 nanometers	CELL			English	Review							NUCLEAR-PORE COMPLEX; MESSENGER-RNA EXPORT; SCANNING ELECTRON-MICROSCOPY; U-SNRNA EXPORT; PROTEIN IMPORT; SACCHAROMYCES-CEREVISIAE; MEMBRANE DOMAIN; POLY(A)(+) RNA; NUCLEOPORIN; ENVELOPE		European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Mattaj, IW (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Fornerod, Maarten/A-7503-2010	Mattaj, Iain/0000-0002-5537-8284; Fornerod, Maarten/0000-0002-6166-3030				AARONSON RP, 1975, P NATL ACAD SCI USA, V72, P1007, DOI 10.1073/pnas.72.3.1007; AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; AKEY CW, 1993, J CELL BIOL, V122, P1, DOI 10.1083/jcb.122.1.1; AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; BAILER SM, 1998, IN PRESS EMBO J; Bastos R, 1996, J CELL BIOL, V134, P1141, DOI 10.1083/jcb.134.5.1141; Bastos R, 1997, J CELL BIOL, V137, P989, DOI 10.1083/jcb.137.5.989; Belgareh N, 1997, J CELL BIOL, V136, P747, DOI 10.1083/jcb.136.4.747; Bucci M, 1997, J CELL BIOL, V136, P1185, DOI 10.1083/jcb.136.6.1185; Cordes VC, 1997, J CELL BIOL, V136, P515, DOI 10.1083/jcb.136.3.515; Daneholt B, 1997, CELL, V88, P585, DOI 10.1016/S0092-8674(00)81900-5; DelPriore V, 1996, MOL BIOL CELL, V7, P1601, DOI 10.1091/mbc.7.10.1601; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; FAHRENKROG B, 1998, IN PRESS MOL BIOL CE; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; Goldberg MW, 1996, J MOL BIOL, V257, P848, DOI 10.1006/jmbi.1996.0206; Goldberg MW, 1997, J CELL SCI, V110, P409; GOLDBERG MW, 1992, J CELL BIOL, V119, P1429, DOI 10.1083/jcb.119.6.1429; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; GRANDI P, 1995, EMBO J, V14, P76, DOI 10.1002/j.1460-2075.1995.tb06977.x; Grandi P, 1997, MOL BIOL CELL, V8, P2017, DOI 10.1091/mbc.8.10.2017; GREBER UF, 1990, EMBO J, V9, P1495, DOI 10.1002/j.1460-2075.1990.tb08267.x; GUAN TL, 1995, MOL BIOL CELL, V6, P1591, DOI 10.1091/mbc.6.11.1591; HALLBERG E, 1993, J CELL BIOL, V122, P513, DOI 10.1083/jcb.122.3.513; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; KADOWAKI T, 1992, P NATL ACAD SCI USA, V89, P2312, DOI 10.1073/pnas.89.6.2312; Kenna MA, 1996, MOL CELL BIOL, V16, P2025; Kiseleva E, 1996, J MOL BIOL, V260, P304, DOI 10.1006/jmbi.1996.0401; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; LenzBohme B, 1997, J CELL BIOL, V137, P1001, DOI 10.1083/jcb.137.5.1001; LI O, 1995, MOL BIOL CELL, V6, P401, DOI 10.1091/mbc.6.4.401; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; Macaulay C, 1996, J CELL BIOL, V132, P5, DOI 10.1083/jcb.132.1.5; Macaulay C, 1996, SEMIN CELL DEV BIOL, V7, P475, DOI 10.1006/scdb.1996.0060; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; MATTAJ IW, 1998, IN PRESS ANN REV BIO; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELCHIOR F, 1995, J CELL BIOL, V131, P571, DOI 10.1083/jcb.131.3.571; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; Nehrbass U, 1996, J CELL BIOL, V133, P1153, DOI 10.1083/jcb.133.6.1153; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Pante N, 1996, SCIENCE, V273, P1729, DOI 10.1126/science.273.5282.1729; PANTE N, 1994, CURR OPIN STRUC BIOL, V4, P187, DOI 10.1016/S0959-440X(94)90307-7; POWERS MA, 1995, J CELL BIOL, V128, P721, DOI 10.1083/jcb.128.5.721; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; REICHELT R, 1990, J CELL BIOL, V110, P883, DOI 10.1083/jcb.110.4.883; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; ROUT MP, 1993, J CELL BIOL, V123, P771, DOI 10.1083/jcb.123.4.771; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Saavedra C, 1996, GENE DEV, V10, P1608, DOI 10.1101/gad.10.13.1608; Saavedra CA, 1997, GENE DEV, V11, P2845, DOI 10.1101/gad.11.21.2845; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; Stutz F, 1997, GENE DEV, V11, P2857, DOI 10.1101/gad.11.21.2857; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; vanDeursen J, 1996, EMBO J, V15, P5574, DOI 10.1002/j.1460-2075.1996.tb00942.x; Visa N, 1996, J CELL BIOL, V133, P5, DOI 10.1083/jcb.133.1.5; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; WENTE SR, 1993, J CELL BIOL, V123, P275, DOI 10.1083/jcb.123.2.275; Wilson KL, 1996, SEMIN CELL DEV BIOL, V7, P487, DOI 10.1006/scdb.1996.0061; WOZNIAK RW, 1994, J CELL BIOL, V125, P31, DOI 10.1083/jcb.125.1.31; WOZNIAK RW, 1989, J CELL BIOL, V108, P2083, DOI 10.1083/jcb.108.6.2083; WOZNIAK RW, 1992, J CELL BIOL, V119, P1441, DOI 10.1083/jcb.119.6.1441; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; Yan C, 1997, EMBO J, V16, P3572, DOI 10.1093/emboj/16.12.3572; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0; Zabel U, 1996, J CELL BIOL, V133, P1141, DOI 10.1083/jcb.133.6.1141	98	319	324	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 6	1998	92	3					327	336		10.1016/S0092-8674(00)80926-5	http://dx.doi.org/10.1016/S0092-8674(00)80926-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YX283	9476893	Bronze			2022-12-28	WOS:000072024700005
J	McManus, IC; Richards, P; Winder, BC; Sproston, KA				McManus, IC; Richards, P; Winder, BC; Sproston, KA			Clinical experience, performance in final examinations, and learning style in medical students: prospective study	BRITISH MEDICAL JOURNAL			English	Article							ACADEMIC-PERFORMANCE; EDUCATION; INVENTORIES; DRESSERS; ANXIETY; SCHOOLS	Objective: To assess whether the clinical experience of undergraduate medical students relates to their performance in final examinations and whether learning styles relate either to final examination performance or to the extent of clinical experience. Design: Prospective, longitudinal study of two cohorts of medical students assessed by questionnaire at time of application to medical school and by questionnaire and university examination at the end of their final clinical year. Subjects: Two cohorts of students who had applied to St Mary's Hospital Medical School during 1980 (n = 1478) and 1985 (n = 2399) for admission in 1981 and 1986 respectively. Students in these cohorts who entered any medical school in the United Kingdom were followed up in their final clinical year in 1986-7 and 1991-2. Main outcome measures: Students' clinical experience of a range of acute medical conditions, surgical operations, and practical procedures as assessed by questionnaire in the final year, and final examination results for the students taking their examinations at the University of London. Results: Success in the final examination was not related to a student's clinical experiences. The amount of knowledge gained from clinical experience was, however, related to strategic and deep learning styles both in the final year and also at the time of application, five or six years earlier. Grades in A level examinations did not relate either to study habits or to clinical experience. Success in the final examination was also related to a strategic or deep learning style in the final year (although not at time of entry to medical school). Conclusions: The lack of correlation between examination performance and clinical experience calls into question the validity of final examinations. How much knowledge is gained from clinical experience as a student is able to be predicted from measures of study habits made at the time of application to medical school, some six years earlier, although not from results of A level examinations. Medical schools wishing to select students who will gain the most knowledge from clinical experience cannot use the results of A level examinations alone but could assess a student's learning style.	St Marys Hosp, Imperial Coll Sch Med, Dept Psychiat, London W2 1PG, England; Northwick Pk & St Marks Trust, Harrow HA1 3UJ, Middx, England	Imperial College London	McManus, IC (corresponding author), UCL, Sch Med, Ctr Hlth Informat & Multiprofess Educ, Mortimer St, London N19 5NF, England.	i.mcmanus@ucl.ac.uk		Winder, Belinda/0000-0002-9118-679X; McManus, Ian/0000-0003-3510-4814				Atkinson P., 1981, CLIN EXPERIENCE CONS; BIGGS J, 1993, BRIT J EDUC PSYCHOL, V63, P3, DOI 10.1111/j.2044-8279.1993.tb01038.x; Biggs J. B, 1987, STUDENT APPROACHES L; Biggs JB, 1987, STUDY PROCESS QUESTI; BONNER TN, 1995, BECOMING PHYSICIAN M; Bulstrode C, 1996, BRIT MED J, V312, P326; COLES CR, 1985, MED EDUC, V19, P308, DOI 10.1111/j.1365-2923.1985.tb01327.x; DENT THS, 1990, BRIT MED J, V300, P713, DOI 10.1136/bmj.300.6726.713; Entwistle N, 1981, STYLES LEARNING TEAC; Flexner A, 1925, MED ED COMP STUDY; *GEN MED COUNC, 1993, TOM DOCT REC UND MED; Jolly BC, 1996, ACAD MED, V71, P909, DOI 10.1097/00001888-199608000-00021; KLEIJN WC, 1994, PSYCHOL REP, V75, P1219, DOI 10.2466/pr0.1994.75.3.1219; LANGDORF MI, 1990, ANN EMERG MED, V19, P764, DOI 10.1016/S0196-0644(05)81700-7; LEIDEN LI, 1990, ACAD MED, V65, P395, DOI 10.1097/00001888-199006000-00009; LOCKWOOD DNJ, 1986, MED EDUC, V20, P216, DOI 10.1111/j.1365-2923.1986.tb01171.x; LOCKWOOD DNJ, 1986, J ROY SOC MED, V79, P38, DOI 10.1177/014107688607900112; LUCAS CJ, 1976, BRIT J PSYCHIAT, V129, P598, DOI 10.1192/bjp.129.6.598; MARTEAU TM, 1990, BRIT MED J, V300, P849, DOI 10.1136/bmj.300.6728.849; MARTENSON DF, 1986, MED EDUC, V20, P532, DOI 10.1111/j.1365-2923.1986.tb01395.x; MCMANUS IC, 1984, BRIT MED J, V289, P1201, DOI 10.1136/bmj.289.6453.1201; MCMANUS IC, 1993, LANCET, V341, P941, DOI 10.1016/0140-6736(93)91225-B; McManus IC, 1996, MED EDUC, V30, P195, DOI 10.1111/j.1365-2923.1996.tb00742.x; MCMANUS IC, 1989, BRIT MED J, V298, P723, DOI 10.1136/bmj.298.6675.723; MCMANUS IC, 1990, MED EDUC, V24, P181; NEWBLE DI, 1986, MED EDUC, V20, P162, DOI 10.1111/j.1365-2923.1986.tb01163.x; ONEIL MJ, 1984, BRIT J EDUC PSYCHOL, V54, P228, DOI 10.1111/j.2044-8279.1984.tb02584.x; PEERS IS, 1994, BRIT J EDUC PSYCHOL, V64, P1, DOI 10.1111/j.2044-8279.1994.tb01081.x; PICKERING G, 1978, QUEST EXCELLENCE MED; RAMSDEN P, 1981, BRIT J EDUC PSYCHOL, V51, P368, DOI 10.1111/j.2044-8279.1981.tb02493.x; SALTER RH, 1995, BRIT MED J, V310, P538, DOI 10.1136/bmj.310.6978.538; Schon D.A, 2017, REFLECTIVE PRACTITIO; Sinclair D.C., 1972, BASIC MED ED; Slotnick HB, 1996, ACAD MED, V71, P28, DOI 10.1097/00001888-199601000-00014; TOMLINSON RWS, 1977, MED EDUC, V11, P103, DOI 10.1111/j.1365-2923.1977.tb00569.x; TOOTH D, 1989, MED EDUC, V23, P416, DOI 10.1111/j.1365-2923.1989.tb00896.x	36	156	164	2	27	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 31	1998	316	7128					345	350		10.1136/bmj.316.7128.345	http://dx.doi.org/10.1136/bmj.316.7128.345			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YV793	9487168	Green Submitted, Green Published, Green Accepted, Bronze			2022-12-28	WOS:000071863900023
J	Downward, J				Downward, J			Signal transduction - Lipid-regulated kinases: Some common themes at last	SCIENCE			English	Article									Imperial Canc Res Fund, Signal Transduct Lab, London WC2A 3PX, England	Cancer Research UK	Downward, J (corresponding author), Imperial Canc Res Fund, Signal Transduct Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	downward@europa.lif.icnet.uk		Downward, Julian/0000-0002-2331-4729				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567	12	181	190	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	1998	279	5351					673	674		10.1126/science.279.5351.673	http://dx.doi.org/10.1126/science.279.5351.673			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9471728				2022-12-28	WOS:000071731500025
J	Gibb, DM; MacDonagh, SE; Gupta, R; Tookey, PA; Peckham, CS; Ades, AE				Gibb, DM; MacDonagh, SE; Gupta, R; Tookey, PA; Peckham, CS; Ades, AE			Factors affecting uptake of antenatal HIV testing in London: results of a multicentre study	BRITISH MEDICAL JOURNAL			English	Article							TRANSMISSION; ZIDOVUDINE	Objectives: To measure the uptake of antenatal HIV testing and determine its relation to risk of HIV and to screening practices. Design: Multicentre prospective questionnaire study. Subjects: Pregnant women attending six maternity units. Setting: Inner London, 1995-6. Main outcome measures: Uptake of testing by risk factors for HIV ethnicity, and factors about the antenatal interview. Results: All units had a "universal offer" policy for HIV testing. In five units forms were completed for 18 791 (88%) of 21 247 pregnant women. The sixth unit, where the response rate was too low to assess uptake, was excluded from the analysis. Uptake ranged from 3.4% to 51.2% (overall 22.9%), in parallel with detection of previously undiagnosed infection in pregnant women (4.9-60%). Controlling for unit, uptake was higher among the 7% who disclosed risk factors. Among those at low risk, uptake varied by ethnic group (South Asian women 9%; Latin American and Mediterranean women 33%). The relation between uptake and HIV risk category varied greatly across units. Despite increased HIV seroprevalence in black African women, uptake was similar in this group to that among women at low risk (24%). Uptake increased 2.1-fold if HIV transmission was discussed. Midwives reported spending 7 (2-15) minutes discussing HIV issues. Conclusions: Uptake of HIV testing was unacceptably low in all units, with maternity unit the strongest predictor. New approaches to antenatal HIV testing are urgently required and uptake should be audited routinely.	Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England	University of London; University College London	Gibb, DM (corresponding author), Inst Child Hlth, Dept Epidemiol & Publ Hlth, 30 Guilford St, London WC1N 1EH, England.		Tookey, Pat A/G-2732-2010	Tookey, Pat A/0000-0001-6258-0387; Gibb, Diana/0000-0002-9738-5490				CONNOR EM, 1995, PEDIATR INFECT DIS J, V14, P536, DOI 10.1097/00006454-199506000-00012; DeCock KM, 1997, BRIT MED J, V314, P1747, DOI 10.1136/bmj.314.7096.1747; *DEP HLTH, 1994, GUID OFF VOL NAM HIV; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; Gibb DM, 1997, AIDS, V11, pF53, DOI 10.1097/00002030-199707000-00001; KAHTAN S, 1993, BRIT MED J, V306, P1479, DOI 10.1136/bmj.306.6890.1479-a; LINDGREN S, 1993, BRIT MED J, V307, P1447, DOI 10.1136/bmj.307.6917.1447; MacDonagh SE, 1996, BRIT MED J, V313, P532; MAYAUX MJ, 1998, IN PRESS J PEDIAT; Nicoll A, 1998, BRIT MED J, V316, P253, DOI 10.1136/bmj.316.7127.253; REY D, 1998, IN PRESS BR J OBSTET	12	47	47	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					259	261		10.1136/bmj.316.7127.259	http://dx.doi.org/10.1136/bmj.316.7127.259			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472505	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000071702100018
J	de Lange, T				de Lange, T			Telomeres and senescence: Ending the debate	SCIENCE			English	Article							HUMAN FIBROBLASTS; IMMORTAL CELLS; CARCINOMA		Rockefeller Univ, Cell Biol & Genet Lab, New York, NY 10021 USA	Rockefeller University	de Lange, T (corresponding author), Rockefeller Univ, Cell Biol & Genet Lab, 1230 York Ave, New York, NY 10021 USA.		de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X				ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LUNDBLAD V, 1989, CELL, V57, P5633; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498	19	131	136	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					334	335		10.1126/science.279.5349.334	http://dx.doi.org/10.1126/science.279.5349.334			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9454329				2022-12-28	WOS:000071570800031
J	Wilson, KS; Noller, HF				Wilson, KS; Noller, HF			Mapping the position of translational elongation factor EF-G in the ribosome by directed hydroxyl radical probing	CELL			English	Article							ESCHERICHIA-COLI RIBOSOME; TRANSFER-RNA; CRYSTAL-STRUCTURE; P-SITE; CROSS-LINKING; BINDING-SITES; FACTOR-TU; 16S RNA; 23S RNA; A-SITE	The interaction of translational elongation factor EF-G with the ribosome in the posttranslocational state has been mapped by directed hydroxyl radical probing. Localized hydroxyl radicals were generated from Fe(II) tethered to 18 different sites on the surface of EF-G bound to the ribosome. Cleavages in ribosomal RNA were mapped, providing proximity relationships between specific sites of EF-G and rRNA elements of the ribosome. Collectively, these data provide a set of constraints by which EF-G can be positioned unambiguously in the ribosome at low resolution. The proximities of different domains of EF-G to well-characterized elements of rRNA have additional implications for the mechanism of protein synthesis.	Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Noller, HF (corresponding author), Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA.							Abel K, 1996, STRUCTURE, V4, P229, DOI 10.1016/S0969-2126(96)00027-5; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BODLEY JW, 1970, NATURE, V227, P60, DOI 10.1038/227060a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRETSCHER MS, 1968, NATURE, V218, P675, DOI 10.1038/218675a0; BRIGOTTI M, 1989, BIOCHEM J, V257, P723, DOI 10.1042/bj2570723; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; DORING T, 1994, EMBO J, V13, P2677, DOI 10.1002/j.1460-2075.1994.tb06558.x; EGEBJERG J, 1990, J MOL BIOL, V213, P275, DOI 10.1016/S0022-2836(05)80190-1; EVARSSON A, 1995, J MOL EVOL, V41, P1096; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; GAVRILOVA LP, 1976, J MOL BIOL, V101, P537, DOI 10.1016/0022-2836(76)90243-6; GORDON J, 1969, J BIOL CHEM, V244, P5680; HAUSNER TP, 1987, BIOCHIMIE, V69, P911, DOI 10.1016/0300-9084(87)90225-2; Heilek GM, 1996, SCIENCE, V272, P1659, DOI 10.1126/science.272.5268.1659; HEILEK GM, 1995, P NATL ACAD SCI USA, V92, P1113, DOI 10.1073/pnas.92.4.1113; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; JOHANSON U, 1994, GENE, V143, P55, DOI 10.1016/0378-1119(94)90604-1; Joseph S, 1997, SCIENCE, V278, P1093, DOI 10.1126/science.278.5340.1093; MAASSEN JA, 1981, EUR J BIOCHEM, V115, P279, DOI 10.1111/j.1432-1033.1981.tb05235.x; MITCHELL P, 1992, BIOCHEMISTRY-US, V31, P3004, DOI 10.1021/bi00126a023; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; Mueller F, 1997, J MOL BIOL, V271, P524, DOI 10.1006/jmbi.1997.1210; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; NOLLER HF, 1989, RIBOSOME STRUCTURE F, P73; OAKES MI, 1989, RIBOSOME STRUCTURE F, P180; PESTKA S, 1969, J BIOL CHEM, V244, P1533; POWERS T, 1993, P NATL ACAD SCI USA, V90, P1364, DOI 10.1073/pnas.90.4.1364; POWERS T, 1995, RNA, V1, P194; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; RANA TM, 1990, J AM CHEM SOC, V112, P2457, DOI 10.1021/ja00162a077; RICHMAN N, 1972, P NATL ACAD SCI USA, V69, P686, DOI 10.1073/pnas.69.3.686; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; ROSSET R, 1969, J MOL BIOL, V39, P95, DOI 10.1016/0022-2836(69)90336-2; SAMAHA RR, 1994, P NATL ACAD SCI USA, V91, P7884, DOI 10.1073/pnas.91.17.7884; SCHILLINGBARTETZKO S, 1992, J BIOL CHEM, V267, P4703; SERDYUK I, 1992, BIOCHIMIE, V74, P299, DOI 10.1016/0300-9084(92)90107-P; SKOLD SE, 1983, NUCLEIC ACIDS RES, V11, P4923, DOI 10.1093/nar/11.14.4923; SPIRIN AS, 1985, PROG NUCLEIC ACID RE, V32, P75, DOI 10.1016/S0079-6603(08)60346-3; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STERN S, 1988, METHOD ENZYMOL, V164, P481; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; SZEWCZAK AA, 1993, P NATL ACAD SCI USA, V90, P9581, DOI 10.1073/pnas.90.20.9581; THOMPSON J, 1982, J BIOL CHEM, V257, P7915; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232	51	180	187	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 9	1998	92	1					131	139		10.1016/S0092-8674(00)80905-8	http://dx.doi.org/10.1016/S0092-8674(00)80905-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489706	Bronze			2022-12-28	WOS:000071473700014
J	Madeley, D; Taylor, C				Madeley, D; Taylor, C			''Outbreak''?	LANCET			English	Article											Madeley, D (corresponding author), ROYAL VICTORIA INFIRM,DEPT VIROL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							[Anonymous], 1995, BRIT MED J, V311, P1415; BENNETT D, 1995, BRIT MED J, V310, P1344, DOI 10.1136/bmj.310.6991.1344; LEVY JA, 1995, LANCET, V346, P786, DOI 10.1016/S0140-6736(95)91611-3; MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702; ZUCKERMAN AJ, 1995, LANCET, V345, P1453, DOI 10.1016/S0140-6736(95)91032-8; 1995, BRIT MED J, V311, P1420; 1995, BRIT MED J, V311, P1418	7	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S27	S27		10.1016/0140-6736(95)90026-8	http://dx.doi.org/10.1016/0140-6736(95)90026-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454045				2022-12-28	WOS:A1995TN12200027
J	Montaner, JSG; Schechter, MT				Montaner, JSG; Schechter, MT			A year of transformation in HIV AIDS	LANCET			English	Article											Montaner, JSG (corresponding author), UNIV BRITISH COLUMBIA,FAC MED,VANCOUVER,BC V5T 123,CANADA.			Schechter, Martin/0000-0001-6063-2155				GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S12	S12						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454029				2022-12-28	WOS:A1995TN12200012
J	Fried, LP; Kronmal, RA; Newman, AB; Bild, DE; Mittelmark, MB; Polak, JF; Robbins, JA; Gardin, JM				Fried, LP; Kronmal, RA; Newman, AB; Bild, DE; Mittelmark, MB; Polak, JF; Robbins, JA; Gardin, JM		Cardiovasc Hlth Stud Collabor Res Grp	Risk factors for 5-year mortality in older adults - The cardiovascular health study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALL-CAUSE MORTALITY; PHYSICAL-DISABILITY; NATIONAL COHORT; LONG-TERM; FOLLOW-UP; MEN; DISEASE; ASSOCIATION; ATHEROSCLEROSIS; CORONARY	Context.-Multiple factors contribute to mortality in older adults, but the extent to which subclinical disease and other factors contribute independently to mortality risk is not known. Objective.-To determine the disease, functional, and personal characteristics that jointly predict mortality in community-dwelling men and women aged 65 years or older. Design.-Prospective population-based cohort study with 5 years of follow-up and a validation cohort of African Americans with 4.25-year follow-up. Setting.-Four US communities. Participants.-A total of 5201 and 685 men and women aged 65 years or older in the original and African American cohorts, respectively. Main Outcome Measures.-Five-year mortality. Results.-In the main cohort, 646 deaths (12%) occurred within 5 years. Using Cox proportional hazards models, 20 characteristics (of 78 assessed) were each significantly (P<.05) and independently associated with mortality: increasing age, male sex, income less than $50 000 per year, low weight, lack of moderate or vigorous exercise, smoking for more than 50 pack-years, high brachial (>169 mm Hg) and low tibial (less than or equal to 127 mm Hg) systolic blood pressure, diuretic use by those without hypertension or congestive heart failure, elevated fasting glucose level (>7.2 mmol/L [130 mg/dL]), low albumin level (less than or equal to 37 g/L), elevated creatinine level (greater than or equal to 106 mu mol/L [1.2 mg/dL]), low forced vital capacity (12.06 mL), aortic stenosis (moderate or severe) and abnormal left ventricular ejection fraction (by echocardiography), major electrocardiographic abnormality, stenosis of internal carotid artery (by ultrasound), congestive heart failure, difficulty in any instrumental activity of daily living, and low cognitive function by Digit Symbol Substitution test score. Neither high-density lipoprotein cholesterol nor low-density lipoprotein cholesterol was associated with mortality. After adjustment for other factors, the association between age and mortality diminished, but the reduction in mortality with female sex persisted. Finally, the risk of mortality was validated in the second cohort; quintiles of risk ranged from 2% to 39% and 0% to 26% for the 2 cohorts. Conclusions.-Objective measures of subclinical disease and disease severity were independent and joint predictors of 5-year mortality in older adults, along with male sex, relative poverty, physical activity, smoking, indicators of frailty, and disability. Except for history of congestive heart failure, objective, quantitative measures of disease were better predictors of mortality than was clinical history of disease.	Cardiovasc Hlth Study Collaborat Res Grp, Coordinating Ctr, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Epidemiol, Baltimore, MD 21205 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA; NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA; Univ Bergen, Sch Psychol, Bergen, Norway; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA; Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA; Univ Calif Irvine, Dept Med, Div Cardiol, Irvine, CA 92717 USA; CHS Coordinating Ctr, Seattle, WA 98101 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Bergen; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of California System; University of California Davis; University of California System; University of California Irvine; Johns Hopkins University; Johns Hopkins Medicine	Fried, LP (corresponding author), Cardiovasc Hlth Study Collaborat Res Grp, Coordinating Ctr, Welch Ctr Prevent Epidemiol & Clin Res, 2024 E Monument St,Suite 2600, Baltimore, MD 21205 USA.		Newman, Anne B./C-6408-2013	Newman, Anne B./0000-0002-0106-1150	NHLBI NIH HHS [N01-HC-87079, N01-HC-87080, N01-HC-87081] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANG KM, 1993, CHEST, V103, P536, DOI 10.1378/chest.103.2.536; CAMPBELL AJ, 1985, J EPIDEMIOL COMMUN H, V39, P337, DOI 10.1136/jech.39.4.337; CORNONIHUNTLEY JC, 1991, J CLIN EPIDEMIOL, V44, P743, DOI 10.1016/0895-4356(91)90126-T; CORTI MC, 1994, JAMA-J AM MED ASSOC, V272, P1036, DOI 10.1001/jama.272.13.1036; CRIQUI MH, 1985, CIRCULATION, V72, P768, DOI 10.1161/01.CIR.72.4.768; CUSHMAN M, 1995, CLIN CHEM, V41, P264; EAKER ED, 1989, AM HEART J, V117, P71, DOI 10.1016/0002-8703(89)90658-3; ENRIGHT PL, 1993, AM REV RESPIR DIS, V147, P125, DOI 10.1164/ajrccm/147.1.125; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; FRIED LP, 1994, J CLIN EPIDEMIOL, V47, P747, DOI 10.1016/0895-4356(94)90172-4; Gardin J M, 1992, J Am Soc Echocardiogr, V5, P63; HARRIS T, 1989, AM J PUBLIC HEALTH, V79, P698, DOI 10.2105/AJPH.79.6.698; HARRIS T, 1988, JAMA-J AM MED ASSOC, V259, P1520; HARRIS T, 1992, J CLIN EPIDEMIOL, V45, P595, DOI 10.1016/0895-4356(92)90131-6; Hazzard WR, 1994, PRINCIPLES GERIATRIC; IRIBARREN C, 1995, NEW ENGL J MED, V333, P686, DOI 10.1056/NEJM199509143331102; JANGHORBANI M, 1993, INT J EPIDEMIOL, V22, P1056, DOI 10.1093/ije/22.6.1056; KOHN RR, 1982, JAMA-J AM MED ASSOC, V247, P2793, DOI 10.1001/jama.247.20.2793; LACROIX AZ, 1991, NEW ENGL J MED, V324, P1619, DOI 10.1056/NEJM199106063242303; MANOLIO TA, 1993, CIRCULATION, V87, P728, DOI 10.1161/01.CIR.87.3.728; Menotti A, 1996, PREV MED, V25, P319, DOI 10.1006/pmed.1996.0062; OGREN M, 1995, BMJ-BRIT MED J, V310, P1294, DOI 10.1136/bmj.310.6990.1294; OLEARY DH, 1991, STROKE, V22, P1155, DOI 10.1161/01.STR.22.9.1155; ORME JG, 1986, J CLIN PSYCHOL, V42, P28, DOI 10.1002/1097-4679(198601)42:1<28::AID-JCLP2270420104>3.0.CO;2-T; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; POLAK JF, 1993, RADIOLOGY, V188, P363, DOI 10.1148/radiology.188.2.8327679; Psaty Bruce M., 1995, Annals of Epidemiology, V5, P270, DOI 10.1016/1047-2797(94)00092-8; SCHOENFELD DE, 1994, J GERONTOL, V49, pM109, DOI 10.1093/geronj/49.3.M109; STAMLER J, 1993, CARDIOLOGY, V82, P191, DOI 10.1159/000175868; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; STORANDT M, 1984, ARCH NEUROL-CHICAGO, V41, P497, DOI 10.1001/archneur.1984.04050170043013; SWAN GE, 1995, AM J EPIDEMIOL, V141, P32, DOI 10.1093/oxfordjournals.aje.a117342; Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; WINGARD DL, 1983, AM J EPIDEMIOL, V117, P165, DOI 10.1093/oxfordjournals.aje.a113527; Wolf HK, 1973, COMPUTER APPLICATION, P231	37	850	861	2	51	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	1998	279	8					585	592		10.1001/jama.279.8.585	http://dx.doi.org/10.1001/jama.279.8.585			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX457	9486752	Bronze			2022-12-28	WOS:000072041900033
J	Gilbert, SC; Plebanski, M; Gupta, S; Morris, J; Cox, M; Aidoo, M; Kwiatkowski, D; Greenwood, BM; Whittle, HC; Hill, AVS				Gilbert, SC; Plebanski, M; Gupta, S; Morris, J; Cox, M; Aidoo, M; Kwiatkowski, D; Greenwood, BM; Whittle, HC; Hill, AVS			Association of malaria parasite population structure, HLA, and immunological antagonism	SCIENCE			English	Article							T-CELL EPITOPES; PLASMODIUM-FALCIPARUM; CIRCUMSPOROZOITE PROTEIN; PEPTIDE; POLYMORPHISM; RESPONSES; VARIANTS; VACCINE; VIRUS; BLOOD	Host-parasite coevolution has been likened to a molecular arms race, with particular parasite genes evolving to evade specific host defenses, Study of the variants of an antigenic epitope of Plasmodium falciparum that induces a cytotoxic T cell response supports this view, In African children with malaria, the variants present are influenced by the presence of a human leukocyte antigen (HLA) type that restricts the immune response to this epitope. The distribution of parasite variants may be further influenced by the ability of cohabiting parasite strains to facilitate each other's survival by down-regulating cellular immune responses, using altered peptide ligand antagonism.	Univ Oxford, Nuffield Dept Med, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Inst Mol Med,Mol Immunol Grp, Oxford OX3 9DU, England; Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3PS, England; Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, London WC1E 7HT, England; MRC Labs, Fajara, Senegal	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of Oxford; University of London; London School of Hygiene & Tropical Medicine	Hill, AVS (corresponding author), Univ Oxford, Nuffield Dept Med, Wellcome Trust Ctr Human Genet, Windmill Rd, Oxford OX3 7BN, England.		Gilbert, Sarah C./H-2857-2019; Plebanski, Magdalena/AAU-3144-2021; HILL, Adrian V>S>/C-1306-2008	Gilbert, Sarah C./0000-0002-6823-9750; Kwiatkowski, Dominic/0000-0002-5023-0176; , Magdalena/0000-0001-6889-3667	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aidoo M, 1997, INT IMMUNOL, V9, P731, DOI 10.1093/intimm/9.5.731; AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8; BABIKER HA, 1994, PARASITOLOGY, V109, P413, DOI 10.1017/S0031182000080665; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; CONWAY DJ, 1991, PARASITOLOGY, V1, P1; DAVENPORT MP, 1995, IMMUNOL TODAY, V16, P432, DOI 10.1016/0167-5699(95)80020-4; Dong T, 1996, EUR J IMMUNOL, V26, P335, DOI 10.1002/eji.1830260210; ELVIN J, 1991, EUR J IMMUNOL, V21, P2025, DOI 10.1002/eji.1830210909; GUPTA S, 1994, SCIENCE, V263, P961, DOI 10.1126/science.8310293; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; KLENERMAN P, 1995, EUR J IMMUNOL, V25, P1927, DOI 10.1002/eji.1830250720; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; LALVANI A, 1994, RES IMMUNOL, V145, P461, DOI 10.1016/S0923-2494(94)80177-0; LOCKYER MJ, 1989, MOL BIOCHEM PARASIT, V37, P275, DOI 10.1016/0166-6851(89)90159-X; Nei M., 1987, MOL EVOLUTIONARY GEN; PAUL REL, 1995, SCIENCE, V269, P1709, DOI 10.1126/science.7569897; PLEBANSKI M, 1995, EUR J IMMUNOL, V25, P1783, DOI 10.1002/eji.1830250645; Plebanski M, 1997, J IMMUNOL, V158, P2849; PLEBANSKI M, UNPUB; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; SNOKE K, 1993, J IMMUNOL, V151, P6815; THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; YOSHIDA N, 1990, EXP PARASITOL, V71, P386, DOI 10.1016/0014-4894(90)90064-J	25	225	229	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1173	1177		10.1126/science.279.5354.1173	http://dx.doi.org/10.1126/science.279.5354.1173			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469800				2022-12-28	WOS:000072115200032
J	Swain, A; Narvaez, S; Burgoyne, P; Camerino, G; Lovell-Badge, R				Swain, A; Narvaez, S; Burgoyne, P; Camerino, G; Lovell-Badge, R			Dax1 antagonizes Sry action in mammalian sex determination	NATURE			English	Article							ADRENAL HYPOPLASIA CONGENITA; HORMONE-RECEPTOR SUPERFAMILY; DETERMINING GENE; CAMPOMELIC DYSPLASIA; DETERMINING REGION; Y-CHROMOSOME; HYPOGONADOTROPIC HYPOGONADISM; REVERSAL; EXPRESSION; MICE	DAX1, which encodes an unusual member of the nuclear hormone-receptor superfamily, is a gene that may be responsible for a sex-reversal syndrome in humans, referred to as dosage-sensitive sex reversal, in which XY individuals carrying duplications of Xp21, part of the small arm of the X chromosome, develop as females, XY mice carrying extra copies of mouse Dax1 as a transgene show delayed testis development when the gene Is expressed at high levels, but do not normally show sex reversal. Complete sex reversal occurs, however, when the transgene is tested against weak alleles of the sex-determining Y-chromosome gene Sry, These results show that DAX1 is largely, if not solely, responsible for dosage-sensitive sex reversal and provide a model for early events in mammalian sex determination, when precise levels and timing of gene expression are critical.	Natl Inst Med Res, MRC, Div Dev Genet, London NW7 1AA, England; Univ Autonoma Estad Morelos, Fac Ciencias, Cuernavaca 62210, Morelos, Mexico; Univ Pavia, I-27100 Pavia, Italy	MRC National Institute for Medical Research; Universidad Autonoma del Estado de Morelos; University of Pavia	Lovell-Badge, R (corresponding author), Natl Inst Med Res, MRC, Div Dev Genet, Ridgeway,Mill Hill, London NW7 1AA, England.			Swain, Amanda/0000-0001-8666-1608; Narvaez Padilla, Veronica/0000-0002-3484-1612; Lovell-Badge, Robin/0000-0001-9364-4179	Medical Research Council [MC_U117562207] Funding Source: Medline; Telethon [B.38] Funding Source: Medline; MRC [MC_U117562207] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Telethon(Fondazione Telethon); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; CAPEL B, 1993, NAT GENET, V5, P301, DOI 10.1038/ng1193-301; CAPEL B, 1993, ADV DEV BIOL, V2, P1; CLEPET C, 1993, HUM MOL GENET, V2, P2007, DOI 10.1093/hmg/2.12.2007; COWARD P, 1994, NAT GENET, V6, P245, DOI 10.1038/ng0394-245; DABOVIC B, 1995, MAMM GENOME, V6, P571, DOI 10.1007/BF00352360; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; DUBIN RA, 1994, MOL ENDOCRINOL, V8, P1182, DOI 10.1210/me.8.9.1182; Eicher EM, 1995, PHILOS T R SOC B, V350, P263, DOI 10.1098/rstb.1995.0160; Eicher EM, 1996, NAT GENET, V14, P206, DOI 10.1038/ng1096-206; EICHER EM, 1982, SCIENCE, V217, P535, DOI 10.1126/science.7089579; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Graves JAM, 1995, PHILOS T R SOC B, V350, P305, DOI 10.1098/rstb.1995.0166; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUO WW, 1995, BIOCHEM MOL MED, V56, P8, DOI 10.1006/bmme.1995.1049; HACKER A, 1995, DEVELOPMENT, V121, P1603; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HAWKINS JR, 1994, HUM MOL GENET, V3, P1463, DOI 10.1093/hmg/3.suppl_1.1463; HONDA S, 1993, J BIOL CHEM, V268, P7494; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; Ikeda Y, 1996, MOL ENDOCRINOL, V10, P1261, DOI 10.1210/me.10.10.1261; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; JESKE YWA, 1995, NAT GENET, V10, P480, DOI 10.1038/ng0895-480; Kent J, 1996, DEVELOPMENT, V122, P2813; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KWOK C, 1995, AM J HUM GENET, V57, P1028; LovellBadge R, 1995, PHILOS T R SOC B, V350, P205, DOI 10.1098/rstb.1995.0153; LOVELLBADGE R, 1993, PHILOS T R SOC B, V339, P159, DOI 10.1098/rstb.1993.0012; LOVELLBADGE R, 1990, DEVELOPMENT, V109, P635; MCLAREN A, 1991, BIOESSAYS, V13, P151, DOI 10.1002/bies.950130402; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; NARVAEZ V, 1996, THESIS U LONDON; PALMER SJ, 1991, DEVELOPMENT, V113, P709; PALMER SJ, 1991, DEVELOPMENT, V112, P265; Pask A, 1997, GENOMICS, V41, P422, DOI 10.1006/geno.1997.4651; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; Renfree MB, 1995, PHILOS T R SOC B, V350, P243, DOI 10.1098/rstb.1995.0158; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SMITH RL, 1995, J VIROL, V69, P4593, DOI 10.1128/JVI.69.8.4593-4599.1995; Swain A, 1996, NAT GENET, V12, P404, DOI 10.1038/ng0496-404; Tamai KT, 1996, MOL ENDOCRINOL, V10, P1561, DOI 10.1210/me.10.12.1561; TUCKER PK, 1993, NATURE, V364, P715, DOI 10.1038/364715a0; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0	50	417	442	2	21	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 19	1998	391	6669					761	767		10.1038/35799	http://dx.doi.org/10.1038/35799			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486644				2022-12-28	WOS:000072089500043
J	Shapiro, D				Shapiro, D			Perspective shift	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Arizona, Tucson, AZ 85721 USA	University of Arizona	Shapiro, D (corresponding author), Univ Arizona, Tucson, AZ 85721 USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	1998	279	7					500	500		10.1001/jama.279.7.500	http://dx.doi.org/10.1001/jama.279.7.500			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW470	9480348				2022-12-28	WOS:000071938900011
J	Berwick, DM; Nolan, TW				Berwick, DM; Nolan, TW			Physicians as leaders in improving health care: A new series in Annals of Internal Medicine	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY MANAGEMENT; DOCTORS ROLE; NHS	Searching for one word to describe the state of mind of the physician in the United States today, we might choose beleaguered. Threats appear from all sides-from payers, would-be managers of care, the growth of technology, and even patients. The rhetoric is one of siege and battle, and the dynamic seems to be a clash of values from which only one winner can emerge. But scientific and health services research suggest otherwise. Science suggests that health care could, indeed, perform a great deal better than it does today and that a shared aim of improving health outcomes for patients at a cost that society can afford is sensible and within reach. However, achievement of these improvements will require of physicians not handwringing and resistance to change but concerted, positive, capable leadership. The goal of this series in Annals is to describe a new knowledge base that will help physicians participate effectively in the redesign of the health care system. The series is intended to raise the curiosity of physicians about the skills they will need to become more active and influential citizens of the health care community in accomplishing improvements. These skills will help physicians better deploy their clinical expertise and professional purpose in a debate that has heretofore been informed primarily by economics.	Inst Healthcare Improvement, Boston, MA 02215 USA	Institute for Healthcare Improvement	Berwick, DM (corresponding author), Inst Healthcare Improvement, 135 Francis St, Boston, MA 02215 USA.							AARON HJ, 1984, PAINFUL PRESCRIPTION; [Anonymous], 1996, DARTMOUTH ATLAS HLTH; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; BERWICK DM, 1992, BRIT MED J, V304, P235, DOI 10.1136/bmj.304.6821.235; BERWICK DM, 1992, BRIT MED J, V304, P304, DOI 10.1136/bmj.304.6822.304; BERWICK DM, 1994, JAMA-J AM MED ASSOC, V272, P797, DOI 10.1001/jama.272.10.797; Berwick DM, 1997, BRIT MED J, V314, P1564, DOI 10.1136/bmj.314.7094.1564; BERWICK DM, 1992, QUALITY MED CARE S, V1, P51; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; DOUMERAI SB, 1997, JAMA-J AM MED ASSOC, V277, P115; Kassirer JP, 1997, NEW ENGL J MED, V336, P1666, DOI 10.1056/NEJM199706053362308; Nolan TW, 1998, ANN INTERN MED, V128, P293, DOI 10.7326/0003-4819-128-4-199802150-00009	13	149	150	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1998	128	4					289	292		10.7326/0003-4819-128-4-199802150-00008	http://dx.doi.org/10.7326/0003-4819-128-4-199802150-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX170	9471932				2022-12-28	WOS:000072013400006
J	Katz, BA; Clark, JM; Finer-Moore, JS; Jenkins, TE; Johnson, CR; Ross, MJ; Luong, C; Moore, WR; Stroud, RM				Katz, BA; Clark, JM; Finer-Moore, JS; Jenkins, TE; Johnson, CR; Ross, MJ; Luong, C; Moore, WR; Stroud, RM			Design of potent selective zinc-mediated serine protease inhibitors	NATURE			English	Article							COMPLEX; BINDING; TRYPSIN; BIS(5-AMIDINO-2-BENZIMIDAZOLYL)METHANE; DERIVATIVES; CHEMISTRY; AMIDINES; MODEL	Many serine proteases are targets for therapeutic intervention because they often play key roles in disease(1). Small molecule inhibitors of serine proteases with high affinity are especially interesting as they could be used as scaffolds from which to develop drugs selective for protease targets. One such inhibitor is bis(5-amidino-2-benzimidazolyl)methane (BABIM), standing out as the best inhibitor of trypsin (by a factor of over 100) in a series of over 60 relatively closely related analogues(2-4). By probing the structural basis of inhibition, we discovered, using crystallographic methods, a new mode of high-affinity binding in which a Zn2+ ion is tetrahedrally coordinated between two chelating nitrogens of BABIM and two active site residues, His 57 and Ser 195. Zn2+, at subphysiological levels, enhances inhibition by over 10(3)-fold. The distinct Zn2+ coordination geometry implies a strong dependence of affinity on substituents. This unique structural paradigm has enabled development of potent, highly selective, Zn2+-dependent inhibitors of several therapeutically important serine proteases, using a physiologically ubiquitous metal ion.	Arris Pharmaceut Corp, S San Francisco, CA 94080 USA; Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Katz, BA (corresponding author), Arris Pharmaceut Corp, 385 Oyster Point Blvd,Suite 3, S San Francisco, CA 94080 USA.		Stroud, Rhonda M./C-5503-2008; Stroud, Rhonda/GQZ-0151-2022	Stroud, Rhonda M./0000-0001-5242-8015; Stroud, Rhonda/0000-0001-5242-8015				BernersPrice SJ, 1996, COORDIN CHEM REV, V151, P1; Brinen LS, 1996, BIOCHEMISTRY-US, V35, P5999, DOI 10.1021/bi9530200; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, XPLOR MANUAL VERSION; CAUGHEY GH, 1993, J PHARMACOL EXP THER, V264, P676; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; GROVES JT, 1985, INORG CHEM, V24, P2715, DOI 10.1021/ic00212a001; HAMBRIDGE KM, 1996, TRACE ELEMENTS HUMAN, V2; IPPOLITO JA, 1990, J MOL BIOL, V215, P457, DOI 10.1016/S0022-2836(05)80364-X; JENNETTE JC, 1987, AM J PATHOL, V127, P499; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KATZ BA, 1995, BIOCHEMISTRY-US, V34, P8264, DOI 10.1021/bi00026a008; Katz BA, 1997, J BIOL CHEM, V272, P13220, DOI 10.1074/jbc.272.20.13220; KIMURA E, 1990, J AM CHEM SOC, V112, P5805, DOI 10.1021/ja00171a020; KRIEGER M, 1974, J MOL BIOL, V83, P209, DOI 10.1016/0022-2836(74)90388-X; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LENTER C, 1984, GEIGY SCI TABLES, V3; Lippard S. J., 1994, BIOINORG CHEM, P505; Lipscomb WN, 1996, CHEM REV, V96, P2375, DOI 10.1021/cr950042j; Matthews DJ, 1994, CHEM BIOL, V1, P25, DOI 10.1016/1074-5521(94)90037-X; McGrath ME, 1997, FEBS LETT, V413, P486, DOI 10.1016/S0014-5793(97)00962-9; PERONA JJ, 1995, PROTEIN SCI, V4, P337; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; STROUD RM, 1974, SCI AM, V231, P74, DOI 10.1038/scientificamerican0774-74; TANAKA RD, 1995, INT ARCH ALLERGY IMM, V107, P408, DOI 10.1159/000237056; TIDWELL RR, 1983, J MED CHEM, V26, P294, DOI 10.1021/jm00356a036; TIDWELL RR, 1978, J MED CHEM, V21, P613, DOI 10.1021/jm00205a005; TIDWELL RR, 1984, ANTIMICROB AGENTS CH, V26, P591, DOI 10.1128/AAC.26.4.591; Tong L, 1996, NATURE, V383, P272, DOI 10.1038/383272a0; VEDANI A, 1990, J AM CHEM SOC, V112, P4759, DOI 10.1021/ja00168a021	30	155	167	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 5	1998	391	6667					608	612		10.1038/35422	http://dx.doi.org/10.1038/35422			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468142				2022-12-28	WOS:000071842300058
J	Holmberg, SD; Moorman, AC; Von Bargen, J; Palella, FJ; Loveless, MO; Ward, DJ; Navin, TR				Holmberg, SD; Moorman, AC; Von Bargen, J; Palella, FJ; Loveless, MO; Ward, DJ; Navin, TR		HOPS Investigators	Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTESTINAL CRYPTOSPORIDIOSIS; AIDS; PROPHYLAXIS	Context.-Cryptosporidium parvum infection, a common cause of diarrhea in persons infected with the human immunodeficiency virus (HIV), is difficult to treat or prevent. Objective.-To evaluate relative rates of cryptosporidiosis in HIV-infected patients who were either receiving or not receiving chemoprophylaxis or treatment for Mycobacterium avium complex. Design.-Analysis of prospectively collected data from HIV-infected patients' visits to their physicians since 1992. Setting.-Ten (8 private, 2 publicly funded) HIV clinics in 9 US cities. Patients.-A total of 1019 HIV-infected patients with CD4(+) cell counts less than 0.075 x 10(9)/L. Main Outcome Measures.-Incidence of clinical cryptosporidiosis during treatment with clarithromycin, rifabutin, and azithromycin. Results.-Five of the 312 patients reportedly taking clarithromycin developed cryptosporidiosis vs 30 of the 707 patients not taking clarithromycin (relative hazard [RH], 0.25 [95% confidence interval (CI), 0.10-0.67]; P=.004). Two of the 214 patients taking rifabutin developed cryptosporidiosis vs 33 of the 805 not taking rifabutin (RH, 0.15 [95% CI, 0.04-0.62]; P=.01). Prophylactic efficacy of either drug was 75% or greater. No protective effect was seen in the 54 patients reportedly taking azithromycin (RH, 1.48 [95% CI, 0.44-5.04]; P=.46). Conclusions.-Clarithromycin and rifabutin were highly protective against development of cryptosporidiosis in immune-suppressed HIV-infected persons in this analysis; further study is warranted.	Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Northwestern Univ, Sch Med, Chicago, IL USA; Oregon Hlth Sci Univ, Portland, OR 97201 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Northwestern University; Oregon Health & Science University	Holmberg, SD (corresponding author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Mailstop E-45,1600 Clifton Rd NE, Atlanta, GA 30333 USA.			Moorman, Anne/0000-0003-2411-2798				BLAGBURN BL, 1997, CRYPTOSPORIDIUM CRYP, P113; Blanshard C, 1997, INT J STD AIDS, V8, P124, DOI 10.1258/0956462971919543; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P669; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P661; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; DIBARI MA, 1996, 11 INT C AIDS JUL 7; FAYER R, 1993, J PARASITOL, V79, P553, DOI 10.2307/3283382; FLANIGAN T, 1992, ANN INTERN MED, V116, P840, DOI 10.7326/0003-4819-116-10-840; Flanigan T P, 1993, Prog Clin Parasitol, V3, P1; GIACOMETTI A, 1996, 36 INT C ANT AG CHEM; HOSMER DW, 1989, APPL LOGISTIC REGRES, P66; Jordan WC, 1996, J NATL MED ASSOC, V88, P425; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; MCGOWAN I, 1993, AIDS, V7, P349, DOI 10.1097/00002030-199303000-00007; PETERSEN C, 1992, CLIN INFECT DIS, V15, P903, DOI 10.1093/clind/15.6.903; PORTNOY D, 1984, ANN INTERN MED, V101, P202, DOI 10.7326/0003-4819-101-2-202; REHG JE, 1991, J PROTOZOOL S, V38, pS147; RITCHIE DJ, 1994, ANN PHARMACOTHER, V28, P767, DOI 10.1177/106002809402800615; WHITE AC, 1994, J INFECT DIS, V170, P419, DOI 10.1093/infdis/170.2.419	20	50	56	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					384	386		10.1001/jama.279.5.384	http://dx.doi.org/10.1001/jama.279.5.384			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459473	Bronze			2022-12-28	WOS:000071731300030
J	Prasad, N; Srikanthan, VS; Wright, A; Dunn, FG				Prasad, N; Srikanthan, VS; Wright, A; Dunn, FG			Management of suspected myocardial infarction before admission: updated audit	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Stobhill NHS Trust, Dept Cardiol, Glasgow G21 3UW, Lanark, Scotland		Dunn, FG (corresponding author), Stobhill NHS Trust, Dept Cardiol, Glasgow G21 3UW, Lanark, Scotland.							[Anonymous], 1988, LANCET, V2, P349; BURNS JMA, 1989, BRIT HEART J, V61, P322; JULIAN DG, 1989, BMJ-BRIT MED J, V299, P555; WYLLIE HR, 1994, BMJ-BRIT MED J, V308, P760, DOI 10.1136/bmj.308.6931.760a	4	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 31	1998	316	7128					353	353		10.1136/bmj.316.7128.353	http://dx.doi.org/10.1136/bmj.316.7128.353			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487171	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000071863900026
J	Torgerson, DJ; Sibbald, B				Torgerson, DJ; Sibbald, B			Understanding controlled trials - What is a patient preference trial?	BRITISH MEDICAL JOURNAL			English	Article									Univ York, Ctr Hlth Econ, Natl Primary Care Res & Dev Ctr, York YO1 5DD, N Yorkshire, England; Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England	University of York - UK; University of Manchester	Torgerson, DJ (corresponding author), Univ York, Ctr Hlth Econ, Natl Primary Care Res & Dev Ctr, York YO1 5DD, N Yorkshire, England.		Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275				BREWIN CR, 1989, BRIT MED J, V299, P313, DOI 10.1136/bmj.299.6694.313; Fairhurst K, 1996, J Health Serv Res Policy, V1, P77; HENSHAW RC, 1993, BRIT MED J, V307, P714, DOI 10.1136/bmj.307.6906.714; NICOLAIDES K, 1994, LANCET, V344, P435, DOI 10.1016/S0140-6736(94)91769-8; OLSCHEWSKI M, 1985, METHOD INFORM MED, V24, P131; Silverman WA, 1996, LANCET, V347, P171, DOI 10.1016/S0140-6736(96)90347-5; Torgerson D J, 1996, J Health Serv Res Policy, V1, P194; [No title captured]	8	179	179	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 31	1998	316	7128					360	360		10.1136/bmj.316.7128.360	http://dx.doi.org/10.1136/bmj.316.7128.360			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487173	Green Published			2022-12-28	WOS:000071863900028
J	Alcolado, J				Alcolado, J			Genetics of diabetic complications	LANCET			English	Editorial Material							NEPHROPATHY; MELLITUS; SUSCEPTIBILITY; LOCUS		Univ Wales Hosp, Dept Med, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	Alcolado, J (corresponding author), Univ Wales Hosp, Dept Med, Cardiff CF4 4XN, S Glam, Wales.		Alcolado, John/B-4999-2009	Alcolado, John/0000-0003-0666-0352				ALCOLADO JC, 1993, HUM HERED, V43, P126, DOI 10.1159/000154129; ALCOLADO JC, 1995, DIABETIC MED, V12, P102, DOI 10.1111/j.1464-5491.1995.tb00438.x; Baynes KCR, 1997, QJM-MON J ASSOC PHYS, V90, P557, DOI 10.1093/qjmed/90.9.557; BORCHJOHNSEN K, 1992, KIDNEY INT, V41, P719, DOI 10.1038/ki.1992.112; Diabet Control Complications Trial Res Grp, 1997, DIABETES, V46, P1829; Hanis CL, 1996, NAT GENET, V13, P161, DOI 10.1038/ng0696-161; Heesom AE, 1997, DIABETES, V46, P287, DOI 10.2337/diabetes.46.2.287; Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384; NEEL JV, 1965, GENETICS EPIDEMIOLOG, P105; Quinn M, 1996, DIABETOLOGIA, V39, P940; SEAQUIST ER, 1989, NEW ENGL J MED, V320, P1161, DOI 10.1056/NEJM198905043201801; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Todd JA, 1996, HUM MOL GENET, V5, P1443, DOI 10.1093/hmg/5.Supplement_1.1443; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	15	18	19	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 24	1998	351	9098					230	231		10.1016/S0140-6736(05)78278-7	http://dx.doi.org/10.1016/S0140-6736(05)78278-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU294	9457089				2022-12-28	WOS:000071702200005
J	Hacohen, N; Kramer, S; Sutherland, D; Hiromi, Y; Krasnow, MA				Hacohen, N; Kramer, S; Sutherland, D; Hiromi, Y; Krasnow, MA			sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways	CELL			English	Article							MIDLINE GLIAL-CELLS; TRACHEAL SYSTEM; RECEPTOR HOMOLOG; GENE; TRANSCRIPTION; MIGRATION; PATHWAY; PROTEIN; DIFFERENTIATION; EXPRESSION	Antagonists of several growth factor signaling pathways play important roles in developmental patterning by limiting the range of the cognate inducer. Here, we describe an antagonist of FGF signaling that patterns apical branching of the Drosophila airways. In wild-type embryos, the Branchless FGF induces secondary branching by activating the Breathless FGF receptor near the tips of growing primary branches. In sprouty mutants, the FGF pathway is overactive and ectopic branches are induced on the stalks of primary branches. We show that FGF signaling induces sprouty expression in the nearby tip cells, and sprouty acts nonautonomously and in a competitive fashion to block signaling to the more distant stalk cells. sprouty encodes a novel cysteine-rich protein that defines a new family of putative signaling molecules that may similarly function as FGF antagonists in vertebrate development.	Stanford Univ, Howard Hughes Med Inst, Dept Biochem, Sch Med, Stanford, CA 94305 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Howard Hughes Medical Institute; Stanford University; Princeton University	Krasnow, MA (corresponding author), Stanford Univ, Howard Hughes Med Inst, Dept Biochem, Sch Med, Stanford, CA 94305 USA.							AFFOLTER M, 1994, DEVELOPMENT, V120, P743; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Beiman M, 1996, GENE DEV, V10, P2993, DOI 10.1101/gad.10.23.2993; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BRAND AH, 1993, DEVELOPMENT, V118, P401; Gabay L, 1996, DEVELOPMENT, V122, P3355; GLAZER L, 1991, GENE DEV, V5, P697, DOI 10.1101/gad.5.4.697; Golembo M, 1996, DEVELOPMENT, V122, P223; Guillemin K, 1996, DEVELOPMENT, V122, P1353; HACOHEN N, 1997, THESIS STANFORD U ST; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; KLAES A, 1994, CELL, V78, P149, DOI 10.1016/0092-8674(94)90581-9; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KRAMER S, 1995, DEVELOPMENT, V121, P1361; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; Lee T, 1996, GENE DEV, V10, P2912, DOI 10.1101/gad.10.22.2912; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; Manning Gerards, 1993, P609; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PERRIMON N, 1991, DEV GENET, V12, P238, DOI 10.1002/dvg.1020120309; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; SCHOLZ H, 1993, GENETICS, V135, P455; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WOHLWILL AD, 1991, GENETICS, V128, P763; WOLPERT L, 1983, CIBA F SYMP, V100, P1; XU T, 1993, DEVELOPMENT, V117, P1223; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	35	629	659	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					253	263		10.1016/S0092-8674(00)80919-8	http://dx.doi.org/10.1016/S0092-8674(00)80919-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458049	Bronze			2022-12-28	WOS:000071672600014
J	Zallen, JA; Yi, BA; Bargmann, CI				Zallen, JA; Yi, BA; Bargmann, CI			The conserved immunoglobulin superfamily member SAX-3/Robo directs multiple aspects of axon guidance in C-elegans	CELL			English	Article							GROWTH CONE GUIDANCE; CAENORHABDITIS-ELEGANS; COLORECTAL-CANCER; COMMISSURAL AXONS; NERVOUS-SYSTEM; NETRIN CUES; CNS MIDLINE; GUIDES CELL; DROSOPHILA; RECEPTOR	The C. elegans sax-3 gene encodes a predicted transmembrane protein with five immunoglobulin domains and three fibronectin type III repeats that is closely related to Drosophila Robe. Mutations in sax-3 lead to repeated midline crossing by ventral cord axons that normally do not cross the midline after they join the ventral cord, a phenotype similar to that of robe mutants. sax-3 is also required for guidance of some axons to the ventral cord, implicating this gene in two different types of guidance events. A sax-3:GFP fusion gene is expressed in developing neurons during axon outgrowth, and sax-3 function is required at the time of axon guidance, suggesting that this gene mediates cell interactions during guidance decisions.	Univ Calif San Francisco, Howard Hughes Med Inst, Program Dev Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Genet Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bargmann, CI (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Program Dev Biol, San Francisco, CA 94143 USA.			Bargmann, Cornelia/0000-0002-8484-0618				BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; Baum PD, 1997, NEURON, V19, P51, DOI 10.1016/S0896-6273(00)80347-5; BRENNER S, 1974, GENETICS, V77, P71; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; Drescher U, 1997, CURR OPIN NEUROBIOL, V7, P75, DOI 10.1016/S0959-4388(97)80123-7; Friedman GC, 1996, CURR OPIN NEUROBIOL, V6, P127, DOI 10.1016/S0959-4388(96)80018-3; GARRIGA G, 1993, DEVELOPMENT, V117, P1071; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; Kang JS, 1997, J CELL BIOL, V138, P203, DOI 10.1083/jcb.138.1.203; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LUSCINSKAS FW, 1994, J CELL BIOL, V125, P1417, DOI 10.1083/jcb.125.6.1417; MARICQ AV, 1995, NATURE, V378, P78, DOI 10.1038/378078a0; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; MYERS PZ, 1993, J NEUROSCI, V13, P127; Sambrook J., 2002, MOL CLONING LAB MANU; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; STOECKLI ET, 1995, NEURON, V14, P1165, DOI 10.1016/0896-6273(95)90264-3; Stoeckli ET, 1997, NEURON, V18, P209, DOI 10.1016/S0896-6273(00)80262-7; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Tear G, 1996, NEURON, V16, P501, DOI 10.1016/S0896-6273(00)80070-7; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITE JG, 1976, PHILOS T R SOC B, V275, P327, DOI 10.1098/rstb.1976.0086; Wightman B, 1997, DEVELOPMENT, V124, P2571; Wightman B, 1996, DEVELOPMENT, V122, P671; [No title captured]	45	239	244	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					217	227		10.1016/S0092-8674(00)80916-2	http://dx.doi.org/10.1016/S0092-8674(00)80916-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458046	Bronze			2022-12-28	WOS:000071672600011
J	Cheasty, M; Clare, AW; Collins, C				Cheasty, M; Clare, AW; Collins, C			Relation between sexual abuse in childhood and adult depression: case-control study	BRITISH MEDICAL JOURNAL			English	Article							AFFECTIVE-DISORDERS; MENTAL-HEALTH; LIFE; SCHIZOPHRENIA; EXPERIENCES; SCHEDULE	Objective: To examine the association between sexual abuse in childhood and adult depression in women. Design: Two stage, case detection and case identification design, using the 30-item general health questionnaire and the Beck depression inventory for screening and the affective items relating to current functioning on the schizophrenia and affective disorders schedule to identify depressed cases. Details of sexual abuse in childhood were elicited retrospectively by semistructured interview, and social problems by the social problems questionnaire. Setting: Three general practices, in middle class suburban, deprived inner city, and rural areas. Subjects: 1189 women were screened and 237 subsequently interviewed; 132 were depressed. Results: 49 (37%) of the depressed interviewees and 24 (23%) of the non-depressed interviewees reported experience of sexual abuse when they were aged under 16 years. A positive association existed between the more severe abuse and depression-all those who had experienced penetration were depressed as adults. A relation was also found between sexual abuse in childhood and sexual problems, housing problems, and problems with their children at school. Conclusion: A positive association between child sexual abuse and depression was confirmed, but this was confined to more severe abuse (penetration or attempted penetration).	St Patricks Hosp, Dublin 8, Ireland	Trinity College Dublin	Cheasty, M (corresponding author), St Patricks Hosp, Jamess St, Dublin 8, Ireland.							ARNOLD RP, 1990, BRIT MED J, V300, P705, DOI 10.1136/bmj.300.6726.705; BAGLEY C, 1988, SOCIAL WORK HUMAN SE, V4, P23; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BIFULCO A, 1991, BRIT J PSYCHIAT, V159, P115, DOI 10.1192/bjp.159.1.115; CORNEY RH, 1985, PSYCHOL MED, V15, P637, DOI 10.1017/S0033291700031494; ENDICOTT J, 1979, AM J PSYCHIAT, V136, P52; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; Finkelhor D., 1984, CHILD SEXUAL ABUSE N; GELINAS DJ, 1983, PSYCHIATRY, V46, P312, DOI 10.1080/00332747.1983.11024207; Goldberg D, 1987, MANUAL GEN HLTH QUES; Goodwin J., 1981, CHILD ABUSE NEGLECT, V5, P87, DOI [10.1016/0145-2134(81)90025-9, DOI 10.1016/0145-2134(81)90025-9]; HERMAN JL, 1986, AM J ORTHOPSYCHIAT, V56, P137, DOI 10.1111/j.1939-0025.1986.tb01550.x; HRMAN J, 1981, FATHER DAUGHTER INVE; JACOBSON A, 1987, AM J PSYCHIAT, V144, P908; MEISSELMAN KC, 1978, INCEST PSYCHOL STUDY; MRAZEK D, 1987, CHILD MALTREATMENT C; MULLEN PE, 1988, LANCET, V1, P841; MULLEN PE, 1993, BRIT J PSYCHIAT, V163, P721, DOI 10.1192/bjp.163.6.721; MULLEN PE, 1994, BRIT J PSYCHIAT, V165, P35, DOI 10.1192/bjp.165.1.35; OATES RK, 1987, AUST PAEDIATR J, V23, P267; PALMER RL, 1992, BRIT J PSYCHIAT, V160, P261, DOI 10.1192/bjp.160.2.261; PETERS SD, 1984, THESIS U CALIFORNIA; Russell D E, 1983, Child Abuse Negl, V7, P133, DOI 10.1016/0145-2134(83)90065-0; [No title captured]	24	59	61	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					198	201						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YT531	9468687				2022-12-28	WOS:000071616400029
J	Cairns, J; Shackley, P				Cairns, J; Shackley, P			The dog in the manger?	LANCET			English	Article											Cairns, J (corresponding author), DEPT PUBL HLTH,HLTH ECON RES UNIT,UNIV MED BLDG,FORESTERHILL,ABERDEEN AB9 2ZD,SCOTLAND.		Cairns, John/AAD-1168-2020	Shackley, Philip/0000-0002-1862-0596				DONALDSON C, 1995, HEALTH POLICY, V33, P77, DOI 10.1016/0168-8510(95)90043-8; JONES A, 1995, HEALTH ECON, V4, P155, DOI 10.1002/hec.4730040301; PHELPS CE, 1995, HEALTH ECON, V4, P335, DOI 10.1002/hec.4730040501; WILLIAMS A, 136 U YORK CTR HLTH; 1995, J HLTH EC, V14, P1	5	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S10	S10		10.1016/0140-6736(95)90009-8	http://dx.doi.org/10.1016/0140-6736(95)90009-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TN122	9454027				2022-12-28	WOS:A1995TN12200010
J	Schrenk, MO; Edwards, KJ; Goodman, RM; Hamers, RJ; Banfield, JF				Schrenk, MO; Edwards, KJ; Goodman, RM; Hamers, RJ; Banfield, JF			Distribution of Thiobacillus ferrooxidans and Leptospirillum ferrooxidans: Implications for generation of acid mine drainage	SCIENCE			English	Article							IN-SITU; IDENTIFICATION; BACTERIA	Although Thiobacillus ferrooxidans and Leptospirillum ferrooxidans are widely considered to be the microorganisms that control the rate of generation of acid mine drainage, little is known about their natural distribution and abundance. Fluorescence in situ hybridization studies showed that at Iron Mountain, California, T. ferrooxidans occurs in peripheral slime-based communities (at pH over 1.3 and temperature under 30 degrees C) but not in important subsurface acid-forming environments (pH 0.3 to 0.7, temperature 30 degrees to 50 degrees C). Leptospirillum ferrooxidans is abundant in slimes and as a planktonic organism in environments with lower pH. Thiobacillus ferrooxidans affects the precipitation of ferric iron solids but plays a limited role in acid generation, and neither species controls direct catalysis at low pH at this site.	Univ Wisconsin, Dept Geol & Geophys, Madison, WI 53706 USA; Univ Wisconsin, Dept Plant Pathol, Madison, WI 53706 USA; Univ Wisconsin, Dept Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Edwards, KJ (corresponding author), Univ Wisconsin, Dept Geol & Geophys, 1215 W Dayton St, Madison, WI 53706 USA.	katrina@geology.wisc.edu	Hamers, Robert J/C-6466-2008; Matthew, Schrenk/AAH-5682-2020	Hamers, Robert J/0000-0003-3821-9625; Schrenk, Matthew/0000-0002-5623-8558; Banfield, Jill/0000-0001-8203-8771				Alm EW, 1996, APPL ENVIRON MICROB, V62, P3557, DOI 10.1128/AEM.62.10.3557-3559.1996; AMANN RI, 1995, MICROBIOL REV, V59, P143, DOI 10.1128/MMBR.59.1.143-169.1995; BARNS SM, 1994, P NATL ACAD SCI USA, V91, P1609, DOI 10.1073/pnas.91.5.1609; Benson DA, 1996, NUCLEIC ACIDS RES, V24, P1, DOI 10.1093/nar/24.1.1; COLMER AR, 1947, SCIENCE, V106, P253, DOI 10.1126/science.106.2751.253; EDWARDS KA, UNPUB; EDWARDS KJ, 1996, GEOLOGICAL SOC AM AB, V28, P35; EHRLICH HL, 1996, GEOMICROBIOLOGY, P330; HELLE U, 1988, APPL MICROBIOL BIOT, V28, P553, DOI 10.1007/BF00250411; IRELAND J, 1997, THESIS U WISCONSIN M; LEITCH AR, 1994, ROYAL MICROSCOPY SOC, V27; Li SX, 1997, APPL ENVIRON MICROB, V63, P3261, DOI 10.1128/AEM.63.8.3261-3267.1997; Luther G. W., 1990, AQUATIC CHEM KINETIC, P173; Maidak BL, 1997, NUCLEIC ACIDS RES, V25, P109, DOI 10.1093/nar/25.1.109; MOSES CO, 1987, GEOCHIM COSMOCHIM AC, V51, P1561, DOI 10.1016/0016-7037(87)90337-1; Nordstrom DK, 1997, REV MINERAL, V35, P361; NORDSTROM DK, 1987, AM J SCI, V287, P171; Norris P.R., 1990, MICROBIAL MINERAL RE, P3; PACE NR, 1986, ADV MICROB ECOL, V9, P1; Pace NR, 1986, ADV MICROB ECOL, P1; RODGERS TM, 1997, LPI CONTRIBUTION, V921, P234; SAND W, 1992, APPL ENVIRON MICROB, V58, P85, DOI 10.1128/AEM.58.1.85-92.1992; SILVERMAN M. P., 1964, Advances in Applied Microbiology, V6, P153, DOI 10.1016/S0065-2164(08)70626-9; SINGER PC, 1970, SCIENCE, V167, P1121, DOI 10.1126/science.167.3921.1121; Vasquez M, 1997, APPL ENVIRON MICROB, V63, P332, DOI 10.1128/AEM.63.1.332-334.1997; WARD DM, 1992, ADV MICROB ECOL, V12, P219; Weiss P, 1996, APPL ENVIRON MICROB, V62, P1998, DOI 10.1128/AEM.62.6.1998-2005.1996; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	28	249	278	2	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 6	1998	279	5356					1519	1522		10.1126/science.279.5356.1519	http://dx.doi.org/10.1126/science.279.5356.1519			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488647				2022-12-28	WOS:000072372900060
J	Thorndike, AN; Rigotti, NA; Stafford, RS; Singer, DE				Thorndike, AN; Rigotti, NA; Stafford, RS; Singer, DE			National patterns in the treatment of smokers by physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH PROMOTION; PRIMARY-CARE; TRANSDERMAL NICOTINE; SMOKING CESSATION; PATCH USERS; PRACTITIONERS; INTERNISTS; ADVICE; PROJECT; QUIT	Context.-Routine treatment of smokers by physicians is a national health objective for the year 2000, a quality measure for health care plans, and the subject of evidence-based clinical guidelines. There are few national data on how physicians' practices compare with these standards. Objective.-To assess recent trends in the treatment of smokers by US physicians in ambulatory care and to determine whether physicians' practices meet current standards. Design.-Analysis of 1991-1995 data from the National Ambulatory Medical Care Survey, an annual survey of a random sample of US office-based physicians. Setting.-Physicians' offices. Patients.-A total of 3254 physicians recorded data on 145716 adult patient visits. Main Outcome Measures.-The proportion of visits at which physicians (1) identified a patient's smoking status, (2) counseled a smoker to quit, and (3) used nicotine replacement therapy. Results.-Smoking counseling by physicians increased from 16% of smokers' visits in 1991 to 29% in 1993 (P<.001) and then decreased to 21% of smokers' visits in 1995 (P<.001). Nicotine replacement therapy use followed a similar pattern, increasing from 0.4% of smokers' visits in 1991 to 2.2% in 1993 (P<.001) and decreasing to 1.3% of smokers' visits in 1995 (P=.007). Physicians identified patients' smoking status at 67% of all visits in 1991; this proportion did not increase overtime. Primary care physicians were more likely to provide treatment to smokers than were specialists. All physicians were more likely to treat patients with smoking-related diagnoses. Conclusions.-US physicians' treatment of smokers improved little in the first half of the 1990s, although a transient peak in counseling and nicotine replacement use occurred in 1993 after the introduction of the nicotine patch. Physicians' practices fell far short of national health objectives and practice guidelines. In particular, patient visits for diagnoses not related to smoking represent important missed opportunities for intervention.	Massachusetts Gen Hosp, Div Gen Med, Med Serv, Gen Med Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Tobacco Res & Treatment Ctr, Boston, MA USA; Hlth Policy Res & Dev Unit, Boston, MA USA; Clin Epidemiol Unit, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Thorndike, AN (corresponding author), Massachusetts Gen Hosp, Div Gen Med, Med Serv, Gen Med Unit, S50-9, Boston, MA 02114 USA.	Thorndike.Anne@mgh.harvard.edu	Thorndike, Anne/R-6291-2019; Stafford, Randall/F-3974-2017	Thorndike, Anne/0000-0003-1096-9221; Stafford, Randall/0000-0003-1805-1271	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007892] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K07CA001673] Funding Source: NIH RePORTER; AHRQ HHS [HS07892] Funding Source: Medline; NCI NIH HHS [CA01673] Funding Source: Medline; NHLBI NIH HHS [HL03548] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM MED ASS, 1994, AM MED ASS GUID DIAG; ANDA RF, 1987, JAMA-J AM MED ASSOC, V257, P1916; [Anonymous], 1990, SAS STAT US GUID VER; BRYANT E, 1988, VITAL HLTH STAT, V2; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P854; Centers for Disease Control and Prevention (CDC), 1996, MMWR-MORBID MORTAL W, V45, P588; COHEN SJ, 1987, AM J PUBLIC HEALTH, V77, P313, DOI 10.2105/AJPH.77.3.313; CUMMINGS SR, 1989, ARCH INTERN MED, V149, P345, DOI 10.1001/archinte.149.2.345; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; FIORE MC, 1995, MAYO CLIN PROC, V70, P209, DOI 10.4065/70.3.209; FIORE MC, 1996, SMOKING CESSATION CL; FORTMANN SP, 1985, PREV MED, V14, P70, DOI 10.1016/0091-7435(85)90022-2; FRANK E, 1991, JAMA-J AM MED ASSOC, V266, P3139, DOI 10.1001/jama.266.22.3139; GILPIN EA, 1993, J GEN INTERN MED, V8, P549, DOI 10.1007/BF02599637; Glynn TJ, 1990, NIH PUBLICATION, P1990; Goldstein MG, 1997, ARCH INTERN MED, V157, P1313, DOI 10.1001/archinte.157.12.1313; HAXBY D, 1994, J FAM PRACTICE, V38, P459; LEWIS CE, 1991, ANN INTERN MED, V114, P54, DOI 10.7326/0003-4819-114-1-54; McBride PE, 1997, ARCH FAM MED, V6, P165, DOI 10.1001/archfami.6.2.165; *NAT COMM QUAL ASS, 1997, HEDIS 3 0, V2; National Center for Health Statistics, 1991, PUBL US DAT TAP DOC; ORLEANS CT, 1994, JAMA-J AM MED ASSOC, V271, P601, DOI 10.1001/jama.271.8.601; ORLEANS CT, 1985, PREV MED, V14, P636, DOI 10.1016/0091-7435(85)90083-0; ROSEN MA, 1984, PREV MED, V13, P535, DOI 10.1016/0091-7435(84)90022-7; RUSSELL MAH, 1979, BRIT MED J, V2, P231, DOI 10.1136/bmj.2.6184.231; SCHNEEWEISS R, 1986, J FAM PRACTICE, V22, P69; Swartz SH, 1995, J GEN INTERN MED, V10, P656, DOI 10.1007/BF02602757; TANOUYE E, 1996, WALL STREET J   0422, pB8; *US DEP HHS, 1991, PUBL US DEP HLTH HUM; *US DEP HHS, 1989, PUBL US DEP HLTH HUM; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; VALENTE C M, 1986, American Journal of Preventive Medicine, V2, P82; Wechsler H, 1996, NEW ENGL J MED, V334, P996, DOI 10.1056/NEJM199604113341519; WELLS KB, 1986, AM J PUBLIC HEALTH, V76, P1009, DOI 10.2105/AJPH.76.8.1009; World Health Organization, 1977, INT CLASSIFICATION D	35	318	319	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	1998	279	8					604	608		10.1001/jama.279.8.604	http://dx.doi.org/10.1001/jama.279.8.604			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX457	9486755	Bronze			2022-12-28	WOS:000072041900036
J	Gard, EE; Kleeman, MJ; Gross, DS; Hughes, LS; Allen, JO; Morrical, BD; Fergenson, DP; Dienes, T; Galli, ME; Johnson, RJ; Cass, GR; Prather, KA				Gard, EE; Kleeman, MJ; Gross, DS; Hughes, LS; Allen, JO; Morrical, BD; Fergenson, DP; Dienes, T; Galli, ME; Johnson, RJ; Cass, GR; Prather, KA			Direct observation of heterogeneous chemistry in the atmosphere	SCIENCE			English	Article							SEA-SALT; ANTHROPOGENIC AEROSOLS; NITRIC-ACID; NITROGEN; PARTICLES; OXIDES; NACL; TROPOSPHERE; MECHANISM; CHLORIDE	The heterogeneous replacement of chloride by nitrate in individual sea-salt particles was monitored continuously over time in the troposphere with the use of aerosol time-of-flight mass spectrometry. Modeling calculations show that the observed chloride displacement process is consistent with a heterogeneous chemical reaction between sea-salt particles and gas-phase nitric acid, leading to sodium nitrate production in the particle phase accompanied by liberation of gaseous HCl from the particles. Such single-particle measurements, combined with a single-particle model, make it possible to monitor and explain heterogeneous gas/particle chemistry as it occurs in the atmosphere.	CALTECH, Dept Environm Engn Sci, Pasadena, CA 91125 USA; Univ Calif Riverside, Dept Chem, Riverside, CA 92521 USA	California Institute of Technology; University of California System; University of California Riverside	Cass, GR (corresponding author), CALTECH, Dept Environm Engn Sci, Pasadena, CA 91125 USA.		Prather, Kim/A-3892-2008	Prather, Kim/0000-0003-3048-9890; Allen, Jonathan/0000-0002-5310-5266				BEHNKE W, 1993, J AEROSOL SCI, V24, pS115; Beichert P, 1996, J PHYS CHEM-US, V100, P15218, DOI 10.1021/jp960925u; BRUYNSEELS F, 1985, ATMOS ENVIRON, V19, P1969, DOI 10.1016/0004-6981(85)90023-X; Calvert J, 1984, SO2 NO NO2 OXIDATION, P1; CALVERT JG, 1978, ATMOS ENVIRON, V12, P197, DOI 10.1016/0004-6981(78)90201-9; Carson PG, 1997, AEROSOL SCI TECH, V26, P291, DOI 10.1080/02786829708965431; CHARLSON RJ, 1992, SCIENCE, V255, P423, DOI 10.1126/science.255.5043.423; Eldering A, 1996, J GEOPHYS RES-ATMOS, V101, P19343, DOI 10.1029/95JD02928; FENTER FF, 1994, J PHYS CHEM-US, V98, P9801, DOI 10.1021/j100090a014; Finlayson-Pitts B.J., 1986, ATMOSPHERIC CHEM FUN; FINLAYSONPITTS BJ, 1989, NATURE, V337, P241, DOI 10.1038/337241a0; Gard E, 1997, ANAL CHEM, V69, P4083, DOI 10.1021/ac970540n; GOODIN WR, 1979, J APPL METEOROL, V18, P761, DOI 10.1175/1520-0450(1979)018<0761:ACOIMF>2.0.CO;2; GROSJEAN D, 1977, OZONE OTHER PHOTOCHE, P45; Gross D., UNPUB; Hinz KP, 1996, AEROSOL SCI TECH, V24, P233, DOI 10.1080/02786829608965368; HUGHES L, UNPUB; KARLSSON R, 1995, J AEROSOL SCI, V26, P39, DOI 10.1016/0021-8502(94)00098-J; Kleeman MJ, 1997, J GEOPHYS RES-ATMOS, V102, P21355, DOI 10.1029/97JD01261; Langer S, 1997, J PHYS CHEM A, V101, P1277, DOI 10.1021/jp962122c; LAUX JM, 1994, GEOPHYS RES LETT, V21, P1623, DOI 10.1029/94GL01196; LEU MT, 1995, J PHYS CHEM-US, V99, P13203, DOI 10.1021/j100035a026; MAMANE Y, 1990, J AEROSOL SCI, V21, pS225, DOI 10.1016/0021-8502(90)90225-M; Murphy DM, 1997, J GEOPHYS RES-ATMOS, V102, P6341, DOI 10.1029/96JD00858; National Research Council, 1993, PROT VIS NAT PARKS W; Odum JR, 1997, SCIENCE, V276, P96, DOI 10.1126/science.276.5309.96; PANDIS SN, 1992, ATMOS ENVIRON A-GEN, V26, P2269, DOI 10.1016/0960-1686(92)90358-R; PENNER JE, 1994, B AM METEOROL SOC, V75, P375, DOI 10.1175/1520-0477(1994)075<0375:QAMUOC>2.0.CO;2; PSZENNY AAP, 1993, GEOPHYS RES LETT, V20, P699, DOI 10.1029/93GL00047; Reilly PTA, 1997, ANAL CHEM, V69, P36, DOI 10.1021/ac960564e; RVISHANKARA AR, 1997, SCIENCE, V276, P1058; Seinfeld JH, 1986, ENV POL SUS DEV, V40, P26; *US EPA, 1996, EPA600P95AFCF US EPA; Vogt R, 1996, ATMOS ENVIRON, V30, P1729, DOI 10.1016/1352-2310(95)00392-4; Vogt R, 1996, NATURE, V383, P327, DOI 10.1038/383327a0; VOGT R, 1994, GEOPHYS RES LETT, V21, P2291, DOI 10.1029/94GL02238; Weiss M, 1997, J AEROSOL SCI, V28, P159, DOI 10.1016/S0021-8502(96)00067-5	37	303	317	2	111	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1184	1187		10.1126/science.279.5354.1184	http://dx.doi.org/10.1126/science.279.5354.1184			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469803				2022-12-28	WOS:000072115200035
J	Braun, E; Eichen, Y; Sivan, U; Ben-Yoseph, G				Braun, E; Eichen, Y; Sivan, U; Ben-Yoseph, G			DNA-templated assembly and electrode attachment of a conducting silver wire	NATURE			English	Article							TRANSPORT; MOLECULES; GOLD	Recent research in the field of nanometre-scale electronics has focused on two fundamental issues: the operating principles of small-scale devices, and schemes that lead to their realization and eventual integration into useful circuits, Experimental studies on molecular(1) to submicrometre(2) quantum dots and on the electrical transport in carbon nanotubes(3-5) have confirmed theoretical predictions(6-8) of an increasing role for charging effects as the device size diminishes. Nevertheless, the construction of nanometre-scale circuits from such devices remains problematic, largely owing to the difficulties of achieving inter-element wiring and electrical interfacing to macroscopic electrodes. The use of molecular recognition processes and the self-assembly of molecules into supramolecular structures(9,10) might help overcome these difficulties. In this context, DNA has the appropriate molecular-recognition(11) and mechanical(12-16) properties, but poor electrical characteristics prevent its direct use in electrical circuits. Here we describe a two-step procedure that may allow the application of DNA tc, the construction of functional circuits, In our scheme, hybridization of the DNA molecule with surface-bound oligonucleotides is first used to stretch it between two gold electrodes; the DNA molecule is then used as a template for the vectorial growth of a 12 mu m long, 100 nm wide conductive silver wire. The experiment confirms that the recognition capabilities of DNA can be exploited for the targeted attachment of functional wires.	Technion Israel Inst Technol, Dept Phys, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Dept Chem, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Inst Solid State, IL-32000 Haifa, Israel	Technion Israel Institute of Technology; Technion Israel Institute of Technology; Technion Israel Institute of Technology	Braun, E (corresponding author), Technion Israel Inst Technol, Dept Phys, IL-32000 Haifa, Israel.	erez@physics.technion.ac.il						Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; Arkin MR, 1996, SCIENCE, V273, P475, DOI 10.1126/science.273.5274.475; Atwood J.L., 1996, COMPREHENSIVE SUPRAM, DOI DOI 10.1021/jacs.6b12949; Austin RH, 1997, PHYS TODAY, V50, P32, DOI 10.1063/1.881674; Averin D., 1991, MESOSCOPIC PHENOMENA, P173, DOI DOI 10.1016/B978-0-444-88454-1.50012-7; BARTON JK, 1994, BIOINORGANIC CHEM, pCH8; BENSIMON A, 1994, SCIENCE, V265, P2096, DOI 10.1126/science.7522347; BENSIMON D, 1995, PHYS REV LETT, V74, P4754, DOI 10.1103/PhysRevLett.74.4754; BIRRELL GB, 1986, J HISTOCHEM CYTOCHEM, V34, P339, DOI 10.1177/34.3.3950384; Bockrath M, 1997, SCIENCE, V275, P1922, DOI 10.1126/science.275.5308.1922; BURROUGHES JH, 1990, NATURE, V347, P539, DOI 10.1038/347539a0; Coffer JL, 1996, APPL PHYS LETT, V69, P3851, DOI 10.1063/1.117126; Eichhorn GL, 1973, INORGANIC BIOCH, V2; GRABERT H, 1992, SINGLE CHARGE TUNNEL; Hall DB, 1996, NATURE, V382, P731, DOI 10.1038/382731a0; HOLGATE CS, 1983, J HISTOCHEM CYTOCHEM, V31, P938, DOI 10.1177/31.7.6189883; KASTNER MA, 1992, REV MOD PHYS, V64, P849, DOI 10.1103/RevModPhys.64.849; Langer L, 1996, PHYS REV LETT, V76, P479, DOI 10.1103/PhysRevLett.76.479; Lehn J.-M., 1995, SUPRAMOLECULAR CHEM; Lewis FD, 1997, SCIENCE, V277, P673, DOI 10.1126/science.277.5326.673; MARZILLI LG, 1977, J AM CHEM SOC, V99, P2797, DOI 10.1021/ja00450a066; Meirav U, 1996, SEMICOND SCI TECH, V11, P255, DOI 10.1088/0268-1242/11/3/003; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; PORATH D, 1997, J APPL PHYS, V81, P1; SCHWARTZ DC, 1989, NATURE, V338, P520, DOI 10.1038/338520a0; Spiro TG, 1980, NUCL ACID METAL ION; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; Watson J. D., 1987, MOL BIOL GENE; WIRTZ D, 1995, PHYS REV LETT, V75, P2436, DOI 10.1103/PhysRevLett.75.2436; ZIMMERMANN RM, 1994, NUCLEIC ACIDS RES, V22, P492, DOI 10.1093/nar/22.3.492	30	2137	2260	8	609	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 19	1998	391	6669					775	778		10.1038/35826	http://dx.doi.org/10.1038/35826			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486645				2022-12-28	WOS:000072089500047
J	Evans, WE; Relling, MV; Rodman, JH; Crom, WR; Boyett, JM; Pui, CH				Evans, WE; Relling, MV; Rodman, JH; Crom, WR; Boyett, JM; Pui, CH			Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE LYMPHOCYTIC-LEUKEMIA; HIGH-DOSE METHOTREXATE; CLINICAL PHARMACOKINETICS; SYSTEMIC EXPOSURE; ANTICANCER DRUGS; B-LINEAGE; IN-VIVO; PHARMACODYNAMICS; ACCUMULATION; TENIPOSIDE	Background The rate of clearance of antileukemic agents differs by a factor of 3 to 10 among children with acute lymphoblastic leukemia, We hypothesized that the outcome of treatment would be improved if doses were individualized to prevent low systemic exposure to the drugs in patients with fast drug clearance. Methods We stratified and randomly assigned 182 children with newly diagnosed acute lymphoblastic leukemia to postremission regimens that included high-dose methotrexate and teniposide plus cytarabine. The doses of these drugs were based on body-surface area (in the conventional-therapy group) or the rates of clearance of the three medications in each patient (in the individualized-treatment group). In the individualized-treatment group, doses were increased in patients with rapid clearance and decreased in patients with very slow clearance. Results Patients who received individualized doses had significantly fewer courses of treatment with systemic exposures below the target range than did patients who received conventional doses (P<0.001 for each medication). Among the patients with B-lineage leukemia, those who received individualized therapy had a significantly better outcome than those given conventional therapy (P=0.02); the mean (+/-SE) rates of continuous complete remission at five years were 76+/-6 percent and 66+/-7 percent, respectively. There was no significant difference between treatments for patients with T-lineage leukemia (P=0.54). In a proportional-hazards model, the time-dependent systemic exposure to methotrexate, but not to teniposide or cytarabine, was significantly related to the risk of early relapse in children with B-lineage leukemia. Conclusions; Adjusting the dose of methotrexate to account for the patient's ability to clear the drug can improve the outcome in children with B-lineage acute lymphoblastic leukemia. (C) 1998, Massachusetts Medical Society.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biostat & Epidemiol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Coll Pharm, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Coll Med, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Evans, WE (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.		Evans, William E./C-2069-2012; Relling, Mary/N-5032-2018; Pui, Ching-Hon/N-8076-2018	Evans, William E./0000-0002-9333-5322; Pui, Ching-Hon/0000-0003-0303-5658	NATIONAL CANCER INSTITUTE [P01CA020180, R01CA051001, R37CA036401, R29CA051001] Funding Source: NIH RePORTER; NCI NIH HHS [CA20180, R37 CA36401, CA51001] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARREDO JC, 1994, BLOOD, V84, P564; BEHM FG, 1992, BLOOD, V79, P1011; DEVITA VT, 1986, J CLIN ONCOL, V4, P1157, DOI 10.1200/JCO.1986.4.8.1157; EVANS WE, 1991, SEMIN HEMATOL, V28, P15; EVANS WE, 1989, CLIN PHARMACOKINET, V16, P327, DOI 10.2165/00003088-198916060-00001; EVANS WE, 1986, NEW ENGL J MED, V314, P471, DOI 10.1056/NEJM198602203140803; EVANS WE, 1992, J PHARMACOL EXP THER, V260, P71; Galpin AJ, 1997, MOL PHARMACOL, V52, P155, DOI 10.1124/mol.52.1.155; MAHONEY DH, 1995, CANCER, V75, P2623, DOI 10.1002/1097-0142(19950515)75:10<2623::AID-CNCR2820751033>3.0.CO;2-Y; Masson E, 1996, J CLIN INVEST, V97, P73, DOI 10.1172/JCI118409; NIEMEYER CM, 1991, BLOOD, V78, P2514, DOI 10.1182/blood.V78.10.2514.2514; PINKEL D, 1971, CANCER-AM CANCER SOC, V27, P247, DOI 10.1002/1097-0142(197102)27:2<247::AID-CNCR2820270202>3.0.CO;2-C; PLUNKETT W, 1987, CANCER RES, V47, P3005; PUI CH, 1995, NEW ENGL J MED, V332, P1618, DOI 10.1056/NEJM199506153322407; REITER A, 1994, BLOOD, V84, P3122, DOI 10.1182/blood.V84.9.3122.3122; RELLING MV, 1994, J CLIN ONCOL, V12, P1667, DOI 10.1200/JCO.1994.12.8.1667; RIVERA GK, 1991, LANCET, V337, P61, DOI 10.1016/0140-6736(91)90733-6; RODMAN JH, 1987, J CLIN ONCOL, V5, P1007, DOI 10.1200/JCO.1987.5.7.1007; RODMAN JH, 1993, SEMIN ONCOL, V20, P18; RODMAN JH, 1993, J CLIN ONCOL, V11, P287, DOI 10.1200/JCO.1993.11.2.287; SIMONE JV, 1979, CANCER RES, V39, P43081; SINKULE JA, 1983, J CHROMATOGR, V274, P87, DOI 10.1016/S0378-4347(00)84411-4; SYNOLD TW, 1994, J CLIN INVEST, V94, P1996, DOI 10.1172/JCI117552; Veerman AJP, 1996, J CLIN ONCOL, V14, P911, DOI 10.1200/JCO.1996.14.3.911; WILLIAMS DL, 1984, CANCER GENET CYTOGEN, V13, P239, DOI 10.1016/0165-4608(84)90046-3	25	381	388	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 19	1998	338	8					499	505		10.1056/NEJM199802193380803	http://dx.doi.org/10.1056/NEJM199802193380803			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX639	9468466				2022-12-28	WOS:000072061400003
J	Ginzberg, E				Ginzberg, E			The changing US health care agenda	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Columbia Univ, Eisenhower Ctr Conservat Human Resources, New York, NY 10115 USA	Columbia University	Ginzberg, E (corresponding author), Columbia Univ, Eisenhower Ctr Conservat Human Resources, 475 Riverside Dr,Suite 248, New York, NY 10115 USA.								0	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	1998	279	7					501	504		10.1001/jama.279.7.501	http://dx.doi.org/10.1001/jama.279.7.501			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW470	9480349				2022-12-28	WOS:000071938900012
J	Pierce, JP; Choi, WS; Gilpin, EA; Farkas, AJ; Berry, CC				Pierce, JP; Choi, WS; Gilpin, EA; Farkas, AJ; Berry, CC			Tobacco industry promotion cigarettes and adolescent smoking	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							START SMOKING; UNITED-STATES; CHILDREN; SUSCEPTIBILITY; RECOGNITION; CALIFORNIA; CAMEL; ONSET	Context.-Whether tobacco advertising and promotion increases the likelihood that youths will begin smoking has important public policy implications. Objective.-To evaluate the association between receptivity to tobacco advertising and promotional activities and progress in the smoking uptake process, defined sequentially as never smokers who would not consider experimenting with smoking, never smokers who would consider experimenting, experimenters (smoked at least once but fewer than 100 cigarettes), or established smokers (smoked at least 100 cigarettes). Design.-Prospective cohort study with a 3-year follow-up through November 1996. Setting and Participants.-A total of 1752 adolescent never smokers who were not susceptible to smoking when first interviewed in 1993 in a population-based random-digit dial telephone survey in California were reinterviewed in 1996. Main Outcome Measure.-Becoming susceptible to smoking or experimenting by 1996. Results.-More than half the sample (n=979) named a favorite cigarette advertisement in 1993 and Joe Camel advertisements were the most popular. Less than 5% (n=92) at baseline possessed a promotional item but a further 10% (n=172) were willing to use an item. While having a favorite advertisement in 1993 predicted which adolescents would progress by 1996 (odds ratio [OR] =1.82; 95% confidence interval [CI], 1.04-3.20), possession or willingness to use a promotional item was even more strongly associated with future progression (OR=2.89; 95% CI, 1.47-5.68). From these data, we estimate that 34% of all experimentation in California between 1993 and 1996 can be attributed to tobacco promotional activities. Nationally, this would be over 700 000 adolescents each year. Conclusion.-These findings provide the first longitudinal evidence to our knowledge that tobacco promotional activities are causally related to the onset of smoking.	Univ Calif San Diego, Ctr Canc, Canc Prevent & Control Program, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Pierce, JP (corresponding author), Univ Calif San Diego, Ctr Canc, Canc Prevent & Control Program, La Jolla, CA 92093 USA.	jppierce@ucsd.edu	Choi, Won S/G-7441-2015	Choi, Won S/0000-0002-5634-844X; Pierce, John/0000-0002-0075-7471				Altman DG, 1996, AM J PUBLIC HEALTH, V86, P1590, DOI 10.2105/AJPH.86.11.1590; [Anonymous], 1982, JACKKNIFE BOOTSTRAP; BAL DG, 1990, JAMA-J AM MED ASSOC, V264, P1570, DOI 10.1001/jama.264.12.1570; BAUGH JG, 1982, AM J PUBLIC HEALTH, V72, P1161, DOI 10.2105/AJPH.72.10.1161; BRISK JM, 1996, USERS GUIDE WESVARPC; *CDCP, 1992, MMWR-MORBID MORTAL W, V41, P169; *CDCP, 1992, MMWR-MORBID MORTAL W, V41, P179; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P577; CHASSIN L, 1990, HEALTH PSYCHOL, V9, P701, DOI 10.1037/0278-6133.9.6.701; CHASSIN L, 1984, J APPL SOC PSYCHOL, V14, P224, DOI 10.1111/j.1559-1816.1984.tb02233.x; Choi WS, 1997, AM J PREV MED, V13, P385, DOI 10.1016/S0749-3797(18)30159-4; CONRAD KM, 1992, BRIT J ADDICT, V87, P1711; Cummings K M, 1995, MMWR Morb Mortal Wkly Rep, V44, P521; DIFRANZA JR, 1991, JAMA-J AM MED ASSOC, V266, P3149, DOI 10.1001/jama.266.22.3149; EVANS N, 1995, J NATL CANCER I, V87, P1538, DOI 10.1093/jnci/87.20.1538; FISCHER PM, 1991, JAMA-J AM MED ASSOC, V266, P3145, DOI 10.1001/jama.266.22.3145; FLY BR, 1993, SPRINGER SERIES BEHA, V10; Gilpin E A, 1997, Tob Control, V6, P122; Gilpin EA, 1997, PREV MED, V26, P14, DOI 10.1006/pmed.1996.9980; Hennekens C.H., 1987, EPIDEMIOLOGY MED; LEVENTHAL H, 1980, PSYCHOL BULL, V88, P370, DOI 10.1037/0033-2909.88.2.370; McGuire W.J., 1985, HDB SOCIAL PSYCHOL, V2; MIZERSKI R, 1995, J MARKETING, V59, P58, DOI 10.2307/1252328; Petty R. E., 1981, ATTITUDES PERSUASION; Pierce J.P, 1993, TOBACCO USE CALIFORN; Pierce JP, 1996, AM J PUBLIC HEALTH, V86, P253, DOI 10.2105/AJPH.86.2.253; PIERCE JP, 1991, JAMA-J AM MED ASSOC, V266, P3154, DOI 10.1001/jama.266.22.3154; Pierce JP, 1996, HEALTH PSYCHOL, V15, P355, DOI 10.1037/0278-6133.15.5.355; PIERCE JP, 1995, HEALTH PSYCHOL, V14, P500, DOI 10.1037/0278-6133.14.6.500; Pierce JP, 1994, TOBACCO USE CALIFORN; Pollay RW, 1996, J MARKETING, V60, P1, DOI 10.2307/1251927; Ray M. L., 1982, ADVERTISING COMMUNIC; SLADE J, 1992, TOB CONTROL, V1, P207; Susser M., 1973, CAUSAL THINKING HLTH; *US DHHS, 1989, US DEP HLTH HUMAN SE; *US DHHS, 1994, US DEP HLTH HUM SERV; *US DHHS, 1964, PHS PUBL, V1103	37	415	419	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	1998	279	7					511	515		10.1001/jama.279.7.511	http://dx.doi.org/10.1001/jama.279.7.511			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YW470	9480360				2022-12-28	WOS:000071938900031
J	Horton, R				Horton, R			Welcome to CoPUSIM	LANCET			English	Editorial Material									The Lancet, London WC1B 3SL, England		Horton, R (corresponding author), The Lancet, London WC1B 3SL, England.							Fuller Jack, 1996, NEWS VALUES; Horton R, 1997, LANCET, V350, P1043, DOI 10.1016/S0140-6736(05)70449-9; OXMAN AD, 1993, J CLIN EPIDEMIOL, V46, P987, DOI 10.1016/0895-4356(93)90166-X; Whiteman MC, 1997, LANCET, V350, P541, DOI 10.1016/S0140-6736(96)03141-8	4	0	0	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	1998	351	9101					466	466		10.1016/S0140-6736(05)78680-3	http://dx.doi.org/10.1016/S0140-6736(05)78680-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482436				2022-12-28	WOS:000072097700007
J	Basade, MM; Gulati, SC				Basade, MM; Gulati, SC			High-dose chemotherapy in metastatic breast cancer	LANCET			English	Editorial Material							RESCUE		Tata Mem Ctr, Rural Canc Project, Dept Med & Paediat Oncol, Barshi 413401, Maharashtra, India; New York Hosp, Cornell Med Ctr, Stem Cell Transplantat & Clin Res Div Hematol Onc, New York, NY USA	Tata Memorial Centre (TMC); Cornell University; NewYork-Presbyterian Hospital	Basade, MM (corresponding author), Tata Mem Ctr, Rural Canc Project, Dept Med & Paediat Oncol, Barshi 413401, Maharashtra, India.							BEZWODA WR, 1995, J CLIN ONCOL, V13, P2483, DOI 10.1200/JCO.1995.13.10.2483; BROUN ER, 1992, HIGH DOSE CANCER THE, P690; Dillman RO, 1996, BREAST CANCER RES TR, V37, P277, DOI 10.1007/BF01806509; GOLDSTONE AH, 1992, HIGH DOSE CANCER THE, P662; GULATI SC, 1993, PURGING BONE MARROW, P45; PETERS WP, 1995, P AN M AM SOC CLIN, V14, P317; PETERS WP, 1996, P AN M AM SOC CLIN, V15, P121; ROWLINGS PA, 1997, P AM SOC CLIN ONCOL, V16, pA117; UNG O, 1995, J CLIN ONCOL, V13, P435, DOI 10.1200/JCO.1995.13.2.435	9	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					386	387		10.1016/S0140-6736(05)78349-5	http://dx.doi.org/10.1016/S0140-6736(05)78349-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482287				2022-12-28	WOS:000071982600005
J	Swingler, GH; Hussey, GD; Zwarenstein, M				Swingler, GH; Hussey, GD; Zwarenstein, M			Randomised controlled trial of clinical outcome after chest radiograph in ambulatory acute lower-respiratory infection in children	LANCET			English	Article							DIAGNOSIS; PNEUMONIA	Background When available, chest radiographs are used widely in acute lower-respiratory-tract infections in children. Their impact on clinical outcome is unknown, Methods 522 children aged 2 to 59 months who met the WHO case definition for pneumonia were randomly allocated to have a chest radiograph or not. The main outcome was time to recovery, measured in a subset of 295 patients contactable by telephone. Subsidiary outcomes included diagnosis, management, and subsequent use of health facilities, Findings; There was a marginal improvement in time to recovery which was not clinically significant. The median time to recovery was 7 days in both groups (95% CI 6-8 days and 6-9 days in the radiograph and control groups respectively, p=0.50, log-rank test) and the hazard ratio for recovery was 1.08 (95% CI 0.85-1.34), This lack of effect was not modified by clinicians' experience and no subgroups were identified in which the chest radiograph had an effect, Pneumonia and upper-respiratory infections were diagnosed more often and bronchiolitis less often in the radiograph group. Antibiotic use was higher in the radiograph group (60.8% vs 52-2%, p=0.05). There was no difference in subsequent use of health facilities. Interpretation!on Chest radiograph did not affect clinical outcome in outpatient children with acute lower-respiratory infection. This lack of effect is independent of clinicians' experience, There are no clinically identifiable subgroups of children within the WHO case definition of pneumonia who are likely to benefit from a chest radiograph. We conclude that routine use of chest radiography is not beneficial in ambulatory children aged over 2 months with acute lower-respiratory-tract infection.	Red Cross Childrens Hosp, Dept Paediat & Child Hlth, ZA-7700 Cape Town, South Africa; Univ Cape Town, ZA-7700 Cape Town, South Africa; MRC, Hlth Syst Div, Cape Town, South Africa	University of Cape Town	Swingler, GH (corresponding author), Red Cross Childrens Hosp, Dept Paediat & Child Hlth, ZA-7700 Cape Town, South Africa.		Zwarenstein, Merrick F/P-5210-2014	Zwarenstein, Merrick F/0000-0003-0162-7027				ALARIO AJ, 1987, J PEDIATR-US, V111, P187, DOI 10.1016/S0022-3476(87)80065-3; FOSARELLI PD, 1987, CLIN PEDIATR, V26, P296, DOI 10.1177/000992288702600606; FRIIS B, 1990, ACTA PAEDIATR SCAND, V79, P219, DOI 10.1111/j.1651-2227.1990.tb11442.x; GROSSMAN LK, 1988, ANN EMERG MED, V17, P43, DOI 10.1016/S0196-0644(88)80502-X; GUYATT GH, 1986, J CHRON DIS, V39, P295, DOI 10.1016/0021-9681(86)90051-2; KRAMER MS, 1992, PEDIATRICS, V90, P11; LEVENTHAL JM, 1979, 19 M AMB PED ASS ATL; MALBYE H, 1992, ACTA RADIOL, V33, P79; Power M, 1997, S AFR MED J, V87, P36; STICKLER GB, 1984, CLIN PEDIATR, V23, P398, DOI 10.1177/000992288402300707; World Health 0rganization, 1995, MAN AC RESP INF CHIL	11	109	112	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					404	408		10.1016/S0140-6736(97)07013-X	http://dx.doi.org/10.1016/S0140-6736(97)07013-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482294				2022-12-28	WOS:000071982600012
J	Tai, KK; Goldstein, SAN				Tai, KK; Goldstein, SAN			The conduction pore of a cardiac potassium channel	NATURE			English	Article							K+ CHANNEL; XENOPUS-OOCYTES; SELECTIVITY; MUTATIONS; RESIDUES; BLOCK; ISK; CHARYBDOTOXIN; K(V)LQT1; PROTEINS	Ion channels form transmembrane water-filled pores that allow ions to cross membranes in a rapid and selective fashion, The amino acid residues that line these pores have been sought to reveal the mechanisms of ion conduction and selectivity(1-7). The pore (P) loop(8) is a stretch of residues that influences single-channel-current amplitude, selectivity among ions and open-channel blockade(2,3,5) and is conserved in potassium-channel subunits previously recognized to contribute to pore formation(5,9). To date, potassium-channel pores have been shown to form by symmetrical alignment of four P loops around a central conduction pathway(10-12). Here we show that the selectivity-determining pore region of the voltage-gated potassium channel of human heart through which the I-Ks current passes includes the transmembrane segment of the non-P-loop protein minK. Two adjacent residues in this segment of minK are exposed in the pore on either side of a short barrier that restricts the movement of sodium, cadmium and zinc ions across the membrane, Thus, potassium-selective pores are not restricted to P loops or a strict P-loop geometry.	Yale Univ, Sch Med, Dept Pediat, Sect Dev Biol & Biophys, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Cellular & Mol Physiol, New Haven, CT 06536 USA	Yale University; Yale University	Goldstein, SAN (corresponding author), Yale Univ, Sch Med, Dept Pediat, Sect Dev Biol & Biophys, 295 Congress Ave, New Haven, CT 06536 USA.		Goldstein, Steven A./E-9817-2015	Goldstein, Steven A./0000-0001-5207-5061				ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BLUMENTHAL EM, 1994, J NEUROSCI, V14, P3097; DWYER TM, 1980, J GEN PHYSIOL, V75, P469, DOI 10.1085/jgp.75.5.469; GLOWATZKI E, 1995, P ROY SOC B-BIOL SCI, V261, P251, DOI 10.1098/rspb.1995.0145; Goldstein SAN, 1998, J MOL MED-JMM, V76, P13, DOI 10.1007/s109-1998-8100-0; Goldstein SAN, 1996, NEURON, V16, P717, DOI 10.1016/S0896-6273(00)80092-6; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; LATORRE R, 1983, J MEMBRANE BIOL, V71, P11, DOI 10.1007/BF01870671; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Romey G, 1997, J BIOL CHEM, V272, P16713, DOI 10.1074/jbc.272.27.16713; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SHEN KZ, 1994, PFLUG ARCH EUR J PHY, V426, P440, DOI 10.1007/BF00388308; Tai KK, 1997, J BIOL CHEM, V272, P1654, DOI 10.1074/jbc.272.3.1654; Wang KW, 1996, NEURON, V16, P571, DOI 10.1016/S0896-6273(00)80076-8; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YELLEN G, 1994, BIOPHYS J, V66, P1068, DOI 10.1016/S0006-3495(94)80888-4	30	109	110	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 5	1998	391	6667					605	608		10.1038/35416	http://dx.doi.org/10.1038/35416			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468141	Green Submitted			2022-12-28	WOS:000071842300057
J	Rimm, EB; Willett, WC; Hu, FB; Sampson, L; Colditz, GA; Manson, JE; Hennekens, C; Stampfer, MJ				Rimm, EB; Willett, WC; Hu, FB; Sampson, L; Colditz, GA; Manson, JE; Hennekens, C; Stampfer, MJ			Folate and vitamin B-6 from diet and supplements in relation to risk of coronary heart disease among women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOOD FREQUENCY QUESTIONNAIRE; OCCLUSIVE ARTERIAL-DISEASE; FOLIC-ACID; PLASMA HOMOCYSTEINE; MYOCARDIAL-INFARCTION; ELDERLY POPULATION; METABOLISM; METHIONINE; HYPERHOMOCYSTEINEMIA; HOMOCYST(E)INE	Context.-Hyperhomocysteinemia is caused by genetic and lifestyle influences, including low intakes of folate and vitamin B-6. However, prospective data relating intake of these vitamins to risk of coronary heart disease (CHD) are not available, Objective.-To examine intakes of folate and vitamin B-6 in relation to the incidence of nonfatal myocardial infarction (MI) and fatal CHD. Design.-Prospective cohort study. Setting and Patients.-In 1980, a total of 80 082 women from the Nurses' Health Study with no previous history of cardiovascular disease, cancer, hypercholesterolemia, or diabetes completed a detailed food frequency questionnaire from which we derived usual intake of folate and vitamin B-6. Main Outcome Measure.-Nonfatal MI and fatal CHD confirmed by World Health Organization criteria. Results.-During 14 years of follow-up, we documented 658 incident cases of nonfatal MI and 281 cases of fatal CHD. After controlling for cardiovascular risk factors, including smoking and hypertension and intake of alcohol, fiber, vitamin E, and saturated, polyunsaturated, and trans fat, the relative risks (RRs) of CHD between extreme quintiles were 0.69 (95% confidence interval [CI], 0.55-0.87) for folate (median intake, 696 mu g/d vs 158 mu g/d) and 0.67 (95% CI, 0.53-0.85) for vitamin B-6 (median intake, 4.6 mg/d vs 1.1 mg/d). Controlling for the same variables, the RR was 0.55 (95% CI, 0.41-0.74) among women in the highest quintile of both folate and vitamin B-6 intake compared with the opposite extreme. Risk of CHD was reduced among women who regularly used multiple vitamins (RR=0.76; 95% CI, 0.65-0.90), the major source of folate and vitamin B-6, and after excluding multiple vitamin users, among those with higher dietary intakes of folate and vitamin B-6. In a subgroup analysis, compared with nondrinkers, the inverse association between a high-folate diet and CHD was strongest among women who consumed up to 1 alcoholic beverage per day (RR=0.69; 95% CI, 0.49-0.97) or more than 1 drink per day (RR=0.27; 95% CI, 0.13-0.58). Conclusion.-These results suggest that intake of folate and vitamin B-6 above the current recommended dietary allowance may be important in the primary prevention of CHD among women.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Rimm, EB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	eric.rimm@channing.harvard.edu	Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL34594] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Appel LJ, 1996, JAMA-J AM MED ASSOC, V275, P681, DOI 10.1001/jama.1996.03530330025013; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BENDICH A, 1994, J NUTR EDUC, V26, P294; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BOSTOM AG, 1995, ATHEROSCLEROSIS, V116, P147, DOI 10.1016/0021-9150(95)05529-6; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BRATTSTROM L, 1990, ATHEROSCLEROSIS, V81, P51, DOI 10.1016/0021-9150(90)90058-Q; BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; ChasanTaber L, 1996, J AM COLL NUTR, V15, P136; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Durand P, 1996, ATHEROSCLEROSIS, V121, P231, DOI 10.1016/0021-9150(95)06724-8; Food and Nutrition Board Commission on Life Sciences National Research Council, 1989, REC DIET ALL; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P875, DOI 10.1093/jnci/85.11.875; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; HERBERT VD, 1988, MODERN NUTRITION HLT, P388; ISRAELSSON B, 1988, ATHEROSCLEROSIS, V71, P227, DOI 10.1016/0021-9150(88)90147-5; JACOB RA, 1994, J NUTR, V124, P1072, DOI 10.1093/jn/124.7.1072; KANG SS, 1986, J CLIN INVEST, V77, P1482, DOI 10.1172/JCI112461; MALINOW MR, 1989, CIRCULATION, V79, P1180, DOI 10.1161/01.CIR.79.6.1180; MCCULLY KS, 1969, AM J PATHOL, V56, P111; MILLER JW, 1994, AM J CLIN NUTR, V59, P1033, DOI 10.1093/ajcn/59.5.1033; Morrison HI, 1996, JAMA-J AM MED ASSOC, V275, P1893, DOI 10.1001/jama.275.24.1893; MUDD SH, 1964, SCIENCE, V143, P1443, DOI 10.1126/science.143.3613.1443; NAURATH HJ, 1995, LANCET, V346, P85, DOI 10.1016/S0140-6736(95)92113-3; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; Oakley GP, 1997, AM J CLIN NUTR, V65, P1889, DOI 10.1093/ajcn/65.6.1889; OKEEFE CA, 1995, J NUTR, V125, P2717; PANCHARUNITI N, 1994, AM J CLIN NUTR, V59, P940, DOI 10.1093/ajcn/59.4.940; RIMM EB, 1996, CIRCULATION, V93, P625; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; SHAW S, 1989, BIOCHEM J, V257, P277, DOI 10.1042/bj2570277; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Stampfer MJ, 1996, JAMA-J AM MED ASSOC, V275, P1929, DOI 10.1001/jama.275.24.1929; SUBAR AF, 1989, AM J CLIN NUTR, V50, P508, DOI 10.1093/ajcn/50.3.508; Tawakol A, 1997, CIRCULATION, V95, P1119; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; Tucker KL, 1996, JAMA-J AM MED ASSOC, V276, P1879, DOI 10.1001/jama.276.23.1879; UBBINK JB, 1994, J NUTR, V124, P1927, DOI 10.1093/jn/124.10.1927; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; *USDA, 1993, USDA AGR HDB SER, V8; Verhoef P, 1996, AM J EPIDEMIOL, V143, P845, DOI 10.1093/oxfordjournals.aje.a008828; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W., 1990, NUTR EPIDEMIOLOGY; WILLETT WC, 1987, J AM DIET ASSOC, V87, P43; WILLETT WC, 1983, AM J CLIN NUTR, V38, P631, DOI 10.1093/ajcn/38.4.631; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; Wilson JW, 1997, DATA TABLES COMBINED	52	620	651	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					359	364		10.1001/jama.279.5.359	http://dx.doi.org/10.1001/jama.279.5.359			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459468	Green Accepted, Bronze			2022-12-28	WOS:000071731300025
J	Gottlieb, JP; Kusunoki, M; Goldberg, ME				Gottlieb, JP; Kusunoki, M; Goldberg, ME			The representation of visual salience in monkey parietal cortex	NATURE			English	Article							LATERAL INTRAPARIETAL AREA; EYE-MOVEMENTS; MACAQUE; FIELD; ORGANIZATION	When natural scenes are viewed, a multitude of objects that are stable in their environments are brought in and out of view by eye movements. The posterior parietal cortex is crucial for the analysis of space, visual attention and movement(1). Neurons in one of its subdivisions, the lateral intraparietal area (LIP), have visual responses to stimuli appearing abruptly at particular retinal locations (their receptive fields)(2). We have rested the responses of LIP neurons to stimuli that entered their receptive field by saccades. Neurons had little or no response to stimuli brought into their receptive field by saccades, unless the stimuli were behaviourally significant. We established behavioural significance in two ways: either by making a stable stimulus task-relevant, or by taking advantage of the attentional attraction of an abruptly appearing stimulus. Our results show that under ordinary circumstances the entire visual world is only weakly represented in LIP. The visual representation in LIP is sparse, with only the most salient or behaviourally relevant objects being strongly represented.	NEI, Sensorimotor Res Lab, Bethesda, MD 20892 USA; Georgetown Univ, Sch Med, Dept Neurol, Washington, DC 20007 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Georgetown University	Goldberg, ME (corresponding author), NEI, Sensorimotor Res Lab, Bldg 10, Bethesda, MD 20892 USA.							Andersen R A, 1989, Rev Oculomot Res, V3, P315; Andersen R A, 1992, Curr Opin Neurobiol, V2, P840, DOI 10.1016/0959-4388(92)90143-9; BAIZER JS, 1991, J NEUROSCI, V11, P168; BARASH S, 1991, J NEUROPHYSIOL, V66, P1095, DOI 10.1152/jn.1991.66.3.1095; BLATT GJ, 1990, J COMP NEUROL, V299, P421, DOI 10.1002/cne.902990404; BURMAN DD, 1994, J NEUROPHYSIOL, V71, P1266, DOI 10.1152/jn.1994.71.3.1266; Colby CL, 1996, J NEUROPHYSIOL, V76, P2841, DOI 10.1152/jn.1996.76.5.2841; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P183; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; GNADT JW, 1988, EXP BRAIN RES, V70, P216; Hays AV, 1982, WESCON C P, V2, P1; Irwin DE, 1996, CURR DIR PSYCHOL SCI, V5, P94, DOI 10.1111/1467-8721.ep10772833; KOCH C, 1985, HUM NEUROBIOL, V4, P219; Livingstone MS, 1996, COLD SPRING HARB SYM, V61, P27; LYNCH JC, 1985, J COMP NEUROL, V235, P241, DOI 10.1002/cne.902350207; RAO RPN, 1996, ADV NEURAL INFORMATI, V8; RICHMOND BJ, 1987, J NEUROPHYSIOL, V57, P147, DOI 10.1152/jn.1987.57.1.147; Snyder LH, 1997, NATURE, V386, P167, DOI 10.1038/386167a0; STANTON GB, 1995, J COMP NEUROL, V353, P291, DOI 10.1002/cne.903530210; Treisman A, 1996, CURR OPIN NEUROBIOL, V6, P171, DOI 10.1016/S0959-4388(96)80070-5; WOLFE JM, 1994, PSYCHON B REV, V1, P202, DOI 10.3758/BF03200774; Yantis S., 1996, ATTENTIONAL CAPTURE	22	802	813	1	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 29	1998	391	6666					481	484		10.1038/35135	http://dx.doi.org/10.1038/35135			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461214				2022-12-28	WOS:000071701800049
J	Rubenstein, E				Rubenstein, E			Relationship of senescence of cerebrospinal fluid circulatory system to dementias of the aged	LANCET			English	Article							ARTERY TERRITORY INFARCTION; ALZHEIMERS-DISEASE; CHOROID-PLEXUS; BRAIN; VOLUMES; ATROPHY	In common with other organ systems, the cerebrospinal fluid circulatory system is subject to senescence. Cerebrospinal fluid production and turnover rates decline. The choroid plexus calcifies and its blood supply falters. Microvascular disease violates the integrity of: the blood-brain barrier. The arachnoid membranes thicken. Arachnoid villi occlude and degenerate. The consequent functional losses are exacerbated by the deterioration of other interacting organ systems. Eventually, the cerebrospinal fluid circulatory system may fail, resulting in stagnation, contamination, compositional deficiencies, and impaired clearance of noxious substances. The hypothesis is that senescence of the cerebrospinal fluid circulatory system plays a part in some dementias of the aged.	Stanford Univ, Sch Med, Stanford, CA 94305 USA	Stanford University	Rubenstein, E (corresponding author), 5 Waverly Pl, Hillsborough, CA 94010 USA.	exr@leland.stanford.edu						ALDRED AR, 1995, COMP BIOCHEM PHYS B, V111, P1, DOI 10.1016/0305-0491(94)00229-N; BELLUR SN, 1980, ARCH PATHOL LAB MED, V104, P414; BRUNO A, 1989, STROKE, V20, P616, DOI 10.1161/01.STR.20.5.616; CUTLER RWP, 1968, BRAIN, V91, P707, DOI 10.1093/brain/91.4.707; Davson H, 1996, PHYSL CSF BLOOD BRAI; Eastwood R, 1996, LANCET, V347, P1303; EMERSON JF, 1994, NEUROREPORT, V5, P1699, DOI 10.1097/00001756-199409080-00003; Ferreira A, 1990, Arq Neuropsiquiatr, V48, P448; Forstl H, 1995, BRIT J PSYCHIAT, V167, P739, DOI 10.1192/bjp.167.6.739; Galasko D, 1997, NEUROLOGY, V48, P632, DOI 10.1212/WNL.48.3.632; GARTON MJ, 1991, J NEUROL SCI, V104, P74, DOI 10.1016/0022-510X(91)90218-V; Greitz D, 1996, AM J NEURORADIOL, V17, P431; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; KOHN MI, 1991, RADIOLOGY, V178, P115, DOI 10.1148/radiology.178.1.1984289; KUIPER MA, 1994, J NEURAL TRANSM-PARK, V7, P109, DOI 10.1007/BF02260965; KWAK R, 1988, Brain and Nerve (Tokyo), V40, P707; LEYS D, 1994, STROKE, V25, P837, DOI 10.1161/01.STR.25.4.837; LOEFFLER DA, 1994, ALZ DIS ASSOC DIS, V8, P190, DOI 10.1097/00002093-199408030-00005; Matsumae M, 1996, J NEUROSURG, V84, P982, DOI 10.3171/jns.1996.84.6.0982; MAY C, 1990, NEUROLOGY, V40, P500, DOI 10.1212/WNL.40.3_Part_1.500; MODIC MT, 1980, RADIOLOGY, V135, P369, DOI 10.1148/radiology.135.2.7367628; Neau JP, 1996, ANN NEUROL, V39, P779, DOI 10.1002/ana.410390614; PARNETTI L, 1995, NEUROSCI LETT, V199, P231, DOI 10.1016/0304-3940(95)12058-C; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; SEROT JM, 1994, HUM PATHOL, V25, P1185, DOI 10.1016/0046-8177(94)90035-3; SKOOG I, 1993, NEW ENGL J MED, V328, P153, DOI 10.1056/NEJM199301213280301; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; SPECTOR R, 1989, SCI AM, V261, P68, DOI 10.1038/scientificamerican1189-68; SUZUKI H, 1992, NEUROSURGERY, V31, P132, DOI 10.1227/00006123-199207000-00021; TORVIK A, 1978, ACTA NEUROCHIR, V41, P137, DOI 10.1007/BF01809144; TRIPATHI R, 1974, BRAIN RES, V80, P503, DOI 10.1016/0006-8993(74)91033-6; VINAS FC, 1995, NEUROL RES, V17, P334, DOI 10.1080/01616412.1995.11740339	32	84	86	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 24	1998	351	9098					283	285		10.1016/S0140-6736(97)09234-9	http://dx.doi.org/10.1016/S0140-6736(97)09234-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU294	9457114				2022-12-28	WOS:000071702200044
J	Lin, RL; Hill, RJ; Priess, JR				Lin, RL; Hill, RJ; Priess, JR			POP-1 and anterior-posterior fate decisions in C-elegans embryos	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; ASYMMETRIC CELL DIVISIONS; BLASTOMERE IDENTITY; MATERNAL GENES; AB LINEAGE; HMG BOX; SPECIFICATION; ENCODES; PROTEIN; PIE-1	Blastomeres in C. elegans embryos execute lineage programs wherein the fate of a cell is correlated reproducibly with the division sequence by which that cell is born. We provide evidence that the pop-1 gene functions to link anterior-posterior cell divisions with cell fate decisions. Each anterior cell resulting from an anterior-posterior division appears to have a higher level of nuclear POP-1 protein than does its posterior sister. Genes in the C. elegans Wnt pathway are required for this inequality in POP-1 levels. We show that loss of pop-1(+) activity leads to several types of anterior cells adopting the fates of their posterior sisters. These results suggest a mechanism for the invariance of blastomere lineages.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Howard Hughes Med Inst, Seattle, WA 98104 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Priess, JR (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Howard Hughes Med Inst, 1124 Columbia St, Seattle, WA 98104 USA.							BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BRENNER S, 1974, GENETICS, V77, P71; GENDREAU SB, 1994, DEV BIOL, V166, P770, DOI 10.1006/dbio.1994.1355; GOLDSTEIN B, 1993, DEVELOPMENT, V118, P1267; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; Guedes S, 1997, DEVELOPMENT, V124, P731; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Hunter CP, 1996, CELL, V87, P217, DOI 10.1016/S0092-8674(00)81340-9; HUTTER H, 1995, DEVELOPMENT, V121, P1559; HUTTER H, 1994, DEVELOPMENT, V120, P2051; JUNKERSDORF B, 1992, ROUX ARCH DEV BIOL, V202, P17, DOI 10.1007/BF00364593; KEMPHUES KJ, 1997, NEMATODE C; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; MANGO SE, 1994, DEVELOPMENT, V120, P2305; MCGHEE JD, 1995, DEV GENET, V17, P155, DOI 10.1002/dvg.1020170207; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; Moon RT, 1997, TRENDS GENET, V13, P256, DOI 10.1016/S0168-9525(97)01196-7; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Moskowitz IPG, 1996, DEVELOPMENT, V122, P4105; MOSKOWITZ IPG, 1994, DEVELOPMENT, V120, P3325; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Peifer M, 1996, SCIENCE, V272, P974, DOI 10.1126/science.272.5264.974; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Sawa H, 1996, GENE DEV, V10, P2189, DOI 10.1101/gad.10.17.2189; Schnabel R, 1996, MECH DEVELOP, V54, P133, DOI 10.1016/0925-4773(95)00466-1; SCHNABEL R, 1997, NEMATODE C; Seydoux G, 1996, NATURE, V382, P713, DOI 10.1038/382713a0; STERNBERG PW, 1988, DEV BIOL, V130, P67, DOI 10.1016/0012-1606(88)90414-9; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; Thomas C, 1996, SCIENCE, V273, P603, DOI 10.1126/science.273.5275.603; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873	38	227	229	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					229	239		10.1016/S0092-8674(00)80917-4	http://dx.doi.org/10.1016/S0092-8674(00)80917-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458047	Bronze			2022-12-28	WOS:000071672600012
J	Sarasin, FP; Bounameaux, H				Sarasin, FP; Bounameaux, H			Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACTIVATED PROTEIN-C; MOLECULAR-WEIGHT HEPARIN; COAGULATION-FACTOR-V; VENOUS THROMBOEMBOLISM; PULMONARY-EMBOLISM; OPTIMAL DURATION; THERAPY; RESISTANCE; MUTATION; RISK	Objective: To assess the risks and benefits of oral anticoagulant treatment extended beyond 3 months after a first episode of deep vein thrombosis in patients who carry factor V Leiden mutation. Such patients have over twice the risk of recurrence after the recommended treatment period, but more information is required before widespread genetic screening can be recommended. Design: A decision analysis Markov model (with data extracted form literature) representing the risks of developing symptomatic venous thromboembolism, the risks of major bleeding, and the efficacy of anticoagulant treatment. Subjects: A hypothetical cohort of 1000 carriers of factor V Leiden recovering from a first episode of deep vein thrombosis in the lower limbs. Main outcome measures: Risks and benefits of, firstly, stopping oral anticoagulation 3 months after first episode of thrombosis with reinitiation of treatment only after recurrent thrombosis and, secondly, extension of oral anticoagulation up to 1 to 5 years. Results: Despite consistent biases in favour of extended oral anticoagulation, analysis revealed that among factor V carriers the number of major haemorrhages induced by oral anticoagulants would exceed that of clinical pulmonary emboli prevented over the entire range of duration of anticoagulation (1 to 5 years). On the other hand, the number of recurrent deep vein thrombi prevented would exceed that of iatrogenic major bleedings. Conclusion: The lack of evidence of a net clinical benefit of prolonged oral anticoagulation, at least beyond 1 year, among patients recovering from acute deep vein thrombosis does not support the decision to promote widespread genetic screening programmes to detect the factor V mutation.	Univ Geneva, Hosp Cantonal,Sch Med, Dept Internal Med, Med Clin, CH-1211 Geneva 14, Switzerland; Univ Geneva, Hosp Cantonal,Sch Med, Dept Internal Med, Div Angiol & Haemostasis, CH-1211 Geneva 14, Switzerland	University of Geneva; University of Geneva	Sarasin, FP (corresponding author), Univ Geneva, Hosp Cantonal,Sch Med, Dept Internal Med, Med Clin, 24 Rue Micheli Crest, CH-1211 Geneva 14, Switzerland.	sarasin-francois@diogenes.hcuge.ch						BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BEYTH RJ, 1995, ARCH INTERN MED, V218, P279; Bounameaux H, 1996, BLOOD COAGUL FIBRIN, V7, P507, DOI 10.1097/00001721-199607000-00001; CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; CLAGETT GP, 1995, CHEST, V108, pS312, DOI 10.1378/chest.108.4_Supplement.312S; DAHLBACK B, 1995, BLOOD, V85, P607, DOI 10.1182/blood.V85.3.607.bloodjournal853607; Desmarais S, 1996, LANCET, V347, P1374, DOI 10.1016/S0140-6736(96)91013-2; Eichinger S, 1997, THROMB HAEMOSTASIS, V77, P624; Ginsberg JS, 1996, NEW ENGL J MED, V335, P1816, DOI 10.1056/NEJM199612123352407; HOLMGREN KAJ, 1985, ACTA MED SCAND, V218, P279; Koepke JA, 1996, AM J CLIN PATHOL, V106, P161; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; LEVINE MN, 1995, THROMB HAEMOSTASIS, V74, P606; LEVINE MN, 1995, CHEST, V108, pS276, DOI 10.1378/chest.108.4_Supplement.276S; Manten B, 1996, THROMB HAEMOSTASIS, V76, P510; Marinelli I, 1997, THROMB HAEMOSTASIS, V77, P440; MONREAL M, 1992, CHEST, V102, P677, DOI 10.1378/chest.102.3.677; PARASKOS JA, 1973, NEW ENGL J MED, V289, P55, DOI 10.1056/NEJM197307122890201; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; Ridker PM, 1997, ANN INTERN MED, V126, P528, DOI 10.7326/0003-4819-126-7-199704010-00005; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; SCHULMAN S, 1985, ACTA MED SCAND, V217, P547; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; Simioni P, 1997, NEW ENGL J MED, V336, P399, DOI 10.1056/NEJM199702063360602; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; SUDLOW MF, 1992, LANCET, V340, P873; Vandenbroucke JP, 1996, BRIT MED J, V313, P1127, DOI 10.1136/bmj.313.7065.1127; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0	31	43	43	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 10	1998	316	7125					95	99						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR408	9462312				2022-12-28	WOS:000071492300014
J	Barrett, TE; Savva, R; Panayotou, G; Barlow, T; Brown, T; Jiricny, J; Pearl, LH				Barrett, TE; Savva, R; Panayotou, G; Barlow, T; Brown, T; Jiricny, J; Pearl, LH			Crystal structure of a G : T/U mismatch-specific DNA glycosylase: Mismatch recognition by complementary-strand interactions	CELL			English	Article							BASE-EXCISION-REPAIR; ESCHERICHIA-COLI; NUCLEAR EXTRACTS; G.T MISPAIRS; HUMAN-CELLS; HELA-CELLS; URACIL; THYMINE; PROTEIN; PURIFICATION	G:U mismatches resulting from deamination of cytosine are the most common promutagenic lesions occurring in DNA. Uracil is removed in a base-excision repair pathway by uracil DNA-glycosylase (UDG), which excises uracil from both single-and double-stranded DNA. Recently, a biochemically distinct family of DNA repair enzymes has been identified, which excises both uracil and thymine, but only from mispairs with guanine. Crystal structures of the mismatch-specific uracil DNA-glycosylase (MUG) from E. coli, and of a DNA complex, reveal a remarkable structural and functional homology to UDGs despite low sequence identity. Details of the MUG structure explain its thymine DNA-glycosylase activity and the specificity for G:U/T mispairs, which derives from direct recognition of guanine on the complementary strand.	Univ London Univ Coll, Dept Biochem & Mol Biol, London WC1E 6BT, England; UCL, Ludwig Inst Canc Res, London W1P 8BT, England; Univ Southampton, Dept Chem, Southampton SO17 1BJ, Hants, England; Inst Med Radiobiol, CH-8029 Zurich, Switzerland	University of London; University College London; Ludwig Institute for Cancer Research; University of London; University College London; University of Southampton	Pearl, LH (corresponding author), Univ London Univ Coll, Dept Biochem & Mol Biol, Gower St, London WC1E 6BT, England.		Brown, Tom/B-8521-2008; Brown, Tom/C-9185-2016	Brown, Tom/0000-0003-4683-1873; Pearl, Laurence/0000-0002-6910-1809; Brown, Tom/0000-0002-6538-3036; Savva, Renos/0000-0001-7375-2340				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BJELLAND S, 1994, J BIOL CHEM, V269, P30489; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; BROWN T, 1989, J MOL BIOL, V207, P455, DOI 10.1016/0022-2836(89)90268-4; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHAYEN NE, 1990, J APPL CRYSTALLOGR, V23, P297, DOI 10.1107/S0021889890003260; CONE R, 1980, J BIOL CHEM, V255, P354; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOMENA JD, 1988, BIOCHEMISTRY-US, V27, P6742, DOI 10.1021/bi00418a015; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JIRICNY J, 1996, GENETIC INSTABILITY, V28, P47; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE A, 1995, MOSFLM USERS GUIDE; LETTIERI T, 1997, BASE EXCISION REPAIR, P45; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; NICHOLLS A, 1993, BIOPHYS J, V64, pA116; Orengo CA, 1996, METHOD ENZYMOL, V266, P617; ORNSTEIN RL, 1978, BIOPOLYMERS, V17, P2341, DOI 10.1002/bip.1978.360171005; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; Panayotou G, 1998, J BIOL CHEM, V273, P45, DOI 10.1074/jbc.273.1.45; Pearl LH, 1996, NAT STRUCT BIOL, V3, P485, DOI 10.1038/nsb0696-485; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; ROY R, 1994, BIOCHEMISTRY-US, V33, P15131, DOI 10.1021/bi00254a024; SAVVA R, 1995, NAT STRUCT BIOL, V2, P752, DOI 10.1038/nsb0995-752; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; Scharer OD, 1997, P NATL ACAD SCI USA, V94, P4878, DOI 10.1073/pnas.94.10.4878; SHIEH HS, 1980, NUCLEIC ACIDS RES, V8, P85, DOI 10.1093/nar/8.1.85; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0	45	221	229	2	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JAN 9	1998	92	1					117	129		10.1016/S0092-8674(00)80904-6	http://dx.doi.org/10.1016/S0092-8674(00)80904-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489705	Bronze			2022-12-28	WOS:000071473700013
J	Mansuy, IM; Mayford, M; Jacob, B; Kandel, ER; Bach, ME				Mansuy, IM; Mayford, M; Jacob, B; Kandel, ER; Bach, ME			Restricted and regulated overexpression reveals calcineurin as a key component in the transition from short-term to long-term memory	CELL			English	Article							HIPPOCAMPAL CA1 REGION; DAY-OLD CHICKS; GENE-EXPRESSION; HUMAN AMNESIA; RATS; MONKEYS; LESIONS; MODEL; POTENTIATION; NOVELTY	To investigate the roles phosphatases play in hippocampal-dependent memory, we studied transgenic mice overexpressing a truncated form of calcineurin. These mice have normal short-term memory but defective long-term memory evident on both a spatial task and on a visual recognition task, providing genetic evidence for the role of the rodent hippocampus in spatial and nonspatial memory. The defect in longterm memory could be fully rescued by increasing the number of training trials, suggesting that the mice have the capacity for long-term memory. We next analyzed mice overexpressing calcineurin in a regulated manner and found the memory defect is reversible and not due to a developmental abnormality. Our behavioral results suggest that calcineurin has a role in the transition from short-to long-term memory, which correlates with a novel intermediate phase of LTP.	Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Ctr Neurobiol & Behav, New York, NY 10032 USA; Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; New York State Psychiatry Institute; Howard Hughes Medical Institute	Mansuy, IM (corresponding author), Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Ctr Neurobiol & Behav, New York, NY 10032 USA.		Mansuy, Isabelle M/N-3042-2015	Mansuy, Isabelle M/0000-0001-7785-5371; Mayford, Mark/0000-0002-9001-5024				Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; AGGLETON JP, 1985, Q J EXP PSYCHOL-B, V37, P279, DOI 10.1080/14640748508401171; ALVAREZ P, 1994, P NATL ACAD SCI USA, V91, P5637, DOI 10.1073/pnas.91.12.5637; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; Bennett PC, 1996, BRAIN RES, V730, P107; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CHERKIN A, 1969, P NATL ACAD SCI USA, V63, P1094, DOI 10.1073/pnas.63.4.1094; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIK FIM, 1972, J VERB LEARN VERB BE, V11, P671, DOI 10.1016/S0022-5371(72)80001-X; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; Ebbinghaus H., 1885, MEMORY CONTRIBUTION; EICHENBAUM H, 1995, NATURE, V378, P131, DOI 10.1038/378131a0; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; FRIEDER B, 1982, PHYSIOL BEHAV, V29, P1071, DOI 10.1016/0031-9384(82)90300-6; GIBBS ME, 1977, BIOBEHAV REV, V1, P113, DOI 10.1016/0147-7552(77)90017-1; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hogan B, 1994, MANIPULATING MOUSE E; Huang Y Y, 1994, Learn Mem, V1, P74; Huang YY, 1996, LEARN MEMORY, V3, P74, DOI 10.1101/lm.3.2-3.74; James W., 1890, PRINCIPLES PSYCHOL, P449, DOI [https://doi.org/10.1037/11059-009, DOI 10.1037/11059-009]; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KLEE CB, 1983, METHOD ENZYMOL, V102, P227; Knight RT, 1996, NATURE, V383, P256, DOI 10.1038/383256a0; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; MANDEL RJ, 1989, BEHAV BRAIN RES, V31, P221, DOI 10.1016/0166-4328(89)90004-1; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MCGAUGH JL, 1968, MULTITRACE VIEW MEMO; MISHKIN M, 1978, NATURE, V273, P297, DOI 10.1038/273297a0; MUMBY DG, 1995, PSYCHOBIOLOGY, V23, P26; MYHRER T, 1988, BEHAV NEUROSCI, V102, P356, DOI 10.1037/0735-7044.102.3.356; MYHRER T, 1988, PHYSIOL BEHAV, V42, P371, DOI 10.1016/0031-9384(88)90279-X; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; OVERMAN WH, 1990, EXP BRAIN RES, V79, P18; PHILLIPS RR, 1988, BEHAV BRAIN RES, V27, P99, DOI 10.1016/0166-4328(88)90035-6; REED JM, 1997, BEHAV NEUROSCI, V111, P1; ROSENZWEIG MR, 1993, BEHAV BRAIN RES, V57, P193, DOI 10.1016/0166-4328(93)90135-D; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Squire L. R., 1987, MEMORY BRAIN; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Thomas MJ, 1996, NEURON, V17, P475, DOI 10.1016/S0896-6273(00)80179-8; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; Tulving E, 1996, CEREB CORTEX, V6, P71, DOI 10.1093/cercor/6.1.71; WEISKRANTZ L, 1970, LONG TERM VIEW SHORT; WICKELGREN WA, 1973, PSYCHOL BULL, V80, P425, DOI 10.1037/h0035255; ZHAO WQ, 1995, BRAIN RES BULL, V36, P557, DOI 10.1016/0361-9230(94)00244-U; ZHAO WQ, 1995, NEUROBIOL LEARN MEM, V64, P106, DOI 10.1006/nlme.1995.1049; ZOLAMORGAN S, 1985, BEHAV NEUROSCI, V99, P22, DOI 10.1037/0735-7044.99.1.22	52	291	305	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 9	1998	92	1					39	49		10.1016/S0092-8674(00)80897-1	http://dx.doi.org/10.1016/S0092-8674(00)80897-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489698	hybrid			2022-12-28	WOS:000071473700006
J	Winder, DG; Mansuy, IM; Osman, M; Moallem, TM; Kandel, ER				Winder, DG; Mansuy, IM; Osman, M; Moallem, TM; Kandel, ER			Genetic and pharmacological evidence for a novel, intermediate phase of long-term potentiation suppressed by calcineurin	CELL			English	Article							HIPPOCAMPAL CA1 REGION; PROTEIN-KINASE; RAT-BRAIN; PHOSPHATASE INHIBITOR-1; NMDA RECEPTORS; LTP; EXPRESSION; CAMP; MEMORY; BETA	To investigate the role of phosphatases in synaptic plasticity using genetic approaches, we generated transgenic mice that overexpress a truncated form of calcineurin under the control of the CaMKII alpha promoter. Mice expressing this transgene show increased calcium-dependent phosphatase activity in the hippocampus. Physiological studies of these mice and parallel pharmacological experiments in wild-type mice reveal a novel, intermediate phase of LTP (I-LTP) in the CA1 region of the hippocampus. This intermediate phase differs from E-LTP by requiring multiple trains for induction and in being dependent on PKA. It differs from L-LTP in not requiring new protein synthesis. These data suggest that calcineurin acts as an inhibitory constraint on I-LTP that is relieved by PKA. This inhibitory constraint acts as a gate to regulate the synaptic induction of L-LTP.	Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Howard Hughes Med Inst, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; New York State Psychiatry Institute	Kandel, ER (corresponding author), Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Howard Hughes Med Inst, Ctr Neurobiol & Behav, New York, NY 10032 USA.		Mansuy, Isabelle M/N-3042-2015; Winder, Danny G./H-4857-2013	Mansuy, Isabelle M/0000-0001-7785-5371; 				ABEL T, 1997, CELL, V88, P1; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; Bear MF, 1996, ANNU REV NEUROSCI, V19, P437, DOI 10.1146/annurev.ne.19.030196.002253; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; Bolshakov VY, 1997, NEURON, V19, P635, DOI 10.1016/S0896-6273(00)80377-3; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FIGUROV A, 1993, EUR J NEUROSCI, V5, P1035, DOI 10.1111/j.1460-9568.1993.tb00956.x; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GUSTAFSON EL, 1991, J COMP NEUROL, V310, P170, DOI 10.1002/cne.903100204; Helekar SA, 1997, P NATL ACAD SCI USA, V94, P5432, DOI 10.1073/pnas.94.10.5432; Hogan B, 1994, MANIPULATING MOUSE E; Huang YY, 1996, LEARN MEMORY, V3, P74, DOI 10.1101/lm.3.2-3.74; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; KLEE CB, 1983, METHOD ENZYMOL, V102, P227; KUNO T, 1992, J NEUROCHEM, V58, P1643, DOI 10.1111/j.1471-4159.1992.tb10036.x; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; Lu YF, 1996, BRAIN RES, V729, P142, DOI 10.1016/0006-8993(96)00568-9; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Mayford M, 1997, CURR BIOL, V7, pR580, DOI 10.1016/S0960-9822(06)00287-9; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; MULLER D, 1995, NEURON, V14, P599, DOI 10.1016/0896-6273(95)90316-X; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Osten P, 1996, J NEUROSCI, V16, P2444; PARSONS JN, 1994, J BIOL CHEM, V269, P19610; PATERSON JM, 1995, BIOCHEM BIOPH RES CO, V214, P1000, DOI 10.1006/bbrc.1995.2385; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; Roberson ED, 1996, LEARN MEMORY, V3, P1, DOI 10.1101/lm.3.1.1; SAKAGAMI H, 1994, MOL BRAIN RES, V25, P7, DOI 10.1016/0169-328X(94)90273-9; SCHWANINGER M, 1995, J BIOL CHEM, V270, P8860, DOI 10.1074/jbc.270.15.8860; STANTON PK, 1984, J NEUROSCI, V4, P3080; Thomas MJ, 1996, NEURON, V17, P475, DOI 10.1016/S0896-6273(00)80179-8; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; Traynelis SF, 1997, J PHYSIOL-LONDON, V503, P513, DOI 10.1111/j.1469-7793.1997.513bg.x; Wang JH, 1996, LEARN MEMORY, V3, P170, DOI 10.1101/lm.3.2-3.170; WANG JH, 1994, NEUROREPORT, V5, P2377, DOI 10.1097/00001756-199411000-00041; Wang JH, 1997, J NEUROSCI, V17, P4600; Yakel JL, 1997, TRENDS PHARMACOL SCI, V18, P124, DOI 10.1016/S0165-6147(97)01046-8; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	43	284	295	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 9	1998	92	1					25	37		10.1016/S0092-8674(00)80896-X	http://dx.doi.org/10.1016/S0092-8674(00)80896-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489697	hybrid			2022-12-28	WOS:000071473700005
J	Quintero, RA; Evans, MI				Quintero, RA; Evans, MI			Bringing surgery to the fetus	LANCET			English	Article									WAYNE STATE UNIV,HUTZEL HOSP,DEPT MOLEC MED,DETROIT,MI 48201; WAYNE STATE UNIV,HUTZEL HOSP,DEPT GENET & PATHOL,DETROIT,MI 48201	Wayne State University; Wayne State University	Quintero, RA (corresponding author), WAYNE STATE UNIV,HUTZEL HOSP,CTR FETAL DIAG & THERAPY,DEPT OBSTET & GYNECOL,DETROIT,MI 48201, USA.							DIFIORE JW, 1994, J PEDIATR SURG, V29, P248, DOI 10.1016/0022-3468(94)90328-X; NICOLAIDES KH, 1994, BRIT J OBSTET GYNAEC, V101, P782, DOI 10.1111/j.1471-0528.1994.tb11946.x; QUINTERO RA, 1995, LANCET, V346, P537, DOI 10.1016/S0140-6736(95)91381-5; QUINTERO RA, 1994, NEW ENGL J MED, V330, P469, DOI 10.1056/NEJM199402173300705; VILLE Y, 1995, NEW ENGL J MED, V332, P224, DOI 10.1056/NEJM199501263320404	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S18	S18		10.1016/0140-6736(95)90017-9	http://dx.doi.org/10.1016/0140-6736(95)90017-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454035				2022-12-28	WOS:A1995TN12200018
J	Gurnis, M; Muller, RD; Moresi, L				Gurnis, M; Muller, RD; Moresi, L			Cretaceous vertical motion of Australia and the Australian-Antarctic discordance	SCIENCE			English	Article							OCEAN RIDGE; MANTLE; CONVECTION; CONTINENTS; BOUNDARY; DEPTH; SLABS	A three-dimensional model of mantle convection in which the known history of plate tectonics is imposed predicts the anomalous Cretaceous vertical motion of Australia and the present-day distinctive geochemistry and geophysics of the Australian-Antarctic Discordance. The dynamic models infer that a subducted slab associated with the long-lived Gondwanaland-Pacific converging margin passed beneath Australia during the Cretaceous, partially stagnated in the mantle transition zone, and is presently being drawn up by the Southeast Indian Ridge.	CALTECH, Seismol Lab, Pasadena, CA 91125 USA; Univ Sydney, Dept Geol & Geophys, Sydney, NSW 2006, Australia; Commonwealth Sci & Ind Res Org Explorat & Min, Australian Geodynam Cooperat Res Ctr, Nedlands, WA 6009, Australia	California Institute of Technology; University of Sydney; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Gurnis, M (corresponding author), CALTECH, Seismol Lab, Pasadena, CA 91125 USA.	gurnis@caltech.edu; dietmar@es.su.oz.au; louis@ned.dem.csiro.au	Moresi, Louis/H-1390-2011; Müller, Dietmar/L-1200-2019	Moresi, Louis/0000-0003-3685-174X; Müller, Dietmar/0000-0002-3334-5764				ASIMOW PD, 1997, THESIS CALTECH PASAD; *BMR PAL GROUP, 1990, CRET PAL MAPS REC 19, V14; BOND G, 1978, GEOLOGY, V6, P247, DOI 10.1130/0091-7613(1978)6<247:SORSCA>2.0.CO;2; BRYAN S, 1996, EXTENDED ABSTRACTS G, V43, P124; CHRISTENSEN U, 1984, GEOPHYS J ROY ASTR S, V77, P343, DOI 10.1111/j.1365-246X.1984.tb01939.x; COCHRAN JR, 1977, GEOPHYS J ROY ASTR S, V50, P495, DOI 10.1111/j.1365-246X.1977.tb01334.x; EXON N F, 1976, BMR (Bureau of Mineral Resources) Journal of Australian Geology and Geophysics, V1, P33; Gallagher K., 1989, BASIN RES, V2, P115, DOI [10.1111/j.1365-2117.1989.tb00030.x, DOI 10.1111/J.1365-2117.1989.TB00030.X]; Gallagher K, 1994, BASIN RES, V6, P77, DOI 10.1111/j.1365-2117.1994.tb00077.x; GURNIS M, 1990, NATURE, V344, P754, DOI 10.1038/344754a0; HART SR, 1984, NATURE, V309, P753, DOI 10.1038/309753a0; KLEIN EM, 1987, J GEOPHYS RES-SOLID, V92, P8089, DOI 10.1029/JB092iB08p08089; KLEIN EM, 1988, NATURE, V333, P623, DOI 10.1038/333623a0; LANGMUIR CH, 1992, GEOPH MONOG SERIES, V71, P183; LAWVER LA, 1993, NATO ADV SCI INST SE, V391, P225; Lecroart P, 1997, EARTH PLANET SC LETT, V149, P49, DOI 10.1016/S0012-821X(97)00062-9; LithgowBertelloni C, 1997, GEOLOGY, V25, P735; Moresi L, 1996, EARTH PLANET SC LETT, V138, P15, DOI 10.1016/0012-821X(95)00221-W; MULLER RD, 1993, GEOLOGY, V21, P275, DOI 10.1130/0091-7613(1993)021<0275:RPMRTT>2.3.CO;2; Muller RD, 1997, J GEOPHYS RES-SOL EA, V102, P3211, DOI 10.1029/96JB01781; PRIBAC F, 1991, THESIS AUSTR NATL U; PYLE DG, 1992, EARTH PLANET SC LETT, V112, P161, DOI 10.1016/0012-821X(92)90014-M; PYLE DG, 1995, J GEOPHYS RES-SOL EA, V100, P22261, DOI 10.1029/95JB01424; Rehkamper M, 1997, EARTH PLANET SC LETT, V147, P93, DOI 10.1016/S0012-821X(97)00009-5; Russell M, 1994, BASIN RES, V6, P63, DOI 10.1111/j.1365-2117.1994.tb00076.x; Sloss L.L., 1988, SEDIMENTARY COVER N, VD-2, P25, DOI [10.1130/DNAG-GNA-D2.25, DOI 10.1130/DNAG-GNA-D2.25]; STOREY BC, 1995, NATURE, V377, P301, DOI 10.1038/377301a0; STRUCKMEYER HIM, 1990, 199011 BMR; TOLSTOY M, 1995, EOS T AGU, V76, P570; VANDERHILST R, 1993, EARTH PLANET SC LETT, V120, P395, DOI 10.1016/0012-821X(93)90253-6; VANDERHILST R, 1995, NATURE, V374, P154, DOI 10.1038/374154a0; VEEVERS JJ, 1982, NATURE, V295, P315, DOI 10.1038/295315a0; VEEVERS JJ, 1984, PHANEROZOIC EARTH HI, P210; Watts A. B., 1979, Deep Drilling Results in the Atlantic Ocean: Continental Margins and Paleoenvironment. Second Maurice Ewing Symposium, P218, DOI 10.1029/ME003p0218; WEISSEL JK, 1974, J GEOPHYS RES, V79, P2579, DOI 10.1029/JB079i017p02579; West BP, 1997, J GEOPHYS RES-SOL EA, V102, P7783, DOI 10.1029/96JB03895; WILLIAMS N, 1996, EXTENDED ABSTRACTS G, V43, P564; ZHONG S, 1997, EARTH INTERACT, V1	38	179	185	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 6	1998	279	5356					1499	1504		10.1126/science.279.5356.1499	http://dx.doi.org/10.1126/science.279.5356.1499			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488643				2022-12-28	WOS:000072372900056
J	Joyce, S; Woods, AS; Yewdell, JW; Bennink, JR; De Silva, AD; Boesteanu, A; Balk, SP; Cotter, RJ; Brutkiewicz, RR				Joyce, S; Woods, AS; Yewdell, JW; Bennink, JR; De Silva, AD; Boesteanu, A; Balk, SP; Cotter, RJ; Brutkiewicz, RR			Natural ligand of mouse CD1d1: Cellular glycosylphosphatidylinositol	SCIENCE			English	Article							FAST ATOM BOMBARDMENT; T-CELLS; MASS-SPECTROMETRY; PEPTIDES; FAMILY	Mouse CD1d1, a member of the CD1 family of evolutionarily conserved major histocompatibility antigen-like molecules, controls the differentiation and function of a T lymphocyte subset, NK1(+) natural T cells, proposed to regulate immune responses. The CD1d1 crystal structure revealed a large hydrophobic binding site occupied by a ligand of unknown chemical nature. Mass spectrometry and metabolic radiolabeling were used to identify cellular glycosylphosphatidylinositol as a major natural ligand of CD1d1. CD1d1 bound glycosylphosphatidylinositol through its phosphatidylinositol aspect with high affinity. Glycosylphosphatidylinositol or another glycolipid could be a candidate natural ligand for CD1d1-restricted T cells.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Joyce, S (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA.		yewdell, jyewdell@nih.gov jonathan/A-1702-2012	Brutkiewicz, Randy/0000-0002-7396-480X; JOYCE, Sebastian/0000-0002-3183-1451				ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; Baxter AG, 1997, DIABETES, V46, P572, DOI 10.2337/diabetes.46.4.572; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; BROOKS EG, 1993, P NATL ACAD SCI USA, V90, P11787, DOI 10.1073/pnas.90.24.11787; BRUTKIEWICZ RR, 1995, J EXP MED, V182, P1913, DOI 10.1084/jem.182.6.1913; CASTANO AR, 1995, SCIENCE, V269, P223, DOI 10.1126/science.7542403; Chen YH, 1997, IMMUNITY, V6, P459, DOI 10.1016/S1074-7613(00)80289-7; Exley M, 1997, J EXP MED, V186, P109, DOI 10.1084/jem.186.1.109; HELLER DN, 1988, ANAL CHEM, V60, P2787, DOI 10.1021/ac00175a029; HELLER DN, 1987, ANAL CHEM, V59, P2806, DOI 10.1021/ac00150a018; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JOYCE S, 1994, J EXP MED, V179, P577; JOYCE SA, UNPUB; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; MARTIN LH, 1986, P NATL ACAD SCI USA, V83, P9154, DOI 10.1073/pnas.83.23.9154; Mendiratta SK, 1997, IMMUNITY, V6, P469, DOI 10.1016/S1074-7613(00)80290-3; Smiley ST, 1997, SCIENCE, V275, P977, DOI 10.1126/science.275.5302.977; Sugita M, 1996, SCIENCE, V273, P349, DOI 10.1126/science.273.5273.349; SYKES M, 1990, J IMMUNOL, V145, P3209; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VARKI A, 1994, METHOD ENZYMOL, V230, P16; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411; WOODS AS, 1995, ANAL BIOCHEM, V226, P15, DOI 10.1006/abio.1995.1185; YOSHIMOTO T, 1995, SCIENCE, V270, P1845, DOI 10.1126/science.270.5243.1845; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	27	353	368	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1541	1544		10.1126/science.279.5356.1541	http://dx.doi.org/10.1126/science.279.5356.1541			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488653				2022-12-28	WOS:000072372900066
J	Gale, CA; Bendel, CM; McClellan, M; Hauser, M; Becker, JM; Berman, J; Hostetter, MK				Gale, CA; Bendel, CM; McClellan, M; Hauser, M; Becker, JM; Berman, J; Hostetter, MK			Linkage of adhesion, filamentous growth, and virulence in Candida albicans to a single gene, INT1	SCIENCE			English	Article							CELL-ADHESION; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; EPITHELIAL ADHESION; HYPHAL FORMATION; INTEGRIN ANALOG; PROTEIN; YEAST; MORPHOGENESIS; EXPRESSION	Adhesion and the ability to form filaments are thought to contribute to the pathogenicity of Candida albicans, the leading cause of fungal disease in immunocompromised patients. Int1p is a C. albicans surface protein with limited similarity to vertebrate integrins. INT1 expression in Saccharomyces cerevisiae was sufficient to direct the adhesion of this normally nonadherent yeast to human epithelial cells, Furthermore, disruption of INT1 in C. albicans suppressed hyphal growth, adhesion to epithelial cells, and virulence in mice, Thus, INT1 links adhesion, filamentous growth, and pathogenicity in C. albicans and Int1p may be an attractive target for the development of antifungal therapies.	Univ Minnesota, Dept Plant Biol, Biol Sci Ctr 220, St Paul, MN 55108 USA; Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA; Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Tennessee System; University of Tennessee Knoxville	Berman, J (corresponding author), Univ Minnesota, Dept Plant Biol, Biol Sci Ctr 220, 220 Biol Sci Ctr, St Paul, MN 55108 USA.		Berman, Judith/AAS-5115-2021; Berman, Judith/ABA-8528-2021	Berman, Judith/0000-0002-8577-0084; Bendel, Catherine/0000-0001-6093-5930	NIAID NIH HHS [AI25827] Funding Source: Medline; NICHD NIH HHS [HD00850, HD33692] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025827] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; BECKER JM, 1995, INFECT IMMUN, V63, P4515, DOI 10.1128/IAI.63.11.4515-4518.1995; BENDEL C, UNPUB; BENDEL CM, 1993, J CLIN INVEST, V92, P1840, DOI 10.1172/JCI116775; BENDEL CM, 1995, J INFECT DIS, V171, P1660, DOI 10.1093/infdis/171.6.1660; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COLE MF, 1995, FEMS MICROBIOL LETT, V126, P177, DOI 10.1111/j.1574-6968.1995.tb07413.x; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; FONZI WA, 1993, GENETICS, V134, P717; Gale C, 1996, P NATL ACAD SCI USA, V93, P357, DOI 10.1073/pnas.93.1.357; Gale C., UNPUB; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUSTAFSON KS, 1991, J CLIN INVEST, V87, P1896, DOI 10.1172/JCI115214; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JITSURONG S, 1993, MYCOPATHOLOGIA, V123, P95, DOI 10.1007/BF01365086; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KLOTZ SA, 1991, J INFECT DIS, V163, P604, DOI 10.1093/infdis/163.3.604; Kohler JR, 1996, P NATL ACAD SCI USA, V93, P13223, DOI 10.1073/pnas.93.23.13223; KURTZ MB, 1986, MOL CELL BIOL, V6, P142, DOI 10.1128/MCB.6.1.142; Leberer E, 1996, P NATL ACAD SCI USA, V93, P13217, DOI 10.1073/pnas.93.23.13217; LIU HP, 1994, SCIENCE, V266, P1723, DOI 10.1126/science.7992058; Lo HJ, 1997, CELL, V90, P939, DOI 10.1016/S0092-8674(00)80358-X; MAISCH PA, 1980, INFECT IMMUN, V27, P650, DOI 10.1128/IAI.27.2.650-656.1980; ODDS FC, 1988, CANDIDA CANDIDOSIS, P46; RADFORD DR, 1994, J MED MICROBIOL, V40, P416, DOI 10.1099/00222615-40-6-416; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAPORITOIRWIN SM, 1995, MOL CELL BIOL, V15, P601; WENZEL RP, 1991, INFECT CONT HOSP EP, V12, P523, DOI 10.1086/646403; Yan SH, 1996, INFECT IMMUN, V64, P2930, DOI 10.1128/IAI.64.8.2930-2935.1996	30	271	292	2	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	1998	279	5355					1355	1358		10.1126/science.279.5355.1355	http://dx.doi.org/10.1126/science.279.5355.1355			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478896				2022-12-28	WOS:000072251800051
J	Maccaferri, G; Toth, K; McBain, CJ				Maccaferri, G; Toth, K; McBain, CJ			Target-specific expression of presynaptic mossy fiber plasticity	SCIENCE			English	Article							LONG-TERM POTENTIATION; METABOTROPIC GLUTAMATE-RECEPTOR; RAT HIPPOCAMPUS; SYNAPSES; CELLS	Mossy fiber synaptic transmission at hippocampal CA3 pyramidal cells and interneurons was compared in rat brain slices to determine whether mossy terminals are functionally equivalent, Tetanic stimulation of mossy fibers induced long-term potentiation in pyramidal neurons but was either without effect or it induced depression at synapses onto interneurons. Unlike transmission onto pyramidal neurons, transmission onto interneurons was not potentiated after adenosine 3',5'-monophosphate (cAMP) activation. Furthermore, metabotropic glutamate receptor depression of transmission onto interneurons did not involve cAMP-dependent pathways, Thus, synaptic terminals arising from a common afferent pathway do not function as a single compartment but are specialized, depending on their postsynaptic target.	NICHHD, Lab Cellular & Mol Neurophysiol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	McBain, CJ (corresponding author), NICHHD, Lab Cellular & Mol Neurophysiol, Room 5A72,Bldg 49,9000 Rockville Pike, Bethesda, MD 20892 USA.							ACSADY L, 1997, 27 ANN M SOC NEUR NE; AMARAL DG, 1979, ANAT EMBRYOL, V155, P241, DOI 10.1007/BF00317638; BUZSAKI G, 1995, CURR OPIN NEUROBIOL, V5, P504, DOI 10.1016/0959-4388(95)80012-3; CLAIBORNE BJ, 1993, HIPPOCAMPUS, V3, P115, DOI 10.1002/hipo.450030202; Debanne D, 1996, J PHYSIOL-LONDON, V491, P163, DOI 10.1113/jphysiol.1996.sp021204; FROTSCHER M, 1985, J NEUROCYTOL, V14, P245, DOI 10.1007/BF01258450; GULYAS AI, 1992, NEUROSCIENCE, V48, P1, DOI 10.1016/0306-4522(92)90334-X; HOPKINS WF, 1988, J NEUROPHYSIOL, V59, P667, DOI 10.1152/jn.1988.59.2.667; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; Kamiya H, 1997, NEUROSCIENCE, V80, P89, DOI 10.1016/S0306-4522(97)00098-5; Kamiya H, 1996, J PHYSIOL-LONDON, V493, P447, DOI 10.1113/jphysiol.1996.sp021395; KATO K, 1993, NEUROSCIENCE, V53, P39, DOI 10.1016/0306-4522(93)90282-K; LANGDON RB, 1995, J NEUROBIOL, V26, P370, DOI 10.1002/neu.480260309; Maccaferri G, 1996, J NEUROSCI, V16, P5334; MACCAFERRI G, 1997, CAN J PHYSL PHARM, V75, P488; MACCAFERRI G, 1995, NEURON, V15, P135; McMahon LL, 1997, NEURON, V18, P295, DOI 10.1016/S0896-6273(00)80269-X; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; REYES AD, 1997, 27 ANN M SOC NEUR NE; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; Shigemoto R, 1996, NATURE, V381, P523, DOI 10.1038/381523a0; Thomson AM, 1997, J PHYSIOL-LONDON, V502, P131, DOI 10.1111/j.1469-7793.1997.131bl.x; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; WEISSKOPF MG, 1995, NATURE, V376, P256, DOI 10.1038/376256a0; WILLIAMS S, 1989, NEURON, V3, P583, DOI 10.1016/0896-6273(89)90268-7; XIANG Z, 1994, J NEUROPHYSIOL, V71, P2551; ZALUTSKY RA, 1990, SCIENCE, V248, P532	27	169	172	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	1998	279	5355					1368	1370		10.1126/science.279.5355.1368	http://dx.doi.org/10.1126/science.279.5355.1368			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478900				2022-12-28	WOS:000072251800055
J	Rouse, D; Mackay, P; Stirnberg, P; Estelle, M; Leyser, O				Rouse, D; Mackay, P; Stirnberg, P; Estelle, M; Leyser, O			Changes in auxin response from mutations in an AUX/IAA gene	SCIENCE			English	Article							ARABIDOPSIS-THALIANA; REGULATED GENES; MESSENGER-RNAS; LINKAGE MAP; EXPRESSION; TISSUE; ACID	Transcription of the AUX/IAA family of genes is rapidly induced by the plant hormone auxin, but evidence that AUX/IAA genes mediate further responses to auxin has been elusive. Changes in diverse auxin responses result from mutations in the Arabidopsis AXR3 gene. AXR3 was shown to be a member of the AUX/IAA family, providing direct evidence that AUX/IAA genes are central in auxin signaling, Molecular characterization of axr3 gain-of-function and loss-of-function mutations established the functional importance of domains conserved among AUX/IAA proteins.	Univ York, Dept Biol, York YO1 5YW, N Yorkshire, England; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	University of York - UK; Indiana University System; Indiana University Bloomington	Leyser, O (corresponding author), Univ York, Dept Biol, York YO1 5YW, N Yorkshire, England.		Rouse, Dean/B-3636-2009; Leyser, Ottoline/AAC-5577-2019	Leyser, Ottoline/0000-0003-2161-3829				ABEL S, 1995, J MOL BIOL, V251, P533, DOI 10.1006/jmbi.1995.0454; ABEL S, 1994, P NATL ACAD SCI USA, V91, P326, DOI 10.1073/pnas.91.1.326; AINLEY WM, 1988, J BIOL CHEM, V263, P10658; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; CONNER TW, 1990, PLANT MOL BIOL, V15, P3210; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; GIL P, 1994, PLANT PHYSIOL, V104, P777, DOI 10.1104/pp.104.2.777; Kim J, 1997, P NATL ACAD SCI USA, V94, P11786, DOI 10.1073/pnas.94.22.11786; KOORNNEEF M, 1983, J HERED, V74, P265, DOI 10.1093/oxfordjournals.jhered.a109781; Leyser HMO, 1996, PLANT J, V10, P403, DOI 10.1046/j.1365-313x.1996.10030403.x; LEYSER HMO, 1997, PHYSIOL PLANTARUM, V100, P407; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; PUTTERILL J, 1993, MOL GEN GENET, V239, P145, DOI 10.1007/BF00281613; SIMMONS C, 1995, J EXP BOT, V46, P143, DOI 10.1093/jxb/46.1.143; STIRNBERG P, UNPUB; THEOLOGIS A, 1985, J MOL BIOL, V183, P53, DOI 10.1016/0022-2836(85)90280-3; Ulmasov T, 1997, SCIENCE, V276, P1865, DOI 10.1126/science.276.5320.1865; WILSON AK, 1990, MOL GEN GENET, V222, P377, DOI 10.1007/BF00633843; YAMAMOTO KT, 1992, PLANT CELL PHYSIOL, V33, P93	20	281	304	11	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	1998	279	5355					1371	1373		10.1126/science.279.5355.1371	http://dx.doi.org/10.1126/science.279.5355.1371			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478901				2022-12-28	WOS:000072251800056
J	O'Connor, PG; Schottenfeld, RS				O'Connor, PG; Schottenfeld, RS			Medical progress - Patients with alcohol problems	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CARBOHYDRATE-DEFICIENT TRANSFERRIN; HEALTH-CARE COSTS; UNITED-STATES; WITHDRAWAL SYNDROME; CAGE QUESTIONNAIRE; PSYCHIATRIC-DISORDERS; DISULFIRAM TREATMENT; RELAPSE PREVENTION; MENTAL-DISORDERS; SUBSTANCE-ABUSE		Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA	Yale University; Yale University	O'Connor, PG (corresponding author), Yale Univ, Sch Med, Primary Care Ctr, Suite A,333 Cedar St,POB 208025, New Haven, CT 06520 USA.							Adams WL, 1996, JAMA-J AM MED ASSOC, V276, P1964; ALLEN JP, 1995, ARCH INTERN MED, V155, P1726, DOI 10.1001/archinte.155.16.1726; Allen JP, 1997, J STUD ALCOHOL, V58, P7; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; American Society of Addiction Medicine, 1996, PAT PLAC CRIT TREATM; Amodei N, 1996, J ADDICT DIS, V15, P19, DOI 10.1300/J069v15n01_02; ANDA RF, 1988, JAMA-J AM MED ASSOC, V260, P2529, DOI 10.1001/jama.260.17.2529; ASHLEY MJ, 1994, CAN MED ASSOC J, V151, P809; AVINS AL, 1994, JAMA-J AM MED ASSOC, V271, P515, DOI 10.1001/jama.271.7.515; BABOR TF, 1987, J STUD ALCOHOL, V48, P410, DOI 10.15288/jsa.1987.48.410; BERESFORD TP, 1990, LANCET, V336, P482, DOI 10.1016/0140-6736(90)92022-A; BIEN TH, 1993, ADDICTION, V88, P315, DOI 10.1111/j.1360-0443.1993.tb00820.x; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; BROWN SA, 1995, AM J PSYCHIAT, V152, P45; BUCHSBAUM DG, 1995, ARCH INTERN MED, V155, P104, DOI 10.1001/archinte.155.1.104; BUCHSBAUM DG, 1991, ANN INTERN MED, V115, P774, DOI 10.7326/0003-4819-115-10-774; BUSH B, 1987, AM J MED, V82, P231, DOI 10.1016/0002-9343(87)90061-1; Camargo CA, 1997, ARCH INTERN MED, V157, P79, DOI 10.1001/archinte.157.1.79; Carroll KM, 1997, MED CLIN N AM, V81, P927, DOI 10.1016/S0025-7125(05)70556-3; CHAPPEL JN, 1992, PSYCHIAT ANN, V22, P409, DOI 10.3928/0048-5713-19920801-06; CHERPITEL CJ, 1994, ALCOHOL ALCOHOLISM, V29, P211; CHICK J, 1992, BRIT J PSYCHIAT, V161, P84, DOI 10.1192/bjp.161.1.84; CLEARY PD, 1988, AM J MED, V85, P466; Committee on Treatment of Alcohol Problems, 1990, BROAD BAS TREATM ALC; Cornel M, 1996, ALCOHOL ALCOHOLISM, V31, P287; Dawson D A, 1995, J Subst Abuse, V7, P331, DOI 10.1016/0899-3289(95)90026-8; Dawson DA, 1996, ALCOHOL CLIN EXP RES, V20, P771, DOI 10.1111/j.1530-0277.1996.tb01685.x; DuPont R. L., 1994, BRIDGE RECOVERY INTR; Finney JW, 1996, ADDICTION, V91, P1773, DOI 10.1046/j.1360-0443.1996.911217733.x; FLEMING MF, 1991, J STUD ALCOHOL, V52, P33, DOI 10.15288/jsa.1991.52.33; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; FREZZA M, 1990, NEW ENGL J MED, V322, P95, DOI 10.1056/NEJM199001113220205; FRIEDMAN GD, 1993, NEW ENGL J MED, V329, P1882, DOI 10.1056/NEJM199312163292510; FUCHS CS, 1995, NEW ENGL J MED, V332, P1245, DOI 10.1056/NEJM199505113321901; FULLER RK, 1986, JAMA-J AM MED ASSOC, V256, P1449, DOI 10.1001/jama.256.11.1449; GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501; GERBERT B, 1991, JAMA-J AM MED ASSOC, V266, P2837, DOI 10.1001/jama.266.20.2837; GERSTEIN DR, 1990, NEW ENGL J MED, V323, P844, DOI 10.1056/NEJM199009203231230; Grant BF, 1996, J SUBST ABUSE, V8, P195, DOI 10.1016/S0899-3289(96)90249-7; Hanna EZ, 1997, ALCOHOL CLIN EXP RES, V21, P111; HAYASHIDA M, 1989, NEW ENGL J MED, V320, P358, DOI 10.1056/NEJM198902093200605; HELZER JE, 1988, J STUD ALCOHOL, V49, P219, DOI 10.15288/jsa.1988.49.219; HELZER JE, 1991, PSYCHIAT DISORDERS A, P81; Hill S Y, 1995, Recent Dev Alcohol, V12, P181; HOLDER H, 1991, J STUD ALCOHOL, V52, P517, DOI 10.15288/jsa.1991.52.517; HORWITZ RI, 1989, ARCH INTERN MED, V149, P1089, DOI 10.1001/archinte.149.5.1089; Humphreys K, 1996, PSYCHIATR SERV, V47, P709; Hurt RD, 1996, JAMA-J AM MED ASSOC, V275, P1097, DOI 10.1001/jama.275.14.1097; *I MED, 1989, PREV TREATM ALC PROB; ISAACSON JH, 1994, J GEN INTERN MED, V9, P550, DOI 10.1007/BF02599279; JOHNSON NP, 1994, J SUBST ABUSE TREAT, V11, P137; Kessler RC, 1996, AM J ORTHOPSYCHIAT, V66, P17, DOI 10.1037/h0080151; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KITCHENS JM, 1994, JAMA-J AM MED ASSOC, V272, P1782, DOI 10.1001/jama.272.22.1782; Kristenson H, 1995, ALCOHOL ALCOHOLISM, V30, P775; LANGENBUCHER J, 1994, ALCOHOL CLIN EXP RES, V18, P1033, DOI 10.1111/j.1530-0277.1994.tb00079.x; Lesch OM, 1996, ALCOHOL ALCOHOLISM, V31, P265; Lewis DC, 1996, J ADDICT DIS, V15, P1, DOI 10.1300/J069v15n01_01; LIEBER CS, 1995, NEW ENGL J MED, V333, P1058, DOI 10.1056/NEJM199510193331607; Light JM, 1996, J STUD ALCOHOL, V57, P507, DOI 10.15288/jsa.1996.57.507; LISKOW B, 1995, J STUD ALCOHOL, V56, P277, DOI 10.15288/jsa.1995.56.277; Litten RZ, 1996, ALCOHOL CLIN EXP RES, V20, P859, DOI 10.1111/j.1530-0277.1996.tb05264.x; MayoSmith MF, 1997, JAMA-J AM MED ASSOC, V278, P144, DOI 10.1001/jama.278.2.144; McCrady, 1993, RES ALCOHOLICS ANONY, P41; McCrady BS, 1996, ARCH GEN PSYCHIAT, V53, P737; MCCRADY BS, 1989, HDB ALCOHOLISM TREAT, P153; Miller B A, 1995, Recent Dev Alcohol, V12, P81; Miller W, 2002, MOTIVATIONAL INTERVI, V2nd; MONTI PM, 1990, J STUD ALCOHOL, V51, P263, DOI 10.15288/jsa.1990.51.263; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; MORSE RM, 1992, JAMA-J AM MED ASSOC, V268, P1012, DOI 10.1001/jama.268.8.1012; MULLER A, 1996, ADDICTION, V91, P321; *NAT I ALC AB ALC, 1995, NIH PUBL; OBRIEN CP, 1994, ALCOHOL, V11, P433, DOI 10.1016/0741-8329(94)90063-9; OCONNOR PG, 1994, NEW ENGL J MED, V331, P450, DOI 10.1056/NEJM199408183310707; OFARRELL TJ, 1993, J STUD ALCOHOL, V54, P652, DOI 10.15288/jsa.1993.54.652; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; OMALLEY SS, 1995, PSYCHIAT ANN, V25, P681, DOI 10.3928/0048-5713-19951101-11; PAILLE FM, 1995, ALCOHOL ALCOHOLISM, V30, P239; Parish DC, 1997, JAMA-J AM MED ASSOC, V277, P1079, DOI 10.1001/jama.277.13.1079; Potter JD, 1997, NEW ENGL J MED, V337, P1763, DOI 10.1056/NEJM199712113372410; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; RIVARA FP, 1993, JAMA-J AM MED ASSOC, V270, P1962, DOI 10.1001/jama.270.16.1962; SAITZ R, 1995, J GEN INTERN MED, V10, P479, DOI 10.1007/BF02602395; SAITZ R, 1994, JAMA-J AM MED ASSOC, V272, P519, DOI 10.1001/jama.272.7.519; Samet JH, 1996, ARCH INTERN MED, V156, P2287, DOI 10.1001/archinte.156.20.2287; Sass H, 1996, ARCH GEN PSYCHIAT, V53, P673; Sass H, 1996, ARCH GEN PSYCHIAT, V53, P1097; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schiodt FV, 1997, NEW ENGL J MED, V337, P1112, DOI 10.1056/NEJM199710163371602; *SECR HLTH HUM SER, 1995, NIH PUBL; SELLERS EM, 1983, CLIN PHARMACOL THER, V34, P822, DOI 10.1038/clpt.1983.256; Sher KJ, 1996, ALCOHOL CLIN EXP RES, V20, P485, DOI 10.1111/j.1530-0277.1996.tb01079.x; Skog OJ, 1996, ADDICTION, V91, P325, DOI 10.1111/j.1360-0443.1996.tb02283.x; Sobell LC, 1996, AM J PUBLIC HEALTH, V86, P966, DOI 10.2105/AJPH.86.7.966; SULLIVAN JT, 1989, BRIT J ADDICT, V84, P1353; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; TONNESEN H, 1994, BRIT J CANCER, V69, P327, DOI 10.1038/bjc.1994.59; TURNER RC, 1989, J GEN INTERN MED, V4, P432, DOI 10.1007/BF02599697; U.S. Preventive Services Task Force, 1996, GUID CLIN PREV SERV; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; VOLPICELLI JR, 1995, LANCET, V346, P456, DOI 10.1016/S0140-6736(95)91316-5; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663; WALSH DC, 1991, NEW ENGL J MED, V325, P775, DOI 10.1056/NEJM199109123251105; Watson CG, 1996, J NERV MENT DIS, V184, P623, DOI 10.1097/00005053-199610000-00007; Whitworth AB, 1996, LANCET, V347, P1438, DOI 10.1016/S0140-6736(96)91682-7; *WHO BRIEF INT STU, 1996, AM J PUBLIC HEALTH, V86, P949; Wilk AI, 1997, J GEN INTERN MED, V12, P274; WILSON A, 1985, ALCOHOL CLIN EXP RES, V9, P23, DOI 10.1111/j.1530-0277.1985.tb05043.x; YERSIN B, 1995, ARCH INTERN MED, V155, P1907, DOI 10.1001/archinte.155.17.1907; 1995, AM J PSYCHIAT S, V152, P1	112	197	202	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 26	1998	338	9					592	602		10.1056/NEJM199802263380907	http://dx.doi.org/10.1056/NEJM199802263380907			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YY708	9475768				2022-12-28	WOS:000072175700007
J	Jadad, AR; Gagliardi, A				Jadad, AR; Gagliardi, A			Rating health information on the Internet - Navigating to knowledge or to Babel?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RANDOMIZED CONTROLLED TRIALS; QUALITY	Context.-The rapid growth of the Internet has triggered an information revolution of unprecedented magnitude. Despite its obvious benefits, the increase in the availability of information could also result in many potentially harmful effects on both consumers and health professionals who do not use it appropriately. Objectives.-To identify instruments used to rate Web sites providing health information on the Internet, rate criteria used by them, establish the degree of validation of the instruments, and provide future directions for research in this area. Data Sources.-MEDLINE (1966-1997), CINHAL (1982-1997), HEALTH (1975-1997), Information Science Abstracts (1966 to September 1995), Library and Information Science Abstracts (1969-1995), and Library Literature (1984-1996);the search engines Lycos, Excite, Open Text, Yahoo, HotBot, Infoseek, and Magellan; Internet discussion lists; meeting proceedings; multiple Web pages; and reference lists. Instrument Selection.-Instruments used at least once to rate the quality of Web sites providing health information with their rating criteria available on the Internet. Data Extraction.-The name of the developing organization, Internet address, rating criteria, information on the development of the instrument, number and background of people generating the assessments, and data on the validity and reliability of the measurements. Data Synthesis.-A total of 47 rating instruments were identified. Fourteen provided a description of the criteria used to produce the ratings, and 5 of these provided instructions for their use. None of the instruments identified provided information on the interobserver reliability and construct validity of the measurements. Conclusions.-Many incompletely developed instruments to evaluate health information exist on the Internet. It is unclear, however, whether they should exist in the first place, whether they measure what they claim to measure, or whether they lead to more good than harm.	McMaster Univ, Dept Clin Epidemiol & Biostat, Hlth Informat Res Unit, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Canadian Cochrane Network & Ctr, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Support Canc Care Res Unit, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, McMaster Evidence Based Practice Ctr, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University; McMaster University; McMaster University	Jadad, AR (corresponding author), McMaster Univ, Med Ctr, Hlth Informat Res Unit, 3H7,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.							Bennett-Clark J., 1996, KIPLINGERS PERSO JUN, P96; Bero LA, 1997, ANN INTERN MED, V127, P37, DOI 10.7326/0003-4819-127-1-199707010-00007; Degner L., 1995, CANCER PRACT, V3, P275; FERGUSON T, 1996, HLTH FORUM J     JAN, P28; Fernsler J., 1995, CANCER PRACT, V3, P277; Hayward RSA, 1997, HLTH MEASURES, P28; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; Moher D, 1996, INT J TECHNOL ASSESS, V12, P195, DOI 10.1017/S0266462300009570; Peters R, 1997, JAMA-J AM MED ASSOC, V277, P1258, DOI 10.1001/jama.277.15.1258; REDELMEIER DA, 1993, JAMA-J AM MED ASSOC, V270, P72, DOI 10.1001/jama.270.1.72; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244; Vaitones V, 1995, Cancer Pract, V3, P274; Widman LE, 1997, ARCH INTERN MED, V157, P209, DOI 10.1001/archinte.157.2.209; Wyatt JC, 1997, BRIT MED J, V314, P1879, DOI 10.1136/bmj.314.7098.1879	14	491	500	0	39	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	1998	279	8					611	614		10.1001/jama.279.8.611	http://dx.doi.org/10.1001/jama.279.8.611			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX457	9486757				2022-12-28	WOS:000072041900038
J	Swiss, S; Jennings, PJ; Aryee, GV; Brown, GH; Jappah-Samukai, RM; Kamara, MS; Schaack, RDH; Turay-Kanneh, RS				Swiss, S; Jennings, PJ; Aryee, GV; Brown, GH; Jappah-Samukai, RM; Kamara, MS; Schaack, RDH; Turay-Kanneh, RS			Violence against women during the Liberian civil conflict	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RAPE	Context.-Civilians were often the casualties of fighting during the recent Liberian civil conflict. Liberian health care workers played a crucial role in documenting violence against women by soliders and fighters during the war. Objective.-To document women's experiences of violence, including rape and sexual coercion, from a soldier or fighter during 5 years of the Liberian civil war from 1989 through 1994. Design.-Interview and survey. Setting.-High schools, markets, displaced persons camps, and urban communities in Monrovia, Liberia, in 1994. Participants.-A random sample of 205 women and girls between the ages of 15 and 70 years (88% participation rate). Results.-One hundred (49%) of 205 participants reported experiencing at least 1 act of physical or sexual Violence by a soldier or fighter. Survey participants reported being beaten, tied up, or detained in a room under armed guard (17%); strip-searched 1 or more times (32%); and raped, subjected to attempted rape, or sexually coerced (15%). Women who were accused of belonging to a particular ethnic group or fighting faction or who were forced to cook for a soldier or fighter were at increased risk for physical and sexual violence. Of the 106 women and girls accused of belonging to an ethnic group or faction, 65 (61%) reported that they were beaten, locked up, strip-searched, or subjected to attempted rape, compared with 27 (27%) of the 99 women who were not accused (P less than or equal to.02, .07, .001, and .06, respectively). Women and girls who were forced to cook for a soldier or fighter were more likely to report experiencing rape, attempted rape, or sexual coercion than those who were not forced to cook (55% vs 10%; P less than or equal to.001, .06, and .001, respectively). Young women (those younger than 25 years) were more likely than women 25 years or older to report experiencing attempted rape and sexual coercion (18% vs 4%, P=.02 and .04, respectively). Conclusions.-This collaborative research allowed Liberian women to document wartime violence against women in their own communities and to develop a unique program to address violence against women in Liberia.	Womens Rights Int, Laramie, WY 82073 USA; Boston Univ, Sch Publ Hlth, Boston, MA USA; Univ Wyoming, Dept Psychol, Laramie, WY 82071 USA; Don Bosco Polytech, Mother Patern Coll Hlth Sci, Womens Hlth & Dev Program, Monrovia, Liberia	Boston University; University of Wyoming	Swiss, S (corresponding author), Womens Rights Int, POB 1667, Laramie, WY 82073 USA.							*AG INT DEV OFF US, 1991, 17 AG INT DEV OFF US; *CDCP, 1994, EP INF COMP PROGR VE; *HUM RIGHTS WATCH, 1997, LIB EM DESTR; KOSS MP, 1993, J INTERPERS VIOLENCE, V8, P198, DOI 10.1177/088626093008002004; *SPSS INC, 1995, SPSS COMP SOFTW VERS; SWISS S, 1993, JAMA-J AM MED ASSOC, V270, P612, DOI 10.1001/jama.270.5.612; *UN, ECN4199854; *UN COMM HUM RIGHT, IN PRESS REP SPEC RA	8	67	67	2	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	1998	279	8					625	629		10.1001/jama.279.8.625	http://dx.doi.org/10.1001/jama.279.8.625			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YX457	9486762				2022-12-28	WOS:000072041900043
J	King, C; Siegel, M; Celebucki, C; Connolly, GN				King, C; Siegel, M; Celebucki, C; Connolly, GN			Adolescent exposure to cigarette advertising in magazines - An evaluation of brand-specific advertising in relation to youth readership	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADS	Context.-Understanding the relationship between cigarette advertising and youth smoking is essential to develop effective interventions. Magazine advertising accounts for nearly half of all cigarette advertising expenditures. Objective.-To investigate whether cigarette brands popular among adolescent smokers are more likely than adult brands to advertise in magazines with high adolescent readerships. Design.-Cross-sectional analysis of 1994 data on (1) the presence of advertising by 12 cigarette brands in a sample of 39 popular US magazines; and (2) the youth (ages 12-17 years), young adult (ages 18-24 years), and total readership for each magazine. Main Outcome Measures.-The presence or absence of advertising in each of the 39 magazines in 1994 for each of the 12 cigarette brands. Results.-After controlling for total magazine readership, the percentage of young adult readers, advertising costs and expenditures, and magazine demographics, youth cigarette brands (those smoked by more than 2.5% of 10- to 15-year-old smokers in 1993) were more likely than adult brands to advertise in magazines with a higher percentage of youth readers. Holding all other variables constant at their sample means, the estimated probability of an adult brand advertising in a magazine decreased over the observed range of youth readership from 0.73 (95% confidence interval [CI], 0.50-0.96) for magazines with 4% youth readers to 0.18 (95% CI, 0.00-0.47) for magazines with 34% youth readers, In contrast, the estimated probability of a youth brand advertising in a magazine increased from 0.32 (95% CI, 0.00-0.65) at 4% youth readership to 0.92 (95% CI, 0.67-1.00) at 34% youth readership. Conclusion.-Cigarette brands popular among young adolescents are more likely than adult brands to advertise in magazines with high youth readerships.	Boston Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02118 USA; Harvard Univ, Grad Sch Business Adm, Boston, MA USA; Massachusetts Dept Publ Hlth, Massachusetts Tobacco Control Program, Boston, MA USA	Boston University; Harvard University; Massachusetts Department of Public Health	Siegel, M (corresponding author), Boston Univ, Sch Publ Hlth, Dept Social & Behav Sci, 715 Albany St, Boston, MA 02118 USA.	mbsiegel@bu.edu						ALBRIGHT CL, 1988, HEALTH EDUC QUART, V15, P225, DOI 10.1177/109019818801500207; ALTMAN DG, 1987, J COMMUN, V37, P95, DOI 10.1111/j.1460-2466.1987.tb01010.x; Basil M, 1991, HEALTH COMMUN, V3, P75; *CONC SOFTW INC, 1994, DBMS COPY TOOL SOFTW; *FED TRAD COMM, 1996, FED TRAD COMM REP C; FOX BJ, 1997, ANAL PROPOSED RESOLU; FREEMAN H, 1993, TOBACCO USE AM CRISI, P32; HUANG PP, 1992, TOB CONTROL, V1, P249; HUTCHINGS R, 1981, P NAT C SMOK HLTH DE, P249; KING KW, 1991, J PUBLIC POLICY MARK, V10, P63, DOI 10.1177/074391569101000106; KRUPKA LR, 1990, J DRUG EDUC, V20, P15, DOI 10.2190/6BWW-RG2B-CV80-XYXN; *LEAD NAT ADV, 1994, 1994 BRAND DET REP; Lynch BS., 1994, GROWING TOBACCO FREE; *MED RES INC, 1994, MED RES INC MRI TEEN; Pollay RW, 1996, J MARKETING, V60, P1, DOI 10.2307/1251927; POLLAY RW, 1993, ADV CONSUM RES, V20, P266; *SAS I INC, 1994, SAS STAT SOFTW CHANG; *SIMM MARK RES BUR, 1994, SIMM STUD MED MARK P; *SIMM MARK RES BUR, 1994, SIMM STUD MED MARK M; *SIMM MARK RES BUR, 1994, SIMM STUD MED MARK D; *SIMM MARK RES BUR, 1994, SIMM TEEN AG RES STU; *SRDS, 1997, SRDS CONS MAG ADV SO; *STAT CORP, 1997, STATA STAT SOFTW REL; *US DHHS, 1994, PREV TOB US YOUNG PE; Warner K.E., 1992, TOB CONTROL, V1, P25; WARNER KE, 1985, HEALTH EDUC QUART, V12, P115, DOI 10.1177/109019818501200111; WARNER KE, 1986, SELLING SMOKE CIGARE; 1984, TIME MAGAZINE   0409, V123, P91; 1996, FED REG, P44396	29	57	57	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	1998	279	7					516	520		10.1001/jama.279.7.516	http://dx.doi.org/10.1001/jama.279.7.516			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YW470	9480361	Bronze			2022-12-28	WOS:000071938900032
J	Moore, WB; Schubert, G; Tackley, P				Moore, WB; Schubert, G; Tackley, P			Three-dimensional simulations of plume-lithosphere interaction at the Hawaiian swell	SCIENCE			English	Article							TEMPERATURE-DEPENDENT VISCOSITY; HOT-SPOT SWELLS; THERMAL ORIGIN; SUBLITHOSPHERIC DEPTHS; PERIDOTITE KLB-1; HOTSPOT SWELLS; HEAT-FLOW; CONVECTION; MANTLE; INSTABILITIES	Rapid lithospheric thinning by mantle plumes has not been achieved in numerical experiments performed to date. Efficient thinning depends on small-scale instabilities that convectively remove lithospheric material. These instabilities are favored by hotter plumes or stronger temperature dependence of viscosity, and a simple scaling independent of rheology controls their onset. This scaling allows extrapolation of the results of numerical experiments to the Earth's mantle. Mantle plumes between 100 and 150 kelvins hotter than the background mantle should exhibit small-scale convective rolls aligned with the plate motion. The unusual variation in heat flow across the Hawaiian swell may be due to such instabilities. It was found that the spreading of the plume creates a downwelling curtain of material that isolates it from the rest of the mantle for distances of at least 1000 kilometers from the plume origin. This isolation has important consequences for the geochemical heterogeneity of the lithosphere and upper mantle.	Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Moore, WB (corresponding author), Univ Calif Los Angeles, Dept Earth & Space Sci, 3806 Geol Bldg, Los Angeles, CA 90095 USA.		Tackley, Paul J/D-8155-2016	Tackley, Paul J/0000-0003-4878-621X				BORCH RS, 1989, PHYS EARTH PLANET IN, V55, P269, DOI 10.1016/0031-9201(89)90075-7; BUSSE FH, 1971, J FLUID MECH, V47, P305, DOI 10.1017/S0022112071001071; CALDWELL JG, 1979, J GEOPHYS RES, V84, P7572, DOI 10.1029/JB084iB13p07572; CROUGH ST, 1978, GEOPHYS J ROY ASTR S, V55, P451, DOI 10.1111/j.1365-246X.1978.tb04282.x; CROUGH ST, 1976, EARTH PLANET SC LETT, V31, P397, DOI 10.1016/0012-821X(76)90121-7; DAVAILLE A, 1993, J FLUID MECH, V253, P141, DOI 10.1017/S0022112093001740; DAVAILLE A, 1994, J GEOPHYS RES-SOL EA, V99, P19853, DOI 10.1029/94JB01405; DAVIES GF, 1988, J GEOPHYS RES-SOLID, V93, P10467, DOI 10.1029/JB093iB09p10467; DETRICK RS, 1978, J GEOPHYS RES, V83, P1236, DOI 10.1029/JB083iB03p01236; DIETZ RS, 1953, J GEOL, V61, P99, DOI 10.1086/626059; FISHBEIN EF, 1988, THESIS U CALIFORNIA; FLEITOUT L, 1984, J GEOPHYS RES, V89, P9227, DOI 10.1029/JB089iB11p09227; FLEITOUT L, 1986, TECTONOPHYSICS, V132, P271, DOI 10.1016/0040-1951(86)90037-5; FOWLER AC, 1985, STUD APPL MATH, V72, P189; Gliko A. O., 1986, Izvestiya Academy of Sciences USSR, Physics of the Solid Earth, V22, P257; GRIFFITHS RW, 1991, J GEOPHYS RES-SOL EA, V96, P18295, DOI 10.1029/91JB01897; LIU MA, 1989, J GEOPHYS RES-SOLID, V94, P5571, DOI 10.1029/JB094iB05p05571; MONNEREAU M, 1993, J GEOPHYS RES-SOL EA, V98, P809, DOI 10.1029/92JB01677; MORRIS S, 1984, PHYS EARTH PLANET IN, V36, P35; NATAF HC, 1982, PHYS EARTH PLANET IN, V29, P320, DOI 10.1016/0031-9201(82)90020-6; PHIPPSMORGAN WJ, 1995, J GEOPHYS RES, V100, P8045; RIBE NM, 1994, J GEOPHYS RES-SOL EA, V99, P669, DOI 10.1029/93JB02386; Ribe NM, 1996, J GEOPHYS RES-SOL EA, V101, P16195, DOI 10.1029/96JB01187; RICHTER FM, 1983, J FLUID MECH, V129, P173, DOI 10.1017/S0022112083000713; RICHTER FM, 1973, J GEOPHYS RES, V78, P8735, DOI 10.1029/JB078i035p08735; ROBINSON EM, 1987, EARTH PLANET SC LETT, V82, P335, DOI 10.1016/0012-821X(87)90207-X; ROBINSON EM, 1988, J GEOPHYS RES-SOLID, V93, P3469, DOI 10.1029/JB093iB04p03469; SANDWELL DT, 1982, J GEOPHYS RES, V87, P1001, DOI 10.1029/JB087iB02p01001; SLEEP NH, 1990, J GEOPHYS RES-SOLID, V95, P6715, DOI 10.1029/JB095iB05p06715; Sleep NH, 1996, J GEOPHYS RES-SOL EA, V101, P28065, DOI 10.1029/96JB02463; SLEEP NH, 1994, J GEOPHYS RES-SOL EA, V99, P9327, DOI 10.1029/94JB00240; SPOHN T, 1983, TECTONOPHYSICS, V94, P67, DOI 10.1016/0040-1951(83)90010-0; Tackley PJ, 1996, J GEOPHYS RES-SOL EA, V101, P3311, DOI 10.1029/95JB03211; TACKLEY PJ, 1994, THESIS CALTECH PASAD; TAKAHASHI E, 1986, J GEOPHYS RES-SOLID, V91, P9367, DOI 10.1029/JB091iB09p09367; VANKEKEN PE, 1995, J GEOPHYS RES-SOL EA, V100, P20291, DOI 10.1029/95JB01152; VONHERZEN RP, 1989, J GEOPHYS RES-SOLID, V94, P13783, DOI 10.1029/JB094iB10p13783; VONHERZEN RP, 1982, J GEOPHYS RES, V87, P6711, DOI 10.1029/JB087iB08p06711; Woods MT, 1996, GEOPHYS J INT, V125, P325, DOI 10.1111/j.1365-246X.1996.tb00002.x; YUEN DA, 1985, NATURE, V313, P125, DOI 10.1038/313125a0; ZHANG JZ, 1994, J GEOPHYS RES-SOL EA, V99, P17729, DOI 10.1029/94JB01406	41	86	87	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1008	1011		10.1126/science.279.5353.1008	http://dx.doi.org/10.1126/science.279.5353.1008			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461428				2022-12-28	WOS:000072006400040
J	Yang, ZY; Delgado, R; Xu, L; Todd, RF; Nabel, EG; Sanchez, A; Nabel, GJ				Yang, ZY; Delgado, R; Xu, L; Todd, RF; Nabel, EG; Sanchez, A; Nabel, GJ			Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins	SCIENCE			English	Article							MARBURG VIRUS; CELLS	The mechanisms by which Ebola virus evades detection and infects cells to cause hemorrhagic fever have not been defined, though its glycoprotein, synthesized in either a secreted or transmembrane form, is likely involved. Here the secreted glycoprotein was found to interact with neutrophils through CD16b, the neutrophil-specific form of the Fc gamma receptor III, whereas the transmembrane glycoprotein was found to interact with endothelial cells but not neutrophils. A murine retroviral vector pseudotyped with the transmembrane glycoprotein preferentially infected endothelial cells. Thus, the secreted glycoprotein inhibits early neutrophil activation, which likely affects the host response to infection, whereas binding of the transmembrane glycoprotein to endothelial cells may contribute to the hemorrhagic symptoms of this disease.	Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Ctr Dis Control & Prevent, Atlanta, GA 30333 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Centers for Disease Control & Prevention - USA	Nabel, GJ (corresponding author), Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.		Todd, Robert/GWM-4486-2022; DELGADO, RAFAEL/A-2938-2012; Delgado, Rafael/C-4910-2016	Delgado, Rafael/0000-0002-6912-4736				BOWEN ETW, 1977, LANCET, V1, P571; CDC, 1995, MMWR-MORBID MORTAL W, V44, P381; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EMBRETSON JE, 1987, J VIROL, V61, P3454, DOI 10.1128/JVI.61.11.3454-3462.1987; Gallaher WR, 1996, CELL, V85, P477, DOI 10.1016/S0092-8674(00)81248-9; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; LEGUENNO B, 1995, LANCET, V345, P1271, DOI 10.1016/S0140-6736(95)90925-7; Peters C.J., 1996, FIELDS VIROLOGY, P1161; SANCHEZ A, 1993, VIRUS RES, V29, P215, DOI 10.1016/0168-1702(93)90063-S; Sanchez A, 1996, P NATL ACAD SCI USA, V93, P3602, DOI 10.1073/pnas.93.8.3602; SANCHEZ A, UNPUB; SCHNITTLER HJ, 1993, J CLIN INVEST, V91, P1301, DOI 10.1172/JCI116329; Volchkov VE, 1995, VIROLOGY, V214, P421, DOI 10.1006/viro.1995.0052; Xu L, 1998, NAT MED, V4, P37, DOI 10.1038/nm0198-037; YANG ZB, UNPUB	15	216	238	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1034	1037		10.1126/science.279.5353.1034	http://dx.doi.org/10.1126/science.279.5353.1034			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461435				2022-12-28	WOS:000072006400047
J	Mossessova, E; Gulbis, JM; Goldberg, J				Mossessova, E; Gulbis, JM; Goldberg, J			Structure of the guanine nucleotide exchange factor Sec7 domain of human Arno and analysis of the interaction with ARF GTPase	CELL			English	Article							ADP-RIBOSYLATION FACTOR-1; PROTEIN-PROTEIN RECOGNITION; HA-RAS P21; AMINO-TERMINUS; MOLECULAR MECHANISM; ESCHERICHIA-COLI; MYRISTOYLATION; IDENTIFICATION; BINDING; SURFACE	Sec7-related guanine nucleotide exchange factors (GEFs) initiate vesicle budding from the Golgi membrane surface by converting the GTPase ARF to a GTP-bound, membrane-associated form. Here we report the crystal structure of the catalytic Sec7 homology domain of Arno, a human GEF for ARF1, determined at 2.2 Angstrom resolution. The Sec7 domain is an elongated, all-helical protein with a distinctive hydrophobic groove that is phylogenetically conserved. Structure-based mutagenesis identifies the groove and an adjacent conserved loop as the ARF-interacting surface. The sites of Sec7 domain interaction on ARF1 have subsequently been mapped, by protein footprinting experiments, to the switch 1 and switch 2 GTPase regions, leading to a model for the interaction between ARF GTPases and Sec7 domain exchange factors.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Goldberg, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.							ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1992, XPLOR VERSION 3 1 MA; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Crechet JB, 1996, J BIOL CHEM, V271, P17234, DOI 10.1074/jbc.271.29.17234; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; FRANCO M, 1993, J BIOL CHEM, V268, P24531; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; HEYDUK E, 1994, BIOCHEMISTRY-US, V33, P9643, DOI 10.1021/bi00198a033; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; JANIN J, 1990, J BIOL CHEM, V265, P16027; KAHN RA, 1992, J BIOL CHEM, V267, P13039; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; Liemann S, 1997, CELL MOL LIFE SCI, V53, P516, DOI 10.1007/s000180050065; Mendenhall W., 1988, STAT ENG COMPUTER SC; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; RANDAZZO PA, 1994, J BIOL CHEM, V269, P29490; RANDAZZO PA, 1995, J BIOL CHEM, V270, P14809, DOI 10.1074/jbc.270.24.14809; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Wang Y, 1997, J MOL BIOL, V270, P648, DOI 10.1006/jmbi.1997.1139; YOUNG L, 1994, PROTEIN SCI, V3, P717; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0	52	146	150	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 6	1998	92	3					415	423		10.1016/S0092-8674(00)80933-2	http://dx.doi.org/10.1016/S0092-8674(00)80933-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YX283	9476900	hybrid			2022-12-28	WOS:000072024700012
J	Eyer, J; Cleveland, DW; Wong, PC; Peterson, AC				Eyer, J; Cleveland, DW; Wong, PC; Peterson, AC			Pathogenesis of two axonopathies does not require axonal neurofilaments	NATURE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DISEASE; DYSTONIA-MUSCULORUM; MOUSE MODEL; DEGENERATION; MICE; GENE; SUBUNIT; PATHOLOGY; TRANSGENE	Neurofilaments are a major component of the axonal cytoskeleton and their abnormal accumulation is a prominent feature of the cytopathology encountered in several neurodegenerative diseases(1-8). Thus, an attractive and widely held model of pathogenesis involves the participation of disrupted neurofilaments as a common toxic intermediate(9-13). Here, in direct contrast to this hypothesis, we show that two neurodegenerative disease models in the mouse, dystonia musculorum (dt)(14,15) and a superoxide dismutase 1 (SOD1)-mediated form of human motor neuron disease (amyotrophic lateral sclerosis, ALS)(16,17), progress with little or no abatement on a transgenic background in which neurofilaments are withheld from the axonal compartment(18). By specifically excluding a necessary role for axonal neurofilaments, our observations redefine the components of the pathogenic pathway leading to axon disruption in these two degenerative diseases.	McGill Univ, Royal Victoria Hosp, Mol Oncol Grp, Dev Biol Lab, Montreal, PQ H3A 1A1, Canada; INSERM, CJF 97 08, F-49033 Angers, France; Univ Angers, CHU, F-49033 Angers, France; Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA	McGill University; Royal Victoria Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Johns Hopkins University	Peterson, AC (corresponding author), McGill Univ, Royal Victoria Hosp, Mol Oncol Grp, Dev Biol Lab, H-5,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	Alan@devbiol2.molonc.mcgill.ca	Eyer, Joel/K-4265-2015; Cleveland, Don/AAN-9783-2021; Eyer, Joel/V-8679-2019	Eyer, Joel/0000-0001-6301-7465; Eyer, Joel/0000-0001-6301-7465; Cleveland, Don/0000-0002-1934-3682				BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BROWN A, 1995, NAT GENET, V10, P301, DOI 10.1038/ng0795-301; CAMPBELL RM, 1992, NEURON, V9, P693, DOI 10.1016/0896-6273(92)90032-9; CARDEN MJ, 1986, NEUROCHEM PATHOL, V5, P25, DOI 10.1007/BF03028034; CARPENTER S, 1968, NEUROLOGY, V18, P841, DOI 10.1212/WNL.18.9.841; CLEVELAND DW, 1996, NEUROLOGY, V47, P54; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; DICKSON DW, 1986, ACTA NEUROPATHOL, V71, P216, DOI 10.1007/BF00688042; Duchen L W, 1976, Adv Neurol, V14, P353; EYER J, 1989, J NEUROCHEM, V52, P1759, DOI 10.1111/j.1471-4159.1989.tb07254.x; EYER J, 1994, NEURON, V12, P389, DOI 10.1016/0896-6273(94)90280-1; FIGLEWICZ DA, 1994, HUM MOL GENET, V3, P1757, DOI 10.1093/hmg/3.10.1757; GOLDMAN JE, 1986, ANN NEUROL, V19, P209, DOI 10.1002/ana.410190302; GRIFFIN JW, 1980, EXPT CLIN NEUROTOXIC, P161; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HILL WD, 1991, J COMP NEUROL, V309, P150, DOI 10.1002/cne.903090111; KOTHARY R, 1988, NATURE, V335, P435, DOI 10.1038/335435a0; LEE MK, 1994, CURR OPIN CELL BIOL, V6, P34, DOI 10.1016/0955-0674(94)90113-9; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; Plummer J, 1995, MOL CELL NEUROSCI, V6, P532, DOI 10.1006/mcne.1995.0005; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SOTELO C, 1988, NEUROSCIENCE, V27, P403, DOI 10.1016/0306-4522(88)90277-1; Tu PH, 1997, J NEUROSCI, V17, P1064; Vechio JD, 1996, ANN NEUROL, V40, P603, DOI 10.1002/ana.410400410; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; Yang YM, 1996, CELL, V86, P655, DOI 10.1016/S0092-8674(00)80138-5	30	84	87	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 5	1998	391	6667					584	587		10.1038/35378	http://dx.doi.org/10.1038/35378			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468135				2022-12-28	WOS:000071842300051
J	Olatunbosun, OA; Edouard, L; Pierson, RA				Olatunbosun, OA; Edouard, L; Pierson, RA			Physicians' attitudes toward evidence based obstetric practice: a questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article									Univ Saskatchewan, Coll Med, Dept Obstet & Gynaecol, Saskatoon, SK S7N 0W8, Canada; Univ Saskatchewan, Coll Med, Dept Epidemiol & Community Hlth, Saskatoon, SK S7N 0W0, Canada	University of Saskatchewan; University of Saskatchewan	Olatunbosun, OA (corresponding author), Univ Saskatchewan, Coll Med, Dept Obstet & Gynaecol, Saskatoon, SK S7N 0W8, Canada.		Pierson, Roger/A-4395-2008	Pierson, Roger/0000-0003-4435-0515				[Anonymous], 1995, LANCET, V346, P785; *COCHR COLL, 1996, COCHR DAT SYST REV C; GRIMES D, 1993, JAMA-J AM MED ASSOC, V28, P3030; Knottnerus JA, 1997, BRIT MED J, V315, P1109; Olatunbosun OA, 1997, INT J GYNECOL OBSTET, V56, P171, DOI 10.1016/S0020-7292(96)02803-2	5	59	62	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 31	1998	316	7128					365	366		10.1136/bmj.316.7128.365	http://dx.doi.org/10.1136/bmj.316.7128.365			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487175	Green Published			2022-12-28	WOS:000071863900030
J	Pencheon, D				Pencheon, D			NHS direct: managing demand	BRITISH MEDICAL JOURNAL			English	Article									Univ Cambridge, Inst Publ Hlth, Cambridge CB2 2SR, England	University of Cambridge	Pencheon, D (corresponding author), Univ Cambridge, Inst Publ Hlth, Cambridge CB2 2SR, England.							*CHIEF MED OFF, 1997, DEV EM SERV COMM; Flood AB, 1996, J GEN INTERN MED, V11, P342, DOI 10.1007/BF02600045; SABIN JE, 1992, BRIT MED J, V305, P514, DOI 10.1136/bmj.305.6852.514	3	12	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					215	216						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468696				2022-12-28	WOS:000071616400041
J	Sibbald, B; Roland, M				Sibbald, B; Roland, M			Understanding controlled trials - Why are randomised controlled trials important?	BRITISH MEDICAL JOURNAL			English	Article									Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England	University of Manchester	Sibbald, B (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.							BREWIN CR, 1989, BRIT MED J, V299, P313, DOI 10.1136/bmj.299.6694.313; Fairhurst K, 1996, J Health Serv Res Policy, V1, P77; LANMAN JT, 1954, JAMA-J AM MED ASSOC, V155, P223, DOI 10.1001/jama.1954.03690210001001; RUSSELL I, 1995, BRIT MED J, V311, P1243, DOI 10.1136/bmj.311.7015.1243; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SMITHELLS RW, 1980, LANCET, V1, P339; WALD N, 1991, LANCET, V338, P131; [No title captured]	8	391	397	0	48	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					201	201						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468688				2022-12-28	WOS:000071616400030
J	Orphanides, G; LeRoy, G; Chang, CH; Luse, DS; Reinberg, D				Orphanides, G; LeRoy, G; Chang, CH; Luse, DS; Reinberg, D			FACT, a factor that facilitates transcript elongation through nucleosomes	CELL			English	Article							RNA-POLYMERASE-II; REMODELING FACTOR; CHROMATIN; DNA; STIMULATION; ACTIVATION; TEMPLATES; COMPLEX; BINDING; PURIFICATION	The requirements for transcriptional activation by RNA polymerase II were examined using chromatin templates assembled in vitro and a transcription system composed of the human general transcription factors and RNA polymerase II. Activator-induced, energy-dependent chromatin remodeling promoted efficient preinitiation complex formation and transcription initiation, but was not sufficient for productive transcription. Polymerases that initiated transcription on remodeled chromatin templates encountered a block to transcription proximal to the promoter. Entry into productive transcription required an accessory factor present in HeLa cell nuclear extract, FACT (facilitates chromatin transcription), which we have purified. FACT acts subsequent to transcription initiation to release RNA polymerase II from a nucleosome-induced block to productive transcription. The biochemical properties anal polypeptide composition of FACT suggest that it is a novel protein factor that facilitates transcript elongation through nucleosomes.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucle Acid Enzymol,Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Cleveland Clinic Foundation	Reinberg, D (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucle Acid Enzymol,Howard Hughes Med Inst, Piscataway, NJ 08854 USA.			Reinberg, Danny/0000-0003-4288-2016	NIGMS NIH HHS [GM-37120, GM-29487] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029487, R37GM037120, R01GM037120] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Bulger M., 1994, METH MOL G, V5, P241; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Chang CH, 1997, J BIOL CHEM, V272, P23427, DOI 10.1074/jbc.272.37.23427; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DING HF, 1994, SCIENCE, V265, P796, DOI 10.1126/science.8047885; FLORES O, 1992, J BIOL CHEM, V267, P2786; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GRALLA JD, 1985, P NATL ACAD SCI USA, V82, P3078, DOI 10.1073/pnas.82.10.3078; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GUARENTE L, 1995, TRENDS BIOCHEM SCI, V20, P517, DOI 10.1016/S0968-0004(00)89120-3; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LUSE DS, 1987, J BIOL CHEM, V262, P289; Ma DM, 1996, P NATL ACAD SCI USA, V93, P6583, DOI 10.1073/pnas.93.13.6583; Maldonado E, 1996, METHOD ENZYMOL, V274, P72; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; REECE RJ, 1993, GENE, V126, P105, DOI 10.1016/0378-1119(93)90596-U; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; UCKER DS, 1984, J BIOL CHEM, V259, P7416; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; WOLFFE AP, 1994, CURR BIOL, V4, P523; WOLFFE AP, 1993, METH MOL G, V2, P314; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	47	491	503	2	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 9	1998	92	1					105	116		10.1016/S0092-8674(00)80903-4	http://dx.doi.org/10.1016/S0092-8674(00)80903-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489704	Bronze			2022-12-28	WOS:000071473700012
J	Tajbakhsh, S; Sporle, R				Tajbakhsh, S; Sporle, R			Somite development: Constructing the vertebrate body	CELL			English	Article; Proceedings Paper	Meeting on Somite Development - Constructing the Vertebrate Body	OCT, 1997	FRANCE				CELLS		Inst Pasteur, Dept Mol Biol, CNRS, URA 1947, F-75724 Paris 15, France; GSF, Natl Res Ctr Environm & Hlth, Inst Mammalian Genet, ISG, D-85764 Neuherberg, Germany	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Tajbakhsh, S (corresponding author), Inst Pasteur, Dept Mol Biol, CNRS, URA 1947, 25 Rue Dr Roux, F-75724 Paris 15, France.							Blagden CS, 1997, GENE DEV, V11, P2163, DOI 10.1101/gad.11.17.2163; Borycki AG, 1997, DEV BIOL, V185, P185, DOI 10.1006/dbio.1997.8555; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; Denetclaw WF, 1997, DEVELOPMENT, V124, P1601; Dietrich S, 1997, DEVELOPMENT, V124, P3895; DU JS, 1997, J CELL BIOL, V139, P145; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; Gossler A, 1998, CURR TOP DEV BIOL, V38, P225; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Huang R, 1996, ACTA ANAT, V155, P231; Johnston SH, 1997, DEVELOPMENT, V124, P2245; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; Nicolas JF, 1996, DEVELOPMENT, V122, P2933; Orioli D, 1997, TRENDS GENET, V13, P354, DOI 10.1016/S0168-9525(97)01220-1; Palmeirim I, 1997, CELL, V91, P639, DOI 10.1016/S0092-8674(00)80451-1; Sporle R, 1997, CURR OPIN GENET DEV, V7, P507, DOI 10.1016/S0959-437X(97)80078-0; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Tonegawa A, 1997, DEVELOPMENT, V124, P1975; vanEeden FJM, 1996, DEVELOPMENT, V123, P153	22	54	54	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 9	1998	92	1					9	16		10.1016/S0092-8674(00)80894-6	http://dx.doi.org/10.1016/S0092-8674(00)80894-6			8	Biochemistry & Molecular Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489695	Bronze			2022-12-28	WOS:000071473700003
J	SanchezTapias, JM; Rodes, J				SanchezTapias, JM; Rodes, J			Interferon in chronic hepatitis C	LANCET			English	Article											SanchezTapias, JM (corresponding author), UNIV BARCELONA,FAC MED,HOSP CLIN,DEPT MED,LIVER UNIT,VILLARROEL 170,E-080306 BARCELONA,SPAIN.							CHEMELLO L, 1995, HEPATOLOGY, V22, P700, DOI 10.1016/0270-9139(95)90286-4; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; SHINDO M, 1995, ANN INTERN MED, V122, P586, DOI 10.7326/0003-4819-122-8-199504150-00005; TERRAULT N, 1995, NEW ENGL J MED, V332, P1509, DOI 10.1056/NEJM199506013322211	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S11	S11		10.1016/0140-6736(95)90010-1	http://dx.doi.org/10.1016/0140-6736(95)90010-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454028				2022-12-28	WOS:A1995TN12200011
J	Lee, MJ; Van Brocklyn, JR; Thangada, S; Liu, CH; Hand, AR; Menzeleev, R; Spiegel, S; Hla, T				Lee, MJ; Van Brocklyn, JR; Thangada, S; Liu, CH; Hand, AR; Menzeleev, R; Spiegel, S; Hla, T			Sphingosine-1-phosphate as a ligand for the G protein coupled receptor EDG-1	SCIENCE			English	Article							CELL-ADHESION; MAP KINASE; TYROSINE PHOSPHORYLATION; LYSOPHOSPHATIDIC ACID; SIGNALING PATHWAY; MOLECULAR-CLONING; GROWTH-FACTOR; MORPHOGENESIS; FIBROBLASTS; ACTIVATION	The sphingolipid metabolite sphingosine-1-phosphate (SPP) has been implicated as a second messenger in cell proliferation and survival. However, many of its biological effects are due to binding to unidentified receptors on the cell surface, SPP activated the heterotrimeric guanine nucleotide binding protein (G protein)-coupled orphan receptor EDG-1, originally cloned as Endothelial Differentiation Gene-1, EDG-1 bound SPP with high affinity (dissociation constant = 8.1 nM) and high specificity, Overexpression of EDG-1 induced exaggerated cell-cell aggregation, enhanced expression of cadherins, and formation of well-developed adherens junctions in a manner dependent on SPP and the small guanine nucleotide binding protein Rho.	Univ Connecticut, Sch Med, Dept Physiol, Farmington, CT 06030 USA; Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Univ Connecticut, Ctr Hlth, Dept Pediat Dent, Farmington, CT 06030 USA	University of Connecticut; Georgetown University; University of Connecticut	Hla, T (corresponding author), Univ Connecticut, Sch Med, Dept Physiol, Farmington, CT 06030 USA.		Van Brocklyn, Jim/A-9733-2010; Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065	NHLBI NIH HHS [HL49094] Funding Source: Medline; NIDDK NIH HHS [DK45659] Funding Source: Medline; NIGMS NIH HHS [GM43880] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880, R01GM043880] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; Bohm SK, 1997, BIOCHEM J, V322, P1; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HLA T, 1990, J BIOL CHEM, V265, P9308; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Lee M., UNPUB; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Masana MI, 1995, RECEPTOR CHANNEL, V3, P255; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; MURAYAMA T, 1983, J BIOL CHEM, V258, P3319; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Pyne S, 1996, EUR J BIOCHEM, V237, P819, DOI 10.1111/j.1432-1033.1996.0819p.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; TAKEICHI M, 1992, COLD SPRING HARB SYM, V57, P327, DOI 10.1101/SQB.1992.057.01.037; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; Yatomi Y, 1997, J BIOCHEM, V121, P969; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193	45	846	875	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1552	1555		10.1126/science.279.5356.1552	http://dx.doi.org/10.1126/science.279.5356.1552			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488656				2022-12-28	WOS:000072372900069
J	Baumgartner, S; Beer, J; Masarik, J; Wagner, G; Meynadier, L; Synal, HA				Baumgartner, S; Beer, J; Masarik, J; Wagner, G; Meynadier, L; Synal, HA			Geomagnetic modulation of the Cl-36 flux in the GRIP ice core, Greenland	SCIENCE			English	Article							ENHANCED BE-10 DEPOSITION; INTENSITY VARIATION; FIELD INTENSITY; ANTARCTIC ICE; SEDIMENTS; RECORDS; CLIMATE; SEA; PALEOINTENSITY	Geomagnetic field strength is expected to affect the production rate of cosmogenic isotopes such as beryllium-10, carbon-14, or chlorine-36. Chlorine-36 data from the Greenland Ice Gore Project (GRIP) ice core agree well with a production rate calculation based on a paleomagnetic reconstruction for the past 100,000 years over both lane-and short-term variations, A chlorine-36 peak at 38,000 years ago previously found in the beryllium-10 record from the Vostok ice core can be explained by a period of law geomagnetic field intensity.	Swiss Fed Inst Sci & Technol, CH-8600 Dubendorf, Switzerland; Inst Phys Globe, CNRS, Lab Geochim & Cosmochim 1758, F-75252 Paris 5, France; ETH Honggerberg, Paul Scherrer Inst, CH-8093 Zurich, Switzerland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Swiss Federal Institutes of Technology Domain; ETH Zurich; Paul Scherrer Institute	Beer, J (corresponding author), Swiss Fed Inst Sci & Technol, CH-8600 Dubendorf, Switzerland.		Masarik, Jozef/A-8008-2018; Meynadier, Laure/A-6349-2011; Synal, Hans-Arno/AAD-4556-2019	Masarik, Jozef/0000-0002-0963-0055; Meynadier, Laure/0000-0003-3411-4551; Synal, Hans-Arno/0000-0001-5621-3089				BAMGARTNER S, 1997, J GEOPHYS RES, V102, P26659; Bard E, 1997, EARTH PLANET SC LETT, V150, P453, DOI 10.1016/S0012-821X(97)00082-4; BEER J, 1988, NATURE, V331, P675, DOI 10.1038/331675a0; BEER J, 1992, NATO ASI SER, V12, P141; BENDER M, 1994, NATURE, V372, P663, DOI 10.1038/372663a0; Bentley HW, 1986, HDB ENV ISOTOPE GE B, P427; CASTAGNOLI GC, 1995, GEOPHYS RES LETT, V22, P707, DOI 10.1029/95GL00298; CHARLES CD, 1994, SCIENCE, V263, P508, DOI 10.1126/science.263.5146.508; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; Finkel RC, 1997, J GEOPHYS RES-OCEANS, V102, P26699, DOI 10.1029/97JC01282; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; Guyodo Y, 1996, EARTH PLANET SC LETT, V143, P23, DOI 10.1016/0012-821X(96)00121-5; HAMMER CU, 1993, NATURE, V363, P666, DOI 10.1038/363666g0; Johnsen SJ, 1989, TELLUS B, V41, P452, DOI 10.1111/j.1600-0889.1989.tb00321.x; KENT DV, 1977, NATURE, V266, P156, DOI 10.1038/266156a0; Lal D., 1967, HANDBUCH PHYSIK    2, V46, P551, DOI [DOI 10.1007/978-3-642-46079-1_7, 10.1007/978-3-642-46079-1_7]; Lehman B, 1996, PHYS EARTH PLANET IN, V93, P269, DOI 10.1016/0031-9201(95)03070-0; MASARIK J, 1997, P 25 INT COSM RAY C, V2, P461; MAZAUD A, 1994, GEOPHYS RES LETT, V21, P337, DOI 10.1029/93GL02789; MCHARGUE LR, 1995, GEOPHYS RES LETT, V22, P659, DOI 10.1029/95GL00169; MEYNADIER L, 1992, EARTH PLANET SC LETT, V114, P39, DOI 10.1016/0012-821X(92)90150-T; RAISBECK GM, 1987, NATURE, V326, P273, DOI 10.1038/326273a0; Robinson C, 1995, EARTH PLANET SC LETT, V136, P551, DOI 10.1016/0012-821X(95)00202-N; SCHNEIDER DA, 1993, EARTH PLANET SC LETT, V120, P301, DOI 10.1016/0012-821X(93)90246-6; SHARMA P, 1990, 5 INT C AMS NORTH HO, P410; SONETT CP, 1992, RADIOCARBON, V34, P239, DOI 10.1017/S0033822200013680; Steig EJ, 1996, GEOPHYS RES LETT, V23, P523, DOI 10.1029/96GL00255; STONER JS, 1995, EARTH PLANET SC LETT, V134, P237, DOI 10.1016/0012-821X(95)00134-X; TRIC E, 1992, J GEOPHYS RES-SOL EA, V97, P9337, DOI 10.1029/91JB01620; Yamazakia T, 1995, EARTH PLANET SC LETT, V136, P525, DOI 10.1016/0012-821X(95)00189-J; Yiou F, 1997, J GEOPHYS RES-OCEANS, V102, P26783, DOI 10.1029/97JC01265	31	95	98	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	1998	279	5355					1330	1332		10.1126/science.279.5355.1330	http://dx.doi.org/10.1126/science.279.5355.1330			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478888				2022-12-28	WOS:000072251800043
J	Silva, M; Richard, C; Benito, A; Sanz, C; Olalla, I; Fernandez-Luna, JL				Silva, M; Richard, C; Benito, A; Sanz, C; Olalla, I; Fernandez-Luna, JL			Expression of Bcl-x in erythroid precursors from patients with polycythemia vera	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH FACTOR-I; CELL-DEATH; ERYTHROPOIETIN; APOPTOSIS; MARROW; DIFFERENTIATION; ERYTHROCYTOSIS; PROGENITORS; MECHANISM; SURVIVAL	Background Deregulating the expression of Bcl-x(L), an inhibitor of apoptosis, in an erythropoietin-dependent erythroblast cell line averts apoptosis induced by the withdrawal of erythropoietin. Since in polycythemia vera an abnormal clone of erythroid progenitors is independent of erythropoietin, we investigated whether the endogenous expression of Bcl-x(L) was deregulated in these cells. Methods Erythroid colonies from patients with polycythemia vera and normal subjects were cultured in the presence and absence of erythropoietin and assessed by immunocytochemical and flow-cytometric analysis with anti-Bcl-x antibodies that recognize the two species of Bcl-x (Bcl-x(L) and Bcl-x(S)). Reverse-transcriptase-polymerase-chain-reaction analysis was used to determine which one of the two species was responsible for anti-Bcl-x staining. Bone marrow mononuclear cells from 8 healthy bone marrow donors, 14 patients with polycythemia vera, 19 patients with other myeloproliferative syndromes, and 12 patients with secondary erythrocytosis were analyzed by flow cytometry with antibodies against Bcl-x and glycophorin A, an erythroid marker. Results Erythroid cells from patients with polycythemia vera survived in vitro without erythropoietin, and this finding correlated with the expression of Bcl-x protein (Bcl-x(L) messenger RNA was the main species of Bcl-x found), even in mature erythroblasts that normally do not express Bcl-x. The mean (+/-SD) percentage of cells positive for both glycophorin A and Bcl-x in the 14 patients with polycythemia vera (21.8+/-3.6 percent) was significantly higher than that in 8 normal donors (6.62+/-1.58 percent), 12 patients with secondary erythrocytosis (6.87+/-1.95 percent), 9 patients with essential thrombocythemia (3.81+/-0.97 percent), and 10 patients with chronic myeloid leukemia (2.7+/-0.41 percent). Conclusions Deregulated expression of Bcl-x may contribute to the erythropoietin-independent survival of erythroid-lineage cells in polycythemia vera and thereby contribute to the pathogenesis of this disease. (C) 1998, Massachusetts Medical Society.	Hosp Univ Marques de Valdecilla, Serv Immunol, INSALUD, Santander 39008, Spain; Hosp Univ Marques Valdecilla, Serv Hematol, Santander 39008, Spain	Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario Marques de Valdecilla (HUMV)	Fernandez-Luna, JL (corresponding author), Hosp Univ Marques de Valdecilla, Serv Immunol, INSALUD, Santander 39008, Spain.							BENITO A, 1995, AM J PATHOL, V146, P481; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; BERLIN NI, 1975, SEMIN HEMATOL, V12, P339; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CORREA PN, 1994, BLOOD, V83, P99; COTES PM, 1986, NEW ENGL J MED, V315, P283, DOI 10.1056/NEJM198607313150503; ERIDANI S, 1984, BRIT J HAEMATOL, V56, P157, DOI 10.1111/j.1365-2141.1984.tb01282.x; FISHER MJ, 1994, BLOOD, V84, P1982; GREENBERG BR, 1977, NEW ENGL J MED, V296, P1080, DOI 10.1056/NEJM197705122961902; HESS G, 1994, BRIT J HAEMATOL, V88, P794, DOI 10.1111/j.1365-2141.1994.tb05119.x; Hoffman Ronald, 1995, P1121; Hughes Timothy P., 1995, P1142; KELLEY LL, 1993, BLOOD, V82, P2340; KOEFFLER HP, 1981, ANN INTERN MED, V94, P44, DOI 10.7326/0003-4819-94-1-44; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRANTZ SB, 1991, BLOOD, V77, P419; LEMOINE F, 1986, BLOOD, V68, P996; Liu Q, 1997, J IMMUNOL, V159, P829; Mirza AM, 1997, BLOOD, V89, P1862, DOI 10.1182/blood.V89.6.1862; MUTA K, 1993, J CELL PHYSIOL, V156, P264, DOI 10.1002/jcp.1041560207; PRCHAL JF, 1974, NEW ENGL J MED, V290, P1382; Sanz C, 1997, BLOOD, V89, P3199, DOI 10.1182/blood.V89.9.3199; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; SOKOL L, 1993, LANCET, V342, P115, DOI 10.1016/0140-6736(93)91317-F; TEPPERMAN AD, 1974, BLOOD, V44, P659, DOI 10.1182/blood.V44.5.659.659; YARBRO JW, 1992, SEMIN ONCOL, V19, P1	27	173	182	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 26	1998	338	9					564	571		10.1056/NEJM199802263380902	http://dx.doi.org/10.1056/NEJM199802263380902			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY708	9475763				2022-12-28	WOS:000072175700002
J	Cascalho, M; Wong, J; Steinberg, C; Wabl, M				Cascalho, M; Wong, J; Steinberg, C; Wabl, M			Mismatch repair co-opted by hypermutation	SCIENCE			English	Article							NONPOLYPOSIS COLON-CANCER; ESCHERICHIA-COLI; HOMOLOG; MICE; MOUSE; METHYLATION; MUTATIONS; ANTIBODY; EXTRACTS; MSH2	Mice homozygous for a disrupted allele of the mismatch repair gene Pms2 have a mutator phenotype. When this allele is crossed into quasi-monoclonal (QM) mice, which have a very limited B cell repertoire, homozygotes have fewer somatic mutations at the immunoglobulin heavy chain acid lambda chain loci than do heterozygotes or wild-type QM mice, That is, mismatch repair seems to contribute to somatic hypermutation rather than stifling it. It is suggested that at immunoglobulin loci in hypermutable B cells, mismatched base pairs are "corrected" according to the newly synthesized DNA strand, thereby fixing incipient mutations instead of eliminating them.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wabl, M (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.	mutator@itsa.ucsf.edu		Cascalho, Marilia/0000-0002-2695-3921	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037699] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01 GM37699] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BRENNER S, 1966, NATURE, V211, P242, DOI 10.1038/211242a0; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Cascalho M, 1997, J IMMUNOL, V159, P5795; Cascalho M, 1996, SCIENCE, V272, P1649, DOI 10.1126/science.272.5268.1649; CASCALHO M, UNPUB; CHEN JZ, 1993, EMBO J, V12, P821, DOI 10.1002/j.1460-2075.1993.tb05722.x; CHEN JZ, 1993, INT IMMUNOL, V5, P647, DOI 10.1093/intimm/5.6.647; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; IMANISHIKARI T, UNPUB; Kim N, 1997, J EXP MED, V186, P413, DOI 10.1084/jem.186.3.413; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Loeb LA, 1997, SCIENCE, V277, P1449, DOI 10.1126/science.277.5331.1449; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; MCKEAN D, 1984, P NATL ACAD SCI-BIOL, V81, P3180, DOI 10.1073/pnas.81.10.3180; MESELSON M, 1988, RECOMBINATION GENETI, P91; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; NEVERS P, 1975, MOL GEN GENET, V139, P233, DOI 10.1007/BF00268974; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PUKKILA PJ, 1983, GENETICS, V104, P571; Reynaud C A, 1996, Semin Immunol, V8, P125, DOI 10.1006/smim.1996.0016; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Wabl M, 1996, CURR OPIN IMMUNOL, V8, P89, DOI 10.1016/S0952-7915(96)80110-5; WABL M, 1987, IMMUNOL REV, V96, P90, DOI 10.1111/j.1600-065X.1987.tb00511.x; WEIGERT MG, 1970, NATURE, V228, P1045, DOI 10.1038/2281045a0	30	138	150	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	1998	279	5354					1207	1210		10.1126/science.279.5354.1207	http://dx.doi.org/10.1126/science.279.5354.1207			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469811				2022-12-28	WOS:000072115200043
J	Giroir, BP				Giroir, BP			New therapies for severe meningococcal disease	LANCET			English	Letter									Univ Texas, SW Med Ctr, Dept Paediat, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Giroir, BP (corresponding author), Univ Texas, SW Med Ctr, Dept Paediat, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							DEDRICK RL, 1995, INFECT IMMUN, V63, P1362, DOI 10.1128/IAI.63.4.1362-1368.1995; DEGROOT R, 1996, ADV TREATM MEN SEPT; Duncan A, 1997, LANCET, V350, P1565, DOI 10.1016/S0140-6736(05)64007-X; Giroir BP, 1997, LANCET, V350, P1439, DOI 10.1016/S0140-6736(97)06468-4; MCCLOSKEY RV, 1994, ANN INTERN MED, V121, P1, DOI 10.7326/0003-4819-121-1-199407010-00001	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	1998	351	9101					526	527						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482481				2022-12-28	WOS:000072097700062
J	Sheth, SG; LaMont, JT				Sheth, SG; LaMont, JT			Toxic megacolon	LANCET			English	Article							SEVERE ULCERATIVE-COLITIS; INFLAMMATORY BOWEL-DISEASE; NITRIC-OXIDE SYNTHASE; SELF-LIMITED COLITIS; PSEUDOMEMBRANOUS ENTEROCOLITIS; CONTROLLED TRIAL; MANAGEMENT; DILATATION; INFECTION; THERAPY		Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	LaMont, JT (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, 330 Brookline Ave, Boston, MA 02215 USA.	jlamont@bidmc.harvard.edu						ALEMAYEHU G, 1991, AM J GASTROENTEROL, V86, P187; Arienti V, 1996, AM J GASTROENTEROL, V91, P2163; ATHERTON LD, 1984, GASTROENTEROLOGY, V86, P1583; BEAUGERIE L, 1994, GASTROENTEROLOGY, V107, P858, DOI 10.1016/0016-5085(94)90137-6; BLOCK GE, 1977, SURGERY, V82, P531; BOULTON R, 1994, AM J GASTROENTEROL, V89, P931; BROWN CH, 1968, AM J DIG DIS, V13, P813, DOI 10.1007/BF02233098; BURKE GW, 1988, AM J GASTROENTEROL, V83, P304; CAPRILLI R, 1976, GUT, V17, P763, DOI 10.1136/gut.17.10.763; CAPRILLI R, 1987, J CLIN GASTROENTEROL, V9, P160, DOI 10.1097/00004836-198704000-00010; CHRISTIANSON K A, 1987, Journal of the Royal College of Surgeons of Edinburgh, V32, P109; CONNOLLY GM, 1987, POSTGRAD MED J, V63, P1103, DOI 10.1136/pgmj.63.746.1103; COOPER HS, 1977, GASTROENTEROLOGY, V72, P1253; DALTON HR, 1991, ANN MED, V23, P389, DOI 10.3109/07853899109148078; DANOVITCH SH, 1989, GASTROENTEROL CLIN N, V18, P73; DAVIDSON T, 1991, BRIT J SURG, V78, P924, DOI 10.1002/bjs.1800780809; DICKINSON RJ, 1980, GASTROENTEROLOGY, V79, P1199; EDWARDS FC, 1964, GUT, V5, P1; FARMER RG, 1993, DIGEST DIS SCI, V38, P1137, DOI 10.1007/BF01295733; FAZIO VW, 1980, CLIN GASTROENTEROL, V9, P389; FLATMARK A, 1975, SCAND J GASTROENTERO, V10, P427; GARRETT JM, 1967, GASTROENTEROLOGY, V53, P93; GONZALEZ A, 1985, ARCH INTERN MED, V145, P2120, DOI 10.1001/archinte.145.11.2120; GRAND RJ, 1995, GASTROENTEROL CLIN N, V24, P613; GRANT CS, 1984, AM J SURG, V147, P106, DOI 10.1016/0002-9610(84)90042-4; GREENSTEIN AJ, 1975, AM J GASTROENTEROL, V63, P117; GRIECO MB, 1980, ANN SURG, V191, P75, DOI 10.1097/00000658-198001000-00015; JALAN KN, 1969, GASTROENTEROLOGY, V57, P68, DOI 10.1016/s0016-5085(19)33962-9; KALKAY MN, 1983, AM J GASTROENTEROL, V78, P557; KOUDAHL G, 1975, SCAND J GASTROENTERO, V10, P417; LENNARDJONES JE, 1975, GUT, V16, P579, DOI 10.1136/gut.16.8.579; MARSHAK RH, 1950, GASTROENTEROLOGY, V16, P768, DOI 10.1016/S0016-5085(19)36490-X; MCINERNEY GT, 1962, GASTROENTEROLOGY, V42, P244; MCINTYRE PB, 1986, GUT, V27, P481, DOI 10.1136/gut.27.5.481; MEYERS S, 1983, GASTROENTEROLOGY, V85, P351; MORRIS JB, 1990, AM J SURG, V160, P535, DOI 10.1016/S0002-9610(05)81024-4; Mourelle M, 1996, AM J PHYSIOL-GASTR L, V270, pG425, DOI 10.1152/ajpgi.1996.270.3.G425; MOURELLE M, 1995, GASTROENTEROLOGY, V109, P1497, DOI 10.1016/0016-5085(95)90636-3; NORLAND CC, 1969, MEDICINE, V48, P229, DOI 10.1097/00005792-196905000-00003; ORLOFF JJ, 1989, AM J GASTROENTEROL, V84, P794; PANOS MZ, 1993, GUT, V34, P1726, DOI 10.1136/gut.34.12.1726; PRANTERA C, 1989, HEPATO-GASTROENTEROL, V36, P240; PRANTERA C, 1991, J CLIN GASTROENTEROL, V13, P231; PRESENT DH, 1988, J CLIN GASTROENTEROL, V10, P485, DOI 10.1097/00004836-198810000-00004; RUBIN MS, 1995, DIS COLON RECTUM, V38, P350, DOI 10.1007/BF02054220; SNOWDEN JA, 1994, Q J MED, V87, P55; STRAUSS RJ, 1976, ANN SURG, V184, P682, DOI 10.1097/00000658-197612000-00004; STUART RC, 1986, BRIT J SURG, V73, P590, DOI 10.1002/bjs.1800730726; SURAWICZ CM, 1994, GASTROENTEROLOGY, V107, P755, DOI 10.1016/0016-5085(94)90124-4; Travis SPL, 1996, GUT, V38, P905, DOI 10.1136/gut.38.6.905; TRIADAFILOPOULOS G, 1991, GASTROENTEROLOGY, V101, P685, DOI 10.1016/0016-5085(91)90526-Q; TRUDEL JL, 1995, DIS COLON RECTUM, V38, P1033, DOI 10.1007/BF02133974; VELANOVICH V, 1992, DIS COLON RECTUM, V35, P369, DOI 10.1007/BF02048116; WIG JD, 1981, BRIT J SURG, V68, P135, DOI 10.1002/bjs.1800680222	54	116	122	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 14	1998	351	9101					509	513		10.1016/S0140-6736(97)10475-5	http://dx.doi.org/10.1016/S0140-6736(97)10475-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482465				2022-12-28	WOS:000072097700044
J	Bosco, D; Meda, P				Bosco, D; Meda, P			Cellular aggregation in the pancreas	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Geneva, Sch Med, CH-1211 Geneva 4, Switzerland	University of Geneva	Bosco, D (corresponding author), Univ Geneva, Sch Med, CH-1211 Geneva 4, Switzerland.			Bosco, Domenico/0000-0003-3453-9613					0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 12	1998	338	7					435	435		10.1056/NEJM199802123380705	http://dx.doi.org/10.1056/NEJM199802123380705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW122	9459647				2022-12-28	WOS:000071900100005
J	De Broe, ME; Elseviers, MM				De Broe, ME; Elseviers, MM			Analgesic nephropathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; STAGE RENAL-FAILURE; DIAGNOSTIC-CRITERIA; DISEASE; RISK; PHENACETIN; MORTALITY; BELGIUM; KIDNEY; ABUSE		Univ Antwerp, Dept Nephrol Hypertens, B-2020 Antwerp, Belgium	University of Antwerp	De Broe, ME (corresponding author), Univ Antwerp Hosp, Wilrijkstr 10, B-2650 Edegem, Belgium.			Elseviers, Monique/0000-0001-9415-6900				Barrett BJ, 1996, AM J KIDNEY DIS, V28, pS14, DOI 10.1016/S0272-6386(96)90563-6; BEARD K, 1988, J CLIN PHARMACOL, V28, P431, DOI 10.1002/j.1552-4604.1988.tb05755.x; Bennett WM, 1996, AM J KIDNEY DIS, V28, pS56, DOI 10.1016/S0272-6386(96)90570-3; BLUEMLE LW, 1968, J CLIN INVEST, V47, P2507, DOI 10.1172/JCI105932; BRUNNER FP, 1994, NEPHROL DIAL TRANSPL, V9, P1371; DeBroe ME, 1996, NEPHROL DIAL TRANSPL, V11, P2407, DOI 10.1093/oxfordjournals.ndt.a027203; Delzell E, 1996, AM J KIDNEY DIS, V28, P783, DOI 10.1016/S0272-6386(96)90266-8; DUBACH UC, 1983, NEW ENGL J MED, V308, P357, DOI 10.1056/NEJM198302173080703; Duggin GG, 1996, AM J KIDNEY DIS, V28, pS39, DOI 10.1016/S0272-6386(96)90568-5; ELSEVIERS MM, 1995, KIDNEY INT, V48, P1912, DOI 10.1038/ki.1995.491; ELSEVIERS MM, 1995, KIDNEY INT, V48, P1316, DOI 10.1038/ki.1995.416; Elseviers MM, 1996, AM J KIDNEY DIS, V28, pS48, DOI 10.1016/S0272-6386(96)90569-7; ELSEVIERS MM, 1995, NEPHROL DIAL TRANSPL, V10, P808; ELSEVIERS MM, 1994, NEPHROL DIAL TRANSPL, V9, P1840; ELSEVIERS MM, 1992, NEPHROL DIAL TRANSPL, V7, P479; GURWITZ JH, 1990, JAMA-J AM MED ASSOC, V264, P471, DOI 10.1001/jama.264.4.471; Henrich WL, 1996, AM J KIDNEY DIS, V27, P162, DOI 10.1016/S0272-6386(96)90046-3; KINCAIDSMITH P, 1993, DIS KIDNEY, V2, P1099; MCCREDIE M, 1982, CANCER, V49, P2617, DOI 10.1002/1097-0142(19820615)49:12<2617::AID-CNCR2820491235>3.0.CO;2-X; MORLANS M, 1990, BRIT J CLIN PHARMACO, V30, P717, DOI 10.1111/j.1365-2125.1990.tb03841.x; MURRAY MD, 1993, ANNU REV PHARMACOL, V33, P434; MURRAY RM, 1978, KIDNEY INT, V13, P50, DOI 10.1038/ki.1978.7; MURRAY TG, 1983, ARCH INTERN MED, V143, P1687, DOI 10.1001/archinte.143.9.1687; Nanra R S, 1972, Prog Biochem Pharmacol, V7, P285; NANRA RS, 1993, KIDNEY INT, V44, pS86; NANRA RS, 1978, KIDNEY INT, V13, P79, DOI 10.1038/ki.1978.11; NOELS LM, 1995, NEPHROL DIAL TRANSPL, V10, P167; NUYTS GD, 1995, LANCET, V346, P7, DOI 10.1016/S0140-6736(95)92648-8; PERNEGER TV, 1995, NEW ENGL J MED, V332, P1515; PERNEGER TV, 1994, NEW ENGL J MED, V331, P1675, DOI 10.1056/NEJM199412223312502; POMMER W, 1989, AM J NEPHROL, V9, P403, DOI 10.1159/000168002; PRESCOTT LF, 1982, DRUGS, V23, P75, DOI 10.2165/00003495-198223010-00004; RAAFLAUB J, 1969, KLIN WOCHENSCHR, V47, P1286, DOI 10.1007/BF01487561; SANDLER DP, 1989, NEW ENGL J MED, V320, P1238, DOI 10.1056/NEJM198905113201903; SANDLER DP, 1991, ANN INTERN MED, V115, P165, DOI 10.7326/0003-4819-115-3-165; SEGASOTHY M, 1994, AM J KIDNEY DIS, V24, P17, DOI 10.1016/S0272-6386(12)80155-7; SPUHLER O, 1953, Z KLIN MED, V151, P1; STEWART JH, 1993, ANALGESIC NSAID INDU, P58; ZAMBRASKI EJ, 1995, SEMIN NEPHROL, V15, P205	39	82	83	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 12	1998	338	7					446	452		10.1056/NEJM199802123380707	http://dx.doi.org/10.1056/NEJM199802123380707			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW122	9459649				2022-12-28	WOS:000071900100007
J	Black, PN; Brodie, SM				Black, PN; Brodie, SM			Nitric oxide and response to inhaled bradykinin in severe asthma	LANCET			English	Letter									Univ Auckland, Dept Med, Auckland, New Zealand	University of Auckland	Black, PN (corresponding author), Univ Auckland, Dept Med, Private Bag 92019, Auckland, New Zealand.			Ricciardolo, Fabio Luigi Massimo/0000-0003-1826-5018				Ricciardolo FLM, 1997, LANCET, V350, P1297, DOI 10.1016/S0140-6736(05)62474-9	1	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					449	449		10.1016/S0140-6736(05)78399-9	http://dx.doi.org/10.1016/S0140-6736(05)78399-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482336				2022-12-28	WOS:000071982600065
J	Wright, A; Cull, C; Holman, R; Turner, R; Murchison, L; Wright, AD; Oakley, N; Kohner, E; Hayes, R; Scarpello, J; Hadden, D; Spathis, AG; Yudkin, J; Greenwood, R; Borthwick, L; Day, J; Newton, R; Fox, C; Paisey, R; Roland, J; Humphriss, D; Peacock, I; Boulton, A; Dornan, T; Burden, F; Tooke, J				Wright, A; Cull, C; Holman, R; Turner, R; Murchison, L; Wright, AD; Oakley, N; Kohner, E; Hayes, R; Scarpello, J; Hadden, D; Spathis, AG; Yudkin, J; Greenwood, R; Borthwick, L; Day, J; Newton, R; Fox, C; Paisey, R; Roland, J; Humphriss, D; Peacock, I; Boulton, A; Dornan, T; Burden, F; Tooke, J		United Kingdom Prospective Diabet Study Grp	United kingdom prospective diabetes study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy	ANNALS OF INTERNAL MEDICINE			English	Article							RESISTANCE; GLUCOSE	Background: Uncertainty exists about the suitability of oral hypoglycemic drugs and insulin therapy for patients with newly diagnosed type 2 diabetes. Objective: To assess and compare response to sulfonylurea, insulin, or metformin over 6 years in patients with newly diagnosed type 2 diabetes in whom disease could and could not be controlled with diet therapy alone. Design: Multicenter, randomized, controlled trial. Setting: Outpatient diabetes clinics of 15 hospitals in the United Kingdom. Intervention: Sulfonylurea (chlorpropamide or glyburide), insulin, or metformin (if patients were obese). Patients: 458 patients with newly diagnosed type 2 diabetes that could not be controlled with diet and had hyperglycemic symptoms or fasting plasma glucose levels greater than 15 mmol/L during the initial 3 months of diet therapy (primary diet failure group) and 1620 patients in whom disease was controlled by diet therapy and who had fasting plasma glucose levels of 6 to 15 mmol/L and no hyperglycemic symptoms while receiving diet therapy alone. Measurements: Fasting plasma levels of glucose and insulin, hemoglobin A(1c) concentrations, body weight, and therapy required. Results: Compared with the diet-controlled group, the primary diet failure group was younger and less obese and had more retinopathy, lower fasting plasma insulin levels, and reduced beta-cell function. At 6 years, patients allocated to insulin had lower fasting plasma glucose levels than did patients allocated to oral agents, but hemoglobin A(1c) concentrations were similar. Forty-eight percent (95% CI, 37% to 58%) of patients in the primary diet failure group maintained hemoglobin A(1c) concentrations less than 0.08. By 6 years, 51% of patients (CI, 42% to 62%) allocated to ultralente insulin required additional short-acting insulin and 66% of patients (CI, 58% to 73%) allocated to sulfonylurea required additional therapy with metformin or insulin to control symptoms and maintain fasting plasma glucose levels less than 15 mmol/L. Patients allocated to insulin gained more weight and had more hypoglycemic attacks than did patients allocated to sulfonylurea. Obese patients allocated to metformin gained the least weight and had the fewest hypoglycemic attacks. For all therapies, control achieved at 6 years was worse in the primary diet failure group than in the diet-controlled group. Conclusions: Because initial insulin therapy induced more hypoglycemic reactions and weight gain without necessarily providing better control, it may be reasonable to start with oral agents and change to insulin if goals for glycemic levels are not achieved.	Radcliffe Infirm, United Kingdom Prospect Diabet Study Grp, Diabet Res Labs, Oxford OX2 6HE, England; Aberdeen Royal Infirm, Aberdeen, Scotland; Gen Hosp, Birmingham B4 6NH, W Midlands, England; St George Hosp, London, England; Hammersmith Hosp, London, England; Belfast City Hosp, Belfast BT9 7AD, Antrim, North Ireland; N Staffordshire Royal Infirm, Stoke On Trent, Staffs, England; Royal Victoria Hosp, Belfast BT12 6BA, Antrim, North Ireland; St Helier Hosp, Carshalton SM5 1AA, Surrey, England; Whittington Hosp, London N19 5NF, England; Norfolk & Norwich Hosp, Norwich NR1 3SR, Norfolk, England; Lister Hosp, Stevenage, Herts, England; Ipswich Hosp, Ipswich, Suffolk, England; Ninewells Hosp, Dundee DD1 9SY, Scotland; Northampton Gen Hosp, Northampton, England; Torbay Hosp, Torquay, England; Peterborough Dist Gen Hosp, Peterborough PE3 6DA, England; Scarborough Gen Hosp, Scarborough, England; Derbyshire Royal Infirm, Derby DE1 2QY, England; Manchester Royal Infirm, Manchester M13 9WL, Lancs, England; Hope Hosp, Salford M6 8HD, Lancs, England; Leicester Gen Hosp, Leicester LE5 4PW, Leics, England; Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England	Radcliffe Infirmary; University of Oxford; University of Aberdeen; St Georges University London; Imperial College London; Belfast City Hospital; Keele University; University Hospital of North Staffordshire NHS Trust; St Helier Hospital; University of London; University College London; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital; Lister Hospital; Ipswich Hospital NHS Trust; Ipswich Hospital; University of Dundee; University of Manchester; University Hospitals of Leicester NHS Trust; Leicester General Hospital; University of Exeter	Wright, A (corresponding author), Radcliffe Infirm, United Kingdom Prospect Diabet Study Grp, Diabet Res Labs, Woodstock Rd, Oxford OX2 6HE, England.		Yudkin, John S/C-1988-2008		NATIONAL EYE INSTITUTE [U10EY007049] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033152] Funding Source: NIH RePORTER; NEI NIH HHS [5 U10 EY07049-11] Funding Source: Medline; NIDDK NIH HHS [2 R01 DK33152-07] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1995, Diabetes, V44, P1249; DAVIS MD, 1985, DIABETES, V34, P42, DOI 10.2337/diab.34.3.S42; GROOP L, 1989, AM J MED, V87, P183; HARRIS MI, 1993, DIABETES CARE, V16, P642, DOI 10.2337/diacare.16.4.642; KILO C, 1980, JAMA-J AM MED ASSOC, V243, P450, DOI 10.1001/jama.243.5.450; MANLEY SE, 1994, DIABETIC MED, V11, P534; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; NABARRO JDN, 1992, J ROY COLL PHYS LOND, V26, P50; PHILLIPS M, 1979, Q J MED, V48, P493; RUDENSKI AS, 1991, METABOLISM, V40, P908, DOI 10.1016/0026-0495(91)90065-5; *SAS I, 1990, US MAN STAT AN SYST; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; The University Group Diabetes Program, 1975, DIABETES, V24, P65; Turner R, 1997, LANCET, V350, P1288, DOI 10.1016/S0140-6736(97)03062-6; TURNER RC, 1991, DIABETOLOGIA, V34, P877; TURNER RC, 1988, DIABETIC MED, V5, P444; United Kingdom Prospective Diabetes Study (UKPDS), 1995, BMJ-BRIT MED J, V310, P83, DOI DOI 10.1136/BMJ.310.6972.83; WU MS, 1990, DIABETES CARE, V13, P1, DOI 10.2337/diacare.13.1.1; 1996, DIABETES CARE S1, V19, pS54; 1993, J R COLL PHYSICIANS, V27, P259	20	303	307	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1998	128	3					165	175		10.7326/0003-4819-128-3-199802010-00001	http://dx.doi.org/10.7326/0003-4819-128-3-199802010-00001			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU303	9454524				2022-12-28	WOS:000071703200001
J	O'Neill, B; Rodway, A				O'Neill, B; Rodway, A			ABC of palliative care - Care in the community	BRITISH MEDICAL JOURNAL			English	Review									British Med Assoc, London, England		O'Neill, B (corresponding author), British Med Assoc, BMA House, London, England.								0	7	7	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 31	1998	316	7128					373	377		10.1136/bmj.316.7128.373	http://dx.doi.org/10.1136/bmj.316.7128.373			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487177	Green Published			2022-12-28	WOS:000071863900035
J	Gershlick, AH; More, RS				Gershlick, AH; More, RS			Recent advances - Treatment of myocardial infarction	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RECOMBINANT PLASMINOGEN-ACTIVATOR; PRIMARY ANGIOPLASTY REGISTRY; CHRONIC CANINE MODEL; CORONARY THROMBOLYSIS; ADJUNCTIVE THERAPY; TISSUE-TYPE; R-HIRUDIN; TRIAL; PREVENTION; STREPTOKINASE		Univ Leicester, Dept Med & Therapeut, Div Cardiol, Leicester LE3 9QP, Leics, England; St Marys Hosp, Portsmouth PO3 6AQ, Hants, England	University of Leicester	Gershlick, AH (corresponding author), Univ Leicester, Dept Med & Therapeut, Div Cardiol, Leicester LE3 9QP, Leics, England.							ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1988, LANCET, V2, P349; Antman EM, 1996, EUR HEART J, V17, P971; Bode C, 1996, CIRCULATION, V94, P891, DOI 10.1161/01.CIR.94.5.891; BRODIE BR, 1994, CIRCULATION, V90, P156, DOI 10.1161/01.CIR.90.1.156; CANNON CP, 1994, J AM COLL CARDIOL, V23, P993, DOI 10.1016/0735-1097(94)90581-9; COLLEN D, 1993, CIRCULATION, V87, P1850, DOI 10.1161/01.CIR.87.6.1850; COLLINS R, 1995, LANCET, V345, P669; *COR ART AC COR SY, 1997, NEW ENGL J MED, V336, P1621; DAVIES MJ, 1985, BRIT HEART J, V53, P363; FITZGERALD DJ, 1988, CIRCULATION, V77, P142, DOI 10.1161/01.CIR.77.1.142; GERSHLICK A, 1992, INT J CARDIOL, V36, P49, DOI 10.1016/0167-5273(92)90107-E; GOLD H, 1996, CIRCULATION, V94, P558; HAMPTON J, 1993, LANCET, V342, P759; HUNT D, 1992, LANCET, V339, P753; KAWAI C, 1992, CIRCULATION S, V86, P1; LEE CD, 1989, BLOOD, V73, P185; LEE LV, 1995, AM J CARDIOL, V75, P7, DOI 10.1016/S0002-9149(99)80517-7; LIJNEN HR, 1995, THROMB HAEMOSTASIS, V74, P387; MARTIN U, 1992, FIBRINOLYSIS, V6, P39, DOI 10.1016/0268-9499(92)90046-K; MEIJER A, 1993, CIRCULATION, V87, P1524, DOI 10.1161/01.CIR.87.5.1524; MORE RS, 1993, BRIT HEART J, V69, P49; ONEILL WW, 1994, AM J CARDIOL, V73, P627, DOI 10.1016/0002-9149(94)90924-5; REMIMER KA, 1977, CIRCULATION, V56, P786; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; ROTE WE, 1994, J CARDIOVASC PHARM, V23, P194, DOI 10.1097/00005344-199402000-00004; ROTE WE, 1994, J CARDIOVASC PHARM, V23, P203, DOI 10.1097/00005344-199402000-00005; RUBSAMEN K, 1995, THROMB HAEMOSTASIS, V74, P1353; STONE GW, 1995, J AM COLL CARDIOL, V25, P370, DOI 10.1016/0735-1097(94)00367-Y; Stone GW, 1997, NEW ENGL J MED, V337, P1168; TEO KK, 1993, JAMA-J AM MED ASSOC, V270, P1589, DOI 10.1001/jama.270.13.1589; Topol E, 1997, NEW ENGL J MED, V337, P1118; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VANDEWERF F, 1993, CORONARY ARTERY DIS, V4, P929; WILCOX RG, 1988, LANCET, V2, P525; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V	36	9	11	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 24	1998	316	7127					280	284		10.1136/bmj.316.7127.280	http://dx.doi.org/10.1136/bmj.316.7127.280			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472514	Green Published			2022-12-28	WOS:000071702100029
J	Meade, TW; Wilkes, HC; Kelleher, CC; Roderick, PJ; Brennan, PJ; Wilson, CW; Howarth, DJ; Stirling, Y; Garrow, K; Dickinson, CJ; Rose, G; Miller, GJ; Peart, WS; Breckenridge, AM; Grahame-Smith, DG; Pocock, SJ; Zuhrie, SR				Meade, TW; Wilkes, HC; Kelleher, CC; Roderick, PJ; Brennan, PJ; Wilson, CW; Howarth, DJ; Stirling, Y; Garrow, K; Dickinson, CJ; Rose, G; Miller, GJ; Peart, WS; Breckenridge, AM; Grahame-Smith, DG; Pocock, SJ; Zuhrie, SR		Med Res Counc Gen Pract Res Framework	Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk	LANCET			English	Article							HEMOSTATIC FUNCTION	Background We aimed to evaluate low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease (IHD). Methods 5499 men aged between 45 years and 69 years at high risk of IHD were recruited from 108 practices in the UK that belong to the Medical Research Council's General Practice Research Framework. Initially, warfarin or placebo was randomly allocated to 1427 men; 1013 of these men later moved to a factorial stage of the trial, retaining their warfarin or placebo warfarin allocation and adding randomly allocated active or placebo aspirin. Another 4072 men entered directly into the factorial stage making a total of 5085 men. The four factorial treatment groups were: active warfarin and active aspirin (WA, n=1277), active warfarin and placebo aspirin (W, n=1268), placebo warfarin and active aspirin (A, n=1268), and placebo warfarin and placebo aspirin (P, n=1272). The primary end-point was all IHD defined as the sum of coronary death and fatal and nonfatal myocardial infarction(MI). Findings The mean International Normalised Ratio (INR) of those on active warfarin was 1.47. The mean warfarin dose was 4.1 mg a day (range 0.5 mg-12.5 mg). There were 410 IHD events (142 fatal, 268 non-fatal). The main effect of warfarin (ie, WA and W vs A and P) was a reduction in all IHD of 21% (95% CI 4-35, p=0.02) chiefly due to a 39% reduction (15-57, p=0.003) in fatal events so that warfarin reduced the death rate from all causes by 17% (1-30, p=0.04). The main effect of aspirin (ie, WA and A vs W, and P) was a reduction in all IHD of 20% (1-35, p=0.04) almost entirely due to a 32% reduction (12-48, p=0.004) in nonfatal events, Absolute reductions in all IHD due to warfarin; or aspirin were 2.6 and 2.3 per 1000 person years, respectively. WA reduced all IHD by 34% (11-51, p=0.006) compared with P. WA increased haemorrhagic and fatal strokes. Ruptured aortic or dissecting aneurysms occurred in 15 of those who were or had been on warfarin compared with three of those who had not (p=0.01). Interpretation These results add to evidence that aspirin reduces non-fatal IHD, Warfarin reduced all IHD chiefly because of an effect on fatal events. Combined treatment with warfarin and aspirin is more effective in the reduction of IHD than either agent on its own.	Univ London St Bartholomews Hosp Med Coll, MRC, Epidemiol & Med Care Unit, London EC1M 6BQ, England; Royal London Sch Med & Dent, London EC1M 6BQ, England	University of London; Queen Mary University London; University of London; Queen Mary University London	Meade, TW (corresponding author), Univ London St Bartholomews Hosp Med Coll, MRC, Epidemiol & Med Care Unit, London EC1M 6BQ, England.		kelleher, cecily c/A-4233-2013	kelleher, cecily c/0000-0001-9548-4914				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1988, BRIT MED J, V296, P320; Blackshear JL, 1996, LANCET, V348, P633; Campeau L, 1997, NEW ENGL J MED, V336, P153; CLARKE RJ, 1991, NEW ENGL J MED, V325, P1137, DOI 10.1056/NEJM199110173251605; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; Fuster V, 1997, LANCET, V350, P389; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HENNEKENS CH, 1989, CIRCULATION, V80, P749, DOI 10.1161/01.CIR.80.4.749; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HIRSH J, 1996, ORAL ANTICOAGULANTS, P167; JONKER JJC, 1994, LANCET, V343, P499; Lancaster T, 1997, BRIT MED J, V314, P1563, DOI 10.1136/bmj.314.7094.1563; MEADE TW, 1988, EUR HEART J, V9, P836, DOI 10.1093/oxfordjournals.eurheartj.a062576; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEADE TW, 1980, LANCET, V1, P1050; MEADE TW, 1986, INT J EPIDEMIOL, V15, P331, DOI 10.1093/ije/15.3.331; MEADE TW, 1992, THROMB HAEMOSTASIS, V68, P1; MEADE TW, 1996, ORAL ANTICOAGULANTS, P132; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OLIVER MF, 1984, LANCET, V2, P600; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; Peverill RE, 1997, LANCET, V350, P1177, DOI 10.1016/S0140-6736(05)63824-X; POLLER L, 1987, BRIT MED J, V295, P1309, DOI 10.1136/bmj.295.6609.1309; PRICHARD PJ, 1989, BMJ-BRIT MED J, V298, P493, DOI 10.1136/bmj.298.6672.493; Roderick P J, 1995, J Cardiovasc Risk, V2, P353, DOI 10.1097/00043798-199508000-00011; ROOS J, 1980, LANCET, V2, P989; RUDDOCK V, 1994, Q J MED, V87, P403; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; TURPIE AGG, 1993, NEW ENGL J MED, V329, P524, DOI 10.1056/NEJM199308193290802; VANBERGEN PFMM, 1995, JAMA-J AM MED ASSOC, V273, P925, DOI 10.1001/jama.273.12.925; *WHO REG OFF EUR, 1976, MYOC INF COMM REG	35	725	752	0	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 24	1998	351	9098					233	241						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU294	9457092				2022-12-28	WOS:000071702200008
J	Shapiro, J				Shapiro, J			Counting and accounting in the new NHS	BRITISH MEDICAL JOURNAL			English	Article									Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England	University of Birmingham	Shapiro, J (corresponding author), Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					296	297		10.1136/bmj.316.7127.296	http://dx.doi.org/10.1136/bmj.316.7127.296			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472520	Green Published			2022-12-28	WOS:000071702100037
J	Smith, GD; Egger, M				Smith, GD; Egger, M			Meta-analysis - Unresolved issues and future developments	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIALS; ACUTE MYOCARDIAL-INFARCTION; OTITIS-MEDIA; METAANALYSES; EFFICACY; EFFUSION; SURVIVAL; REVIEWS; THERAPY		Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	Smith, GD (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	zetkin@bristol.ac.uk	Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Egger, Matthias/0000-0001-7462-5132				Altman D.G., 1991, PRACTICAL STAT MED R; [Anonymous], 1991, LANCET, V337, P401; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Armitage P., 2001, STAT METHODS MED RES; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; CANTEKIN EI, 1991, JAMA-J AM MED ASSOC, V266, P3309; CLARKE MJ, 1994, BRIT MED J, V309, P1007, DOI 10.1136/bmj.309.6960.1007; Cochrane A. L, 1972, PUBLIC HEALTH, DOI DOI 10.1016/S0033-3506(73)80082-4; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; Eddy DM, 1992, METAANALYSIS CONFIDE; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; EGGER M, METAANALYSIS SOFTWAR; EGGERM, 1998, BMJ-BRIT MED J, V316, P61; Gelber R D, 1993, Recent Results Cancer Res, V127, P167; *GRUPP IT STUD STR, 1986, LANCET, P397; Hedges LV, 2014, STAT METHODS META AN; *ISIS 2 COLL GROUP, 1988, LANCET, V2, P3249; LAW MR, 1993, BMJ-BRIT MED J, V308, P367; LILIENFELD DE, 1994, FDN EPIDEMIOLOGY; MANDEL EM, 1987, NEW ENGL J MED, V316, P432, DOI 10.1056/NEJM198702193160803; NAKIELNY J, 1993, BRIT MED J, V306, P1125, DOI 10.1136/bmj.306.6885.1125-b; Naylor C D, 1995, J Eval Clin Pract, V1, P127, DOI 10.1111/j.1365-2753.1995.tb00018.x; NYLENNA M, 1994, JAMA-J AM MED ASSOC, V272, P149, DOI 10.1001/jama.272.2.149; Orwin R.G., 1994, HDB RES SYNTHESIS; Petitti D, 1994, METAANALYSIS DECISIO; RENIE D, 1991, BALANCING ACT ESSAYS; RENNIE D, 1991, JAMA-J AM MED ASSOC, V266, P3333, DOI 10.1001/jama.266.23.3333; ROSENDAAL FR, 1994, J CLIN EPIDEMIOL, V47, P1325, DOI 10.1016/0895-4356(94)90074-4; SIMOONS ML, 1985, LANCET, V2, P578; SMITH GD, IN PRESS OXFORD TXB; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; STAMPFER MJ, 1982, NEW ENGL J MED, V307, P1180, DOI 10.1056/NEJM198211043071904; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; TAKARO T, 1976, CIRCULATION, V54, P107; WARDLAW JM, 1996, STROKE MODULE COCHRA; WARREN KS, 1993, DOING MORE GOOD THAN; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	40	110	116	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 17	1998	316	7126					221	225						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468698				2022-12-28	WOS:000071616400046
J	Bodnar, AG; Ouellette, M; Frolkis, M; Holt, SE; Chiu, CP; Morin, GB; Harley, CB; Shay, JW; Lichtsteiner, S; Wright, WE				Bodnar, AG; Ouellette, M; Frolkis, M; Holt, SE; Chiu, CP; Morin, GB; Harley, CB; Shay, JW; Lichtsteiner, S; Wright, WE			Extension of life-span by introduction of telomerase into normal human cells	SCIENCE			English	Article							MAMMARY EPITHELIAL-CELLS; HUMAN FIBROBLASTS; CELLULAR SENESCENCE; REPLICATIVE SENESCENCE; PIGMENT EPITHELIUM; IMMORTAL CELLS; AGE; LENGTH; EXPRESSION; INVITRO	Normal human cells undergo a finite number of cell divisions and ultimately enter a nondividing state called replicative senescence. It has been proposed that telomere shortening is the molecular clock that triggers senescence, To test this hypothesis, two telomerase-negative normal human cell types, retinal pigment epithelial cells and foreskin fibroblasts, were transfected with vectors encoding the human telomerase catalytic subunit. In contrast to telomerase-negative control clones, which exhibited telomere shortening and senescence, telomerase-expressing clones had elongated telomeres, divided vigorously, and showed reduced staining for beta-galactosidase, a biomarker for senescence, Notably, the telomerase-expressing clones have a normal karyotype and have already exceeded their normal life-span by at least 20 doublings, thus establishing a causal relationship between telomere shortening and in vitro cellular senescence. The ability to maintain normal human cells in a phenotypically youthful state could have important applications in research and medicine.	Geron Corp, Menlo Park, CA 94025 USA; Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA	Geron Corporation; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wright, WE (corresponding author), Geron Corp, 230 Constitut Dr, Menlo Park, CA 94025 USA.	slichtste@geron.com; wright@utsw.swmed.edu	Morin, Gregg B/E-9123-2012; Shay, Jerry W/F-7878-2011; Wilson, Matthew H/K-3193-2013	Morin, Gregg B/0000-0001-8949-4374; 	NIA NIH HHS [AG07992, AG05747] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [F32AG005747, R01AG007992] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; BODNAR AG, UNPUB; BOULTON M, 1990, VISION RES, V30, P1291, DOI 10.1016/0042-6989(90)90003-4; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DELLORCO RT, 1973, EXP CELL RES, V77, P356, DOI 10.1016/0014-4827(73)90588-0; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Effros RB, 1996, AIDS, V10, pF17, DOI 10.1097/00002030-199607000-00001; ELMORE E, 1976, J CELL PHYSIOL, V87, P229, DOI 10.1002/jcp.1040870211; Engelhardt M, 1997, BLOOD, V90, P182; Faragher RGA, 1997, DRUG DISCOV TODAY, V2, P64, DOI 10.1016/S1359-6446(97)83293-X; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLEY CB, 1978, J CELL PHYSIOL, V97, P509, DOI 10.1002/jcp.1040970326; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KONKEL LMC, 1995, P NATL ACAD SCI USA, V92, P5558, DOI 10.1073/pnas.92.12.5558; Kumazaki Tsutomu, 1993, Hiroshima Journal of Medical Sciences, V42, P97; Lendvay TS, 1996, GENETICS, V144, P1399; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LICHTSTEINER S, UNPUB; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; MARTIN GM, 1970, LAB INVEST, V23, P86; MEYERSON M, 1997, CELL, V90, P78; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; OHNO T, 1979, MECH AGEING DEV, V11, P179, DOI 10.1016/0047-6374(79)90053-8; SCHNEIDER EL, 1972, P SOC EXP BIOL MED, V141, P1092; SCHNEIDER EL, 1976, P NATL ACAD SCI USA, V73, P3584, DOI 10.1073/pnas.73.10.3584; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1993, ONCOGENE, V8, P1407; SHAY JW, 1993, INT J ONCOL, V3, P559; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1997, EUR J CANCER, V33, P777; SMITH JR, 1979, J CELL PHYSIOL, V98, P597, DOI 10.1002/jcp.1040980317; STANULISPRAEGER BM, 1987, MECH AGEING DEV, V38, P1, DOI 10.1016/0047-6374(87)90109-6; TAKEDA K, 1992, J CELL PHYSIOL, V153, P450, DOI 10.1002/jcp.1041530303; TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; VAZIRI H, 1993, AM J HUM GENET, V52, P661; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; WENG NP, 1995, P NATL ACAD SCI USA, V92, P11091, DOI 10.1073/pnas.92.24.11091; WEST MD, 1994, ARCH DERMATOL, V130, P87, DOI 10.1001/archderm.130.1.87; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Wright WE, 1996, DEV GENET, V18, P173; WRIGHT WE, 1995, TRENDS CELL BIOL, V5, P293, DOI 10.1016/S0962-8924(00)89044-3; WynfordThomas D, 1996, ONCOL RES, V8, P387	62	3789	4095	14	487	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	1998	279	5349					349	352		10.1126/science.279.5349.349	http://dx.doi.org/10.1126/science.279.5349.349			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9454332				2022-12-28	WOS:000071570800037
J	des Portes, V; Pinard, JM; Billuart, P; Vinet, MC; Koulakoff, A; Carrie, A; Gelot, A; Dupuis, E; Motte, J; Berwald-Netter, Y; Catala, M; Kahn, A; Beldjord, C; Chelly, J				des Portes, V; Pinard, JM; Billuart, P; Vinet, MC; Koulakoff, A; Carrie, A; Gelot, A; Dupuis, E; Motte, J; Berwald-Netter, Y; Catala, M; Kahn, A; Beldjord, C; Chelly, J			A novel CNS gene required for neuronal migration and involved in X-linked subcortical laminar heterotopia and lissencephaly syndrome	CELL			English	Article							CORTICAL DYSPLASIA; CEREBRAL-CORTEX; CELL-MIGRATION; PROTEIN; SEQUENCE; EXPRESSION; BINDING; IDENTIFICATION; MALFORMATIONS; TRANSCRIPTION	X-SCLH/LIS syndrome is a neuronal migration disorder with disruption of the six-layered neocortex. It consists of subcortical laminar heterotopia (SCLH, band heterotopia, or double cortex) in females and lissencephaly (LIS) in males, leading to epilepsy and cognitive impairment. We report the characterization of a novel CNS gene encoding a 40 kDa predicted protein that we named Doublecortin and the identification of mutations in four unrelated X-SCLH/LIS cases. The predicted protein shares significant homology with the N-terminal segment of a protein containing a protein kinase domain at its C-terminal part. This novel gene is highly expressed during brain development, mainly in fetal neurons including precursors. The complete disorganization observed in lissencephaly and heterotopia thus seems to reflect a failure of early events associated with neuron dispersion.	Fac Med Cochin, ICGM, INSERM, U129, F-75014 Paris, France; Hop Raymond Poincare, Serv Neuropediat, Garches, France; Coll France, F-75231 Paris 05, France; Hop St Vincent de Paul, Lab Histoembryol Cytogenet, F-75014 Paris, France; Amer Mem Hosp, Serv Neuropediat, F-51092 Reims, France; Hop La Pitie Salpetriere, Lab Histoembryol Cytogenet, F-75651 Paris 13, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; UDICE-French Research Universities; PSL Research University Paris; College de France; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU de Reims; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Chelly, J (corresponding author), Fac Med Cochin, ICGM, INSERM, U129, 24 Rue Faubourg St Jacques, F-75014 Paris, France.		Billuart, Pierre/K-3832-2017; Chelly, Jamel/J-7528-2015	Billuart, Pierre/0000-0003-1913-1687; Chelly, Jamel/0000-0002-0939-8719; Gelot, Antoinette/0000-0002-3032-014X; Catala, Martin/0000-0003-1554-9007				AICARDI J, 1991, BRAIN DEV-JPN, V13, P1; ALLENDOERFER KL, 1994, ANNU REV NEUROSCI, V17, P185, DOI 10.1146/annurev.neuro.17.1.185; [Anonymous], 1982, MOL CLONING LAB MANU; BACHNER D, 1995, HUM MOL GENET, V4, P701, DOI 10.1093/hmg/4.4.701; BANFI S, 1994, NAT GENET, V7, P513, DOI 10.1038/ng0894-513; Bienvenu T, 1997, EUR J HUM GENET, V5, P105, DOI 10.1159/000484743; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; desPortes V, 1997, J MED GENET, V34, P177, DOI 10.1136/jmg.34.3.177; Dobyns WB, 1996, NEUROLOGY, V47, P331, DOI 10.1212/WNL.47.2.331; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; Harding B, 1996, DYSPLASIAS OF CEREBRAL CORTEX AND EPILEPSY, P81; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; HOUDOU S, 1990, PEDIATR NEUROL, V6, P402, DOI 10.1016/0887-8994(90)90009-P; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOMECKI E, 1988, SCIENCE, V240, P1792; KOMURO H, 1992, SCIENCE, V257, P806, DOI 10.1126/science.1323145; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUZNIECKY R, 1993, NEUROLOGY, V43, P681, DOI 10.1212/WNL.43.4.681; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEHRACH H., 1990, GENOME ANAL, P39; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; LoNigro C, 1997, HUM MOL GENET, V6, P157, DOI 10.1093/hmg/6.2.157; LUSKIN MB, 1988, NEURON, V1, P653; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; OROURKE NA, 1995, DEVELOPMENT, V121, P2165; PALMINI A, 1991, NEUROLOGY, V41, P1656, DOI 10.1212/WNL.41.10.1656; PINARD JM, 1994, J NEUROL NEUROSUR PS, V57, P914, DOI 10.1136/jnnp.57.8.914; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1995, NEURON, V14, P1101, DOI 10.1016/0896-6273(95)90258-9; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAYMOND AA, 1995, BRAIN, V118, P629, DOI 10.1093/brain/118.3.629; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; ROSS E, 1997, HUM MOL GENET, V6, P555; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SCHREIBER E, 1993, NUCLEIC ACIDS RES, V21, P253, DOI 10.1093/nar/21.2.253; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; SHISHEVA A, 1994, MOL CELL BIOL, V14, P3459, DOI 10.1128/MCB.14.5.3459; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAN SS, 1993, NATURE, V362, P638, DOI 10.1038/362638a0; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8	53	611	623	0	19	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 9	1998	92	1					51	61						11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489699				2022-12-28	WOS:000071473700007
J	Sablowski, RWM; Meyerowitz, EM				Sablowski, RWM; Meyerowitz, EM			A homolog of NO APICAL MERISTEM is an immediate target of the floral homeotic genes APETALA3/PISTILLATA	CELL			English	Article							ARABIDOPSIS-THALIANA; FLOWER DEVELOPMENT; ORGAN-IDENTITY; DIFFERENTIAL DISPLAY; PROTEINS APETALA1; PATTERN-FORMATION; MESSENGER-RNA; PISTILLATA; DOMAIN; MUTATIONS	To understand how homeotic genes affect morphogenesis and differentiation, their target genes must be identified. In Arabidopsis flowers, the homeotic protein heterodimer APETALA3/PISTILLATA is necessary for petal and stamen formation. Here, AP3/PI function was put under posttranslational control to analyze its immediate effect on the floral mRNA population, with indirect effects blocked by cycloheximide. Using differential display, a target gene of AP3/PI was identified (NAP: NAC-LIKE, ACTIVATED BY AP3/PI), which is homologous to genes required for meristem establishment and separation of floral organs. The expression pattern of NAP and the phenotypes caused by its mis-expression suggest that it functions in the transition between growth by cell division and cell expansion in stamens and petals.	CALTECH, Div Biol 15629, Pasadena, CA 91125 USA	California Institute of Technology	Meyerowitz, EM (corresponding author), CALTECH, Div Biol 15629, Pasadena, CA 91125 USA.		Meyerowitz, Elliot M/A-7118-2009	Sablowski, Robert/0000-0002-1732-2909				Aida M, 1997, PLANT CELL, V9, P841, DOI 10.1105/tpc.9.6.841; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREW DJ, 1992, NEW BIOL, V4, P5; Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; BARKER DD, 1992, GENE DEV, V6, P2312, DOI 10.1101/gad.6.12a.2312; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENNETT SRM, 1995, PLANT J, V8, P505, DOI 10.1046/j.1365-313X.1995.8040505.x; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COMELISSEN M, 1989, NUCLEIC ACIDS RES, V17, P833; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; Fryxell KJ, 1996, TRENDS GENET, V12, P364, DOI 10.1016/S0168-9525(96)80020-5; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GOTO K, 1994, GENE DEV, V8, P1548, DOI 10.1101/gad.8.13.1548; Graba Y, 1997, BIOESSAYS, V19, P379, DOI 10.1002/bies.950190505; HILL JP, 1989, CAN J BOT, V67, P2922, DOI 10.1139/b89-375; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; Jacobs T, 1997, PLANT CELL, V9, P1021, DOI 10.1105/tpc.9.7.1021; Jacobson D R, 1991, PCR Methods Appl, V1, P146; John I, 1997, PLANT MOL BIOL, V33, P641, DOI 10.1023/A:1005746831643; KLIMYUK VI, 1993, PLANT J, V3, P493, DOI 10.1046/j.1365-313X.1993.t01-26-00999.x; KONAT GW, 1994, PCR TECHNOLOGY CURRE; Krizek BA, 1996, DEVELOPMENT, V122, P11; Krizek BA, 1996, P NATL ACAD SCI USA, V93, P4063, DOI 10.1073/pnas.93.9.4063; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LLOYD AM, 1994, SCIENCE, V266, P436, DOI 10.1126/science.7939683; MARTIN C, 1993, PLANT CELL, V5, P1253, DOI 10.1105/tpc.5.10.1253; MCKINNEY EC, 1995, PLANT J, V8, P613, DOI 10.1046/j.1365-313X.1995.8040613.x; Meyerowitz EM, 1997, CELL, V88, P299, DOI 10.1016/S0092-8674(00)81868-1; Munster T, 1997, P NATL ACAD SCI USA, V94, P2415, DOI 10.1073/pnas.94.6.2415; Reuber TL, 1995, METHOD CELL BIOL, V49, P431, DOI 10.1016/S0091-679X(08)61471-5; Riechmann JL, 1996, NUCLEIC ACIDS RES, V24, P3134, DOI 10.1093/nar/24.16.3134; Riechmann JL, 1997, MOL BIOL CELL, V8, P1243, DOI 10.1091/mbc.8.7.1243; Riechmann JL, 1996, P NATL ACAD SCI USA, V93, P4793, DOI 10.1073/pnas.93.10.4793; Riechmann JL, 1997, BIOL CHEM, V378, P1079; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; Souer E, 1996, CELL, V85, P159, DOI 10.1016/S0092-8674(00)81093-4; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; YANOFSKY MF, 1995, ANNU REV PLANT PHYS, V46, P167, DOI 10.1146/annurev.pp.46.060195.001123; ZACHGO S, 1995, DEVELOPMENT, V121, P2861; ZHAO S, 1995, BIOTECHNIQUES, V18, P842	52	447	510	4	51	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 9	1998	92	1					93	103		10.1016/S0092-8674(00)80902-2	http://dx.doi.org/10.1016/S0092-8674(00)80902-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489703	Bronze			2022-12-28	WOS:000071473700011
J	Ferrari, G; Cusella-De Angelis, G; Coletta, M; Paolucci, E; Stornaiuolo, A; Cossu, G; Mavilio, F				Ferrari, G; Cusella-De Angelis, G; Coletta, M; Paolucci, E; Stornaiuolo, A; Cossu, G; Mavilio, F			Muscle regeneration by bone marrow derived myogenic progenitors	SCIENCE			English	Article							IMMUNE-DEFICIENCY; PRECURSOR CELLS; MICE; EXPRESSION; THERAPY	Growth and repair of skeletal muscle are normally mediated by the satellite cells that surround muscle fibers, In regenerating muscle, however, the number of myogenic precursors exceeds that of resident satellite cells, implying migration or recruitment of undifferentiated progenitors from other sources. Transplantation of genetically marked bone marrow into Immunodeficient mice revealed that marrow-derived cells migrate into areas of induced muscle degeneration, undergo myogenic differentiation, and participate in the regeneration of the damaged fibers, Genetically modified, marrow-derived myogenic progenitors could potentially be used to target therapeutic genes to muscle tissue, providing an alternative strategy for treatment of muscular dystrophies.	Univ Rome La Sapienza, Dipartimento Istol & Embriol Med, I-00161 Rome, Italy; Hosp San Raffaele, Telethon Inst Gene Therapy, I-20132 Milan, Italy; Univ Pavia, Ist Anat Umana Normale, I-27100 Pavia, Italy	Sapienza University Rome; Fondazione Telethon; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Pavia	Cossu, G (corresponding author), Univ Rome La Sapienza, Dipartimento Istol & Embriol Med, Piazzale Aldo Moro 5, I-00161 Rome, Italy.		Ferrari, Giuliana/AAB-5546-2019	Ferrari, Giuliana/0000-0003-0790-3133; Mavilio, Fulvio/0000-0003-0459-4320; Cusella De Angelis, Maria Gabriella/0000-0003-2642-3346	Telethon [A.067, TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		BLAU HM, 1993, TRENDS GENET, V9, P269, DOI 10.1016/0168-9525(93)90012-7; CAMPION DR, 1984, INT REV CYTOL, V87, P225, DOI 10.1016/S0074-7696(08)62444-4; Cossu G, 1997, HISTOL HISTOPATHOL, V12, P755; EMERY A, 1993, DUCHENNE MUSCULAR DY, V1; FULOP GM, 1986, J IMMUNOL, V136, P4438; GROUNDS MD, 1992, CELL TISSUE RES, V267, P99, DOI 10.1007/BF00318695; KELLY R, 1995, J CELL BIOL, V129, P383, DOI 10.1083/jcb.129.2.383; Krensky AM, 1997, NAT BIOTECHNOL, V15, P720, DOI 10.1038/nbt0897-720; Miller AD, 1997, NAT MED, V3, P278, DOI 10.1038/nm0397-278; MURPHY WJ, 1987, J EXP MED, V165, P1212, DOI 10.1084/jem.165.4.1212; PARTRIDGE TA, 1991, MUSCLE NERVE, V14, P197, DOI 10.1002/mus.880140302; PARTRIDGE TA, 1995, BRIT MED BULL, V51, P123, DOI 10.1093/oxfordjournals.bmb.a072942; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; SALVATORI G, 1995, J CELL SCI, V108, P2733; SALVATORI G, 1993, HUM GENE THER, V4, P713, DOI 10.1089/hum.1993.4.6-713; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCHULTZ E, 1980, MECH AGEING DEV, V13, P105; TAJBAKHSH S, 1994, NEURON, V13, P813, DOI 10.1016/0896-6273(94)90248-8; WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212	20	2135	2389	1	130	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1528	1530		10.1126/science.279.5356.1528	http://dx.doi.org/10.1126/science.279.5356.1528			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488650				2022-12-28	WOS:000072372900063
J	Klahr, S; Miller, SB				Klahr, S; Miller, SB			Current concepts - Acute oliguria	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE-RENAL-FAILURE; DOSE DOPAMINE		Washington Univ, Sch Med, Dept Med, Div Renal, St Louis, MO 63110 USA	Washington University (WUSTL)	Klahr, S (corresponding author), Barnes Jewish Hosp, Dept Med, N Campus,216 S Kingshighway, St Louis, MO 63110 USA.							Alkhunaizi AM, 1996, AM J KIDNEY DIS, V28, P315, DOI 10.1016/S0272-6386(96)90487-4; Allgren RL, 1997, NEW ENGL J MED, V336, P828, DOI 10.1056/NEJM199703203361203; Anderson RI, 1997, DIS KIDNEY, P1069; Bywaters EGL, 1941, BRIT MED J, V1941, P427, DOI 10.1136/bmj.1.4185.427; Clark BA, 1997, AM J KIDNEY DIS, V30, P82, DOI 10.1016/S0272-6386(97)90568-0; CONGER JD, 1995, AM J KIDNEY DIS, V26, P565, DOI 10.1016/0272-6386(95)90590-1; CUMMING AD, 1994, RENAL FAILURE, V16, P169, DOI 10.3109/08860229409044858; DAVIDMAN M, 1991, ARCH INTERN MED, V151, P1809, DOI 10.1001/archinte.151.9.1809; Denton MD, 1996, KIDNEY INT, V50, P4, DOI 10.1038/ki.1996.280; DuBose TD, 1997, AM J KIDNEY DIS, V29, P793, DOI 10.1016/S0272-6386(97)90136-0; Edelstein CL, 1997, KIDNEY INT, V51, P1341, DOI 10.1038/ki.1997.183; Elasy TA, 1996, SEMIN DIALYSIS, V9, P438, DOI 10.1111/j.1525-139X.1996.tb00304.x; FEEST TG, 1993, BMJ-BRIT MED J, V306, P481, DOI 10.1136/bmj.306.6876.481; Feinstein E I, 1983, Kidney Int Suppl, V16, pS319; FEINSTEIN EI, 1981, MEDICINE, V60, P124, DOI 10.1097/00005792-198103000-00005; FINN WF, 1993, ACUTE RENAL FAILURE, P553; FLANCBAUM L, 1994, CRIT CARE MED, V22, P61, DOI 10.1097/00003246-199401000-00014; Franklin SC, 1997, AM J PHYSIOL-RENAL, V272, pF257, DOI 10.1152/ajprenal.1997.272.2.F257; HAKIM RM, 1994, NEW ENGL J MED, V331, P1338, DOI 10.1056/NEJM199411173312003; Hamel MB, 1997, ANN INTERN MED, V127, P195, DOI 10.7326/0003-4819-127-3-199708010-00003; HARRINGTON JT, 1975, NEW ENGL J MED, V292, P89, DOI 10.1056/NEJM197501092920208; HAUG CE, 1993, TRANSPLANTATION, V55, P766, DOI 10.1097/00007890-199304000-00016; Himmelfarb J, 1998, J AM SOC NEPHROL, V9, P257; HOU SH, 1983, AM J MED, V74, P243, DOI 10.1016/0002-9343(83)90618-6; KLAHR S, 1997, DIS KIDNEY, P709; KOPPLE JD, 1997, NUTR MANAGEMENT RENA, P713; LEVINSKY NG, 1988, ACUTE RENAL FAILURE, P841; Majumdar S, 1996, SEMIN DIALYSIS, V9, P454, DOI 10.1111/j.1525-139X.1996.tb00307.x; MEHTA RL, 1994, SEMIN NEPHROL, V14, P64; MILLER SB, 1995, MANUAL MED THERAPEUT, P262; NOIRI E, 1995, KIDNEY INT, V48, P1375, DOI 10.1038/ki.1995.426; PALLER MS, 1994, PRIMER KIDNEY DIS, P126; Romanov V, 1997, KIDNEY INT, V52, P93, DOI 10.1038/ki.1997.308; SOLOMON R, 1994, NEW ENGL J MED, V331, P1416, DOI 10.1056/NEJM199411243312104; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; WARDLE EN, 1994, NEPHRON, V66, P380; Yagi N, 1997, SEMIN NEPHROL, V17, P306	37	84	88	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1998	338	10					671	675		10.1056/NEJM199803053381007	http://dx.doi.org/10.1056/NEJM199803053381007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ844	9486997				2022-12-28	WOS:000072299700007
J	Chiu, DT; Lillard, SJ; Scheller, RH; Zare, RN; Rodriguez-Cruz, SE; Williams, ER; Orwar, O; Sandberg, M; Lundqvist, JA				Chiu, DT; Lillard, SJ; Scheller, RH; Zare, RN; Rodriguez-Cruz, SE; Williams, ER; Orwar, O; Sandberg, M; Lundqvist, JA			Probing single secretory vesicles with capillary electrophoresis	SCIENCE			English	Article							TRANSFORM MASS-SPECTROMETRY; ELECTROSPRAY-IONIZATION; FLUORESCENCE DETECTION; APLYSIA-CALIFORNICA; ATRIAL GLAND; CELLS; DERIVATIZATION; ION; LOCALIZATION	Secretory vesicles obtained from the atrial gland of the gastropod mollusk Aplysia californica were chemically analyzed individually with a combination of optical trapping, capillary electrophoresis separation, and a laser-induced fluorescence detection. With the use of optical trapping, a single Vesicle that had attoliters (10(-18) liters) of volume was introduced into the tapered inlet of a separation capillary, Once the vesicle was injected, it was lysed, and its components were fluorescently labeled with naphthalene-2,3-dicarboxaldehyde before separation, The resultant electropherograms indicated distinct variations in the contents of single vesicles.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Gothenburg Univ, Dept Chem, SE-41296 Gothenburg, Sweden; Gothenburg Univ, Dept Anat & Cell Biol, SE-41390 Gothenburg, Sweden	Stanford University; Howard Hughes Medical Institute; Stanford University; University of California System; University of California Berkeley; University of Gothenburg; University of Gothenburg	Zare, RN (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.		Zare, Richard N./A-8410-2009; Williams, Evan/I-3924-2013	Zare, Richard/0000-0001-5266-4253	NIDA NIH HHS [DA09873] Funding Source: Medline; NIGMS NIH HHS [GM18386, 1R29GM50336-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018386, R29GM050336, R01GM018386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009873] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		CASTRO A, 1995, ANAL CHEM, V67, P3181, DOI 10.1021/ac00114a013; Chiu DT, 1997, ANAL CHEM, V69, P1801, DOI 10.1021/ac961226g; DEMONTIGNY P, 1987, ANAL CHEM, V59, P1096, DOI 10.1021/ac00135a007; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; GILMAN SD, 1995, ANAL CHEM, V67, P58, DOI 10.1021/ac00097a010; GROSS DS, 1995, J AM CHEM SOC, V117, P883, DOI 10.1021/ja00108a004; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; JANKOWSKI JA, 1995, TRAC-TREND ANAL CHEM, V14, P170, DOI 10.1016/0165-9936(95)98315-Y; KALDANY RRJ, 1985, ANNU REV NEUROSCI, V8, P431; LI X, 1996, BRAIN RES, V706, P86; LILIARD SJ, 1996, HDB CAPILLARY ELECTR, P523; Lillard SJ, 1996, ANAL CHEM, V68, P2897, DOI 10.1021/ac960412j; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; MCCAMAN R, 1977, J NEUROCHEM, V29, P739; NAGLE GT, 1988, J BIOL CHEM, V263, P9223; OLEFIROWICZ TM, 1990, ANAL CHEM, V62, P1872, DOI 10.1021/ac00216a026; ORWAR O, 1995, ANAL CHEM, V67, P4261, DOI 10.1021/ac00119a010; PIHEL K, 1995, ANAL CHEM, V67, P4514, DOI 10.1021/ac00120a014; RodriguezCruz SE, 1997, J AM SOC MASS SPECTR, V8, P565, DOI 10.1016/S1044-0305(97)00020-2; SOSSIN WS, 1989, J BIOL CHEM, V264, P16933; VANHEUMEN WRA, 1995, CELL TISSUE RES, V279, P13, DOI 10.1007/BF00300687; WILLIAMS ER, 1994, TRAC-TREND ANAL CHEM, V13, P247, DOI 10.1016/0165-9936(94)87050-0	22	100	103	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1190	1193		10.1126/science.279.5354.1190	http://dx.doi.org/10.1126/science.279.5354.1190			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469805				2022-12-28	WOS:000072115200037
J	Dans, AL; Dans, LF; Guyatt, GH				Dans, AL; Dans, LF; Guyatt, GH		Evidence Based Med Working Grp	Users' guides to the medical literature - XIV. How to decide on the applicability of clinical trial results to your patient	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; METAANALYSIS; THERAPY; PREVENTION; ARTICLE; HEALTH		McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Biostat, Hamilton, ON, Canada; Univ Philippines, Coll Med, Dept Internal Med, Manila, Philippines; Univ Philippines, Coll Med, Dept Pediat, Manila, Philippines; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; University of the Philippines System; University of the Philippines Manila; University of the Philippines System; University of the Philippines Manila; University of Texas System; University of Texas Health San Antonio	Guyatt, GH (corresponding author), McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol, 1200 Main St W,Room 2C12, Hamilton, ON L8N 3Z5, Canada.							[Anonymous], 1988, LANCET, V2, P349; BAILEY KR, 1994, CONTROL CLIN TRIALS, V15, P15, DOI 10.1016/0197-2456(94)90024-8; BALGOS AA, 1984, PHILIPPINE J CARDIOL, V12, P104; Barnett HJM, 1996, NEUROLOGY, V46, P603, DOI 10.1212/WNL.46.3.603; CANLAS MM, 1980, PHILIPP J INTERN MED, V18, P65; DAVIS CE, 1994, CONTROL CLIN TRIALS, V15, P11, DOI 10.1016/0197-2456(94)90023-X; DELAPAZ AG, 1988, PHILIPPINE J CARDIOL, V17, P185; FALKNER B, 1990, HYPERTENSION, V15, P36, DOI 10.1161/01.HYP.15.1.36; Farmer JA, 1997, BRAUNWALDS HEART DIS, V5, P1126; Friedman LM, 1985, FUNDAMENTALS CLIN TR; GERSH BJ, 1991, DRUGS HEART; GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356; GOODMAN GA, 1991, PHARMACOL BASIS THER, P71; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; HORAI Y, 1987, Rational Drug Therapy, V21, P1; KEYS A, 1989, INT J EPIDEMIOL 1 S3, V18, pS38; MARTINO E, 1984, ANN INTERN MED, V101, P28, DOI 10.7326/0003-4819-101-1-28; MIDGETTE AS, 1990, ANN INTERN MED, V113, P961, DOI 10.7326/0003-4819-113-12-961; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; RAJA SN, 1994, SOC SCI MED, V39, P213, DOI 10.1016/0277-9536(94)90330-1; ROBERTS WC, 1990, J AM COLL CARDIOL, V15, P196, DOI 10.1016/0735-1097(90)90201-Y; ROTHWELL PM, 1995, LANCET, V345, P1616, DOI 10.1016/S0140-6736(95)90120-5; SAZAWAL S, 1992, LANCET, V340, P528, DOI 10.1016/0140-6736(92)91720-S; Sharp SJ, 1996, BRIT MED J, V313, P735; WARD J, 1990, NEW ENGL J MED, V323, P1415; *WHO, 1994, WKLY EPIDEMIOL REC, V69, P309; WILSON TW, 1986, LANCET, V1, P784; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	31	144	148	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	1998	279	7					545	549		10.1001/jama.279.7.545	http://dx.doi.org/10.1001/jama.279.7.545			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW470	9480367				2022-12-28	WOS:000071938900038
J	Nolan, TW				Nolan, TW			Understanding medical systems	ANNALS OF INTERNAL MEDICINE			English	Article								The prominence of physicians in highly interdependent medical systems confers tremendous power on them, individually and as a profession. With this power comes an ethical responsibility to be deeply concerned about medical systems. Examples of medical systems include the process of treating patients with diabetes; a hospital; the development and testing of new medical procedures; and a medical practice, including locations of care, billing, and collection of fees for medical care. The physician who is willing to learn about the nature of systems,how to control them, and how to improve them can significantly influence medical systems. Many persons in health care organizations identify strongly with their individual profession or department. Management structures, professional organizations, and methods of billing for services reinforce these divisions. This fragmented environment allows the structure of medical systems to evolve piecemeal from the various actions and points of view of physicians, nurses, administrators, patients, and payers. Improvement results from new structures that are purposefully designed. To achieve improvement, people must look beyond their own professional or organizational identities and see themselves as part of the larger system. Even a rudimentary understanding of the structures and dynamics of systems combined with clinical knowledge can equip a physician to collaborate with colleagues to diagnose faults of a system and design remedies. This paper explores the nature of medical systems and develops ideas their proper application to medicine and the activities of physicians.	Associates Proc Improvement, Silver Spring, MD 20910 USA		Nolan, TW (corresponding author), Associates Proc Improvement, 1110 Bonifant St,Suite 420, Silver Spring, MD 20910 USA.							AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; Batalden PB, 1996, JOINT COMM J QUAL IM, V22, P651, DOI 10.1016/S1070-3241(16)30272-3; Berwick DM, 1998, ANN INTERN MED, V128, P289, DOI 10.7326/0003-4819-128-4-199802150-00008; BERWICK DM, 1994, JAMA-J AM MED ASSOC, V272, P797, DOI 10.1001/jama.272.10.797; BERWICK DM, IN PRESS ANN INTERN; BOROWSKY SJ, 1995, J AM COLL CARDIOL, V26, P1484, DOI 10.1016/0735-1097(95)00337-1; Fisher R., 1991, GETTING YES NEGOTIAT; Langley Gj., 1996, IMPROVEMENT GUIDE PR; MARKSON LE, 1994, ARCH INTERN MED, V154, P1497, DOI 10.1001/archinte.154.13.1497; Nash DB, 1997, ANN INTERN MED, V127, P72, DOI 10.7326/0003-4819-127-1-199707010-00012; REINERTSEN JL, IN PRESS ANN INTERN; Senge PM, 2006, 5 DISCIPLINE ART PRA; Tenner Edward., 1997, WHY THINGS BITE BACK; VONBERTALANFFY L, 1988, GEN SYSTEM THEORY	14	87	87	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1998	128	4					293	298		10.7326/0003-4819-128-4-199802150-00009	http://dx.doi.org/10.7326/0003-4819-128-4-199802150-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX170	9471933				2022-12-28	WOS:000072013400007
J	Gagan, MK; Ayliffe, LK; Hopley, D; Cali, JA; Mortimer, GE; Chappell, J; McCulloch, MT; Head, MJ				Gagan, MK; Ayliffe, LK; Hopley, D; Cali, JA; Mortimer, GE; Chappell, J; McCulloch, MT; Head, MJ			Temperature and surface-ocean water balance of the mid-Holocene tropical Western Pacific	SCIENCE			English	Article							LAST GLACIAL MAXIMUM; OXYGEN ISOTOPES; SEA-LEVEL; WARM POOL; CLIMATE; RECORDS; SR/CA; CONSTRAINTS; CORALS	Skeletal Sr/Ca and O-18/O-16 ratios in corals from the Great Barrier Reef, Australia, indicate that the tropical ocean surface similar to 5350 years ago was 1 degrees C warmer and enriched in O-18 by 0.5 per mil relative to modern seawater. The results suggest that the temperature increase enhanced the evaporative enrichment of O-18 in seawater. Transport of part of the additional atmospheric water vapor to extratropical latitudes may have sustained the O-18/O-16 anomaly. The reduced glacial-Holocene shift in seawater O-18/O-16 ratio produced by the mid-Holocene O-18 enrichment may help to reconcile the different temperature histories for the last deglaciation given by coral Sr/Ca thermometry and foraminiferal oxygen-isotope-records.	Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; James Cook Univ N Queensland, Sir George FIsher Ctr, Townsville, Qld 4811, Australia; Australian Natl Univ, Res Sch Pacific & Asian Studies, Canberra, ACT 0200, Australia	Australian National University; James Cook University; Australian National University	Gagan, MK (corresponding author), Australian Natl Univ, Res Sch Earth Sci, GPO Box 4, Canberra, ACT 0200, Australia.		Gagan, Michael/L-5014-2018; Ayliffe, Linda/C-3627-2009; McCulloch, Malcolm T/C-3651-2009	Gagan, Michael/0000-0002-8279-323X; Ayliffe, Linda/0000-0001-7662-5494; McCulloch, Malcolm T/0000-0003-1538-1558				Alibert C, 1997, PALEOCEANOGRAPHY, V12, P345, DOI 10.1029/97PA00318; BECK JW, 1992, SCIENCE, V257, P644, DOI 10.1126/science.257.5070.644; Beck JW, 1997, NATURE, V385, P705, DOI 10.1038/385705a0; Birchfield GE, 1987, PALEOCEANOGRAPHY, V2, P431, DOI 10.1029/PA002i004p00431; BONY S, 1995, CLIM DYNAM, V11, P307, DOI 10.1007/BF00211682; Broecker W, 1996, SCIENCE, V272, P1902, DOI 10.1126/science.272.5270.1902; Broecker WS, 1989, PALEOCEANOGRAPHY, V4, P207, DOI 10.1029/PA004i002p00207; BROECKER WS, 1989, GEOCHIM COSMOCHIM AC, V53, P2465, DOI 10.1016/0016-7037(89)90123-3; BROECKER WS, 1986, QUATERNARY RES, V26, P121, DOI 10.1016/0033-5894(86)90087-6; CHAPPELL J, 1986, NATURE, V324, P137, DOI 10.1038/324137a0; Chappell J, 1996, EARTH PLANET SC LETT, V141, P227, DOI 10.1016/0012-821X(96)00062-3; CLIMAP, 1981, GEOL SOC AM MAP CHAR, V36; Craig H., 1965, DEUTERIUM OXYGEN 18, P9, DOI DOI 10.1109/ISSRE.1993.624301; DEVILLIERS S, 1994, GEOCHIM COSMOCHIM AC, V58, P197, DOI 10.1016/0016-7037(94)90457-X; DEVILLIERS S, 1995, SCIENCE, V269, P1247, DOI 10.1126/science.269.5228.1247; EREZ J, 1983, GEOCHIM COSMOCHIM AC, V47, P1025, DOI 10.1016/0016-7037(83)90232-6; FAIRBANKS RG, 1989, NATURE, V342, P637, DOI 10.1038/342637a0; GAGAN MK, 1995, GEOPHYS RES LETT, V22, P1069, DOI 10.1029/95GL00607; GAGAN MK, 1994, EARTH PLANET SC LETT, V121, P549, DOI 10.1016/0012-821X(94)90090-6; Gagan MK, 1996, GEOLOGY, V24, P1009, DOI 10.1130/0091-7613(1996)024<1009:TCBCHU>2.3.CO;2; Gillespie R., 1979, RADIOCARBON DATING, P404; GUILDERSON TP, 1994, SCIENCE, V263, P663, DOI 10.1126/science.263.5147.663; HOU AY, 1993, J ATMOS SCI, V50, P3553, DOI 10.1175/1520-0469(1993)050<3553:TIOTHD>2.0.CO;2; KUTZBACH JE, 1988, SCIENCE, V241, P1043, DOI 10.1126/science.241.4869.1043; LINDZEN RS, 1994, CLIM DYNAM, V10, P49, DOI 10.1007/BF00210336; Lough JM, 1997, J EXP MAR BIOL ECOL, V211, P29, DOI 10.1016/S0022-0981(96)02710-4; Martinez JI, 1997, MAR MICROPALEONTOL, V32, P311; MARTINEZ JI, 1994, PALAEOGEOGR PALAEOCL, V112, P19, DOI 10.1016/0031-0182(94)90133-3; MCCULLOCH MT, 1994, GEOCHIM COSMOCHIM AC, V58, P2747, DOI 10.1016/0016-7037(94)90142-2; MCGLONE MS, 1994, EL NINO HIST PALEOCL, P435; Norton FL, 1997, PALEOCEANOGRAPHY, V12, P15, DOI 10.1029/96PA02832; OSTLUND HG, 1987, SHOREBASED DATA GRAP; REYNOLDS RW, 1994, J CLIMATE, V7, P929, DOI 10.1175/1520-0442(1994)007<0929:IGSSTA>2.0.CO;2; RIND D, 1990, J GEOPHYS RES-ATMOS, V95, P9983, DOI 10.1029/JD095iD07p09983; RIND D, 1987, J ATMOS SCI, V44, P3235, DOI 10.1175/1520-0469(1987)044<3235:TDCCIO>2.0.CO;2; RIND D, 1985, QUATERNARY RES, V24, P1, DOI 10.1016/0033-5894(85)90080-8; Schrag DP, 1996, SCIENCE, V272, P1930, DOI 10.1126/science.272.5270.1930; SHACKLETON N, 1967, NATURE, V215, P15, DOI 10.1038/215015a0; SHACKLETON NJ, 1987, QUATERNARY SCI REV, V6, P183, DOI 10.1016/0277-3791(87)90003-5; Shen CC, 1996, GEOCHIM COSMOCHIM AC, V60, P3849, DOI 10.1016/0016-7037(96)00205-0; SMITH SV, 1979, SCIENCE, V204, P404, DOI 10.1126/science.204.4391.404; STUIVER M, 1977, RADIOCARBON, V19, P353; STUTE M, 1995, SCIENCE, V269, P379, DOI 10.1126/science.269.5222.379; THOMPSON LG, 1995, SCIENCE, V269, P46, DOI 10.1126/science.269.5220.46	44	391	413	1	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1014	1018		10.1126/science.279.5353.1014	http://dx.doi.org/10.1126/science.279.5353.1014			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461430				2022-12-28	WOS:000072006400042
J	Cho, YH; Giese, KP; Tanila, H; Silva, AJ; Eichenbaum, H				Cho, YH; Giese, KP; Tanila, H; Silva, AJ; Eichenbaum, H			Abnormal hippocampal spatial representations in alpha CaMKIIT286A and CREB alpha Delta- mice	SCIENCE			English	Article							II MUTANT MICE; MEMORY; RAT; LTP	Hippocampal "place cells" fire selectively when an animal is in a specific location. The fine-tuning and stability of place cell firing was compared in two types of mutant mice with different long-term potentiation (LTP) and place learning impairments. Place cells from both mutants showed decreased spatial selectivity. Place cell stability was also deficient in both mutants and, consistent with the severities in their LTP and spatial learning deficits, was more affected in mice with a point mutation [threonine (T) at position 286 mutated to alanine (A)] in the alpha calmodulin kinase II (alpha CaMKIIT286A) than in mice deficient for the a and a isoforms of adenosine 3'5'-monophosphate-responsive element binding proteins (CREBalpha Delta-). Thus, LTP appears to be important for the fine tuning and stabilization of place cells, and these place cell properties may be necessary for spatial learning.	Boston Univ, Dept Psychol, Boston, MA 02215 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Kuopio, Dept Neurol & Neurosci, FIN-70211 Kuopio, Finland	Boston University; Cold Spring Harbor Laboratory; University of Eastern Finland	Eichenbaum, H (corresponding author), Boston Univ, Dept Psychol, 64 Cummington St, Boston, MA 02215 USA.	hbe@bu.edu	Silva, Alcino/ABD-7684-2021; Giese, Karl P/A-3112-2011	Silva, Alcino/0000-0002-1587-4558; Giese, Karl P/0000-0003-4503-7344; Silva, Alcino/0000-0001-5525-0494	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG013622, R01AG013622] Funding Source: NIH RePORTER; NIA NIH HHS [AG13622] Funding Source: Medline; NIMH NIH HHS [MH51570] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AUSTIN K B, 1990, Society for Neuroscience Abstracts, V16, P263; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Eichenbaum H, 1996, LEARN MEMORY, V3, P61, DOI 10.1101/lm.3.2-3.61; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; Kogan JH, 1997, CURR BIOL, V7, P1, DOI 10.1016/S0960-9822(06)00022-4; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; McHugh TJ, 1996, CELL, V87, P1339, DOI 10.1016/S0092-8674(00)81828-0; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Morris RGM, 1997, PHILOS T ROY SOC B, V352, P1489, DOI 10.1098/rstb.1997.0136; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1976, EXP NEUROL, V51, P78, DOI 10.1016/0014-4886(76)90055-8; OLTON DS, 1978, EXP NEUROL, V58, P387, DOI 10.1016/0014-4886(78)90096-1; Rotenberg A, 1996, CELL, V87, P1351, DOI 10.1016/S0092-8674(00)81829-2; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Tanila H, 1997, J NEUROSCI, V17, P5155; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Wilson MA, 1997, TRENDS NEUROSCI, V20, P102, DOI 10.1016/S0166-2236(96)01023-5; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520	21	144	150	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	1998	279	5352					867	869		10.1126/science.279.5352.867	http://dx.doi.org/10.1126/science.279.5352.867			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452387				2022-12-28	WOS:000071923500045
J	Henn, V; Slupsky, JR; Grafe, M; Anagnostopoulos, I; Forster, R; Muller-Berghaus, G; Kroczek, RA				Henn, V; Slupsky, JR; Grafe, M; Anagnostopoulos, I; Forster, R; Muller-Berghaus, G; Kroczek, RA			CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells	NATURE			English	Article							ADHESION MOLECULE EXPRESSION; X-LINKED IMMUNODEFICIENCY; T-CELLS; DEFECTIVE EXPRESSION; HYPER-IGM; CYTOKINES; INTERLEUKIN-8; ESTABLISHMENT; SURFACE; PROTEIN	CD40 ligand (CD40L, CD154), a transmembrane protein structurally related to the cytokine TNF-alpha, was originally identified on stimulated CD4(+) T cells(1-3), and later on stimulated mast cells and basophils(4). Interaction of CD40L on T cells with CD40 on B cells is of paramount importance for the development and function of the humoral immune system(5). CD40 is not only constitutively present on B cells, but it is also found on monocytes, macrophages and endothelial cells, suggesting that CD40L has a broader function in vivo. We now report that platelets express CD40L within seconds of activation in vitro and in the process of thrombus formation in vivo. Like TNF-alpha and interleukin-1, CD40L on platelets induces endothelial cells to secrete chemokines and to express adhesion molecules, thereby generating signals for the recruitment and extravasation of leukocytes at the site of injury. Our results indicate that platelets are not only involved in haemostasis but that they also directly initiate an inflammatory response of the vessel wall.	Robert Koch Inst, D-13353 Berlin, Germany; Max Planck Inst Physiol & Klin Forsch, Haemostasis Res Unit, D-61231 Bad Nauheim, Germany; Deutsch Herrzzentrum, D-13353 Berlin, Germany; Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pathol, D-12200 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Robert Koch Institute; Max Planck Society; German Heart Center Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kroczek, RA (corresponding author), Robert Koch Inst, D-13353 Berlin, Germany.	Kroczek@rki.de	Förster, Reinhold/D-6770-2011; Slupsky, Joseph/H-2843-2019	Slupsky, Joseph/0000-0002-7410-9004; Forster, Reinhold/0000-0001-6190-7923				ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; Clark R., 1996, Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, P3; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; Davies MJ, 1996, THROMB RES, V82, P1, DOI 10.1016/0049-3848(96)00035-7; Ebnet K, 1996, ANNU REV IMMUNOL, V14, P155, DOI 10.1146/annurev.immunol.14.1.155; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; GRAF D, 1995, EUR J IMMUNOL, V25, P1749, DOI 10.1002/eji.1830250639; HAWRYLOWICZ CM, 1991, J EXP MED, V174, P785, DOI 10.1084/jem.174.4.785; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; Holmsen H., 1994, HEMOSTASIS THROMBOSI, P524; KAPLANSKI G, 1993, BLOOD, V81, P2492; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; Kenny D, 1997, BLOOD, V90, P2626, DOI 10.1182/blood.V90.7.2626.2626_2626_2633; KIENER PA, 1995, J IMMUNOL, V155, P4917; KOMATSU N, 1991, CANCER RES, V51, P341; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KROCZEK RA, 1994, IMMUNOL REV, V138, P39, DOI 10.1111/j.1600-065X.1994.tb00846.x; LAUFFER L, 1995, BEHRING I MITT, V96, P21; LEDERMAN S, 1992, J EXP MED, V175, P1091, DOI 10.1084/jem.175.4.1091; NIEUWENHUIS HK, 1987, BLOOD, V70, P838; OGURA M, 1985, BLOOD, V66, P1384; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; WARE JA, 1993, NEW ENGL J MED, V328, P628; YELLIN MJ, 1995, J EXP MED, V182, P1857, DOI 10.1084/jem.182.6.1857	29	1592	1663	1	52	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 5	1998	391	6667					591	594		10.1038/35393	http://dx.doi.org/10.1038/35393			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468137				2022-12-28	WOS:000071842300053
J	Hunter, T				Hunter, T			Prolyl isomerases and nuclear function	CELL			English	Review							C-MYB; PROTEIN		Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA	Salk Institute	Hunter, T (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.							CRENSHAW DG, 1998, IN PRESS EMBO J; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; Dolinski K, 1997, P NATL ACAD SCI USA, V94, P13093, DOI 10.1073/pnas.94.24.13093; Dolinski K, 1997, MOL BIOL CELL, V8, P2267, DOI 10.1091/mbc.8.11.2267; DOLINSKI K, 1997, GUIDEBOOK MOL CHAPER, P359; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; JIN YJ, 1993, P NATL ACAD SCI USA, V90, P7769, DOI 10.1073/pnas.90.16.7769; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; Lu KP, 1996, NATURE, V380, P544; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; OGATA K, 1994, CELL, V79, P539; RAHFELD JU, 1994, FEBS LETT, V352, P180, DOI 10.1016/0014-5793(94)00932-5; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; SCHMID FX, 1995, CURR BIOL, V5, P993, DOI 10.1016/S0960-9822(95)00197-7; Scholz C, 1997, J MOL BIOL, V273, P752, DOI 10.1006/jmbi.1997.1301; Scholz C, 1997, FEBS LETT, V414, P69, DOI 10.1016/S0014-5793(97)00979-4; SHEN M, 1998, IN PRESS GENES DEV; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; YANG WM, 1995, J BIOL CHEM, V270, P15187, DOI 10.1074/jbc.270.25.15187	22	102	106	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					141	143		10.1016/S0092-8674(00)80906-X	http://dx.doi.org/10.1016/S0092-8674(00)80906-X			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458036	Bronze			2022-12-28	WOS:000071672600001
J	Kumar, L; Gulati, SC				Kumar, L; Gulati, SC			Peripheral stem-cell transplantation	LANCET			English	Article									NEW YORK HOSP,NEW YORK,NY 10021; CORNELL MED CTR,NEW YORK,NY	NewYork-Presbyterian Hospital; Cornell University	Kumar, L (corresponding author), ALL INDIA INST MED SCI,INST ROTARY CANC HOSP,NEW DELHI 110029,INDIA.							BENSINGER W, 1995, J CLIN ONCOL, V13, P2547, DOI 10.1200/JCO.1995.13.10.2547; BRUGGER W, 1995, NEW ENGL J MED, V333, P283, DOI 10.1056/NEJM199508033330503; DUNBAR CE, 1995, BLOOD, V85, P3048, DOI 10.1182/blood.V85.11.3048.bloodjournal85113048; MOORE MAS, 1995, CLIN CANCER RES, V1, P3; SCHMITZ N, 1995, BLOOD, V85, P1666, DOI 10.1182/blood.V85.6.1666.bloodjournal8561666	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S9	S9		10.1016/0140-6736(95)90008-X	http://dx.doi.org/10.1016/0140-6736(95)90008-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454052				2022-12-28	WOS:A1995TN12200009
J	Valway, SE; Sanchez, MPC; Shinnick, TF; Orme, I; Agerton, T; Hoy, D; Jones, JS; Westmoreland, H; Onorato, IM				Valway, SE; Sanchez, MPC; Shinnick, TF; Orme, I; Agerton, T; Hoy, D; Jones, JS; Westmoreland, H; Onorato, IM			An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	35th Annual Meeting of the Infectious-Diseases-Society-of-America	SEP 07-16, 1997	SAN FRANCISCO, CALIFORNIA	Infect Dis Soc Amer			COMMUNITY; INFECTION; EPIDEMIC; CHILDREN	Background and Methods From 1994 to 1996, there was a large outbreak of tuberculosis in a small, rural community with a population at low risk for tuberculosis. Twenty-one patients with tuberculosis (15 with positive cultures) were identified; the DNA fingerprints of the 13 isolates available for testing were identical. To determine the extent of transmission, we investigated both the close and casual contacts of the patients. Using a mouse model, we also studied the virulence of the strain of Mycobacterium tuberculosis that caused the outbreak. Results The index patient, in whom tuberculosis was diagnosed in 1995; the source patient, in whom the disease was diagnosed in 1994; and a patient in whom the disease was diagnosed in 1996 infected the other 18 persons. In five, active disease developed after only brief, casual exposure. There was extensive transmission from the three patients to both close and casual contacts. Of the 429 contacts, 311 (72 percent) had positive skin tests, including 86 with documented skin-test conversions. Mice infected with the virulent Erdman strain of M. tuberculosis had approximately 1000 bacilli per lung after 10 days and about 10,000 bacilli per lung after 20 days. In contrast, mice infected with the strain involved in the outbreak had about 10,000 bacilli per lung after 10 days and about 10 million bacilli per lung after 20 days. Conclusions In this outbreak of tuberculosis, the growth characteristics of the strain involved greatly exceeded those of other clinical isolates of M. tuberculosia. The extensive transmission of tuberculosis may have been due to the increased virulence of the strain rather than to environmental factors or patient characteristics. (C) 1998, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Div TB Eliminat, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Epidemiol Intelligence Serv, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div AIDS STD & TB Lab Res, Atlanta, GA 30333 USA; Colorado State Univ, Dept Microbiol & Immunol, Ft Collins, CO 80523 USA; Tennessee Dept Hlth, Upper Cumberland Reg, Cookeville, TN 38501 USA; Kentucky Dept Hlth Serv, Frankfort, KY 40601 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Colorado State University; Tennessee Department Health	Valway, SE (corresponding author), Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Div TB Eliminat, Mailstop E-10,1600 Clifton Rd, Atlanta, GA 30333 USA.							Allos BM, 1996, ANN INTERN MED, V125, P114, DOI 10.7326/0003-4819-125-2-199607150-00007; BOSLEY ARJ, 1986, LANCET, V1, P1141; BRADEN CR, 1995, CLIN INFECT DIS, V21, P565, DOI 10.1093/clinids/21.3.565; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; Chaves F, 1996, J CLIN MICROBIOL, V34, P1118, DOI 10.1128/JCM.34.5.1118-1123.1996; Decker J., 1995, APPL OCCUPATIONAL EN, V10, P887; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; GRIFFITH DE, 1995, AM J RESP CRIT CARE, V152, P808, DOI 10.1164/ajrccm.152.2.7633747; HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204, DOI 10.1086/646003; HILL JD, 1983, BRIT MED J, V286, P1471, DOI 10.1136/bmj.286.6376.1471; HOGE CW, 1994, AM J EPIDEMIOL, V139, P520, DOI 10.1093/oxfordjournals.aje.a117035; HOUK VN, 1968, ARCH ENVIRON HEALTH, V16, P26, DOI 10.1080/00039896.1968.10665011; Jacobs H, 1996, SCIENCE, V274, P17; KLINE SE, 1995, NEW ENGL J MED, V333, P222, DOI 10.1056/NEJM199507273330404; Lincoln E M, 1965, Bibl Tuberc, V21, P157; Moreira AL, 1997, TUBERCLE LUNG DIS, V78, P47, DOI 10.1016/S0962-8479(97)90015-0; NORTH RJ, 1993, J EXP MED, V177, P1723, DOI 10.1084/jem.177.6.1723; ORDWAY DJ, 1995, INFECT IMMUN, V63, P741, DOI 10.1128/IAI.63.2.741-743.1995; RAO VR, 1980, BRIT MED J, V281, P187, DOI 10.1136/bmj.281.6234.187; SACKS JJ, 1985, AM J PUBLIC HEALTH, V75, P361, DOI 10.2105/AJPH.75.4.361	20	320	325	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1998	338	10					633	639		10.1056/NEJM199803053381001	http://dx.doi.org/10.1056/NEJM199803053381001			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ844	9486991				2022-12-28	WOS:000072299700001
J	Herold, BC; Immergluck, LC; Maranan, MC; Lauderdale, DS; Gaskin, RE; Boyle-Vavra, S; Leitch, CD; Daum, RS				Herold, BC; Immergluck, LC; Maranan, MC; Lauderdale, DS; Gaskin, RE; Boyle-Vavra, S; Leitch, CD; Daum, RS			Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTRAVENOUS DRUG-ABUSERS; UNITED-STATES HOSPITALS; INFECTIONS; OUTBREAK; COLONIZATION; EPIDEMIOLOGY; EVOLUTION; STRAINS; MRSA	Context.-Community-acquired methicillin-resistant Staphylococcus aureus (MRSA) infections in children have occurred primarily in individuals with recognized predisposing risks. Community-acquired MRSA infections in the absence of identified risk factors have been reported infrequently. Objectives.-To determine whether community-acquired MRSA infections in children with no identified predisposing risks are increasing and to define the spectrum of disease associated with MRSA isolation. Design.-Retrospective review of medical records. Patients.-Hospitalized children with S aureus isolated between August 1988 and July 1990 (1988-1990) and between August 1993 and July 1995 (1993-1995). Setting.-The University of Chicago Children's Hospital. Main Outcome Measures.-Prevalence of community-acquired MRSA over time, infecting vs colonizing isolates, and risk factors for disease. Results.-The number of children hospitalized with community-acquired MRSA disease increased from 8 in 1988-1990 to 35 in 1993-1995. Moreover, the prevalence of community-acquired MRSA without identified risk increased from 10 per 100 000 admissions in 1988-1990 to 259 per 100 000 admissions in 1993-1995 (P<.001), and a greater proportion of isolates produced clinical infection. The clinical syndromes associated with MRSA in children without identified risk were similar to those associated with community-acquired methicillin-susceptible S aureus. Notably, 7 (70%) of 10 community-acquired MRSA isolates obtained from children with an identified risk were nonsusceptible to at least 2 drugs, compared with only 6 (24%) of 25 isolates obtained from children without an identified risk (P=.02). Conclusions.-These findings demonstrate that the prevalence of community-acquired MRSA among children without identified risk factors is increasing.	Univ Chicago Hosp, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago Hosp, Dept Hlth Studies, Chicago, IL 60637 USA; Univ Chicago Hosp, Clin Microbiol Labs, Chicago, IL 60637 USA; Vet Affairs Med Ctr, Res Serv, Boston, MA USA	University of Chicago; University of Illinois System; University of Chicago; University of Illinois System; University of Chicago; University of Illinois System; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Herold, BC (corresponding author), Univ Chicago Hosp, Dept Pediat, 5841 S Maryland Ave,MC6054, Chicago, IL 60637 USA.			Herold, Betsy/0000-0001-9974-0786				BERMAN DS, 1993, NEW ENGL J MED, V329, P1896, DOI 10.1056/NEJM199312163292517; BERMAN DS, 1987, J INFECT DIS, V155, P829, DOI 10.1093/infdis/155.4.829-a; BOXERBAUM B, 1988, PEDIATR PULM, V4, P159, DOI 10.1002/ppul.1950040307; BOYCE JM, 1981, INFECT CONT HOSP EP, V2, P110, DOI 10.1017/S0195941700053881; BOYCE JM, 1982, INFECT CONTROL, V3, P337; *CDC, 1981, MMWR-MORBID MORTAL W, V30, P557; CRAVEN DE, 1986, AM J MED, V80, P770, DOI 10.1016/0002-9343(86)90614-5; CROSSLEY K, 1979, J INFECT DIS, V139, P273, DOI 10.1093/infdis/139.3.273; DUNKLE LM, 1981, AM J MED, V70, P455, DOI 10.1016/0002-9343(81)90787-7; EMBIL J, 1994, INFECT CONT HOSP EP, V15, P646; HALEY RW, 1982, ANN INTERN MED, V97, P297, DOI 10.7326/0003-4819-97-3-297; HIRAMATSU K, 1992, MICROBIOL IMMUNOL, V36, P445, DOI 10.1111/j.1348-0421.1992.tb02043.x; HIRAMATSU K, 1995, MICROBIOL IMMUNOL, V39, P531, DOI 10.1111/j.1348-0421.1995.tb02239.x; Immergluck LC, 1996, PEDIATR INFECT DIS J, V15, P96, DOI 10.1097/00006454-199601000-00025; KALLEN AJ, 1997, 35 ANN M INF DIS SOC; KLINE MW, 1987, J INFECT DIS, V156, P205, DOI 10.1093/infdis/156.1.205; LAYTON MC, 1995, INFECT CONT HOSP EP, V16, P12; LEVINE DP, 1982, ANN INTERN MED, V97, P330, DOI 10.7326/0003-4819-97-3-330; LOCKSLEY RM, 1982, ANN INTERN MED, V97, P317, DOI 10.7326/0003-4819-97-3-317; Maranan MC, 1997, INFECT DIS CLIN N AM, V11, P813, DOI 10.1016/S0891-5520(05)70392-5; MARANAN MC, 1997, 35 ANN M INF DIS SOC; MARCINAK JF, 1997, 35 ANN M INF DIS SOC; Maslow Joel N., 1993, P563; MORENO F, 1995, CLIN INFECT DIS, V21, P1308, DOI 10.1093/clinids/21.5.1308; MURPHY S, 1992, J AM GERIATR SOC, V40, P213, DOI 10.1111/j.1532-5415.1992.tb02070.x; *NAT COMM CLIN LAB, 1993, M7A3 NCCLS, P13; PANLILIO AL, 1992, INFECT CONT HOSP EP, V13, P582; PATE KR, 1995, LANCET, V346, P132; RIBNER BS, 1989, AM J INFECT CONTROL, V17, P244, DOI 10.1016/0196-6553(89)90170-3; ROSENBERG J, 1995, LANCET, V346, P132, DOI 10.1016/S0140-6736(95)91203-7; RYFFEL C, 1990, GENE, V94, P137, DOI 10.1016/0378-1119(90)90481-6; SARAVOLATZ LD, 1982, ANN INTERN MED, V96, P11, DOI 10.7326/0003-4819-96-1-11; SARAVOLATZ LD, 1982, ANN INTERN MED, V97, P325, DOI 10.7326/0003-4819-97-3-325; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; THOMPSON RL, 1982, ANN INTERN MED, V97, P309, DOI 10.7326/0003-4819-97-3-309; WENZEL RP, 1976, AM J EPIDEMIOL, V103, P251, DOI 10.1093/oxfordjournals.aje.a112223	36	1116	1168	0	38	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	1998	279	8					593	598		10.1001/jama.279.8.593	http://dx.doi.org/10.1001/jama.279.8.593			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX457	9486753	Bronze			2022-12-28	WOS:000072041900034
J	Agrawal, AA				Agrawal, AA			Induced responses to herbivory and increased plant performance	SCIENCE			English	Article							INDUCED RESISTANCE; GOSSYPIUM-THURBERI; NATURAL-SELECTION; IPOMOEA-PURPUREA; RAPHANUS-SATIVUS; PARASITIC WASPS; TOMATO PLANTS; SPIDER MITES; NATIVE SHRUB; LEAVES	Plant resistance to herbivores was induced in a field experiment to evaluate the consequences of induced responses for subsequent herbivory and plant fitness. Induction early in the season resulted in halving of herbivory by chewing herbivores and a reduction in the abundance of phloem-feeding aphids when compared with controls. A correlate of lifetime plant fitness, seed mass, was enhanced by over 60 percent for individuals that were induced.	Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA; Univ Calif Davis, Ctr Populat Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Agrawal, AA (corresponding author), Univ Calif Davis, Dept Entomol, 1 Shields Ave, Davis, CA 95616 USA.	aaagrawal@ucdavis.edu	Agrawal, Anurag A/Y-2497-2019	Agrawal, Anurag A/0000-0003-0095-1220				AGRAWAL AA, IN PRESS ECOLOGY; AGRAWAL AA, IN PRESS ECOLOGY EVO; AGRAWAL AF, UNPUB; Alborn HT, 1997, SCIENCE, V276, P945, DOI 10.1126/science.276.5314.945; ASHMAN TL, 1993, OECOLOGIA, V96, P102, DOI 10.1007/BF00318036; BALDWIN IT, 1990, TRENDS ECOL EVOL, V5, P91, DOI 10.1016/0169-5347(90)90237-8; BALDWIN IT, 1988, OECOLOGIA, V75, P367, DOI 10.1007/BF00376939; BALDWIN IT, 1991, PHYTOCHEMICAL INDUCT, P47; BAUR R, 1991, OECOLOGIA, V87, P219, DOI 10.1007/BF00325259; Bi JL, 1997, J CHEM ECOL, V23, P97, DOI 10.1023/B:JOEC.0000006348.62578.fd; BRYANT JP, 1981, SCIENCE, V213, P889, DOI 10.1126/science.213.4510.889; CARROLL CR, 1980, SCIENCE, V209, P414, DOI 10.1126/science.209.4454.414; CHET I, 1987, INNOVATIVE APPROACHE, P255; DRUKKER B, 1995, ENTOMOL EXP APPL, V77, P193, DOI 10.1007/BF02383034; ERNEST KA, 1994, ECOLOGY, V75, P1684, DOI 10.2307/1939628; GIAMOUSTARIS A, 1995, ANN APPL BIOL, V126, P347, DOI 10.1111/j.1744-7348.1995.tb05371.x; GREEN TR, 1972, SCIENCE, V175, P776, DOI 10.1126/science.175.4023.776; Hansson LA, 1996, P ROY SOC B-BIOL SCI, V263, P1241, DOI 10.1098/rspb.1996.0182; HARVELL CD, 1990, Q REV BIOL, V65, P323, DOI 10.1086/416841; HAUKIOJA E, 1985, ECOLOGY, V66, P1303, DOI 10.2307/1939183; Haukioja E, 1977, Annales Zool fenn, V14, P48; HAUKIOJA E, 1975, REP KEVO SUBARCTIC R, V12, P1; HERMS DA, 1992, Q REV BIOL, V67, P283, DOI 10.1086/417659; KARBAN R, 1987, SCIENCE, V235, P678, DOI 10.1126/science.235.4789.678; Karban R, 1997, ECOLOGY, V78, P1351; KARBAN R, 1984, SCIENCE, V225, P53, DOI 10.1126/science.225.4657.53; KARBAN R, 1986, ENTOMOL EXP APPL, V42, P239, DOI 10.1007/BF00629310; KARBAN R, 1993, ECOLOGY, V74, P9, DOI 10.2307/1939496; KARBAN R, 1993, ECOLOGY, V74, P1, DOI 10.2307/1939495; Karban R., 1997, INDUCED RESPONSES HE, DOI 10.7208/chicago/9780226424972.001.0001; Koptur S, 1989, EVOLUTIONARY ECOLOGY, P323; KUC J, 1982, BIOSCIENCE, V32, P854, DOI 10.2307/1309008; MARQUIS RJ, 1984, SCIENCE, V226, P537, DOI 10.1126/science.226.4674.537; MARQUIS RJ, 1992, PLANT RESISTANCE HER, P392; MATTIACCI L, 1995, P NATL ACAD SCI USA, V92, P2036, DOI 10.1073/pnas.92.6.2036; MATTSON W J, 1988, P157; MAURICIO R, 1993, ECOLOGY, V74, P2066, DOI 10.2307/1940852; MILEWSKI AV, 1991, OECOLOGIA, V86, P70, DOI 10.1007/BF00317391; MOUND L. A., 1962, Empire Cotton Growing Review, V39, P254; NUNEZFARFAN J, 1994, EVOLUTION, V48, P423, DOI [10.2307/2410102, 10.1111/j.1558-5646.1994.tb01321.x]; Obeso JR, 1997, PLANT ECOL, V129, P149, DOI 10.1023/A:1009767931817; Rhoades D. F., 1979, HERBIVORES THEIR INT, P3; Schneider M, 1996, INT REV CYTOL, V168, P303, DOI 10.1016/S0074-7696(08)60887-6; SELDAL T, 1994, OIKOS, V70, P3, DOI 10.2307/3545692; Shimoda T, 1997, J CHEM ECOL, V23, P2033, DOI 10.1023/B:JOEC.0000006487.49221.df; Simms E. L., 1992, PLANT RESISTANCE HER, P363; SIMMS EL, 1995, OECOLOGIA, V102, P494, DOI 10.1007/BF00341362; SIMMS EL, 1989, EVOLUTION, V43, P573, DOI 10.1111/j.1558-5646.1989.tb04253.x; SMITH LL, 1990, ECOLOGY, V71, P107, DOI 10.2307/1940251; STANTON ML, 1984, ECOLOGY, V65, P1105, DOI 10.2307/1938318; Stout MJ, 1996, ENTOMOL EXP APPL, V79, P273, DOI 10.1007/BF00186286; Stout MJ, 1996, ENTOMOL EXP APPL, V79, P255, DOI 10.1007/BF00186285; Takabayashi J, 1996, TRENDS PLANT SCI, V1, P109, DOI 10.1016/S1360-1385(96)90004-7; Tallamy D.W., 1991, P155; TURLINGS TCJ, 1990, SCIENCE, V250, P1251, DOI 10.1126/science.250.4985.1251; WHITHAM TG, 1980, AM NAT, V115, P449, DOI 10.1086/283573; Wold EN, 1997, ECOLOGY, V78, P1356, DOI 10.1890/0012-9658(1997)078[1356:IDIWOE]2.0.CO;2; Wolfe GV, 1997, NATURE, V387, P894, DOI 10.1038/43168; YOUNG TP, 1987, OECOLOGIA, V71, P436, DOI 10.1007/BF00378718; Zangerl A. R., 1992, Plant resistance to herbivores and pathogens: ecology, evolution, and genetics., P363; ZUCKER WV, 1982, ECOLOGY, V63, P972, DOI 10.2307/1937237	61	432	484	2	242	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1201	1202		10.1126/science.279.5354.1201	http://dx.doi.org/10.1126/science.279.5354.1201			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469809				2022-12-28	WOS:000072115200041
J	Schweizer, FE; Dresbach, T; DeBello, WM; O'Connor, V; Augustine, GJ; Betz, H				Schweizer, FE; Dresbach, T; DeBello, WM; O'Connor, V; Augustine, GJ; Betz, H			Regulation of neurotransmitter release kinetics by NSF	SCIENCE			English	Article							SENSITIVE FUSION PROTEIN; SYNAPTIC VESICLE FUSION; SQUID GIANT SYNAPSE; N-TYPE; TRANSMITTER RELEASE; CA2+ CHANNELS; ALPHA-SNAP; IN-VITRO; EXOCYTOSIS; ACTIVATION	NSF (N-ethylmaleimide-sensitive factor) is an adenosine triphosphatase (ATPase) that contributes to a protein complex essential for membrane fusion. The synaptic function of this protein was investigated by injecting, into the giant presynaptic terminal of squid, peptides that inhibit the ATPase activity of NSF stimulated by the soluble NSF attachment protein (SNAP). These peptides reduced the amount and slowed the kinetics of neurotransmitter release as a result of actions that required vesicle turnover and occurred at a step subsequent to vesicle docking. These results define NSF as an essential participant in synaptic vesicle exocytosis that regulates the kinetics of neurotransmitter release and, thereby, the integrative properties of synapses.	Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; Marine Biol Lab, Woods Hole, MA 02543 USA; Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany	Duke University; Marine Biological Laboratory - Woods Hole; Max Planck Society	Augustine, GJ (corresponding author), Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA.		Augustine, George James/J-9228-2013					Augustine GJ, 1996, ANNU REV PHARMACOL, V36, P659, DOI 10.1146/annurev.pa.36.040196.003303; AUGUSTINE GJ, 1984, J PHYSIOL-LONDON, V346, P257, DOI 10.1113/jphysiol.1984.sp015020; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BAMARD RJO, 1997, J CELL BIOL, V139, P875; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; Byrne JH, 1996, J NEUROSCI, V16, P425; Colombo MI, 1996, J BIOL CHEM, V271, P18810, DOI 10.1074/jbc.271.31.18810; CORRIE JET, 1993, J PHYSIOL-LONDON, V465, P1; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Diamond JS, 1997, J NEUROSCI, V17, P4672; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HESS SD, 1993, SCIENCE, V259, P1169, DOI 10.1126/science.8438167; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; ISAACSON JS, 1993, J NEUROPHYSIOL, V70, P2187, DOI 10.1152/jn.1993.70.5.2187; KATZ B, 1965, PROC R SOC SER B-BIO, V161, P483, DOI 10.1098/rspb.1965.0016; MANN DW, 1978, J NEUROBIOL, V9, P329, DOI 10.1002/neu.480090410; Martin TFJ, 1995, COLD SPRING HARB SYM, V60, P197, DOI 10.1101/SQB.1995.060.01.022; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Mochida S, 1996, NEURON, V17, P781, DOI 10.1016/S0896-6273(00)80209-3; MORGAN A, 1994, J BIOL CHEM, V269, P29347; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; OConnor V, 1997, P NATL ACAD SCI USA, V94, P12186, DOI 10.1073/pnas.94.22.12186; OConnor V, 1996, BIOCHEM SOC T, V24, P666, DOI 10.1042/bst0240666; PALLANCK L, 1995, NATURE, V376, P25, DOI 10.1038/376025a0; PARNAS H, 1994, J MEMBRANE BIOL, V142, P267; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; PELLEGRINI LL, 1995, EMBO J, V14, P4705, DOI 10.1002/j.1460-2075.1995.tb00152.x; Rahamimoff R, 1997, NEURON, V18, P17, DOI 10.1016/S0896-6273(01)80043-X; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHELLER RH, 1995, NEURON, V14, P893; SIDDIQI O, 1976, P NATL ACAD SCI USA, V73, P3253, DOI 10.1073/pnas.73.9.3253; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; Vogel SS, 1996, J CELL BIOL, V134, P329, DOI 10.1083/jcb.134.2.329; Vyshedskiy A, 1997, J NEUROPHYSIOL, V78, P1791, DOI 10.1152/jn.1997.78.4.1791; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WIEBOLDT R, 1994, P NATL ACAD SCI USA, V91, P8752, DOI 10.1073/pnas.91.19.8752; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Young JZ, 1939, PHILOS T ROY SOC B, V229, P465, DOI 10.1098/rstb.1939.0003	48	86	89	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1203	1206		10.1126/science.279.5354.1203	http://dx.doi.org/10.1126/science.279.5354.1203			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469810				2022-12-28	WOS:000072115200042
J	Berg, BW; Saenger, JS				Berg, BW; Saenger, JS			Exogenous lipoid pneumonia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Tripler Army Med Ctr, Honolulu, HI 96859 USA	United States Department of Defense; United States Army	Berg, BW (corresponding author), Tripler Army Med Ctr, Honolulu, HI 96859 USA.		Gartner, Silvia/I-3935-2017; Berg, Benjamin/AAL-3277-2021	Gartner, Silvia/0000-0002-8190-5092; Berg, Benjamin/0000-0002-4748-5020					0	10	11	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 19	1998	338	8					512	512		10.1056/NEJM199802193380805	http://dx.doi.org/10.1056/NEJM199802193380805			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX639	9468468				2022-12-28	WOS:000072061400005
J	Mayeux, R; Saunders, AM; Shea, S; Mirra, S; Evans, D; Roses, AD; Hyman, BT; Crain, B; Tang, MX; Phelps, CH				Mayeux, R; Saunders, AM; Shea, S; Mirra, S; Evans, D; Roses, AD; Hyman, BT; Crain, B; Tang, MX; Phelps, CH		Alzheimer's Dis Ctr Consortium Apolipoprotein	Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							E ALLELE EPSILON-4; CLINICAL-DIAGNOSIS; DIFFERENTIAL-DIAGNOSIS; VASCULAR DEMENTIA; CRITERIA; ACCURACY; RELIABILITY	Background The epsilon 4 allele of the gene encoding apolipoprotein E (APOE) is strongly associated with Alzheimer's disease, but its value in the diagnosis remains uncertain. Methods We reviewed clinical diagnoses and diagnoses obtained at autopsy in 2188 patients referred to 1 of 26 Alzheimer's disease centers for evaluation of dementia. The sensitivity and specificity of the clinical diagnosis or the presence of an APOE epsilon 4 allele were calculated, with pathologically confirmed Alzheimer's disease used as the standard, The added value of the APOE genotype was estimated with pretest and post-test probabilities from multivariate analyses to gene rare receiver-operating-characteristic curves plotting sensitivity against the false positive rate. Result's Of the 2188 patients, 1833 were given a clinical diagnosis of Alzheimer's disease, and The diagnosis was confirmed pathologically in 1770 patients at autopsy. Sixty-two percent of patients with clinically diagnosed Alzheimer's disease, as compared with 65 percent of those with pathologically confirmed Alzheimer's disease, had at least one APOE epsilon 4 allele, The sensitivity of the clinical diagnosis was 93 percent, and the specificity was 55 percent, whereas the sensitivity and specificity of the APOE epsilon E4 allele were 65 and 68 percent, respectively. The addition of: information about the APOE genotype increased the overall specificity to 84 percent in patients who met the clinical criteria for Alzheimer's disease, although the sensitivity decreased, The improvement in specificity remained statistically significant in the multivariate analysis after adjustment for differences in age, clinical diagnosis, sex, and center. Conclusions APOE genotyping does not provide sufficient sensitivity or specificity to be used alone as a diagnostic test ibr Alzheimer's disease, but when used in combination with clinical criteria, it improves the specificity of the diagnosis, (C) 1998, Massachusetts Medical Society.	Columbia Univ, Gertrude H Sergievsky Ctr, Coll Phys & Surg, New York, NY 10032 USA; Columbia Univ, Taub Alzheimers Dis Res Ctr, Coll Phys & Surg, New York, NY 10032 USA; Columbia Univ, Dept Med, Coll Phys & Surg, New York, NY 10032 USA; Duke Univ, Med Ctr, Bryan Alzheimers Dis Res Ctr, Durham, NC USA; Emory Univ, Emory Alzheimers Dis Res Ctr, Atlanta, GA 30322 USA; Vet Affairs Med Ctr, Atlanta, GA 30033 USA; Rush Presbyterian St Lukes Med Ctr, Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; NIA, Bethesda, MD 20892 USA	Columbia University; Columbia University; Columbia University; Duke University; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Rush University; Harvard University; Harvard Medical School; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Mayeux, R (corresponding author), Columbia Univ, Gertrude H Sergievsky Ctr, Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.				NATIONAL INSTITUTE ON AGING [P50AG008702, R35AG010963] Funding Source: NIH RePORTER; NIA NIH HHS [AG8702, AG05128, AG10963] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3; BURNS A, 1990, BRIT MED J, V301, P1026, DOI 10.1136/bmj.301.6759.1026; CHUI HC, 1992, NEUROLOGY, V42, P473, DOI 10.1212/WNL.42.3.473; CUMMINGS JL, 1992, DEMENTIA CLIN APPROA, P1; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; DESOUZA AT, 1995, ONCOGENE, V10, P1725; DICKSON DW, 1987, ACTA NEUROPATHOL, V75, P8, DOI 10.1007/BF00686786; FARRER LA, 1995, JAMA-J AM MED ASSOC, V274, P1627, DOI 10.1001/jama.1995.03530200063039; FLEISS JL, 1981, STATISTICAL METHODS, P160; FRIEDENREICH CM, 1994, EPIDEMIOLOGY, V5, P66, DOI 10.1097/00001648-199401000-00011; GORDIS L, 1996, EPIDEMIOLOGY, P58; HALVORSEN KT, 1992, MED USES STAT, P413; HANSEN L, 1990, NEUROLOGY, V40, P1; HENDERSON AS, 1995, LANCET, V346, P1387, DOI 10.1016/S0140-6736(95)92405-1; HIXSON J, 1991, J LIPID RES, V31, P545; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KUKULL WA, 1990, NEUROLOGY, V40, P257, DOI 10.1212/WNL.40.2.257; LOPEZ OL, 1990, NEUROLOGY, V40, P1517, DOI 10.1212/WNL.40.10.1517; MAESTRE G, 1995, ANN NEUROL, V37, P254, DOI 10.1002/ana.410370217; MAYEUX R, 1995, AM J PUBLIC HEALTH, V85, P1280, DOI 10.2105/AJPH.85.9.1280; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; MORRIS JC, 1988, ANN NEUROL, V24, P17, DOI 10.1002/ana.410240105; osmer D. W, 1989, APPL LOGISTIC REGRES, P38; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; Relkin NR, 1996, LANCET, V347, P1091, DOI 10.1016/S0140-6736(96)90284-6; RISSE SC, 1990, AM J PSYCHIAT, V147, P168; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; ROSES AD, 1995, ANN NEUROL, V38, P6, DOI 10.1002/ana.410380105; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Saunders AM, 1996, LANCET, V348, P90, DOI 10.1016/S0140-6736(96)01251-2; Schofield PW, 1995, NEUROLOGY, V45, P2159, DOI 10.1212/WNL.45.12.2159; Slooter AJC, 1996, LANCET, V348, P334, DOI 10.1016/S0140-6736(05)64501-1; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; SWETS JA, 1982, EVALUATION DIAGNOSTI, P15; *US BUR CENS, 1991, CENS POP; VANGOOL WA, 1994, LANCET, V344, P275, DOI 10.1016/S0140-6736(94)93044-9; WADE JPH, 1987, ARCH NEUROL-CHICAGO, V44, P24, DOI 10.1001/archneur.1987.00520130016010; 1996, LANCET, V348, P483	43	382	394	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 19	1998	338	8					506	511		10.1056/NEJM199802193380804	http://dx.doi.org/10.1056/NEJM199802193380804			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX639	9468467				2022-12-28	WOS:000072061400004
J	Jones, CG; Ostfeld, RS; Richard, MP; Schauber, EM; Wolff, JO				Jones, CG; Ostfeld, RS; Richard, MP; Schauber, EM; Wolff, JO			Chain reactions linking acorns to gypsy moth outbreaks and Lyme disease risk	SCIENCE			English	Article							LEPIDOPTERA-LYMANTRIIDAE POPULATIONS; IXODES-DAMMINI ACARI; BORRELIA-BURGDORFERI; PEROMYSCUS-LEUCOPUS; DISPAR LEPIDOPTERA; NATURAL ENEMIES; NORTH-AMERICA; MAST; CONSEQUENCES; DYNAMICS	In eastern U.S. oak forests, defoliation by gypsy moths and the risk of Lyme disease are determined by interactions among acorns, white-footed mice, moths, deer, and ticks. Experimental removal of mice, which eat moth pupae, demonstrated that moth outbreaks are caused by reductions in mouse density that occur when there are no acorns. Experimental acorn addition increased mouse density. Acorn addition also increased densities of black-legged ticks, evidently by attracting deer, which are key tick hosts. Mice are primarily responsible for infecting ticks with the Lyme disease agent. The results have important implications for predicting and managing forest health and human health.	Inst Ecosyst Studies, Millbrook, NY 12545 USA; Univ Connecticut, Dept Ecol & Evolutionary Biol, Storrs, CT 06269 USA; Oregon State Univ, Dept Fisheries & Wildlife, Corvallis, OR 97331 USA	Cary Institute of Ecosystem Studies; University of Connecticut; Oregon State University	Jones, CG (corresponding author), Inst Ecosyst Studies, POB AB, Millbrook, NY 12545 USA.		Jones, Clive G/I-4603-2014; Schauber, Eric/K-4043-2019	Jones, Clive G/0000-0001-7630-7285; Schauber, Eric/0000-0002-0667-2604; Ostfeld, Richard/0000-0002-3707-9301				BARBOUR AG, 1993, SCIENCE, V260, P1610, DOI 10.1126/science.8503006; BATZLI GO, 1977, AM MIDL NAT, V97, P18, DOI 10.2307/2424681; Bess Henry A., 1947, HARVARD FOREST BULL, V22, P1; CAMPBELL ROBERT W., 1967, FOREST SCI MONOGR, V15, P1; CAMPBELL RW, 1977, ENVIRON ENTOMOL, V6, P323, DOI 10.1093/ee/6.2.323; CAMPBELL RW, 1977, ENVIRON ENTOMOL, V6, P315, DOI 10.1093/ee/6.2.315; CAMPBELL RW, 1972, NE236 USDA FOR SERV; CAMPBELL RW, 1977, FOR SCI MONOGR, V19; DESY EA, 1989, ECOLOGY, V70, P411, DOI 10.2307/1937546; DOANE CC, 1970, J INVERTEBR PATHOL, V15, P21, DOI 10.1016/0022-2011(70)90094-7; ELKINTON JS, 1990, ANNU REV ENTOMOL, V35, P571, DOI 10.1146/annurev.en.35.010190.003035; Elkinton JS, 1996, ECOLOGY, V77, P2332, DOI 10.2307/2265735; FALCO RC, 1992, EXP APPL ACAROL, V14, P165, DOI 10.1007/BF01219108; Fish Durland, 1993, P25; Forbush E. H., 1896, GYPSY MOTH; Gottschalk K. W., 1990, P WORKSH SO APP MAST, P42; GOULD JR, 1990, J ANIM ECOL, V59, P213, DOI 10.2307/5169; HAJEK AE, 1990, P NATL ACAD SCI USA, V87, P6979, DOI 10.1073/pnas.87.18.6979; HANSEN LP, 1978, CAN J ZOOL, V56, P230; HOLT RD, 1994, ANNU REV ECOL SYST, V25, P495, DOI 10.1146/annurev.es.25.110194.002431; KROHNE DT, 1988, CAN J ZOOL, V66, P2170, DOI 10.1139/z88-324; LALONDE RG, 1992, AM NAT, V139, P1293, DOI 10.1086/285387; LANE RS, 1991, ANNU REV ENTOMOL, V36, P587, DOI 10.1146/annurev.en.36.010191.003103; LEVINE JF, 1985, AM J TROP MED HYG, V34, P355, DOI 10.4269/ajtmh.1985.34.355; MATHER TN, 1989, AM J EPIDEMIOL, V130, P143, DOI 10.1093/oxfordjournals.aje.a115306; MCSHEA W J, 1992, Virginia Journal of Science, V43, P177; MCSHEA WJ, 1993, J MAMMAL, V74, P999, DOI 10.2307/1382439; Ostfeld RS, 1996, J MAMMAL, V77, P266, DOI 10.2307/1382727; Ostfeld RS, 1996, J MED ENTOMOL, V33, P90, DOI 10.1093/jmedent/33.1.90; Ostfeld RS, 1997, AM SCI, V85, P338; Ostfeld RS, 1996, BIOSCIENCE, V46, P323, DOI 10.2307/1312946; PIESMAN J, 1986, J MED ENTOMOL, V23, P219, DOI 10.1093/jmedent/23.2.219; Piesman Joseph, 1994, P327; Pimm SL, 1991, BALANCE NATURE ECOLO; Price M.V., 1986, P191; SKALLER PM, 1985, ENVIRON ENTOMOL, V14, P106, DOI 10.1093/ee/14.2.106; SMITH HR, 1985, WILDLIFE SOC B, V13, P166; SORK VL, 1993, ECOLOGY, V74, P528, DOI 10.2307/1939313; WILSON ML, 1988, J MED ENTOMOL, V25, P224, DOI 10.1093/jmedent/25.4.224; WOLFF JO, 1986, J MAMMAL, V67, P409, DOI 10.2307/1380900; Wolff JO, 1996, J MAMMAL, V77, P850, DOI 10.2307/1382690; WOOTTON JT, 1994, ANNU REV ECOL SYST, V25, P443, DOI 10.1146/annurev.es.25.110194.002303	42	313	326	2	288	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1023	1026		10.1126/science.279.5353.1023	http://dx.doi.org/10.1126/science.279.5353.1023			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461433				2022-12-28	WOS:000072006400045
J	Cotter, G; Metzkor, E; Kaluski, E; Faigenberg, Z; Miller, R; Simovitz, A; Shaham, O; Marghitay, D; Koren, M; Blatt, A; Moshkovitz, Y; Zaidenstein, R; Golik, A				Cotter, G; Metzkor, E; Kaluski, E; Faigenberg, Z; Miller, R; Simovitz, A; Shaham, O; Marghitay, D; Koren, M; Blatt, A; Moshkovitz, Y; Zaidenstein, R; Golik, A			Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema	LANCET			English	Article							CONGESTIVE HEART-FAILURE; MYOCARDIAL-INFARCTION; FRUSEMIDE	Background Nitrates and furosemide, commonly administered in the treatment of pulmonary oedema, have not been compared in a prospective clinical trial. We compared the efficacy and safety of these drugs in a randomised trial of patients with severe pulmonary oedema and oxygen saturation below 90%., Methods Patients presenting to mobile emergency units with signs of congestive heart failure were treated with oxygen 10 L/min, intravenous furosemide 40 mg, and morphine 3 mg bolus. 110 patients were randomly assigned either to group A, who received isosorbide dinitrate (3 mg bolus administered intravenously every 5 min; n=56) or to group B, who received furosemide (80 mg bolus administered intravenously every 15 min, as well as isosorbide dinitrate 1 mg/h, increased every 10 min by 1 mg/h; n=54). Six patients were withdrawn on the basis of chest radiography results. Treatment was continued until oxygen saturation was above 96% or mean arterial blood pressure had decreased by 30% or to below 90 mm Hg. The main endpoints were death, need for mechanical ventilation, and myocardial infarction. The analyses were by intention to treat. Findings Mechanical ventilation was required in seven (13%) of 52 group-A patients and 21 (40%) of 52 group-B patients (p=0.0041). Myocardial infarction occurred in nine (17%) and 19 (37%) patients, respectively (p=0.047). One patient in group A and three in group B died (p=0.61). One or more of these endpoints occurred in 13 (25%) and 24 (46%) patients, respectively (p=0.041). Interpretation High-dose isosorbide dinitrate, given as repeated intravenous boluses after low-dose intravenous furosemide, is safe and effective in controlling severe pulmonary oedema, This treatment regimen is more effective than high-dose furosemide with low-dose isosorbide nitrate in terms of need for mechanical ventilation and frequency of myocardial infarction.	Assaf Harofeh Med Ctr, Dept Med A, IL-70300 Zerifin, Israel; Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel; Magen David Adom Emergency Med Serv, Tel Hashomer, Israel	Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Cotter, G (corresponding author), Assaf Harofeh Med Ctr, Dept Med A, IL-70300 Zerifin, Israel.		Kaluski, Edo/Q-1972-2019	Kaluski, Edo/0000-0002-1400-3988; Cotter, Gad/0000-0002-9613-3339; Koren-Michowitz, Maya/0000-0002-7223-328X				Atherton JJ, 1997, LANCET, V349, P1720, DOI 10.1016/S0140-6736(96)05109-4; BOSC E, 1982, ANN CARDIOL ANGEIOL, V31, P477; BRAUNWALD E, 1994, APHCPR PUBLICATION, V10; Colucci WS., 1997, HEART DIS TXB CARDIO, P394; COTTER G, IN PRESS AM J EMERG; Cotter Gad, 1996, Journal of the American College of Cardiology, V27, p333A; DIKSHIT K, 1973, NEW ENGL J MED, V288, P1087, DOI 10.1056/NEJM197305242882102; Dormans TPJ, 1996, CARDIOVASC RES, V32, P988, DOI 10.1016/S0008-6363(96)00134-4; FRANCIS GS, 1985, ANN INTERN MED, V103, P1, DOI 10.7326/0003-4819-103-1-1; IMHOF PR, 1980, EUR J CLIN PHARMACOL, V18, P455, DOI 10.1007/BF00874655; KULICK D, 1988, J AM COLL CARDIOL, V12, P1023, DOI 10.1016/0735-1097(88)90471-8; MORRISON RA, 1983, CLIN PHARMACOL THER, V33, P747, DOI 10.1038/clpt.1983.102; NELSON GIC, 1983, LANCET, V1, P730; Northridge D, 1996, LANCET, V347, P667, DOI 10.1016/S0140-6736(96)91209-X; Pickkers P, 1996, LANCET, V347, P1338, DOI 10.1016/S0140-6736(96)90990-3	15	346	371	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					389	393		10.1016/S0140-6736(97)08417-1	http://dx.doi.org/10.1016/S0140-6736(97)08417-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482291				2022-12-28	WOS:000071982600009
J	Baumeister, W; Walz, J; Zuhl, F; Seemuller, E				Baumeister, W; Walz, J; Zuhl, F; Seemuller, E			The proteasome: Paradigm of a self-compartmentalizing protease	CELL			English	Review							20S PROTEASOME; 26S PROTEASOME; MULTICATALYTIC PROTEINASE; SACCHAROMYCES-CEREVISIAE; IN-VIVO; THERMOPLASMA-ACIDOPHILUM; ANTIGEN PRESENTATION; STRUCTURAL FEATURES; FUNCTIONAL-ANALYSIS; REGULATORY SUBUNIT		Max Planck Inst Biochem, D-82152 Martinsried, Germany	Max Planck Society	Baumeister, W (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.							Ahn K, 1996, J BIOL CHEM, V271, P18237, DOI 10.1074/jbc.271.30.18237; Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; AMSTERDAM A, 1993, P NATL ACAD SCI USA, V90, P99, DOI 10.1073/pnas.90.1.99; Anand G, 1997, J BIOL CHEM, V272, P19140, DOI 10.1074/jbc.272.31.19140; Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; ARRIGO AP, 1988, NATURE, V331, P192, DOI 10.1038/331192a0; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; Baumeister W, 1997, BIOL CHEM, V378, P121; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; BOLDIN MP, 1995, FEBS LETT, V367, P39, DOI 10.1016/0014-5793(95)00534-G; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CARDOZO C, 1993, ENZYME PROTEIN, V47, P296, DOI 10.1159/000468687; CASTLE LA, 1994, PLANT CELL, V6, P25, DOI 10.1105/tpc.6.1.25; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; CHUANG SE, 1993, GENE, V134, P1, DOI 10.1016/0378-1119(93)90167-2; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAHLMANN B, 1992, EUR J BIOCHEM, V208, P789, DOI 10.1111/j.1432-1033.1992.tb17249.x; DAHLMANN B, 1988, BIOCHEM J, V255, P750; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DEMARINI DJ, 1995, MOL CELL BIOL, V15, P6311; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; DICK LR, 1994, J IMMUNOL, V152, P3884; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; DUBIEL W, 1994, BIOL CHEM H-S, V375, P237, DOI 10.1515/bchm3.1994.375.4.237; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; Ehring B, 1996, EUR J BIOCHEM, V235, P404, DOI 10.1111/j.1432-1033.1996.00404.x; ENENKEL C, 1994, FEBS LETT, V341, P193, DOI 10.1016/0014-5793(94)80455-9; ENGEL A, 1995, SCIENCE, V269, P832, DOI 10.1126/science.7638600; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fraser RA, 1997, J BIOL CHEM, V272, P7122, DOI 10.1074/jbc.272.11.7122; Gerards WLH, 1997, J BIOL CHEM, V272, P10080; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Goldberg AL, 1995, COLD SPRING HARB SYM, V60, P479, DOI 10.1101/SQB.1995.060.01.052; Gordon C, 1996, J BIOL CHEM, V271, P5704, DOI 10.1074/jbc.271.10.5704; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GRZIWA A, 1994, EUR J BIOCHEM, V223, P1061, DOI 10.1111/j.1432-1033.1994.tb19084.x; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; HILT W, 1995, MOL BIOL REP, V21, P3, DOI 10.1007/BF00990964; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; KISSELEV AF, 1998, IN PRESS J BIOL CHEM; Knipfer N, 1997, MOL MICROBIOL, V25, P375, DOI 10.1046/j.1365-2958.1997.4721837.x; Knowlton JR, 1997, NATURE, V390, P639, DOI 10.1038/37670; Kominami K, 1997, MOL BIOL CELL, V8, P171, DOI 10.1091/mbc.8.1.171; Kopp F, 1997, P NATL ACAD SCI USA, V94, P2939, DOI 10.1073/pnas.94.7.2939; Kuehn L, 1996, ARCH BIOCHEM BIOPHYS, V329, P87, DOI 10.1006/abbi.1996.0195; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1993, ENZYME PROTEIN, V47, P252, DOI 10.1159/000468684; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P195, DOI 10.1016/S0968-0004(97)01058-X; Lupas A, 1997, MOL BIOL REP, V24, P125, DOI 10.1023/A:1006803512761; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P399, DOI 10.1016/S0968-0004(97)01117-1; LUPAS A, 1994, TRENDS BIOCHEM SCI, V19, P533, DOI 10.1016/0968-0004(94)90054-X; Lupas A, 1995, COLD SPRING HARB SYM, V60, P515, DOI 10.1101/SQB.1995.060.01.055; MAUPINFURLOW JA, 1995, J BIOL CHEM, V270, P28617, DOI 10.1074/jbc.270.48.28617; McDonald HB, 1997, J CELL BIOL, V137, P539, DOI 10.1083/jcb.137.3.539; Nandi D, 1997, EMBO J, V16, P5363, DOI 10.1093/emboj/16.17.5363; Nederlof PM, 1995, P NATL ACAD SCI USA, V92, P12060, DOI 10.1073/pnas.92.26.12060; Niedermann G, 1997, J EXP MED, V186, P209, DOI 10.1084/jem.186.2.209; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; Paesen GC, 1996, BBA-GENE STRUCT EXPR, V1309, P9, DOI 10.1016/S0167-4781(96)00116-9; PALMER A, 1994, EUR J CELL BIOL, V64, P163; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; PICKETT SD, 1993, J MOL BIOL, V231, P825, DOI 10.1006/jmbi.1993.1329; REALINI C, 1994, J BIOL CHEM, V269, P20727; Richmond C, 1997, J BIOL CHEM, V272, P13403, DOI 10.1074/jbc.272.20.13403; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; Russell SJ, 1996, J BIOL CHEM, V271, P32810, DOI 10.1074/jbc.271.51.32810; SCHAUER TM, 1993, J STRUCT BIOL, V111, P135, DOI 10.1006/jsbi.1993.1044; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; Schmidtke G, 1997, J MOL BIOL, V268, P95, DOI 10.1006/jmbi.1997.0947; Seeger M, 1997, J BIOL CHEM, V272, P8145, DOI 10.1074/jbc.272.13.8145; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; Song XL, 1996, J BIOL CHEM, V271, P26410, DOI 10.1074/jbc.271.42.26410; Tamura T, 1996, SCIENCE, V274, P1385, DOI 10.1126/science.274.5291.1385; TAMURA T, 1995, CURR BIOL, V5, P766, DOI 10.1016/S0960-9822(95)00153-9; Tsurumi C, 1996, EUR J BIOCHEM, V239, P912, DOI 10.1111/j.1432-1033.1996.0912u.x; USTRELL V, 1995, FEBS LETT, V376, P155, DOI 10.1016/0014-5793(95)01257-9; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Walz J, 1997, MOL CELL, V1, P59, DOI 10.1016/S1097-2765(00)80007-6; WALZ J, 1998, IN PRESS J STRUCT BI; Wang HR, 1997, EUR J CELL BIOL, V73, P105; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; Weeda G, 1997, NUCLEIC ACIDS RES, V25, P2274, DOI 10.1093/nar/25.12.2274; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; WOLF S, 1998, IN PRESS J MOL BIOL; XU QL, 1995, MOL CELL BIOL, V15, P6025; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687; Yokota K, 1996, MOL BIOL CELL, V7, P853, DOI 10.1091/mbc.7.6.853; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050; Zuhl F, 1997, FEBS LETT, V418, P189, DOI 10.1016/S0014-5793(97)01370-7; Zuhl F, 1997, FEBS LETT, V400, P83, DOI 10.1016/S0014-5793(96)01403-2; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765	113	1247	1280	5	56	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 6	1998	92	3					367	380		10.1016/S0092-8674(00)80929-0	http://dx.doi.org/10.1016/S0092-8674(00)80929-0			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YX283	9476896	Bronze			2022-12-28	WOS:000072024700008
J	Bukau, B; Horwich, AL				Bukau, B; Horwich, AL			The Hsp70 and Hsp60 chaperone machines	CELL			English	Review							ESCHERICHIA-COLI DNAJ; SHOCK COGNATE PROTEIN; SUBSTRATE-BINDING DOMAINS; MOLECULAR CHAPERONE; ATP HYDROLYSIS; ALPHA-LACTALBUMIN; CRYSTAL-STRUCTURE; CENTRAL CAVITY; MITOCHONDRIAL RHODANESE; SECONDARY STRUCTURE		Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet, New Haven, CT 06536 USA	University of Freiburg; Howard Hughes Medical Institute; Yale University; Yale University	Bukau, B (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.		Gimenez, Luis E Diaz/D-9291-2011	Bukau, Bernd/0000-0003-0521-7199				AGARD DA, 1993, SCIENCE, V260, P1903, DOI 10.1126/science.8100365; BOCHKAREVA ES, 1994, J BIOL CHEM, V269, P23869; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; Buchberger A, 1996, J MOL BIOL, V261, P328, DOI 10.1006/jmbi.1996.0465; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Dekker PJT, 1997, J MOL BIOL, V270, P321, DOI 10.1006/jmbi.1997.1131; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; ELLIS RJ, 1996, CHAPERONINS; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; Gamer J, 1996, EMBO J, V15, P607, DOI 10.1002/j.1460-2075.1996.tb00393.x; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; GAO BC, 1993, J BIOL CHEM, V268, P8507; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; Gervasoni P, 1996, P NATL ACAD SCI USA, V93, P12189, DOI 10.1073/pnas.93.22.12189; Goldberg MS, 1997, P NATL ACAD SCI USA, V94, P1080, DOI 10.1073/pnas.94.4.1080; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GORDON CL, 1994, J BIOL CHEM, V269, P27941; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; Gross M, 1996, PROTEIN SCI, V5, P2506, DOI 10.1002/pro.5560051213; HA JH, 1994, BIOCHEMISTRY-US, V33, P14625, DOI 10.1021/bi00252a031; HA JH, 1995, BIOCHEMISTRY-US, V34, P11635, DOI 10.1021/bi00036a040; HA JH, 1997, MOL CHAPERONES LIFE, P35; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; HUNT JF, 1997, CELL, V90, P367; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; Katsumata K, 1996, J MOL BIOL, V258, P827, DOI 10.1006/jmbi.1996.0290; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LAUFEN T, 1997, MOL CHAPERONES LIFE, P241; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; LEVY EJ, 1995, FEBS LETT, V368, P435, DOI 10.1016/0014-5793(95)00704-D; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; LIN S, 1995, J BIOL CHEM, V270, P1011; Lorimer G, 1997, NATURE, V388, P720, DOI 10.1038/41892; Mande SC, 1996, SCIENCE, V271, P203, DOI 10.1126/science.271.5246.203; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MCCARTY JS, 1995, J MOL BIOL, V249, P129; MENDOZA JA, 1992, J BIOL CHEM, V267, P24648; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; Miao BJ, 1997, J MOL BIOL, V265, P541, DOI 10.1006/jmbi.1996.0762; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; MURAI N, 1995, J BIOL CHEM, V270, P19957, DOI 10.1074/jbc.270.34.19957; OBrien MC, 1996, J BIOL CHEM, V271, P15874, DOI 10.1074/jbc.271.27.15874; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Pellecchia M, 1996, J MOL BIOL, V260, P236, DOI 10.1006/jmbi.1996.0395; Pierpaoli EV, 1997, J MOL BIOL, V269, P757, DOI 10.1006/jmbi.1997.1072; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Qian YQ, 1996, J MOL BIOL, V260, P224, DOI 10.1006/jmbi.1996.0394; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; Reid BG, 1996, J BIOL CHEM, V271, P7212, DOI 10.1074/jbc.271.12.7212; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SMITH KE, 1995, J BIOL CHEM, V270, P21517, DOI 10.1074/jbc.270.37.21517; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Sparrer H, 1997, J BIOL CHEM, V272, P14080, DOI 10.1074/jbc.272.22.14080; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; TAGUCHI H, 1995, FEBS LETT, V359, P195, DOI 10.1016/0014-5793(95)00041-7; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; WALL D, 1994, J BIOL CHEM, V269, P5446; Walter S, 1996, P NATL ACAD SCI USA, V93, P9425, DOI 10.1073/pnas.93.18.9425; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; WILBANKS SM, 1995, BIOCHEMISTRY-US, V34, P12095, DOI 10.1021/bi00038a002; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yeh SR, 1997, NAT STRUCT BIOL, V4, P51, DOI 10.1038/nsb0197-51; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001; Zahn R, 1996, SCIENCE, V271, P642, DOI 10.1126/science.271.5249.642; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; ZIEGELHOFFER T, 1995, J BIOL CHEM, V270, P10412, DOI 10.1074/jbc.270.18.10412	112	2328	2445	8	277	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 6	1998	92	3					351	366		10.1016/S0092-8674(00)80928-9	http://dx.doi.org/10.1016/S0092-8674(00)80928-9			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YX283	9476895	hybrid			2022-12-28	WOS:000072024700007
J	Li, CW; Chen, JY; Hua, TE				Li, CW; Chen, JY; Hua, TE			Precambrian sponges with cellular structures	SCIENCE			English	Article							EVOLUTION; FOSSILS; ORIGIN; PHYLA; TIME	Sponge remains have been identified in the Early Vendian Doushantuo phosphate deposit in central Guizhou (South China), which has an age of similar to 580 million years ago, Their skeletons consist of siliceous, monaxonal spicules, All are referred to as the Porifera, class Demospongiae., Preserved soft tissues include the epidermis, porocytes, amoebocytes, sclerocytes, and spongocoel. Among thousands of metazoan embryos is a parenchymella-type of sponge larvae having a shoe-shaped morphology and dense peripheral flagella. The presence of possible amphiblastula larva suggests that the calcareous sponges may have an extended history in the Late Precambrian, The fauna indicates that animals lived 40 to 50 million years before the Cambrian Explosion.	Natl Tsing Hua Univ, Dept Life Sci, Hsinchu, Taiwan; Acad Sinica, Nanjing Inst Geol & Palaeontol, Nanjing 210008, Peoples R China	National Tsing Hua University; Chinese Academy of Sciences	Li, CW (corresponding author), Natl Tsing Hua Univ, Dept Life Sci, Hsinchu, Taiwan.							Bengtson S, 1997, SCIENCE, V277, P1645, DOI 10.1126/science.277.5332.1645; Benus AP., 1988, GEOLOGICAL SURVEY B, P8; Brasier M, 1997, GEOLOGY, V25, P303, DOI 10.1130/0091-7613(1997)025<0303:ESSCFS>2.3.CO;2; Chen J.-y., 1989, Acta Palaeontologica Sinica, V28, P17; Chen J.-y., 1990, Acta Palaeontologica Sinica, V29, P402; Chen J.-y., 1991, P57; CHEN M, 1986, GEOL SIN, V1, P46; CHN JY, 1996, CHENGJIANG BIOTA UNI; DAVIDSON EH, 1995, SCIENCE, V270, P1319, DOI 10.1126/science.270.5240.1319; Fedonkin MA, 1997, NATURE, V388, P868, DOI 10.1038/42242; FELL PE, 1974, REPRODUCTION MARINE, V1, P51; FRANCIS S, 1978, PRECAMBRIAN RES, V6, P65, DOI 10.1016/0301-9268(78)90055-4; Gehling JG, 1996, J PALEONTOL, V70, P185, DOI 10.1017/S0022336000023283; GLAESSNNER MA, 1984, DAWN ANIMAL LIFE BIO; Gould S J, 1994, Sci Am, V271, P84; GROTZINGER JP, 1995, SCIENCE, V270, P598, DOI 10.1126/science.270.5236.598; KNOLL AH, 1995, PRECAMBRIAN RES, V73, P251, DOI 10.1016/0301-9268(94)00081-2; Knoll AH, 1996, PALEOBIOLOGY, V22, P1; MOLDOWAN JM, 1995, TERRA NOVA, V6, P6; MORRIS SC, 1993, PALAEONTOLOGY, V36, P593; MORRIS SC, 1994, EARLY LIFE EARTH, P450; MULLER WEG, 1994, J MOL EVOL, V39, P369, DOI 10.1007/BF00160269; Reiswig H.M., 1976, P99; Reitner J., 1990, P33; Reitner Joachim, 1995, Geologisch-Palaeontologische Mitteilungen, V20, P335; RETALLACK GJ, 1994, PALEOBIOLOGY, V20, P523, DOI 10.1017/S0094837300012975; RUNNEGAR B, 1982, LETHAIA, V15, P199, DOI 10.1111/j.1502-3931.1982.tb00645.x; RUNNEGAR B, 1995, NEUES JB GEOLOGIE PA, V195, P305; Rutzler K., 1990, P455; SEILACHER A, 1989, LETHAIA, V22, P229, DOI 10.1111/j.1502-3931.1989.tb01332.x; SEILACHER A, 1984, PATTERN CHANGE EARTH; Simpson T., 1984, CELL BIOL SPONGES; Steiner M., 1993, Berliner Geowissenschaftliche Abhandlungen Reihe E Palaeobiologie, V9, P293; TANG T., 1978, ACTA STRATIGRAPHICA, V2, P32; Vermeij GJ, 1996, SCIENCE, V274, P525, DOI 10.1126/science.274.5287.525; WAINRIGHT PO, 1993, SCIENCE, V260, P340, DOI 10.1126/science.8469985; WANG YG, 1980, SINIAN SYSTEM CHINA, P147; WOOD R, 1992, Palaios, V7, P131, DOI 10.2307/3514925; Wray GA, 1996, SCIENCE, V274, P568, DOI 10.1126/science.274.5287.568; Xue Yao-song, 1995, Acta Palaeontologica Sinica, V34, P688; YIN LM, 1978, B NANJING I GEOL PAL, V10, P41; YIN LM, 1993, J BOT, V5, P168; YING CF, 1990, ACTA MICROPALAEONTOL, V7, P265; Yuan X.L., 1993, ACTA MICROPALAEONT S, V10, P409; ZHANG XG, 1994, SCIENCE, V266, P637, DOI 10.1126/science.266.5185.637; ZHANG Y, 1992, LETHAIA, V25, P1; Zhang Y., 1989, LETHAIA, V22, P113	47	375	465	4	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					879	882		10.1126/science.279.5352.879	http://dx.doi.org/10.1126/science.279.5352.879			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452391				2022-12-28	WOS:000071923500049
J	Wolf, AR; Stoddart, P				Wolf, AR; Stoddart, P			Awake spinal anaesthesia in ex-premature infants	LANCET			English	Article									UNIV BRISTOL,UNIV DEPT ANAESTHESIA,BRISTOL BS2 8BJ,AVON,ENGLAND	University of Bristol	Wolf, AR (corresponding author), ROYAL HOSP SICK CHILDREN,BRISTOL BS2 8BJ,AVON,ENGLAND.							BRAWN WJ, 1995, ANN THORAC SURG, V59, P1441, DOI 10.1016/0003-4975(95)00147-D; COTE CJ, 1995, ANESTHESIOLOGY, V82, P809, DOI 10.1097/00000542-199504000-00002; HAOUARI N, 1995, BRIT MED J, V310, P1498, DOI 10.1136/bmj.310.6993.1498; KRANE EJ, 1995, ANESTH ANALG, V80, P7, DOI 10.1097/00000539-199501000-00003; OBERLANDER TF, 1995, ANESTH ANALG, V80, P20, DOI 10.1097/00000539-199501000-00005	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S13	S13		10.1016/0140-6736(95)90012-8	http://dx.doi.org/10.1016/0140-6736(95)90012-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454030	Bronze			2022-12-28	WOS:A1995TN12200013
J	Smith, PE; Evensen, NM; York, D; Odin, GS				Smith, PE; Evensen, NM; York, D; Odin, GS			Single-grain 40Ar-39Ar ages of glauconies: Implications for the geologic time scale and global sea level variations	SCIENCE			English	Article								The mineral series glaucony supplies 40% of the absolute-age database for the geologic time scale of the last 250 million years. However, glauconies have long Been suspected of giving young potassium-argon ages on bulk samples. Laser-probe argon-argon dating shows that glaucony populations comprise grains with a wide range of ages, suggesting a period of genesis several times longer (similar to 5 million years) than previously thought. An estimate of the age of their enclosing sediments (and therefore of time scale boundaries) is given by the oldest nonrelict grains in the glaucony populations, whereas the formation times of the younger grains appear to be modulated by global sea level.	Univ Toronto, Dept Phys, Toronto, ON M5S 1A7, Canada; Univ Paris 06, Dept Geol Sedimentaire, F-75252 Paris 05, France	University of Toronto; UDICE-French Research Universities; Sorbonne Universite	Smith, PE (corresponding author), Univ Toronto, Dept Phys, 60 St George St, Toronto, ON M5S 1A7, Canada.							BAKSI AK, 1992, EOS T AGU, V73, P328; BERGGREN WA, 1985, GEOL SOC AM BULL, V96, P1407, DOI 10.1130/0016-7606(1985)96<1407:CG>2.0.CO;2; COX A, 1967, J GEOPHYS RES, V72, P2603, DOI 10.1029/JZ072i010p02603; DONG HL, 1995, SCIENCE, V267, P355, DOI 10.1126/science.267.5196.355; GRADSTEIN FM, 1988, SCIENCE, V241, P599, DOI 10.1126/science.241.4865.599-a; HAQ BU, 1987, SCIENCE, V235, P1156, DOI 10.1126/science.235.4793.1156; HARLAND WB, 1989, GEOLOGICAL TIME SCAL; Miller KG, 1996, SCIENCE, V271, P1092, DOI 10.1126/science.271.5252.1092; MORTON JP, 1984, J SEDIMENT PETROL, V54, P495; Obradovich JD, 1988, PALEOCEANOGRAPHY, V3, P757, DOI 10.1029/PA003i006p00757; Odin G. S., 1988, GREEN MARINE CLAYS; ODIN GS, 1994, CR ACAD SCI II, V318, P59; ODIN GS, 1982, NUMERICAL DATING S 1, P151; SMITH PE, 1993, GEOLOGY, V21, P41, DOI 10.1130/0091-7613(1993)021<0041:FSAADO>2.3.CO;2; WASSERBURG GJ, 1956, GEOCHIM COSMOCHIM AC, V10, P153, DOI 10.1016/0016-7037(56)90041-2	15	31	36	2	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 6	1998	279	5356					1517	1519		10.1126/science.279.5356.1517	http://dx.doi.org/10.1126/science.279.5356.1517			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488646				2022-12-28	WOS:000072372900059
J	Annas, GJ				Annas, GJ			A national bill of patients' rights	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARE							Annas, George/0000-0001-5836-7831				ANNAS G, 1989, RIGHTS PATIENTS; Annas G. J., 1975, RIGHTS HOSP PATIENTS; ANNAS GJ, 1995, NEW ENGL J MED, V333, P1647, DOI 10.1056/NEJM199512143332420; Annas GJ, 1997, NEW ENGL J MED, V337, P210, DOI 10.1056/NEJM199707173370323; ANNAS GJ, 1990, JAMA-J AM MED ASSOC, V263, P858, DOI 10.1001/jama.263.6.858; ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; ANNAS GJ, 1974, VANDERBILT LAW REV, V27, P243; FURROW BR, 1997, GA L REV, V31, P419; Kassirer JP, 1997, NEW ENGL J MED, V337, P338, DOI 10.1056/NEJM199707313370509; Mariner WK, 1996, AM J PUBLIC HEALTH, V86, P863, DOI 10.2105/AJPH.86.6.863; Millenson ML., 1997, DEMANDING MED EXCELL; PEAR R, 1997, NY TIMES        0216, pA1; Rodwin M. A., 1993, MED MONEY MORALS PHY; Starr Paul, 1982, SOCIAL TRANSFORMATIO, P388; 1997, MODERN HLTHCARE 0512, P36; 1998, NY TIMES        0128, pA19	16	51	55	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1998	338	10					695	699		10.1056/NEJM199803053381020	http://dx.doi.org/10.1056/NEJM199803053381020			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YZ844	9487001	Green Published			2022-12-28	WOS:000072299700030
J	Estacio, RO; Jeffers, BW; Hiatt, WR; Biggerstaff, SL; Gifford, N; Schrier, RW				Estacio, RO; Jeffers, BW; Hiatt, WR; Biggerstaff, SL; Gifford, N; Schrier, RW			The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; CONVERTING ENZYME-INHIBITION; MYOCARDIAL-INFARCTION; INDEPENDENT PREDICTOR; BLOOD-PRESSURE; MORTALITY; TRIAL; NEPHROPATHY; ATHEROSCLEROSIS; PROGRESSION	Background It has recently been reported that the use of calcium-channel blockers for hypertension may be associated with an increased risk of cardiovascular complications. Because this issue remains controversial, we studied the incidence of such complications in patients with non-insulin-dependent diabetes mellitus and hypertension who were randomly assigned to treatment with either the calcium-channel blocker nisoldipine or the angiotensin-converting-enzyme inhibitor enalapril as part of a larger study. Methods The Appropriate Blood Pressure Control in Diabetes (ABCD) Trial is a prospective, randomized, blinded trial comparing the effects of moderate control of blood pressure (target diastolic pressure, 80 to 89 mm Hg) with those of intensive control of blood pressure (target diastolic pressure, 75 mm Hg) on the incidence and progression of complications of diabetes. The study also compared nisoldipine with enalapril as a first-line antihypertensive agent in terms of the prevention and progression of complications of diabetes. In the current study, we analyzed data on a secondary end point (the incidence of myocardial infarction) in the subgroup of patients in the ABCD Trial who had hypertension. Results Analysis of the 470 patients in the trial who had hypertension (base-line diastolic blood pressure, greater than or equal to 90 mm Hg) showed similar control of blood pressure, blood glucose and lipid concentrations, and smoking behavior in the nisoldipine group (235 patients) and the enalapril group (235 patients) throughout five years of follow-up. Using a multiple logistic-regression model with adjustment for cardiac risk factors, we found that nisoldipine was associated with a higher incidence of fatal and nonfatal myocardial infarctions (a total of 25) than enalapril (total, 5) (risk ratio, 9.5; 95 percent confidence interval, 2.3 to 21.4). Conclusions In this population of patients with diabetes and hypertension, we found a significantly higher incidence of fatal and nonfatal myocardial infarction among those assigned to therapy with the calcium-channel blocker nisoldipine than among those assigned to receive enalapril. Since our findings are based on a secondary end point, they will require confirmation. (C) 1998, Massachusetts Medical Society.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Renal Dis & Hypertens, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Geriatr & Cardiol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Sect Vasc Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Colorado Prevent Ctr, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Div Internal Med, Denver, CO 80262 USA; Denver Hlth, Dept Community Hlth Serv, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Denver Health Medical Center	Schrier, RW (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Renal Dis & Hypertens, 4200 E 9th Ave,Box B-178, Denver, CO 80262 USA.				NIDDK NIH HHS [DK50298-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050298] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1991, Ophthalmology, V98, P786; Borhani NO, 1996, JAMA-J AM MED ASSOC, V276, P785, DOI 10.1001/jama.276.10.785; Cohn JN, 1996, NEW ENGL J MED, V335, P490, DOI 10.1056/NEJM199608153350707; COLLINS R, 1995, LANCET, V345, P669; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; DEVITA C, 1994, LANCET, V343, P1115; Estacio RO, 1996, CONTROL CLIN TRIALS, V17, P242, DOI 10.1016/0197-2456(95)00154-9; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GLASSER SP, 1995, J CLIN PHARMACOL, V35, P780, DOI 10.1002/j.1552-4604.1995.tb04120.x; Heublein B, 1996, CLIN THER, V18, P448, DOI 10.1016/S0149-2918(96)80025-7; HEYDEN S, 1971, ARCH INTERN MED, V128, P961, DOI 10.1001/archinte.128.6.961; HIATT WR, 1990, J CLIN EPIDEMIOL, V43, P597, DOI 10.1016/0895-4356(90)90164-K; JANKA HU, 1985, HYPERTENSION, V7, P90; KAHN R, 1988, ANN NEUROL, V24, P99, DOI 10.1002/ana.410240120; KORNITZER M, 1995, ANGIOLOGY, V46, P211, DOI 10.1177/000331979504600304; KOSKINEN P, 1992, DIABETES CARE, V15, P820, DOI 10.2337/diacare.15.7.820; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; Lewis EJ, 1996, CONTRIB NEPHROL, V118, P206; LICHTLEN PR, 1990, LANCET, V335, P1109, DOI 10.1016/0140-6736(90)91121-P; MANOLIO TA, 1995, ARCH INTERN MED, V155, P829, DOI 10.1001/archinte.155.8.829; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; MCKENNA M, 1991, ATHEROSCLEROSIS, V87, P119, DOI 10.1016/0021-9150(91)90014-T; MOGENSEN CE, 1989, PREVENTION TREATMENT, P41; MOSS SE, 1991, AM J PUBLIC HEALTH, V81, P1158, DOI 10.2105/AJPH.81.9.1158; *NAT CTR HLTH STAT, 1988, MONTHL VIT STAT REP, V37, P1; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; PANZRAM G, 1987, DIABETOLOGIA, V30, P364; PARVING HH, 1995, AM J KIDNEY DIS, V26, P99, DOI 10.1016/0272-6386(95)90162-0; Parving HH, 1996, J DIABETES COMPLICAT, V10, P133, DOI 10.1016/1056-8727(96)00031-1; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; Ravid M, 1996, ARCH INTERN MED, V156, P286, DOI 10.1001/archinte.156.3.286; SAVAGE S, 1993, ONLINE J CURR C 1124; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; WATERS D, 1992, CIRCULATION, V86, P111; WEINSTEIN DB, 1989, AM J HYPERTENS, V2, P205, DOI 10.1093/ajh/2.3.205; World Health Organization, 1985, WHO TECH REP SER, V727, P7	38	872	896	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1998	338	10					645	652		10.1056/NEJM199803053381003	http://dx.doi.org/10.1056/NEJM199803053381003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ844	9486993				2022-12-28	WOS:000072299700003
J	Oppo, DW; McManus, JF; Cullen, JL				Oppo, DW; McManus, JF; Cullen, JL			Abrupt climate events 500,000 to 340,000 years ago: Evidence from subpolar north Atlantic sediments	SCIENCE			English	Article							LAST GLACIAL MAXIMUM; GREENLAND ICE; OCEAN; CIRCULATION; PALEOCLIMATOLOGY; VARIABILITY; DISCHARGES; EVOLUTION; RECORDS; SURFACE	Subpolar North Atlantic proxy records document millennial-scale climate variations 500,000 to 340,000 years ago. The cycles have an approximately constant pacing that is similar to that documented for the last glacial cycle. These findings suggest that such climate variations are inherent tp the late Pleistocene, regardless of glacial state. Sea surface temperature during the warm peak of Marine Isotope Stage 11 (MIS 11) varied by 0.5 degrees to 1 degrees C, less than the 4 degrees to 4.5 degrees C estimated during times of ice growth and the 3 degrees C estimated for glacial maxima. Coherent deep ocean circulation changes were associated with glacial oscillations in sea surface temperature.	Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02543 USA; Salem State Coll, Dept Geol Sci, Salem, MA 01970 USA	Woods Hole Oceanographic Institution; Massachusetts System of Public Higher Education; Salem State University	Oppo, DW (corresponding author), Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02543 USA.							BARGER AL, 1978, J ATMOS SCI, V35, P2362; Be A.W.H., 1971, MICROPALEONTOLOGY OC, P105; Bond G, 1997, SCIENCE, V278, P1257, DOI 10.1126/science.278.5341.1257; BOND G, 1992, NATURE, V360, P245, DOI 10.1038/360245a0; BOND G, 1993, NATURE, V365, P143, DOI 10.1038/365143a0; BOND GC, 1995, SCIENCE, V267, P1005, DOI 10.1126/science.267.5200.1005; BOYLE EA, 1987, NATURE, V330, P35, DOI 10.1038/330035a0; BROECKER W, 1993, ICE CLIMATE SYSTEM, V12, P161; Broecker W, 1992, CLIM DYNAM, V6, P265, DOI 10.1007/BF00193540; Broecker WS, 1990, PALEOCEANOGRAPHY, V5, P469, DOI 10.1029/PA005i004p00469; BROECKER WS, 1970, REV GEOPHYS SPACE GE, V8, P169, DOI 10.1029/RG008i001p00169; CORTIJO E, 1995, PALEOCEANOGRAPHY, V10, P911, DOI 10.1029/95PA02021; Curry WB, 1997, PALEOCEANOGRAPHY, V12, P1, DOI 10.1029/96PA02413; Dansgaard W, 1984, CLIMATE PROCESSES CL, V5, P288, DOI 10.1029/GM029p0288; EPSTEIN S, 1953, GEOL SOC AM BULL, V64, P1315, DOI 10.1130/0016-7606(1953)64[1315:RCITS]2.0.CO;2; GROUSSET FE, 1993, PALEOCEANOGRAPHY, V8, P175, DOI 10.1029/92PA02923; HEINRICH H, 1988, QUATERNARY RES, V29, P142, DOI 10.1016/0033-5894(88)90057-9; Howard WR, 1997, NATURE, V388, P418, DOI 10.1038/41201; Jenkins G., 1968, SPECTRAL ANAL ITS AP; KEIGWIN LD, 1994, J GEOPHYS RES-OCEANS, V99, P12397, DOI 10.1029/94JC00525; KEIGWIN LD, 1996, J GEOPHYS RES, V274, P1504; KELLOGG TB, 1980, BOREAS, V9, P115; KOHFIELD KE, 1906, PALEOCEANOGRAPHY, V11, P679; LABEYRIE L, 1995, PHILOS T ROY SOC B, V348, P255, DOI 10.1098/rstb.1995.0067; LEHMAN SJ, 1992, NATURE, V356, P757, DOI 10.1038/356757a0; MARCHITTO TMJ, UNPUB; Mayewski PA, 1997, J GEOPHYS RES-OCEANS, V102, P26345, DOI 10.1029/96JC03365; MCMANUS JF, 1994, NATURE, V371, P326, DOI 10.1038/371326a0; Mikolajewicz U, 1997, NATURE, V387, P384, DOI 10.1038/387384a0; OBRIEN SR, 1995, SCIENCE, V270, P1962, DOI 10.1126/science.270.5244.1962; OPPO DW, 1993, SCIENCE, V259, P1148, DOI 10.1126/science.259.5098.1148; Oppo DW, 1997, PALEOCEANOGRAPHY, V12, P51, DOI 10.1029/96PA03133; OPPO DW, 1995, PALEOCEANOGRAPHY, V10, P901, DOI 10.1029/95PA02089; PISIAS NG, 1981, EARTH PLANET SC LETT, V52, P450, DOI 10.1016/0012-821X(81)90197-7; RAYMO ME, 1990, EARTH PLANET SC LETT, V97, P353, DOI 10.1016/0012-821X(90)90051-X; RAYMO ME, UNPUB; ROBINSON SG, 1995, PALEOCEANOGRAPHY, V10, P221, DOI 10.1029/94PA02683; Ruddiman WF, 1989, PALEOCEANOGRAPHY, V4, P353, DOI 10.1029/PA004i004p00353; RUDDIMAN WF, 1986, EARTH PLANET SC LETT, V80, P117, DOI 10.1016/0012-821X(86)90024-5; Sakai K, 1997, J CLIMATE, V10, P949, DOI 10.1175/1520-0442(1997)010<0949:DOOIAC>2.0.CO;2; Sarnthein M, 1990, PALEOCEANOGRAPHY, V5, P1041, DOI 10.1029/PA005i006p01041; SHACKLETON NJ, 1990, T R SOC EDINBURGH EA, V81, P25; THOMSON DJ, 1990, PHILOS T R SOC A, V332, P539, DOI 10.1098/rsta.1990.0130; Vidal L, 1997, EARTH PLANET SC LETT, V146, P13, DOI 10.1016/S0012-821X(96)00192-6	44	196	202	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	1998	279	5355					1335	1338		10.1126/science.279.5355.1335	http://dx.doi.org/10.1126/science.279.5355.1335			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478890				2022-12-28	WOS:000072251800045
J	Magnaghi-Jaulin, L; Groisman, R; Naguibneva, I; Robin, P; Lorain, S; Le Villain, JP; Troalen, F; Trouche, D; Harel-Bellan, A				Magnaghi-Jaulin, L; Groisman, R; Naguibneva, I; Robin, P; Lorain, S; Le Villain, JP; Troalen, F; Trouche, D; Harel-Bellan, A			Retinoblastoma protein represses transcription by recruiting a histone deacetylase	NATURE			English	Article							GENE-PRODUCT; E2F; INTERACT; BINDING; MOTIF; PRB	The retinoblastoma tumour-suppressor protein Rb-1 inhibits cell proliferation by repressing a subset of genes that are controlled by the E2F family of transcription factors(2) and which are involved in progression from the G1 to the S phase of the cell cycle, Rb, which is recruited to target promoters by E2F1 (ref. 3), represses transcription by masking the E2F1 transactivation domain(4) and by inhibiting surrounding enhancer elements(5-8), an active repression that could be crucial for the proper control of progression through the cell cycle(9). Some transcriptional regulators act by acetylating or deacetylating the tails protruding from the core histones(10), thereby modulating the local structure of chromatin: for example, some transcriptional repressors function through the recruitment of histone deacetylases(11). We show here that the histone deacetylase HDAC1 physically interacts and cooperates with Rb, In HDAC1, the sequence involved is an LXCXE motif, similar to that used by viral transforming proteins to contact Rb, Our results strongly suggest that the Rb/HDAC1 complex is a key element in the control of cell proliferation and differentiation and that it is a likely target for transforming viruses.	CNRS UPR 9079, Lab Oncogenese Differciat & Transduct Signal, IFC 1, F-94801 Villejuif, France; Inst Gustave Roussy, CNRS URA 1156, F-94805 Villejuif, France; Inst Gustave Roussy, Unite Marqueurs Biol & Mol, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Harel-Bellan, A (corresponding author), CNRS UPR 9079, Lab Oncogenese Differciat & Transduct Signal, IFC 1, F-94801 Villejuif, France.	ahbellan@vjf.cnrs.fr	Trouche, Didier/B-2854-2008; Harel-Bellan, Annick/M-9795-2015	Naguibneva, Irina/0000-0001-9566-6152; Trouche, Didier/0000-0003-1398-6481; Harel-Bellan, Annick/0000-0002-2339-153X; Groisman, Regina/0000-0003-3990-7622; Groisman, Sonia/0000-0003-1153-3841; Lorain, Stephanie/0000-0001-5266-9994				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1474; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Groisman R, 1996, J BIOL CHEM, V271, P5258; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NEVINS JR, 1992, SCIENCE, V258, P424; PAZINMJ, 1997, CELL, V89, P325; Tauton J, 1996, SCIENCE, V272, P408; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; TROUCHE D, 1997, P NATL ACAD SCI USA, V94, P11295; TURNER BM, 1991, J CELL SCI, V99, P13; WEINBERG RA, 1992, CANCER SURV, V12, P43; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zacksenhaus E, 1996, EMBO J, V15, P5917, DOI 10.1002/j.1460-2075.1996.tb00978.x; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	30	770	789	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 5	1998	391	6667					601	605		10.1038/35410	http://dx.doi.org/10.1038/35410			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468140				2022-12-28	WOS:000071842300056
J	Tsevat, J; Dawson, NV; Wu, AW; Lynn, J; Soukup, JR; Cook, EF; Vidaillet, H; Philips, RS				Tsevat, J; Dawson, NV; Wu, AW; Lynn, J; Soukup, JR; Cook, EF; Vidaillet, H; Philips, RS		HELP Investigators	Health values of hospitalized patients 80 years or older	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	17th Annual Meeting of the Society-of-General-Internal-Medicine	APR 27-29, 1994	WASHINGTON, D.C.	Soc Gen Internal Med			HUMAN-IMMUNODEFICIENCY-VIRUS; SERIOUSLY ILL; FUNCTIONAL STATUS; ADULTS; PREFERENCES; UTILITIES; OUTCOMES; POLICY	Context.-Health values (utilities or preferences for health states) are often incorporated into clinical decisions and health care policy when issues of quality vs length of life arise, but little is known about health values of the very old. Objective.-To assess health values of older hospitalized patients, compare their values with those of their surrogate decision makers, investigate possible determinants of health values, and determine whether health values change overtime. Design.-A prospective, longitudinal, multicenter cohort study. Setting.-Four academic medical centers. Participants.-Four hundred fourteen hospitalized patients aged 80 years or older and their surrogate decision makers who were interviewed and understood the task. Main Outcome Measures.-Time-trade-off utilities, reflecting preferences for current health relative to a shorter but healthy life. Results.-On average, patients equated living 1 year in their current state of health with living 9.7 months in excellent health (mean [SD] utility, 0.81 [0.28]). Although only 126 patients (30.7%) rated their current quality of life as excellent or very good, 284 (68.6%) were willing to give up at most 1 month of 12 in exchange for excellent health (utility greater than or equal to 0.92). At the other extreme, 25 (6.0%) were willing to live 2 weeks or less in excellent health rather than 1 year in their current state of health (utility less than or equal to 0.04). Patients were willing to trade significantly less time for a healthy life than their surrogates assumed they would (mean difference, 0.05; P=.007); 61 surrogates (20.3%) underestimated the patient's time-trade-off score by 0.25 (3 months of 12) or more. Patients willing to trade less time for better health were more likely to want resuscitation and other measures to extend life. Time-trade-off score correlated only modestly with quality-of-life rating (r=0.28) and inversely with depression score (r=-0.27), but there were few other clinical or demographic predictors of health values, When patients who survived were asked the time-trade-off question again at 1 year, they were willing to trade less time for better health than at baseline (mean difference, 0.04; P=.04). Conclusion.-Very old hospitalized patients who could be interviewed were able, in most cases, to have their health values assessed using the time-trade-off technique. Most patients were unwilling to trade much time for excellent health, but preferences varied greatly. Because proxies and multivariable analyses cannot gauge health values of elderly hospitalized patients accurately, health values of the very old should be elicited directly from the patient.	Univ Cincinnati, Med Ctr, Dept Internal Med, Div Gen Internal Med,Sect Outcomes Res, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Inst Hlth Policy & Hlth Serv Res, Ctr Clin Effectiveness, Cincinnati, OH 45267 USA; Case Western Reserve Univ, Sch Med, Metrohlth Med Ctr, Div Gen Internal Med, Cleveland, OH 44106 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Hlth Serv Res & Dev Ctr, Baltimore, MD 21218 USA; George Washington Univ, Med Ctr, Ctr Improve Care Dying, Washington, DC 20037 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Gen Med & Primary Care, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp,Dept Med, Div Gen Med & Primary Care,Sect Clin Epidemiol, Boston, MA 02115 USA; Marshfield Clin Fdn Med Res & Educ, Dept Cardiol, Marshfield, WI 54449 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Case Western Reserve University; MetroHealth System; Johns Hopkins University; George Washington University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Marshfield Clinic	Tsevat, J (corresponding author), Univ Cincinnati, Med Ctr, Dept Internal Med, Div Gen Internal Med,Sect Outcomes Res, 231 Bethesda Ave, Cincinnati, OH 45267 USA.	joel.tsevat@uc.edu	Wu, Albert/AAJ-4780-2021					BERGNER M, 1989, MED CARE, V27, pS148, DOI 10.1097/00005650-198903001-00012; Bosch JL, 1996, MED DECIS MAKING, V16, P217, DOI 10.1177/0272989X9601600305; COULTON CJ, 1990, J CLIN EPIDEMIOL, V43, pS51, DOI 10.1016/0895-4356(90)90219-F; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; FROBERG DG, 1989, J CLIN EPIDEMIOL, V42, P585, DOI 10.1016/0895-4356(89)90155-8; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Gold MR, 1996, COST EFFECTIVENESS H; Guyatt GH, 1997, JAMA-J AM MED ASSOC, V277, P1232, DOI 10.1001/jama.277.15.1232; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; Hamel MB, 1996, J AM GERIATR SOC, V44, P1043, DOI 10.1111/j.1532-5415.1996.tb02935.x; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; KASSIRER JP, 1994, NEW ENGL J MED, V330, P1895, DOI 10.1056/NEJM199406303302611; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Kolata Gina, 1992, NY TIMES, pC3; LANDEFELD CS, 1990, J CLIN EPIDEMIOL, V43, pS37, DOI 10.1016/0895-4356(90)90216-C; LAPUMA J, 1990, JAMA-J AM MED ASSOC, V263, P2917, DOI 10.1001/jama.263.21.2917; LENDERKING WR, 1994, NEW ENGL J MED, V330, P738, DOI 10.1056/NEJM199403173301102; LLEWELLYNTHOMAS HA, 1991, MED DECIS MAKING, V11, P180, DOI 10.1177/0272989X9101100307; MANTON KG, 1995, NEW ENGL J MED, V333, P1232, DOI 10.1056/NEJM199511023331824; MURPHY DJ, 1990, J CLIN EPIDEMIOL, V43, pS11, DOI 10.1016/0895-4356(90)90213-9; NEASE RF, 1995, JAMA-J AM MED ASSOC, V273, P1185, DOI 10.1001/jama.273.15.1185; OYE RK, 1990, J CLIN EPIDEMIOL, V43, pS83, DOI 10.1016/0895-4356(90)90226-F; PATRICK DL, 1992, HLTH STATUS HLTH POL; Pauker S P, 1987, Birth Defects Orig Artic Ser, V23, P151; PHILLIPS RS, 1990, J CLIN EPIDEMIOL, V43, pS33, DOI 10.1016/0895-4356(90)90215-B; PLANTE DA, 1986, AM J MED, V80, P1169, DOI 10.1016/0002-9343(86)90680-7; REVICKI DA, 1992, MED CARE, V30, pMS274, DOI 10.1097/00005650-199205001-00027; SHACHAM S, 1983, J PERS ASSESS, V47, P305, DOI 10.1207/s15327752jpa4703_14; STUCK AE, 1995, NEW ENGL J MED, V333, P1184, DOI 10.1056/NEJM199511023331805; Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559; Torrance G W, 1972, Health Serv Res, V7, P118; TSEVAT J, 1990, J CLIN EPIDEMIOL, V43, pS73, DOI 10.1016/0895-4356(90)90224-D; Tsevat J, 1996, MED CARE, V34, P44, DOI 10.1097/00005650-199601000-00004; TSEVAT J, 1991, MED CARE, V29, P1153, DOI 10.1097/00005650-199111000-00007; TSEVAT J, 1995, ANN INTERN MED, V122, P514, DOI 10.7326/0003-4819-122-7-199504010-00007; TSEVAT J, 1994, J GEN INTERN MED, V9, P576, DOI 10.1007/BF02599287; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Weinstein MC, 1980, CLIN DECISION ANAL; WU AW, 1995, ANN INTERN MED, V122, P342, DOI 10.7326/0003-4819-122-5-199503010-00004; 1990, J CLIN EPIDEMIOL S, V43, pS109	42	214	215	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					371	375		10.1001/jama.279.5.371	http://dx.doi.org/10.1001/jama.279.5.371			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459470	Bronze			2022-12-28	WOS:000071731300027
J	Grotewiel, MS; Beck, CDO; Wu, KH; Zhu, XR; Davis, RL				Grotewiel, MS; Beck, CDO; Wu, KH; Zhu, XR; Davis, RL			Integrin-mediated short-term memory in Drosophila	NATURE			English	Article							APLYSIA SENSORY NEURONS; MUSHROOM BODIES; TRANSMITTER RELEASE; PREFERENTIAL EXPRESSION; PROTEIN-SYNTHESIS; GENE; FACILITATION; MODULATION; POTENTIATION; INDUCTION	Volado is a new memory mutant of Drosophila. the locus encodes two isoforms of a new a-integrin, a molecule that dynamically mediates cell adhesion and signal transduction. The Volado gene is expressed preferentially in mushroom body cells, which are neurons known to mediate olfactory learning in insects. Volado proteins are concentrated in the mushroom body neuropil, brain areas that contain mushroom body processes in synaptic contact with other neurons. Volado mutants display impaired olfactory memories within 3 min of training, indicating that the integrin is required for short-term memory processes. Conditional expression of a Volado transgene during adulthood rescues the memory impairment. This rescue of memory is reversible, fading over time along with expression of the transgene. Thus the Volado integrin is essential for the physiological processes underlying memory. We propose a model in which integrins act as dynamic regulators of synapse structure or the signalling events underlying short-term memory formation.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Davis, RL (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	rdavis@bcm.tmc.edu	Grotewiel, Mike/AAX-4094-2020; Davis, Ronald/J-4998-2013	Grotewiel, Mike/0000-0001-7302-3252; Davis, Ronald/0000-0002-5986-7608				ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; Bahr BA, 1997, J NEUROSCI, V17, P1320; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BAUSENWEIN B, 1994, J COMP NEUROL, V340, P255, DOI 10.1002/cne.903400210; Byrne John H., 1993, V27, P47; CHEN BM, 1995, SCIENCE, V269, P1578, DOI 10.1126/science.7667637; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; Davis RL, 1996, PHYSIOL REV, V76, P299, DOI 10.1152/physrev.1996.76.2.299; DAVIS RL, 1993, NEURON, V11, P1, DOI 10.1016/0896-6273(93)90266-T; Davis RL, 1996, CURR BIOL, V6, P146, DOI 10.1016/S0960-9822(02)00447-5; DEDHAR S, 1994, TRENDS BIOCHEM SCI, V19, P269, DOI 10.1016/0968-0004(94)90001-9; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; FEANY MB, 1995, SCIENCE, V268, P869, DOI 10.1126/science.7754370; GHIRARDI M, 1992, NEURON, V9, P479, DOI 10.1016/0896-6273(92)90185-G; GRANT SGN, 1994, TRENDS NEUROSCI, V17, P71, DOI 10.1016/0166-2236(94)90077-9; Han KA, 1996, NEURON, V16, P1127, DOI 10.1016/S0896-6273(00)80139-7; Han PL, 1996, J NEUROBIOL, V31, P88, DOI 10.1002/(SICI)1097-4695(199609)31:1<88::AID-NEU8>3.0.CO;2-B; HAN PL, 1992, NEURON, V9, P619, DOI 10.1016/0896-6273(92)90026-A; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; Hing ALY, 1996, J NEUROBIOL, V30, P454; HUSTON JP, 1995, BEHAV BRAIN RES, V66, P117, DOI 10.1016/0166-4328(94)00132-Y; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jones LS, 1996, TRENDS NEUROSCI, V19, P68; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; Lindman H. R., 1992, ANAL VARIANCE EXPT D; MELLO CV, 1995, J NEUROBIOL, V26, P145, DOI 10.1002/neu.480260112; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NIGHORN A, 1991, NEURON, V6, P455, DOI 10.1016/0896-6273(91)90253-V; Pirrotta V., 1986, DROSOPHILA PRACTICAL, P83; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; SKOULAKIS EMC, 1996, NEURON, V17, P951; STAUBLI U, 1990, BEHAV NEURAL BIOL, V53, P1, DOI 10.1016/0163-1047(90)90712-F; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; ZHANG SD, 1995, P NATL ACAD SCI USA, V92, P5525, DOI 10.1073/pnas.92.12.5525; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0	42	232	243	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 29	1998	391	6666					455	460		10.1038/35079	http://dx.doi.org/10.1038/35079			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461212				2022-12-28	WOS:000071701800040
J	Sepkowitz, KA				Sepkowitz, KA			Effect of HAART on natural history of AIDS-related opportunistic disorders	LANCET			English	Editorial Material									Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Sepkowitz, KA (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.							CARR A, 1997, LANCET, V349, P996; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P165; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; CHLOREMIS CB, 1955, AM REV TUBERC, V72, P527; Elliot B, 1997, LANCET, V349, P850, DOI 10.1016/S0140-6736(05)61753-9; GELBER RH, 1995, PRINCIPLES PRACTICE, P2243; GILQUIN J, 1997, 4 C RETR OPP INF WAS; Hicks CB, 1997, CLIN INFECT DIS, V24, P1023, DOI 10.1093/clinids/24.5.1023; Jacobson MA, 1997, LANCET, V349, P1443, DOI 10.1016/S0140-6736(96)11431-8; Murphy M, 1997, AIDS, V11, P261; SCHNEIDER MME, 1997, 37 INT C ANT AG CHEM; Whitcup SM, 1997, JAMA-J AM MED ASSOC, V277, P1519, DOI 10.1001/jama.277.19.1519	12	156	159	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 24	1998	351	9098					228	230		10.1016/S0140-6736(05)78279-9	http://dx.doi.org/10.1016/S0140-6736(05)78279-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU294	9457088				2022-12-28	WOS:000071702200004
J	Simpson, WM; Johnstone, FD; Boyd, FM; Goldberg, DJ; Hart, GJ; Prescott, RJ				Simpson, WM; Johnstone, FD; Boyd, FM; Goldberg, DJ; Hart, GJ; Prescott, RJ			Uptake and acceptability of antenatal HIV testing: randomised controlled trial of different methods of offering the test	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ZIDOVUDINE TREATMENT; TRANSMISSION; VOLUNTARY; PREGNANCY; INFANT; RISK	Objective: To determine the uptake and acceptability Of different methods of a universal offer of voluntary HIV testing to pregnant women. Design: Randomised controlled trial involving four combinations of written and verbal communication, followed by the direct offer of a test. The control group receive no information and no direct offer of a test, although testing was available on request. Setting: Hospital antenatal clinic covering most of the population of the city of Edinburgh. Subjects: 3024 pregnant women booking at the clinic over a 10 month period. Main outcome measures: Uptake af HIV testing and women's knowledge, satisfaction and anxiety. Results: Uptake rates were 6% for those in the control group and 35% for those directly offered the test. Neither the style of leaflet nor the length of discussion had an effect on uptake. Significant independent predictors of uptake were a direct test offer the midwife seen and being unmarried, previous tested and younger age. Knowledge of the specific benefits of testing increased with the amount of information given, but neither satisfaction nor anxiety was affected by the type of offer. Conclusions: The universal offer of HIV testing is not intrusive and is acceptable to pregnant women. A policy of offering the HIV test to all women resulted in higher uptake and did not increase anxiety or dissatisfaction. Uptake depends more on the midwife than the method of offering the test. Low uptake rates and inadequate detection of HIV infection point to the need to assess a more routine approach to testing.	Univ Edinburgh, Ctr Reprod Biol, Dept Obstet & Gynaecol, Edinburgh EH3 9EW, Midlothian, Scotland; Ruchill Hosp, Scottish Ctr Infect & Environm Hlth, Glasgow G20 9NB, Lanark, Scotland; Univ Glasgow, MRC, Med Sociol Unit, Glasgow G12 8RZ, Lanark, Scotland; Univ Edinburgh, Dept Publ Hlth Sci, Med Stat Unit, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh; University of Glasgow; University of Edinburgh	Simpson, WM (corresponding author), Univ Edinburgh, Ctr Reprod Biol, Dept Obstet & Gynaecol, Edinburgh EH3 9EW, Midlothian, Scotland.		Hart, Graham J/C-1591-2008	Hart, Graham/0000-0001-9676-6577				CARSTAIRS V R M, 1990, Health Bulletin (Edinburgh), V48, P162; CHRISTIE IL, 1995, AIDS CARE, V7, P135; CHRYSTIE IL, 1995, BRIT MED J, V311, P928, DOI 10.1136/bmj.311.7010.928; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; GOLDBERG DJ, 1992, BMJ-BRIT MED J, V304, P1082, DOI 10.1136/bmj.304.6834.1082; JOHNSTONE F, IN PRESS AIDS; Ley P, 1988, PSYCHOL MED SERIES; LINDGREN S, 1993, BRIT MED J, V307, P1447, DOI 10.1136/bmj.307.6917.1447; MacDonagh SE, 1996, BRIT MED J, V313, P532; MACDONAGH SE, 1996, BR J MIDWIFERY, V4, P466; Marteau T.M., 1990, PSYCHOL HEALTH, V5, P47; MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x; Meadows J, 1993, Midwifery, V9, P17, DOI 10.1016/0266-6138(93)90038-T; MEADOWS J, 1990, AIDS Care, V2, P229, DOI 10.1080/09540129008257735; MENNIE ME, 1993, J MED GENET, V30, P543, DOI 10.1136/jmg.30.7.543; Mercey D, 1996, BRIT J OBSTET GYNAEC, V103, P1129, DOI 10.1111/j.1471-0528.1996.tb09596.x; MILLER R, DIPLOMATE, V426, P97; *SCOTT CTR INF ENV, 1995, ANSWER           DEC, P1; SHERR L, 1995, PSYCHOL PREGNANCY CH, P130; SMITH R, 1996, ANSWER          0223, pAM20; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; THORNTON JG, 1995, BMJ-BRIT MED J, V311, P1127, DOI 10.1136/bmj.311.7013.1127; ZELEN M, 1979, NEW ENGL J MED, V300, P1241	24	107	108	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					262	267		10.1136/bmj.316.7127.262	http://dx.doi.org/10.1136/bmj.316.7127.262			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YU293	9472506	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000071702100019
J	Kidd, T; Brose, K; Mitchell, KJ; Fetter, RD; Tessier-Lavigne, M; Goodman, CS; Tear, G				Kidd, T; Brose, K; Mitchell, KJ; Fetter, RD; Tessier-Lavigne, M; Goodman, CS; Tear, G			Roundabout controls axon crossing of the CNS midline and defines a novel subfamily of evolutionarily conserved guidance receptors	CELL			English	Article							GROWTH CONE GUIDANCE; C-ELEGANS; GENETIC-ANALYSIS; FASCICLIN-I; COLORECTAL-CANCER; COMMISSURAL AXONS; TYROSINE KINASE; SPINAL-CORD; NETRIN CUES; DROSOPHILA	The robe gene in Drosophila was identified in a large-scale mutant screen for genes that control the decision by axons to cross the CNS midline. In robe mutants, too many axons cross and recross the midline. Here we show that robe encodes an axon guidance receptor that defines a novel subfamily of immunoglobulin superfamily proteins that is highly conserved from fruit flies to mammals. For those axons that never cross the midline, Robe is expressed on their growth cones from the outset; for the majority of axons that do cross the midline, Robe is expressed at high levels on their growth cones only after they cross the midline. Transgenic rescue experiments reveal that Robe can function in a cell-autonomous fashion. Robe appears to function as the gatekeeper controlling midline crossing.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AZ, England	Howard Hughes Medical Institute; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Imperial College London	Kidd, T (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.		Kidd, Thomas/AAT-9993-2020; Tear, Guy/C-5444-2009	Mitchell, Kevin/0000-0002-3433-4530; Kidd, Thomas/0000-0001-7190-4208	NINDS NIH HHS [NS18366] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018366] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1984, ADV ANAT EMBRYOL CEL, V85, P1; BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Kang JS, 1997, J CELL BIOL, V138, P203, DOI 10.1083/jcb.138.1.203; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; MYERS PZ, 1993, J NEUROSCI, V13, P127; NIEKBUHR K, 1997, EMBO J, V16, P5433; Patel N, 1994, METHODS CELL BIOL, V44; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; STOECKLI ET, 1995, NEURON, V14, P1165, DOI 10.1016/0896-6273(95)90264-3; Stoeckli ET, 1997, NEURON, V18, P209, DOI 10.1016/S0896-6273(00)80262-7; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Tear G, 1996, NEURON, V16, P501, DOI 10.1016/S0896-6273(00)80070-7; Tear G, 1993, Perspect Dev Neurobiol, V1, P183; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; Zallen JA, 1998, CELL, V92, P217, DOI 10.1016/S0092-8674(00)80916-2; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	32	705	734	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					205	215		10.1016/S0092-8674(00)80915-0	http://dx.doi.org/10.1016/S0092-8674(00)80915-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458045	Bronze			2022-12-28	WOS:000071672600010
J	Lomas, DJ; Dixon, AK				Lomas, DJ; Dixon, AK			100 years and running: The medical imaging revolution	LANCET			English	Article											Lomas, DJ (corresponding author), UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT RADIOL, CAMBRIDGE CB2 2QQ, ENGLAND.			LOMAS, David/0000-0003-2904-8617				JAMAR F, 1995, RADIOLOGY, V194, P843, DOI 10.1148/radiology.194.3.7532314; LAUBENBERGER R, 1995, MAGNET RESON MED, V33, P18, DOI 10.1002/mrm.1910330104; REES MR, 1995, LANCET, V346, P943, DOI 10.1016/S0140-6736(95)91560-5; SCHENCK JF, 1995, RADIOLOGY, V195, P805, DOI 10.1148/radiology.195.3.7754014; VINNICOMBE SJ, 1995, RADIOLOGY, V194, P349, DOI 10.1148/radiology.194.2.7824709	5	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	1995	346			S			S20	S20		10.1016/0140-6736(95)90019-5	http://dx.doi.org/10.1016/0140-6736(95)90019-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454038				2022-12-28	WOS:A1995TN12200020
J	Naglie, G; Gordon, M				Naglie, G; Gordon, M			The coming of age of geriatric care	LANCET			English	Article											Naglie, G (corresponding author), UNIV TORONTO,TORONTO HOSP,BAYCREST CTR GERIATR CARE,200 ELIZABETH ST,EN G-238,TORONTO,ON M5G 2C4,CANADA.			Naglie, Gary/0000-0002-6274-0894				CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; INSUA JT, 1994, ANN INTERN MED, V121, P355, DOI 10.7326/0003-4819-121-5-199409010-00008; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0	5	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S7	S7		10.1016/0140-6736(95)90006-3	http://dx.doi.org/10.1016/0140-6736(95)90006-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454050				2022-12-28	WOS:A1995TN12200007
J	Hage, W; Liedl, KR; Hallbrucker, A; Mayer, E				Hage, W; Liedl, KR; Hallbrucker, A; Mayer, E			Carbonic acid in the gas phase and its astrophysical relevance	SCIENCE			English	Article							PHYSICO-CHEMICAL PHENOMENA; PROTON IRRADIATED H2O+CO2; ENHANCED BE-10 DEPOSITION; C-13 ISOTOPIC FORMS; COMET HALLEY; VIBRATIONAL FREQUENCIES; CLATHRATE HYDRATE; GLASSY SOLUTIONS; RAMAN-SPECTRA; FTIR SPECTRA	In outer space, high-energy irradiation of cryogenic ice mixtures of abundant water and carbon dioxide is expected to form solid carbonic acid, Experiments and thermodynamic analyses show that crystalline carbonic acid sublimates without decomposition. Free-energy considerations based on highly accurate molecular quantum mechanics, in combination With vapor pressures resulting from experimental sublimation rates, suggest that in the gas phase, a monomer and dimer of carbonic acid are in equilibrium, comparable to that of formic acid. Gaseous carbonic acid could be present in comets, an Mars and outer solar system bodies, in interstellar icy grains, and in Earth's upper atmosphere.	Univ Innsbruck, Inst Allgemeine Anorgan & Theoret Chem, A-6020 Innsbruck, Austria	University of Innsbruck	Liedl, KR (corresponding author), Univ Innsbruck, Inst Allgemeine Anorgan & Theoret Chem, A-6020 Innsbruck, Austria.	klaus.liedl@vibk.ac.at; erwin.mayer@uibk.ac.at	Liedl, Klaus/ABB-4725-2021; Liedl, Klaus R/F-3099-2015	Liedl, Klaus/0000-0002-0985-2299; Liedl, Klaus R/0000-0002-0985-2299				Bard E, 1997, EARTH PLANET SC LETT, V150, P453, DOI 10.1016/S0012-821X(97)00082-4; BEER J, 1992, NATO ASI SER, V12, P141; BERTIE JE, 1982, J CHEM PHYS, V76, P886, DOI 10.1063/1.443061; BLAKE D, 1991, SCIENCE, V254, P548, DOI 10.1126/science.11538372; Brucato JR, 1997, ICARUS, V125, P135, DOI 10.1006/icar.1996.5561; CASTAGNOLI GC, 1995, GEOPHYS RES LETT, V22, P707, DOI 10.1029/95GL00298; CHANG YT, 1987, J AM CHEM SOC, V109, P7245, DOI 10.1021/ja00258a001; CHYBA C, 1987, NATURE, V330, P350, DOI 10.1038/330350a0; COMBES M, 1986, NATURE, V321, P266, DOI 10.1038/321266a0; COMBES M, 1988, ICARUS, V76, P404, DOI 10.1016/0019-1035(88)90013-9; Crovisier J, 1996, ASTRON ASTROPHYS, V315, pL385; Davidson D.W., 1984, J INCLUSION PHENOM, V2, P231, DOI 10.1007/BF00663261; DELLORUSSO N, 1993, J GEOPHYS RES-PLANET, V98, P5505, DOI 10.1029/92JE02325; Delsemme A., 1952, ANN ASTROPHYS, V15, P1; DELSEMME AH, 1970, PLANET SPACE SCI, V18, P717, DOI 10.1016/0032-0633(70)90053-X; DELSEMME AH, 1970, PLANET SPACE SCI, V18, P709, DOI 10.1016/0032-0633(70)90052-8; Eigen M., 1961, Z PHYS CHEM FRANKFUR, V30, P130; ENGLE S, 1990, ICARUS, V85, P380; HAGE W, 1993, J AM CHEM SOC, V115, P8427, DOI 10.1021/ja00071a061; Hage W, 1996, J CHEM SOC FARADAY T, V92, P3197, DOI 10.1039/ft9969203197; HAGE W, 1995, J CHEM SOC FARADAY T, V91, P2823, DOI 10.1039/ft9959102823; Hage W, 1996, J CHEM SOC FARADAY T, V92, P3183, DOI 10.1039/ft9969203183; Hage W, 1997, J MOL STRUCT, V408, P527, DOI 10.1016/S0022-2860(96)09701-3; HALLBRUCKER A, 1991, ICARUS, V90, P176, DOI 10.1016/0019-1035(91)90078-8; HENDERSON G, 1987, J CHEM EDUC, V64, P88, DOI 10.1021/ed064p88; Johnson RE, 1997, J GEOPHYS RES-PLANET, V102, P10985, DOI 10.1029/97JE00068; JONSSON B, 1977, J AM CHEM SOC, V99, P4628, DOI 10.1021/ja00456a018; Kern D.M., 1960, J CHEM EDUC, V37, P14, DOI [10.1021/ed037p14, DOI 10.1021/ED037P14]; KHANNA RK, 1994, ICARUS, V112, P541, DOI 10.1006/icar.1994.1206; KRANKOWSKY D, 1986, NATURE, V321, P326, DOI 10.1038/321326a0; LAZAAR KI, 1985, J AM CHEM SOC, V107, P3769, DOI 10.1021/ja00299a004; Liedl KR, 1997, J AM CHEM SOC, V119, P3782, DOI 10.1021/ja961802q; LUNINE JI, 1985, ASTROPHYS J SUPPL S, V58, P493, DOI 10.1086/191050; MADDOX J, 1986, NATURE, V321, P366, DOI 10.1038/321366a0; MCHARGUE LR, 1995, GEOPHYS RES LETT, V22, P659, DOI 10.1029/95GL00169; MILLER SL, 1973, PHYSICS CHEM ICE, P42; MILLIKAN RC, 1958, J AM CHEM SOC, V80, P3515, DOI 10.1021/ja01547a007; MIYAZAWA T, 1959, J CHEM PHYS, V30, P1076, DOI 10.1063/1.1730085; MOORE MH, 1991, J GEOPHYS RES-PLANET, V96, P17541, DOI 10.1029/91JE01682; MOORE MH, 1991, SPECTROCHIM ACTA A, V47, P255, DOI 10.1016/0584-8539(91)80097-3; NGUYEN MT, 1984, J AM CHEM SOC, V106, P599, DOI 10.1021/ja00315a023; Nguyen MT, 1997, J PHYS CHEM A, V101, P7379, DOI 10.1021/jp9701045; PIETSCH EHE, 1973, GMELING HDB ANORG C3, V14, P117; POCKER Y, 1977, J AM CHEM SOC, V99, P6537, DOI 10.1021/ja00462a012; RAISBECK GM, 1987, NATURE, V326, P273, DOI 10.1038/326273a0; ROESSLER K, 1992, HDB HOT ATOM CHEM, P601; SONETT CP, 1992, RADIOCARBON, V34, P239, DOI 10.1017/S0033822200013680; Steig EJ, 1996, GEOPHYS RES LETT, V23, P523, DOI 10.1029/96GL00255; Strazzulla G, 1996, PLANET SPACE SCI, V44, P1447, DOI 10.1016/S0032-0633(96)00079-7; TERLOUW JK, 1987, ANGEW CHEM INT EDIT, V26, P354, DOI 10.1002/anie.198703541; TERLOUW JK, 1990, ANGEW CHEM, V102, P431; UMRATH W, 1983, MIKROSKOPIE, V40, P9; WIGHT CA, 1995, J PHYS CHEM-US, V99, P12125, DOI 10.1021/j100032a012; YOKOYAMA I, 1991, J AM CHEM SOC, V113, P6458, DOI 10.1021/ja00017a016	54	106	107	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	1998	279	5355					1332	1335		10.1126/science.279.5355.1332	http://dx.doi.org/10.1126/science.279.5355.1332			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478889				2022-12-28	WOS:000072251800044
J	Zachariae, W; Shevchenko, A; Andrews, PD; Ciosk, R; Galova, M; Stark, MJR; Mann, M; Nasmyth, K				Zachariae, W; Shevchenko, A; Andrews, PD; Ciosk, R; Galova, M; Stark, MJR; Mann, M; Nasmyth, K			Mass spectrometric analysis of the anaphase-promoting complex from yeast: Identification of a subunit related to cullins	SCIENCE			English	Article							SISTER-CHROMATID SEPARATION; SACCHAROMYCES-CEREVISIAE; POLYACRYLAMIDE GELS; CYCLIN; UBIQUITIN; PROTEINS; TRANSITION; FAMILY; PROTEOLYSIS; REPLICATION	Entry into anaphase and exit from mitosis depend on a ubiquitin-protein ligase complex called the anaphase-promoting complex (APC) or cyclosome. At least 12 different subunits were detected in the purified particle from budding yeast, including the previously identified proteins Apc1p, Cdc16p, Cdc23p, Cdc26p, and Cdc27p, Five additional subunits purified in low nanogram amounts were identified by tandem mass spectrometric sequencing, Apc2p, Apc5p, and the RING-finger protein Apc11p are conserved from yeast to humans, Apc2p is similar to the cullin Cdc53p, which is a subunit of the ubiquitin-protein ligase complex SCFCdc4 required for the initiation of DNA replication.	European Mol Biol Lab, D-69012 Heidelberg, Germany; Res Inst Mol Pathol, A-1030 Vienna, Austria; Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland	European Molecular Biology Laboratory (EMBL); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Dundee	Nasmyth, K (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69012 Heidelberg, Germany.		Mann, Matthias/A-3454-2013; Ciosk, Rafal/L-7327-2013; Stark, Michael J. R./B-2815-2014	Mann, Matthias/0000-0003-1292-4799; Stark, Michael J. R./0000-0001-9086-191X; Ciosk, Rafal/0000-0003-2234-6216; Nasmyth, Kim/0000-0001-7030-4403; Andrews, Paul/0000-0001-7699-5604				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hwang LH, 1997, MOL BIOL CELL, V8, P1877, DOI 10.1091/mbc.8.10.1877; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Lamond AI, 1997, TRENDS CELL BIOL, V7, P139, DOI 10.1016/S0962-8924(97)01031-3; MACKELVIE SH, 1995, MOL CELL BIOL, V15, P3777; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Neubauer G, 1997, P NATL ACAD SCI USA, V94, P385, DOI 10.1073/pnas.94.2.385; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SHEVCHENKO A, UNPUB; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TYERS MB, COMMUNICATION; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791	33	289	302	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1216	1219		10.1126/science.279.5354.1216	http://dx.doi.org/10.1126/science.279.5354.1216			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469814				2022-12-28	WOS:000072115200046
J	Davis, AJ; Jenkinson, LS; Lawton, JH; Shorrocks, B; Wood, S				Davis, AJ; Jenkinson, LS; Lawton, JH; Shorrocks, B; Wood, S			Making mistakes when predicting shifts in species range in response to global warming	NATURE			English	Article							TEMPERATURE; CLIMATE; LIMITS	Many attempts to predict the biotic responses to climate change rely on the 'climate envelope' approach(1-3), in which the current distribution of a species is mapped in climate-space and then, if the position of that climate-space changes, the distribution of the species is predicted to shift accordingly(4-6). The flaw in this approach is that distributions of species also reflect the influence of interactions with other species(7-10), so predictions based on climate envelopes may be very misleading if the interactions between species are altered by climate change(11). An additional problem is that current distributions may be the result of sources and sinks(12), in which species appear to thrive in places where they really persist only because individuals disperse into them from elsewhere(13,14). Here we use microcosm experiments on simple but realistic assemblages to show how misleading the climate envelope approach can be. We show that dispersal and interactions, which are important elements of population dynamics(15), must be included in predictions of biotic responses to climate change.	Univ Leeds, Dept Biol, Ecol & Evolut Grp, Leeds LS2 9JT, W Yorkshire, England; Univ London Imperial Coll Sci Technol & Med, NERC, Ctr Populat Biol, Ascot SL5 7PY, Berks, England	University of Leeds; Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)	Davis, AJ (corresponding author), Univ Leeds, Dept Biol, Ecol & Evolut Grp, Leeds LS2 9JT, W Yorkshire, England.	a.j.davis@leeds.ac.uk	Wood, Simon N/B-3058-2010	Wood, Simon N/0000-0002-2034-7453				BEERLING DJ, 1993, J BIOGEOGR, V20, P45, DOI 10.2307/2845738; Bennetts D. A., 1995, P49; BRUSSARD PF, 1984, ANNU REV ECOL SYST, V15, P25, DOI 10.1146/annurev.es.15.110184.000325; CONNELL JH, 1970, ECOL MONOGR, V40, P49, DOI 10.2307/1942441; Coope GR, 1995, INSECTS CHANGING ENV, P30; Davis M.B., 1986, COMMUNITY ECOL, P269; Graham R.W., 1992, P76; Graham RW, 1996, SCIENCE, V272, P1601; HANSKI I, 1997, METAPOPULATION BIOL; HOLT RD, 1994, ANNU REV ECOL SYST, V25, P495, DOI 10.1146/annurev.es.25.110194.002431; Jeffree CE, 1996, FUNCT ECOL, V10, P562, DOI 10.2307/2390166; KRAAIJEVELD AR, 1995, EVOL ECOL, V9, P10, DOI 10.1007/BF01237692; Lasalle John, 1993, P197; Lawton J.H., 1984, P451; NORDLANDER G, 1980, ENTOMOL SCAND, V11, P428; PACALA SW, 1993, BIOTIC INTERACTIONS AND GLOBAL CHANGE, P57; PAINE RT, 1966, AM NAT, V100, P65, DOI 10.1086/282400; Parmesan C, 1996, NATURE, V382, P765, DOI 10.1038/382765a0; Porter J., 1995, P93; PULLIAM HR, 1988, AM NAT, V132, P652, DOI 10.1086/284880; RODRIGUEZ J, 1994, J ANIM ECOL, V63, P31, DOI 10.2307/5580; ROGERS DJ, 1993, PARASITOL TODAY, V9, P266, DOI 10.1016/0169-4758(93)90074-P; SCOTT D, 1991, HYDROBIOLOGIA, V222, P147, DOI 10.1007/BF00006102; Sutherst R. W., 1995, P59; Valentine James W., 1993, P341; WATKINSON AR, 1985, J ECOL, V73, P569, DOI 10.2307/2260494; Wheeler M.R., 1986, GENETICS BIOL DROS E, P1	27	843	871	1	319	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					783	786		10.1038/35842	http://dx.doi.org/10.1038/35842			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486646				2022-12-28	WOS:000072089500050
J	McKim, KS; Green-Marroquin, BL; Sekelsky, JJ; Chin, G; Steinberg, C; Khodosh, R; Hawley, RS				McKim, KS; Green-Marroquin, BL; Sekelsky, JJ; Chin, G; Steinberg, C; Khodosh, R; Hawley, RS			Meiotic synapsis in the absence of recombination	SCIENCE			English	Article							DROSOPHILA-MELANOGASTER FEMALES; SYNAPTONEMAL COMPLEX; SACCHAROMYCES-CEREVISIAE; CAENORHABDITIS-ELEGANS; GENE CONVERSION; WILD-TYPE; MEIOSIS; YEAST; TRANSLOCATIONS; FREQUENCY	Although in Saccharomyces cerevisiae the initiation of meiotic recombination, as indicated by double-strand break formation, appears to be functionally linked to the initiation of synapsis, meiotic chromosome synapsis in Drosophila females occurs in the absence of meiotic exchange. Electron microscopy of oocytes from females homozygous for either of two meiotic mutants (mei-W68 and mei-P22), which eliminate both meiotic crossing over and gene conversion, revealed normal synaptonemal complex formation. Thus, synapsis in Drosophila is independent of meiotic recombination, consistent with a model in which synapsis is required for the initiation of meiotic recombination. Furthermore, the basic processes of early meiosis may have different functional or temporal relations, or both, in yeast and Drosophila.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis	McKim, KS (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA.			Hawley, R. Scott/0000-0002-6478-0494				BAKER B, COMMUNICATION; BURNHAM CR, 1972, GENETICS, V71, P111; CARPENTER ATC, 1975, CHROMOSOMA, V51, P157, DOI 10.1007/BF00319833; CARPENTER ATC, 1994, CIBA F SYMP, V182, P223; CARPENTER ATC, 1979, CHROMOSOMA, V75, P259, DOI 10.1007/BF00293472; CARPENTER ATC, 1979, GENETICS, V92, P511; CARPENTER AW, COMMUNICATION; CRAYMER L, 1984, GENETICS, V108, P573; CRAYMER L, 1981, GENETICS, V99, P75; CURTIS D, 1991, GENETICS, V127, P739; DEMASSY B, 1994, P NATL ACAD SCI USA, V91, P11929, DOI 10.1073/pnas.91.25.11929; GILBERTSON LA, 1994, P NATL ACAD SCI USA, V91, P11934, DOI 10.1073/pnas.91.25.11934; Goldman ASH, 1996, GENETICS, V144, P43; HABER JE, 1991, P NATL ACAD SCI USA, V88, P1120, DOI 10.1073/pnas.88.4.1120; HALL J, 1977, INFORMATION SERVICE, V52, P142; HAWLEY RC, UNPUB; HAWLEY RS, 1980, GENETICS, V94, P625; HAWLEY RS, 1993, CELL, V72, P301, DOI 10.1016/0092-8674(93)90108-3; HILLIKER AJ, 1991, GENETICS, V129, P779; HINTON CW, 1960, GENETICS, V45, P87; HIPEAUJACQUOTTE R, 1989, MOL GEN GENET, V220, P140, DOI 10.1007/BF00260868; JINKSROBERTSON S, 1986, GENETICS, V114, P731; KLECKNER N, 1991, COLD SH Q B, V56, P729; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; LICHTEN M, 1987, GENETICS, V115, P233; LUTKEN T, 1979, MUTAT RES, V61, P221, DOI 10.1016/0027-5107(79)90129-5; MAGUIRE MP, 1984, J THEOR BIOL, V106, P605, DOI 10.1016/0022-5193(84)90010-9; MCKIM KS, 1988, GENETICS, V120, P987; MCKIM KS, 1993, GENETICS, V134, P749; MCKIM KS, UNPUB; Moens PB, 1997, GENOME, V40, P770, DOI 10.1139/g97-799; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; ROBERTS PA, 1970, GENETICS, V65, P429; ROBERTS PA, 1972, GENETICS, V71, P401; ROCKMILL B, 1990, GENETICS, V126, P563; ROEDER GS, 1995, P NATL ACAD SCI USA, V92, P10450, DOI 10.1073/pnas.92.23.10450; ROSE AM, 1984, MOL GEN GENET, V195, P52, DOI 10.1007/BF00332723; ROSENBLUTH RE, 1981, GENETICS, V99, P415; SHERMAN F, 1978, GENETICS, V88, P689; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X	40	217	226	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					876	878		10.1126/science.279.5352.876	http://dx.doi.org/10.1126/science.279.5352.876			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452390	Green Submitted			2022-12-28	WOS:000071923500048
J	Vogel, JP; Andrews, HL; Wong, SK; Isberg, RR				Vogel, JP; Andrews, HL; Wong, SK; Isberg, RR			Conjugative transfer by the virulence system of Legionella pneumophila	SCIENCE			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; RANGE PLASMID RSF1010; T-DNA TRANSFER; AGROBACTERIUM-TUMEFACIENS; MOLECULAR CHARACTERIZATION; CITRATE UTILIZATION; GENE ORGANIZATION; ESCHERICHIA-COLI; HUMAN-MONOCYTES; PHAGOSOME	Legionella pneumophila, the causative agent of Legionnaires' pneumonia, replicates within alveolar macrophages by preventing phagosome-lysosome fusion. Here, a large number of mutants called dof (defective for organelle trafficking) that were unable to replicate intracellularly because of an inability of the bacteria to alter the endocytic pathway of macrophages were isolated. The dot virulence genes encoded a large putative membrane complex that functioned as a secretion system that was able to transfer plasmid DNA from one cell to another.	Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02111 USA	Tufts University; Howard Hughes Medical Institute; Tufts University	Isberg, RR (corresponding author), Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA.	risberg@opal.tufts.edu						AltMorbe J, 1996, J BACTERIOL, V178, P4248, DOI 10.1128/jb.178.14.4248-4257.1996; ANDREWS HL, IN PRESS INFECT IMMU; BACHMAN BJ, 1987, SALMONELLA TYPHIMURI, P1190; BELJERSBERGEN A, 1992, SCIENCE, V256, P1324; BERGER KH, 1994, MOL MICROBIOL, V14, P809, DOI 10.1111/j.1365-2958.1994.tb01317.x; BERGER KH, 1993, MOL MICROBIOL, V7, P7, DOI 10.1111/j.1365-2958.1993.tb01092.x; BRAND BC, 1994, MOL MICROBIOL, V14, P797, DOI 10.1111/j.1365-2958.1994.tb01316.x; BUCHANANWOLLASTON V, 1987, NATURE, V328, P172, DOI 10.1038/328172a0; CATRENICH CE, 1989, INFECT IMMUN, V57, P1862, DOI 10.1128/IAI.57.6.1862-1864.1989; Christie PJ, 1997, J BACTERIOL, V179, P3085, DOI 10.1128/jb.179.10.3085-3094.1997; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; FREIBERG C, 1997, NATURE, V387, P3954; FREY J, 1992, GENE, V113, P101, DOI 10.1016/0378-1119(92)90675-F; Fullner KJ, 1996, SCIENCE, V273, P1107, DOI 10.1126/science.273.5278.1107; Furuya N, 1996, J BACTERIOL, V178, P1491, DOI 10.1128/jb.178.6.1491-1497.1996; HORWITZ MA, 1983, J EXP MED, V158, P1319, DOI 10.1084/jem.158.4.1319; HORWITZ MA, 1984, J CELL BIOL, V99, P1936, DOI 10.1083/jcb.99.6.1936; ISHIGURO N, 1985, J BACTERIOL, V164, P977, DOI 10.1128/JB.164.3.977-982.1985; Joiner KA, 1997, J CLIN INVEST, V99, P1814, DOI 10.1172/JCI119347; KELLEHER JE, 1991, J BACTERIOL, V173, P5220, DOI 10.1128/jb.173.16.5220-5223.1991; KULDAU GA, 1990, MOL GEN GENET, V221, P256, DOI 10.1007/BF00261729; Lee CA, 1996, INFECT AGENT DIS, V5, P1; LESSL M, 1992, J BIOL CHEM, V267, P20471; Mecsas J, 1996, EMERG INFECT DIS, V2, P271, DOI 10.3201/eid0204.960403; PEARLMAN E, 1988, MICROB PATHOG, V63, P4928; POHLMAN RF, 1994, MOL MICROBIOL, V14, P655, DOI 10.1111/j.1365-2958.1994.tb01304.x; PORTILLO FG, 1995, TRENDS MICROBIOL, V3, P373; ROGOWSKY PM, 1990, PLASMID, V23, P85, DOI 10.1016/0147-619X(90)90028-B; ROY C, UNPUB; Roy CR, 1997, INFECT IMMUN, V65, P571, DOI 10.1128/IAI.65.2.571-578.1997; SALMOND GPC, 1994, ANNU REV PHYTOPATHOL, V32, P181, DOI 10.1146/annurev.py.32.090194.001145; SASATSU M, 1985, J BACTERIOL, V164, P983, DOI 10.1128/JB.164.3.983-993.1985; SCHOLZ P, 1989, GENE, V75, P271, DOI 10.1016/0378-1119(89)90273-4; Segal G, 1997, INFECT IMMUN, V65, P5057, DOI 10.1128/IAI.65.12.5057-5066.1997; Swanson MS, 1996, INFECT IMMUN, V64, P2585, DOI 10.1128/IAI.64.7.2585-2594.1996; Vogel JP, 1996, ANN NY ACAD SCI, V797, P271, DOI 10.1111/j.1749-6632.1996.tb52975.x; WEISS AA, 1993, P NATL ACAD SCI USA, V90, P2970, DOI 10.1073/pnas.90.7.2970; Winans SC, 1996, TRENDS MICROBIOL, V4, P64, DOI 10.1016/0966-842X(96)81513-7	38	576	598	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					873	876		10.1126/science.279.5352.873	http://dx.doi.org/10.1126/science.279.5352.873			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452389				2022-12-28	WOS:000071923500047
J	Saeed, SR				Saeed, SR			Fortnightly review - Diagnosis and treatment of Meniere's disease	BRITISH MEDICAL JOURNAL			English	Review							ENDOLYMPHATIC SAC; EQUILIBRIUM GUIDELINES; HEARING; LABYRINTHECTOMY; COMMITTEE; SURGERY		Univ Manchester, Manchester Royal Infirm, Dept Otolaryngol Head & Neck Surg, Manchester M13 9WL, Lancs, England	University of Manchester	Saeed, SR (corresponding author), Univ Manchester, Manchester Royal Infirm, Dept Otolaryngol Head & Neck Surg, Manchester M13 9WL, Lancs, England.			Saeed, Shakeel/0000-0002-2316-5655				BACHOR E, 1995, ORL J OTO-RHINO-LARY, V57, P129, DOI 10.1159/000276725; Brookes GB, 1996, CLIN OTOLARYNGOL, V21, P3, DOI 10.1111/j.1365-2273.1996.tb01016.x; CALENOFF E, 1995, ARCH OTOLARYNGOL, V121, P861; Derebery MJ, 1996, OTOLARYNG HEAD NECK, V114, P360, DOI 10.1016/S0194-5998(96)70204-8; DORNHOFFER JL, 1993, LARYNGOSCOPE, V103, P1027; Hallpike CS., 1938, J LARYNGOL OTOL, V53, P625, DOI [10.1017/S0022215100003947, DOI 10.1017/S0022215100003947]; Hawke M., 1987, DIS EAR CLIN PATHOLO, p2.21; HELLSTROM S, 1994, OTOLARYNG CLIN N AM, V27, P307; KNIGHT LC, 1995, LARYNGOSCOPE, V105, P635; Magnan J, 1995, Rev Laryngol Otol Rhinol (Bord), V116, P115; Meniere P., 1861, GAZ MED PARIS, V16, P597; MOFFAT DA, 1992, OTOLARYNG HEAD NECK, V107, P370, DOI 10.1177/019459989210700304; MOFFAT DA, 1994, CLIN OTOLARYNGOL, V19, P261, DOI 10.1111/j.1365-2273.1994.tb01228.x; MOFFAT DA, 1997, SCOTTBROWNS OTOLARYN; MORRISON AW, 1995, J LARYNGOL OTOL, V109, P499, DOI 10.1017/S0022215100130567; MORRISON AW, 1981, J ROY SOC MED, V74, P183, DOI 10.1177/014107688107400304; NEDZELSKI JM, 1992, AM J OTOL, V13, P18; PARKER W, 1995, ARCH OTOLARYNGOL, V121, P377; PEARSON BW, 1985, OTOLARYNG HEAD NECK, V93, P579, DOI 10.1177/019459988509300501; PORTMANN G, 1927, ARCH OTOLARYNGOL, V83, P316; RUCKENSTEIN MJ, 1991, LARYNGOSCOPE, V101, P211; SAEED SR, 1994, BRIT J HOSP MED, V51, P603; SANTOS PM, 1993, OTOLARYNG HEAD NECK, V109, P680, DOI 10.1177/019459989310900408; SILVERSTEIN H, 1989, OTOLARYNG HEAD NECK, V100, P6, DOI 10.1177/019459988910000102; STEPHENS SDG, 1975, J LARYNGOL OTOL, V89, P479, DOI 10.1017/S0022215100080646; WELLING DB, 1994, AM J OTOL, V15, P639; Yamamoto E, 1993, Acta Otolaryngol Suppl, V504, P46; ZENNER HP, 1994, EUR ARCH OTO-RHINO-L, V251, P143	28	24	24	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 31	1998	316	7128					368	372		10.1136/bmj.316.7128.368	http://dx.doi.org/10.1136/bmj.316.7128.368			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487176	Green Published			2022-12-28	WOS:000071863900033
J	Adar, R				Adar, R			Compensatory hyperhidrosis after thoracic sympathectomy	LANCET			English	Editorial Material							UPPER DORSAL SYMPATHECTOMY; CHAIN		Tel Aviv Univ, Sackler Fac Med, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Dept Surg, IL-52621 Tel Hashomer, Israel	Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center	Adar, R (corresponding author), Tel Aviv Univ, Sackler Fac Med, IL-52621 Tel Hashomer, Israel.							ADAMS DCR, 1992, EUR J VASCULAR SURG, V6, P558, DOI 10.1016/S0950-821X(05)80633-4; ADAR R, 1979, J NEUROSURG, V51, P424; ADAR R, 1994, EUR J SURG S, V572, P9; Andrews BT, 1997, BRIT J SURG, V84, P1702, DOI 10.1046/j.1365-2168.1997.02821.x; CLAES G, 1993, SCAND J PLAST RECONS, V27, P29, DOI 10.3109/02844319309080288; DROTT C, 1993, ARCH SURG-CHICAGO, V128, P237; PAPA MZ, 1986, ANN SURG, V204, P715, DOI 10.1097/00000658-198612000-00016; SHIH CJ, 1979, J NEUROSURG, V50, P88, DOI 10.3171/jns.1979.50.1.0088	8	22	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 24	1998	351	9098					231	232		10.1016/S0140-6736(05)78277-5	http://dx.doi.org/10.1016/S0140-6736(05)78277-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU294	9457090				2022-12-28	WOS:000071702200006
J	De Cock, KM; Johnson, AM				De Cock, KM; Johnson, AM			From exceptionalism to normalisation: A reappraisal of attitudes and practice around HIV testing	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFECTION; TRANSMISSION; THERAPY; VIRUS; POLICY; PLASMA; LONDON		UCL, Sch Med, Dept Sexually Transmitted Dis, London WC1E 6AU, England; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of London; University College London; UCL Medical School; University of London; London School of Hygiene & Tropical Medicine	Johnson, AM (corresponding author), UCL, Sch Med, Dept Sexually Transmitted Dis, London WC1E 6AU, England.	Ajohnson@gum.ucl.ac.uk		Johnson, Anne/0000-0003-1330-7100				Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; [Anonymous], 1994, MMWR Recomm Rep, V43, P1; BAYER R, 1991, NEW ENGL J MED, V324, P1500, DOI 10.1056/NEJM199105233242111; Beiser C, 1997, BRIT MED J, V314, P579, DOI 10.1136/bmj.314.7080.579; Berridge V., 1996, AIDS UK MAKING POLIC; BIRTWHISTLE K, 1996, HLTH TRENDS, V28, P60; BLANCHE S, 1997, 4 C RETR OPP INF WAS, pA380; BOR R, 1994, AIDS, V8, P697, DOI 10.1097/00002030-199405000-00019; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P861; Cohn JA, 1997, BRIT MED J, V314, P487, DOI 10.1136/bmj.314.7079.487; *COMM DIS SURV CTR, 1997, CDR, V7, P381; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DeCock KM, 1997, BRIT MED J, V314, P1747, DOI 10.1136/bmj.314.7096.1747; *DEP HLTH, 1994, GUID OFF VOL NAM HIV; DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601; Fiscus Susan A., 1996, JAMA (Journal of the American Medical Association), V275, P1483, DOI 10.1001/jama.275.19.1483; Gazzard BG, 1997, LANCET, V349, P1086, DOI 10.1016/S0140-6736(96)12073-0; Gibb DM, 1997, AIDS, V11, pF53, DOI 10.1097/00002030-199707000-00001; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; JANSSEN RS, 1992, NEW ENGL J MED, V327, P445, DOI 10.1056/NEJM199208133270701; LOES SK, 1995, NEW ENGL J MED, V333, P408; MacDonagh SE, 1996, BRIT MED J, V313, P532; MEADOWS J, 1990, AIDS Care, V2, P229, DOI 10.1080/09540129008257735; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Merson MH, 1997, LANCET, V349, P352, DOI 10.1016/S0140-6736(96)08260-8; MILLER D, 1986, BRIT MED J, V292, P941, DOI 10.1136/bmj.292.6525.941; Miller R, 1996, BRIT MED J, V313, P130, DOI 10.1136/bmj.313.7050.130; OAKLEY A, 1995, AIDS, V9, P479, DOI 10.1097/00002030-199509050-00010; Schilts Randy, 1987, BAND PLAYED POLITICS; SCHOPPER D, 1996, AIDS, V13, P1455; Stephenson JM, 1996, AIDS, V10, P1683, DOI 10.1097/00002030-199612000-00013; TEMMERMAN M, 1995, LANCET, V345, P1506; *UNL AN HIV SER MO, 1996, REP UNL AN SURV STEE; WACHTER RM, 1992, NEW ENGL J MED, V326, P128, DOI 10.1056/NEJM199201093260209; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; ZENILMAN JM, 1992, JAMA-J AM MED ASSOC, V267, P843, DOI 10.1001/jama.267.6.843	39	95	96	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 24	1998	316	7127					290	293		10.1136/bmj.316.7127.290	http://dx.doi.org/10.1136/bmj.316.7127.290			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472517	Green Published			2022-12-28	WOS:000071702100033
J	Granier, S; Owen, P; Pill, R; Jacobson, L				Granier, S; Owen, P; Pill, R; Jacobson, L			Recognising meningococcal disease in primary care: Qualitative study of how general practitioners process clinical and contextual information	BRITISH MEDICAL JOURNAL			English	Article							MENINGITIS; INFECTIONS; PENICILLIN; DIAGNOSIS; FEATURES; CHILDREN	Objectives: To describe the presentation of meningococcal disease in primary care; to explore how general practitioners process clinical and contextual information in children with meningococcal disease; and to describe ho rv this information affects management. Design: Qualitative analysis of semistructured interviews. Setting: General practices in South Glamorgan. Subjects: 26 general practitioners who between January 1994 and December 1996 admitted 31 children (under 16 years of age) in whom meningococcal disease was diagnosed. Main outcome measures: Categories of clinical rules and techniques used by general practitioners in processing each case. Results: 22 children had rashes; in 16 of them the rashes were non-blanching. When present, a haemorrhagic rash was the most important factor in the doctor's decision to admit a child. 22 children had clinical features not normally expected in children with acute self limiting illnesses-for example, lethargy poor eye contact, altered mental states, pallor with a high temperature, and an abnormal cry. Contextual information such as knowledge of parents' consultation patterns and their normal degree of anxiety, played an important part in the management decisions in 15 cases. Use of penicillin was associated with the certainty of diagnosis and the presence and type of haemorrhagic rash. Conclusion: The key clinical feature of meningococcal disease-a haemorrhagic rash-was present ill only half of the study children. The general practitioners specifically hunted for the rash in some ill children, but doctors should not be deterred from diagnosing meningococcal disease and starting antibiotic treatment if the child is otherwise well, if the rash has an unusual or scanty distribution, or if the rash is non-haemorrhagic.	Univ London Kings Coll, Sch Med & Dent, Dept Gen Practice & Primary Care, London SE5 9PJ, England; Llanedeyrn Hlth Ctr, Cardiff CF3 7PN, S Glam, Wales; Univ Wales Coll Med, Dept Gen Practice, Cardiff CF3 7PN, S Glam, Wales	University of London; King's College London; Cardiff University	Granier, S (corresponding author), Univ London Kings Coll, Sch Med & Dent, Dept Gen Practice & Primary Care, London SE5 9PJ, England.							CARTWRIGHT K, 1992, BRIT MED J, V305, P774, DOI 10.1136/bmj.305.6856.774; CARTWRIGHT K, 1992, BMJ-BRIT MED J, V305, P143, DOI 10.1136/bmj.305.6846.143; CARTWRIGHT K, 1992, BRIT MED J, V304, P115; *DEP HLTH SOC SEC, 1988, CMO882 DEP HLTH SOC; DONALD PR, 1980, S AFR MED J, V60, P271; KILPI T, 1991, LANCET, V338, P406, DOI 10.1016/0140-6736(91)91032-P; Koorevaar R, 1995, EUR J GEN PRACT, V1, P21; MARZOUK O, 1991, ARCH DIS CHILD, V66, P486; MCAVOY B, 1989, BRIT MED J, V313, P732; Nielsen B, 1988, Scand J Prim Health Care, V6, P229, DOI 10.3109/02813438809009322; OLCEN P, 1979, SCAND J INFECT DIS, V11, P111, DOI 10.3109/inf.1979.11.issue-2.03; PALMER SR, 1992, J INFECTION, V25, P321, DOI 10.1016/0163-4453(92)91699-C; Riordan FAI, 1996, BRIT MED J, V313, P1255, DOI 10.1136/bmj.313.7067.1255; SORENSEN HT, 1992, BRIT MED J, V305, P774, DOI 10.1136/bmj.305.6856.774-a; STRANG JR, 1992, BRIT MED J, V305, P141, DOI 10.1136/bmj.305.6846.141; VOSS L, 1989, NEW ZEAL MED J, V102, P243; WONG VK, 1989, PEDIATR INFECT DIS J, V8, P224; Woodward C M, 1995, Commun Dis Rep CDR Rev, V5, pR135	18	45	45	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					276	279		10.1136/bmj.316.7127.276	http://dx.doi.org/10.1136/bmj.316.7127.276			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472513	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000071702100027
J	Hood, S; Birnie, D; Swan, L; Hillis, WS				Hood, S; Birnie, D; Swan, L; Hillis, WS			Questionnaire survey of thrombolytic treatment in accident and emergency departments in United Kingdom	BRITISH MEDICAL JOURNAL			English	Article									Victoria Infirm, Dept Cardiol, Glasgow G42 9TY, Lanark, Scotland; Dumfries & Galloway Royal Infirm, Dept Med, Dumfries DG1 4AL, Scotland; Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Hood, S (corresponding author), Royal Infirm, Dept Med Cardiol, Glasgow G31 2ER, Lanark, Scotland.		Hood, Sean David/H-5058-2014	Hood, Sean David/0000-0003-2852-7923				APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BIRKHEAD JS, 1992, BMJ-BRIT MED J, V305, P445, DOI 10.1136/bmj.305.6851.445; *CMA MED DAT, 1997, UK DIR EM SPEC CAR U; Hood S, 1996, Health Bull (Edinb), V54, P131	4	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					274	274		10.1136/bmj.316.7127.274	http://dx.doi.org/10.1136/bmj.316.7127.274			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472511	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000071702100025
J	Nicoll, A; McGarrigle, C; Brady, AR; Ades, AE; Tookey, P; Duong, T; Mortimer, J; Cliffe, S; Goldberg, D; Tappin, D; Hudson, C; Peckham, C				Nicoll, A; McGarrigle, C; Brady, AR; Ades, AE; Tookey, P; Duong, T; Mortimer, J; Cliffe, S; Goldberg, D; Tappin, D; Hudson, C; Peckham, C			Epidemiology and detection of HIV-1 among pregnant women in the United Kingdom: results from national surveillance 1988-96	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; INFECTION; TRANSMISSION; TYPE-1	Objective: To describe the epidemiology of HIV-1 infection in pregnant women in the United Kingdom. Design: Serial unlinked serosurveillance for HIV-1 in neonatal specimens and surveillance through registers of diagnosed maternal and paediatric infections from reporting by obstetricians, paediatricians, and microbiologists. Setting: United Kingdom, 1988-96. Subjects: Pregnant women proceeding to live births and their children Main outcome measures: Time trends in prevalence of HIV-1 seropositivity in newborn infants (as a proxy for infection in mothers); the proportions of mothers with diagnosed HIV-1 infections, and their characteristics. Results: HIV-1 prevalence among mothers in London rose sixfold between 1988 and 1996 (0.19% of women tested; 1 in 520 in 1996). Apart from in Edinburgh and Dundee, levels remained low in Scotland (0.025%; 1 in 3970) and elsewhere in the United Kingdom (0.016%; 1 in 1930). Over a third of births to infected mothers in 1996 occurred outside London. In London the reported infections were predominantly among black African women, whereas in Scotland most were associated with drug injecting. The contribution of reported infection among African women increased over time as that of drug injecting declined. In Scotland 51% of mothers' infections were diagnosed before the birth. In England, despite a national policy initiative in 1992 to increase the antenatal detection rate of HIV, no improvement in detection was observed, and in 1996 only 15% of previously unrecognised HN infections were diagnosed during pregnancy. Conclusions: HIV-1 infection affects mothers throughout the United Kingdom but is most common in London. Levels of diagnosis in pregnant women have not improved. Surveillance data can monitor effectively the impact of initiatives to reduce preventable HIV-1 infections in children.	Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, AIDS & Sexually Transmitted Dis Ctr, London NW9 5EQ, England; Inst Child Hlth, Dept Biostat & Epidemiol, London WC1N 1EH, England; Ruchill Hosp, Scottish Ctr Infect & Environm Hlth, Glasgow G20 9NB, Lanark, Scotland; St Bartholomews Hosp, Dept Obstet & Gynaecol, London EC1A 7BF, England; Royal Hosp Sick Children, Dept Child Hlth, Glasgow G3 8SJ, Lanark, Scotland	Public Health England; University of London; University College London; University of London; Queen Mary University London; University of Glasgow	Nicoll, A (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, AIDS & Sexually Transmitted Dis Ctr, London NW9 5EQ, England.	anicoll@phls.co.uk	Tookey, Pat A/G-2732-2010; McGarrigle, Christine/J-8331-2017	Tookey, Pat A/0000-0001-6258-0387; McGarrigle, Christine/0000-0001-5814-5673; Brady, Tony/0000-0003-4751-7616				ADES AE, 1993, BRIT MED J, V306, P1296, DOI 10.1136/bmj.306.6888.1296; ADES AE, 1992, AIDS, V6, P1031, DOI 10.1097/00002030-199209000-00018; ADES AE, 1995, J ACQ IMMUN DEF SYND, V9, P490; ADES AE, 1991, LANCET, V337, P1562, DOI 10.1016/0140-6736(91)93260-G; [Anonymous], 1994, MMWR Recomm Rep, V43, P1; Boisson E, 1996, J ACQ IMMUN DEF SYND, V13, P434, DOI 10.1097/00042560-199612150-00006; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; *DEP HLTH, 1994, GUID OFF VOL NAM HIV; *DEP HLTH, 1992, OFF VOL NAM HIV ANT; Dunn D T, 1995, J Med Screen, V2, P35; *EUR CTR EP MON AI, 1996, HIV AIDS SURV EUR 19, P7; Gibb DM, 1997, AIDS, V11, pF53, DOI 10.1097/00002030-199707000-00001; GIBB DM, 1996, COM DIS REP CDR REV, V5, pR123; GIBB DM, 1998, BMJ, V316; Holland F J, 1994, J Med Screen, V1, P176; JONES S, 1998, BMJ, V316; Lalvani A, 1996, LANCET, V347, P1349, DOI 10.1016/S0140-6736(96)91007-7; MacDonagh SE, 1996, BRIT MED J, V313, P532; MAYAUX MJ, IN PRESS J PEDIAT; MERCEY D, 1997, BRIT J OBSTET GYNAEC, V103, P1129; MILLER R, 1997, DIPLOMATE, V4, P26; Noone A, 1997, BRIT MED J, V314, P1429, DOI 10.1136/bmj.314.7092.1429; PAPPAIOANOU M, 1993, AIDS, V7, P483, DOI 10.1097/00002030-199304000-00005; *PUBL HLTH LAB SER, 1991, COM DIS REP CDR REV, V1, pR51; *PUBL HLTH LAB SER, 1995, UNPUB; ROGERS MF, 1995, MMWR-MORBID MORTAL W, V44, P1; *SCOTT CTR INF ENV, 1995, ANSWER AIDS NEWS S, pI104; *SCOTT OFF NAT HLT, 1995, OFF VOL NAM HIV ANT; Stephenson JM, 1996, AIDS, V10, P1683, DOI 10.1097/00002030-199612000-00013; Stimson GV, 1996, AIDS, V10, P657, DOI 10.1097/00002030-199606000-00012; TAPPIN DM, 1991, LANCET, V337, P1565; *UK DEP HLTH, 1995, HIV AIDS HLTH PROM E; *UNL ANN HIV SURV, 1997, UNL AN HIV PREV MON; *US DEP HHS, 1997, MMWR-MORBID MORTAL W, V46, P1086; VANHUIS M, 1997, C WOM CHILDR HIV AID; Wiznia AA, 1996, JAMA-J AM MED ASSOC, V275, P1504, DOI 10.1001/jama.275.19.1504	36	66	69	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					253	258		10.1136/bmj.316.7127.253	http://dx.doi.org/10.1136/bmj.316.7127.253			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472504	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000071702100017
J	Race, EM; Adelson-Mitty, J; Kriegel, GR; Barlam, TF; Reimann, KA; Letvin, NL; Japour, AJ				Race, EM; Adelson-Mitty, J; Kriegel, GR; Barlam, TF; Reimann, KA; Letvin, NL; Japour, AJ			Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease	LANCET			English	Article							IMMUNODEFICIENCY VIRUS PROTEASE; AVIUM COMPLEX INFECTION; VIRAL INFECTIVITY; RITONAVIR; MATURATION; ZIDOVUDINE; AIDS	Background Inhibitors of HIV-1 protease produce a rapid decrease in plasma HIV-1 RNA, with concomitant increases in CD4 T-helper lymphocyte counts, The main side-effects of the protease inhibitors currently in use include gastrointestinal disturbances, paraesthesias, hyperbilirubinaemia, and nephrolithiasis. The increasing use of these agents in patients with advanced HIV-1 infection and CD4 counts of less than 50 cells/mu L may be associated with unforeseen adverse effects not observed in earlier studies of patients with higher CD4 counts, Methods Five HIV-infected patients with baseline CD4 lymphocyte counts of less than 50 cells/mL were admitted to the Beth Israel Deaconess Medical Center (Boston. MA; USA) with high fever (>39 degrees C), leucocytosis, and evidence of lymph-node enlargement within 1-3 weeks of starting indinavir therapy. Informed consent was obtained for studies that entailed CD4 lymphocyte counts, immunophenotyping, isolator radiological scans, Biopsy paratracheal, or mesenteric lymph nodes were taken for culture and pathology in four patients. Findings Lymph-node biopsy samples showed that focal lymphadenitis after initiation of indinavir resulted from unsuspected local or disseminated Mycobacterium avium complex (MAC) infection, The prominent inflammatory response to previously subclinical MAC infection was associated with leucocytosis in ail patients and with an Tr, the absolute lymphocyte counts in four Three patients with follow-up CD4 counts showed two-fold to 19-fold increases after 1-3 weeks of indinavir therapy. immunophenotyping after therapy in two patients showed that more than 90% of the CD4 cells were of the memory phenotype. Interpretation The initiation of indinavir therapy in patients with CD4 counts of less than 50 cells/mL and subclinical MAC infection may be associated with a severe illness, (>39 degrees C), leucocytosis, and thoracic, or abdominal), The intense inflammatory reactions that make admission to necessary may be secondary to significant of functionally competent immune cells becoming available to respond to a heavy mycobacterial burden, Prophylaxis or screening for subclinical MAC infection, or both, should therefore be done before the beginning of protease-inhibitor therapy in patients with advanced HIV infection.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Infect Dis, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Japour, AJ (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Infect Dis, Dana 617,E Campus,330 Brookline Ave, Boston, MA 02215 USA.			Barlam, Tamar/0000-0002-0511-7641				CADEO GP, 1990, INT C AIDS, V6, P249; CHAISSON RE, 1992, AM REV RESPIR DIS, V146, P285, DOI 10.1164/ajrccm/146.2.285; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; COPELAND TD, 1988, GENE ANAL TECH, V5, P109, DOI 10.1016/0735-0651(88)90010-6; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; DEBOUCK C, 1987, P NATL ACAD SCI USA, V84, P8903, DOI 10.1073/pnas.84.24.8903; FLEGG PJ, 1995, QJM-MON J ASSOC PHYS, V88, P617; GILQUIN J, 1997, 4 C RETR OPP INF WAS, P129; HAVLIK JA, 1992, J INFECT DIS, V165, P577, DOI 10.1093/infdis/165.3.577; HELLEN CUT, 1989, BIOCHEMISTRY-US, V28, P9881, DOI 10.1021/bi00452a001; JACOBSON MA, 1997, 4 C RETR OPP INF WAS, P129; JACOMET C, 1993, INT C AIDS, V9, P328; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; KLATT EC, 1987, HUM PATHOL, V18, P709, DOI 10.1016/S0046-8177(87)80242-3; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; LEDERMAN M, 1997, 4 C RETR OPP INF WAS, P208; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; Massari F., 1996, P90; MASSARI F, 1995, 35 INT C ANT AG CHEM, P9; MICHELET C, 1997, 4 C RETR OPP INF, P122; NIGHTINGALE SD, 1992, J INFECT DIS, V165, P1082, DOI 10.1093/infdis/165.6.1082; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; PENG C, 1989, J VIROL, V63, P2550, DOI 10.1128/JVI.63.6.2550-2556.1989; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; ROEDERER M, 1995, J CLIN INVEST, V95, P2061, DOI 10.1172/JCI117892; ROSE JR, 1994, AM J RESP CRIT CARE, V150, pS176, DOI 10.1164/ajrccm/150.6_Pt_2.S176; Steigbigel Roy T., 1996, P80; Stein Daniel S., 1996, P80; TOMASSELLI AG, 1990, J BIOL CHEM, V265, P14675; WALLACE JM, 1988, CHEST, V93, P926, DOI 10.1378/chest.93.5.926	30	293	301	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 24	1998	351	9098					252	255		10.1016/S0140-6736(97)04352-3	http://dx.doi.org/10.1016/S0140-6736(97)04352-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU294	9457095				2022-12-28	WOS:000071702200011
J	Rosenstein, BJ; Zeitlin, PL				Rosenstein, BJ; Zeitlin, PL			Cystic fibrosis	LANCET			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; NASAL POTENTIAL DIFFERENCE; MILD LUNG-DISEASE; GENE-TRANSFER; VAS-DEFERENS; PULMONARY INFLAMMATION; PANCREATIC FUNCTION; CONGENITAL ABSENCE; FETAL HEMOGLOBIN; BETA-THALASSEMIA		Johns Hopkins Univ, Sch Med, Baltimore, MD USA	Johns Hopkins University	Rosenstein, BJ (corresponding author), Johns Hopkins Univ Hosp, Park 316, Baltimore, MD 21287 USA.	brosenst@welchlink.welch.jhu.edu		Zeitlin, Pamela/0000-0002-2719-1834				ALTON EWFW, 1990, EUR RESPIR J, V3, P922; Aris RM, 1997, AM J RESP CRIT CARE, V155, P1699, DOI 10.1164/ajrccm.155.5.9154879; BalfourLynn IM, 1997, ARCH DIS CHILD, V76, P38, DOI 10.1136/adc.76.1.38; Bellon G, 1997, HUM GENE THER, V8, P15, DOI 10.1089/hum.1997.8.1-15; BOUCHER RC, 1994, HUM GENE THER, V5, P615, DOI 10.1089/hum.1994.5.5-615; Brown CR, 1997, J CLIN INVEST, V99, P1432, DOI 10.1172/JCI119302; BURKE W, 1992, CHEST, V102, P506, DOI 10.1378/chest.102.2.506; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1995, AM J PHYSIOL-LUNG C, V268, pL615, DOI 10.1152/ajplung.1995.268.4.L615; CHILLON M, 1995, NEW ENGL J MED, V332, P1475, DOI 10.1056/NEJM199506013322204; Colin AA, 1996, CHEST, V110, P440, DOI 10.1378/chest.110.2.440; COLLEDGE WH, 1994, CURR OPIN GENET DEV, V4, P466, DOI 10.1016/0959-437X(94)90037-X; COLLINS AF, 1995, BLOOD, V85, P43, DOI 10.1182/blood.V85.1.43.bloodjournal85143; COREY M, 1989, J PEDIATR-US, V115, P274, DOI 10.1016/S0022-3476(89)80082-4; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DOVER GJ, 1992, NEW ENGL J MED, V327, P569; Dreyfus DH, 1996, AM J RESP CRIT CARE, V153, P858, DOI 10.1164/ajrccm.153.2.8564145; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; DURIEU I, 1995, MEDICINE, V74, P42, DOI 10.1097/00005792-199501000-00004; EGAN ME, 1995, AM J PHYSIOL-CELL PH, V268, pC243, DOI 10.1152/ajpcell.1995.268.1.C243; FIBACH E, 1993, BLOOD, V82, P2203, DOI 10.1182/blood.V82.7.2203.bloodjournal8272203; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; FitzSimmons SC, 1997, NEW ENGL J MED, V336, P1283, DOI 10.1056/NEJM199705013361803; Frederiksen B, 1997, PEDIATR PULM, V23, P330, DOI 10.1002/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; GAN KH, 1995, NEW ENGL J MED, V333, P95, DOI 10.1056/NEJM199507133330204; GAN KH, 1995, THORAX, V50, P1301, DOI 10.1136/thx.50.12.1301; GILBERT F, 1995, AM J MED GENET, V58, P356, DOI 10.1002/ajmg.1320580411; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; GUAYBRODER C, 1995, BIOCHEMISTRY-US, V34, P9079, DOI 10.1021/bi00028a017; HAMOSH A, 1993, NEW ENGL J MED, V329, P1308; HAMOSH A, 1992, HUM MOL GENET, V1, P542, DOI 10.1093/hmg/1.7.542; Hofmann T, 1997, AM J RESP CRIT CARE, V155, P1908; Howard M, 1996, NAT MED, V2, P467, DOI 10.1038/nm0496-467; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; ILLEK B, 1995, AM J PHYSIOL-CELL PH, V268, pC886, DOI 10.1152/ajpcell.1995.268.4.C886; JOHNSON LG, 1992, NAT GENET, V2, P21, DOI 10.1038/ng0992-21; Kant JA, 1995, CLIN LAB MED, V15, P877, DOI 10.1016/S0272-2712(18)30305-6; Kelley TJ, 1997, P NATL ACAD SCI USA, V94, P2604, DOI 10.1073/pnas.94.6.2604; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Kerem E, 1997, AM J RESP CRIT CARE, V155, P1914, DOI 10.1164/ajrccm.155.6.9196095; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; KNOWLES MR, 1995, HUM GENE THER, V6, P445, DOI 10.1089/hum.1995.6.4-445; Knowles MR, 1997, J CLIN INVEST, V100, P2588, DOI 10.1172/JCI119802; Ko YH, 1997, FEBS LETT, V405, P200, DOI 10.1016/S0014-5793(97)00189-0; KONSTAN MW, 1995, NEW ENGL J MED, V332, P848, DOI 10.1056/NEJM199503303321303; KONSTAN MW, 1994, AM J RESP CRIT CARE, V150, P448, DOI 10.1164/ajrccm.150.2.8049828; KOTLOFF RM, 1992, CLIN CHEST MED, V13, P623; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; KUBESCH P, 1993, LANCET, V341, P189, DOI 10.1016/0140-6736(93)90062-L; Kunzelmann K, 1997, FEBS LETT, V400, P341, DOI 10.1016/S0014-5793(96)01414-7; LeGrys VA, 1996, J PEDIATR-US, V129, P892, DOI 10.1016/S0022-3476(96)70034-3; LESTER LA, 1994, PEDIATRICS, V93, P114; MOHON RT, 1993, J PEDIATR-US, V122, P550, DOI 10.1016/S0022-3476(05)83534-6; *NAT I HLTH WORKSH, 1990, NEW ENGL J MED, V323, P70; NEGLIA JP, 1995, NEW ENGL J MED, V332, P494, DOI 10.1056/NEJM199502233320803; Nikolaizik WH, 1996, J PEDIATR-US, V128, P271, DOI 10.1016/S0022-3476(96)70407-9; Olivier K N, 1996, Semin Respir Infect, V11, P272; PERRINE SP, 1993, NEW ENGL J MED, V328, P81, DOI 10.1056/NEJM199301143280202; RAMSEY BW, 1993, NEW ENGL J MED, V328, P1740, DOI 10.1056/NEJM199306173282403; Rosenfeld M, 1997, AM J EPIDEMIOL, V145, P794; Rosenstein B J, 1995, Curr Opin Pulm Med, V1, P444, DOI 10.1097/00063198-199511000-00003; Rubenstein RC, 1997, J CLIN INVEST, V100, P2457, DOI 10.1172/JCI119788; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Stern RC, 1997, NEW ENGL J MED, V336, P487, DOI 10.1056/NEJM199702133360707; Sweet SC, 1997, AM J RESP CRIT CARE, V155, P1027, DOI 10.1164/ajrccm.155.3.9116982; TABLAN OC, 1987, CHEST, V91, P527, DOI 10.1378/chest.91.4.527; THOMASSEN MJ, 1987, PEDIATR PULM, V3, P334, DOI 10.1002/ppul.1950030510; Thomson MA, 1996, J PEDIATR-US, V129, P367, DOI 10.1016/S0022-3476(96)70068-9; Trulock EP, 1997, AM J RESP CRIT CARE, V155, P789, DOI 10.1164/ajrccm.155.3.9117010; TSUI LC, 1995, AM J RESP CRIT CARE, V151, pS47, DOI 10.1164/ajrccm/151.3_Pt_2.S47; VEEZE HJ, 1994, J CLIN INVEST, V93, P461, DOI 10.1172/JCI116993; Wallis C, 1997, ARCH DIS CHILD, V76, P85, DOI 10.1136/adc.76.2.85; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WEAVER LT, 1994, ARCH DIS CHILD, V70, P84, DOI 10.1136/adc.70.2.84; WELSH MJ, 1993, J CELL SCI, P235; WILCKEN B, 1995, J PEDIATR-US, V127, P965, DOI 10.1016/S0022-3476(95)70040-4; Yang ICH, 1997, AM J PHYSIOL-CELL PH, V272, pC142, DOI 10.1152/ajpcell.1997.272.1.C142; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K; ZEITLIN PL, 1997, GENE THERAPY DIS LUN, P53	82	150	157	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 24	1998	351	9098					277	282		10.1016/S0140-6736(97)09174-5	http://dx.doi.org/10.1016/S0140-6736(97)09174-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU294	9457113	hybrid			2022-12-28	WOS:000071702200043
J	Parston, G; McMahon, L				Parston, G; McMahon, L			A third way? England-yes; Scotland-maybe	BRITISH MEDICAL JOURNAL			English	Article									Off Publ Management, London WC1X 8JT, England		Parston, G (corresponding author), Off Publ Management, London WC1X 8JT, England.								0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					213	213						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468693				2022-12-28	WOS:000071616400039
J	Passmore, SJ; Draper, G; Brownbill, P; Kroll, M				Passmore, SJ; Draper, G; Brownbill, P; Kroll, M			Case-control studies of relation between childhood cancer and neonatal vitamin K administration	BRITISH MEDICAL JOURNAL			English	Article							NEWBORN	Objective: To investigate the possible link between neonatal administration of intramuscular vitamin K and childhood cancer. Design: Matched case-control study. Setting: Selected large maternity units in England and Wales. Subjects: Children with cancer born 1968-85, diagnosed 1969-86; controls matched for sex, month of birth, and hospital of birth. Main exposure measures: Neonatal administration of vitamin K, length of gestation, birth weight type of delivery, admission to special care baby unit. Results: After exclusion of cases with missing notes or unknown hospital vitamin K policy, 597 cases and matched controls were studied. Written records on the use of vitamin K were available for only about 40% of these, and to avoid possible bias from selective recording it tvas assumed that the stated hospital policy was followed. The association between cancer generally and intramuscular vitamin K was of borderline significance (odds ratio 1.44, P = 0.05); the association was strongest for leukaemia. There was, however, also an effect of abnormal delivery, which could explain some of the findings. Conclusions: The lack of consistency between the various studies so far published, including this one, and the low relative risks found in most of them suggest that the risk, if any, attributable to the use of vitamin K cannot be large, but the possibility that there is some risk cannot be excluded. A comparison of the predicted consequences of various policies shows that even a 10% increase would imply that prophylaxis using the commonly recommended 1 mg intramuscular dose should be restricted to babies at particularly high risk of vitamin K deficiency bleeding; alternatively a lower dose might be given to a larger proportion of those at risk.	Childhood Canc Res Grp, Oxford OX2 6HJ, England	University of Oxford	Draper, G (corresponding author), Childhood Canc Res Grp, Oxford OX2 6HJ, England.							Ansell P, 1996, BRIT MED J, V313, P204, DOI 10.1136/bmj.313.7051.204; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; Cornelissen M, 1997, EUR J PEDIATR, V156, P126, DOI 10.1007/s004310050570; EKELUND H, 1993, BRIT MED J, V307, P89, DOI 10.1136/bmj.307.6896.89; FRANCIS B, 1993, GLIM SYSTEM GEN LINE; GOLDING J, 1990, BRIT J CANCER, V62, P304, DOI 10.1038/bjc.1990.283; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; HANDEL J, 1991, BRIT MED J, V303, P1109, DOI 10.1136/bmj.303.6810.1109; KLEBANOFF MA, 1993, NEW ENGL J MED, V329, P905, DOI 10.1056/NEJM199309233291301; McKinney PA, 1998, BRIT MED J, V316, P173, DOI 10.1136/bmj.316.7126.173; OLSEN JH, 1994, BRIT MED J, V308, P895, DOI 10.1136/bmj.308.6933.895; Parker L, 1998, BRIT MED J, V316, P189, DOI 10.1136/bmj.316.7126.189; PASSMORE J, 1998, BRIT MED J, V316, P184; Stiller CA, 1995, EUR J CANCER, V31A, P2028, DOI 10.1016/0959-8049(95)00428-9; vonKries R, 1996, BRIT MED J, V313, P199, DOI 10.1136/bmj.313.7051.199	15	33	34	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					178	184						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468681	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000071616400021
J	Ponsonby, AL; Dwyer, T; Couper, D; Cochrane, J				Ponsonby, AL; Dwyer, T; Couper, D; Cochrane, J			Association between use of a quilt and sudden infant death syndrome: case-control study	BRITISH MEDICAL JOURNAL			English	Article									Univ Tasmania, Menzies Ctr Populat Hlth Res, Hobart, Tas 7001, Australia	University of Tasmania	Ponsonby, AL (corresponding author), Univ Tasmania, Menzies Ctr Populat Hlth Res, GPO Box 252-23, Hobart, Tas 7001, Australia.		Ponsonby, Anne-Louise/AAE-4351-2019	Couper, David/0000-0002-4313-9235; Ponsonby, Anne-Louise/0000-0002-6581-3657				BRESLOW NE, 1980, STATISTICAL METHODS, V1, P196; Fleming PJ, 1996, BMJ-BRIT MED J, V313, P191, DOI 10.1136/bmj.313.7051.191; ILLINGSWORTH RS, 1983, NORMAL CHILD SOME PR, P16; PONSONBY AL, 1993, NEW ENGL J MED, V329, P377, DOI 10.1056/NEJM199308053290601; WILSON CA, 1994, J PAEDIATR CHILD H, V30, P506, DOI 10.1111/j.1440-1754.1994.tb00722.x	5	42	43	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					195	196						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468685				2022-12-28	WOS:000071616400026
J	Engels, EA; Falagas, ME; Lau, J; Bennish, ML				Engels, EA; Falagas, ME; Lau, J; Bennish, ML			Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity	BRITISH MEDICAL JOURNAL			English	Article								Objective: To estimate the efficacy and toxicity of typhoid fever vaccines. Design: Meta-analysis of randomised efficacy trials and both randomised and non-randomised toxicity studies of the parenteral whole cell, oral Ty21a, and parenteral Vi vaccines. Subjects: 1 866 951 subjects in 17 efficacy trials; 11 204 subjects in 20 toxicity studies. Main outcome measures: Pooled estimates of three year cumulative efficacy, year specific efficacy and incidence of adverse events. Results: Three year cumulative efficacy was 73% (95% confidence interval 65% to 80%) for two doses of whole cell vaccines (based on seven trials); 51% (35% to 63%) for three doses of Ty21a vaccine (four trials), and 55% (30% to 71%) for one dose of Vi vaccine (one trial). For whole cell and Ty21a vaccines, regimens of fewer doses were less effective. Efficacy was shown to be significant for five years for whole cell vaccines, four years for Ty21a vaccine, and two years for Vi vaccine. Neither the age of vaccine recipient nor the incidence of typhoid fever in the control group (varying from 6 to 810 cases per 100 000 person years) affected the efficacy of the whole cell or Ty21a vaccines. After vaccination, fever occurred in 15.7% (11.5% to 21.2%) of whole cell vaccine recipients, 2.0% (0.7% to 5.3%) of Ty21a vaccine recipients, and 1.1% (0.1% to 12.3%) of Vi vaccine recipients. Conclusions: Whole cell vaccines are more effective than the Ty21a and Vi vaccines but are more frequently associated with adverse events. Whether the added efficacy of the whole cell vaccines outweighs their toxicity will depend on the setting in which vaccination is used.	Tufts Univ, New England Med Ctr, Sch Med, Dept Med,Div Clin Care Res, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr, Sch Med, Tupper Res Inst,Dept Med,Div Geog Med & Infect Di, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University	Engels, EA (corresponding author), Tufts Univ, New England Med Ctr, Sch Med, Dept Med,Div Clin Care Res, Box 63,750 Washington St, Boston, MA 02111 USA.	eric.engels@es.nem.org			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000060] Funding Source: NIH RePORTER; AHRQ [5T32HS000060-17] Funding Source: Federal RePORTER; AHRQ HHS [T32 HS00060] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BENNISH ML, 1995, INFECT DIS CLIN PRAC, V4, P114, DOI 10.1097/00019048-199503000-00011; *I MED, 1986, NEW VACC DEV EST PRI; Pearson K, 1904, BRIT MED J, V3, P1243; Shadish WR, 1994, HDB RES SYNTHESIS, P262	4	124	133	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 10	1998	316	7125					110	115						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR408	9462316	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000071492300019
J	Kaur, B; Anderson, HR; Austin, J; Burr, M; Harkins, LS; Strachan, DP; Warner, JO				Kaur, B; Anderson, HR; Austin, J; Burr, M; Harkins, LS; Strachan, DP; Warner, JO			Prevalence of asthma symptoms, diagnosis, and treatment in 12-14 year old children across Great Britain (international study of asthma and allergies in childhood, ISAAC UK)	BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY SYMPTOMS; BRONCHIAL HYPERRESPONSIVENESS; ABERDEEN SCHOOLCHILDREN; TRENDS; QUESTIONNAIRE; SEVERITY; ATOPY	Objective: To investigate variations in the prevalence of self reported symptoms, diagnosis, and treatment of asthma in 12-14 year old children. Design: Self completion questionnaire. Setting: Great Britain. Subjects: All pupils aged 12-14 years in a stratified cluster sample of 93 large mixed secondary schools in 1995. Main outcome measures: Self reported prevalence of symptoms, diagnosis, and treatment of asthma at four geographical levels. Results: 27 507 questionnaires were completed (85.9% response rate). The national 12 month prevalence of any wheezing, speech limiting wheeze, four or more attacks of wheeze, and frequent night waking with wheeze was 33.3% (n = 9155), 8.8% (2427), 9.6% (2634), and 3.7% (1023) respectively. The prevalence of ever having had a diagnosis of asthma was 20.9% (5736). In total, 19.8% (5438/27 507) of pupils reported treatment with anti-asthma drugs in the past year, but, of pupils reporting frequent nocturnal wheeze in the past year, 33.8% (342/1012) had no diagnosis of asthma and 38.6% (395/1023) denied receiving inhaler therapy. The 12 month prevalence of wheeze was highest in Scotland (36.7%, 1633/4444), but in England and Wales there was no discernible north-south or east-west gradient. Wheeze prevalence was slightly higher in non-metropolitan ar eas (35.0%, 6155/17 605) than in metropolitan areas (30.3%, 3000/9902). The prevalence of self reported asthma diagnosis and inhaler use showed no discernible national, regional, north-south, or east-west geographical pattern but was higher in non-metropolitan areas. Conclusion: Prevalence of self reported symptoms, diagnosis, and treatment of asthma was high among 12-14 year olds throughout Great Britain with little geographical or urban-rural variation. Underdiagnosis and undertreatment were substantial.	Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; Royal No Infirm, Highland Communities NHS Trust, Dept Child Hlth, Inverness IV3 5SF, Scotland; Temple Peace & Hlth, Ctr Appl Publ Hlth Med, Cardiff CF1 3NW, S Glam, Wales; Southampton Gen Hosp, Southampton SO16 6YD, Hants, England	St Georges University London; University of Southampton	Kaur, B (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England.		Anderson, Hugh R/A-7417-2016; Warner, John/AAF-9587-2020					ANDERSON HR, 1994, BRIT MED J, V308, P1600, DOI 10.1136/bmj.308.6944.1600; ANDERSON HR, 1995, OPCS SER DS, V11, P111; ANDERSON HR, 1994, HLTH CARE NEEDS ASSE, P256; Asher M. I., 1996, European Respiratory Journal Supplement, V9, p410S; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; AUSTIN JB, 1994, ARCH DIS CHILD, V71, P211, DOI 10.1136/adc.71.3.211; BLAND M, 1994, CLINSTAT; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; *CENTR HLTH MON UN, 1995, EP OV SER, V1; *CYT SOFTW CORP, 1991, STATX VERS 2; DuranTauleria E, 1996, BRIT MED J, V313, P148, DOI 10.1136/bmj.313.7050.148; *I EP SOZ U, 1993, ISAAC INT STUD ASTHM, P3; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; LEWIS S, 1996, THORAX, V51, P6706; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; *OFF POP CENS SURV, 1988, SER OHS; Omran M, 1996, BRIT MED J, V312, P34, DOI 10.1136/bmj.312.7022.34; PEARCE N, 1993, EUR RESPIR J, V6, P1455; RONA RJ, 1995, THORAX, V50, P992, DOI 10.1136/thx.50.9.992; *SAS I, 1990, SAS US GUID BAS STAT; SHAW R, 1995, INT J EPIDEMIOL, V24, P597, DOI 10.1093/ije/24.3.597; STRACHAN DP, 1994, ARCH DIS CHILD, V70, P174, DOI 10.1136/adc.70.3.174; STRACHAN DP, 1990, J EPIDEMIOL COMMUN H, V44, P231, DOI 10.1136/jech.44.3.231; WHINCUP PH, 1993, ARCH DIS CHILD, V68, P729, DOI 10.1136/adc.68.6.729	25	199	201	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 10	1998	316	7125					118	124						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR408	9462318				2022-12-28	WOS:000071492300024
J	Hayward, PE; DiazRossello, JL				Hayward, PE; DiazRossello, JL			New evidence for preventive perinatal care	LANCET			English	Article											Hayward, PE (corresponding author), WHO,PAN AMER HLTH ORG,LATIN AMER CTR HUMAN DEV,CASILLA CORREOS 627,MONTEVIDEO,URUGUAY.							CROWLEY PA, 1995, AM J OBSTET GYNECOL, V173, P322, DOI 10.1016/0002-9378(95)90222-8; DIAZROSSELLO J, 1995, PEDIATR RES, V37, pA254; WRIGHT LL, 1995, AM J OBSTET GYNECOL, V173, P263, DOI 10.1016/0002-9378(95)90211-2; 1995, AM J OBSTET GYNECOL, V173, P246; 1995, LANCET, V345, P877	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S17	S17		10.1016/0140-6736(95)90016-0	http://dx.doi.org/10.1016/0140-6736(95)90016-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454034				2022-12-28	WOS:A1995TN12200017
J	Stewart, L; Redinbo, MR; Qiu, XY; Hol, WGJ; Champoux, JJ				Stewart, L; Redinbo, MR; Qiu, XY; Hol, WGJ; Champoux, JJ			A model for the mechanism of human topoisomerase I	SCIENCE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; DNA; SEQUENCE; PROGRAM; ERRORS; MAPS	The three-dimensional structure of a 70-kilodalton amino terminally truncated form of human topoisomerase I in complex with a 22-base pair duplex oligonucleotide, determined to a resolution of 2.8 angstroms, reveals all of the structural elements of the enzyme that contact DNA. The linker region that connects the central core of the enzyme to the carboxyl-terminal domain assumes a coiled-coil configuration and protrudes away from the remainder of the enzyme, The positively charged DNA-proximal surface of the linker makes only a few contacts with the DNA downstream of the cleavage site. In combination with the crystal structures of the reconstituted human topoisomerase before and after DNA cleavage, this information suggests which amino acid residues are involved in catalyzing phosphodiester bond breakage and religation. The structures also lead to the proposal that the topoisomerization step occurs by a mechanism termed "controlled rotation."	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Biomol Struct Ctr, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Champoux, JJ (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA.	emerald_biostructures@rocketmail.com; champoux@u.washington.edu			NCI NIH HHS [CA65656] Funding Source: Medline; NIGMS NIH HHS [GM49156, GM16713] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049156, F32GM016713] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN AH, 1985, NUCLEIC ACIDS RES, V13, P1543, DOI 10.1093/nar/13.5.1543; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; Brunger A.T., 1993, X PLOR VERSION 3 1 S; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CHAMPOUX JJ, IN PRESS PROG NUCL A; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; Jensen AD, 1996, EUR J BIOCHEM, V236, P389, DOI 10.1111/j.1432-1033.1996.00389.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; LEVIN NA, 1993, GENETICS, V133, P799; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; MADDEN KR, 1992, CANCER RES, V52, P525; MCCOUBREY WK, 1986, J BIOL CHEM, V261, P5130; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOORE JM, 1988, BIOCHEMISTRY-US, V27, P7806, DOI 10.1021/bi00420a033; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; Petersen BO, 1997, J BIOL CHEM, V272, P3891, DOI 10.1074/jbc.272.7.3891; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; STEBBINS CE, 1995, NATURE, V373, P636, DOI 10.1038/373636a0; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; Stivers JT, 1997, BIOCHEMISTRY-US, V36, P5212, DOI 10.1021/bi962880t; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; VLASSI M, 1994, NAT STRUCT BIOL, V1, P706, DOI 10.1038/nsb1094-706; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WITTSCHIEBEN J, 1994, J BIOL CHEM, V269, P29978; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001	39	599	619	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 6	1998	279	5356					1534	1541		10.1126/science.279.5356.1534	http://dx.doi.org/10.1126/science.279.5356.1534			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488652				2022-12-28	WOS:000072372900065
J	Rinzel, J; Terman, D; Wang, XJ; Ermentrout, B				Rinzel, J; Terman, D; Wang, XJ; Ermentrout, B			Propagating activity patterns in large-scale inhibitory neuronal networks	SCIENCE			English	Article							SYNCHRONIZED OSCILLATIONS; IONIC MECHANISMS; SPINDLE WAVES; IN-VITRO; MODEL; NUCLEUS; GENERATION; NEOCORTEX; THALAMUS; CIRCUITS	The propagation of activity is studied in a spatially structured network model of gamma-aminobutyric acid-containing (GABAergic) neurons exhibiting postinhibitory rebound. In contrast to excitatory-coupled networks, recruitment spreads very slowly because cells fire only after the postsynaptic conductance decays, and with two possible propagation modes. If the connection strength decreases monotonically with distance (on-center), then propagation occurs in a discontinuous manner. If the self-and nearby connections are absent (off-center), propagation can proceed smoothly. Modest changes in the synaptic reversal potential can result in depolarization-mediated waves that are 25 times faster. Functional and developmental roles for these behaviors and implications for thalamic circuitry are suggested.	NIDDKD, Math Res Branch, NIH, Bethesda, MD 20892 USA; Ohio State Univ, Dept Math, Columbus, OH 43210 USA; Brandeis Univ, Ctr Complex Syst, Waltham, MA 02254 USA; Brandeis Univ, Dept Phys, Waltham, MA 02254 USA; Univ Pittsburgh, Dept Math, Pittsburgh, PA 15260 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University System of Ohio; Ohio State University; Brandeis University; Brandeis University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Rinzel, J (corresponding author), NYU, Ctr Neural Sci, 4 Washington Pl,Room 809, New York, NY 10003 USA.	rinzel@cns.nyu.edu	Wang, Xiao-Jing/D-2722-2009		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH047150] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 47150, MH53717-01] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAL T, 1995, J PHYSIOL-LONDON, V483, P665, DOI 10.1113/jphysiol.1995.sp020613; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; CHERVIN RD, 1988, J NEUROPHYSIOL, V60, P1695, DOI 10.1152/jn.1988.60.5.1695; Destexhe A, 1996, J NEUROPHYSIOL, V76, P2049, DOI 10.1152/jn.1996.76.3.2049; FREUND TF, 1996, HIPPOCAMPUS, V6, P345; Golomb D, 1997, J NEUROPHYSIOL, V78, P1199, DOI 10.1152/jn.1997.78.3.1199; Golomb D, 1996, J NEUROPHYSIOL, V75, P750, DOI 10.1152/jn.1996.75.2.750; KIM U, 1995, J NEUROPHYSIOL, V74, P1301, DOI 10.1152/jn.1995.74.3.1301; Kim U, 1997, SCIENCE, V278, P130, DOI 10.1126/science.278.5335.130; KISVARDAY ZF, 1993, J COMP NEUROL, V327, P398, DOI 10.1002/cne.903270307; LO FS, 1994, EXP BRAIN RES, V100, P365; Marder E, 1996, PHYSIOL REV, V76, P687, DOI 10.1152/physrev.1996.76.3.687; MILES R, 1988, J NEUROPHYSIOL, V60, P1481, DOI 10.1152/jn.1988.60.4.1481; PERKEL DH, 1974, SCIENCE, V185, P181, DOI 10.1126/science.185.4146.181; RINZEL J, UNPUB; Rinzel J., 1989, METHODS NEURONAL MOD, P135; SanchezVives MV, 1997, J NEUROSCI, V17, P8894; SATTERLIE RA, 1985, SCIENCE, V229, P402, DOI 10.1126/science.229.4711.402; Sharp AA, 1996, J NEUROPHYSIOL, V76, P867, DOI 10.1152/jn.1996.76.2.867; Sherman SM, 1996, J NEUROPHYSIOL, V76, P1367, DOI 10.1152/jn.1996.76.3.1367; STALEY KJ, 1995, SCIENCE, V269, P977, DOI 10.1126/science.7638623; STERIADE M, 1984, BRAIN RES REV, V8, P1, DOI 10.1016/0165-0173(84)90017-1; Tamas G, 1997, J NEUROSCI, V17, P6352; TERMAN D, IN PRESS PHYSICA D; THOMSON AM, 1994, TRENDS NEUROSCI, V17, P119, DOI 10.1016/0166-2236(94)90121-X; Ulrich D, 1997, J NEUROPHYSIOL, V78, P1748, DOI 10.1152/jn.1997.78.3.1748; Van Vreeswijk C, 1994, J Comput Neurosci, V1, P313; VONKROSIGK M, 1993, SCIENCE, V261, P361, DOI 10.1126/science.8392750; Wagner S, 1997, NATURE, V387, P598, DOI 10.1038/42468; WANG XJ, 1993, NEUROSCIENCE, V53, P899, DOI 10.1016/0306-4522(93)90474-T; WANG XJ, 1992, NEURAL COMPUT, V4, P84, DOI 10.1162/neco.1992.4.1.84; Wang XJ, 1996, J NEUROSCI, V16, P6402; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0	33	110	113	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	1998	279	5355					1351	1355		10.1126/science.279.5355.1351	http://dx.doi.org/10.1126/science.279.5355.1351			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478895				2022-12-28	WOS:000072251800050
J	Broadus, J; Fuerstenberg, S; Doe, CQ				Broadus, J; Fuerstenberg, S; Doe, CQ			Staufen-dependent localization of prospero mRNA contributes to neuroblast daughter-cell fate	NATURE			English	Article							ASYMMETRIC SEGREGATION; NERVOUS-SYSTEM; MOTHER CELLS; DROSOPHILA; PROTEIN; NEUROGENESIS; GENE; EXPRESSION; CORTEX	The generation of cellular diversity is essential in embryogenesis, especially in the central nervous system, During neurogenesis, cell interactions or asymmetric protein localization during mitosis can generate daughter cells with different fates(1-4). Were we describe the asymmetric localization of a messenger RNA and an RNA-binding protein that creates molecular and developmental differences between Drosophila neural precursors (neuroblasts) and their daughter cells, ganglion mother cells (GMCs). The prospero (pros) mRNA and the RNA-binding protein Staufen (Stau) are asymmetrically localized in mitotic neuroblasts and are specifically partitioned into the GMC, as is Pros protein(5-7). Stau is required for localization of pros RNA but not of Pros protein. Loss of localization of Stau or of pros RNA alters GMC development, but only in embryos with reduced levels of Pros protein, suggesting that pros RNA and Pros protein act redundantly to specify GMC fate. We also find that GMCs do not transcribe the pros gene, showing that inheritance of pros RNA and/or Pros protein from the neuroblast is essential for GMC specification.	Univ Illinois, Howard Hughes Med Inst, Dept Cell & Struct Biol, Urbana, IL 61801 USA	Howard Hughes Medical Institute; University of Illinois System; University of Illinois Urbana-Champaign	Doe, CQ (corresponding author), Univ Illinois, Howard Hughes Med Inst, Dept Cell & Struct Biol, Urbana, IL 61801 USA.							Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; Broadus J, 1997, CURR BIOL, V7, P827, DOI 10.1016/S0960-9822(06)00370-8; Broadus J, 1995, DEVELOPMENT, V121, P3989; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; Guenther C, 1996, DEVELOPMENT, V122, P3509; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; IkeshimaKataoka H, 1997, NATURE, V390, P625, DOI 10.1038/37641; JAN YN, 1995, NEURON, V14, P1; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Li P, 1997, CELL, V90, P437, DOI 10.1016/S0092-8674(00)80504-8; Lin HF, 1997, TRENDS GENET, V13, P33, DOI 10.1016/S0168-9525(96)10050-0; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; LUNDELL MJ, 1994, BIOTECHNIQUES, V16, P434; MATSUZAKI F, 1992, BIOCHEM BIOPH RES CO, V182, P1326, DOI 10.1016/0006-291X(92)91878-T; MCCONNELL SK, 1995, NEURON, V15, P761, DOI 10.1016/0896-6273(95)90168-X; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; SPANA EP, 1995, DEVELOPMENT, V121, P3187; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8	23	214	222	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					792	795		10.1038/35861	http://dx.doi.org/10.1038/35861			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486649				2022-12-28	WOS:000072089500053
J	Miesner, HJ; Stamper-Kurn, DM; Andrews, MR; Durfee, DS; Inouye, S; Ketterle, W				Miesner, HJ; Stamper-Kurn, DM; Andrews, MR; Durfee, DS; Inouye, S; Ketterle, W			Bosonic stimulation in the formation of a Bose-Einstein condensate	SCIENCE			English	Article							GAS	The formation of a Bose-Einstein condensate of a dilute atomic gas has been studied in situ with a nondestructive, time-resolved imaging technique. Sodium atoms were evaporatively cooled close to the onset of Bose-Einstein condensation and then suddenly quenched to below the transition temperature. The subsequent equilibration and condensate formation showed a slow onset distinctly different from simple relaxation. This behavior provided evidence for the process of bosonic stimulation, or coherent matter-wave amplification, crucial to the concept of an atom laser.	MIT, Dept Phys, Cambridge, MA 02139 USA; MIT, Elect Res Lab, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Miesner, HJ (corresponding author), MIT, Dept Phys, Cambridge, MA 02139 USA.		Stamper-Kurn, Dan/B-5442-2015	Stamper-Kurn, Dan/0000-0002-4845-5835				ANDERSON MH, 1995, SCIENCE, V269, P198, DOI 10.1126/science.269.5221.198; Andrews MR, 1997, SCIENCE, V275, P637, DOI 10.1126/science.275.5300.637; Andrews MR, 1996, SCIENCE, V273, P84, DOI 10.1126/science.273.5271.84; Andrews MR, 1997, PHYS REV LETT, V79, P553, DOI 10.1103/PhysRevLett.79.553; [Anonymous], SOV PHYS JETP; [Anonymous], 1992, SOV PHYS JETP; Baym G, 1996, PHYS REV LETT, V76, P6, DOI 10.1103/PhysRevLett.76.6; Bradley CC, 1997, PHYS REV LETT, V78, P985, DOI 10.1103/PhysRevLett.78.985; BRADLEY CC, 1995, PHYS REV LETT, V75, P1687, DOI 10.1103/PhysRevLett.75.1687; DAVIS KB, 1995, PHYS REV LETT, V75, P3969, DOI 10.1103/PhysRevLett.75.3969; ECKERN U, 1984, J LOW TEMP PHYS, V54, P333, DOI 10.1007/BF00683281; Gardiner CW, 1997, PHYS REV LETT, V79, P1793, DOI 10.1103/PhysRevLett.79.1793; GRIFFIN A, 1995, BOSEEINSTEIN CONDENS; HECHT E, 1989, OPTICS, P2; Kagan Y, 1997, PHYS REV LETT, V79, P3331, DOI 10.1103/PhysRevLett.79.3331; Kagan Y., 1995, BOSE EINSTEIN CONDEN, P202; Ketterle W, 1996, ADV ATOM MOL OPT PHY, V37, P181; LEVICH E, 1977, PHYS REV B, V15, P243, DOI 10.1103/PhysRevB.15.243; Mewes MO, 1997, PHYS REV LETT, V78, P582, DOI 10.1103/PhysRevLett.78.582; Mewes MO, 1996, PHYS REV LETT, V77, P416, DOI 10.1103/PhysRevLett.77.416; SEMIKOZ DV, 1995, PHYS REV LETT, V74, P3093, DOI 10.1103/PhysRevLett.74.3093; SNOKE DW, 1989, PHYS REV B, V39, P4030, DOI 10.1103/PhysRevB.39.4030; Stoof HTC, 1997, PHYS REV LETT, V78, P768, DOI 10.1103/PhysRevLett.78.768; STOOF HTC, 1991, PHYS REV LETT, V66, P3148, DOI 10.1103/PhysRevLett.66.3148; STOOF HTC, 1995, BOSE EINSTEIN CONDEN, P226; Svistunov B. V., 1991, Journal of the Moscow Physical Society, V1, P373; Tikhodeev S. G., 1990, Soviet Physics - JETP, V70, P380; Wu H, 1997, PHYS REV A, V56, P560, DOI 10.1103/PhysRevA.56.560	28	179	179	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1005	1007		10.1126/science.279.5353.1005	http://dx.doi.org/10.1126/science.279.5353.1005			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461427				2022-12-28	WOS:000072006400039
J	Tan, S; Richmond, TJ				Tan, S; Richmond, TJ			Crystal structure of the yeast MAT alpha 2/MCM1/DNA ternary complex	NATURE			English	Article							HOMEO DOMAIN PROTEIN; HOMEODOMAIN PROTEINS; REPRESSOR ALPHA-2; DNA-BINDING; SACCHAROMYCES-CEREVISIAE; SECONDARY STRUCTURE; MCM1 PROTEIN; EF-TU; TRANSCRIPTION; OPERATOR	The structure of a complex containing the homeodomain repressor protein MAT alpha 2 and the MADS-box transcription factor MCM1 bound to DNA has been determined by X-ray crystallography at 2.25 Angstrom resolution. It reveals the protein-protein interactions responsible for cooperative binding of MAT alpha 2 and MCM1 to DNA. The otherwise flexible amino-terminal extension of the MAT alpha 2 homeodomain forms a beta-hairpin that grips the MCM1 surface through parallel beta-strand hydrogen bonds and dose-packed, predominantly hydrophobic, side chains. DNA bending induced by MCM1 brings the two proteins closer together, facilitating their interaction. An unusual feature of the complex is that an eight-amino-acid sequence adopts an alpha-helical conformation in one of two copies of the MAT alpha 2 monomer and a beta-strand conformation in the other. This 'chameleon' sequence of MAT alpha 2 may be important for recognizing natural operator sites.	ETH Zurich, Inst Mol Biol & Biophys, ETH Honggerberg, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Richmond, TJ (corresponding author), ETH Zurich, Inst Mol Biol & Biophys, ETH Honggerberg, CH-8093 Zurich, Switzerland.							Abel K, 1996, STRUCTURE, V4, P1153, DOI 10.1016/S0969-2126(96)00123-2; ACTON TB, 1997, MOL CELL BIOL, V17, P1778; ALTHOEFER H, 1995, MOL CELL BIOL, V15, P5917; BRUHN L, 1994, MOL CELL BIOL, V14, P2534, DOI 10.1128/MCB.14.4.2534; BRUNGER AT, 1992, XPLOR 3 1 MANUAL; CHRIST C, 1991, GENE DEV, V5, P751, DOI 10.1101/gad.5.5.751; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; HALL MN, 1987, SCIENCE, V237, P1007, DOI 10.1126/science.2887035; JOHNSON AD, 1995, CURR OPIN GENET DEV, V5, P552, DOI 10.1016/0959-437X(95)80022-0; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; Kuo MH, 1997, MOL CELL BIOL, V17, P819, DOI 10.1128/MCB.17.2.819; Labeots LA, 1997, J MOL BIOL, V269, P113, DOI 10.1006/jmbi.1997.1026; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; MAHER M, 1995, MOL CELL BIOL, V15, P3129; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; Mead J, 1996, MOL CELL BIOL, V16, P2135; Minor DL, 1996, NATURE, V380, P730, DOI 10.1038/380730a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; Perutz MF, 1997, NATURE, V385, P773, DOI 10.1038/385773a0; PHILLIPS CL, 1991, GENE DEV, V5, P764, DOI 10.1101/gad.5.5.764; Polekhina G, 1996, STRUCTURE, V4, P1141, DOI 10.1016/S0969-2126(96)00122-0; PRIMIG M, 1991, EMBO J, V10, P4209, DOI 10.1002/j.1460-2075.1991.tb04999.x; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; TRONRUD DE, 1992, ACTA CRYSTALLOGR A, V48, P912, DOI 10.1107/S0108767392005415; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; Vershon AK, 1996, CURR OPIN BIOTECH, V7, P392, DOI 10.1016/S0958-1669(96)80113-3; WILSON DS, 1995, CURR BIOL, V5, P32, DOI 10.1016/S0960-9822(95)00010-8; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; Wolberger C, 1996, CURR OPIN STRUC BIOL, V6, P62, DOI 10.1016/S0959-440X(96)80096-0; Wright HT, 1996, BIOESSAYS, V18, P453, DOI 10.1002/bies.950180607; WYNNE J, 1992, NUCLEIC ACIDS RES, V20, P3297, DOI 10.1093/nar/20.13.3297; Zhong HL, 1997, J BIOL CHEM, V272, P8402, DOI 10.1074/jbc.272.13.8402	42	191	196	1	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 12	1998	391	6668					660	666		10.1038/35563	http://dx.doi.org/10.1038/35563			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490409				2022-12-28	WOS:000071982500042
J	Cohen, AT				Cohen, AT			Prevention of perioperative myocardial ischaemia and its complications	LANCET			English	Editorial Material							NONCARDIAC SURGERY; MORBIDITY		Univ London Kings Coll, Sch Med & Dent, Dept Med, London SE5 9DP, England	University of London; King's College London	Cohen, AT (corresponding author), Univ London Kings Coll, Sch Med & Dent, Dept Med, London SE5 9DP, England.							*ACC AHA, 1996, CIRCULATION, V93, P1280; Bodenheimer MM, 1996, ANN INTERN MED, V124, P763, DOI 10.7326/0003-4819-124-8-199604150-00010; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1389, DOI 10.1016/0895-4356(94)90083-3; Eagle KA, 1996, NEW ENGL J MED, V335, P1761, DOI 10.1056/NEJM199612053352309; HOLLENBERG M, 1994, AM J CARDIOL, V73, pB30, DOI 10.1016/0002-9149(94)90263-1; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; Mangano DT, 1997, JAMA-J AM MED ASSOC, V277, P325, DOI 10.1001/jama.277.4.325; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; Martin E, 1997, ANESTHESIOLOGY, V86, P346; Palda VA, 1997, ANN INTERN MED, V127, P313, DOI 10.7326/0003-4819-127-4-199708150-00012; Palda VA, 1997, ANN INTERN MED, V127, P309, DOI 10.7326/0003-4819-127-4-199708150-00012	11	5	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					385	386		10.1016/S0140-6736(05)78348-3	http://dx.doi.org/10.1016/S0140-6736(05)78348-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482286				2022-12-28	WOS:000071982600004
J	Cassel, CK; Nelson, EA; Smith, TW; Schwab, CW; Barlow, B; Gary, NE				Cassel, CK; Nelson, EA; Smith, TW; Schwab, CW; Barlow, B; Gary, NE			Internists' and surgeons' attitudes toward guns and firearm injury prevention	ANNALS OF INTERNAL MEDICINE			English	Article							PUBLIC-HEALTH; VIOLENCE PREVENTION; TRAUMA SURGEONS; PEDIATRICIANS; OWNERSHIP; CHILDREN; HANDGUNS; HOMICIDE; AMERICA; SUICIDE	Background: The high rates of death, injury, and longterm disability related to firearms in the United States have led to growing concern in the health care community. Medical organizations and journals are devoting increasing attention to firearm violence as a public health problem; however, few reports discuss physician attitudes toward guns and prevention of firearm-related injury. Objective: To determine internists' and surgeons' attitudes toward guns and firearm injury prevention. Design: Analysis of results of a structured telephone interview. Setting: Internal medicine and surgical offices. Participants: 457 internists and 458 surgeons. Measures: 55 questions that covered six domains: experience with firearms, knowledge about clinical sequelae of firearm injury, knowledge about public policies on firearm violence, attitudes toward public policies on firearm violence, clinical practice behavior, and education and training. Results: The interview response rate was 45.3%, with a compliance rate of 82.5% and a 95% probability (error rate, +/- 5%). Ninety-four percent of internists and 87% of surgeons believe firearm violence is a major public health issue. A majority of internists and surgeons also support community efforts to enact legislation to restrict the possession or sale of handguns (84% and 64%, respectively). Furthermore, although 84% of internists and 72% of surgeons believe that physicians should be involved with firearm injury prevention, less than 20% of respondents usually engage in some form of firearm injury prevention practice in patient care. Conclusion: Many internists and surgeons think that firearm injuries are a public health issue of growing importance, that physicians should incorporate firearm safety screening and counseling into their practice, that physicians should join community efforts to regulate handguns, and that specific gun regulation measures should be adopted as public policy.	Amer Coll Physicians, Res Ctr, Philadelphia, PA 19106 USA; Mt Sinai Med Ctr, Henry L Schwartz Dept Geriatr & Adult Dev, New York, NY 10029 USA; Harlem Hosp Med Ctr, New York, NY 10037 USA; Columbia Univ, Coll Phys & Surg, New York, NY USA; Univ Chicago, Natl Opin Res Ctr, Chicago, IL 60637 USA; Educ Commiss Foreign Med Graduates, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Div Traumatol & Surg Crit Care, Philadelphia, PA 19104 USA	American College of Physicians; Icahn School of Medicine at Mount Sinai; Columbia University; University of Chicago; University of Pennsylvania	Nelson, EA (corresponding author), Amer Coll Physicians, Res Ctr, 6th St & Race, Philadelphia, PA 19106 USA.							ADELSON L, 1992, ARCH SURG-CHICAGO, V127, P171; ADLER KP, 1994, JAMA-J AM MED ASSOC, V271, P1281, DOI 10.1001/jama.271.16.1281; *AM AC PED DEP RES, 1994, ATT COUNS PRACT REG; *AM COLL PHYS, 1991, MED KNOWL SELF ASS P; *AM COLL PHYS, 1994, MED KNOWL SELF ASS P; Ash P, 1996, JAMA-J AM MED ASSOC, V275, P1754, DOI 10.1001/jama.275.22.1754; BARONDESS JA, 1994, JAMA-J AM MED ASSOC, V272, P1409, DOI 10.1001/jama.1994.03520180030025; BATOK GR, 1993, AM J EMERG MED, V11, P678, DOI 10.1016/0735-6757(93)90038-D; BECKMANN CRB, 1994, JAMA-J AM MED ASSOC, V272, P1407, DOI 10.1001/jama.1994.03520180030020; BLACKMAN PH, 1994, JAMA-J AM MED ASSOC, V272, P1406, DOI 10.1001/jama.272.18.1406; Blackman PH, 1996, JAMA-J AM MED ASSOC, V275, P1723, DOI 10.1001/jama.1996.03530460027014; Blumstein A, 1995, J CRIM LAW CRIM, V86, P10, DOI 10.2307/1143998; BROWNING CH, 1976, JAMA-J AM MED ASSOC, V236, P2198, DOI 10.1001/jama.236.19.2198; CHENG TL, 1993, AM J EMERG MED, V11, P183, DOI 10.1016/0735-6757(93)90116-S; CHENG TL, 1993, AM J EMERG MED, V11, P680, DOI 10.1016/0735-6757(93)90039-E; CHING ESH, 1994, JAMA-J AM MED ASSOC, V272, P1407, DOI 10.1001/jama.1994.03520180030021; CHRISTOFFEL KK, 1991, PEDIATRICS, V88, P294; Cook PJ, 1996, JAMA-J AM MED ASSOC, V275, P1765, DOI 10.1001/jama.275.22.1765; CORNWELL EE, 1995, JAMA-J AM MED ASSOC, V273, P1788, DOI 10.1001/jama.273.22.1788; Cummings P, 1997, AM J PUBLIC HEALTH, V87, P974, DOI 10.2105/AJPH.87.6.974; DAVIS JH, 1995, J TRAUMA, V38, P162, DOI 10.1097/00005373-199502000-00002; Eilers R, 1994, N J Med, V91, P859; Eilers R, 1989, N J Med, V86, P875; FARGASON CA, 1995, ARCH PEDIAT ADOL MED, V149, P442, DOI 10.1001/archpedi.1995.02170160096014; Ferguson JS, 1996, JAMA-J AM MED ASSOC, V275, P1724; Giesecke A H, 1993, Tex Med, V89, P7; Hannon E, 1992, Iowa Med, V82, P364; Hargarten SW, 1996, JAMA-J AM MED ASSOC, V275, P1724, DOI 10.1001/jama.1996.03530460027017; Hein H A, 1993, Tex Med, V89, P7; KASSIRER JP, 1991, NEW ENGL J MED, V325, P1647, DOI 10.1056/NEJM199112053252311; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; KELLERMANN AL, 1986, NEW ENGL J MED, V314, P1557, DOI 10.1056/NEJM198606123142406; Kellermann AL, 1997, AM J PUBLIC HEALTH, V87, P910, DOI 10.2105/AJPH.87.6.910; KOOP CE, 1992, JAMA-J AM MED ASSOC, V267, P3075, DOI 10.1001/jama.267.22.3075; LOFTIN C, 1991, NEW ENGL J MED, V325, P1615, DOI 10.1056/NEJM199112053252305; Mainous AG, 1996, JAMA-J AM MED ASSOC, V275, P1723, DOI 10.1001/jama.1996.03530460027015; Mattix H, 1994, Indiana Med, V87, P8; McFaul R B, 1993, Tex Med, V89, P8; MCGINTY JB, 1996, ORTHOPEDICS TODAY, V16, P3; MCGONIGAL MD, 1993, J TRAUMA, V35, P532, DOI 10.1097/00005373-199310000-00006; MCKAY RD, 1994, JAMA-J AM MED ASSOC, V272, P1408, DOI 10.1001/jama.1994.03520180030022; MERCY JA, 1988, NEW ENGL J MED, V319, P1283, DOI 10.1056/NEJM198811103191911; NELLSCH V, 1994, JAMA-J AM MED ASSOC, V272, P1408, DOI 10.1001/jama.1994.03520180030023; ORGAN CH, 1992, ARCH SURG-CHICAGO, V127, P651; OVERMYER M, 1994, PHYSICIANS MANAGEMEN, V34, P20; OVERMYER M, 1994, PHYSICIANS MANAGEMEN, V34, P48; Pratt L, 1995, Wis Med J, V94, P572; REED B, 1994, JAMA-J AM MED ASSOC, V272, P1408, DOI 10.1001/jama.1994.03520180030024; SCHWAB CW, 1995, J TRAUMA, V38, P163; Schwab CW, 1996, J TRAUMA, V40, P671, DOI 10.1097/00005373-199604000-00032; SCHWAB CW, 1993, J TRAUMA, V35, P657, DOI 10.1097/00005373-199311000-00001; SCHWAB CW, 1996, TXB INTERNAL MED, P281; SENTURIA YD, 1994, PEDIATRICS, V93, P469; Senturia YD, 1996, ARCH PEDIAT ADOL MED, V150, P265, DOI 10.1001/archpedi.1996.02170280035006; Sinauer N, 1996, JAMA-J AM MED ASSOC, V275, P1740; SINGH GK, 1996, MONTHLY VITAL STAT S, V45; SLOAN JH, 1988, NEW ENGL J MED, V319, P1256, DOI 10.1056/NEJM198811103191905; Tellez ML, 1996, J TRAUMA, V40, P602, DOI 10.1097/00005373-199604000-00014; TEPAS JJ, 1994, J PEDIATR SURG, V29, P369, DOI 10.1016/0022-3468(94)90352-2; TRUNKEY D, 1995, J TRAUMA, V38, P161, DOI 10.1097/00005373-199502000-00001; Vassar MJ, 1996, JAMA-J AM MED ASSOC, V275, P1734, DOI 10.1001/jama.275.22.1734; WEBSTER DW, 1992, PEDIATRICS, V89, P902; WHITE LJ, 1995, ANN INTERN MED, V122, P311; WIKTOR SZ, 1994, WESTERN J MED, V161, P137; Wintemute GJ, 1996, JAMA-J AM MED ASSOC, V275, P1749, DOI 10.1001/jama.275.22.1749; Zimring FE, 1995, J CRIM LAW CRIM, V86, P1, DOI 10.2307/1143997	66	55	55	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1998	128	3					224	230		10.7326/0003-4819-128-3-199802010-00009	http://dx.doi.org/10.7326/0003-4819-128-3-199802010-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU303	9454531				2022-12-28	WOS:000071703200008
J	Free, C; McKee, M				Free, C; McKee, M			Meeting the needs of black and minority ethnic groups	BRITISH MEDICAL JOURNAL			English	Article									Univ London Kings Coll, Sch Med & Dent, Dept Gen Practice & Primary Care, London SE5 9PJ, England; Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England	University of London; King's College London; University of London; London School of Hygiene & Tropical Medicine	Free, C (corresponding author), Univ London Kings Coll, Sch Med & Dent, Dept Gen Practice & Primary Care, London SE5 9PJ, England.		Mckee, Martin/E-6673-2018; McKee, Marc D/E-2187-2011	Mckee, Martin/0000-0002-0121-9683; McKee, Marc D/0000-0001-8349-965X				Balarajan R, 1995, Health Trends, V27, P114; CARRRHILL R, 1996, LOST OPPORTUNITIES L; FREE C, 1996, PRIMARY CARE MANAGEM, V6, P3; Hicks C, 1991, Health Serv Manage Res, V4, P89; NAISH J, 1994, BRIT MED J, V309, P1126; SMAJE C, 1995, HLTH RACE ETHNICITY	6	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 31	1998	316	7128					380	380		10.1136/bmj.316.7128.380	http://dx.doi.org/10.1136/bmj.316.7128.380			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487180	Green Published			2022-12-28	WOS:000071863900039
J	Green, S; Buchbinder, R; Glazier, R; Forbes, A				Green, S; Buchbinder, R; Glazier, R; Forbes, A			Systematic review of randomised controlled trials of interventions for painful shoulder: selection criteria, outcome assessment, and efficacy	BRITISH MEDICAL JOURNAL			English	Article							ROTATOR CUFF TENDINITIS; DOUBLE-BLIND; FROZEN SHOULDER; CORTICOSTEROID INJECTIONS; ADHESIVE CAPSULITIS; STEROID INJECTIONS; DICLOFENAC SODIUM; CLINICAL-TRIALS; STIFF SHOULDER; PERIARTHRITIS	Objective: To review the efficacy of common interventions for shoulder pain. Design: All randomised controlled trials of non-steroidal anti-inflammatory drugs, intra-articular and subacromial glucocorticosteroid injection, oral glucocorticosteroid treatment, physiotherapy, manipulation under anaesthesia, hydrodilatation, and surgery for shoulder pain that were identified by computerised and hand searches of the literature and had a blinded assessment of outcome were included. Main outcome measures: Methodological quality (score out of 40), selection criteria, and outcome measures. Effect sizes were calculated and combined in a pooled analysis if study population, end point and intervention were comparable. Results: Thirty one trials met inclusion criteria. Mean methodological quality score was 16.8 (9.5-22). Selection criteria varied widely, even for the same diagnostic label. There was no uniformity in the outcome measures used, and their measurement properties were rarely reported. Effect sizes for individual trials were small(range -1.4 to 3.0). The results of only three studies investigating "rotator cuff tendinitis" could be pooled. The only positive finding was that subacromial steroid injection is better than placebo in improving the range of abduction (weighted difference between means 35 degrees (95% confidence interval 14 to 55)). Conclusions: There is little evidence to support or refute the efficacy of common interventions for shoulder pain. As well as the need for further well designed clinical trials, more research is needed to establish a uniform method of defining shoulder disorders and developing outcome measures which are valid, reliable, and responsive in affected people.	Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3186, Australia; Univ Turin, Toronto, ON, Canada	Monash University; University of Turin	Green, S (corresponding author), Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3186, Australia.	rachelle.buchbinder@med.monash.edu.au	Buchbinder, Rachelle/G-2952-2011; Glazier, Richard H/E-5255-2012	Buchbinder, Rachelle/0000-0002-0597-0933; Green, Sally Elizabeth/0000-0002-9564-9050; Forbes, Andrew/0000-0003-4269-914X				ADEBAJO A, 1990, J RHEUMATOL, V7, P1207; BERRY H, 1980, CURR MED RES OPIN, V7, P121, DOI 10.1185/03007998009112038; BINDER A, 1986, BRIT J RHEUMATOL, V25, P288; BINDER A, 1984, LANCET, V1, P695; BLOCKEY NJ, 1954, BRIT MED J, V1, P1455, DOI 10.1136/bmj.1.4877.1455; BULGEN DY, 1984, ANN RHEUM DIS, V43, P353, DOI 10.1136/ard.43.3.353; COHEN A, 1968, PA MED, V1, P66; CORBEIL V, 1992, J CAN ASSOC RADIOL, V43, P127; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DUKE O, 1981, RHEUMATOL REHABIL, V20, P54, DOI 10.1093/rheumatology/20.1.54; ENGLAND S, 1989, SCAND J RHEUMATOL, V18, P427, DOI 10.3109/03009748909102106; FAMAEY JP, 1984, J INT MED RES, V12, P238, DOI 10.1177/030006058401200403; FRIIS J, 1992, CLIN RHEUMATOL, V11, P105, DOI 10.1007/BF02207095; GINSBERG F, 1985, CURR MED RES OPIN, V9, P442, DOI 10.1185/03007998509109617; GLAZIER R, 1995, ARTHRITIS RHEUM, V38, P533, DOI 10.1002/art.1780380412; GOTTER G, 1987, European Journal of Rheumatology and Inflammation, V9, P95; Goupille P, 1996, CLIN EXP RHEUMATOL, V14, P561; HOLLINGWORTH GR, 1983, BRIT MED J, V287, P1339, DOI 10.1136/bmj.287.6402.1339; HUSKISSON EC, 1983, CURR MED RES OPIN, V8, P350, DOI 10.1185/03007998309112396; JACOBS LGH, 1991, BRIT MED J, V302, P1498, DOI 10.1136/bmj.302.6791.1498; LECLAIRE R, 1991, ARCH PHYS MED REHAB, V72, P284; Nicholson G G, 1985, J Orthop Sports Phys Ther, V6, P238; Oxman A., 1994, COCHRANE COLLABORATI; PETRI M, 1987, ARTHRITIS RHEUM-US, V30, P1040, DOI 10.1002/art.1780300911; RHIND V, 1982, RHEUMATOL REHABIL, V21, P51, DOI 10.1093/rheumatology/21.1.51; RICHARDSON AT, 1975, P ROY SOC MED, V68, P11; RIZK TE, 1991, ARCH PHYS MED REHAB, V72, P20; SMITH MD, 1986, PHARMATHERAPEUTICA, V4, P585; THOMAS D, 1980, RHEUMATOL REHABIL, V19, P173, DOI 10.1093/rheumatology/19.3.173; THUMB N, 1987, J INT MED RES, V15, P327, DOI 10.1177/030006058701500601; vanderHeijden GJMG, 1997, BRIT MED J, V315, P25, DOI 10.1136/bmj.315.7099.25; vanderHeijden GJMG, 1996, BRIT J GEN PRACT, V46, P309; VANDERWINDT DAWM, 1995, J CLIN EPIDEMIOL, V48, P691, DOI 10.1016/0895-4356(94)00170-U; WARD MC, 1986, BRIT J RHEUMATOL, V25, P412; WHITE RH, 1986, J RHEUMATOL, V13, P608; WIELANDTS L, 1979, CURR MED RES OPIN, V6, P85, DOI 10.1185/03007997909109515; WITHRINGTON RH, 1985, SCAND J RHEUMATOL, V14, P76, DOI 10.3109/03009748509102022; YAMAMOTO M, 1983, EUR J RHEUMATOL INFL, V6, P266	38	243	246	0	22	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 31	1998	316	7128					354	360		10.1136/bmj.316.7128.354	http://dx.doi.org/10.1136/bmj.316.7128.354			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487172	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000071863900027
J	Danziger, R				Danziger, R			HIV testing and HIV prevention in Sweden	BRITISH MEDICAL JOURNAL			English	Article									Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Danziger, R (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, Keppel St, London WC1E 7HT, England.							BLAXHULT A, 1993, AIDS, V7, P1625, DOI 10.1097/00002030-199312000-00013; BLAXHULT A, 1993, HIV ADIS SWEDEN EPID; Faxelid EA, 1997, SOC SCI MED, V44, P1239, DOI 10.1016/S0277-9536(96)00312-7; GIESECKE J, 1991, LANCET, V338, P1096, DOI 10.1016/0140-6736(91)91962-T; Hart GJ, 1996, AIDS, V10, P337, DOI 10.1097/00002030-199603000-00014; HENRIKKSON B, 1992, AIDS IND DEMOCRACIES; *MIN HLTH SOC AFF, 1989, COMM DIS ACT OTH LEG; *NAT I PUBL HLTH, 1996, GET SUR TEST HIV WHY; *STOCKH COUNT COUN, 1995, HIV AIDS PROGR PREV, P34; *SWED I INF DIS CO, 1995, EP ENH ARSR	10	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					293	295		10.1136/bmj.316.7127.293	http://dx.doi.org/10.1136/bmj.316.7127.293			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472518	Green Published			2022-12-28	WOS:000071702100034
J	Lyall, EGH; Stainsby, C; Taylor, GP; Ait-Khaled, M; Bingham, S; Evans, JA; Wright, A; Weber, JN; McClure, MO; Walters, S; Tudor-Williams, G				Lyall, EGH; Stainsby, C; Taylor, GP; Ait-Khaled, M; Bingham, S; Evans, JA; Wright, A; Weber, JN; McClure, MO; Walters, S; Tudor-Williams, G			Review of uptake of interventions to reduce mother to child transmission of HIV by women aware of their HIV status	BRITISH MEDICAL JOURNAL			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; ZIDOVUDINE TREATMENT; INFANT	Objectives: To examine the change in uptake of interventions to reduce transmission of HIV from mothers to infants from January 1994 to July 1997. Design: Review of mother-infant pairs who presented for infant diagnosis of HIV infection. Setting: Central London hospital with facilities for diagnosis of infant HIV infection. Subjects: 57 consecutive mother-infant pairs, mainly from central London but also referred from surrounding hospitals. Interventions: Data were collected on mother's country of origin; CD4 count at delivery; plasma HIV RNA copies/ml; made of delivery; antiretroviral therapy; infant feeding; and HIV infection in infants. Main outcome measures: HIV infection of infants. Results: The vertical transmission rate was 12% (7 pairs; 95% confidence interval 3% to 22%). All mothers chose not to breast feed, The caesarean section rate was 53% (30/57). Antiretroviral therapy was taken by 68.5% (39/57) of mother-infant pairs. With antiretroviral therapy or caesarean section, or both, transmission occurred in 6% (0% to 13%) of pairs (3/50), During the 24 months of 1994 and 1995, 21% (4/19) of infants were infected with HIV; 7.9% (3/38) were infected over the 19 months January 1996 to July 1997. The caesarean section rate did not change over these periods. Use of antiretroviral therapy increased from 31.5% (6/19) to 86.8% (33/38) (P < 0.0001). Conclusion: Women with a diagnosis of HIV infection acted to reduce the risk of transmission to their infants. Uptake of antiretroviral therapy increased significantly over time, and the caesarean section rate was persistently high.	St Marys Hosp, Imperial Coll Sch Med, Dept Paediat, London W2 1PG, England; St Marys Hosp, Imperial Coll Sch Med, Dept Genitourinary Med & Communicable Dis, Jefferiss Res Trust Labs, London W2 1PG, England	Imperial College London; Imperial College London	Lyall, EGH (corresponding author), St Marys Hosp, Imperial Coll Sch Med, Dept Paediat, Praed St, London W2 1PG, England.			Stainsby, Chris/0000-0002-8890-9918				[Anonymous], 1994, MMWR Recomm Rep, V43, P1; BLANCHE S, 1997, 4 INT C RETR OPP INF; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; *DEP HLTH, 1996, UNL AN HIV PREV MON; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; Gibb DM, 1997, AIDS, V11, pF53, DOI 10.1097/00002030-199707000-00001; MCCLURE MO, 1995, NATURE, V375, P637, DOI 10.1038/375637a0; *NAT I CHILD HLTH, 1997, PED ACTG PROT 185 EX; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201	9	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					268	270		10.1136/bmj.316.7127.268	http://dx.doi.org/10.1136/bmj.316.7127.268			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472507	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000071702100021
J	Carey, M				Carey, M			The enhanceosome and transcriptional synergy	CELL			English	Review							PROTEIN INTERACTIONS; IN-VIVO; ACTIVATION; COMPLEXES		Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Carey, M (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.			Carey, Michael/0000-0003-3899-6280				Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; COUREY AJ, 1995, BBA-GENE STRUCT EXPR, V1261, P1, DOI 10.1016/0167-4781(94)00234-T; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Mayall TP, 1997, GENE DEV, V11, P887, DOI 10.1101/gad.11.7.887; MERIKA M, 1998, IN PRESS MOL CELL, V1; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; Paull TT, 1996, GENE DEV, V10, P2769, DOI 10.1101/gad.10.21.2769; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Ptashne M., 1992, A GENETIC SWITCH; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Tanaka M, 1996, P NATL ACAD SCI USA, V93, P4311, DOI 10.1073/pnas.93.9.4311; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649	20	446	459	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 9	1998	92	1					5	8		10.1016/S0092-8674(00)80893-4	http://dx.doi.org/10.1016/S0092-8674(00)80893-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489694	Bronze			2022-12-28	WOS:000071473700002
J	Zhang, WG; Sloan-Lancaster, J; Kitchen, J; Trible, RP; Samelson, LE				Zhang, WG; Sloan-Lancaster, J; Kitchen, J; Trible, RP; Samelson, LE			LAT: The ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation	CELL			English	Article							ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTER PROTEIN; SH2 DOMAINS; GRB2; PHOSPHORYLATION; SLP-76; PHOSPHOPROTEIN; ASSOCIATION	Despite extensive study, several of the major components involved in T cell receptor-mediated signaling remain unidentified. Here we report the cloning of the cDNA for a highly tyrosine-phosphorylated 36-38 kDa protein, previously characterized by its association with Grb2, phospholipase C-gamma 1, and the p85 subunit of phosphoinositide 3-kinase. Deduced amino acid sequence identifies a novel integral membrane protein containing multiple potential tyrosine phosphorylation sites. We show that this protein is phosphorylated by ZAP-70/Syk protein tyrosine kinases leading to recruitment of multiple signaling molecules. Its function is demonstrated by inhibition of T cell activation following overexpression of a mutant form lacking critical tyrosine residues. Therefore, we propose to name the molecule LAT-linker for activation of T cells.	NICHHD, Sect Lymphocyte Signalling, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Zhang, WG (corresponding author), NICHHD, Sect Lymphocyte Signalling, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.							BUDAY L, 1994, J BIOL CHEM, V269, P9019; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Chu DH, 1996, EMBO J, V15, P6251, DOI 10.1002/j.1460-2075.1996.tb01015.x; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; Isakov N, 1996, J BIOL CHEM, V271, P15753, DOI 10.1074/jbc.271.26.15753; JUNE CH, 1990, J IMMUNOL, V144, P1591; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Pao LI, 1997, J IMMUNOL, V158, P2663; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SloanLancaster J, 1997, J EXP MED, V186, P1713, DOI 10.1084/jem.186.10.1713; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Takaki S, 1997, J BIOL CHEM, V272, P14562, DOI 10.1074/jbc.272.23.14562; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; VONHEIJNE G, 1994, MEMBRANE PROTEIN STR, P27; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Zoller KE, 1997, J IMMUNOL, V158, P1650	33	1027	1062	4	39	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 9	1998	92	1					83	92		10.1016/S0092-8674(00)80901-0	http://dx.doi.org/10.1016/S0092-8674(00)80901-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489702	Bronze			2022-12-28	WOS:000071473700010
J	Schenk, PM; Bulmer, MH				Schenk, PM; Bulmer, MH			Origin of mountains on lo by thrust faulting and large-scale mass movements	SCIENCE			English	Article							LANDSLIDE	Voyager stereoimages of Euboea Montes, lo, indicate that this mountain formed when a large crustal block was uplifted 10.5 kilometers and tilted by approximately 6 degrees. Uplift triggered a massive slope failure on the northwest flank, forming one of the largest debris aprons in the solar system. This slope failure probably involved relatively unconsolidated layers totaling approximately 2 kilometers in thickness, overlying a rigid crust (or lithosphere) at least 11 kilometers thick. Mountain formation on lo may involve localized deep-rooted thrust faulting and block rotation, due to compression at depth induced during vertical recycling of lo's crust.	Lunar & Planetary Inst, Houston, TX 77055 USA; Smithsonian Inst, Natl Air & Space Museum, Ctr Earth & Planetary Sci, Washington, DC 20560 USA	Smithsonian Institution	Schenk, PM (corresponding author), Lunar & Planetary Inst, 3303 NASA Rd 1, Houston, TX 77055 USA.	schenk@lpi3.jsc.nasa.gov						ALLMENDINGER RW, 1992, GEOLOGY N AM G, V3, P583; BULMER M, UNPUB; BULMER M, IN PRESS LUNAR PLANE; Bulmer MH, 1996, GEOL SOC SP, P349, DOI 10.1144/GSL.SP.1996.110.01.25; BULMER MH, 1994, THESIS U LONDON; CARR M, 1997, LOW OBS GAL ER C FLA; CARR M, 1997, GEOL SOC AM ABSTR, V29, pA311; CRUDEN DM, 1980, GEOL SOC AM BULL, V91, P63, DOI 10.1130/0016-7606(1980)91<63:ALLOMD>2.0.CO;2; DINGLE RV, 1977, J GEOL SOC LONDON, V134, P293, DOI DOI 10.1144/GSJGS.134.3.0293; FRANCIS PW, 1983, J GEOPHYS RES, V88, P8333, DOI 10.1029/JB088iB10p08333; FRANCIS PW, 1988, B VOLCANOL, V50, P258, DOI 10.1007/BF01047488; GUEST JE, 1971, GEOLOGY PHYSICS MOON, P93; HELM A, 1932, BERGSTRUZ MENSCHEINL, P218; JORDAN TE, 1986, AM J SCI, V286, P737, DOI 10.2475/ajs.286.10.737; LOPES R, 1982, J GEOPHYS RES, V87, P9917, DOI 10.1029/JB087iB12p09917; LOPES RMC, 1980, MOON PLANETS, V22, P221, DOI 10.1007/BF00898433; LopesGautier R, 1997, GEOPHYS RES LETT, V24, P2439, DOI 10.1029/97GL02662; LUCCHITTA BK, 1978, GEOL SOC AM BULL, V89, P1601, DOI 10.1130/0016-7606(1978)89<1601:ALLOM>2.0.CO;2; MCCAULEY JF, 1979, NATURE, V280, P736, DOI 10.1038/280736a0; MCEWEN A, 1989, NASA SPEC PUBL, V494, P3; MILLER DM, 1992, CORDILLERAN OROGEN G, V3, P205; Moore JM, 1996, ICARUS, V122, P63, DOI 10.1006/icar.1996.0109; Muller L., 1968, FELSMECH ENGENIEURGE, V6, P1; NASH DB, 1986, SATELLITES, P629; SCHABER GG, 1982, SATELLITES JUPITER, P556; SCHENK P, 1997, LUNAR PLANET SCI, V28, P1247; Schenk PM, 1997, GEOPHYS RES LETT, V24, P2467, DOI 10.1029/97GL02688; Shaller P.J., 1991, THESIS CALTECH; SHALLER PJ, 1991, CAN GEOTECH J, V28, P584, DOI 10.1139/t91-073; SHREVE RL, 1966, SCIENCE, V154, P1639, DOI 10.1126/science.154.3757.1639; SMITHSON SB, 1979, J GEOPHYS RES, V84, P5955, DOI 10.1029/JB084iB11p05955; SUMMERHAYES CP, 1979, MAR GEOL, V31, P265, DOI 10.1016/0025-3227(79)90037-9; VEEDER GJ, 1994, J GEOPHYS RES-PLANET, V99, P17095, DOI 10.1029/94JE00637; VOIGHT B, 1978, GEOTECHNICAL ENG, P1; YARNOLD JC, 1993, GEOL SOC AM BULL, V105, P345, DOI 10.1130/0016-7606(1993)105<0345:RACIDC>2.3.CO;2	35	87	87	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1514	1517		10.1126/science.279.5356.1514	http://dx.doi.org/10.1126/science.279.5356.1514			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488645				2022-12-28	WOS:000072372900058
J	Kuvin, JT				Kuvin, JT			Electrocardiographic changes of hyperkalemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									New England Med Ctr, Boston, MA 02111 USA	Tufts Medical Center	Kuvin, JT (corresponding author), New England Med Ctr, 750 Washington St, Boston, MA 02111 USA.								0	11	11	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1998	338	10					662	662		10.1056/NEJM199803053381005	http://dx.doi.org/10.1056/NEJM199803053381005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ844	9486995				2022-12-28	WOS:000072299700005
J	Smith-Warner, SA; Spiegelman, D; Yaun, SS; van den Brandt, PA; Folsom, AR; Goldbohm, RA; Graham, S; Holmberg, L; Howe, GR; Marshall, JR; Miller, AB; Potter, JD; Speizer, FE; Willett, WC; Wolk, A; Hunter, DJ				Smith-Warner, SA; Spiegelman, D; Yaun, SS; van den Brandt, PA; Folsom, AR; Goldbohm, RA; Graham, S; Holmberg, L; Howe, GR; Marshall, JR; Miller, AB; Potter, JD; Speizer, FE; Willett, WC; Wolk, A; Hunter, DJ			Alcohol and breast cancer in women - A pooled analysis of cohort studies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							FOOD FREQUENCY QUESTIONNAIRE; POSTMENOPAUSAL WOMEN; BEVERAGE CONSUMPTION; DIETARY FACTORS; PREMENOPAUSAL WOMEN; SEX-HORMONES; LUTEINIZING-HORMONE; CIGARETTE-SMOKING; URINE ESTROGENS; YOUNG-WOMEN	Objective.-To assess the risk of invasive breast cancer associated with total and beverage-specific alcohol consumption and to evaluate whether dietary and nondietary factors modify the association. Data Sources.-We included in these analyses 6 prospective studies that had at least 200 incident breast cancer cases, assessed long-term intake of food and nutrients, and used a validated diet assessment instrument. The studies were conducted in Canada, the Netherlands, Sweden, and the United States. Alcohol intake was estimated by food frequency questionnaires in each study. The studies included a total of 322 647 women evaluated for up to 11 years, including 4335 participants with a diagnosis of incident invasive breast cancer. Data Extraction.-Pooled analysis of primary data using analyses consistent with each study's original design and the random-effects model for the overall pooled analyses. Data Synthesis.-For alcohol intakes less than 60 g/d (reported by >99% of participants), risk increased linearly with increasing intake; the pooled multivariate relative risk for an increment of 10 g/d of alcohol (about 0.75-1 drink) was 1.09 (95% confidence interval [CI], 1.04-1.13; P for heterogeneity among studies, .71). The multivariate-adjusted relative risk for total alcohol intakes of 30 to less than 60 g/d (about 2-5 drinks) vs nondrinkers was 1.41 (95% CI, 1.18-1.69), Limited data suggested that alcohol intakes of at least 60 g/d were not associated with further increased risk. The specific type of alcoholic beverage did not strongly influence risk estimates. The association between alcohol intake and breast cancer was not modified by other factors. Conclusions.-Alcohol consumption is associated with a linear increase in breast cancer incidence in women over the range of consumption reported by most women. Among women who consume alcohol regularly, reducing alcohol consumption is a potential means to reduce breast cancer risk.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Maastricht, Dept Epidemiol, Maastricht, Netherlands; Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA; TNO, Nutr & Food Res Inst, Dept Epidemiol, NL-3700 AJ Zeist, Netherlands; SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA; Uppsala Univ Hosp, Dept Surg, Uppsala, Sweden; Univ Toronto, Fac Med, Dept Prevent Med & Biostat, Natl Canc Inst Canada,Epidemiol Unit, Toronto, ON, Canada; Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85721 USA; Fred Hutchinson Canc Res Ctr, Canc Prevent Res Program, Seattle, WA 98104 USA; Harvard Ctr Canc Prevent, Boston, MA 02115 USA; Karolinska Inst, Dept Med Epidemiol, Stockholm, Sweden	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Maastricht University; University of Minnesota System; University of Minnesota Twin Cities; Netherlands Organization Applied Science Research; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Uppsala University; Uppsala University Hospital; Queens University - Canada; Canadian Cancer Trials Group; University of Toronto; Arizona Center Cancer Care; University of Arizona; Fred Hutchinson Cancer Center; Harvard University; Karolinska Institutet	Smith-Warner, SA (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.			Potter, John/0000-0001-5439-1500; van den Brandt, Piet/0000-0001-8781-8099	NCI NIH HHS [CA55075, CA50597] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050597, P01CA055075] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1988, BRIT J CANCER, V58, P832, DOI 10.1038/bjc.1988.320; BECKER U, 1991, J HEPATOL, V13, P25, DOI 10.1016/0168-8278(91)90859-A; Bowlin SJ, 1997, INT J EPIDEMIOL, V26, P915, DOI 10.1093/ije/26.5.915; BYERS T, 1985, AM J EPIDEMIOL, V121, P664, DOI 10.1093/aje/121.5.664; CAULEY JA, 1989, AM J EPIDEMIOL, V129, P1120, DOI 10.1093/oxfordjournals.aje.a115234; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DORGAN JF, 1994, CANCER CAUSE CONTROL, V5, P53, DOI 10.1007/BF01830726; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; EWERTZ M, 1991, CANCER CAUSE CONTROL, V2, P247, DOI 10.1007/BF00052141; Feskanich Diane, 1994, Annals of Epidemiology, V4, P181, DOI 10.1016/1047-2797(94)90095-7; FREUDENHEIM JL, 1995, NUTR CANCER, V23, P1, DOI 10.1080/01635589509514356; FRIEDENREICH CM, 1993, AM J EPIDEMIOL, V137, P512, DOI 10.1093/oxfordjournals.aje.a116704; FUCHS CS, 1995, NEW ENGL J MED, V332, P1245, DOI 10.1056/NEJM199505113321901; GAPSTUR SM, 1992, AM J EPIDEMIOL, V136, P1221, DOI 10.1093/oxfordjournals.aje.a116430; GARRO AJ, 1990, ANNU REV PHARMACOL, V30, P219, DOI 10.1146/annurev.pa.30.040190.001251; GAVALER JS, 1992, ALCOHOL CLIN EXP RES, V16, P87, DOI 10.1111/j.1530-0277.1992.tb00642.x; GAVALER JS, 1992, HEPATOLOGY, V16, P312, DOI 10.1002/hep.1840160206; Ginsburg ES, 1996, JAMA-J AM MED ASSOC, V276, P1747, DOI 10.1001/jama.276.21.1747; GINSBURG ES, 1995, FERTIL STERIL, V63, P1227, DOI 10.1016/S0015-0282(16)57602-X; GOLDBOHM RA, 1995, EUR J CLIN NUTR, V49, P420; GOLDBOHM RA, 1994, EUR J CLIN NUTR, V48, P253; GRAHAM S, 1992, AM J EPIDEMIOL, V136, P1327, DOI 10.1093/oxfordjournals.aje.a116445; HANKINSON SE, 1995, J NATL CANCER I, V87, P1297, DOI 10.1093/jnci/87.17.1297; HIATT RA, 1984, AM J EPIDEMIOL, V120, P676, DOI 10.1093/oxfordjournals.aje.a113934; HIATT RA, 1988, CANCER RES, V48, P2284; *HIR INT CORP, 1993, EPICURE US GUID PEAN; HOLMBERG L, 1994, ARCH INTERN MED, V154, P1805, DOI 10.1001/archinte.154.16.1805; HOLMBERG L, 1995, CANCER EPIDEM BIOMAR, V4, P843; Hunter DJ, 1997, CANCER CAUSE CONTROL, V8, P49, DOI 10.1023/A:1018431104786; Hunter DJ, 1996, NEW ENGL J MED, V334, P356, DOI 10.1056/NEJM199602083340603; HUNTER DJ, 1993, EPIDEMIOL REV, V15, P110, DOI 10.1093/oxfordjournals.epirev.a036096; JAIN MG, 1982, AM J CLIN NUTR, V36, P931, DOI 10.1093/ajcn/36.5.931; KAPLAN E, 1958, J AM STAT ASSOC, V8, P699; KATO I, 1992, BREAST CANCER RES TR, V24, P51, DOI 10.1007/BF01832358; KATSOUYANNI K, 1991, ONCOLOGY-BASEL, V48, P490; KATSOUYANNI K, 1994, INT J CANCER, V58, P356, DOI 10.1002/ijc.2910580308; KATSOUYANNI K, 1986, INT J CANCER, V38, P815, DOI 10.1002/ijc.2910380606; KELSEY JL, 1993, EPIDEMIOL REV, V15, P7, DOI 10.1093/oxfordjournals.epirev.a036118; Landa M C, 1994, Eur J Cancer Prev, V3, P313, DOI 10.1097/00008469-199407000-00003; LE MG, 1984, AM J EPIDEMIOL, V120, P350, DOI 10.1093/oxfordjournals.aje.a113899; Levi F, 1996, EUR J CANCER, V32A, P2108, DOI 10.1016/S0959-8049(96)00229-8; LEVI F, 1993, NUTR CANCER, V19, P327, DOI 10.1080/01635589309514263; LONDON S, 1991, AM J CLIN NUTR, V53, P166, DOI 10.1093/ajcn/53.1.166; LONGNECKER MP, 1995, CANCER EPIDEM BIOMAR, V4, P721; LONGNECKER MP, 1995, JNCI-J NATL CANCER I, V87, P923, DOI 10.1093/jnci/87.12.923; LONGNECKER MP, 1994, CANCER CAUSE CONTROL, V5, P73, DOI 10.1007/BF01830729; MARTINMORENO JM, 1993, CANCER CAUSE CONTROL, V4, P345, DOI 10.1007/BF00051337; MENDELSON JH, 1989, J PHARMACOL EXP THER, V250, P902; MENDELSON JH, 1987, J STUD ALCOHOL, V48, P287, DOI 10.15288/jsa.1987.48.287; MENDELSON JH, 1988, PSYCHOPHARMACOLOGY, V94, P464, DOI 10.1007/BF00212838; MILLS P, 1989, CANCER-AM CANCER SOC, V64, P582, DOI 10.1002/1097-0142(19890801)64:3&lt;582::AID-CNCR2820640304&gt;3.0.CO;2-V; MUNGER RG, 1992, AM J EPIDEMIOL, V136, P192, DOI 10.1093/oxfordjournals.aje.a116485; NEWCOMB PA, 1995, EPIDEMIOLOGY, V6, P318, DOI 10.1097/00001648-199505000-00022; OCONNELL DL, 1987, J NATL CANCER I, V78, P229; PETTERSSON P, 1990, J INTERN MED, V228, P311, DOI 10.1111/j.1365-2796.1990.tb00238.x; PRENTICE RL, 1986, BIOMETRIKA, V73, P1; REICHMAN ME, 1993, J NATL CANCER I, V85, P722, DOI 10.1093/jnci/85.9.722; RICHEDWARDS JW, 1995, NEW ENGL J MED, V332, P1758, DOI 10.1056/NEJM199506293322607; ROHAN TE, 1993, NUTR CANCER, V20, P167, DOI 10.1080/01635589309514283; ROSENBERG L, 1993, EPIDEMIOL REV, V15, P133, DOI 10.1093/oxfordjournals.epirev.a036097; ROSENBERG L, 1982, LANCET, V1, P267; *SAS I INC, 1991, SAS STAT SOFTW PHREG; SCHATZKIN A, 1989, J NATL CANCER I, V81, P31, DOI 10.1093/jnci/81.1.31; SMITH PL, 1979, AM STAT, V33, P57, DOI 10.2307/2683222; SMITH SJ, 1994, BRIT J CANCER, V70, P112, DOI 10.1038/bjc.1994.258; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; Swanson CA, 1997, EPIDEMIOLOGY, V8, P231, DOI 10.1097/00001648-199705000-00001; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; TRICHOPOULOS D, 1987, INT J CANCER, V40, P721, DOI 10.1002/ijc.2910400602; VALIMAKI MJ, 1995, ACTA OBSTET GYN SCAN, V74, P462, DOI 10.3109/00016349509024410; VANDENBRANDT PA, 1995, AM J EPIDEMIOL, V141, P907, DOI 10.1093/oxfordjournals.aje.a117357; Viel JF, 1997, EUR J EPIDEMIOL, V13, P639, DOI 10.1023/A:1007368115200; Weiss HA, 1996, BRIT J CANCER, V73, P1298, DOI 10.1038/bjc.1996.248; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	75	636	644	2	50	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	1998	279	7					535	540		10.1001/jama.279.7.535	http://dx.doi.org/10.1001/jama.279.7.535			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW470	9480365	Green Published			2022-12-28	WOS:000071938900036
J	Murray, JE				Murray, JE			Heartsick	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Wisconsin, Sch Med, Dept Med, Gen Internal Med Sect, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Murray, JE (corresponding author), Univ Wisconsin, Sch Med, Dept Med, Gen Internal Med Sect, 600 Highland Ave,J5-210 CSC, Madison, WI 53792 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1998	128	4					315	316		10.7326/0003-4819-128-4-199802150-00015	http://dx.doi.org/10.7326/0003-4819-128-4-199802150-00015			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX170	9471937				2022-12-28	WOS:000072013400011
J	Hogg, RS; Heath, KV; Yip, B; Craib, KJP; O'Shaughnessy, MV; Schechter, MT; Montaner, JSG				Hogg, RS; Heath, KV; Yip, B; Craib, KJP; O'Shaughnessy, MV; Schechter, MT; Montaner, JSG			Improved survival among HIV-infected individuals following initiation of antiretroviral therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; CUBIC MILLIMETER; CONTROLLED TRIAL; CONTINUED ZIDOVUDINE; COMBINATION THERAPY; MONOTHERAPY; LAMIVUDINE; PLASMA; CELLS; AIDS	Context.-Clinical trials have established the efficacy of antiretroviral therapy with double-and triple-drug regimens for individuals infected with the human immunodeficiency virus (HIV), but the effectiveness of these regimens in the population of patients not enrolled in clinical trials is unknown. Objective.-To characterize survival following the initiation of antiretroviral therapy among HIV-infected individuals in the province of British Columbia. Design.-Prospective, population-based Cohort study of patients with antiretroviral therapy available free of charge (median follow-up, 21 months). Setting.-Province of British Columbia, Canada. Patients.-All HIV-positive men and women 18 years of age or older in the province who were first prescribed any antiretroviral therapy between October 1992 and June 1996 and whose CD4(+) cell counts were less than 0.350x10(9)/L. Main Outcome Measures.-Rates of progression from initiation of antiretroviral therapy to death or a primary acquired immunodeficiency syndrome (AIDS) diagnosis for subjects who initially received zidovudine-, didanosine-, or zalcitabine-based therapy (ERA-I) and for those who initially received therapy regimens including lamivudine or stavudine (ERA-II). Results.-A total of 1178 patients (951 ERA-I, 227 ERA-II) were eligible, A total of 390 patients died (367 ERA-I, 23 ERA-II), yielding a crude mortality rate of 33.1%, ERA-I group subjects were almost twice as likely to die as ERA-II group subjects, with a mortality risk ratio of 1.86 (95% confidence interval [CI], 1.21-2.86, P=.005). After adjusting for Pneumocystis carinii and Mycobacterium avium prophylaxis use, AIDS diagnosis, CD4(+) cell count, sex, and age, ERA-I participants were 1.93 times (95% CI, 1.25-2.97; P=.003) more likely to die than ERA-II participants, Among patients without AIDS when treatment was started, ERA-I participants were 2.50 times (95% CI, 1.59-3.93; P<.001) more likely to progress to AIDS or death than ERA-II participants. Conclusion.-The HIV-infected individuals who received initial therapy with regimens including stavudine or lamivudine had significantly fewer mortality and longer AIDS-free survival than those who received initial therapy with regimens limited to zidovudine, didanosine, and zalcitabine.	Univ British Columbia, St Pauls Hosp, AIDS Res Programme, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Dept Hlth Care & Epidemiol, Fac Med, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Dept Pathol, Fac Med, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Dept Med, Fac Med, Vancouver, BC V6Z 1Y6, Canada; Canadian HIV Trials Network, Vancouver, BC, Canada	B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of British Columbia; University of Saskatchewan; University of British Columbia; University of British Columbia; University of British Columbia	Montaner, JSG (corresponding author), Univ British Columbia, St Pauls Hosp, AIDS Res Programme, British Columbia Ctr Excellence HIV AIDS, 667-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.		Montaner, Julio/K-7621-2012; Hogg, Robert S/B-2783-2012	Hogg, Robert S/0000-0003-3463-5488; Schechter, Martin/0000-0001-6063-2155				Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; BROOKMEYER R, 1987, AM J EPIDEMIOL, V126, P14, DOI 10.1093/oxfordjournals.aje.a114646; CAMERON DW, 1996, 11 INT C AIDS JUL 7; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; COLLIER CA, 1996, NEW ENGL J MED, V834, P1011; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; COX DR, 1972, J R STAT SOC B, V34, P187; *CTR EXC HIV AIDS, 1995, THER GUID TREATM HIV; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; Glesby MJ, 1996, ANN INTERN MED, V124, P999, DOI 10.7326/0003-4819-124-11-199606010-00008; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; Graham NMH, 1996, ANN INTERN MED, V124, P1031, DOI 10.7326/0003-4819-124-12-199606150-00002; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KATLAMA C, 1996, 3 C RETR OPP INF JAN; MATHEZ D, 1996, 3 C RETR OPP INF JAN; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Montaner JSG, 1996, JAMA-J AM MED ASSOC, V275, P598, DOI 10.1001/jama.275.8.598; MURRAY HW, 1995, J INFECT DIS S2, V171, P5123; MYERS M, 1996, 11 INT C AIDS JUL 7; Neave H.R., 1998, DISTRIBUTION FREE TE; OBRIEN WA, 1996, NEW ENGL J MED, V334, P425; RIDHY T, 1995, J BIOL CHEM, V270, P29621; VELLA S, 1996, AIDS, V9, P21; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; *WHO, 1990, WKLY EPIDEMIOL REC, V65, P221	33	680	689	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	1998	279	6					450	454		10.1001/jama.279.6.450	http://dx.doi.org/10.1001/jama.279.6.450			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV580	9466638	Bronze			2022-12-28	WOS:000071839800033
J	Beach, R; Proops, R				Beach, R; Proops, R			Management of hyperactive, inattentive children	LANCET			English	Editorial Material									Norfolk & Norwich Hosp, Jenny Linds Childrens Dept, Norwich NR1 3SR, Norfolk, England	Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital	Beach, R (corresponding author), Norfolk & Norwich Hosp, Jenny Linds Childrens Dept, Brunswick Rd, Norwich NR1 3SR, Norfolk, England.								0	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					387	387		10.1016/S0140-6736(05)78350-1	http://dx.doi.org/10.1016/S0140-6736(05)78350-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482288				2022-12-28	WOS:000071982600006
J	Dua, HS				Dua, HS			Bacterial keratitis in the critically ill and comatose patient	LANCET			English	Editorial Material									Univ Nottingham, Queens Med Ctr, Dept Ophthalmol, Nottingham NG7 2UH, England	University of Nottingham	Dua, HS (corresponding author), Univ Nottingham, Queens Med Ctr, Dept Ophthalmol, Nottingham NG7 2UH, England.		Dua, Harminder S/F-3656-2011					HILTON E, 1983, LANCET, V1, P1318; HUTTON WL, 1972, AM J OPHTHALMOL, V73, P37, DOI 10.1016/0002-9394(72)90301-7; Kirwan JF, 1997, BRIT MED J, V314, P433, DOI 10.1136/bmj.314.7078.433; Parkin B, 1997, BRIT J OPHTHALMOL, V81, P1060, DOI 10.1136/bjo.81.12.1060	4	22	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					387	388		10.1016/S0140-6736(05)78351-3	http://dx.doi.org/10.1016/S0140-6736(05)78351-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482289				2022-12-28	WOS:000071982600007
J	Giese, KP; Fedorov, NB; Filipkowski, RK; Silva, AJ				Giese, KP; Fedorov, NB; Filipkowski, RK; Silva, AJ			Autophosphorylation at Thr(286) of the alpha calcium-calmodulin kinase II in LTP and learning	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; MUTANT MICE; CAM KINASE; EXPRESSION; MEMORY; TRANSMISSION; MUTAGENESIS; MECHANISM; MUTATION	The calcium-calmodulin-dependent kinase II (CaMKII) is required for hippocampal longterm potentiation (LTP) and spatial learning. In addition to its calcium-calmodulin (CaM)dependent activity, CaMKII can undergo autophosphorylation, resulting in CaM-independent activity. A point mutation was introduced into the alpha CaMKII gene that blocked the autophosphorylation of threonine at position 286 (Thr(286)) Of this kinase without affecting its CaM-dependent activity, The mutant mice had no N-methyl-D-aspartate receptor-dependent LTP in the hippocampal CAI area and showed no spatial learning in the Morris water maze. Thus, the autophosphorylation of alpha CaMII at Thr(286) appears to be required for LTP and learning.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; M Nencki Inst Expt Biol, Dept Neurophysiol, PL-02093 Warsaw, Poland	Cold Spring Harbor Laboratory; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Silva, AJ (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.		Silva, Alcino/ABD-7684-2021; Giese, Karl P/A-3112-2011	Silva, Alcino/0000-0002-1587-4558; Giese, Karl P/0000-0003-4503-7344; Silva, Alcino/0000-0001-5525-0494	NIA NIH HHS [AG13622] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG013622, U01AG013622] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; FONG YL, 1989, J BIOL CHEM, V264, P16759; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; Kirkwood A, 1997, P NATL ACAD SCI USA, V94, P3380, DOI 10.1073/pnas.94.7.3380; KOLB SJ, 1995, J NEUROCHEM, V64, P2147; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LISMAN JE, 1988, P NATL ACAD SCI USA, V85, P5320, DOI 10.1073/pnas.85.14.5320; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; OHASAKO S, 1991, J BIOCH, V109, P137; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; Otmakhov N, 1997, J NEUROSCI, V17, P5357; Ouyang Y, 1997, J NEUROSCI, V17, P5416; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; SAUER B, 1993, METHOD ENZYMOL, V225, P890; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Silva AJ, 1996, COLD SPRING HARB SYM, V61, P239; STELZER A, 1994, P NATL ACAD SCI USA, V91, P3058, DOI 10.1073/pnas.91.8.3058; STEVENS CF, 1994, CURR BIOL, V4, P687, DOI 10.1016/S0960-9822(00)00153-6; Tan SE, 1996, BRAIN RES, V711, P234, DOI 10.1016/0006-8993(95)01411-X; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; WAXHAM MN, 1990, P NATL ACAD SCI USA, V87, P1273, DOI 10.1073/pnas.87.4.1273; WOLFMAN C, 1994, BEHAV NEURAL BIOL, V61, P203, DOI 10.1016/S0163-1047(05)80001-9; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	42	814	865	1	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	1998	279	5352					870	873		10.1126/science.279.5352.870	http://dx.doi.org/10.1126/science.279.5352.870			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452388				2022-12-28	WOS:000071923500046
J	Zhu, TF; Korber, BT; Nahmias, AJ; Hooper, E; Sharp, PM; Ho, DD				Zhu, TF; Korber, BT; Nahmias, AJ; Hooper, E; Sharp, PM; Ho, DD			An African HIV-1 sequence from 1959 and implications for the origin of the epidemic	NATURE			English	Article							MAXIMUM-LIKELIHOOD; IMMUNODEFICIENCY VIRUSES; DNA-SEQUENCES; AIDS; INFECTION; MANCHESTER; EVOLUTION; HISTORY; GENES; TREES	There is considerable genetic diversity among viruses of different subtypes (designated A to J) in the major group of human immunodeficiency virus type 1 (HIV-1), the form of HIV that is dominant in the global epidemic(1-3). If available, HIV-1 sequences pre-dating the recognition of AIDS could be crucial in defining the time of origin and the subsequent evolution of these viruses in humans. The oldest known case of HIV-1 infection was reported to be that of a sailor from Manchester who died of an AIDS-like illness in 1959 (refs 4-6); however, the authenticity of this case has not been confirmed(7,8). Genetic analysis of sequences from clinical materials obtained from 1971 to 1976 from members of a Norwegian family infected earlier than 1971 showed that they carried viruses of the HIV-1 outlier group(9,10), a variant form that is mainly restricted to West Africa(1). Here we report the amplification and characterization of viral sequences from a 1959 African plasma sample that was previously found to be HIV-1 seropositive(11). Multiple phylogenetic analyses not only authenticate this case as the oldest known HIV-1 infection, but also place its viral sequence near the ancestral node of subtypes B and D in the major group, indicating that these HIV-1 subtypes, and perhaps all major-group viruses, may have evolved from a single introduction into the African population not long before 1959.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Univ Calif Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA; Santa Fe Inst, Santa Fe, NM 87501 USA; Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30303 USA; Univ Nottingham, Queens Med Ctr, Dept Genet, Nottingham NG7 2UH, England	Rockefeller University; United States Department of Energy (DOE); Los Alamos National Laboratory; The Santa Fe Institute; Emory University; University of Nottingham	Ho, DD (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.		Sharp, Paul M/F-5783-2010; Sharp, Paul M/GPX-1497-2022; Zhu, Tuofu/G-6158-2010; Sharp, Paul/Y-3787-2019	Sharp, Paul M/0000-0001-9771-543X; Sharp, Paul M/0000-0001-9771-543X; Korber, Bette/0000-0002-2026-5757				Altschul SF, 1990, J MOL BIOL, V215, P403; CORBITT G, 1990, LANCET, V336, P51, DOI 10.1016/0140-6736(90)91561-N; EIGEN M, 1990, AIDS (London), V4, pS85; FAULKNER DV, 1988, TRENDS BIOCHEM SCI, V13, P321, DOI 10.1016/0968-0004(88)90129-6; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; FROLAND SS, 1988, LANCET, V1, P1344; Gao F, 1996, J VIROL, V70, P1651, DOI 10.1128/JVI.70.3.1651-1667.1996; GOJOBORI T, 1990, P NATL ACAD SCI USA, V87, P4108, DOI 10.1073/pnas.87.11.4108; Goudsmit J., 1997, VIRAL SEX NATURE AID; Hooper E, 1996, LANCET, V348, P1363, DOI 10.1016/S0140-6736(96)07063-8; Jonassen TO, 1997, VIROLOGY, V231, P43, DOI 10.1006/viro.1997.8510; KELLY JK, 1994, GENET RES, V64, P1, DOI 10.1017/S0016672300032481; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; Leitner T, 1996, P NATL ACAD SCI USA, V93, P10864, DOI 10.1073/pnas.93.20.10864; LEITNER TS, 1995, J VIROL, V71, P4761; LI WH, 1988, MOL BIOL EVOL, V5, P313; LOUWAGIE J, 1993, AIDS, V7, P769, DOI 10.1097/00002030-199306000-00003; LUKASHOV VV, 1995, J VIROL, V69, P6911, DOI 10.1128/JVI.69.11.6911-6916.1995; MOTULSKY AG, 1966, AM J HUM GENET, V18, P514; NAHMIAS AJ, 1986, LANCET, V1, P1279; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0; Sharp P.M., 1994, AIDS S1, V8, pS27; SHARP PM, 1988, NATURE, V336, P315, DOI 10.1038/336315a0; SIEPEL AC, 1995, AIDS RES HUM RETROV, V11, P1413, DOI 10.1089/aid.1995.11.1413; SMITH TF, 1988, NATURE, V333, P573, DOI 10.1038/333573a0; WILLIAMS G, 1983, LANCET, V2, P1136; WILLIAMS G, 1960, LANCET, V2, P951; WOLINSKY S, 1996, SCIENCE, V277, P537; ZHU TF, 1995, NATURE, V374, P503, DOI 10.1038/374503a0	30	285	302	0	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 5	1998	391	6667					594	597		10.1038/35400	http://dx.doi.org/10.1038/35400			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468138	Bronze			2022-12-28	WOS:000071842300054
J	Roland, M; Torgerson, DJ				Roland, M; Torgerson, DJ			Understanding controlled trials - What are pragmatic trials?	BRITISH MEDICAL JOURNAL			English	Review									Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England; Univ York, Ctr Hlth Econ, Natl Primary Care Res & Dev Ctr, York YO1 5DD, N Yorkshire, England	University of Manchester; University of York - UK	Roland, M (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.		Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275				RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0	2	510	525	1	29	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					285	285		10.1136/bmj.316.7127.285	http://dx.doi.org/10.1136/bmj.316.7127.285			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472515	Green Published			2022-12-28	WOS:000071702100030
J	Melamed, D; Benschop, RJ; Cambier, JC; Nemazee, D				Melamed, D; Benschop, RJ; Cambier, JC; Nemazee, D			Developmental regulation of B lymphocyte immune tolerance compartmentalizes clonal selection from receptor selection	CELL			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; ANTIGEN-RECEPTOR; CELL DIFFERENTIATION; BONE-MARROW; NEGATIVE SELECTION; STROMAL CELLS; CROSS-LINKING; EXPRESSION; MOUSE; SELF	B lymphocyte development is a highly ordered process that involves immunoglobulin gene rearrangements, antigen receptor expression, and a learning process that minimizes the development of cells with reactivity to self tissue. Two distinct mechanisms for immune tolerance have been defined that operate during early bone marrow stages of B cell development: apoptosis, which eliminates clones of cells, and receptor editing, which spares the cells but genetically reprograms their autoreactive antigen receptors through nested immunoglobulin L chain gene rearrangements. We show here that sensitivity to antigen-induced apoptosis arises relatively late in B cell development and is preceded by a functionally distinct developmental stage capable of receptor editing. This regulation compartmentalizes clonal selection from receptor selection.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80220 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Melamed, D (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA.			Cambier, John/0000-0002-7803-242X	NIAID NIH HHS [R01 AI033608, R01 AI 33608, K04 AI01161, P01 AI22295] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033608, P01AI022295, K04AI001161] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BILLIPS LG, 1992, BLOOD, V79, P1185; BOEKEL ET, 1995, INT IMMUNOL, V7, P1013; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BRINES RD, 1992, INT IMMUNOL, V4, P765, DOI 10.1093/intimm/4.7.765; Burrows PD, 1997, CURR OPIN IMMUNOL, V9, P239, DOI 10.1016/S0952-7915(97)80142-2; CARSETTI R, 1995, J EXP MED, V181, P2129, DOI 10.1084/jem.181.6.2129; Chen C, 1997, IMMUNITY, V6, P97, DOI 10.1016/S1074-7613(00)80673-1; Choi MSK, 1996, EUR J IMMUNOL, V26, P676, DOI 10.1002/eji.1830260325; Constantinescu A, 1997, J EXP MED, V185, P609, DOI 10.1084/jem.185.4.609; CUMANO A, 1990, EUR J IMMUNOL, V20, P2183, DOI 10.1002/eji.1830201006; FINKELMAN FD, 1995, J EXP MED, V181, P515, DOI 10.1084/jem.181.2.515; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; Hardy RR, 1995, ANN NY ACAD SCI, V764, P19; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; Hertz M, 1997, IMMUNITY, V6, P429, DOI 10.1016/S1074-7613(00)80286-1; KINOSHITA T, 1988, J IMMUNOL, V140, P3066; Klinman NR, 1996, IMMUNITY, V5, P189, DOI 10.1016/S1074-7613(00)80314-3; Lang J, 1997, J EXP MED, V186, P1513, DOI 10.1084/jem.186.9.1513; Lang J, 1996, J EXP MED, V184, P1685, DOI 10.1084/jem.184.5.1685; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; Li Z, 1996, IMMUNITY, V5, P575, DOI 10.1016/S1074-7613(00)80272-1; Lu LW, 1997, J IMMUNOL, V158, P5136; Melamed D, 1997, J IMMUNOL, V159, P1233; Melamed D, 1997, P NATL ACAD SCI USA, V94, P9267, DOI 10.1073/pnas.94.17.9267; MELCHERS F, 1994, ANNU REV IMMUNOL, V12, P209, DOI 10.1146/annurev.immunol.12.1.209; MELCHERS F, 1995, CURR OPIN IMMUNOL, V7, P214, DOI 10.1016/0952-7915(95)80006-9; METCALF ES, 1977, J IMMUNOL, V118, P2111; Monroe JG, 1996, J IMMUNOL, V156, P2657; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NORVELL A, 1995, J IMMUNOL, V154, P4404; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; OJCIUS DM, 1991, EXP CELL RES, V197, P43, DOI 10.1016/0014-4827(91)90477-C; PARRY SL, 1994, J IMMUNOL, V152, P2821; Pelanda R, 1997, IMMUNITY, V7, P765, DOI 10.1016/S1074-7613(00)80395-7; PIKE BL, 1980, J EXP MED, V152, P1407, DOI 10.1084/jem.152.5.1407; Radic MZ, 1995, ANN NY ACAD SCI, V764, P384; Radic MZ, 1996, IMMUNITY, V5, P505, DOI 10.1016/S1074-7613(00)80266-6; RAFF MC, 1975, J EXP MED, V142, P1052, DOI 10.1084/jem.142.5.1052; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RETH M, 1995, IMMUNOL TODAY, V16, P310; ROLINK A, 1991, EUR J IMMUNOL, V21, P2895, DOI 10.1002/eji.1830211137; ROLINK A, 1993, J EXP MED, V178, P1263, DOI 10.1084/jem.178.4.1263; ROLINK A, 1994, INT IMMUNOL, V6, P1257, DOI 10.1093/intimm/6.8.1257; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; Shaffer AL, 1997, J IMMUNOL, V159, P1265; SIDMAN CL, 1975, NATURE, V257, P149, DOI 10.1038/257149a0; Sleckman BP, 1996, ANNU REV IMMUNOL, V14, P459, DOI 10.1146/annurev.immunol.14.1.459; SMITHSON G, 1995, J IMMUNOL, V155, P3409; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; STORB U, 1994, IMMUNOL RES, V13, P291, DOI 10.1007/BF02935620; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TSUBATA T, 1994, CURR BIOL, V4, P8, DOI 10.1016/S0960-9822(00)00003-8; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VILAN BJ, 1997, J IMMUNOL, V159, P231; WINKLER TH, 1995, BLOOD, V85, P2045, DOI 10.1182/blood.V85.8.2045.bloodjournal8582045; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043	65	201	203	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					173	182		10.1016/S0092-8674(00)80912-5	http://dx.doi.org/10.1016/S0092-8674(00)80912-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458042	Bronze			2022-12-28	WOS:000071672600007
J	Abel, T; Martin, KC; Bartsch, D; Kandel, ER				Abel, T; Martin, KC; Bartsch, D; Kandel, ER			Memory suppressor genes: Inhibitory constraints on the storage of long-term memory	SCIENCE			English	Review							CELL-ADHESION MOLECULES; DEPENDENT PROTEIN-KINASE; CAMP-RESPONSIVE ELEMENT; SYNAPTIC PLASTICITY; FUNCTIONAL COMPONENTS; REGULATORY SUBUNITS; APLYSIA; FACILITATION; CREB; DROSOPHILA	Synaptic plasticity, the ability of neurons to alter the strength of their synaptic connections with activity and experience, is thought to play a critical role in memory storage. Molecular studies of gene expression during long-lasting synaptic plasticity related to memory storage initially focused on the identification of positive regulators. More recent work has revealed that the establishment of long-lasting synaptic plasticity and long-term memory also requires the removal of inhibitory constraints. By analogy to tumor supressor genes, which restrain cell proliferation, we propose that these inhibitory constraints on memory storage, which restrain synapse growth, be termed memory suppressor genes.	Columbia Univ, Ctr Neurobiol & Behav, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	Abel, T (corresponding author), Univ Penn, Dept Biol, Leidy Labs, 415 S Univ Ave, Philadelphia, PA 19104 USA.		Abel, Ted/AAX-2825-2021	Abel, Ted/0000-0003-2423-4592				Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; Bailey CH, 1997, NEURON, V18, P913, DOI 10.1016/S0896-6273(00)80331-1; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; BERGOLD PJ, 1990, P NATL ACAD SCI USA, V87, P3788, DOI 10.1073/pnas.87.10.3788; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; CAREW TJ, 1972, SCIENCE, V175, P451, DOI 10.1126/science.175.4020.451; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; Davis GW, 1996, NEURON, V17, P669, DOI 10.1016/S0896-6273(00)80199-3; Davis RL, 1996, PHYSIOL REV, V76, P299, DOI 10.1152/physrev.1996.76.2.299; DODD J, 1995, CELL, V81, P471, DOI 10.1016/0092-8674(95)90066-7; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; Ferguson EL, 1996, CURR OPIN GENET DEV, V6, P424, DOI 10.1016/S0959-437X(96)80063-3; Fields RD, 1996, TRENDS NEUROSCI, V19, P473, DOI 10.1016/S0166-2236(96)30013-1; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GREENBERG SM, 1987, NATURE, V329, P62, DOI 10.1038/329062a0; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; Hegde AN, 1997, CELL, V89, P115, DOI 10.1016/S0092-8674(00)80188-9; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOGAN JH, 1996, CURR BIOL, V7, P1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; McGaugh JL, 1996, P NATL ACAD SCI USA, V93, P13508, DOI 10.1073/pnas.93.24.13508; Muller D, 1996, NEURON, V17, P413, DOI 10.1016/S0896-6273(00)80174-9; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PINSKER HM, 1973, SCIENCE, V182, P1039, DOI 10.1126/science.182.4116.1039; RESCORLA RA, 1988, ANNU REV NEUROSCI, V11, P329, DOI 10.1146/annurev.ne.11.030188.001553; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schuster CM, 1996, NEURON, V17, P655, DOI 10.1016/S0896-6273(00)80198-1; Schuster CM, 1996, NEURON, V17, P641, DOI 10.1016/S0896-6273(00)80197-X; Winder DG, 1998, CELL, V92, P25, DOI 10.1016/S0092-8674(00)80896-X; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; ZHU H, 1994, J NEUROSCI, V14, P6886	45	219	226	4	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					338	341		10.1126/science.279.5349.338	http://dx.doi.org/10.1126/science.279.5349.338			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9454331				2022-12-28	WOS:000071570800034
J	Bernhard, JD				Bernhard, JD			The skin also rises	LANCET			English	Article											Bernhard, JD (corresponding author), UNIV MASSACHUSETTS,MED CTR,DIV DERMATOL,WORCESTER,MA 01655, USA.							ASNIS LA, 1995, J AM ACAD DERMATOL, V33, P393, DOI 10.1016/0190-9622(95)91382-3; ASSIER H, 1995, ARCH DERMATOL, V131, P539, DOI 10.1001/archderm.131.5.539; GREAVES MW, 1995, NEW ENGL J MED, V332, P1767, DOI 10.1056/NEJM199506293322608; HOVANIAN A, 1995, J INVEST DERMATOL, V104, P456; PARKER TL, 1995, J AM ACAD DERMATOL, V32, P233, DOI 10.1016/0190-9622(95)90132-9	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S3	S3		10.1016/0140-6736(95)90002-0	http://dx.doi.org/10.1016/0140-6736(95)90002-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454046				2022-12-28	WOS:A1995TN12200003
J	Sund, T; Rinde, E				Sund, T; Rinde, E			Telemedicine: Still waiting for users	LANCET			English	Article											Sund, T (corresponding author), TELENOR RES & DEV,POB 1156,N-9001 TROMSO,NORWAY.							GLOWNIAK JV, 1995, ANN INTERN MED, V123, P123, DOI 10.7326/0003-4819-123-2-199507150-00008; Grigsby J, 1995, J Med Syst, V19, P19, DOI 10.1007/BF02257187; HOUTCHENS BA, 1995, J MED SYST, V19, P93, DOI 10.1007/BF02257060; KIENZLE M, 1995, B MED LIBR ASSOC, V83, P37; WONG S, 1995, P IEEE, V83, P194, DOI 10.1109/5.364466	5	4	4	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S24	S24		10.1016/0140-6736(95)90023-3	http://dx.doi.org/10.1016/0140-6736(95)90023-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TN122	9454042				2022-12-28	WOS:A1995TN12200024
J	Yu, HT; Peters, JM; King, RW; Page, AM; Hieter, P; Kirschner, MW				Yu, HT; Peters, JM; King, RW; Page, AM; Hieter, P; Kirschner, MW			Identification of a cullin homology region in a subunit of the anaphase-promoting complex	SCIENCE			English	Article							SISTER-CHROMATID SEPARATION; SACCHAROMYCES-CEREVISIAE; UBIQUITIN LIGASE; MITOTIC CYCLINS; CELL-CYCLE; PROTEOLYSIS; DESTRUCTION; TRANSITION; YEAST; DEGRADATION	The anaphase-promoting complex is composed of eight protein subunits, including BimE (APC1), CDC27 (APC3), CDC16 (APC6), and CDC23 (APC8). The remaining four human APC subunits, APC2, APC4, APC5, and APC7, as well as human CDC23, were cloned. APC7 contains multiple copies of the tetratrico peptide repeat, similar to CDC16, CDC23, and CDC27. Whereas APC4 and APC5 share no similarity to proteins of known function, APC2 contains a region that is similar to a sequence in cullins, a family of proteins implicated in the ubiquitination of G(1) phase cyclins and cyclin-dependent kinase inhibitors. The APC2 gene is essential in Saccharomyces cerevisiae, and apc2 mutants arrest at metaphase and are defective in the degradation of Pds1p. APC2 and cullins may be distantly related members of a ubiquitin ligase family that targets cell cycle regulators for degradation.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V6R 2X8, Canada	Harvard University; Harvard Medical School; University of British Columbia	Kirschner, MW (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	marc@hms.harvard.edu		Yu, Hongtao/0000-0002-8861-049X	NCI NIH HHS [CA16519] Funding Source: Medline; NIGMS NIH HHS [GM26875-17, GM39023-08] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039023, R37GM026875, R01GM026875] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; Mathias N, 1996, MOL CELL BIOL, V16, P6634; PAGE AR, UNPUB; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	28	206	223	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	1998	279	5354					1219	1222		10.1126/science.279.5354.1219	http://dx.doi.org/10.1126/science.279.5354.1219			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469815				2022-12-28	WOS:000072115200047
J	Jarvelainen, H; Vainionpaa, H; Kuopio, T; Lehtonen, A				Jarvelainen, H; Vainionpaa, H; Kuopio, T; Lehtonen, A			A woman with nodules in her lungs	LANCET			English	Article							INHALATION; SILICOSIS		Univ Turku, Cent Hosp, Dept Med, FIN-20520 Turku, Finland; Univ Turku, Dept Pathol, SF-20500 Turku, Finland; Turku City Hosp, Dept Geriatr, Turku, Finland	University of Turku; University of Turku; University of Turku	Jarvelainen, H (corresponding author), Univ Turku, Cent Hosp, Dept Med, FIN-20520 Turku, Finland.			Kuopio, Teijo/0000-0003-3503-4094				CHO K, 1994, CHEST, V106, P309, DOI 10.1378/chest.106.1.309; DUMONTET C, 1991, LANCET, V338, P1085, DOI 10.1016/0140-6736(91)91946-R; DUMONTET C, 1991, AM REV RESPIR DIS, V143, P880, DOI 10.1164/ajrccm/143.4_Pt_1.880; GALLARDO M, 1994, LANCET, V344, P412, DOI 10.1016/S0140-6736(94)91441-9; Wagner GR, 1997, LANCET, V349, P1311, DOI 10.1016/S0140-6736(96)07336-9	5	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	1998	351	9101					494	494		10.1016/S0140-6736(97)10491-3	http://dx.doi.org/10.1016/S0140-6736(97)10491-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482442				2022-12-28	WOS:000072097700014
J	Rosenstein, N; Levine, O; Taylor, JP; Evans, D; Plikaytis, BD; Wenger, JD; Perkins, BA				Rosenstein, N; Levine, O; Taylor, JP; Evans, D; Plikaytis, BD; Wenger, JD; Perkins, BA			Efficacy of meningococcal vaccine and barriers to vaccination	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	26th Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 15-18, 1996	NEW ORLEANS, LA	Amer Soc Microbiol			MULTILOCUS ENZYME ELECTROPHORESIS; SEROGROUP-C; GROUP-A; DISEASE; CAMPAIGN; CARRIAGE; CANADA; CAMPUS	Context.-Use of the quadrivalent meningococcal vaccine for control of outbreaks has increased in recent years, but the efficacy of meningococcal vaccine during mass vaccination campaigns in US civilian populations has not been assessed. Objectives.-To evaluate the efficacy of the quadrivalent meningococcal vaccine against serogroup C meningococcal disease in a community outbreak setting and to evaluate potentially modifiable barriers to vaccination in an area with persistent meningococcal disease following immunization. Design.-Matched case-control study of vaccine efficacy using cases of serogroup C meningococcal disease in persons eligible for vaccination during mass vaccination campaigns. Control patients were matched by neighborhood and age. The control group was used to identify possible barriers to vaccination. Setting.-Gregg County, Texas, population 106 076, from 1993 to 1995. Participants.-A total of 17 case patients with serogroup C meningococcal disease eligible for vaccine and 84 control patients. Main Outcome Measures.-Vaccine efficacy and risk factors associated with nonvaccination. Results.-Vaccine efficacy among 2- to 29-year-olds was 85% (95% confidence interval, 27%-97%) and did not change in bivariate analyses with other risk factors that were significant in univariate analysis. Among control patients, older age was strongly associated with nonvaccination; vaccination rates for 2- to 4-year-olds, 5- to 18-year-olds, and 19- to 29-year-olds were 67%, 48%, and 20%, respectively (chi(2) for linear trend, P=.01). Conclusions.-The meningococcal polysaccharide vaccine was effective against serogroup C meningococcal disease in this community outbreak. Although specific barriers to vaccination were not identified, older age was a risk factor for nonvaccination in the target population of 2- to 29-year-olds. In future outbreaks, emphasis should be placed on achieving high vaccination coverage, with special efforts to vaccinate young adults.	Ctr Dis Control & Prevent, NCID, Div Bacterial & Mycot Dis, Childhood & Resp Dis Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, NCID, Div Bacterial & Mycot Dis, Biostat & Informat Management Branch, Atlanta, GA 30333 USA; Texas Dept Hlth, Infect Dis Epidemiol & Surveillance Div, Austin, TX 78756 USA; Texas Dept Hlth, Infect Dis Epidemiol & Surveillance Div, Tyler, TX USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Texas Department of State Health Services; Texas Department of State Health Services	Rosenstein, N (corresponding author), Ctr Dis Control & Prevent, NCID, Div Bacterial & Mycot Dis, Childhood & Resp Dis Branch, Mailstop C-23,1600 Clifton Rd NE, Atlanta, GA 30333 USA.	nar5@cdc.gov						ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; ARTENSTEIN MS, 1970, NEW ENGL J MED, V282, P417, DOI 10.1056/NEJM197002192820803; ASHTON FE, 1991, J CLIN MICROBIOL, V29, P2489, DOI 10.1128/JCM.29.11.2489-2493.1991; BISELLI R, 1993, VACCINE, V11, P578, DOI 10.1016/0264-410X(93)90236-Q; BLAKEBROUGH IS, 1983, ANN TROP MED PARASIT, V77, P175, DOI 10.1080/00034983.1983.11811694; CAUGANT DA, 1987, J BACTERIOL, V169, P2781, DOI 10.1128/jb.169.6.2781-2792.1987; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P21; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; DeWals P, 1996, B WORLD HEALTH ORGAN, V74, P407; Fischer M, 1997, PEDIATR INFECT DIS J, V16, P979, DOI 10.1097/00006454-199710000-00015; GOLD R, 1975, J CLIN INVEST, V56, P1536, DOI 10.1172/JCI108235; GOLD R, 1971, B WORLD HEALTH ORGAN, V45, P279; GOTSCHLICH EC, 1969, J EXP MED, V129, P1385, DOI 10.1084/jem.129.6.1385; HASSANKING MKA, 1988, J INFECTION, V16, P55, DOI 10.1016/S0163-4453(88)96117-8; Imrey PB, 1996, AM J EPIDEMIOL, V143, P624, DOI 10.1093/oxfordjournals.aje.a008792; JACKSON LA, 1995, JAMA-J AM MED ASSOC, V273, P383, DOI 10.1001/jama.273.5.383; Le Saux N, 1992, Can J Infect Dis, V3, P60; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Lieberman JM, 1996, JAMA-J AM MED ASSOC, V275, P1499, DOI 10.1001/jama.275.19.1499; MOORE PS, 1988, JAMA-J AM MED ASSOC, V260, P2686, DOI 10.1001/jama.260.18.2686; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; Roberts CL, 1996, AM J PUBLIC HEALTH, V86, P1155, DOI 10.2105/AJPH.86.8_Pt_1.1155; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; Tappero JW, 1996, NEW ENGL J MED, V335, P833, DOI 10.1056/NEJM199609193351201; TAUNAY A E, 1978, Revista do Instituto Adolfo Lutz, V38, P77; WHITNEY CG, 1996, 10 INT PATH NEISS C; WOODS TC, 1992, J CLIN MICROBIOL, V30, P132, DOI 10.1128/JCM.30.1.132-137.1992	27	81	83	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	1998	279	6					435	439		10.1001/jama.279.6.435	http://dx.doi.org/10.1001/jama.279.6.435			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YV580	9466635	Bronze			2022-12-28	WOS:000071839800030
J	Matlack, KES; Mothes, W; Rapoport, TA				Matlack, KES; Mothes, W; Rapoport, TA			Protein translocation: Tunnel vision	CELL			English	Review							ENDOPLASMIC-RETICULUM MEMBRANE; COLI PREPROTEIN TRANSLOCASE; SIGNAL SEQUENCE RECOGNITION; ESCHERICHIA-COLI; ER-MEMBRANE; SECRETORY PROTEINS; CONDUCTING CHANNEL; SEC PROTEINS; COMPLEX; INSERTION		Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Matlack, KES (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, 240 Longwood Ave, Boston, MA 02115 USA.							AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; BASSILANA M, 1993, BIOCHEMISTRY-US, V32, P2626, DOI 10.1021/bi00061a021; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; Corsi AK, 1996, J BIOL CHEM, V271, P30299, DOI 10.1074/jbc.271.48.30299; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DALBEY RE, 1995, TRENDS CELL BIOL, V5, P380, DOI 10.1016/S0962-8924(00)89079-0; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; DUNLOP J, 1995, EMBO J, V14, P3609, DOI 10.1002/j.1460-2075.1995.tb00030.x; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; FLOWER AM, 1994, J BACTERIOL, V176, P5607, DOI 10.1128/JB.176.18.5607-5614.1994; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; ITO K, 1995, ADV CELL MOL BIOL M, V4, P35; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KIM YJ, 1994, CELL, V78, P845; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; Martoglio B, 1996, TRENDS CELL BIOL, V6, P142, DOI 10.1016/0962-8924(96)10001-5; Matlack KES, 1997, SCIENCE, V277, P938, DOI 10.1126/science.277.5328.938; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; NICCHITTA CV, 1995, J CELL BIOL, V129, P957, DOI 10.1083/jcb.129.4.957; OLIVER J, 1995, FEBS LETT, V362, P126, DOI 10.1016/0014-5793(95)00223-V; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1960, DOI 10.1073/pnas.84.7.1960; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; vanKlompenburg W, 1997, EMBO J, V16, P4261, DOI 10.1093/emboj/16.14.4261; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wickner W, 1996, J BIOL CHEM, V271, P29514, DOI 10.1074/jbc.271.47.29514; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0	52	243	251	1	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 6	1998	92	3					381	390		10.1016/S0092-8674(00)80930-7	http://dx.doi.org/10.1016/S0092-8674(00)80930-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YX283	9476897	Bronze			2022-12-28	WOS:000072024700009
J	Whittle, MJ				Whittle, MJ			Early amniocentesis: time for a rethink	LANCET			English	Editorial Material							VILLUS		Birmingham Womens Hosp, Acad Dept Obstet & Gynaecol, Birmingham B15 2TT, W Midlands, England	Birmingham Women's Hospital	Whittle, MJ (corresponding author), Birmingham Womens Hosp, Acad Dept Obstet & Gynaecol, Birmingham B15 2TT, W Midlands, England.							FEDRICK J, 1978, BRIT J OBSTET GYNAEC, V85, P1, DOI 10.1111/j.1471-0528.1978.tb15816.x; Froster UG, 1996, LANCET, V347, P489, DOI 10.1016/S0140-6736(96)91136-8; Greenough A, 1997, EUR J PEDIATR, V156, P550, DOI 10.1007/s004310050660; HACKETT GA, 1991, PRENAT DIAGN, V11, P331; HISLOP A, 1982, LANCET, V2, P1271; Lowther GW, 1997, EUR J HUM GENET, V5, P84, DOI 10.1159/000484823; Nicolaides KH, 1996, FETAL DIAGN THER, V11, P9, DOI 10.1159/000264272; SMIDTJENSEN S, 1992, LANCET, V340, P1237, DOI 10.1016/0140-6736(92)92946-D	8	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 24	1998	351	9098					226	227		10.1016/S0140-6736(98)22004-6	http://dx.doi.org/10.1016/S0140-6736(98)22004-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU294	9457086				2022-12-28	WOS:000071702200002
J	Butler, T; Roland, M				Butler, T; Roland, M			How will primary care groups work?	BRITISH MEDICAL JOURNAL			English	Article									Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 6PL, Lancs, England	University of Manchester	Butler, T (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 6PL, Lancs, England.								0	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					214	214						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468694				2022-12-28	WOS:000071616400040
J	Passmore, SJ; Draper, G; Brownbill, P; Kroll, M				Passmore, SJ; Draper, G; Brownbill, P; Kroll, M			Ecological studies of relation between hospital policies on neonatal vitamin K administration and subsequent occurrence of childhood cancer	BRITISH MEDICAL JOURNAL			English	Article								Objective: To investigate the possible link between neonatal administration of intramuscular vitamin K and childhood cancer. Design: Ecological studies comparing incidence of cancer in groups of children classified by the vitamin K policy in operation at their hospital of birth. Setting: Selected large maternity units in England, Scotland, and Wales. Subjects: Children born in these units in varying periods between 1966 and 1991. Main outcome measures: Cancer occurring among these children before age 15 years identified by using the National Registry of Childhood Tumours. Ratios of observed to expected numbers of these conditions calculated for hospitals where the policy was to give all babies intramuscular vitamin K (non-selective) and where the policy was to use this treatment only for a selected minority of babies at increased risk of vitamin K deficiency bleeding (selective). Results: These ratios were calculated for children horn in 94 hospitals with varying vitamin K policies. A raised fisk was occasionally associated with vitamin K, but the overall results were not significant, and there was no evidence to support the previously suggested doubling of the risk of childhood cancer. Conclusions: On the basis of the results reported here it is unlikely that there is a greatly increased risk of childhood cancer attributable to intramuscular vitamin K given to newborns, if indeed there is any.	Childhood Canc Res Grp, Oxford OX2 6HJ, England	University of Oxford	Draper, G (corresponding author), Childhood Canc Res Grp, Oxford OX2 6HJ, England.							[Anonymous], BIOMETRIKA TABLES ST; Ansell P, 1996, BRIT MED J, V313, P204, DOI 10.1136/bmj.313.7051.204; BRESLOW NE, 1987, IARC SCI PUBL, V82, P94; GOLDING J, 1990, BRIT J CANCER, V62, P304, DOI 10.1038/bjc.1990.283; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; PASSMORE J, 1998, BRIT MED J, V316, P178	6	23	23	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					184	189						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468682	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000071616400022
J	Ramirez, A; Addington-Hall, J; Richards, M				Ramirez, A; Addington-Hall, J; Richards, M			ABC of palliative care - The carers	BRITISH MEDICAL JOURNAL			English	Review							CANCER		United Med & Dent Sch Guys & St Thomas Hosp, London SE1 9RT, England; Lambeth Healthcare NHS Trust, London, England; Univ London Kings Coll, Sch Med & Dent, London, England; St Christophers Hospice, London, England	University of London; King's College London; University of London; King's College London	Ramirez, A (corresponding author), United Med & Dent Sch Guys & St Thomas Hosp, London SE1 9RT, England.							ADDINGTONHALL J, 1995, PALLIATIVE MED, V9, P295, DOI 10.1177/026921639500900404; ADDINGTONHALL JM, 1992, BRIT MED J, V305, P1317, DOI 10.1136/bmj.305.6865.1317; Faulkner Ann, 1994, TALKING CANC PATIENT; Graham J, 1996, PALLIATIVE MED, V10, P185, DOI 10.1177/026921639601000302; SEALE C, 1991, Palliative Medicine, V5, P12, DOI 10.1177/026921639100500104	5	81	84	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					208	211						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468691				2022-12-28	WOS:000071616400035
J	Neven, P; DeMuylder, X				Neven, P; DeMuylder, X			Hormonal interventions and cancer risk	LANCET			English	Article											Neven, P (corresponding author), ALGEMERE KLIN ST JAN,DEPT OBSTET & GYNAECOL,BROEKST 114,B-1000 BRUSSELS,BELGIUM.							ASSIKIS VJ, 1995, INT J GYNECOL OBSTET, V49, P241, DOI 10.1016/0020-7292(95)02387-R; BERAL V, 1995, J CLIN EPIDEMIOL, V48, P165, DOI 10.1016/0895-4356(94)00114-6; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; SILVA ID, 1995, BRIT J CANCER, V72, P485, DOI 10.1038/bjc.1995.360; TONIOLO PG, 1995, JNCI-J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S8	S8		10.1016/0140-6736(95)90007-1	http://dx.doi.org/10.1016/0140-6736(95)90007-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454051	Bronze			2022-12-28	WOS:A1995TN12200008
J	Squire, SB				Squire, SB			Can we stand the heat?	LANCET			English	Article											Squire, SB (corresponding author), UNIV LIVERPOOL, LIVERPOOL SCH TROP MED, LIVERPOOL L3 5QA, MERSEYSIDE, ENGLAND.			Squire, Stephen/0000-0001-7173-9038				AISU T, 1995, AIDS, V9, P267, DOI 10.1097/00002030-199509030-00008; DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1; DECOCK KM, 1995, LANCET, V346, P675, DOI 10.1016/S0140-6736(95)92284-9; GEBRE N, 1995, T ROY SOC TROP MED H, V89, P191, DOI 10.1016/0035-9203(95)90491-3; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	1995	346			S			S25	S25		10.1016/0140-6736(95)90024-1	http://dx.doi.org/10.1016/0140-6736(95)90024-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454043				2022-12-28	WOS:A1995TN12200025
J	Greenberg, HM				Greenberg, HM			American medicine is on the right track	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE		New York Acad Sci, Board Governors, New York, NY USA		Greenberg, HM (corresponding author), Columbia Univ, St Lukes Roosevelt Hosp, Coll Phys & Surg, 1000 10th Ave, New York, NY 10019 USA.							CHURCHILL LR, 1989, HASTINGS CENT REP, V19, P28, DOI 10.2307/3562740; Ellwood PM, 1996, JAMA-J AM MED ASSOC, V276, P1083, DOI 10.1001/jama.276.13.1083; FIRESTONE D, 1997, NY TIMES        0836, pB1; Fuchs VR, 1997, JAMA-J AM MED ASSOC, V277, P920, DOI 10.1001/jama.277.11.920; Ginzberg E, 1997, NEW ENGL J MED, V336, P1018, DOI 10.1056/NEJM199704033361411; GREENBERG HM, 1994, ANN NY ACAD SCI, V729, P8, DOI 10.1111/j.1749-6632.1994.tb12204.x; GREENLICK MR, 1992, JAMA-J AM MED ASSOC, V267, P1645, DOI 10.1001/jama.267.12.1645; HALL WJ, 1993, HEALTH AFFAIR, V12, P58, DOI 10.1377/hlthaff.12.1.58; Kassirer JP, 1997, NEW ENGL J MED, V336, P1666, DOI 10.1056/NEJM199706053362308; Kassirer JP, 1997, NEW ENGL J MED, V336, P1013, DOI 10.1056/NEJM199704033361408; Lawrence DM, 1997, HEALTH AFFAIR, V16, P72, DOI 10.1377/hlthaff.16.3.72; McArthur JH, 1997, JAMA-J AM MED ASSOC, V277, P985, DOI 10.1001/jama.277.12.985	12	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	1998	279	6					426	428		10.1001/jama.279.6.426	http://dx.doi.org/10.1001/jama.279.6.426			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV580	9466623				2022-12-28	WOS:000071839800013
J	Stull, TM; Hearn, TL; Hancock, JS; Handsfield, JH; Collins, CL				Stull, TM; Hearn, TL; Hancock, JS; Handsfield, JH; Collins, CL			Variation in proficiency testing performance by testing site	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-AMERICAN-PATHOLOGISTS; LABORATORY PERFORMANCE; CLINICAL-CHEMISTRY; DISEASE-CONTROL; WORKING GROUP; ACCURACY; EXPERIENCE; PROGRAMS; CENTERS; IMPACT	Context.-Congress enacted the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to promote uniform quality and standards among all testing sites in the United States. The performance indicators specified in the legislation are proficiency testing (PT) performance and periodic inspections. Objective.-To evaluate variation in PT performance by type of testing facility during the first year of compulsory participation under CLIA. Design.-All 1994 PT score data electronically reported to the Health Care Financing Administration as a component of compliance with the CLIA regulations were obtained. Over 1.2 million PT event scores from 17 058 unique testing sites were sorted into 2 groups based on the type of testing facility: hospitals and independent laboratories (HI) and all other testing sites (AOT). Main Outcome Measures.-Satisfactory and unsatisfactory performance rates for HI and AOT for each analyte and/or test, according to the criteria specified by the CLIA regulations. Results.-The aggregate rates of satisfactory event performance for all regulated analytes, tests, and specialties were 97% and 91% for the HI and AOT groups, respectively. The aggregate odds ratio for unsatisfactory PT event performance for the AOT group compared with the HI group was 2.89, with a range of 2.19 to 7.51 for the individual analytes. Conclusion.-There was a consistent difference in PT performance during the first full year of compulsory PT under the CLIA regulations based on the type of testing facility performing the analysis. Traditional testing sites achieved higher rates of satisfactory performance than newly regulated, alternative testing sites.	Ctr Dis Control & Prevent, Publ Hlth Practice Program Off, Div Lab Syst, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Stull, TM (corresponding author), Ctr Dis Control & Prevent, Publ Hlth Practice Program Off, Div Lab Syst, 4770 Bufrod Hwy NE,Mailstop G-23, Atlanta, GA 30341 USA.							BELK WP, 1947, AM J CLIN PATHOL, V17, P853; BELK WP, 1988, ARCH PATHOL LAB MED, V112, P320; BOONE DJ, 1995, ARCH PATHOL LAB MED, V119, P999; BOONE J, 1982, AM J PUBLIC HEALTH, V72, P1364, DOI 10.2105/AJPH.72.12.1364; CEMBROWSKI GS, 1988, ARCH PATHOL LAB MED, V112, P374; CRAWLEY R, 1986, JAMA-J AM MED ASSOC, V255, P374, DOI 10.1001/jama.255.3.374; EHRMEYER SS, 1994, J CLIN IMMUNOASSAY, V17, P223; Ferris D G, 1995, Arch Fam Med, V4, P34, DOI 10.1001/archfami.4.1.34; GILBERT RK, 1975, AM J CLIN PATHOL, V63, P960; HAIN RF, 1972, SOUTHERN MED J, V65, P608, DOI 10.1097/00007611-197205000-00024; HANSON DJ, 1969, POSTGRAD MED, V46, P51; HOELTGE GA, 1987, ARCH PATHOL LAB MED, V111, P1011; JENNY RW, 1993, CLIN CHEM, V39, P76; JONES RN, 1985, ARCH PATHOL LAB MED, V109, P31; KAUFMAN HW, 1993, ARCH PATHOL LAB MED, V117, P427; LAMOTTE LC, 1977, PUBLIC HEALTH REP, V92, P554; LAMOTTE LC, 1977, HEALTH LAB SCI, V14, P213; LANPHEAR BJ, 1992, CLIN CHEM, V38, P1254; MERRITT B R, 1965, Minn Med, V48, P939; NAITO HK, 1993, ARCH PATHOL LAB MED, V117, P345; Nutting PA, 1996, JAMA-J AM MED ASSOC, V275, P635, DOI 10.1001/jama.275.8.635; POSNER A, 1993, ARCH PATHOL LAB MED, V117, P422; RICKMAN WJ, 1993, ANN NY ACAD SCI, V677, P53, DOI 10.1111/j.1749-6632.1993.tb38764.x; ROSS JW, 1993, ARCH PATHOL LAB MED, V117, P393; ROSS JW, 1991, P 1989 I CRIT ISS HL, P173; *SAS I INC, 1989, SAS STAT US GUID VER, V1, P851; SCHALLA WO, 1996, P 1995 I FRONT LAB P; Stanton N, 1993, J Int Fed Clin Chem, V5, P158; STEINDEL SJ, 1995, SHORT TERM STUDIES L, P1; SUNDERMAN FW, 1992, CLIN CHEM, V38, P1205; TAYLOR RN, 1981, J CLIN MICROBIOL, V13, P29; THOLEN D, 1995, ARCH PATHOL LAB MED, V119, P307; WOOD DE, 1994, AM J CLIN PATHOL, V102, P490, DOI 10.1093/ajcp/102.4.490	33	42	43	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	1998	279	6					463	467		10.1001/jama.279.6.463	http://dx.doi.org/10.1001/jama.279.6.463			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV580	9466641	Bronze			2022-12-28	WOS:000071839800036
J	Wolf, G; Petersen, D; Dietel, M; Petersen, I				Wolf, G; Petersen, D; Dietel, M; Petersen, I			Telemicroscopy via the Internet	NATURE			English	Article									Univ Hosp Charite, Inst Pathol, D-10098 Berlin, Germany; Hannover Med Sch, Blood Bank, D-30623 Hannover, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hannover Medical School	Wolf, G (corresponding author), Univ Hosp Charite, Inst Pathol, Schumannstr 20-21, D-10098 Berlin, Germany.							Maturo R, 1997, BIOTECHNIQUES, V22, P1154, DOI 10.2144/97226bc03	1	37	37	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 5	1998	391	6667					613	614		10.1038/35429	http://dx.doi.org/10.1038/35429			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468143				2022-12-28	WOS:000071842300059
J	Linzer, M				Linzer, M			Leaders or lemmings?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		MCMURRAY JE, 1993, ANN INTERN MED, V119, P812, DOI 10.7326/0003-4819-119-8-199310150-00007; SCHAEF AW, 1988, ADDICTIVE ORG, P79; TIERNEY W, 1996, SGIM FORUM, V10, P3; TIERNEY W, 1996, SGIM FORUM, V10, P12	4	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					341	341		10.1001/jama.279.5.341	http://dx.doi.org/10.1001/jama.279.5.341			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459452				2022-12-28	WOS:000071731300001
J	Davis, D				Davis, D			Continuing medical education - Global health, global learning	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS; LAPAROSCOPIC CHOLECYSTECTOMY; PROGRAM; CARE; EXPERIENCE; NEEDS; PHYSICIANS; TELEMEDICINE; TANZANIA; STRATEGY		Univ Toronto, Fac Med, Toronto, ON M5S 1A8, Canada	University of Toronto	Davis, D (corresponding author), Univ Toronto, Fac Med, Toronto, ON M5S 1A8, Canada.	dave.davis@utoronto.ca						ALI J, 1994, J TRAUMA, V36, P695, DOI 10.1097/00005373-199405000-00017; Badran A, 1995, MED EDUC, V29, P16, DOI 10.1111/j.1365-2923.1995.tb02880.x; BASHOOK PG, IN PRESS BMJ; Berger M, 1996, ANN INTERN MED, V124, P153, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00014; CARRELL J, 1993, COURRIER MED FRIBOUR, V2, P7; CARRELL J, 1993, COURRIER MED FRIBOUR, V2, P11; CHRISTOV VI, 1995, DIABETIC MED, V12, P436, DOI 10.1111/j.1464-5491.1995.tb00510.x; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; DAVIS FA, 1994, PHYSICIAN LEARNER LI; DEVIRGILIO G, 1993, MED EDUC, V27, P266; EAVEY RD, 1993, OTOLARYNG HEAD NECK, V109, P895, DOI 10.1177/019459989310900519; ENGEL CE, 1992, MED EDUC, V26, P389, DOI 10.1111/j.1365-2923.1992.tb00192.x; ETIENNE PA, 1993, COURRIER MED FRIBOUR, V2, P9; Ferguson E W, 1995, J Med Syst, V19, P35, DOI 10.1007/BF02257189; Fischer G C, 1994, Wien Med Wochenschr, V144, P438; FLORES J, 1995, EVALUATION REV, V19, P84; FOLDEVI M, 1994, BRIT J GEN PRACT, V44, P473; GABB R, 1991, MED J AUSTRALIA, V155, P71, DOI 10.5694/j.1326-5377.1991.tb142126.x; GARCIABARBERO M, 1995, MED EDUC, V29, P3, DOI 10.1111/j.1365-2923.1995.tb02793.x; Gill D, 1994, Aust Fam Physician, V23, P663; Gofin J, 1995, Fam Med, V27, P28; GOLDBERG MA, 1994, AM J ROENTGENOL, V163, P1495, DOI 10.2214/ajr.163.6.7992754; Goldstein E, 1996, LANCET, V347, P621, DOI 10.1016/S0140-6736(96)91322-7; GRUESSER M, 1993, DIABETES CARE, V16, P1268, DOI 10.2337/diacare.16.9.1268; GUTIERREZ G, 1994, MED CARE, V32, P436, DOI 10.1097/00005650-199405000-00003; HALLAS J, 1993, EUR J CLIN PHARMACOL, V45, P199, DOI 10.1007/BF00315383; HALSTEAD SB, 1991, J CLIN EPIDEMIOL, V44, P579, DOI 10.1016/0895-4356(91)90222-U; HESKETH TM, 1994, MED EDUC, V28, P252, DOI 10.1111/j.1365-2923.1994.tb02706.x; HEWSON AD, 1991, AUST NZ J OBSTET GYN, V31, P249, DOI 10.1111/j.1479-828X.1991.tb02792.x; HOFTVEDT BO, 1995, J CONTIN EDUC HEALTH, V15, P91; Hornung W P, 1995, Int Psychogeriatr, V7, P105, DOI 10.1017/S104161029500189X; ISLER M, 1994, SCHWEIZERISCHE ARZTE, V75, P215; JOERGENS V, 1995, PATIENT EDUC COUNS, V26, P195, DOI 10.1016/0738-3991(95)00754-N; KRAPF R, 1993, SCHWEIZER ARZTEZEITU, V74, P1738; MARMY A, 1993, COURRIER MED FRIBOUR, V2, P13; MAYNE K, 1994, MED J AUSTRALIA, V161, P630, DOI 10.5694/j.1326-5377.1994.tb127647.x; MOLSTAD S, 1994, FAM PRACT, V11, P282, DOI 10.1093/fampra/11.3.282; MORINO M, 1995, SURG ENDOSC-ULTRAS, V9, P46; MURPHY AW, 1995, MED EDUC, V29, P154, DOI 10.1111/j.1365-2923.1995.tb02820.x; Nakano Miwako, 1993, Acta Paediatrica Japonica (Overseas Edition), V35, P576; Ndeki S S, 1995, World Health Forum, V16, P59; NEWBLE DI, 1988, MED J AUSTRALIA, V148, P5, DOI 10.5694/j.1326-5377.1988.tb104469.x; Newble DI, 1996, J ROY COLL PHYS LOND, V30, P252; NICOLE A, 1993, COURRIER MED FRIBOUR, V2, P4; ODENBACH E, 1990, J CONTIN EDUC HEALTH, V10, P293; Ollenschlager G, 1995, Z Arztl Fortbild (Jena), V89, P75; Ollenschlager G, 1993, Z Arztl Fortbild (Jena), V87, P681; Ollenschlager G, 1995, Z Arztl Fortbild (Jena), V89, P340; PERRIN C, 1993, SCHWEIZER ARZTEZEITU, V74, P374; PHONGSAVAN P, 1995, MED J AUSTRALIA, V162, P139, DOI 10.5694/j.1326-5377.1995.tb138478.x; Piga A, 1995, J Cancer Educ, V10, P203; PIRRALLO RG, 1995, ANN EMERG MED, V25, P656, DOI 10.1016/S0196-0644(95)70180-X; RENSCHLER HE, 1993, ACAD MED, V68, pS57, DOI 10.1097/00001888-199302000-00032; RodriguezTrias H, 1996, AM J PUBLIC HEALTH, V86, P305, DOI 10.2105/AJPH.86.3.305; RUTZ W, 1989, ACTA PSYCHIAT SCAND, V80, P151, DOI 10.1111/j.1600-0447.1989.tb01318.x; SALLAM SA, 1995, AIDS CARE, V7, P49, DOI 10.1080/09540129550126957; SALZBERG R, 1993, COURRIER MED FRIBOUR, V2, P5; SHAHABUDIN SH, 1991, MED EDUC, V25, P430, DOI 10.1111/j.1365-2923.1991.tb00091.x; SHIKHMAN SM, 1994, J CANCER EDUC, V9, P1138; Stewart Alistair, 1993, Indian Journal of Pediatrics, V60, P729, DOI 10.1007/BF02751040; TANER D, 1993, POSTGRAD MED J, V69, pS103; Tausch B, 1995, Z Arztl Fortbild (Jena), V89, P402; TAYLORVAISEY AL, 1995, J CONTIN EDUC HEALTH, V2, P117; Thomas M, 1995, World Health Forum, V16, P33; THOMSON SR, 1994, WORLD J SURG, V18, P700; UMLAND B, 1992, ACAD MED, V67, P307, DOI 10.1097/00001888-199205000-00004; VANMEURS AHJ, 1993, TROP GEOGR MED, V45, P258; Vanzyl A J, 1995, Proc Annu Symp Comput Appl Med Care, P517; VYSOHLID J, 1991, MED EDUC, V25, P452; Walton H, 1994, Verh K Acad Geneeskd Belg, V56, P17; WALTON HJ, 1994, MED EDUC, V28, P333, DOI 10.1111/j.1365-2923.1994.tb02543.x; WARD J, 1993, MED J AUSTRALIA, V159, P20, DOI 10.5694/j.1326-5377.1993.tb137697.x; Webster J D, 1993, Hygie, V12, P16; WEBSTER JD, 1993, HYGIE, V12, P46; WEERAKOON PK, 1991, MED TEACH, V13, P103, DOI 10.3109/01421599109036764; Winker MA, 1996, JAMA-J AM MED ASSOC, V275, P245, DOI 10.1001/jama.275.3.245; YAMASHITA Y, 1994, WORLD J SURG, V18, P279, DOI 10.1007/BF00294415; Young H L, 1995, J Audiov Media Med, V18, P75, DOI 10.3109/17453059509022998	78	35	36	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 31	1998	316	7128					385	389		10.1136/bmj.316.7128.385	http://dx.doi.org/10.1136/bmj.316.7128.385			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YV793	9487183	Green Published			2022-12-28	WOS:000071863900043
J	Gravelle, H				Gravelle, H			How much of the relation between population mortality and unequal distribution of income is a statistical artefact?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UNITED-STATES; INEQUALITY; HEALTH		Univ York, Natl Primary Care Res Dev Ctr, York YO1 5DD, N Yorkshire, England	University of York - UK	Gravelle, H (corresponding author), Univ York, Natl Primary Care Res Dev Ctr, York YO1 5DD, N Yorkshire, England.	hg8@york.ac.uk		Gravelle, Hugh/0000-0002-7753-4233				ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; ATKINSON AB, 1990, ECON J, V100, P808, DOI 10.2307/2233660; ATKINSON AB, 1970, J ECON THEORY, V2, P244, DOI 10.1016/0022-0531(70)90039-6; Beaglehole R, 1993, BASIC EPIDEMIOLOGY, V1st; BenShlomo Y, 1996, BRIT MED J, V312, P1013; Deaton A., 1980, EC CONSUMER BEHAV, DOI DOI 10.1017/CBO9780511805653; Edwards G., 1994, ALCOHOL POLICY PUBLI; Ettner SL, 1996, J HEALTH ECON, V15, P67, DOI 10.1016/0167-6296(95)00032-1; GODFREY C, 1989, BR J ADDICT, V10, P1123; GRAVELLE HSE, 1987, SOC SCI MED, V25, P427, DOI 10.1016/0277-9536(87)90167-5; GRAVELLE HSE, 1984, J HEALTH ECON, V3, P297, DOI 10.1016/0167-6296(84)90016-X; Kaplan GA, 1996, BRIT MED J, V312, P999; Kennedy BP, 1996, BRIT MED J, V312, P1004, DOI 10.1136/bmj.312.7037.1004; PRESTON SH, 1975, POP STUD-J DEMOG, V29, P231, DOI 10.2307/2173509; Pritchett L, 1996, J HUM RESOUR, V31, P841, DOI 10.2307/146149; Robinson WS, 1950, AM SOCIOL REV, V15, P351, DOI 10.2307/2087176; RODGERS GB, 1979, POP STUD-J DEMOG, V33, P343, DOI 10.2307/2173539; ROTHSCHILD M, 1970, J ECON THEORY, V2, P225, DOI 10.1016/0022-0531(70)90038-4; Smith GD, 1996, BRIT MED J, V312, P987; WALDMANN RJ, 1992, Q J ECON, V107, P1283, DOI 10.2307/2118389; Wilkinson R., 1996, UNHEALTHY SOC AFFLIC; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; Wilkinson RG, 1997, BRIT MED J, V314, P591, DOI 10.1136/bmj.314.7080.591; WILKINSON RG, 1995, BRIT MED J, V311, P1285, DOI 10.1136/bmj.311.7015.1285	24	239	245	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 31	1998	316	7128					382	385		10.1136/bmj.316.7128.382	http://dx.doi.org/10.1136/bmj.316.7128.382			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YV793	9487182	Green Published, Green Accepted			2022-12-28	WOS:000071863900042
J	McColl, A; Smith, H; White, P; Field, J				McColl, A; Smith, H; White, P; Field, J			General practitioners' perceptions of the route to evidence based medicine: a questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							CARE; QUALITY	Objectives: To determine the attitude of general practitioners towards evidence based medicine and their related educational needs. Design: A questionnaire study of general practitioners. Setting: General practice in the former Wessex region, England. Subjects: Randomly selected sample of 25% of all general practitioners (452), of whom 302 replied. Main outcome measures: Respondents' attitude towards evidence based medicine, ability to access and interpret evidence, perceived barriers to practising evidence based medicine, and best method of moving from opinion based to evidence based medicine. Results: Respondents mainly welcomed evidence based medicine and agreed that its practice improves patient care. They had a low level of awareness of extracting journals, review publications, and databases (only 40% knew of the Cochrane Database of Systematic Reviews), and, even if a aware, many did not use them. In their surgeries 20% had access to bibliographic databases and 17% to the world wide web. Most had some understanding of the technical terms used. The major perceived barrier to practising evidence based medicine tvas lack of personal time. Respondents thought the most appropriate way to move towards evidence based general practice was by using evidence based guidelines or proposals developed by colleagues. Conclusion: Promoting and improving access to summaries of evidence, rather than teaching all general practitioners literature searching and critical appraisal, would be the more appropriate method of encouraging evidence based general practice. General practitioners who are skilled in accessing and interpreting evidence should be encouraged to develop local evidence based guidelines and advice.	Univ Southampton, Wessex Primary Care Res Network, Aldermoor Hlth Ctr, Southampton SO16 5ST, Hants, England; Nightingale Surg, Romsey SO51 7QN, Hants, England	University of Southampton	McColl, A (corresponding author), Univ Southampton, Wessex Primary Care Res Network, Aldermoor Hlth Ctr, Southampton SO16 5ST, Hants, England.		Smith, Helen E/M-2449-2016	Smith, Helen E/0000-0003-1883-6124				Anderson J, 1996, BMJ-BRIT MED J, V312, P762; BAKER R, 1996, BRIT MED J, V312, P827; BOSANQUET N, 1989, J ROY COLL GEN PRACT, V39, P88; Chikwe J, 1996, BRIT MED J, V313, P114, DOI 10.1136/bmj.313.7049.114; Dawes MG., 1996, BMJ EVID-BASED MED, V1, P68; Eccles M, 1996, BMJ-BRIT MED J, V312, P760; *FIN TIM HEALTHC, 1997, MED DIR 1997; FRASER RC, 1985, BRIT MED J, V291, P1473, DOI 10.1136/bmj.291.6507.1473; Gill P, 1996, BRIT MED J, V312, P819; Greenhalgh T, 1996, BRIT MED J, V313, P957; HYDE C, 1995, BRIT MED J, V310, P1140, DOI 10.1136/bmj.310.6987.1140b; *INF MAN GROUP, 1997, ORG COD FIL; Jacobson LD, 1997, BRIT J GEN PRACT, V47, P449; MacAuley D, 1996, IRISH J MED SCI, V165, P289, DOI 10.1007/BF02943093; McAvoy BR, 1996, BRIT MED J, V313, P732; Meakin R, 1996, BRIT MED J, V313, P114, DOI 10.1136/bmj.313.7049.114a; PATERSONBROWN S, 1993, BMJ-BRIT MED J, V307, P1464, DOI 10.1136/bmj.307.6917.1464; PICKERING A, 1997, EVIDENCE BASED HLTH; RISDALE L, 1996, BR J GEN PRACT, V46, P503; Sackett D.L., 1997, EVIDENCE BASED MED, V2, P39; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71	21	508	526	1	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 31	1998	316	7128					361	365		10.1136/bmj.316.7128.361	http://dx.doi.org/10.1136/bmj.316.7128.361			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487174	Green Published, Green Submitted, Bronze, Green Accepted			2022-12-28	WOS:000071863900029
J	White, S; Szewczyk, JW; Turner, JM; Baird, EE; Dervan, PB				White, S; Szewczyk, JW; Turner, JM; Baird, EE; Dervan, PB			Recognition of the four Watson-Crick base pairs in the DNA minor groove by synthetic ligands	NATURE			English	Article							SEQUENCE-SPECIFIC RECOGNITION; DOUBLE-HELICAL DNA; HAIRPIN POLYAMIDE; BINDING; COMPLEX; MOTIF; OLIGONUCLEOTIDES; TRANSCRIPTION; DISTAMYCIN; IMIDAZOLE	The design of synthetic ligands that read the information stored in the DNA double helix has been along-standing gal at the interface of chemistry and biology(1-5). Cell-permeable small molecules that target predetermined DNA. sequences offer a potential approach for the regulation of gene expression(6). Oligodeoxy-nucleotides that recognize the major groove of double-helical DNA via triple-helix formation bind to a broad range of sequences with high affinity and specificity(3,4), Although oligonucleotides and their analogues have been shown to interfere with gene expression(7,8), the triple-helix approach is limited to recognition of purines and suffers from poor cellular uptake. The subsequent development of pairing rules for minor-groove binding polyamides containing pyrrole (Py) and imidazole (Im) amino acids offers a second code to control sequence specificity(9-11). An Im/Py pair distinguishes G.C from C.G and both of these from A.T/T.A base pairs(9-11). A Py/Py pair specifies A.T from G.C but does not distinguish A.T from T.A(9-14). To break this degeneracy, we have added a new aromatic amino acid, 3-hydroxypyrrole (Hp), to the repertoire to test for pairings that discriminate A.T from T.A. We find that replacement of a single hydrogen atom with a hydroxy group in a Hp/Py pairing regulates affinity and specificity by an order of magnitude. By incorporation of this third amino acid, hydroxy pyrrole-imidazole-pyrrole polyamides form four ring-pairings (Im/Py, Py/Im Hp/Py and Py/Hp) which distinguish all four Watson-Crick base pairs in the minor groove of DNA.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; CALTECH, Beckman Inst, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Dervan, PB (corresponding author), CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.							ADES SE, 1995, BIOCHEMISTRY-US, V34, P14601, DOI 10.1021/bi00044a040; Baird EE, 1996, J AM CHEM SOC, V118, P6141, DOI 10.1021/ja960720z; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; Choo Y, 1997, CURR OPIN STRUC BIOL, V7, P117, DOI 10.1016/S0959-440X(97)80015-2; DERVAN PB, 1986, SCIENCE, V232, P464, DOI 10.1126/science.2421408; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; Gottesfeld JM, 1997, NATURE, V387, P202, DOI 10.1038/387202a0; Kelly JJ, 1996, P NATL ACAD SCI USA, V93, P6981, DOI 10.1073/pnas.93.14.6981; KIELKOPF CL, IN PRESS NATURE STRU; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; MAHER LJ, 1992, BIOCHEMISTRY-US, V31, P70, DOI 10.1021/bi00116a012; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; MRKSICH M, 1995, J AM CHEM SOC, V117, P3325, DOI 10.1021/ja00117a002; MRKSICH M, 1992, P NATL ACAD SCI USA, V89, P7586, DOI 10.1073/pnas.89.16.7586; Nielsen PE, 1997, CHEM-EUR J, V3, P505, DOI 10.1002/chem.19970030404; PELTON JG, 1989, P NATL ACAD SCI USA, V86, P5723, DOI 10.1073/pnas.86.15.5723; Pilch DS, 1996, P NATL ACAD SCI USA, V93, P8306, DOI 10.1073/pnas.93.16.8306; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SLUKA JP, 1990, BIOCHEMISTRY-US, V29, P6551, DOI 10.1021/bi00480a002; STEITZ TA, 1990, Q REV BIOPHYS, V23, P203; Swalley SE, 1997, J AM CHEM SOC, V119, P6953, DOI 10.1021/ja971184t; Swalley SE, 1996, J AM CHEM SOC, V118, P8198, DOI 10.1021/ja9611598; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; Trauger JW, 1996, NATURE, V382, P559, DOI 10.1038/382559a0; WADE WS, 1992, J AM CHEM SOC, V114, P8783, DOI 10.1021/ja00049a006; White S, 1997, CHEM BIOL, V4, P569, DOI 10.1016/S1074-5521(97)90243-X; WHITE S, 1996, BIOCHEMISTRY-US, V35, P6147; WONG JM, 1994, NUCLEIC ACIDS RES, V22, P1890, DOI 10.1093/nar/22.10.1890; ZIMMER C, 1986, PROG BIOPHYS MOL BIO, V47, P31, DOI 10.1016/0079-6107(86)90005-2	30	487	517	1	65	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 29	1998	391	6666					468	471		10.1038/35106	http://dx.doi.org/10.1038/35106			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461213				2022-12-28	WOS:000071701800044
J	Morris, ME; Viswanathan, N; Kuhlman, S; Davis, FC; Weitz, CJ				Morris, ME; Viswanathan, N; Kuhlman, S; Davis, FC; Weitz, CJ			Screen for genes induced in the suprachiasmatic nucleus by light	SCIENCE			English	Article							MAMMALIAN CIRCADIAN CLOCK; IMMEDIATE-EARLY GENES; RETINOHYPOTHALAMIC TRACT; TRANSCRIPTION FACTORS; N-ACETYLTRANSFERASE; MESSENGER-RNAS; C-FOS; EXPRESSION; ENTRAINMENT; INDUCTION	The mechanism by which mammalian circadian clocks are entrained to light-dark cycles is unknown. The clock that drives behavioral rhythms is located in the suprachiasmatic nucleus (SCN) of the brain, and entrainment is thought to require induction of genes in the SCN by light. A complementary DNA subtraction method based on genomic representational difference analysis was developed to identify such genes without making assumptions about their nature. Four clones corresponded to genes induced specifically in the SCN by light, all of which showed gating of induction by the circadian clock. Among these genes are c-fos and nur77, two of the five early-response genes known to be induced in the SCN by light, and egr-3, a zinc finger transcription factor not previously identified in the SCN. In contrast to known examples, egr-3 induction by light is restricted to the ventral SCN, a structure implicated in entrainment.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Northeastern Univ, Dept Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Northeastern University	Weitz, CJ (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.		Jansen, Heiko T./A-5770-2008; Kuhlman, Sandra/Q-1211-2015	Jansen, Heiko T./0000-0003-0178-396X; Kuhlman, Sandra/0000-0003-0450-7282				ABE H, 1991, NEUROSCI LETT, V127, P9, DOI 10.1016/0304-3940(91)90881-S; ABE H, 1992, BRAIN RES BULL, V28, P831, DOI 10.1016/0361-9230(92)90269-4; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARONIN N, 1990, P NATL ACAD SCI USA, V87, P5959, DOI 10.1073/pnas.87.15.5959; EDWARDS LN, 1988, CELLULAR MOL BASES B; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; Guido ME, 1996, BRAIN RES, V739, P132, DOI 10.1016/S0006-8993(96)00816-5; HONKANIEMI J, 1995, MOL BRAIN RES, V28, P157, DOI 10.1016/0169-328X(94)00200-X; HONKANIEMI J, 1994, MOL BRAIN RES, V25, P234, DOI 10.1016/0169-328X(94)90158-9; JOHNSON RF, 1988, BRAIN RES, V460, P297, DOI 10.1016/0006-8993(88)90374-5; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KLEIN DC, 1979, BRAIN RES, V174, P245, DOI 10.1016/0006-8993(79)90848-5; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Miller JD, 1996, SLEEP, V19, P641, DOI 10.1093/sleep/19.8.641; MOORE RY, 1974, BRAIN RES, V71, P17, DOI 10.1016/0006-8993(74)90188-7; Morris M.S., UNPUB; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PAVLIDIS T, 1973, BIOL OSCILLATORS THE; PITTENDRIGH CS, 1976, J COMP PHYSIOL, V106, P291, DOI 10.1007/BF01417859; REA MA, 1989, BRAIN RES BULL, V23, P577, DOI 10.1016/0361-9230(89)90204-9; RUSAK B, 1992, MOL BRAIN RES, V14, P124, DOI 10.1016/0169-328X(92)90019-8; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Silver R, 1996, NEUROREPORT, V7, P1224, DOI 10.1097/00001756-199604260-00026; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; Treep JA, 1995, J BIOL RHYTHM, V10, P299, DOI 10.1177/074873049501000403; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; WOLLNIK F, 1995, EUR J NEUROSCI, V7, P388, DOI 10.1111/j.1460-9568.1995.tb00334.x	31	88	88	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1544	1547		10.1126/science.279.5356.1544	http://dx.doi.org/10.1126/science.279.5356.1544			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488654				2022-12-28	WOS:000072372900067
J	Bellamy, R; Ruwende, C; Corrah, T; McAdam, KPWJ; Whittle, HC; Hill, AVS				Bellamy, R; Ruwende, C; Corrah, T; McAdam, KPWJ; Whittle, HC; Hill, AVS			Variations in the Nrampi gene and susceptibility to tuberculosis in West Africans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATURAL-RESISTANCE; MACROPHAGE PROTEIN; INTRACELLULAR PARASITES; GENOMIC ORGANIZATION; INFECTION; IDENTIFICATION; EXPRESSION; MICE; SEQUENCE; LOCUS	Background Genetic factors may affect the susceptibility to tuberculosis, but no specific genes governing susceptibility have been identified. in mice, natural resistance to infection with some mycobacteria is influenced by the gene for natural-resistance-associated macrophage protein 1 (Nramp1), but the role of the human homologue of this gene, NRAMP1, in tuberculosis is unknown, We typed polymorphisms in NRAMP1 in a case-control study of tuberculosis in the Gambia, West Africa. Methods Sequence-specific oligonucleotide hybridization and microsatellite analysis were used to type NRAMP1 polymorphisms in 410 adults (mean age, 34.7 years) with smear-positive pulmonary tuberculosis and 417 ethnically matched, healthy controls. Patients with human immunodeficiency virus infection were excluded. Results Four NRAMP1 polymorphisms were each significantly associated with tuberculosis, Subjects who were heterozygous for two NRAMP1 polymorphisms in intron 4 and the 3' untranslated region of the gene were particularly overrepresented among those with tuberculosis, as compared with those with the most common NRAMP1 genotype (odds ratio, 4.07; 95-percent confidence interval, 1.86 to 9.12; chi-square=14.58; P<0.001). Conclusions Genetic variation in NRAMP1 affects susceptibility to tuberculosis in West Africans. (C) 1998, Massachusetts Medical Society.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; MRC Labs, Fajara, Gambia	University of Oxford; Wellcome Centre for Human Genetics; MRC Laboratory Molecular Biology	Hill, AVS (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Windmill Rd, Oxford OX3 7BN, England.		Yang, Pan-Chyr/B-8808-2009; HILL, Adrian V>S>/C-1306-2008		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLSOPP CEM, 1992, AM J HUM GENET, V50, P411; Blackwell JM, 1996, MOL MED TODAY, V2, P205, DOI 10.1016/1357-4310(96)88773-9; BLACKWELL JM, 1995, MOL MED, V1, P194, DOI 10.1007/BF03401567; BRADLEY DJ, 1977, CLIN EXP IMMUNOL, V30, P130; CELLIER M, 1994, J EXP MED, V180, P1741, DOI 10.1084/jem.180.5.1741; COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621; CROCKER PR, 1984, INFECT IMMUN, V43, P1033, DOI 10.1128/IAI.43.3.1033-1040.1984; DENIS M, 1990, J LEUKOCYTE BIOL, V47, P25, DOI 10.1002/jlb.47.1.25; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; GOTO Y, 1989, IMMUNOGENETICS, V30, P218, DOI 10.1007/BF02421210; Govoni G, 1996, INFECT IMMUN, V64, P2923, DOI 10.1128/IAI.64.8.2923-2929.1996; GROS P, 1981, J IMMUNOL, V127, P2417; Gruenheid S, 1997, J EXP MED, V185, P717, DOI 10.1084/jem.185.4.717; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; KALLMANN F. J., 1943, American Review of Tuberculosis and Pulmonary Diseases, V47, P549; Lewis LA, 1996, IMMUNOGENETICS, V44, P309, DOI 10.1007/s002510050129; LISSNER CR, 1983, J IMMUNOL, V131, P3006; LIU J, 1995, AM J HUM GENET, V56, P845; MALO D, 1994, GENOMICS, V23, P51, DOI 10.1006/geno.1994.1458; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; PLANT J, 1976, J INFECT DIS, V133, P72, DOI 10.1093/infdis/133.1.72; ROOK GAW, 1988, BRIT MED BULL, V44, P611, DOI 10.1093/oxfordjournals.bmb.a072271; SKAMENE E, 1984, IMMUNOGENETICS, V19, P117, DOI 10.1007/BF00387854; SKAMENE E, 1982, NATURE, V297, P506, DOI 10.1038/297506a0; STACH JL, 1984, J IMMUNOL, V132, P888; STEAD WW, 1992, ANN INTERN MED, V116, P937, DOI 10.7326/0003-4819-116-11-937; STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; VIDAL S, 1995, J EXP MED, V182, P655, DOI 10.1084/jem.182.3.655; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; WHITE JK, 1994, GENOMICS, V24, P295, DOI 10.1006/geno.1994.1619; ZIEGLE JS, 1992, GENOMICS, V14, P1026, DOI 10.1016/S0888-7543(05)80126-0	33	594	635	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1998	338	10					640	644		10.1056/NEJM199803053381002	http://dx.doi.org/10.1056/NEJM199803053381002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ844	9486992				2022-12-28	WOS:000072299700002
J	Johnston, IDA; Strachan, DP; Anderson, HR				Johnston, IDA; Strachan, DP; Anderson, HR			Effect of pneumonia and whooping cough in childhood on adult lung function	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOWER RESPIRATORY ILLNESS; PRIMARY-SCHOOL-CHILDREN; LOW BIRTH-WEIGHT; PULMONARY-FUNCTION; MATERNAL SMOKING; PASSIVE SMOKING; SYMPTOMS; DISEASE; INFANCY; LIFE	Background Previous studies have suggested that respiratory infection during childhood is associated with respiratory disease in adulthood, but the link is unclear because of retrospective ascertainment of childhood infection, selection bias, and confounding factors. Methods We studied the effects of childhood pneumonia and whooping cough in 1392 British adults followed from their births in 1958. Of these, 193 had a history of pneumonia and 215 a history of whooping cough by the age of seven years. When the subjects were 34 or 35 years old, their forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were measured before and after they inhaled albuterol. Results A history of pneumonia was associated with deficits (+/-95 percent confidence limits) in both FEV1 (102+/-73 ml, P=0.006) and FVC (173+/-70 ml, P=0.001) when the analysis was adjusted for sex, height, and smoking, with no change in the ratio of FEV1 to FVC. These deficits persisted after inhalation of albuterol. In subjects with no history of wheezing, the deficit in FEV1 was 155+/-122 ml (P=0.01), in those with past wheezing it was 41+/-128 ml (P=0.53), and in those with current wheezing it was 119+/-133 ml (P=0.08). The effect was no greater for the subjects who had pneumonia at less than two years of age than for those who had it between the ages of two and seven years and was not diminished after control for multiple confounding factors. The deficits associated with whooping cough were smaller (FEV1, 41+/-70 ml; P=0.25; FVC, 81+/-76 ml; P=0.04). Conclusions Childhood pneumonia is associated with reduced ventilatory function in adults. This reduction is independent of a history of wheezing and is not explained by other confounding factors. (C) 1998, Massachusetts Medical Society.	Univ Nottingham Hosp, Queens Med Ctr, Dept Resp Med, Nottingham NG7 2UH, England; St George Hosp, Sch Med, Dept Publ Hlth Sci, London, England	University of Nottingham; St Georges University London	Johnston, IDA (corresponding author), Univ Nottingham Hosp, Queens Med Ctr, Dept Resp Med, Nottingham NG7 2UH, England.		Anderson, Hugh R/A-7417-2016		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1987, Am Rev Respir Dis, V136, P1285; BARKER DJP, 1991, BRIT MED J, V303, P671, DOI 10.1136/bmj.303.6804.671; BRITTEN N, 1987, BRIT MED J, V294, P1317, DOI 10.1136/bmj.294.6583.1317; BRITTEN N, 1986, BRIT MED J, V292, P441, DOI 10.1136/bmj.292.6518.441; Britton J, 1996, AM J RESP CRIT CARE, V154, pS240, DOI 10.1164/ajrccm/154.6_Pt_2.S240; BURROWS B, 1977, AM REV RESPIR DIS, V115, P751; CHAN KN, 1989, ARCH DIS CHILD, V64, P1294, DOI 10.1136/adc.64.9.1294; CHAN KN, 1989, ARCH DIS CHILD, V64, P1284, DOI 10.1136/adc.64.9.1284; CHEN Y, 1986, BRIT MED J, V293, P303, DOI 10.1136/bmj.293.6542.303; FERGUSSON DM, 1980, ARCH DIS CHILD, V55, P358, DOI 10.1136/adc.55.5.358; GOLD DR, 1989, AM REV RESPIR DIS, V140, P877, DOI 10.1164/ajrccm/140.4.877; HASSELBLAD V, 1981, AM REV RESPIR DIS, V123, P479; HENRY RL, 1983, ARCH DIS CHILD, V58, P60, DOI 10.1136/adc.58.1.60; Jarvis D, 1996, LANCET, V347, P426, DOI 10.1016/S0140-6736(96)90009-4; JOHNSTON IDA, 1983, LANCET, V2, P1104; JOHNSTON IDA, 1986, AM REV RESPIR DIS, V134, P270; LEEDER SR, 1976, BRIT J PREV SOC MED, V30, P203; MANN SL, 1992, J EPIDEMIOL COMMUN H, V46, P286, DOI 10.1136/jech.46.3.286; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; MELIA RJW, 1979, INT J EPIDEMIOL, V8, P333, DOI 10.1093/ije/8.4.333; MOK JYQ, 1979, ARCH DIS CHILD, V54, P506, DOI 10.1136/adc.54.7.506; MOK JYQ, 1982, BRIT MED J, V285, P333, DOI 10.1136/bmj.285.6338.333; PAOLETTI P, 1989, EUR RESPIR J, V2, P428; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; RONA RJ, 1993, BMJ-BRIT MED J, V306, P817, DOI 10.1136/bmj.306.6881.817; SAMET JM, 1983, AM REV RESPIR DIS, V127, P508, DOI 10.1164/arrd.1983.127.4.508; *SAS I INC, 1988, SAS STAT US GUID, P549; SHAHEEN SO, 1994, AM J RESP CRIT CARE, V149, P616, DOI 10.1164/ajrccm.149.3.8118627; SOMERVILLE SM, 1988, J EPIDEMIOL COMMUN H, V42, P105, DOI 10.1136/jech.42.2.105; STRACHAN DP, 1990, ARCH DIS CHILD, V65, P161, DOI 10.1136/adc.65.2.161; Strachan DP, 1996, BRIT MED J, V312, P1195; Strachan DP, 1996, AM J RESP CRIT CARE, V154, P1629, DOI 10.1164/ajrccm.154.6.8970346; STRACHAN DP, 1994, INT J EPIDEMIOL, V23, P1060, DOI 10.1093/ije/23.5.1060; TAGER IB, 1983, NEW ENGL J MED, V309, P699, DOI 10.1056/NEJM198309223091204; TAYLOR B, 1987, ARCH DIS CHILD, V62, P786, DOI 10.1136/adc.62.8.786; THURLBECK WM, 1982, THORAX, V37, P564, DOI 10.1136/thx.37.8.564; VEDAL S, 1984, AM REV RESPIR DIS, V130, P187; WATKINS CJ, 1982, INT J EPIDEMIOL, V11, P62, DOI 10.1093/ije/11.1.62; WEISS ST, 1995, EUR RESPIR REV, V5, P303; YOUNG S, 1995, ARCH DIS CHILD, V72, P16, DOI 10.1136/adc.72.1.16	40	118	119	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 26	1998	338	9					581	587		10.1056/NEJM199802263380904	http://dx.doi.org/10.1056/NEJM199802263380904			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY708	9475765				2022-12-28	WOS:000072175700004
J	Fire, A; Xu, SQ; Montgomery, MK; Kostas, SA; Driver, SE; Mello, CC				Fire, A; Xu, SQ; Montgomery, MK; Kostas, SA; Driver, SE; Mello, CC			Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans	NATURE			English	Article							SEX-DETERMINING GENE; HEAVY-CHAIN GENE; PROTEIN; MUSCLE; EXPRESSION; MYOSIN; INHIBITION; EMBRYOS; KINASE; UNC-22	Experimental introduction of RNA into cells can be used in certain biological systems to interfere with function of an endogenous gene(1,2). Such effects have been proposed io result from a simple antisense mechanism that depends on hybridization between the injected RNA and endogenous messenger RNA transcripts, RNA interference has been used in the nematode Caenorhabditis elegans to manipulate gene expression(3,4). Here we investigate the requirements for structure and delivery of the interfering RNA. To our surprise, we found that double-stranded RNA was substantially more effective at producing interference than was either strand individually. After injection into adult animals, purified single strands had at most a modest effect, whereas double-stranded mixtures caused potent and specific interference. The effects of this interference were evident in bath the injected animals and their progeny. Only a few molecules of injected double-stranded RNA were required per affected cell, arguing against stochiometric interference with endogenous mRNA and suggesting that there could be a catalytic or amplification component in the interference process.	Carnegie Inst Washington, Dept Embryol, Baltimore, MD 21210 USA; Johns Hopkins Univ, Biol Grad Program, Baltimore, MD 21218 USA; Univ Massachusetts, Ctr Canc, Dept Cell Biol, Program Mol Med, Worcester, MA 01605 USA	Carnegie Institution for Science; Johns Hopkins University; University of Massachusetts System; University of Massachusetts Worcester	Fire, A (corresponding author), Carnegie Inst Washington, Dept Embryol, 115 W Univ Pkwy, Baltimore, MD 21210 USA.	fire@mail1.ciwemb.edu	Pillay, Nischalan/F-9536-2012	Fire, Andrew/0000-0001-6217-8312	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037706] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM037706] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BENIAN GM, 1993, GENETICS, V134, P1097; BRENNER S, 1974, GENETICS, V77, P71; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHEN LS, 1994, DEVELOPMENT, V120, P1631; CLARK DV, 1995, MOL GEN GENET, V247, P367, DOI 10.1007/BF00293205; DIBB NJ, 1989, J MOL BIOL, V205, P603, DOI 10.1016/0022-2836(89)90229-5; DONIACH T, 1984, DEV BIOL, V106, P223, DOI 10.1016/0012-1606(84)90077-0; Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; EPSTEIN HF, 1974, J MOL BIOL, V90, P291, DOI 10.1016/0022-2836(74)90374-X; FIRE A, 1991, DEVELOPMENT, V113, P503; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; KARN J, 1983, P NATL ACAD SCI-BIOL, V80, P4253, DOI 10.1073/pnas.80.14.4253; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; Latham KE, 1996, TRENDS GENET, V12, P134, DOI 10.1016/0168-9525(96)10017-2; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; Mello C, 1995, METHOD CELL BIOL, V48, P451; MOERMAN DG, 1979, GENETICS, V91, P95; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9	27	10597	13089	75	2182	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					806	811		10.1038/35888	http://dx.doi.org/10.1038/35888			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486653				2022-12-28	WOS:000072089500057
J	Minor, LB				Minor, LB			Gentamicin-induced bilateral vestibular hypofunction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VESTIBULOOCULAR REFLEX; AMINOGLYCOSIDE OTOTOXICITY; REHABILITATION; RECOVERY; TOXICITY		Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21203 USA	Johns Hopkins University	Minor, LB (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, POB 41402, Baltimore, MD 21203 USA.				NIDCD NIH HHS [DC 00979, DC 02390] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002390, P60DC000979] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		[Anonymous], 1952, NEW ENGL J MED, V246, P458; BLACK FO, 1987, LARYNGOSCOPE, V97, P582; Carey JP, 1996, J NEUROPHYSIOL, V76, P3301, DOI 10.1152/jn.1996.76.5.3301; DEMER JL, 1994, AM J OTOL, V15, P340; DUCKERT LG, 1993, J COMP NEUROL, V331, P75, DOI 10.1002/cne.903310105; FEE WE, 1980, LARYNGOSCOPE, V90, P1, DOI 10.1288/00005537-198010001-00001; FINEBERG R, 1987, ARCH OTOLARYNGOL, V113, P1063; HAIN TC, 1987, AM J OTOLARYNG, V8, P36, DOI 10.1016/S0196-0709(87)80017-0; HALMAGYI GM, 1994, OTOLARYNG HEAD NECK, V111, P571, DOI 10.1016/S0194-5998(94)70523-2; HALMAGYI GM, 1990, EXP BRAIN RES, V81, P479, DOI 10.1007/BF02423496; Herdman S J, 1994, J Vestib Res, V4, P71; KAHLMETER G, 1984, J ANTIMICROB CHEMOTH, V13, P9, DOI 10.1093/jac/13.suppl_A.9; KASAI T, 1978, BRAIN RES, V144, P123, DOI 10.1016/0006-8993(78)90439-0; KITSIGIANIS GA, 1988, OTOLARYNG HEAD NECK, V98, P82, DOI 10.1177/019459988809800114; KREBS DE, 1993, OTOLARYNG HEAD NECK, V109, P735, DOI 10.1177/019459989310900417; OLEARY DP, 1995, ACTA OTO-LARYNGOL, P202; Priuska EM, 1995, BIOCHEM PHARMACOL, V50, P1749, DOI 10.1016/0006-2952(95)02160-4; SCHACHT J, 1993, OTOLARYNG CLIN N AM, V26, P845; SHEPARD NT, 1995, OTOLARYNG HEAD NECK, V112, P173, DOI 10.1016/S0194-5998(95)70317-9; Song BB, 1997, J PHARMACOL EXP THER, V282, P369; ZEE DS, 1996, DISORDERS VESTIBULAR, P178	21	64	66	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	1998	279	7					541	544		10.1001/jama.279.7.541	http://dx.doi.org/10.1001/jama.279.7.541			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW470	9480366				2022-12-28	WOS:000071938900037
J	Hauser, WA; Rich, SS; Lee, JRJ; Annegers, JF; Anderson, VE				Hauser, WA; Rich, SS; Lee, JRJ; Annegers, JF; Anderson, VE			Risk of recurrent seizures after two unprovoked seizures	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXTENDED FOLLOW-UP; ADULT LIFE; EPILEPSY; POPULATION; MINNESOTA; CHILDHOOD; PROGNOSIS; ROCHESTER	Background Patients with a single unprovoked seizure have about a 35 percent risk of recurrence in the subsequent five years. We studied the risk of recurrence after two unprovoked seizures. Methods We prospectively followed 204 patients with a first unprovoked seizure from the day of the initial seizure. Information was obtained from patients (and verified by a review of their medical records) about the dates and circumstances of any subsequent seizures. The risk of a second, third, and fourth seizure was estimated by the Kaplan-Meier method. Results Of the 204 patients, 63 had a second seizure, 41 a third seizure, and 26 a fourth seizure. The mean age of the patients was 36 years, 10 percent were less than 16 years of age, 70 percent were male, 71 percent had epilepsy of unknown cause, and 66 percent had generalized seizures. The risk of a second unprovoked seizure was 33 percent. Among those with a second seizure, the risk of a third unprovoked seizure was 73 percent; among those with a third unprovoked seizure, the risk of a fourth was 76 percent. Most recurrences occurred within one year of the second or third seizure. The risk of a third seizure was higher in those with a presumed cause of epilepsy (relative risk, 1.9; 95 percent confidence interval, 1.0 to 3.4). Conclusions Although only about one third of patients with a first unprovoked seizure will have fur ther seizures within five years, about three quarters of those with two or three unprovoked seizures have further seizures within four years. (C) 1998, Massachusetts Medical Society.	Columbia Univ Coll Phys & Surg, GH Sergievsky Ctr, New York, NY 10032 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Neurol, Winston Salem, NC 27103 USA; Ischemia Res & Educ Fdn, San Francisco, CA USA; Univ Texas, Sch Publ Hlth, Houston, TX USA; Univ Minnesota, Div Epidemiol, Minneapolis, MN 55455 USA	Columbia University; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Minnesota System; University of Minnesota Twin Cities	Hauser, WA (corresponding author), Columbia Univ Coll Phys & Surg, GH Sergievsky Ctr, 630 W 168th St, New York, NY 10032 USA.		Hauser, W Allen/AAB-5277-2020	Rich, Stephen/0000-0003-3872-7793	NINDS NIH HHS [NS16308] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS016308] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANNEGERS JF, 1995, EPILEPSIA, V36, P327, DOI 10.1111/j.1528-1157.1995.tb01005.x; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; ANNEGERS JF, 1986, EPILEPSIA, V27, P43, DOI 10.1111/j.1528-1157.1986.tb03499.x; Annegers JR, 1984, ADV EPILEPTOL, P521; [Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1993, EPILEPSIA, V34, P592; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; BENEDETTI MD, 1986, DEV MED CHILD NEUROL, V28, P36; BERAN R G, 1985, Neuroepidemiology, V4, P71, DOI 10.1159/000110217; CAMFIELD PR, 1985, NEUROLOGY, V35, P1657, DOI 10.1212/WNL.35.11.1657; CLELAND PG, 1981, BRIT MED J, V283, P1364, DOI 10.1136/bmj.283.6303.1364; COX DR, 1972, J R STAT SOC B, V34, P187; CUTLER SJ, 1958, J CHRON DIS, V8, P699; Elandt-Johnson RC, 1980, SURVIVAL MODELS DATA, P150; ELWES RDC, 1988, BRIT MED J, V297, P948, DOI 10.1136/bmj.297.6654.948; ELWES RDC, 1985, LANCET, V2, P752; Hauser W, 1990, EPILEPSY FREQUENCY C; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HAUSER WA, 1990, NEUROLOGY, V40, P1163, DOI 10.1212/WNL.40.8.1163; HAUSER WA, 1982, NEW ENGL J MED, V307, P522, DOI 10.1056/NEJM198208263070903; HIRTZ DG, 1984, NEUROLOGY, V34, P637, DOI 10.1212/WNL.34.5.637; HOPKINS A, 1988, LANCET, V1, P721; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; MUSICCO M, 1993, NEUROLOGY, V43, P478; NICOLOSI A, 1986, J INFECT DIS, V154, P399, DOI 10.1093/infdis/154.3.399; PLACENCIA M, 1994, J NEUROL NEUROSUR PS, V57, P320, DOI 10.1136/jnnp.57.3.320; SANDER JWAS, 1990, LANCET, V336, P1267, DOI 10.1016/0140-6736(90)92959-L; SHINNAR S, 1990, PEDIATRICS, V85, P1076; Shinnar S, 1996, PEDIATRICS, V98, P216; So EL, 1996, NEUROLOGY, V46, P350, DOI 10.1212/WNL.46.2.350; *STATA, 1995, STAT STAT SOFTW REL; VANDONSELAAR CA, 1992, ARCH NEUROL-CHICAGO, V49, P231, DOI 10.1001/archneur.1992.00530270045017	33	247	260	2	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 12	1998	338	7					429	434		10.1056/NEJM199802123380704	http://dx.doi.org/10.1056/NEJM199802123380704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW122	9459646				2022-12-28	WOS:000071900100004
J	Feder, G; Griffiths, C				Feder, G; Griffiths, C			Managing established coronary heart disease - Practice teams need support in organising pharmacological and lifestyle interventions	BRITISH MEDICAL JOURNAL			English	Letter									St Bartholomews & Royal London Sch Med & Dent, Dept Gen Practice & Primary Care, London E1 4NS, England	University of London; Queen Mary University London	Feder, G (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Gen Practice & Primary Care, London E1 4NS, England.			Feder, Gene/0000-0002-7890-3926				*E LOND CLIN GUID, 1995, COR HEART DIS GEN PR; FEDER G, 1995, BRIT MED J, V311, P1473, DOI 10.1136/bmj.311.7018.1473; FEDER G, 1997, INF VIEWS E LOND PAT; Moher M, 1997, BMJ-BRIT MED J, V315, P69, DOI 10.1136/bmj.315.7100.69; MOTT S, 1995, FAM PRACT, V12, P252	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					309	309						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472539				2022-12-28	WOS:000071702100059
J	Zhang, JJ; Talbot, WS; Schier, AF				Zhang, JJ; Talbot, WS; Schier, AF			Positional cloning identifies zebrafish one-eyed pinhead as a permissive EGF-related ligand required during gastrulation	CELL			English	Article							MESODERM INDUCTION; XENOPUS EMBRYOS; FGF RECEPTOR; GENE; EXPRESSION; GROWTH; MOUSE; FAMILY; CELLS; ALIGNMENT	The zebrafish one-eyed pinhead (oep) mutation disrupts embryonic development, resulting in cyclopia and defects in endoderm, prechordal plate, and ventral neuroectoderm formation. We report the molecular isolation of oep using a positional cloning approach. The oep gene encodes a novel EGF-related protein with similarity to the EGF-CFC proteins cripto, cryptic, and FRL-1. Wild-type oep protein contains a functional signal sequence and is membrane-associated. Following ubiquitous maternal and zygotic expression, highest levels of oep mRNA are found in the gastrula margin and in axial structures and forebrain. Widespread misexpression of both membrane-attached and secreted forms of oep rescues prechordal plate and forebrain development in mutant embryos but does not lead to the ectopic induction of these cell types in wild-type fish. These results establish an essential but permissive role for an EGF-related ligand during vertebrate gastrulation.	NYU, Med Ctr, Dev Genet Program, Skirball Inst Biomol Med,Dept Cell Biol, New York, NY 10016 USA	New York University	Schier, AF (corresponding author), NYU, Med Ctr, Dev Genet Program, Skirball Inst Biomol Med,Dept Cell Biol, New York, NY 10016 USA.			Schier, Alexander Franz/0000-0001-7645-5325	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR012349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056211] Funding Source: NIH RePORTER; NCRR NIH HHS [1RO1 RR12349-01] Funding Source: Medline; NIGMS NIH HHS [1RO1 GM56211-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelmann HB, 1936, Q REV BIOL, V11, P284, DOI 10.1086/394509; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BAXENDALE S, 1991, NUCLEIC ACIDS RES, V19, P6651, DOI 10.1093/nar/19.23.6651; BRANDT R, 1994, J BIOL CHEM, V269, P17320; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CIARDIELLO F, 1994, ONCOGENE, V9, P291; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; Dale JK, 1997, CELL, V90, P257, DOI 10.1016/S0092-8674(00)80334-7; DONO R, 1993, DEVELOPMENT, V118, P1157; Driever W, 1996, DEVELOPMENT, V123, P37; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; Gupta S K, 1995, J Comput Biol, V2, P459, DOI 10.1089/cmb.1995.2.459; Haffter P, 1996, DEVELOPMENT, V123, P1; Halpern ME, 1995, DEVELOPMENT, V121, P4257; Hammerschmidt M, 1996, DEVELOPMENT, V123, P143; Heasman J, 1997, DEVELOPMENT, V124, P4179; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; JOHNSON SE, 1994, DEV DYNAM, V201, P216, DOI 10.1002/aja.1002010305; KANE DA, 1993, DEVELOPMENT, V119, P447; Kannan S, 1997, J BIOL CHEM, V272, P3330, DOI 10.1074/jbc.272.6.3330; KIMMEL CB, 1989, NATURE, V337, P358, DOI 10.1038/337358a0; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; Li HS, 1997, DEVELOPMENT, V124, P603; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; Lohmeyer M, 1997, BIOCHEMISTRY-US, V36, P3837, DOI 10.1021/bi961542p; Melby AE, 1996, DEVELOPMENT, V122, P2225; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; Muenke M, 1995, CONGENITAL MALFORMAT, P187; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Postlethwait JH, 1997, TRENDS GENET, V13, P183, DOI 10.1016/S0168-9525(97)01129-3; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; Schier AF, 1996, DEVELOPMENT, V123, P165; Schier AF, 1997, DEVELOPMENT, V124, P327; Schier AF, 1997, CURR OPIN NEUROBIOL, V7, P119, DOI 10.1016/S0959-4388(97)80129-8; SchulteMerker S, 1997, NATURE, V387, P862, DOI 10.1038/43092; SCHULTEMERKER S, 1994, DEVELOPMENT, V120, P1009; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; Shen MM, 1997, DEVELOPMENT, V124, P429; SHIH J, 1995, DEVELOPMENT, V121, P2755; SolnicaKrezel L, 1996, DEVELOPMENT, V123, P67; Spemann H., 1938, EMBRYONIC DEV INDUCT; Strahle U, 1997, Genes Funct, V1, P131; TALBOT WS, 1995, NATURE, V378, P150, DOI 10.1038/378150a0; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032	50	375	385	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					241	251		10.1016/S0092-8674(00)80918-6	http://dx.doi.org/10.1016/S0092-8674(00)80918-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458048	hybrid			2022-12-28	WOS:000071672600013
J	Campbell, H; Hotchkiss, R; Bradshaw, N; Porteous, M				Campbell, H; Hotchkiss, R; Bradshaw, N; Porteous, M			Integrated care pathways	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NURSING CASE-MANAGEMENT; PRACTICE GUIDELINES; QUALITY; STAY; LENGTH; COSTS		Western Gen Hosp, Edinburgh EH8 9AG, Midlothian, Scotland; Western Infirm & Associated Hosp, Glasgow G11 6NT, Lanark, Scotland	University of Edinburgh	Campbell, H (corresponding author), Western Gen Hosp, Edinburgh EH8 9AG, Midlothian, Scotland.		Campbell, Harry/E-2959-2010	Campbell, Harry/0000-0002-6169-6262				Baker J, 1996, Nurs Stand, V10, P39; BOWEN J, 1994, NEUROLOGY, V44, P1961, DOI 10.1212/WNL.44.10.1961; Bultema JK, 1996, J NURS ADMIN, V26, P31, DOI 10.1097/00005110-199601000-00007; CATHERWOOD E, 1994, PROG CARDIOVASC DIS, V37, P121, DOI 10.1016/S0033-0620(05)80039-8; Coffey R J, 1992, Qual Manag Health Care, V1, P45; COHEN EL, 1991, J NURS ADMIN, V21, P20; Crombie I K, 1993, Qual Health Care, V2, P47, DOI 10.1136/qshc.2.1.47; DELAMOTHE T, 1993, BRIT MED J, V307, P218, DOI 10.1136/bmj.307.6898.218; EAGLE KA, 1990, JAMA-J AM MED ASSOC, V264, P992, DOI 10.1001/jama.264.8.992; Ethridge P, 1989, Nurs Manage, V20, P30; Gabbay J, 1992, Qual Health Care, V1, P43, DOI 10.1136/qshc.1.1.43; Goodyear H M, 1995, Qual Health Care, V4, P190, DOI 10.1136/qshc.4.3.190; Grimshaw J, 1993, Qual Health Care, V2, P243, DOI 10.1136/qshc.2.4.243; Grimshaw J, 1995, Qual Health Care, V4, P55, DOI 10.1136/qshc.4.1.55; Heymann T, 1994, Int J Health Care Qual Assur, V7, P14, DOI 10.1108/09526869410074702; Hofmann P A, 1993, Jt Comm J Qual Improv, V19, P235; HOYLE RM, 1994, J VASC SURG, V20, P396, DOI 10.1016/0741-5214(94)90138-4; Kitchiner D, 1996, ARCH DIS CHILD, V75, P166, DOI 10.1136/adc.75.2.166; Koch MO, 1996, J UROLOGY, V155, P1681, DOI 10.1016/S0022-5347(01)66164-0; LUMSDON K, 1993, HOSP HLTH NETWO 1020, P34; Mansfield C D, 1995, Qual Health Care, V4, P250, DOI 10.1136/qshc.4.4.250; McNicol M, 1993, Qual Health Care, V2, P215, DOI 10.1136/qshc.2.4.215; MOSHER C, 1992, AM J NURS, V92, P41, DOI 10.2307/3426626; OGILVIEHARRIS DJ, 1993, J ORTHOP TRAUMA, V7, P428, DOI 10.1097/00005131-199310000-00005; Pearson SD, 1996, AM J MED, V100, P283, DOI 10.1016/S0002-9343(97)89486-7; ROSSITER D, 1995, DISABIL REHABIL, V17, P443, DOI 10.3109/09638289509166659; SCHRIEFER J, 1994, JOINT COMM J QUAL IM, V20, P485, DOI 10.1016/S1070-3241(16)30095-5; *SIGN, 1995, CLIN GUID CRIT APPR; STEAD L, 1995, HLTH CARE RISK R NOV, P13; THOMSON R, 1995, BMJ-BRIT MED J, V311, P237, DOI 10.1136/bmj.311.6999.237; TRUBO R, 1993, MED ECON, V69, P69; TURLEY K, 1994, ANN THORAC SURG, V58, P57, DOI 10.1016/0003-4975(94)91072-3; *VAL MON UN, 1996, CLIN PATHW LIT REV; WEINGARTEN S, 1993, AM J CARDIOL, V71, P259, DOI 10.1016/0002-9149(93)90787-D; Wentworth DA, 1996, STROKE, V27, P1040, DOI 10.1161/01.STR.27.6.1040; Williams J G, 1993, Qual Health Care, V2, P73, DOI 10.1136/qshc.2.2.73; ZANDER K, 1988, J NURS ADMIN, V18, P23	37	534	544	1	47	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 10	1998	316	7125					133	137						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YR408	9462322				2022-12-28	WOS:000071492300029
J	Perler, FB				Perler, FB			Protein splicing of inteins and hedgehog autoproteolysis: Structure, function, and evolution	CELL			English	Review									New England Biolabs Inc, Beverly, MA 01915 USA		Perler, FB (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.		Wood, David W/B-2992-2012					BEACHY PA, 1997, IN PRESS COLD SPRING; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; Chong SR, 1997, J BIOL CHEM, V272, P15587, DOI 10.1074/jbc.272.25.15587; Dalgaard JZ, 1997, J COMPUT BIOL, V4, P193, DOI 10.1089/cmb.1997.4.193; Derbyshire V, 1997, P NATL ACAD SCI USA, V94, P11466, DOI 10.1073/pnas.94.21.11466; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Hall TMT, 1997, CELL, V91, P85, DOI 10.1016/S0092-8674(01)80011-8; Kawasaki M, 1997, J BIOL CHEM, V272, P15668, DOI 10.1074/jbc.272.25.15668; KLABUNDE T, 1998, IN PRESS NATURE STRU; Nogami S, 1997, GENETICS, V147, P73; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; PIETROKOVSKI S, 1998, IN PRESS PROTEIN SCI, V7; Shao Y, 1997, CHEM BIOL, V4, P187, DOI 10.1016/S1074-5521(97)90287-8; Telenti A, 1997, J BACTERIOL, V179, P6378, DOI 10.1128/jb.179.20.6378-6382.1997; Wang SL, 1997, J BIOL CHEM, V272, P11869, DOI 10.1074/jbc.272.18.11869; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x	17	170	206	1	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 9	1998	92	1					1	4		10.1016/S0092-8674(00)80892-2	http://dx.doi.org/10.1016/S0092-8674(00)80892-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489693	Bronze			2022-12-28	WOS:000071473700001
J	Courtney, SM; Petit, L; Maisog, JM; Ungerleider, LG; Haxby, JV				Courtney, SM; Petit, L; Maisog, JM; Ungerleider, LG; Haxby, JV			An area specialized for spatial working memory in human frontal cortex	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; HUMAN PREFRONTAL CORTEX; EYE-MOVEMENTS; FUNCTIONAL-ANATOMY; NEURAL SYSTEMS; PET; OBJECT; FIELDS; ACTIVATION; LOCATION	Working memory is the proc!ss of maintaining an active representation of information so that it is available for use. In monkeys, a prefrontal cortical region important for spatial working memory lies in and around the principal sulcus, but in humans the location, and even the existence, of a region for spatial working memory is in dispute. By using functional magnetic resonance imaging in humans, an area in the superior frontal sulcus was identified that is specialized for spatial working memory. This area is located more superiorly and posteriorly in the human than in the monkey brain, which may explain why it was not recognized previously.	NIMH, Lab Brain & Cognit, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Courtney, SM (corresponding author), NIMH, Lab Brain & Cognit, Bldg 10,Room 4C104,10 Ctr Dr, Bethesda, MD 20892 USA.		Petit, Laurent/D-6583-2011; GINSPAN, All/B-8714-2008; Petit, Laurent/M-3888-2019	Petit, Laurent/0000-0003-2499-5367; Petit, Laurent/0000-0003-2499-5367				Baker SC, 1996, CEREB CORTEX, V6, P612, DOI 10.1093/cercor/6.4.612; BRUCE CJ, 1985, J NEUROPHYSIOL, V54, P714, DOI 10.1152/jn.1985.54.3.714; BRUCE CJ, 1985, J NEUROPHYSIOL, V53, P603, DOI 10.1152/jn.1985.53.3.603; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Courtney SM, 1997, NATURE, V386, P608, DOI 10.1038/386608a0; Courtney SM, 1996, CEREB CORTEX, V6, P39, DOI 10.1093/cercor/6.1.39; Fiez JA, 1996, J NEUROSCI, V16, P808; FUNAHASHI S, 1994, NEUROSCI RES, V21, P1, DOI 10.1016/0168-0102(94)90063-9; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; Fuster J.M., 1989, PREFRONTAL CORTEX; Goldberg ME, 1989, NEUROBIOLOGY SACCADI, P283; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; GOTTLIEB JP, 1994, J NEUROPHYSIOL, V72, P1634, DOI 10.1152/jn.1994.72.4.1634; Haxby JV, 1995, HUM BRAIN MAPP, V3, P68, DOI 10.1002/hbm.460030204; HAXBY JV, IN PRESS MAPPING MOD; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; Luna B, 1998, CEREB CORTEX, V8, P40, DOI 10.1093/cercor/8.1.40; MCCARTHY G, 1994, P NATL ACAD SCI USA, V91, P8690, DOI 10.1073/pnas.91.18.8690; McCarthy G, 1996, CEREB CORTEX, V6, P600, DOI 10.1093/cercor/6.4.600; Mellet E, 1996, J NEUROSCI, V16, P6504; Owen AM, 1996, CEREB CORTEX, V6, P31, DOI 10.1093/cercor/6.1.31; Owen AM, 1997, EUR J NEUROSCI, V9, P1329, DOI 10.1111/j.1460-9568.1997.tb01487.x; Paus T, 1996, NEUROPSYCHOLOGIA, V34, P475, DOI 10.1016/0028-3932(95)00134-4; Petit L, 1996, J NEUROSCI, V16, P3714; Petit L, 1997, J NEUROPHYSIOL, V77, P3386, DOI 10.1152/jn.1997.77.6.3386; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; Rao SC, 1997, SCIENCE, V276, P821, DOI 10.1126/science.276.5313.821; Rencher A.C., 1995, METHODS MULTIVARIATE; SMITH EE, 1995, J COGNITIVE NEUROSCI, V7, P337, DOI 10.1162/jocn.1995.7.3.337; Smith EE, 1996, CEREB CORTEX, V6, P11, DOI 10.1093/cercor/6.1.11; STANTON GB, 1989, J COMP NEUROL, V282, P415, DOI 10.1002/cne.902820308; Stuss D.T., 1986, FRONTAL LOBES; Sweeney JA, 1996, J NEUROPHYSIOL, V75, P454, DOI 10.1152/jn.1996.75.1.454; Ungerleider Leslie G., 1994, Current Opinion in Neurobiology, V4, P157, DOI 10.1016/0959-4388(94)90066-3; UNGERLEIDER LG, 1995, SCIENCE, V270, P769, DOI 10.1126/science.270.5237.769; Walker E.A, 1940, J COMP NEUROL, V73, P59; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836	37	717	737	2	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	1998	279	5355					1347	1351		10.1126/science.279.5355.1347	http://dx.doi.org/10.1126/science.279.5355.1347			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478894				2022-12-28	WOS:000072251800049
J	Hackley, SA; Valle-Inclan, F				Hackley, SA; Valle-Inclan, F			Automatic alerting does not speed late motoric processes in a reaction-time task	NATURE			English	Article							REFLEX; ACTIVATION	When an irrelevant 'accessory' stimulus is presented at about the same time as the imperative signal in a choice reaction time-task, the latency of the voluntary response is markedly reduced(1), The most prominent cognitive theories agree that this effect-is attributable to a brief surge in arousal ('automatic alerting'), but they disagree over whether the facilitation is localized to a late, low-level motoric process(2) or to an earlier stage, the process of orienting to and then perceptually categorizing the reaction stimulus(3,4). To lest these alternative hypotheses, we used the onset of the lateralized readiness potential (a movement-related brain potential) as a temporal landmark to partition mean reaction time into two time segments. The first segment included the time required to perceive the visual stimulus and decide which hand to react with; the second included only motoric processes. Presentation of an irrelevant acoustic stimulus shortened the first interval but had no effect on the second. We therefore rejected the motoric hypothesis.	Univ Missouri, Dept Psychol, Columbia, MO 65211 USA; Univ A Coruna, Dept Psychol, La Coruna 15071, Spain	University of Missouri System; University of Missouri Columbia; Universidade da Coruna	Hackley, SA (corresponding author), Univ Missouri, Dept Psychol, 210 Mcalester Hall, Columbia, MO 65211 USA.	shackley@showme.missouri.edu	Valle-Inclán, Fernando/Y-9218-2019	Valle-Inclán, Fernando/0000-0002-4702-0151				BERNSTEIN IH, 1970, PSYCHON SCI, V19, P113, DOI 10.3758/BF03337448; ERIKSEN CW, 1988, PERCEPT PSYCHOPHYS, V44, P191, DOI 10.3758/BF03208712; FernandezDuque D, 1997, NEUROPSYCHOLOGIA, V35, P477, DOI 10.1016/S0028-3932(96)00103-0; GRATTON G, 1988, J EXP PSYCHOL HUMAN, V14, P331, DOI 10.1037/0096-1523.14.3.331; Low KA, 1996, ELECTROEN CLIN NEURO, V98, P385, DOI 10.1016/0013-4694(96)95085-3; MILLER J, 1992, J EXP PSYCHOL GEN, V121, P195, DOI 10.1037/0096-3445.121.2.195; MILLER J, 1991, PERCEPT PSYCHOPHYS, V50, P584, DOI 10.3758/BF03207544; MILLER J, IN PRESS PSYCHOPHYSI; Posner M.I., 1978, CHRONOMETRIC EXPLORA; Sanders A. F., 1980, TUTORIALS MOTOR BEHA, P331, DOI [10.1016/S0166-4115(08)61955-X, DOI 10.1016/S0166-4115(08)61955-X]; SANDERS AF, 1983, ACTA PSYCHOL, V53, P61, DOI 10.1016/0001-6918(83)90016-1; STAFFORD IL, 1990, J NEUROSCI, V10, P99; Stein BE, 1996, J COGNITIVE NEUROSCI, V8, P497, DOI 10.1162/jocn.1996.8.6.497; Sternberg S, 1969, ACTA PSYCHOL, V30, P276, DOI 10.1016/0001-6918(69)90055-9; VALLEINCLAN F, 1997, PSYCHOPHYSIOLOGY, V34, pS92; YOUNG RA, 1976, J COMP PHYSIOL PSYCH, V90, P424, DOI 10.1037/h0077219	16	111	111	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					786	788		10.1038/35849	http://dx.doi.org/10.1038/35849			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YX884	9486647				2022-12-28	WOS:000072089500051
J	Huang, CL; Feng, SY; Hilgemann, DW				Huang, CL; Feng, SY; Hilgemann, DW			Direct activation of inward rectifier potassium channels by PIP2 and its stabilization by G beta gamma	NATURE			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; RECTIFYING K+ CHANNELS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; FUNCTIONAL EXPRESSION; MOLECULAR-PROPERTIES; I-KACH; PROTEINS; SUBUNITS; BINDING; G(BETA-GAMMA)	Inward rectifier K+ channels, which modulate electrical activity in many cell types, are regulated by protein kinases(1,2), guanine-nucleotide-binding proteins (G proteins)(3-6) and probably actin cytoskeleton(7), Generation of phosphatidylinositol 4,5-bisphosphate (PIP2) by ATP-dependent lipid kinases is known to activate inward rectifier Ki(+) channels in cardiac membrane patches(8), Here we report that several cloned inward rectifier K+ channels directly bind PIP2, and that this binding correlates with channel activity. Application of ATP or PIP2 liposomes activates the cloned channels, Stabilized by lipid phosphatase inhibitors, PIP2 antibodies(9) potently inhibit each channel with a unique rate (GIRK1/4 (refs 3-5) approximate to GIRK2 (ref, 6) much greater than IRK1 (ref, 10) approximate to ROMK (ref. 11)). Consistent with the faster dissociation of PIP, from the GIRK channels, the carboxy terminus of GIRK1 binds H-3-PIP2 liposomes more weakly than does that of IRK1 or ROMK1. Mutation of a conserved arginine to glutamine at position 188 reduces the ability of ROMK1 to bind PIP2 and increases its sensitivity to inhibition by PIP2 antibodies. Interactions between GIRK channels and PIP2 are modulated by the beta gamma subunits of the G protein (G beta gamma). When GIRK1/4 channels are allowed to run down completely, they are not activated by addition of G beta gamma alone, but application of PIP2 activates them in minutes without G beta gamma and in just seconds with G beta gamma, Finally, coexpression of G beta gamma with GIRK channels slows the inhibition of K+ currents by PIP2 antibodies by more than 10-fold, Thus G beta gamma activates GIRK channels by stabilizing interactions between PIP2 and the K+ channel.	Univ Texas, SW Med Ctr, Dept Med, Div Nephrol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Huang, CL (corresponding author), Univ Texas, SW Med Ctr, Dept Med, Div Nephrol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	chuanl@mednet.swmed.edu						CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; FAKLER B, 1994, NEURON, V13, P1413, DOI 10.1016/0896-6273(94)90426-X; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; Furukawa T, 1996, PFLUG ARCH EUR J PHY, V431, P504, DOI 10.1007/s004240050028; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; MCNICHOLAS CM, 1994, P NATL ACAD SCI USA, V91, P8077, DOI 10.1073/pnas.91.17.8077; PENNISTON JT, 1982, ANN NY ACAD SCI, V402, P291; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; SCHACHT J, 1976, J NEUROCHEM, V27, P1119, DOI 10.1111/j.1471-4159.1976.tb00318.x; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853	29	741	753	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 19	1998	391	6669					803	806		10.1038/35882	http://dx.doi.org/10.1038/35882			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486652				2022-12-28	WOS:000072089500056
J	Naficy, A; Rao, MR; Paquet, C; Antona, D; Sorkin, A; Clemens, JD				Naficy, A; Rao, MR; Paquet, C; Antona, D; Sorkin, A; Clemens, JD			Treatment and vaccination strategies to control cholera in sub-Saharan refugee settings - A cost-effectiveness analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FIELD TRIAL; DEVELOPING-COUNTRIES; EPIDEMIC CHOLERA; PUBLIC-HEALTH; LATIN-AMERICA; FOLLOW-UP; BANGLADESH; VACCINES; MORTALITY; TRANSMISSION	Context.-There is significant controversy about how best to control cholera epidemics in refugee settings. Specifically, there is marked disagreement about whether to use oral cholera vaccines in these settings, despite the improved safety and effectiveness profiles of these vaccines. Objective.-To determine the cost-effectiveness of alternative intervention strategies, including vaccination, to control cholera outbreaks in sub-Saharan refugee camps. Design.-A cost-effectiveness analysis based on probabilities of cholera outcomes derived from epidemiologic data compiled for refugee settings in Malawi from 1987 through 1993; data for costs were obtained from a large relief agency that provides medical care in such settings. Setting and Participants.-A hypothetical refugee camp with 50 000 persons in sub-Saharan Africa evaluated for a 2-year period. Interventions.-We compared the costs and outcomes of alternative strategies in which appropriate rehydration therapy for cholera is introduced preemptively (at the establishment of a camp) or reactively (once an epidemic is recognized) and in which mass immunization with oral B subunit killed whole-cell (BS-WC) cholera vaccine is added to a rehydration program either preemptively or reactively. Main Outcome Measures.-Cost per cholera case prevented and cost per cholera death averted. Results.-In a situation with no available rehydration therapy suitable for the management of severe cholera, a strategy of preemptive therapy ($320 per death averted) costs less and is more effective than a strategy of reactive therapy ($586 per death averted). Adding vaccination to preemptive therapy is expensive: $1745 per additional death averted for preemptive vaccination and $3833 per additional death averted for reactive vaccination. However, if the cost of vaccine falls below $0.22 per dose, strategies combining vaccination and preemptive therapy become more cost-effective than therapy alone. Conclusions.-Provision for managing cholera outbreaks at the inception of a refugee camp (preemptive therapy) is the most cost-effective strategy for controlling cholera outbreaks in sub-Saharan refugee settings. Should the price of BS-WC cholera vaccine fall below $0.22 per dose, however, supplementation of preemptive therapy with mass vaccination will become a cost-effective option.	NICHHD, Epidemiol Branch, Bethesda, MD 20892 USA; Epicentre, Paris, France; Med Sans Frontieres, Paris, France; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Univ Maryland Baltimore Cty, Dept Econ, Catonsville, MD USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Doctors Without Borders; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore County	Naficy, A (corresponding author), NICHHD, Epidemiol Branch, Room 7B03,6100 Execut Blvd, Bethesda, MD 20892 USA.							[Anonymous], 1995, Lancet, V345, P339; CARPENTER CCJ, 1976, JOHNS HOPKINS MED J, V139, P153; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; Clemens J, 1995, B I PASTEUR, V93, P237, DOI 10.1016/0020-2452(96)85757-5; CLEMENS JD, 1986, LANCET, V2, P124; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; CLEMENS JD, 1988, J INFECT DIS, V158, P60, DOI 10.1093/infdis/158.1.60; CLEMENS JD, 1988, J INFECT DIS, V158, P372, DOI 10.1093/infdis/158.2.372; Clemens John, 1994, P425; CVJETANOVIC B, 1974, CHOLERA, P435; DJEDDAH C, 1988, EUR J EPIDEMIOL, V4, P227, DOI 10.1007/BF00144757; GLASS RI, 1991, LANCET, V338, P791, DOI 10.1016/0140-6736(91)90673-D; ICHINOSE Y, 1986, J TROP MED HYG, V89, P269; LEVINE MM, 1988, LANCET, V2, P468, DOI 10.1016/S0140-6736(88)90120-1; MAHALANABIS D, 1973, JOHNS HOPKINS MED J, V132, P197; MANDARA M P, 1980, Medical Journal of Zambia, V15, P10; MOREN A, 1991, J TROP MED HYG, V94, P1; MORRIS JG, 1982, J INFECT DIS, V145, P131, DOI 10.1093/infdis/145.1.131; *REF HLTH UNT, 1985, 1985 ANN REP; SACK DA, 1994, LANCET, V344, P616, DOI 10.1016/S0140-6736(94)92003-6; SACK DA, 1991, J INFECT DIS, V163, P503, DOI 10.1093/infdis/163.3.503; SANCHEZ JL, 1994, LANCET, V344, P1273, DOI 10.1016/S0140-6736(94)90755-2; Swerdlow David L., 1994, P297; TACKET CO, 1992, J INFECT DIS, V166, P837, DOI 10.1093/infdis/166.4.837; TAUXE RV, 1992, JAMA-J AM MED ASSOC, V267, P1388, DOI 10.1001/jama.267.10.1388; TAUXE RV, 1988, EPIDEMIOL INFECT, V100, P279, DOI 10.1017/S0950268800067418; TOOLE MJ, 1988, B WORLD HEALTH ORGAN, V66, P237; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; TOOLE MJ, 1993, JAMA-J AM MED ASSOC, V270, P600, DOI 10.1001/jama.270.5.600; Weinstein M C, 1981, Med Decis Making, V1, P309, DOI 10.1177/0272989X8100100403; *WHO, 1995, PUBL WHO	31	47	47	2	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	1998	279	7					521	525		10.1001/jama.279.7.521	http://dx.doi.org/10.1001/jama.279.7.521			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW470	9480362	Bronze			2022-12-28	WOS:000071938900033
J	Chapman, DL; Papaioannou, VE				Chapman, DL; Papaioannou, VE			Three neural tubes in mouse embryos with mutations in the T-box gene Tbx6	NATURE			English	Article							EXPRESSION; MESODERM; PROTEIN; GASTRULATION; EVOLUTION; HINDBRAIN; PATTERN; CNS	Somites, segmented mesodermal units of the vertebrate embryo, are the precursors of adult skeletal muscle, bone and cartilage(1). During embryogenesis, somite progenitor cells ingress through the primitive streak, move laterally to a paraxial position (alongside the body axis) and segment into epithelial somites(2). Little is known about how this paraxial mesoderm tissue is specified(1,2). We have previously described a mouse T-box gene, Tbx6 (ref. 3), which codes for a putative DNA-binding protein(4,5). The embryonic pattern of expression of Tbx6 in somite precursor cells suggests that this gene may be involved in the specification of paraxial mesoderm(3). We now report the creation of a mutation in Tbx6 that profoundly affects the differentiation of paraxial mesoderm. Irregular somites form in the neck region of mutant embryos, whereas more posterior paraxial tissue does not form somites but instead differentiates along a neural pathway, forming neural-tube-like structures that flank the axial neural tube. These paraxial tubes show dorsal/ventral patterning that is characteristic of the neural tube, and have differentiated motor neurons, These results indicate that Tbx6 is needed for cells to choose between a mesodermal and a neuronal differentiation pathway during gastrulation; Tbx6 is essential for the specification of posterior paraxial mesoderm, and in its absence cells destined to form posterior somites differentiate along a neuronal pathway.	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA	Columbia University	Chapman, DL (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, 701 W 168th St, New York, NY 10032 USA.			Papaioannou, Virginia/0000-0001-7558-8601; Chapman, Deborah/0000-0002-8695-6243				Agulnik SI, 1996, GENETICS, V144, P249; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; Chapman DL, 1996, DEV BIOL, V180, P534, DOI 10.1006/dbio.1996.0326; Ciruna BG, 1997, DEVELOPMENT, V124, P2829; Deng CX, 1997, DEV BIOL, V185, P42, DOI 10.1006/dbio.1997.8553; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; HOGAN B, 1985, TRENDS GENET, V1, P67, DOI 10.1016/0168-9525(85)90029-0; Irving C, 1996, DEV BIOL, V173, P26, DOI 10.1006/dbio.1996.0004; JOYNER AL, 1993, GENE TARGETING; KISPERT A, 1993, EMBO J, V12, P3211, DOI 10.1002/j.1460-2075.1993.tb05990.x; LEWIS SA, 1985, J CELL BIOL, V100, P843, DOI 10.1083/jcb.100.3.843; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NIETO MA, 1992, DEVELOPMENT, V116, P1137; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; SASAKI H, 1993, DEVELOPMENT, V118, P47; Smith J, 1997, CURR OPIN GENET DEV, V7, P474, DOI 10.1016/S0959-437X(97)80073-1; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; TAM PPL, 1987, DEVELOPMENT, V99, P109; TAM PPL, 1994, ANAT EMBRYOL, V189, P2275; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILKINSON DG, 1992, WHOLE MOUNT IN SITU; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; Yoshikawa Y, 1997, DEV BIOL, V183, P234, DOI 10.1006/dbio.1997.8502	26	317	326	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 12	1998	391	6668					695	697		10.1038/35624	http://dx.doi.org/10.1038/35624			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490412				2022-12-28	WOS:000071982500052
J	Estivill, X; Fortina, P; Surrey, S; Rabionet, R; Melchionda, S; D'Agruma, L; Mansfield, E; Rappaport, E; Govea, N; Mila, M; Zelante, L; Gasparini, P				Estivill, X; Fortina, P; Surrey, S; Rabionet, R; Melchionda, S; D'Agruma, L; Mansfield, E; Rappaport, E; Govea, N; Mila, M; Zelante, L; Gasparini, P			Connexin-26 mutations in sporadic and inherited sensorineural deafness	LANCET			English	Article							GAP-JUNCTIONS; COCHLEA; GENES	Background Hearing impairment affects one infant in 1000 and 4% of people aged younger than 45 years. Congenital deafness is inherited or apparently sporadic. We have shown previously that DFNB1 on chromosome 13 is a major locus for recessive deafness in about 80% of Mediterranean families and that the connexin-26 gene gap junction protein beta 2 (GJB2) is mutated in DFNB1 families, We investigated mutations in the GJB2 gene in familial and sporadic cases of deafness. Methods We obtained DNA samples from 82 families from Italy and Spain with recessive non-syndromic deafness and from 54 unrelated participants with apparently sporadic congenital deafness. We analysed the coding region of the GJB2 gene for mutations. We also tested 280 unrelated people from the general populations of Italy and Spain for the frameshift mutation 35delG. Findings 49% of participants with recessive deafness and 37% of sporadic cases had mutations in the GJB2 gene; The 35delG mutation accounted for 85% of GJB2 mutations, six other mutations accounted for 6% of alleles, and no changes in the coding region of GJB2 were detected in 9% of DFNB1 alleles., The carrier frequency of mutation 35delG among people from the general population was one in 31 (95% CI one in 19 to one in 87). Interpretation Mutations in the GJB2 gene are a major cause of inherited and apparently sporadic congenital deafness. Mutation 35delG is the most common mutation for sensorineural deafness. Identification of 35delG and other mutations in the GJB2 gene should facilitate diagnosis and counselling for the most common genetic form of deafness.	Hosp Duran I Reynals, Ctr Genet Med & Mol, Dept Genet, Barcelona 08907, Catalonia, Spain; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Osped Casa Solllevo Sofferenza, Serv Genet Med, Foggia, Italy; Jefferson Med Coll, Dept Pediat, Wilmington, DE USA; Du Pont Hosp Children, Wilmington, DE USA; Mol Dynam, Sunnyvale, CA USA; Hosp Clin Barcelona, Serv Genet, Barcelona, Catalonia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; IRCCS Casa Sollievo Della Sofferenza; Jefferson University; Nemours Alfred I. duPont Hospital for Children; Pfizer; University of Barcelona; Hospital Clinic de Barcelona	Estivill, X (corresponding author), Hosp Duran I Reynals, Ctr Genet Med & Mol, Dept Genet, Lhospitalet, Barcelona 08907, Catalonia, Spain.	estivill@iro.es	rabionet, raquel/A-7407-2009; Fortina, Paolo/ABE-8350-2020; Rabionet, Raquel/C-8379-2009; Estivill, Xavier/E-2957-2012; Estivill, Xavier/A-3125-2013; Gasparini, Paolo/B-6173-2014; Leonardo, D'Agruma/A-4824-2015	rabionet, raquel/0000-0001-5006-8140; Rabionet, Raquel/0000-0001-5006-8140; Estivill, Xavier/0000-0002-0723-2256; Leonardo, D'Agruma/0000-0001-8308-8957; Fortina, Paolo/0000-0002-5898-2081; Mila, Montserrat/0000-0002-7906-0916	NINDS NIH HHS [1R43NS/MH34589] Funding Source: Medline; Telethon [E.0549] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R43NS034589] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BEYER EC, 1990, J MEMBRANE BIOL, V116, P187, DOI 10.1007/BF01868459; Carrasquillo MM, 1997, HUM MOL GENET, V6, P2163, DOI 10.1093/hmg/6.12.2163; Cohen M. M., 1995, HEREDITARY HEARING L, P9; Denoyelle F, 1997, HUM MOL GENET, V6, P2173, DOI 10.1093/hmg/6.12.2173; DUNN RA, 1975, P NATL ACAD SCI USA, V72, P3599, DOI 10.1073/pnas.72.9.3599; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Gasparini P, 1997, EUR J HUM GENET, V5, P83; ICHIMIYA I, 1994, ANN OTO RHINOL LARYN, V103, P457; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KIKUCHI T, 1995, ANAT EMBRYOL, V191, P101, DOI 10.1007/BF00186783; LATHROP GM, 1988, AM J HUM GENET, V42, P498; Lench NJ, 1997, AM J HUM GENET, V61, pA22; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; Mignon C, 1996, CYTOGENET CELL GENET, V72, P185, DOI 10.1159/000134183; NADOL JB, 1993, NEW ENGL J MED, V329, P1092, DOI 10.1056/NEJM199310073291507; NADOL JB, 1976, AM J ANAT, V147, P281, DOI 10.1002/aja.1001470304; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; RAHMAN S, 1991, J CELL SCI, V100, P567; SOSINSKY G, 1995, P NATL ACAD SCI USA, V92, P9210, DOI 10.1073/pnas.92.20.9210; STAUFFER KA, 1995, J BIOL CHEM, V270, P6768; VanCamp G, 1997, AM J HUM GENET, V60, P758; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; WOLBURG H, 1995, INT REV CYTOL, V157, P315, DOI 10.1016/S0074-7696(08)62161-0; Zelante L, 1997, HUM MOL GENET, V6, P1605, DOI 10.1093/hmg/6.9.1605	27	505	541	0	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 7	1998	351	9100					394	398		10.1016/S0140-6736(97)11124-2	http://dx.doi.org/10.1016/S0140-6736(97)11124-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482292	hybrid			2022-12-28	WOS:000071982600010
J	Brehm, A; Miska, EA; McCance, DJ; Reid, JL; Bannister, AJ; Kouzarides, T				Brehm, A; Miska, EA; McCance, DJ; Reid, JL; Bannister, AJ; Kouzarides, T			Retinoblastoma protein recruits histone deacetylase to repress transcription	NATURE			English	Article							GENE-PRODUCT; BINDING; REGULATOR; YEAST; SITE; CBP	The retinoblastoma protein (Rb) silences specific genes that are active in the S phase of the cell cycle and which are regulated by E2F transcription factors(1). Rb binds to the activation domain of E2F and then actively represses the promoter by a mechanism that is poorly understood(2,3). Here we show that Rb associates with a histone deacetylase, HDAC1, through the Rb 'pocket' domain. Association with the deacetylase is reduced by naturally occurring mutations in the pocket and by binding of the human papilloma virus oncoprotein E7. We find that Rb can recruit histone deacetylase to E2F and that Rb cooperates with HDAC1 to repress the E2F-regulated promoter of the gene encoding the cell-cycle protein cyclin E. Inhibition of histone deacetylase activity by trichostatin A (TSA) inhibits Rb-mediated repression of a chromosomally integrated E2F-regulated promoter. Our results indicate that histone deacetylases are important for regulating the cell cycle and that active transcriptional repression by Rb may involve the modification of chromatin structure.	Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QR, England; Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA	University of Cambridge; University of Cambridge; University of Rochester	Kouzarides, T (corresponding author), Univ Cambridge, Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.			Bannister, Andrew/0000-0002-6312-4436; Kouzarides, Tony/0000-0002-8918-4162; Miska, Eric/0000-0002-4450-576X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Botz J, 1996, MOL CELL BIOL, V16, P3401; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; Tauton J, 1996, SCIENCE, V272, P408; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	25	1034	1074	3	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 5	1998	391	6667					597	601		10.1038/35404	http://dx.doi.org/10.1038/35404			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468139				2022-12-28	WOS:000071842300055
J	Davidson, FF; Steller, H				Davidson, FF; Steller, H			Blocking apoptosis prevents blindness Drosophila retinal degeneration mutants	NATURE			English	Article							PROGRAMMED CELL-DEATH; DOMINANT RETINITIS-PIGMENTOSA; BACULOVIRUS P35 PROTEIN; CAENORHABDITIS-ELEGANS; PHOTORECEPTOR CELL; RHODOPSIN; MELANOGASTER; INHIBITION; EXPRESSION; MUTATION	Apoptosis is a gene-directed form of cell death that is essential for normal development and health. Yet abnormally high levels of apoptosis are linked to many degenerative diseases(1), Some important biochemical events in apoptosis have been identified(2), but the therapeutic utility of blocking cell death remains unclear. An important question in this regard is whether cells rescued from apoptosis can function. We have investigated the mechanism of cell death in two Drosophila mutant strains that exhibit age-related retinal degeneration. One of these mutations also occurs in humans, where it causes retinitis pigmentosa. We found that retinal cell death in rdgC and ninaE(RH27)/+ flies occurred by apoptosis and was blocked by eye-specific expression of the baculoviral cell survival protein p35. Most importantly, the mutant flies expressing p35 showed significant retention of visual function, The results demonstrate a therapeutic benefit of late-stage inhibition of apoptosis to flies, and suggest that similar results may be obtained in higher organisms.	MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Steller, H (corresponding author), MIT, Howard Hughes Med Inst, 31 Ames St, Cambridge, MA 02139 USA.							BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; COHEN GM, 1995, BIOCHEM J, V326, P1; COLLEY NJ, 1995, P NATL ACAD SCI USA, V92, P3070, DOI 10.1073/pnas.92.7.3070; DRYJA TP, 1992, EYE, V6, P1; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HAY BA, 1994, DEVELOPMENT, V120, P2121; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HUMPHRIES P, 1990, CLIN GENET, V38, P1; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KURADA P, 1995, NEURON, V14, P571, DOI 10.1016/0896-6273(95)90313-5; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; Nickells RW, 1996, OPHTHALMIC GENET, V17, P145, DOI 10.3109/13816819609057889; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; RENDAHL KG, 1992, J NEUROSCI, V12, P390; RICHARDS JE, 1995, OPHTHALMOLOGY, V102, P669, DOI 10.1016/S0161-6420(95)30972-4; STEELE F, 1990, NEURON, V4, P883, DOI 10.1016/0896-6273(90)90141-2; STEELE FR, 1992, CELL, V69, P669, DOI 10.1016/0092-8674(92)90230-A; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0	28	144	149	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 5	1998	391	6667					587	591		10.1038/35385	http://dx.doi.org/10.1038/35385			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468136				2022-12-28	WOS:000071842300052
J	Nightingale, SL				Nightingale, SL			Guidance on industry-supported scientific and educational activities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					346	346		10.1001/jama.279.5.346	http://dx.doi.org/10.1001/jama.279.5.346			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459455				2022-12-28	WOS:000071731300006
J	Rosse, T; Olivier, R; Monney, L; Rager, M; Conus, S; Fellay, I; Jansen, B; Borner, C				Rosse, T; Olivier, R; Monney, L; Rager, M; Conus, S; Fellay, I; Jansen, B; Borner, C			Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c	NATURE			English	Article							APOPTOSIS; DEATH; INHIBITION; DOMAINS; BH1	Following exposure of cells to stimuli that trigger programmed cell death (apoptosis), cytochrome c is rapidly released from mitochondria irate the cytoplasm where it activates proteolytic molecules known as caspases that specifically cleave the amino-acid sequence DEVD and are crucial for the execution of apoptosis(1-4). The protein Bcl-2 interferes with this activation of caspases by preventing the release of cytochrome c(2-4). Here we study these molecular interactions during apoptosis induced by the protein Bax, a pro-apoptotic homologue of Bcl-2 (refs 5, 6). We show that in cells transiently transfected with bax, Bax localizes to mitochondria and induces the release of cytochrome c, activation of caspase-3, membrane blebbing, nuclear fragmentation, and cell death. Caspase inibitors do not affect Bax-induced cytochrome c release but block caspase-3 activation and nuclear fragmentation. Unexpectedly, Bcl-2 also fails to prevent Bax-induced cytochrome c release, although it co-localizes with Bax to mitochondria. Cells overexpressing both Bcl-2 and Bax show no signs of caspase activation and survive with significant amounts of cytochrome c in the cytoplasm. These findings indicate that Bcl-2 can interfere with Bax killing downstream of and independently of cytochrome c release.	Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland; Univ Vienna, Vienna Gen Hosp, Dept Clin Pharmacol, Sect Expt Oncol, A-1090 Vienna, Austria; Univ Vienna, Vienna Gen Hosp, Dept Dermatol, Div Gen Dermatol, A-1090 Vienna, Austria	University of Fribourg; University of Vienna; University of Vienna	Borner, C (corresponding author), Univ Fribourg, Inst Biochem, Rue Musee 5, CH-1700 Fribourg, Switzerland.							BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTTER I, IN PRESS J BIOL CHEM; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	13	761	845	3	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 29	1998	391	6666					496	499		10.1038/35160	http://dx.doi.org/10.1038/35160			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461218				2022-12-28	WOS:000071701800053
J	Chaturvedi, N; Jarrett, J; Shipley, MJ; Fuller, JH				Chaturvedi, N; Jarrett, J; Shipley, MJ; Fuller, JH			Socioeconomic gradient in morbidity and mortality in people with diabetes: cohort study findings from the Whitehall study and the WHO multinational study of vascular disease in diabetes	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; BRITISH CIVIL-SERVANTS; RISK-FACTORS; SOCIAL DEPRIVATION; GLYCEMIC CONTROL; MELLITUS; HYPERGLYCEMIA; PROTEINURIA; IDDM; COMPLICATIONS	Objectives: To assess whether the inverse socioeconomic mortality gradient observed in the general population persists in diabetic people. Design: The Whitehall cohort study and the London cohort of the WHO multinational study of vascular disease in diabetes. Setting: London. Subjects: 17 264 male civil servants (17 046 without diabetes, 218 with diabetes) aged 40-64 examined in 1967-9, and 300 people with diabetes aged 35-55 from London clinics examined in 1975-7. Both cohorts were followed up until January 1995. Main outcome measures: Mortality from all causes, cardiovascular disease, and ischaemic heart disease. Results: In both cohorts people in the lower social groups were older, had higher blood pressure, and were more Likely to smoke. In the Whitehall study, the prevalence of heart disease was higher in the lowest social group compared with the highest group, by 6% among non-diabetic people (P = 0.0001) and by 14% among diabetic subjects (P = 0.02). In the WHO study proteinuria was more common in tie lowest social group compared with the highest (27% v 15%, P = 0.01), as was retinopathy (54% v 48%, P = 0.5). There was a clear socioeconomic gradient in all cause mortality in both cohorts, with death rates being about twice as high in the lowest compared with the highest social groups. In the Whitehall study this gradient was similar in both diabetic and non-diabetic subjects, and it persisted for mortality from cardiovascular disease and from ischaemic heart disease. About half of the increased risk of death in the lowest social group was accounted for by blood pressure and smoking. Conclusions: We confirm the existence of an inverse socioeconomic mortality gradient in diabetic people and suggest that this is largely due to conventional cardiovascular risk factors.	UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England	University of London; University College London	Chaturvedi, N (corresponding author), UCL, Dept Epidemiol & Publ Hlth, Mortimer St, London WC1E 6BT, England.	nish@public-health.ucl.ac.uk						ANDERSSON DKG, 1995, DIABETES CARE, V18, P1534, DOI 10.2337/diacare.18.12.1534; BarrettConnor E, 1996, DIABETES CARE, V19, P333, DOI 10.2337/diacare.19.4.333; BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; Chaturvedi N, 1997, DIABETES CARE, V20, P1266, DOI 10.2337/diacare.20.8.1266; Chaturvedi N, 1996, DIABETES CARE, V19, P423, DOI 10.2337/diacare.19.5.423; Connolly VM, 1996, DIABETES CARE, V19, P419, DOI 10.2337/diacare.19.5.419; Diabetes Drafting Group, 1985, DIABETOLOGIA, V28, P615; DORMAN JS, 1985, DIABETES CARE, V8, P54, DOI 10.2337/diacare.8.1.S54; EAMES M, 1993, BRIT MED J, V307, P1097, DOI 10.1136/bmj.307.6912.1097; FULLER JH, 1979, J CHRON DIS, V32, P721, DOI 10.1016/0021-9681(79)90051-1; GOLDBLATT P, 1990, LONGITUDINAL STUDY M, P164; HAFFNER SM, 1989, DIABETES CARE, V12, P128, DOI 10.2337/diacare.12.2.128; KELLY WF, 1994, DIABETIC MED, V11, P344, DOI 10.1111/j.1464-5491.1994.tb00284.x; KELLY WF, 1993, BRIT MED J, V307, P1115, DOI 10.1136/bmj.307.6912.1115; Koskinen SVP, 1996, BRIT MED J, V313, P975, DOI 10.1136/bmj.313.7063.975; KUNST AE, 1994, AM J PUBLIC HEALTH, V84, P932, DOI 10.2105/AJPH.84.6.932; LLOYD CE, 1993, DIABETES RES CLIN PR, V21, P187, DOI 10.1016/0168-8227(93)90068-G; Lowry R, 1996, JAMA-J AM MED ASSOC, V276, P792, DOI 10.1001/jama.276.10.792; MAJEED FA, 1994, BMJ-BRIT MED J, V308, P1426, DOI 10.1136/bmj.308.6941.1426; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; Matsushima M, 1996, DIABETOLOGIA, V39, P710; MORRISH NJ, 1991, DIABETOLOGIA, V34, P584, DOI 10.1007/BF00400278; MUGGEO M, 1995, DIABETOLOGIA, V38, P318, DOI 10.1007/s001250050288; *OFF POP CENS SURV, 1986, SER DS OFF POP CENS, V6, P82; Office of Population Censuses and Surveys, 1980, CLASS OCC; PRINGLE M, 1993, BRIT MED J, V306, P630, DOI 10.1136/bmj.306.6878.630; REID DD, 1974, LANCET, V1, P469; Rose G, 1982, CARDIOVASCULAR SURVE; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SPRAFKA JM, 1993, DIABETIC MED, V10, P627, DOI 10.1111/j.1464-5491.1993.tb00135.x; STEPHENSON JM, 1995, DIABETIC MED, V12, P149, DOI 10.1111/j.1464-5491.1995.tb00446.x; *UK PROSP DIAB STU, 1995, BMJ-BRIT MED J, V310, P83; Unwin N, 1996, DIABETIC MED, V13, P72, DOI 10.1002/(SICI)1096-9136(199601)13:1<72::AID-DIA21>3.3.CO;2-K; Wang SL, 1996, DIABETES CARE, V19, P305, DOI 10.2337/diacare.19.4.305; WILL JC, 1988, AM J PUBLIC HEALTH, V78, P831, DOI 10.2105/AJPH.78.7.831	36	136	136	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 10	1998	316	7125					100	105						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR408	9462313				2022-12-28	WOS:000071492300016
J	Faulkner, A				Faulkner, A			ABC of palliative care - Communication with patients, families, and other professionals	BRITISH MEDICAL JOURNAL			English	Review									Univ Sheffield, Sch Med, Sheffield, S Yorkshire, England; The Mount, Sheffield, S Yorkshire, England	University of Sheffield	Faulkner, A (corresponding author), Univ Sheffield, Sch Med, Sheffield, S Yorkshire, England.							FAULKNER A, 1997, EFFECTIVE INTERACTIO; Faulkner Ann, 1994, TALKING CANC PATIENT; Meredith C, 1996, BMJ-BRIT MED J, V313, P724	3	52	52	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 10	1998	316	7125					130	132						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR408	9462321				2022-12-28	WOS:000071492300028
J	Koskinen, SVP				Koskinen, SVP			Commentary: Problems in Finnish or British data - or a true difference?	BRITISH MEDICAL JOURNAL			English	Editorial Material							MORTALITY		Natl Publ Hlth Inst, Dept Hlth & Disabil, FIN-00300 Helsinki, Finland	Finland National Institute for Health & Welfare	Koskinen, SVP (corresponding author), Natl Publ Hlth Inst, Dept Hlth & Disabil, Mannerheimintie 166, FIN-00300 Helsinki, Finland.							Chaturvedi N, 1997, BRIT MED J, V314, P301, DOI 10.1136/bmj.314.7076.301a; Koskinen SVP, 1996, BRIT MED J, V313, P975, DOI 10.1136/bmj.313.7063.975; LAAKSO M, 1991, AM J EPIDEMIOL, V133, P850, DOI 10.1093/oxfordjournals.aje.a115965; Wang SL, 1996, DIABETES CARE, V19, P305, DOI 10.2337/diacare.19.4.305	4	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 10	1998	316	7125					105	106						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR408	9462314				2022-12-28	WOS:000071492300017
J	Zhou, SJ; Preston, DL; Lomdahl, PS; Beazley, DM				Zhou, SJ; Preston, DL; Lomdahl, PS; Beazley, DM			Large-scale molecular dynamics simulations of dislocation intersection in copper	SCIENCE			English	Article							STRESS; ENERGY	The results of massively parallel three-dimensional molecular dynamics simulations of the perpendicular intersection of extended dislocations in copper are reported. The intersection process, which involves three of the four possible {111} glide planes in the face-centered cubic lattice, begins with junction formation, followed by unzipping, partial dislocation bowing, cutting, and, finally, unit jog formation. The investigation provides insights into this complex atomistic process, which is currently not accessible to experimental investigation.	Univ Calif Los Alamos Natl Lab, Appl Theoret & Computat Phys Div, Los Alamos, NM 87545 USA; Univ Calif Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory	Zhou, SJ (corresponding author), Univ Calif Los Alamos Natl Lab, Appl Theoret & Computat Phys Div, Los Alamos, NM 87545 USA.							BEAZLEY DM, 1994, PARALLEL COMPUT, V20, P173, DOI 10.1016/0167-8191(94)90080-9; CARTER CB, 1979, PHYS STATUS SOLIDI A, V54, P395, DOI 10.1002/pssa.2210540150; CARTER CB, 1977, PHILOS MAG, V35, P1509, DOI 10.1080/14786437708232974; COTTRELL AH, 1952, PHILOS MAG, V43, P645; DAW MS, 1993, MATER SCI REP, V9, P251, DOI 10.1016/0920-2307(93)90001-U; DEVINCRE B, 1994, MODEL SIMUL MATER SC, V2, P559, DOI 10.1088/0965-0393/2/3A/010; FOLLANSBEE PS, 1988, ACTA METALL MATER, V36, P81, DOI 10.1016/0001-6160(88)90030-2; FOREMAN AJE, 1955, ACTA METALL MATER, V3, P322, DOI 10.1016/0001-6160(55)90036-5; Hirth J. P., 1972, THEORY DISLOCATIONS; HIRTH JP, 1961, J APPL PHYS, V32, P700, DOI 10.1063/1.1736074; HIRTH JP, 1962, J APPL PHYS, V33, P2286, DOI 10.1063/1.1728946; JKUHLMANWILSDOR.D, 1966, ACTA METALL, V14, P439; KELLEY A, 1971, STRENGTHENING METHOD; Lomdahl P. S., 1993, Proceedings SUPERCOMPUTING '93, P520, DOI 10.1145/169627.169794; LOMER WM, 1951, PHILOS MAG, V42, P1327; Meyers M.A., 1994, DYNAMIC BEHAV MAT; PFEFFER KH, 1965, JPHYS STAT SOLIDI, V8, P517; VOTER A, 1993, LAUR933901 LOS AL NA; Westbrook J. H., 1995, INTERMETALLIC COMPOU, V1, P77; WOLF U, 1992, PHILOS MAG A, V66, P991, DOI 10.1080/01418619208248003; ZBIB HM, 1996, ADV ENG PLASTICITY I, P15; ZHOU SJ, 1994, PHYS REV B, V49, P6451, DOI 10.1103/PhysRevB.49.6451; Zhou SJ, 1997, PHYS REV LETT, V78, P479, DOI 10.1103/PhysRevLett.78.479	23	168	172	1	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1525	1527		10.1126/science.279.5356.1525	http://dx.doi.org/10.1126/science.279.5356.1525			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488649				2022-12-28	WOS:000072372900062
J	Guo, HW; Yang, WY; Mockler, TC; Lin, CT				Guo, HW; Yang, WY; Mockler, TC; Lin, CT			Regulations of flowering time by Arabidopsis photoreceptors	SCIENCE			English	Article							THALIANA L HEYNH; PHYTOCHROME-B; BLUE; MUTANTS; GENE; RED; INDUCTION; RESPONSES; PHOTOMORPHOGENESIS; PERCEPTION	The shift in plants from vegetative growth to floral development is regulated by red-far-red light receptors (phytochromes) and blue-ultraviolet A light receptors (cryptochromes). A mutation in the Arabidopsis thaliana CRY2 gene encoding a blue-light receptor apoprotein (CRY2) is allelic to the late-flowering mutant, fha. Flowering in cry2/fha mutant plants is only incompletely responsive to photoperiod. Cryptochrome 2 (cry2) is a positive regulator of the flowering-time gene CO, the expression of which is regulated by photoperiod. Analysis of flowering in cry2 and phyB mutants in response to different wavelengths of light indicated that flowering is regulated by the antagonistic actions of phyB and cry2.	Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Lin, CT (corresponding author), Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA.	clin@mcdb.ucla.edu	Ecker, Joseph R/B-9144-2008; Mockler, Todd C/L-2609-2013	Ecker, Joseph R/0000-0001-5799-5895; Mockler, Todd C/0000-0002-0462-5775	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056265, T32GM008375, R29GM056265] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM056265, GM08375, GM56265] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad M, 1996, PLANT MOL BIOL, V30, P851, DOI 10.1007/BF00020798; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Aitchitt M., 1993, Plant Molecular Biology Reporter, V11, P317, DOI 10.1007/BF02905332; ARAKI T, 1993, PLANT J, V3, P231, DOI 10.1046/j.1365-313X.1993.t01-15-00999.x; Aukerman MJ, 1996, SEMIN CELL DEV BIOL, V7, P427, DOI 10.1006/scdb.1996.0053; BAGNALL DJ, 1995, PLANT PHYSIOL, V108, P1495, DOI 10.1104/pp.108.4.1495; Bagnall DJ, 1996, PLANTA, V200, P278, DOI 10.1007/BF00208319; Bradley D, 1997, SCIENCE, V275, P80, DOI 10.1126/science.275.5296.80; BRIGGS W, 1996, CURRENT TOPICS PLANT, V17; BROWN JAM, 1971, PLANT PHYSIOL, V47, P393, DOI 10.1104/pp.47.3.393; Chory J, 1997, PLANT CELL, V9, P1225, DOI 10.1105/tpc.9.7.1225; COUPLAND G, 1995, TRENDS GENET, V11, P393, DOI 10.1016/S0168-9525(00)89122-2; ESKINS K, 1992, PHYSIOL PLANTARUM, V86, P439, DOI 10.1111/j.1399-3054.1992.tb01341.x; Furuya M, 1996, TRENDS PLANT SCI, V1, P301; GOTO N, 1991, PHYSIOL PLANTARUM, V83, P209, DOI 10.1111/j.1399-3054.1991.tb02144.x; HALLIDAY KJ, 1994, PLANT PHYSIOL, V104, P1311, DOI 10.1104/pp.104.4.1311; Hicks KA, 1996, SEMIN CELL DEV BIOL, V7, P409, DOI 10.1006/scdb.1996.0051; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; JOHNSON E, 1994, PLANT PHYSIOL, V105, P141, DOI 10.1104/pp.105.1.141; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; King R, 1996, SEMIN CELL DEV BIOL, V7, P449, DOI 10.1006/scdb.1996.0056; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; KOORNNEEF M, IN PRESS ANN REV PLA; LIN C, 1996, CURRENT TOPICS PLANT, V17; Lin CT, 1998, P NATL ACAD SCI USA, V95, P2686, DOI 10.1073/pnas.95.5.2686; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; LISCUM E, 1994, PLANT CELL ENVIRON, V17, P639, DOI 10.1111/j.1365-3040.1994.tb00155.x; Ma H, 1997, CELL, V89, P821, DOI 10.1016/S0092-8674(00)80265-2; Martinez-Zapater JM, 1994, ARABIDOPSIS, P403; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; MOCKLER T, UNPUB; Mohr Hans, 1994, P353; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Peeters AJM, 1996, SEMIN CELL DEV BIOL, V7, P381, DOI 10.1006/scdb.1996.0048; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; REDEI GP, 1962, GENETICS, V47, P443; REED JW, 1993, PLANT CELL, V5, P147, DOI 10.1105/tpc.5.2.147; Simon R, 1996, SEMIN CELL DEV BIOL, V7, P419, DOI 10.1006/scdb.1996.0052; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; SMITH H, 1995, ANNU REV PLANT PHYS, V46, P289, DOI 10.1146/annurev.pp.46.060195.001445; vonArnim A, 1996, ANNU REV PLANT PHYS, V47, P215, DOI 10.1146/annurev.arplant.47.1.215; Weller JL, 1997, PLANT PHYSIOL, V114, P1225, DOI 10.1104/pp.114.4.1225; Weller JL, 1997, TRENDS PLANT SCI, V2, P412, DOI 10.1016/S1360-1385(97)85580-X; Zagotta MT, 1996, PLANT J, V10, P691, DOI 10.1046/j.1365-313X.1996.10040691.x	46	570	639	5	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	1998	279	5355					1360	1363		10.1126/science.279.5355.1360	http://dx.doi.org/10.1126/science.279.5355.1360			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478898				2022-12-28	WOS:000072251800053
J	Moler, KA; Kirtley, JR; Hinks, DG; Li, TW; Xu, M				Moler, KA; Kirtley, JR; Hinks, DG; Li, TW; Xu, M			Images of interlayer Josephson vortices in Tl2Ba2CuO6+delta	SCIENCE			English	Article							HIGH-TC SUPERCONDUCTORS; HALL-PROBE MICROSCOPY; COUPLED LAYER MODEL; CUO2 PLANES; PSEUDOGAP; FIELD	The strength of the interlayer Josephson tunneling in layered superconductors is an essential test of the interlayer tunneling model as a mechanism for superconductivity, as well as a useful phenomenological parameter. A scanning superconducting quantum interference device (SQUID) microscope was used to image interlayer Josephson vortices in Tl2Ba2CuO6+delta and to obtain a direct measure of the interlayer tunneling in a high-transition temperature superconductor with a single copper oxide plane per unit cell. The measured interlayer penetration depth, lambda(c), is similar to 20 micrometers, about 20 times the penetration depth required by the interlayer tunneling model.	Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; IBM Corp, Thomas J Watson Res Ctr, Yorktown Heights, NY 10598 USA; Argonne Natl Lab, Div Mat Sci, Argonne, IL 60439 USA; Univ Chicago, James Franck Inst, Chicago, IL 60637 USA	Princeton University; International Business Machines (IBM); United States Department of Energy (DOE); Argonne National Laboratory; University of Chicago	Moler, KA (corresponding author), Princeton Univ, Dept Phys, Princeton, NJ 08544 USA.		Moler, Kathryn A/F-2541-2011	Moler, Kathryn/0000-0002-0233-8123				AMBEGAOKAR V, 1963, PHYS REV LETT, V11, P104, DOI 10.1103/PhysRevLett.11.104; AMBEGAOKAR V, 1963, PHYS REV LETT, V10, P486, DOI 10.1103/PhysRevLett.10.486; ANDERSON PW, 1991, PHYSICA C, V185, P11, DOI 10.1016/0921-4534(91)91943-X; Anderson PW, 1998, SCIENCE, V279, P1196, DOI 10.1126/science.279.5354.1196; ANDERSON PW, 1995, SCIENCE, V268, P1154, DOI 10.1126/science.268.5214.1154; ANDERSON PW, 1992, SCIENCE, V256, P1526, DOI 10.1126/science.256.5063.1526; ANDERSON PW, 1991, PHYS REV LETT, V67, P660, DOI 10.1103/PhysRevLett.67.660; BASOV DN, 1994, PHYS REV B, V50, P3511, DOI 10.1103/PhysRevB.50.3511; Bulaevskii LN, 1997, PHYS REV B, V55, P8482, DOI 10.1103/PhysRevB.55.8482; CHAKRAVARTY S, IN PRESS EUR PHYS B; CHAKRAVARTY S, 1993, SCIENCE, V261, P331; CHANG AM, 1992, APPL PHYS LETT, V61, P1974, DOI 10.1063/1.108334; CHANG AM, 1992, EUROPHYS LETT, V20, P645, DOI 10.1209/0295-5075/20/7/012; CLEM JR, 1990, PHYS REV B, V42, P6209, DOI 10.1103/PhysRevB.42.6209; CLEM JR, 1991, PHYS REV B, V44, P2732, DOI 10.1103/PhysRevB.44.2732; DUAN HM, 1992, CHINESE J PHYS, V30, P415; FERTIG HA, 1991, PHYS REV B, V44, P4480, DOI 10.1103/PhysRevB.44.4480; GRAF MJ, 1993, PHYS REV B, V47, P12089, DOI 10.1103/PhysRevB.47.12089; Gurevich A, 1996, PHYS REV B, V54, P13196, DOI 10.1103/PhysRevB.54.13196; Hermann A. M., 1993, Proceedings of the Beijing International Conference: High Temperature Superconductivity (BHTSC '92), P445; Hirschfeld PJ, 1997, PHYS REV B, V55, P12742, DOI 10.1103/PhysRevB.55.12742; KIRTLEY JR, 1995, APPL PHYS LETT, V66, P1138, DOI 10.1063/1.113838; Kirtley JR, 1996, PHYS REV LETT, V76, P1336, DOI 10.1103/PhysRevLett.76.1336; KIRTLEY JR, UNPUB BEDT TTF IS BI; Lawrence W.E., 1971, P 12 INT C LOW TEMP, P361; Leggett AJ, 1996, SCIENCE, V274, P587, DOI 10.1126/science.274.5287.587; Moler KA, 1997, PHYS REV B, V55, P12753, DOI 10.1103/PhysRevB.55.12753; Panagopoulos C, 1997, PHYS REV LETT, V79, P2320, DOI 10.1103/PhysRevLett.79.2320; PEARL J, 1966, J APPL PHYS, V37, P4139, DOI 10.1063/1.1707989; Puchkov AV, 1996, PHYS REV LETT, V77, P3212, DOI 10.1103/PhysRevLett.77.3212; ROJO AG, 1993, PHYS REV B, V48, P16861, DOI 10.1103/PhysRevB.48.16861; Schutzmann J, 1997, PHYS REV B, V55, P11118, DOI 10.1103/PhysRevB.55.11118; TAMASAKU K, 1992, PHYS REV LETT, V69, P1455, DOI 10.1103/PhysRevLett.69.1455; TSUL OKC, 1996, PHYS REV LETT, V76, P819; Van Der Marel D., 1996, Proceedings of the 10th Anniversary HTS Workshop on Physics, Materials and Applications, P357; WHEATLEY J, 1968, NATURE, V333, P121; ZUO F, 1993, PHYS REV B, V47, P8327, DOI 10.1103/PhysRevB.47.8327	37	138	138	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1193	1196		10.1126/science.279.5354.1193	http://dx.doi.org/10.1126/science.279.5354.1193			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469806				2022-12-28	WOS:000072115200038
J	Ballard, RA; Ballard, PL; Cnaan, A; Pinto-Martin, J; Davis, DJ; Padbury, JF; Phibbs, RH; Parer, JT; Hart, MC; Mannino, FL; Sawai, SK				Ballard, RA; Ballard, PL; Cnaan, A; Pinto-Martin, J; Davis, DJ; Padbury, JF; Phibbs, RH; Parer, JT; Hart, MC; Mannino, FL; Sawai, SK		N Am Thyrotropin-Releas Horm Study Grp	Antenatal thyrotropin-releasing hormone to prevent lung disease in preterm infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-DISTRESS SYNDROME; THYROID-HORMONES; FETAL SHEEP; PRENATAL TREATMENT; PREMATURE-INFANTS; CONTROLLED TRIAL; SURFACTANT; MATURATION; THERAPY; GLUCOCORTICOIDS	Background Pulmonary disease is common in preterm infants, de!despite antenatal glucocorticoid therapy. The addition of antenatal thyrotropin-releasing hormone therapy has been reported to decrease pulmonary morbidity in these infants. Methods We enrolled 996 women at 13 North American centers who were in preterm labor at <30 weeks' gestation in a double-blind, placebo-controlled, randomized trial of antenatal thyrotropin-releasing hormone, given intravenously in four doses of 400 mu g each at eight-hour intervals. The primary outcome was chronic lung disease or death of the infant on or before the 28th day after delivery, and secondary outcomes were respiratory distress syndrome and chronic lung disease or death at 36 weeks' postmen strual age, Complete data were available for 981 women and their 1134 live-born infants. The 769 infants born at less than or equal to:32 weeks' gestation were defined as the group at risk.:. Results There were no significant differences between the at-risk treatment and placebo groups in mean (+/-SD) birth weight (1109+/-354 vs. 1097+/-355 g), gestational age (27.9+/-2.1 vs. 27.9+/-2.1 weeks), sex, or race. The frequencies of respiratory distress syndrome (66 percent vs, 65 percent), death at 28 days (11 percent vs. 11 percent), chronic lung disease or death at 28 days (45 percent vs. 42 percent) and at 36 weeks (32 percent vs. 34 percent), and other neonatal complications as well as the severity of; lung disease were not significantly different in the at-risk treatment and placebo groups, Similarly, there were no differences in outcome between the treatment and placebo groups for the infants born at >32 weeks' gestation. Conclusions in preterm infants at risk for lung disease, antenatal administration of thyrotropin-releasing hormone and glucocorticoid is no more beneficial than glucocorticoid alone, (C) 1998, Massachusetts Medical Society.	Univ Penn, Childrens Hosp Philadelphia, Div Neonatol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA; Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada; Harbor UCLA Med Ctr, Torrance, CA 90509 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; St Josephs Hosp, Phoenix, AZ USA; Univ Calif San Diego, San Diego, CA 92103 USA; Good Samaritan Hosp, Phoenix, AZ USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; University of Ottawa; Children's Hospital of Eastern Ontario; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California San Francisco; St. Joseph's Hospital and Medical Center; University of California System; University of California San Diego	Ballard, RA (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Div Neonatol, 34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029201] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000040, M01RR000425] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00040, MO1-RR000425] Funding Source: Medline; NICHD NIH HHS [R01-HD29201] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTHABE F, 1991, PEDIATR RES, V29, pA200; BALLARD PL, 1995, AM J OBSTET GYNECOL, V173, P254, DOI 10.1016/0002-9378(95)90210-4; BALLARD PL, 1992, PEDIATR RES, V32, P673, DOI 10.1203/00006450-199212000-00009; BALLARD PL, 1984, J CLIN INVEST, V74, P898, DOI 10.1172/JCI111507; BALLARD PL, 1986, MONOGR ENDOCRINOL, V28, P197; BALLARD RA, 1992, LANCET, V339, P510, DOI 10.1016/0140-6736(92)90337-3; BOSHIER DP, 1989, J DEV PHYSIOL, V12, P49; CROWLEY PA, 1995, AM J OBSTET GYNECOL, V173, P322, DOI 10.1016/0002-9378(95)90222-8; Crowther CA, 1997, PEDIATRICS, V99, P311, DOI 10.1542/peds.99.3.311; CROWTHER CA, 1995, LANCET, V345, P877; CROWTHER CA, 1994, PREGNANCY CHILDBIRTH; DEZEGHER F, 1992, ARCH DIS CHILD-FETAL, V67, P450, DOI 10.1136/adc.67.4_Spec_No.450; GILSTRAP LC, 1995, JAMA-J AM MED ASSOC, V273, P413, DOI 10.1001/jama.1995.03520290065031; GONZALES LW, 1986, J CLIN ENDOCR METAB, V62, P678, DOI 10.1210/jcem-62-4-678; GROSS I, 1984, PEDIATR RES, V18, P191; IKEGAMI M, 1991, J APPL PHYSIOL, V70, P2268, DOI 10.1152/jappl.1991.70.5.2268; IKEGAMI M, 1987, AM REV RESPIR DIS, V136, P892, DOI 10.1164/ajrccm/136.4.892; KARI MA, 1994, PEDIATRICS, V93, P730; KNIGHT DB, 1994, AM J OBSTET GYNECOL, V171, P11, DOI 10.1016/S0002-9378(94)70070-2; LIGGINS GC, 1972, PEDIATRICS, V50, P515; LIGGINS GC, 1988, J APPL PHYSIOL, V65, P1880, DOI 10.1152/jappl.1988.65.4.1880; MAYA F, 1991, J PEDIATR-US, V119, P966, DOI 10.1016/S0022-3476(05)83057-4; McCormick MC, 1997, PEDIATRICS, V99, P476, DOI 10.1542/peds.99.3.476; MORALES WJ, 1989, OBSTET GYNECOL, V73, P111; MOYA F, 1986, PEDIATR RES, V20, P982, DOI 10.1203/00006450-198610000-00018; MOYA FR, 1993, SEMIN PERINATOL, V17, P267; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; SCHELLENBERG JC, 1988, J APPL PHYSIOL, V65, P94, DOI 10.1152/jappl.1988.65.1.94; Torres J, 1998, AM J OBSTET GYNECOL, V178, P33; WARBURTON D, 1988, PEDIATR RES, V24, P166, DOI 10.1203/00006450-198808000-00005; Zimmerman J J, 1994, Curr Probl Pediatr, V24, P159, DOI 10.1016/0045-9380(94)90033-7	31	49	49	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 19	1998	338	8					493	498		10.1056/NEJM199802193380802	http://dx.doi.org/10.1056/NEJM199802193380802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX639	9468465	Bronze			2022-12-28	WOS:000072061400002
J	Bosch, X				Bosch, X			Hypercalcemia due to endogenous overproduction of active vitamin D in identical twins with cat-scratch disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BACILLARY ANGIOMATOSIS; ROCHALIMAEA	Context.-The extrarenal synthesis of active Vitamin D sterols has a central causative role in the hypercalcemia associated with various granulomatous diseases. Objective.-To study the calcium metabolism in patients with cat-scratch disease who have hypercalcemia. Design.-Case report. Setting.-University hospital in Barcelona, Spain. Patients.-Two identical twins who developed asymptomatic hypercalcemia during the acute phase of cat-scratch disease. Main Outcome Measures.-Serial measures of calcium homeostasis and metabolism over a 2-month period. Results.-On admission and 6 and 7 days later, bath patients were found to have increased levels of serum and urinary calcium serum phosphate, and serum 1,25-dihydroxyvitamin D [1,25(OH)(2)D], whereas they had normal values of serum 25-hydroxyvitamin D and urinary cyclic adenosine monophosphate and decreased serum concentrations of intact parathyroid hormone. Sixteen and 20 days after admission, these abnormalities had resolved without treatment. A direct correlation was observed between the serum 1,25(OH)(2)D levels and both the serum and 24-hour urinary calcium concentrations. Also, the concentrations of calcium and 1,25(OH)(2)D paralleled the clinical activity of the infectious disease over the period these parameters were measured. Conclusions.-Our cases provide evidence that cat-scratch disease can produce hypercalcemia through the unregulated production of the metabolite 1,25(OH)(2)D. Cat-scratch disease should be added to the list of granuloma-forming diseases that are responsible for 1,25(OH)(2)D-mediated hypercalcemia.	Hosp Casa Maternitat, Corp Sanitaria Clin, Internal Med Unit, Barcelona, Spain		Bosch, X (corresponding author), Hosp Clin Barcelona, Serv Med Interne Gen, Villarroel 170, Barcelona 08036, Spain.							ADAL KA, 1994, NEW ENGL J MED, V330, P1509, DOI 10.1056/NEJM199405263302108; ADAMS JS, 1989, ENDOCRIN METAB CLIN, V18, P765, DOI 10.1016/S0889-8529(18)30365-7; BERGMANS AMC, 1995, J INFECT DIS, V171, P916, DOI 10.1093/infdis/171.4.916; Bosch X, 1997, MAYO CLIN PROC, V72, P440, DOI 10.4065/72.5.440; Dockrell DH, 1997, MAYO CLIN PROC, V72, P757; DOLAN MJ, 1993, ANN INTERN MED, V118, P331, DOI 10.7326/0003-4819-118-5-199303010-00002; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; MAURIN M, 1994, J CLIN MICROBIOL, V32, P1166, DOI 10.1128/JCM.32.5.1166-1171.1994; Midani S, 1996, Adv Pediatr, V43, P397; Newman LS, 1997, NEW ENGL J MED, V336, P1224, DOI 10.1056/NEJM199704243361706; Raoult D, 1996, ANN INTERN MED, V125, P646, DOI 10.7326/0003-4819-125-8-199610150-00004; REED T, 1986, AM DERMATOGLYPH ASS, V5, P6; REGNERY RL, 1992, LANCET, V339, P1443, DOI 10.1016/0140-6736(92)92032-B; SMITH SM, 1955, ANN HUM GENET, V19, P273, DOI 10.1111/j.1469-1809.1955.tb01354.x; ZANGWILL KM, 1993, NEW ENGL J MED, V329, P8, DOI 10.1056/NEJM199307013290102	15	32	33	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	1998	279	7					532	534		10.1001/jama.279.7.532	http://dx.doi.org/10.1001/jama.279.7.532			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW470	9480364				2022-12-28	WOS:000071938900035
J	Horton, R				Horton, R			Our healthier nation, possibly	LANCET			English	Editorial Material									The Lancet, London WC1B 3SL, England		Horton, R (corresponding author), The Lancet, London WC1B 3SL, England.							*HM STAT OFF, 1992, HLTH NAT; Horton R, 1998, LANCET, V351, P76, DOI 10.1016/S0140-6736(98)22002-2; *STAT OFF, 1998, OUR HEALTH NAT, P94; WEBSTER P, 1998, TIMES           0201, P1; WOOLF M, 1998, OBSERVER        0201, P9; 1992, INEQUALITIES HLTH	6	4	4	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	1998	351	9101					463	463		10.1016/S0140-6736(05)78677-3	http://dx.doi.org/10.1016/S0140-6736(05)78677-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482433				2022-12-28	WOS:000072097700004
J	Ortqvist, A; Hedlund, J; Burman, LA; Elbel, N; Hofer, M; Leinonen, M; Lindblad, I; Sundelof, B; Kalin, M				Ortqvist, A; Hedlund, J; Burman, LA; Elbel, N; Hofer, M; Leinonen, M; Lindblad, I; Sundelof, B; Kalin, M		Swedish Pneumococcal Vaccination Study Grp	Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people	LANCET			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; OBSTRUCTIVE PULMONARY-DISEASE; STREPTOCOCCUS-PNEUMONIAE; ETIOLOGICAL DIAGNOSIS; PROTECTIVE EFFICACY; RISK; PNEUMOLYSIN; BACTEREMIA; POPULATION; FINLAND	Background We assessed the effectiveness of a 23-valent pneumococcal vaccine in the prevention of pneumococcal pneumonia and of pneumonia overall in nonimmunocompromised middle-aged and elderly people. Methods The prospective, multicentre, double-blind, randomised, placebo-controlled trial was carried out across departments of infectious diseases at six tertiary-care or university hospitals in Sweden. 691 nonimmunocompromised patients aged 50-85 years who had been treated as inpatients for community-acquired pneumonia (CAP) were randomly assigned either 23-valent pneumococcal capsular polysaccharide vaccine or placebo (sodium chloride). We used Cox regression models to estimate the relative risks of pneumonia overall and pneumococcal pneumonia for the placebo group compared with the vaccine group. Findings 63 (19%) of 339 patients in the vaccine group and 57 (16%) of 352 patients in the placebo group developed a new pneumonia, corresponding to a relative risk over time for the placebo group compared with the vaccine group of 0.83 (95% CI 0.58-1.12, p=0.31). Pneumococcal pneumonia was diagnosed in 16 (4.5%) patients in the placebo group and in 19 (5.6%) in the vaccine group, corresponding to a relative risk for the placebo group of 0.78 (95% CI 0.40-1.51, p=0.45). We found no difference in the death rate between the two study groups. Interpretation The 23-valent pneumococcal polysaccharide vaccine did not prevent pneumonia overall or pneumococcal pneumonia in middle-aged and elderly individuals.	Karolinska Inst, Danderyd Hosp, Div Infect Dis, S-18288 Danderyd, Sweden; Karolinska Hosp, S-10401 Stockholm, Sweden; Hosp Vasteras, Dept Infect Dis, Umea, Sweden; Hosp Skovde, Dept Infect Dis, Skovde, Sweden; Karlskrona Hosp, Dept Infect Dis, Karlskrona, Sweden; Gavle Cent Hosp, Dept Infect Dis, Gavle, Sweden; Natl Publ Hlth Inst, Oulu, Finland	Danderyds Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Vasteras Central Hospital; Finland National Institute for Health & Welfare	Ortqvist, A (corresponding author), Karolinska Inst, Danderyd Hosp, Div Infect Dis, S-18288 Danderyd, Sweden.	ake.ortqvist@inf.ds.sll.se						ANDREWS BE, 1987, Q J MED, V62, P195; Austrian R, 1976, Trans Assoc Am Physicians, V89, P184; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; CLEMENS JD, 1984, REV INFECT DIS, V6, P589; Cox D. R., 1984, ANAL SURVIVAL DATA; DAVIS AL, 1987, CHEST, V92, P204, DOI 10.1378/chest.92.2.204; FARR BM, 1995, ARCH INTERN MED, V155, P2336, DOI 10.1001/archinte.155.21.2336; FEDSON DS, 1994, ARCH INTERN MED, V154, P2531, DOI 10.1001/archinte.154.22.2531; FEDSON DS, 1990, JAMA-J AM MED ASSOC, V264, P1117; FINE MJ, 1994, ARCH INTERN MED, V154, P2666, DOI 10.1001/archinte.1994.00420230051007; FORRESTER HL, 1987, AM J MED, V83, P425, DOI 10.1016/0002-9343(87)90751-0; GAILLAT J, 1985, REV EPIDEMIOL SANTE, V33, P437; HEDLUND J, 1995, CLIN INFECT DIS, V21, P948, DOI 10.1093/clinids/21.4.948; HEDLUND JU, 1994, ARCH INTERN MED, V154, P1961, DOI 10.1001/archinte.154.17.1961; HEDLUND JU, 1992, LANCET, V340, P396, DOI 10.1016/0140-6736(92)91473-L; JALONEN E, 1989, J INFECTION, V19, P127, DOI 10.1016/S0163-4453(89)91864-1; JOKINEN C, 1993, AM J EPIDEMIOL, V137, P977, DOI 10.1093/oxfordjournals.aje.a116770; KALIN M, 1983, SCAND J INFECT DIS, V15, P153, DOI 10.3109/inf.1983.15.issue-2.05; KAUPPINEN MT, 1995, J INFECT DIS, V172, P1330, DOI 10.1093/infdis/172.5.1330; LEECH JA, 1987, CAN MED ASSOC J, V136, P361; LEINONEN M, 1990, SERODIAG IMMUN INF D, V4, P451, DOI 10.1016/0888-0786(90)90058-V; MACFARLANE JT, 1982, LANCET, V2, P255; MAGNUS T, 1995, EUR J CLIN MICROBIOL, V14, P229, DOI 10.1007/BF02310362; ORTQVIST A, 1990, EUR RESPIR J, V3, P1105; Plouffe JF, 1996, JAMA-J AM MED ASSOC, V275, P194, DOI 10.1001/jama.275.3.194; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; SIMBERKOFF MS, 1986, NEW ENGL J MED, V315, P1318, DOI 10.1056/NEJM198611203152104; SIMS RV, 1988, ANN INTERN MED, V108, P653, DOI 10.7326/0003-4819-108-5-653; SMIT P, 1977, JAMA-J AM MED ASSOC, V238, P2613, DOI 10.1001/jama.238.24.2613	29	270	288	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 7	1998	351	9100					399	403		10.1016/S0140-6736(97)07358-3	http://dx.doi.org/10.1016/S0140-6736(97)07358-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482293				2022-12-28	WOS:000071982600011
J	Krebs, JR; Anderson, RM; Clutton-Brock, T; Donnelly, CA; Frost, S; Morrison, WI; Woodroffe, R; Young, D				Krebs, JR; Anderson, RM; Clutton-Brock, T; Donnelly, CA; Frost, S; Morrison, WI; Woodroffe, R; Young, D			Policy: Biomedicine - Badgers and bovine TB: Conflicts between conservation and health	SCIENCE			English	Editorial Material							MYCOBACTERIUM-BOVIS; EPIDEMIOLOGY; TUBERCULOSIS; DYNAMICS; VARIANT		NERC, Swindon SN2 1EU, Wilts, England; Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3PS, England; Ctr HIV Res, Edinburgh EH9 3JN, Midlothian, Scotland; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Inst Anim Hlth, Compton RG20 7NN, England; Univ London, St Marys Hosp, Sch Med, London W2 1PG, England	UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); University of Oxford; University of Cambridge; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; Imperial College London; University of London	Krebs, JR (corresponding author), NERC, Polaris House,N Star Ave, Swindon SN2 1EU, Wilts, England.	hqpo@wpo.nerc.ac.uk	Frost, Simon/F-3648-2010	Frost, Simon/0000-0002-5207-9879; Anderson, Roy/0000-0002-9528-3175; Donnelly, Christl/0000-0002-0195-2463				Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; ANDERSON RM, 1985, PHILOS T R SOC B, V310, P327, DOI 10.1098/rstb.1985.0123; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Guerrero A, 1997, LANCET, V350, P1738, DOI 10.1016/S0140-6736(97)07567-3; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Krebs J., 1997, PB3423 HMSO; LITTLE TWA, 1982, VET REC, V111, P550; Swinton J, 1997, PHILOS T R SOC B, V352, P619, DOI 10.1098/rstb.1997.0042; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; ZUCKERMAN, 1980, BADGERS CATTLE TUBER; [No title captured]	13	41	41	0	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	1998	279	5352					817	818		10.1126/science.279.5352.817	http://dx.doi.org/10.1126/science.279.5352.817			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9480550				2022-12-28	WOS:000071923500026
J	Niederman, MS; Peters, SP				Niederman, MS; Peters, SP			Update in pulmonary medicine	ANNALS OF INTERNAL MEDICINE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; CONTROLLED TRIAL; ASTHMA; GUIDELINES; OUTCOMES		Winthrop Univ Hosp, Mineola, NY 11501 USA; Jefferson Med Coll, Philadelphia, PA 19107 USA	Winthrop University Hospital; Jefferson University	Niederman, MS (corresponding author), Winthrop Univ Hosp, 222 Stn Plaza N,Suite 400, Mineola, NY 11501 USA.							Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603; [Anonymous], 1996, Arthritis Rheum, V39, P1791; Apter AJ, 1996, J ALLERGY CLIN IMMUN, V98, P295, DOI 10.1016/S0091-6749(96)70153-7; Bartlett JG, 1997, ANN INTERN MED, V127, P217, DOI 10.7326/0003-4819-127-3-199708010-00007; Buckley LM, 1996, ANN INTERN MED, V125, P961, DOI 10.7326/0003-4819-125-12-199612150-00004; CHAN R, 1995, BRIT MED J, V310, P1360, DOI 10.1136/bmj.310.6991.1360; Clark DJ, 1997, THORAX, V52, P55, DOI 10.1136/thx.52.1.55; Coley CM, 1996, ARCH INTERN MED, V156, P1565, DOI 10.1001/archinte.156.14.1565; Fine MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/jama.275.2.134; Ind PW, 1996, RESP MED, V90, P575, DOI 10.1016/S0954-6111(96)90015-3; Kauppinen MT, 1996, THORAX, V51, P185, DOI 10.1136/thx.51.2.185; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418; Papazian L, 1996, AM J RESP CRIT CARE, V154, P91, DOI 10.1164/ajrccm.154.1.8680705; Pestotnik SL, 1996, ANN INTERN MED, V124, P884, DOI 10.7326/0003-4819-124-10-199605150-00004; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A	15	12	14	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1998	128	3					208	215		10.7326/0003-4819-128-3-199802010-00007	http://dx.doi.org/10.7326/0003-4819-128-3-199802010-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU303	9454529				2022-12-28	WOS:000071703200006
J	Carpita, N; Vergara, C				Carpita, N; Vergara, C			Botany - A recipe for cellulose	SCIENCE			English	Article							ACETOBACTER-XYLINUM; SYNTHASE; OPERON		Purdue Univ, Dept Bot & Plant Pathol, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Carpita, N (corresponding author), Purdue Univ, Dept Bot & Plant Pathol, W Lafayette, IN 47907 USA.							Albersheim P, 1997, PLANT PHYSIOL, V113, P1, DOI 10.1104/pp.113.1.1; Arioli T, 1998, SCIENCE, V279, P717, DOI 10.1126/science.279.5351.717; Carpita N, 1996, PLANT CELL, V8, P1451; Cutler S, 1997, CURR BIOL, V7, pR108, DOI 10.1016/S0960-9822(06)00050-9; Kawagoe Yasushi, 1997, Plant Physiology (Rockville), V114, P85; Koyama M, 1997, P NATL ACAD SCI USA, V94, P9091, DOI 10.1073/pnas.94.17.9091; Pear JR, 1996, P NATL ACAD SCI USA, V93, P12637, DOI 10.1073/pnas.93.22.12637; SAXENA IM, 1991, PLANT MOL BIOL, V16, P947, DOI 10.1007/BF00016067; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; Turner SR, 1997, PLANT CELL, V9, P689, DOI 10.1105/tpc.9.5.689; WONG HC, 1990, P NATL ACAD SCI USA, V87, P8130, DOI 10.1073/pnas.87.20.8130	11	54	57	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 30	1998	279	5351					672	673		10.1126/science.279.5351.672	http://dx.doi.org/10.1126/science.279.5351.672			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9471727				2022-12-28	WOS:000071731500024
J	Adler, MW				Adler, MW			Antiretrovirals for developing world	LANCET			English	Editorial Material									UCL, Sch Med, Dept Sexually Transmitted Dis, London WC1E 6AU, England	University of London; University College London; UCL Medical School	Adler, MW (corresponding author), UCL, Sch Med, Dept Sexually Transmitted Dis, Mortimer St, London WC1E 6AU, England.							FEINMANN J, 1997, LANCET, V250, P1759; *UNAIDS WHO, 1997, UNAIDS WHO REP GLOB; VANPRAAG E, 1997, IMPLICATIONS ANTIRET; *WORLD BANK POL RE, 1997, CONF AIDS PUBL PRIOR	4	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 24	1998	351	9098					232	232		10.1016/S0140-6736(05)78276-3	http://dx.doi.org/10.1016/S0140-6736(05)78276-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU294	9457091				2022-12-28	WOS:000071702200007
J	Light, DW				Light, DW			Is NHS purchasing serious? An American perspective	BRITISH MEDICAL JOURNAL			English	Article							CARE; CALIFORNIA		Univ Med & Dent New Jersey, Stratford, NJ 08084 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Light, DW (corresponding author), Univ Med & Dent New Jersey, Stratford, NJ 08084 USA.							BERGTHOLD L, 1990, PURCHASING POWER HLT; Bevan G, 1998, BRIT MED J, V316, P39, DOI 10.1136/bmj.316.7124.39; BUTLER J, 1994, EVALUATING NHS REFOR, P13; COLTER A, 1997, J HLTH SERV RES POLI, V2, P112; CROSS M, 1997, HLTH SERVICE J  0605, P11; DAWSON D, 1995, REGULATING COMPETITI; DAY P, 1997, STEERING NOT ROWING; DIXON J, 1997, HLTH SERVICE J  0605, P26; Enthoven AC, 1996, HEALTH AFFAIR, V15, P39, DOI 10.1377/hlthaff.15.1.39; Enthoven Alain C., 1988, THEORY PRACTICE MANA; GLENDINNING C, 1997, CURE CARE REFORMS LO; KLEIN R, 1995, MILBANK Q, V73, P299, DOI 10.2307/3350370; LIGHT D, 1990, HLTH SERVICE J  1011, P1513; Light DW, 1997, MILBANK Q, V75, P297, DOI 10.1111/1468-0009.00058; LIGHT DW, 1997, HLTH POLITICS POLICY, P46; LIGHT DW, 1990, HLTH SERVICE J  1025, P1604; LIGHT DW, 1990, HLTH SERVICE J  1004, P1470; LIGHT DW, 1995, EUROPEAN J PUBLIC HL, V5, P145; LIGHT DW, 1990, HLTH SERVICE J  1018, P1552; MAHON A, 1998, IN PRESS TOTAL PURCH; MEYER JA, 1996, EMPLOYER COALITION I, V2; PAULSHAHEEN P, 1987, J HEALTH POLIT POLIC, V12, P741, DOI 10.1215/03616878-12-4-741; RASKIN IE, 1991, EVAL HEALTH PROF, V14, P161, DOI 10.1177/016327879101400203; ROBERTS CJ, 1995, HLTH SERV J      JAN, P15; Robinson JC, 1995, HEALTH AFFAIR, V14, P117, DOI 10.1377/hlthaff.14.4.117; ROBINSON JC, 1996, HEALTH AFFAIR, V151, P7; SANDERS D, 1989, VARIATIONS HOSPITAL; Schauffler HH, 1996, HEALTH AFFAIR, V15, P73, DOI 10.1377/hlthaff.15.1.73; *SCOTT OFF, 1997, DES CAR REN NAT HLTH; Starr P, 1982, SOCIAL TRANSFORMATIO; WILKIN D, 1990, GEN PRACTIONER REFER; YATES J, 1997, DEV QUALITY INDICATO; 1997, NEW NHS MODERN DEPEN	33	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					217	220						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YT531	9468697				2022-12-28	WOS:000071616400044
J	Weinmaster, G				Weinmaster, G			Reprolysins and astacins ... Alive, alive-O	SCIENCE			English	Article									Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Weinmaster, G (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.							Blader P, 1997, SCIENCE, V278, P1937, DOI 10.1126/science.278.5345.1937; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; Holley SA, 1997, BIOESSAYS, V19, P281, DOI 10.1002/bies.950190404; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Sotillos S, 1997, DEVELOPMENT, V124, P4769; Wen CH, 1997, DEVELOPMENT, V124, P4759; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313	11	10	11	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					336	337		10.1126/science.279.5349.336	http://dx.doi.org/10.1126/science.279.5349.336			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9454330				2022-12-28	WOS:000071570800033
J	Kitanaka, S; Takeyama, K; Murayama, A; Sato, T; Okumura, K; Nogami, M; Hasegawa, Y; Niimi, H; Yanagisawa, J; Tanaka, T; Kato, S				Kitanaka, S; Takeyama, K; Murayama, A; Sato, T; Okumura, K; Nogami, M; Hasegawa, Y; Niimi, H; Yanagisawa, J; Tanaka, T; Kato, S			Inactivating mutations in the 25-hydroxyvitamin D(3) 1 alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VITAMIN-D DEPENDENCY; D-RECEPTOR; CDNA; EXPRESSION; CLONING; SEQUENCES; SYSTEM; ALPHA; LIVER; ACID	Background Pseudovitamin D-deficiency rickets is characterized by the early onset of rickets with hy pocalcemia and is thought to be caused by a deficit in renal 25-hydroxyvitamin D(3) 1 alpha-hydroxylase, the key enzyme for the synthesis of 1 alpha,25-dihydroxyvitamin D(3), Methods We cloned human 25-hydroxyvitamin D(3) 1 alpha-hydroxylase complementary DNA (cDNA) using a mouse 1 alpha-hydroxylase cDNA fragment as a probe. its genomic structure was determined, and its chromosomal location was mapped by fluorescence in situ hybridization. We then identified mutations in the 1 alpha-hydroxylase gene in four unrelated patients with pseudovitamin D-deficiency rickets by DNA-sequence analysis. Both the normal and the mutant 1 alpha-hydroxylase proteins were expressed in COS-1 cells and were assayed for 1 alpha-hydroxylase activity. Results The gene for 25-hydroxyvitamin D(3) 1 alpha-hydroxylase was mapped to chromosome 12q13.3, which had previously been reported to be the locus for pseudovitamin D-deficiency rickets by linkage analysis, Four different homozygous missense mutations were detected in this gene in the four patients with pseudovitamin D-deficiency rickets. The unaffected parents and one sibling tested were heterozygous for the mutations. Functional analysis of the mutant 1 alpha-hydroxylase protein revealed that all four mutations abolished 1 alpha-hydroxylase activity. Conclusions Inactivating mutations in the 25-hydroxyvitamin D(3) 1 alpha-hydroxylase gene are a cause of pseudovitamin D-deficiency rickets. (C) 1998, Massachusetts Medical Society.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Mie Univ, Fac Bioresources, Tsu, Mie, Japan; Tokyo Metropolitan Kiyose Hosp, Tokyo, Japan; Chiba Univ, Sch Med, Dept Pediat, Chiba, Japan; Natl Childrens Med Res Ctr, Dept Endocrinol & Metab, Tokyo 154, Japan	University of Tokyo; Mie University; Chiba University; National Center for Child Health & Development - Japan	Kato, S (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Yayoi, Tokyo 1130032, Japan.							BALSAN S, 1991, NESTLE NUTR WORKS SE, V21, P155; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; CHEN KS, 1993, P NATL ACAD SCI USA, V90, P4543, DOI 10.1073/pnas.90.10.4543; CHUA SC, 1987, P NATL ACAD SCI USA, V84, P7193, DOI 10.1073/pnas.84.20.7193; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; COWEN J, 1980, ARCH DIS CHILD, V55, P964, DOI 10.1136/adc.55.12.964; DELVIN EE, 1981, J PEDIATR-US, V99, P26, DOI 10.1016/S0022-3476(81)80952-3; DEMAY MB, 1995, ENDOCRINOLOGY, V2, P1173; Ebihara K, 1996, MOL CELL BIOL, V16, P3393; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; FRASER D, 1973, NEW ENGL J MED, V289, P817, DOI 10.1056/NEJM197310182891601; Fujii H, 1997, EMBO J, V16, P4163, DOI 10.1093/emboj/16.14.4163; GOTOH O, 1992, J BIOL CHEM, V267, P83; GUO YD, 1993, P NATL ACAD SCI USA, V90, P8668, DOI 10.1073/pnas.90.18.8668; HENRY HL, 1992, J CELL BIOCHEM, V49, P4, DOI 10.1002/jcb.240490103; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KAWAJIRI K, 1984, P NATL ACAD SCI-BIOL, V81, P1649, DOI 10.1073/pnas.81.6.1649; KAWASHIMA H, 1981, P NATL ACAD SCI-BIOL, V78, P1199, DOI 10.1073/pnas.78.2.1199; Kitanaka S, 1997, J CLIN ENDOCR METAB, V82, P4054, DOI 10.1210/jc.82.12.4054; KOBORI M, 1993, NUCLEIC ACIDS RES, V21, P2782, DOI 10.1093/nar/21.11.2782; LABUDA M, 1990, AM J HUM GENET, V47, P28; LABUDA M, 1992, J BONE MINER RES, V7, P1447; Liberman Uri A., 1995, P425; MALLOY PJ, 1990, J CLIN INVEST, V86, P2071, DOI 10.1172/JCI114944; MARX SJ, 1995, METABOLIC MOL BASES, V2, P3091; MAWER EB, 1994, J CLIN ENDOCR METAB, V79, P554, DOI 10.1210/jc.79.2.554; MORNET E, 1989, J BIOL CHEM, V264, P20961; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NONAKA Y, 1989, FEBS LETT, V255, P21, DOI 10.1016/0014-5793(89)81053-1; OKUMURA K, 1995, GENOMICS, V27, P377, DOI 10.1006/geno.1995.1062; PEDERSEN JI, 1976, J BIOL CHEM, V251, P3933; PRADER A, 1961, HELV PAEDIATR ACTA, V16, P452; SASAKI H, 1995, BIOCHEMISTRY-US, V34, P370, DOI 10.1021/bi00001a045; SASAKI T, 1961, ENDOCRINOL JAPON, V8, P272; SCRIVER CR, 1978, NEW ENGL J MED, V299, P976, DOI 10.1056/NEJM197811022991803; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; Takeyama K, 1996, BIOCHEM BIOPH RES CO, V222, P395, DOI 10.1006/bbrc.1996.0755; WHITE PC, 1994, HUM MUTAT, V3, P373, DOI 10.1002/humu.1380030408; YANASE T, 1991, ENDOCR REV, V12, P91, DOI 10.1210/edrv-12-1-91; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391	41	235	242	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1998	338	10					653	661		10.1056/NEJM199803053381004	http://dx.doi.org/10.1056/NEJM199803053381004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ844	9486994				2022-12-28	WOS:000072299700004
J	Ransohoff, RM				Ransohoff, RM			Cellular responses to interferons and other cytokines: The JAK-STAT paradigm	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Cleveland Clin Fdn, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Ransohoff, RM (corresponding author), Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA.							DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; STARK G, IN PRESS ANN REV BIO; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; VALAZQUEZ L, 1992, CELL, V70, P313; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779	7	63	66	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 26	1998	338	9					616	618		10.1056/NEJM199802263380911	http://dx.doi.org/10.1056/NEJM199802263380911			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY708	9475772				2022-12-28	WOS:000072175700011
J	Morris, CD; Reller, MD; Menashe, VD				Morris, CD; Reller, MD; Menashe, VD			Thirty-year incidence of infective endocarditis after surgery for congenital heart defect	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VENTRICULAR SEPTAL-DEFECT; BACTERIAL-ENDOCARDITIS; PULMONARY STENOSIS; AORTIC-STENOSIS; PROPHYLAXIS; DISEASE; ADULTS; CHILDHOOD; KNOWLEDGE; CHILDREN	Context.-The incidence of infective endocarditis after surgical repair of congenital heart defects is unknown. Objective.-To determine the long-term incidence of endocarditis after repair of any of 12 congenital heart defects in childhood. Design.-Population-based registry started in 1982. Setting.-State of Oregon. Participants.-All Oregon residents who underwent surgical repair for 1 of 12 major congenital defects at the age of 18 years or younger from 1958 to the present. Main Outcome Measure.-Diagnosis of infective endocarditis confirmed by hospital or autopsy records. Results.-Follow-up data were obtained from 88% of this cohort of 3860 individuals through 1993. At 25 years after surgery, the cumulative incidence of infective endocarditis was 1.3% for tetralogy of Fallot, 2.7% for isolated ventricular septal defect, 3.5% for coarctation of the aorta, 13.3% for valvular aortic stenosis, and 2.8% for primum atrial septal defect. In the cohorts with shorter follow-up, at 20 years after surgery the cumulative incidence was 4.0% for dextrotransposition of the great arteries; at 10 years, the cumulative incidence was 1.1% for complete atrioventricular septal defect, 5.3% for pulmonary atresia with an intact ventricular septum, and 6.4% for pulmonary atresia with ventricular septal defect. No children with secundum atrial septal defect, patent ductus arteriosus, or pulmonic stenosis have had infective endocarditis after surgery. Conclusion.-The continuing incidence of endocarditis after surgery for congenital heart defect, particularly valvular aortic stenosis, merits education about endocarditis prophylaxis for children and adults with repaired congenital heart defects.	Oregon Hlth Sci Univ, Congenital Heart Dis Res Ctr, Div Med Informat & Outcomes Res, BICC, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Congenital Heart Dis Res Ctr, Div Pediat Cardiol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Morris, CD (corresponding author), Oregon Hlth Sci Univ, Congenital Heart Dis Res Ctr, Div Med Informat & Outcomes Res, BICC, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL036856, R29HL039052] Funding Source: NIH RePORTER; NHLBI NIH HHS [R23 HL36856, R29 HL39052] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AWADALLAH SM, 1991, AM J CARDIOL, V68, P90, DOI 10.1016/0002-9149(91)90717-Y; CETTA F, 1995, MAYO CLIN PROC, V70, P50; CETTA F, 1993, PEDIATR CARDIOL, V14, P220, DOI 10.1007/BF00795374; CHILD JS, 1991, J AM COLL CARDIOL, V18, P337, DOI 10.1016/0735-1097(91)90581-S; Dajani AS, 1997, JAMA-J AM MED ASSOC, V277, P1794, DOI 10.1001/jama.277.22.1794; DEGEVIGNEY G, 1995, EUR HEART J, V16, P7, DOI 10.1093/eurheartj/16.suppl_B.7; GERSONY WM, 1993, CIRCULATION, V87, P121; GERSONY WM, 1977, CIRCULATION, V56, P84; GRIFFIN MR, 1985, JAMA-J AM MED ASSOC, V254, P1199, DOI 10.1001/jama.254.9.1199; HANSEN D, 1992, PEDIATR CARDIOL, V13, P198, DOI 10.1007/BF00838776; IGA K, 1991, JPN CIRC J, V55, P437, DOI 10.1253/jcj.55.437; KARL T, 1987, BRIT HEART J, V58, P57; LEPORT C, 1995, EUR HEART J, V16, P126, DOI 10.1093/eurheartj/16.suppl_B.126; MCKINSEY DS, 1987, AM J MED, V82, P681, DOI 10.1016/0002-9343(87)90001-5; MICHEL PL, 1995, EUR HEART J, V16, P2, DOI 10.1093/eurheartj/16.suppl_B.2; MORRIS CD, 1991, JAMA-J AM MED ASSOC, V266, P3447, DOI 10.1001/jama.266.24.3447; SCOVIL JA, 1976, CIRCULATION, V53, P953, DOI 10.1161/01.CIR.53.6.953	17	96	107	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	1998	279	8					599	603		10.1001/jama.279.8.599	http://dx.doi.org/10.1001/jama.279.8.599			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX457	9486754	Bronze			2022-12-28	WOS:000072041900035
J	Kaiser, RI; Ochsenfeld, C; Head-Gordon, M; Lee, YT				Kaiser, RI; Ochsenfeld, C; Head-Gordon, M; Lee, YT			The formation of HCS and HCSH molecules and their role in the collision of comet Shoemaker-Levy 9 with Jupiter	SCIENCE			English	Article							GAUSSIAN-BASIS SETS; IMPACT; THIOFORMALDEHYDE; SPECTROSCOPY; ATMOSPHERE; BEAM	The reaction of hydrogen sulfide with ground-state atomic carbon was examined with crossed molecular beams experiments and ab initio calculations. The thiohydroxycarbene molecule, HCSH, was the reactive intermediate, which fragmented into atomic hydrogen and the thioformyl radical HCS. This finding may account for the unassigned HCS source and an unidentified HCSH radical needed to match observed CS abundances from the collision of comet Shoemaker-Levy 9 into Jupiter. In the shocked jovian atmosphere, HCS could further decompose to H and CS, and CS could react with SH and OH to yield the observed CS2 and COS.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Chem Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Kaiser, RI (corresponding author), Acad Sinica, Inst Atom & Mol Sci, 1,Sect 4,Roosevelt Rd, Taipei 116, Taiwan.		Lee, Yuan-Tseh/F-7914-2012; Head-Gordon, Martin/AAR-4028-2020; Ochsenfeld, Christian/E-8021-2015	Ochsenfeld, Christian/0000-0002-4189-6558				ATREYA S, IN PRESS 3 GALILEOS; Atreya S. K., 1986, ATMOSPHERES IONOSPHE; Atreya S.K., 1985, PLANETARY METEOROLOG; ATREYA SK, 1995, GEOPHYS RES LETT, V22, P1625, DOI 10.1029/95GL01718; Borunov S, 1997, ICARUS, V125, P121, DOI 10.1006/icar.1996.5608; Conrath B.J., 1996, COLLISION COMET SHOE, P293; CROVISIER J, 1996, COLLISION COMET SHOE, P31; DUNNING TH, 1989, J CHEM PHYS, V90, P1007, DOI 10.1063/1.456153; ENTENMANN EA, 1966, THESIS HARVARD U CAM; HACHEY MRJ, 1995, CHEM PHYS, V197, P61, DOI 10.1016/0301-0104(95)00154-G; JUDGE RH, 1980, J MOL SPECTROSC, V81, P37, DOI 10.1016/0022-2852(80)90328-8; Kaiser RI, 1996, SCIENCE, V274, P1508, DOI 10.1126/science.274.5292.1508; Kaiser RI, 1995, REV SCI INSTRUM, V66, P5405, DOI 10.1063/1.1146061; LEE YT, 1987, SCIENCE, V236, P793, DOI 10.1126/science.236.4803.793; LELLOUCH E, 1995, NATURE, V373, P592, DOI 10.1038/373592a0; LELLOUCH E, 1996, COLLISION COMET SHOE, P213; MILLER WB, 1969, THESIS HARVARD U CAM; MOSES JI, 1996, COLLISION COMET SHOE, P243; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; NOLL KS, 1995, SCIENCE, V267, P1307, DOI 10.1126/science.7871428; NOLL KS, 1996, COLLISION COMET SHOE; Ragent B, 1996, SCIENCE, V272, P854, DOI 10.1126/science.272.5263.854; RAGHAVACHARI K, 1989, CHEM PHYS LETT, V157, P479, DOI 10.1016/S0009-2614(89)87395-6; RUSCIC B, 1993, J CHEM PHYS, V98, P2568, DOI 10.1063/1.464139; SCHAFER A, 1992, J CHEM PHYS, V97, P2571, DOI 10.1063/1.463096; SHOEMAKER CS, 1993, 5725 INT ASTR UN; STANTON JF, 1992, INT J QUANTUM CHEM S, V26, P879; Yelle RV, 1996, ICARUS, V119, P90, DOI 10.1006/icar.1996.0004; ZAHNLE K, 1995, GEOPHYS RES LETT, V22, P1593, DOI 10.1029/95GL01190; ZAHNLE K, 1996, COLLISION COMET SHOE, P183	30	36	36	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1181	1184		10.1126/science.279.5354.1181	http://dx.doi.org/10.1126/science.279.5354.1181			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469802				2022-12-28	WOS:000072115200034
J	Lin, RJ; Nagy, L; Inoue, S; Shao, WL; Miller, WH; Evans, RM				Lin, RJ; Nagy, L; Inoue, S; Shao, WL; Miller, WH; Evans, RM			Role of the histone deacetylase complex in acute promyelocytic leukaemia	NATURE			English	Article							PML-RAR-ALPHA; FUSION PROTEIN; TRANSCRIPTIONAL PROPERTIES; LEUKEMIA-CELLS; CO-REPRESSOR; DNA-BINDING; TRANSLOCATION; T(15-17); TRANSACTIVATION; DIFFERENTIATION	Non-liganded retinoic acid receptors (RARs) repress transcription of target genes by recruiting the histone deacetylase complex(1-3) through a class of silencing mediators termed SMRT or N-CoR4,5. Mutant forms of RAR alpha, created by chromosomal translocations with either the PML (for promyelocytic leukaemia)(6-8) or the PLZF (for promyelocytic leukaemia zinc finger)(9,10) locus, are oncogenic and result in human acute promyelocytic leukaemia (APL). PML-RAR alpha APL patients achieve complete remission following treatments with pharmacological doses of retinoic acids (RA); in contrast, PLZF-RAR alpha patients respond very poorly, if at all(11). Here we report that the association of these two chimaeric receptors with the histone deacetylase (HDAC) complex helps to determine both the development of APL and the ability of patients to respond to retinoids. Consistent with these observations, inhibitors of histone deacetylase dramatically potentiate retinoid-induced differentiation of RA-sensitive, and restore retinoid responses of RA-resistant, APL cell lines. Our findings suggest that oncogenic RARs mediate leukaemogenesis through aberrant chromatin acetylation, and that pharmacological manipulation, of nuclear receptor co-factors may be a useful approach in the treatment of human disease.	Howard Hughes Med Inst, La Jolla, CA 92037 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA; Univ Calif San Diego, Sch Med, Grad Program Mol Pathol, La Jolla, CA 92093 USA; McGill Univ, Lady Davis Inst Med Res, Dept Oncol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst Med Res, Dept Med, Montreal, PQ H3T 1E2, Canada	Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University	Evans, RM (corresponding author), Howard Hughes Med Inst, La Jolla, CA 92037 USA.		Evans, Ronald/AAF-4001-2019; Nagy, Laszlo/A-3814-2008	Evans, Ronald/0000-0002-9986-5965; Nagy, Laszlo/0000-0001-6653-2155; Lin, Richard/0000-0002-0834-7880				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; LANOTTE M, 1991, BLOOD, V77, P1080; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Licht JD, 1996, ONCOGENE, V12, P323; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; MILLER WH, 1995, BLOOD, V85, P3021, DOI 10.1182/blood.V85.11.3021.bloodjournal85113021; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; ROUSSELOT P, 1994, ONCOGENE, V9, P545; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	29	947	1002	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					811	814		10.1038/35895	http://dx.doi.org/10.1038/35895			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486654				2022-12-28	WOS:000072089500058
J	Yeo, TC; Malouf, JF; Oh, JK; Seward, JB				Yeo, TC; Malouf, JF; Oh, JK; Seward, JB			Clinical profile and outcome in 52 patients with cardiac pseudoaneurysm	ANNALS OF INTERNAL MEDICINE			English	Review							LEFT-VENTRICULAR PSEUDOANEURYSM; MITRAL-VALVE REPLACEMENT; MYOCARDIAL-INFARCTION; FALSE ANEURYSM; DOPPLER ECHOCARDIOGRAPHY; PSEUDO-ANEURYSM; RUPTURE; DIAGNOSIS; MANAGEMENT; TRUE	Background: Cardiac pseudoaneurysm, a contained cardiac rupture, predisposes patients to further rupture. However, knowledge of the clinical profile and natural history of this cardiac complication is limited. Objective: To study the clinical features and outcomes of patients with cardiac pseudoaneurysm. Design: Retrospective analysis of patients with cardiac pseudoaneurysm seen between January 1980 and September 1996. Setting: Mayo Clinic in Rochester, Minnesota; Scottsdale, Arizona; and Jacksonville, Florida. Patients: 52 patients with pseudoaneurysm. Results: Pseudoaneurysm was discovered incidentally in 25 asymptomatic patients (48%). Four patients (8%) presented acutely (3 with acute myocardial infarction and 1 with cardiac tamponade). Other clinical presentations were congestive heart failure in 8 patients (15%), chest pain in 7 (13%), syncope or arrhythmia in 5 (10%), and systemic embolism in 3 (6%). Initial diagnostic tests were echocardiography in 32 patients, cardiac catheterization in 12, magnetic resonance imaging in 4, and computed tomography in 2. Diagnosis was made intraoperatively in two patients. Pseudoaneurysm occurred after cardiac surgery in 30 patients (58%) and after myocardial infarction in 22 (42%). Location of the pseudoaneurysm was primarily related to its cause: Pseudoaneurysm was located in the inferior or posterolateral wall in 18 of 22 patients (82%) after myocardial infarction, in the right ventricular outflow tract in 13 of 15 patients (87%) after congenital heart surgery, in the posterior subannular region of the mitral valve in 4 of 4 patients (100%) after mitral valve replacement and in the subaortic region in 3 of 3 (100%) after aortic valve replacement. Forty-two patients (81%) had surgical repair (surgical mortality rate, 7%). Ten patients (19%) did not have surgery. Nineteen patients died after a median survival of 2.3 years (range, 3 days to 8.2 years): Eight died of noncardiac cause, 5 of congestive heart failure, 4 of acute myocardial infarction, and 2 of cardiac arrhythmia (ventricular tachycardia). No further cardiac ruptures were documented. Conclusions: A substantial number of patients with pseudoaneurysm are asymptomatic. Although surgical repair is the treatment of choice, conservative management in selected patients with increased surgical risk seems reasonable because no deaths were caused by further rupture.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Mayo Clin Jacksonville, Jacksonville, FL 32224 USA	Mayo Clinic; Mayo Clinic	Oh, JK (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.							Adamick R, 1986, ECHOCARDIOGR-J CARD, V3, P237; ALAM M, 1989, CHEST, V95, P231, DOI 10.1378/chest.95.1.231; Aronstein CG, 1941, AM J CLIN PATHOL, V11, P128; BATES RJ, 1977, AM J CARDIOL, V40, P429, DOI 10.1016/0002-9149(77)90167-9; Becker RC, 1996, J AM COLL CARDIOL, V27, P1321, DOI 10.1016/0735-1097(96)00008-3; BORMAN JB, 1982, SCAND J THORAC CARD, V16, P125, DOI 10.3109/14017438209101797; BROSS W, 1967, J CARDIOVASC SURG, V8, P256; Burn CG, 1943, AM HEART J, V26, P415, DOI 10.1016/S0002-8703(43)90338-2; CATHERWOOD E, 1980, CIRCULATION, V62, P294, DOI 10.1161/01.CIR.62.2.294; CLEARKIN K P, 1955, Thorax, V10, P42, DOI 10.1136/thx.10.1.42; DAVIDSON KH, 1977, ANN INTERN MED, V86, P430, DOI 10.7326/0003-4819-86-4-430; GATEWOOD RP, 1980, AM J CARDIOL, V46, P869, DOI 10.1016/0002-9149(80)90442-7; GRUBE E, 1980, BRIT HEART J, V43, P232; GUERON M, 1975, J THORAC CARDIOV SUR, V69, P736; HURST CO, 1963, CIRCULATION, V28, P427, DOI 10.1161/01.CIR.28.3.427; KAHN J, 1991, MAGN RESON IMAGING, V9, P159, DOI 10.1016/0730-725X(91)90005-7; KERR WF, 1961, BRIT HEART J, V23, P88; KILLEN DA, 1969, CIRCULATION, V39, P101, DOI 10.1161/01.CIR.39.1.101; KOMEDA M, 1993, J THORAC CARDIOV SUR, V106, P1189, DOI 10.1016/S0022-5223(19)33997-2; KUPARI M, 1987, BRIT HEART J, V58, P52; Lanzarini L, 1987, Recenti Prog Med, V78, P402; LEE SJK, 1976, CAN MED ASSOC J, V115, P45; MACKENZIE JW, 1994, TEX HEART I J, V21, P296; Malara D, 1987, Radiol Med, V74, P577; MARCH KL, 1989, CLIN CARDIOL, V12, P531, DOI 10.1002/clc.4960120911; MARTIN RH, 1977, AM J MED, V62, P418, DOI 10.1016/0002-9343(77)90841-5; MCLIMOYLE G, 1973, CAN MED ASSOC J, V109, P388; MILGALTER E, 1987, THORAC CARDIOV SURG, V35, P20, DOI 10.1055/s-2007-1020191; NATARAJAN MK, 1994, CAN J CARDIOL, V10, P927; OLIVA PB, 1993, J AM COLL CARDIOL, V22, P720, DOI 10.1016/0735-1097(93)90182-Z; ONIK G, 1980, J NUCL MED, V21, P177; OREILLY RJ, 1970, AM J DIS CHILD, V120, P252, DOI 10.1001/archpedi.1970.02100080136016; PAPPAS G, 1972, J THORAC CARDIOV SUR, V63, P925, DOI 10.1016/S0022-5223(19)41820-5; QIZILBASH AH, 1973, AM J CARDIOL, V32, P110, DOI 10.1016/S0002-9149(73)80095-5; Rittoo D, 1994, J Am Soc Echocardiogr, V7, P429; ROELANDT J, 1975, CIRCULATION, V52, P466, DOI 10.1161/01.CIR.52.3.466; ROELANDT JRTC, 1988, J AM COLL CARDIOL, V12, P807, DOI 10.1016/0735-1097(88)90325-7; SAKAI K, 1992, AM HEART J, V124, P975, DOI 10.1016/0002-8703(92)90981-Z; SCHWARZ J, 1988, AM HEART J, V116, P1353, DOI 10.1016/0002-8703(88)90461-9; SPINDOLAFRANCO H, 1978, RADIOLOGY, V127, P29, DOI 10.1148/127.1.29; STEWART S, 1981, ANN THORAC SURG, V31, P259, DOI 10.1016/S0003-4975(10)60938-1; Stosiek M, 1986, Rofo, V145, P728, DOI 10.1055/s-2008-1049026; SUTHERLAND GR, 1989, BRIT HEART J, V61, P59; VANTASSEL RA, 1972, CHEST, V61, P104, DOI 10.1378/chest.61.2.104; VLODAVER Z, 1975, CIRCULATION, V51, P567, DOI 10.1161/01.CIR.51.3.567	45	145	153	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1998	128	4					299	305		10.7326/0003-4819-128-4-199802150-00010	http://dx.doi.org/10.7326/0003-4819-128-4-199802150-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX170	9471934				2022-12-28	WOS:000072013400008
J	Osorio, LE; Palacios, R; Chica, ME; Ochoa, MT				Osorio, LE; Palacios, R; Chica, ME; Ochoa, MT			Treatment of cutaneous leishmaniasis in Colombia with dapsone	LANCET			English	Article									Ctr Int Entrenamiento & Invest Med, Cali, Colombia		Osorio, LE (corresponding author), Ctr Int Entrenamiento & Invest Med, Cali, Colombia.		Palacios, Ricardo/B-7248-2018	Palacios, Ricardo/0000-0002-1410-8579; Ochoa, Maria T/0000-0001-6550-5008; Osorio, Lyda/0000-0002-5121-4741				Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684; DOGRA J, 1991, T ROY SOC TROP MED H, V85, P212, DOI 10.1016/0035-9203(91)90025-T; DOGRA J, 1986, INT J DERMATOL, V25, P398, DOI 10.1111/j.1365-4362.1986.tb03435.x	3	13	15	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	1998	351	9101					498	499		10.1016/S0140-6736(05)78687-6	http://dx.doi.org/10.1016/S0140-6736(05)78687-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482449				2022-12-28	WOS:000072097700021
J	Turner, S; Longworth, A; Nunn, AJ; Choonara, I				Turner, S; Longworth, A; Nunn, AJ; Choonara, I			Unlicensed and off label drug use in paediatric wards: prospective study	BRITISH MEDICAL JOURNAL			English	Article							INFANTS	Objective: To determine the extent of use in children in hospital of drugs that are not specifically licensed for use in children (unlicensed) and of drugs that are used outside the terms of their product licence that apply to indication, age, dose, or route of administration (off label). Design: Prospective study of drugs administered on paediatric medical and surgical wards for 13 weeks. Setting: Regional children's hospital. Subjects: Paediatric inpatients in medical and surgical wards. Main outcome measures: Comparison of the use of each drug with its product licence to determine whether the drug was used in an unlicensed or off label manner. Results: 2013 courses of drugs were administered to 609 paediatric patients in 707 admissions. 506 (25%) of the drug courses (prescriptions) were either unlicensed (139) or off label (367) uses. In 256 (36%) of the 707 admissions patients received one or more courses of an unlicensed or off label treatment in hospital. Conclusions: Use of drugs in an off label or unlicensed manner to treat children is widespread. Drugs are more likely to be used in an off label manner than in an unlicensed manner.	Alder Hey Childrens Hosp, Inst Child Hlth, Liverpool L12 2AP, Merseyside, England; Alder Hey Childrens Hosp, Dept Pharm, Liverpool L12 2AP, Merseyside, England	Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; University of Liverpool; Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital	Choonara, I (corresponding author), Derbyshire Childrens Hosp, Acad Div Child Hlth, Derby DE22 3NE, England.		Choonara, Imti/I-3559-2019	Choonara, Imti/0000-0002-3069-6323				*ASS BRIT PHARM IN, 1995, ABPI DAT SHEET COMP; BENINI F, 1993, JAMA-J AM MED ASSOC, V270, P850, DOI 10.1001/jama.270.7.850; *BRIT MED ASS, 1996, 31 BMA RPSGB; *BRIT PAED ASS, 1996, LIC MED CHILDR JOINT; CHOONARA I, 1995, J PHARM MED, V5, P96; CORNELISSEN EAM, 1992, ARCH DIS CHILD, V67, P1250, DOI 10.1136/adc.67.10.1250; Cote CJ, 1996, PEDIATRICS, V98, P118; COTE CJ, 1997, PAEDIAT PERINAT DRUG, V1, P3; *EUR AG EV MED PRO, 1997, NOT GUID CLIN INV ME; Kauffman Ralph E., 1995, Current Opinion in Pediatrics, V7, P195, DOI 10.1097/00008480-199504000-00014; NAHATA MC, 1997, PAEDIAT PERINAT DRUG, V1, P50; Parkinson L, 1997, PAEDIATR ANAESTH, V7, P405, DOI 10.1046/j.1460-9592.1997.d01-109.x; Turner S, 1996, LANCET, V347, P549, DOI 10.1016/S0140-6736(96)91182-4; Turner S, 1997, PAEDIAT PERINATAL DR, V1, P52	14	224	236	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 31	1998	316	7128					343	345		10.1136/bmj.316.7128.343	http://dx.doi.org/10.1136/bmj.316.7128.343			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487167	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000071863900022
J	Duffy, TA; Wolfe, CDA; Varden, C; Kennedy, J; Chrystie, IL; Banatvala, JE				Duffy, TA; Wolfe, CDA; Varden, C; Kennedy, J; Chrystie, IL; Banatvala, JE			Antenatal HIV testing: current problems, future solutions. Survey of uptake in one London hospital	BRITISH MEDICAL JOURNAL			English	Article									United Med & Dent Sch Guys & St Thomas Hosp, Dept Virol, London SE1 7EH, England; St Thomas Hosp, Guys & St Thomas NHS Trust, Dept Midwifery, London SE1 7EH, England	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	Banatvala, JE (corresponding author), United Med & Dent Sch Guys & St Thomas Hosp, Dept Virol, London SE1 7EH, England.			Wolfe, Charles/0000-0001-8264-0981				BOYD KM, 1990, J MED ETHICS, V16, P173, DOI 10.1136/jme.16.4.173; CHRYSTIE IL, 1991, LANCET, V339, P364; *PUBL HLTH LAB SER, 1997, UNL AN HIV PREV MON; *UNL AN SURV STEER, 1996, UNL AN HIV SER MON P; WESTMORLAND T, 1997, INT C GLOB STRAT PRE	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					270	271		10.1136/bmj.316.7127.270	http://dx.doi.org/10.1136/bmj.316.7127.270			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472508	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000071702100022
J	Kleijnen, J; Bonsel, G				Kleijnen, J; Bonsel, G			Guidelines and quality of clinical services in the new NHS	BRITISH MEDICAL JOURNAL			English	Article									Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, Dutch Cochrane Ctr, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Kleijnen, J (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, Dutch Cochrane Ctr, NL-1100 DE Amsterdam, Netherlands.								0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					299	300		10.1136/bmj.316.7127.299	http://dx.doi.org/10.1136/bmj.316.7127.299			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472523	Green Published, Green Submitted			2022-12-28	WOS:000071702100040
J	Esmail, A; Everington, S; Doyle, H				Esmail, A; Everington, S; Doyle, H			Racial discrimination in the allocation of distinction awards? Analysis of list of award holders by type of award, specialty and region	BRITISH MEDICAL JOURNAL			English	Article									Harvard Univ, Sch Med, Boston, MA 02115 USA; Med Practitioners Union, London SE1 1UN, England; Univ Manchester, Dept Gen Practice, Rusholme Hlth Ctr, Manchester M14 5NP, Lancs, England	Harvard University; Harvard Medical School; University of Manchester	Esmail, A (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.		Esmail, Aneez/I-6903-2013					*ADV COMM DIST AW, 1997, REP 1996 AW ROUND; ESMAIL A, 1994, BRIT MED J, V308, P1374; ESMAIL A, 1993, BRIT MED J, V306, P691, DOI 10.1136/bmj.306.6879.691; Esmail A, 1997, BRIT MED J, V314, P1619, DOI 10.1136/bmj.314.7094.1619; *NAT HLTH SERV EX, 1996, HOSP MED STAFF ENGL	5	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					193	195						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468684				2022-12-28	WOS:000071616400024
J	Greenwood, D				Greenwood, D			Sixty years on: Antimicrobial drug resistance comes of age	LANCET			English	Article											Greenwood, D (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DIV MICROBIOL,NOTTINGHAM NG7 2UH,ENGLAND.							BARTLETT JG, 1995, ARCH OTOLARYNGOL, V121, P392; PALLARES R, 1995, NEW ENGL J MED, V333, P474, DOI 10.1056/NEJM199508243330802; VENKATESAN P, 1995, THORAX, V50, P481, DOI 10.1136/thx.50.5.481; 1995, WHO TECH REP SER, V850; 1995, REPORT HOSPITAL INFE	5	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S1	S1		10.1016/0140-6736(95)90000-4	http://dx.doi.org/10.1016/0140-6736(95)90000-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454026				2022-12-28	WOS:A1995TN12200001
J	Prather, MJ				Prather, MJ			Time scales in atmospheric chemistry: Coupled perturbations to N2O, NOy, and O-3	SCIENCE			English	Article							NITROGEN FERTILIZERS; OXIDE	Nitrous oxide (N2O) is one of the top three greenhouse gases whose emissions may be brought under control through the Framework Convention on Climate Change. Current understanding of its global budget, including the balance of natural and anthropogenic sources, is largely based on the atmospheric losses calculated with chemical models. A representative one-dimensional model used here describes the photochemical coupling between N2O and stratospheric ozone (O-3), which can easily be decomposed into its natural modes. The primary, longest lived mode describes most of the atmospheric perturbation due to anthropogenic N2O sources, and this pattern may be observable. The photolytic link between O-3 and N2O is identified as the mechanism causing this mode to decay 10 to 15 percent more rapidly than the N2O mean atmospheric lifetime, affecting the inference of anthropogenic sources.	Univ Calif Irvine, Dept Earth Syst Sci, Irvine, CA 92697 USA	University of California System; University of California Irvine	Prather, MJ (corresponding author), Univ Calif Irvine, Dept Earth Syst Sci, Irvine, CA 92697 USA.	mprather@uci.edu						Chameides W., 1976, J GEOPHYS RES, V81, P4997; CHAMEIDES WL, 1997, BIOGEOCHEMICAL CYCLE, P85; *COMM CHEM PHYS OZ, 1982, CAUS EFF STRAT OZ RE; CRUTZEN P J, 1977, Ambio, V6, P112; FISHER D, 1995, ALTERNATIVE FLUOROCA; HOUGHTON JT, 1995, CLIMATE CHANGE 1994, P73; Jackman CH, 1996, J GEOPHYS RES-ATMOS, V101, P28753, DOI 10.1029/96JD03088; KHALIL MAK, 1992, J GEOPHYS RES-ATMOS, V97, P14651, DOI 10.1029/92JD01222; LIU SC, 1977, TELLUS, V29, P251, DOI 10.1111/j.2153-3490.1977.tb00732.x; Machida T., 1994, P INT S GLOB CYCL AT, P113; MCELROY MB, 1977, PHILOS T R SOC B, V277, P159, DOI 10.1098/rstb.1977.0009; PRATHER MJ, 1994, GEOPHYS RES LETT, V21, P801, DOI 10.1029/94GL00840; Prather MJ, 1996, GEOPHYS RES LETT, V23, P2597, DOI 10.1029/96GL02371; Prather MJ, 1997, GLOBAL BIOGEOCHEM CY, V11, P393, DOI 10.1029/97GB01055; PRATHER MJ, 1993, NASA REF PUBL, V1292; PRINN R, 1990, J GEOPHYS RES-ATMOS, V95, P18369, DOI 10.1029/JD095iD11p18369; SZE N D, 1977, Science (Washington D C), V195, P673, DOI 10.1126/science.195.4279.673; [No title captured]	18	83	86	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	1998	279	5355					1339	1341		10.1126/science.279.5355.1339	http://dx.doi.org/10.1126/science.279.5355.1339			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478891	Green Submitted			2022-12-28	WOS:000072251800046
J	Houart, C; Westerfield, M; Wilson, SW				Houart, C; Westerfield, M; Wilson, SW			A small population of anterior cells patterns for forebrain during zebrafish gastrulation	NATURE			English	Article							NEURONAL DIFFERENTIATION; EXPRESSION; ENDODERM; BRAIN; GENES; HEAD	During gastrulation in vertebrates, dorsal ectoderm is induced to form neural tissue that later gives rise to the brain and spinal card. This induction depends on signals arising from a group of cells on the dorsal side of the gastrula, This group of cells constitutes the organizer(1,2). It is thought that the organizer initially induces neural tissue with anterior, or forebrain, character, and that other signals subsequently posteriorize neural tissue in the trunk(2,3). Here we show that development of the anterior central nervous system of the zebrafish embryo also depends on a small group of ectodermal cells located in the prospective head region. Removal of these ectodermal cells during gastrulation perturbs subsequent neural patterning and results in widespread cell death, Transplantation of these cells shows that they can induce forebrain-specific gene expression in more posterior regions of the neural plate. Our results indicate that an early step in neural patterning is the establishment of a small population of signalling cells within the most anterior region of the embryo. These cells are required for patterning and survival of the anterior brain.	Univ London Kings Coll, Randall Inst, Dev Biol Res Ctr, London WC2 5RL, England; Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA	University of London; King's College London; University of Oregon	Houart, C (corresponding author), Univ London Kings Coll, Randall Inst, Dev Biol Res Ctr, 26-29 Drury Lane, London WC2 5RL, England.		Wilson, Stephen W/B-9404-2008; Zebrafish, UCL/A-3125-2009; Houart, Corinne/B-5128-2009	Wilson, Stephen W/0000-0002-8557-5940; Houart, Corinne/0000-0002-2062-3964	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIMENKO MA, 1994, J NEUROSCI, V14, P3475; ALLENDE ML, 1994, DEV BIOL, V166, P509, DOI 10.1006/dbio.1994.1334; BARTH KA, 1995, DEVELOPMENT, V121, P1755; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Bradley L, 1996, DEVELOPMENT, V122, P2739; Brand M, 1996, DEVELOPMENT, V123, P129; Furthauer M, 1997, DEVELOPMENT, V124, P4253; Heisenberg CP, 1996, DEVELOPMENT, V123, P191; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Lemaire P, 1996, TRENDS GENET, V12, P525, DOI 10.1016/S0168-9525(97)81401-1; LI YB, 1994, MECH DEVELOP, V48, P229, DOI 10.1016/0925-4773(94)90062-0; MACDONALD R, 1994, NEURON, V13, P1039, DOI 10.1016/0896-6273(94)90044-2; Mizuno T, 1996, NATURE, V383, P131, DOI 10.1038/383131a0; MORITA T, 1995, NEUROSCI LETT, V198, P131, DOI 10.1016/0304-3940(95)11988-9; NEAVE B, 1995, MECH DEVELOP, V51, P169, DOI 10.1016/0925-4773(95)00351-7; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; Shimamura K, 1997, DEVELOPMENT, V124, P2709; THISSE C, 1994, DEV BIOL, V164, P420, DOI 10.1006/dbio.1994.1212; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; Varlet I, 1997, DEVELOPMENT, V124, P1033; WESTERFIELD M, 1996, ZEBRAFISH BOOK; Woo K, 1997, SCIENCE, V277, P254, DOI 10.1126/science.277.5323.254	22	182	184	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					788	792		10.1038/35853	http://dx.doi.org/10.1038/35853			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486648				2022-12-28	WOS:000072089500052
J	Ryan, DH; Crowther, MA; Ginsberg, JS; Francis, CW				Ryan, DH; Crowther, MA; Ginsberg, JS; Francis, CW			Relation of factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery	ANNALS OF INTERNAL MEDICINE			English	Article						factor V; thrombophlebitis; arthroplasty, replacement, hip; arthroplasty, replacement, knee; protein C	ACTIVATED PROTEIN-C; MOLECULAR-WEIGHT HEPARIN; TOTAL HIP-REPLACEMENT; COAGULATION-FACTOR-V; VEIN THROMBOSIS; INHERITED RESISTANCE; KNEE SURGERY; ORTHOPEDIC PATIENTS; RANDOMIZED TRIAL; THROMBOEMBOLISM	Background: A point mutation in coagulation factor V (A1691G) is associated with increased risk for venous thrombosis. However, limited information is available about the prospective risk for deep venous thrombosis in specific high-risk clinical settings. Objective: To determine whether the factor V Leiden mutation is associated with an increased occurrence of deep venous thrombosis in patients undergoing hip or knee replacement surgery. Design: Retrospective analysis of plasma samples obtained during six prospective clinical trials that compared different antithrombotic prophylaxis regimens in patients undergoing hip or knee replacement surgery. Setting: Inpatients at the University of Rochester Medical Center, McMaster University Medical Center, Hamilton Civic Hospitals, and the Genesee Hospital. Patients: 825 patients hospitalized for hip or knee replacement surgery. Measurements: Venographically diagnosed postoperative deep venous thrombosis was correlated with factor V genotype. Results: The factor V Leiden mutation was not associated with a significantly increased risk for venographically detected deep venous thrombosis. The absolute incidence of deep venous thrombosis was 31 % (95 % CI, 15 % to 47%) in patients with the mutation and 26% (CI, 22% to 29%) in patients without the mutation (relative risk, 1.2 [CI, 0.6 to 2.9]). The factor V Leiden mutation was not significantly associated with deep venous thrombosis in subgroups of patients receiving warfarin or heparin. The incidence of clinical hemorrhage was similar in patients with (10%) and without (8%) the mutation. Conclusions: The factor V Leiden mutation is not a significant risk factor for acute deep venous thrombosis in this group of patients. Current data do not justify routine preoperative screening for this mutation or intensified perioperative prophylaxis in patients with the factor V Leiden mutation who are undergoing hip or knee joint replacement surgery and are receiving effective antithrombotic prophylaxis.	Univ Rochester, Med Ctr, Rochester, NY 14642 USA; McMaster Univ, Med Ctr, Hamilton, ON L8N 3Z5, Canada	University of Rochester; McMaster University	Ryan, DH (corresponding author), Univ Rochester, Med Ctr, 601 Elmwood Ave, Rochester, NY 14642 USA.	dryan@eznet.net	ginsberg, jeffrey s/ABC-1065-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030616] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30616] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGNELLI G, 1995, THROMB HAEMOSTASIS, V74, P1042; ARBINI AA, 1995, THROMB HAEMOSTASIS, V74, P1255; ASLAM S, 1995, CLIN LAB HAEMATOL, V17, P99; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BERTINA RM, 1995, THROMB HAEMOSTASIS, V74, P449; BIOUSSE V, 1995, J RHEUMATOL, V22, P1215; BRENNER B, 1995, THROMB HAEMOSTASIS, V73, P942; CAMPBELL MJ, 1995, BRIT MED J, V311, P1145, DOI 10.1136/bmj.311.7013.1145; CATTO A, 1995, ARTERIOSCL THROM VAS, V15, P783, DOI 10.1161/01.ATV.15.6.783; CLAGETT GP, 1992, CHEST, V102, pS391, DOI 10.1378/chest.102.4_Supplement.391S; CLAGETT GP, 1994, AM J SURG, V168, P515, DOI 10.1016/S0002-9610(05)80114-X; COLWELL CW, 1995, CLIN ORTHOP RELAT R, V321, P19; DAHLBACK B, 1994, HAEMOSTASIS, V24, P139; DAHLBACK B, 1994, J CLIN INVEST, V94, P923, DOI 10.1172/JCI117458; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; Davidson HC, 1996, AM J ROENTGENOL, V166, P659, DOI 10.2214/ajr.166.3.8623645; Dawson-Saunders B, 1990, BASIC CLIN STAT; Desmarais S, 1996, LANCET, V347, P1374, DOI 10.1016/S0140-6736(96)91013-2; FAUNO P, 1994, J BONE JOINT SURG AM, V76A, P1814, DOI 10.2106/00004623-199412000-00007; Francis CW, 1997, J BONE JOINT SURG AM, V79A, P1365, DOI 10.2106/00004623-199709000-00011; Francis CW, 1996, THROMB HAEMOSTASIS, V75, P706; FRANCIS CW, 1992, JAMA-J AM MED ASSOC, V267, P2911, DOI 10.1001/jama.267.21.2911; GINSBERG JS, 1995, THROMB HAEMOSTASIS, V74, P602; HELLGREN M, 1995, AM J OBSTET GYNECOL, V173, P210, DOI 10.1016/0002-9378(95)90192-2; HULL R, 1993, NEW ENGL J MED, V329, P1370, DOI 10.1056/NEJM199311043291902; IMPERIALE TF, 1994, JAMA-J AM MED ASSOC, V271, P1780, DOI 10.1001/jama.271.22.1780; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LECLERC JR, 1992, THROMB HAEMOSTASIS, V67, P417; Leclerc JR, 1996, ANN INTERN MED, V124, P619, DOI 10.7326/0003-4819-124-7-199604010-00001; LEE DH, 1996, HAEMOPHILIA, V2, P47; Lensen RPM, 1996, BLOOD, V88, P4205, DOI 10.1182/blood.V88.11.4205.bloodjournal88114205; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; Levine MN, 1996, ARCH INTERN MED, V156, P851, DOI 10.1001/archinte.156.8.851; MOHR DN, 1993, ARCH INTERN MED, V153, P2221, DOI 10.1001/archinte.153.19.2221; Otterson GA, 1996, AM J MED, V101, P406, DOI 10.1016/S0002-9343(96)00235-5; Pabinger I, 1996, ARTERIOSCL THROM VAS, V16, P742, DOI 10.1161/01.ATV.16.6.742; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; SCURR JH, 1988, BRIT MED J, V297, P28, DOI 10.1136/bmj.297.6640.28; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; WELLS PS, 1995, ANN INTERN MED, V122, P47, DOI 10.7326/0003-4819-122-1-199501010-00008; WHITEHOUSE G, 1987, BRIT MED J, V295, P801, DOI 10.1136/bmj.295.6602.801; ZOLLER B, 1994, LANCET, V343, P1536, DOI 10.1016/S0140-6736(94)92940-8	47	69	69	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1998	128	4					270	+		10.7326/0003-4819-128-4-199802150-00003	http://dx.doi.org/10.7326/0003-4819-128-4-199802150-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX170	9471929				2022-12-28	WOS:000072013400003
J	Fellman, V; Rapola, J; Pihko, H; Varilo, T; Raivio, KO				Fellman, V; Rapola, J; Pihko, H; Varilo, T; Raivio, KO			Iron-overload disease in infants involving fetal growth retardation, lactic acidosis, liver haemosiderosis, and aminoaciduria	LANCET			English	Article							RESPIRATORY-CHAIN; PERINATAL HEMOCHROMATOSIS; COMPLEX-III; DEFICIENCY; PATHOLOGY	Background Several cases of a distinctive lethal neonatal disorder have been found in the Children's Hospital, Helsinki, Finland. However, the combination of presenting features is not typical of any known metabolic disease. We have analysed all known cases of this disorder in the hospital since 1965 and in Finland since 1990 to define clinical features of the disease. Methods We studied 17 newborn infants with severe growth retardation from 12 Finnish families and traced their genealogy. In addition to routine clinical studies, diagnostic workup included analysis of respiratory-chain function in isolated muscle mitochondria and necropsy specimens, pyruvate dehydrogenase complex activities in fibroblasts, analysis of aminoacids and organic acids in urine, staining of tissue samples for iron, and assay of liver iron content. Findings The infants were born near term (mean 37.8 [SD 3] gestational weeks) but were severely growth retarded (birthweight 1690 [460] g-ie, -3.8 [SD 0.6] SD score for gestational age). By age 24 h, mean pH was 7.00 (0.12), lactate 12.2 (7.5) mmol/L, and pyruvate 121 (57) mu mol/L. All had aminoaciduria and failed to thrive; nine died neonatally (age 2-12 days), and eight died in infancy (1-4 months). The liver of four infants showed microscopic haemosiderosis and increased iron content (2.8-55 mg iron/g dry weight). In those four infants serum ferritin concentration (1260-2700 mu g/L) and transferrin saturation (61-100%) were high, transferrin concentration (0.54-0.76 g/L) was low. Interpretation We describe a previously unrecognised clinical picture of a genetic disease, which presents with fetal growth retardation and lactic acidosis after birth. Genealogical studies indicate an autosomal-recessive mode of inheritance for this disease, which is distinct from other lactic acidoses, neonatal haemochromatosis, and hepatitis. The diagnostic criteria are: fetal growth retardation; severe lactic acidosis; aminoaciduria; iron overload with haemosiderosis of the liver, increased serum ferritin concentration, hypotransferrinaemia, and increased transferrin iron saturation. Organ dysfunction may be partly due to the toxic effects of free iron.	Univ Helsinki, Childrens Hosp, FIN-00290 Helsinki, Finland; Natl Publ Hlth Inst, Helsinki, Finland	University of Helsinki; Finland National Institute for Health & Welfare	Fellman, V (corresponding author), Univ Helsinki, Childrens Hosp, Stenbackinkatu 11, FIN-00290 Helsinki, Finland.							BACON BR, 1990, HEPATOLOGY, V11, P127, DOI 10.1002/hep.1840110122; BALE PM, 1994, PEDIATR PATHOL, V14, P479, DOI 10.3109/15513819409024277; Baynes RD, 1996, CLIN BIOCHEM, V29, P209, DOI 10.1016/0009-9120(96)00010-K; BIRCHMACHIN MA, 1989, PEDIATR RES, V25, P553, DOI 10.1203/00006450-198905000-00025; BRITTON RS, 1991, GASTROENTEROLOGY, V101, P806, DOI 10.1016/0016-5085(91)90543-T; BROWN GK, 1992, J INHERIT METAB DIS, V15, P625, DOI 10.1007/BF01799619; COCKALINGAM U, 1987, J PEDIATR, V111, P283; DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602; HAYASHI A, 1993, AM J HUM GENET, V53, P201; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Knisely A S, 1992, Adv Pediatr, V39, P383; MAJANDER A, 1995, J NEUROL SCI, V134, P95, DOI 10.1016/0022-510X(95)00225-5; MORAES CT, 1991, AM J HUM GENET, V48, P492; MORRIS AAM, 1995, PEDIATR NEPHROL, V9, P407, DOI 10.1007/BF00866711; MUIESAN P, 1995, ARCH DIS CHILD-FETAL, V73, pF178, DOI 10.1136/fn.73.3.F178; NORIO R, 1973, ANN CLIN RES, V5, P109; Robinson B.H., 1995, METABOLIC MOL BASES, P1479; SILVER MM, 1993, AM J PATHOL, V143, P1312; SILVER MM, 1987, AM J PATHOL, V128, P538; SIMPSON RJ, 1993, J PATHOL, V171, P237, DOI 10.1002/path.1711710313; Varilo T, 1996, GENOME RES, V6, P870, DOI 10.1101/gr.6.9.870; Verloes A, 1997, AM J MED GENET, V68, P391, DOI 10.1002/(SICI)1096-8628(19970211)68:4<391::AID-AJMG3>3.0.CO;2-P; Villeneuve JP, 1996, J HEPATOL, V25, P172, DOI 10.1016/S0168-8278(96)80070-5	23	74	75	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	1998	351	9101					490	493		10.1016/S0140-6736(97)09272-6	http://dx.doi.org/10.1016/S0140-6736(97)09272-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482441				2022-12-28	WOS:000072097700013
J	Halligan, PW				Halligan, PW			Inability to recognise disgust in Huntington's disease	LANCET			English	Editorial Material							FACIAL EXPRESSIONS; HUMAN AMYGDALA; EMOTION; DAMAGE		Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England	University of Oxford	Halligan, PW (corresponding author), Univ Oxford, Dept Expt Psychol, S Parks Rd, Oxford OX1 3UD, England.		Halligan, Peter W/A-1669-2010	Halligan, Peter W/0000-0003-2784-6690				ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; BRUCE V, 1986, BRIT J PSYCHOL, V77, P305, DOI 10.1111/j.2044-8295.1986.tb02199.x; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; Gray JM, 1997, BRAIN, V120, P2029, DOI 10.1093/brain/120.11.2029; Morris JS, 1996, NATURE, V383, P812, DOI 10.1038/383812a0; Phillips ML, 1997, NATURE, V389, P495, DOI 10.1038/39051; Sprengelmeyer R, 1996, BRAIN, V119, P1647, DOI 10.1093/brain/119.5.1647; Young AW, 1997, COGNITION, V63, P271, DOI 10.1016/S0010-0277(97)00003-6; YOUNG AW, 1997, PSYCHOL          OCT, P447	9	9	9	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	1998	351	9101					464	464		10.1016/S0140-6736(05)78678-5	http://dx.doi.org/10.1016/S0140-6736(05)78678-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YX958	9482434				2022-12-28	WOS:000072097700005
J	Ho, GYF; Bierman, R; Beardsley, L; Chang, CJ; Burk, RD				Ho, GYF; Bierman, R; Beardsley, L; Chang, CJ; Burk, RD			Natural history of cervicovaginal papillomavirus infection in young women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	14th International Papillomavirus Conference	JUL 21-28, 1995	QUEBEC CITY, CANADA				GENITAL HUMAN PAPILLOMAVIRUS; CYTOLOGICALLY NORMAL WOMEN; TERM FOLLOW-UP; CERVICAL-CANCER; RISK-FACTORS; LONGITUDINAL DATA; PREVALENCE; DYSPLASIA; BEHAVIOR; DNA	Background Genital human papillomavirus (HPV) infection is highly prevalent in sexually active young women. However, precise risk factors for HPV infection and its incidence and duration are not well known. Methods We followed 608 college women at six-month intervals for three years. At each visit, we collected information about lifestyle and sexual behavior and obtained cervicovaginal-lavage samples for the detection of HPV DNA by polymerase chain reaction and Southern blot hybridization. Pap smears were obtained annually. Results The cumulative 36-month incidence of HPV infection was 43 percent (95 percent confidence interval, 36 to 49 percent). An increased risk of HPV infection was significantly associated with younger age, Hispanic ethnicity, black race, an increased number of vaginal-sex partners, high frequencies of vaginal sex and alcohol consumption, anal sex, and certain characteristics of partners (regular partners having an increased number of lifetime partners and not being in school). The median duration of new infections was 8 months (95 percent confidence interval, 7 to 10 months). The persistence of HPV for greater than or equal to 6 months was related to older age, types of HPV associated with cervical cancer, and infection with multiple types of HPV but not with smoking. The risk of an abnormal Pap smear increased with persistent HPV infection, particularly with high-risk types (relative risk, 37.2; 95 percent confidence interval, 14.6 to 94.8). Conclusions The incidence of HPV infection in sexually active young college women is high. The short duration of most HPV infections in these women suggests that the associated cervical dysplasia should be managed conservatively. (C) 1998, Massachusetts Medical Society.	Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Rutgers State Univ, Student Hlth Serv, New Brunswick, NJ 08903 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Rutgers State University New Brunswick	Burk, RD (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, 1300 Morris Pk Ave,Ullmann Bldg,Rm 515, Bronx, NY 10461 USA.		Fahimifar, Sepideh/M-5303-2019		NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031055] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13330] Funding Source: Medline; NIAID NIH HHS [AI-31055] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; BOSCH FX, 1992, INT J CANCER, V52, P750, DOI 10.1002/ijc.2910520514; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BRINTON LA, 1986, J CHRON DIS, V39, P1051, DOI 10.1016/0021-9681(86)90139-6; Brisson J, 1996, J INFECT DIS, V173, P794, DOI 10.1093/infdis/173.4.794; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; BURK RD, 1986, AM J OBSTET GYNECOL, V154, P982, DOI 10.1016/0002-9378(86)90733-7; Burk RD, 1996, J INFECT DIS, V174, P679, DOI 10.1093/infdis/174.4.679; Burk RD, 1996, SEX TRANSM DIS, V23, P333, DOI 10.1097/00007435-199607000-00013; Daling JR, 1996, CANCER EPIDEM BIOMAR, V5, P541; DEVILLIERS EM, 1992, GYNECOL ONCOL, V44, P33, DOI 10.1016/0090-8258(92)90008-7; EVANDER M, 1995, J INFECT DIS, V171, P1026, DOI 10.1093/infdis/171.4.1026; FAIRLEY CK, 1994, OBSTET GYNECOL, V84, P755; GOLDBERG GL, 1989, AM J OBSTET GYNECOL, V161, P1669, DOI 10.1016/0002-9378(89)90947-2; HILDESHEIM A, 1994, J INFECT DIS, V169, P235, DOI 10.1093/infdis/169.2.235; HINCHLIFFE SA, 1995, BRIT J CANCER, V72, P943, DOI 10.1038/bjc.1995.438; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; HSING AW, 1994, J INFECT DIS, V170, P498, DOI 10.1093/infdis/170.2.498; KARLSSON R, 1995, SEX TRANSM DIS, V22, P119, DOI 10.1097/00007435-199503000-00008; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; LEY C, 1991, JNCI-J NATL CANCER I, V83, P997, DOI 10.1093/jnci/83.14.997; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Maiman Mitchell, 1996, P405; MOSCICKI AB, 1992, J INFECT DIS, V166, P951, DOI 10.1093/infdis/166.5.951; MOSCICKI AB, 1990, PEDIATR RES, V28, P507, DOI 10.1203/00006450-199011000-00018; NASIELL K, 1983, OBSTET GYNECOL, V61, P609; NASIELL K, 1986, OBSTET GYNECOL, V67, P665, DOI 10.1097/00006250-198605000-00012; RICHART RM, 1969, AM J OBSTET GYNECOL, V105, P386, DOI 10.1016/0002-9378(69)90268-3; Romney SL, 1997, GYNECOL ONCOL, V65, P483, DOI 10.1006/gyno.1997.4697; ROSENFELD WD, 1992, J PEDIATR-US, V121, P307, DOI 10.1016/S0022-3476(05)81212-0; *SAS I, 1989, SAS STAT US GUID VER, V2; THOMPSON WD, 1994, EPIDEMIOL REV, V16, P33, DOI 10.1093/oxfordjournals.epirev.a036143; VERMUND SH, 1991, AM J OBSTET GYNECOL, V165, P392, DOI 10.1016/0002-9378(91)90101-V; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	35	1789	1893	1	103	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 12	1998	338	7					423	428		10.1056/NEJM199802123380703	http://dx.doi.org/10.1056/NEJM199802123380703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YW122	9459645				2022-12-28	WOS:000071900100003
J	Hurst, J; Nickel, K; Hilborne, LH				Hurst, J; Nickel, K; Hilborne, LH			Are physicians' office laboratory results of comparable quality to those produced in other laboratory settings?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACCURACY	Context.-In 1995, California adopted a bill that brought laboratory laws in line with the 1988 Clinical Laboratory Improvement Amendments' standards for clinical laboratories and mandated a study comparing results in physicians' office laboratories (POLs) with other settings. Objective.-To determine whether persons conducting tests in POLs produce accurate and reliable test results comparable to those produced by non-POLs. Design.-Survey of clinical laboratories using proficiency testing data. Setting.-All California clinical laboratories participating in the American Association of Bioanalysts proficiency testing program in 1996 (n=1110). Main Outcome Measures.-"Unsatisfactory" (single testing event failure) and "unsuccessful" (repeated testing event failure) on proficiency testing samples, Results.-The unsatisfactory failure rate for POLs was nearly 3 times (21.5% vs 8.1%) the rate for the non-POLs and about 1.5 times (21.5% vs 14.0%) for POLs that used laboratory professionals as testing or supervisory personnel (P<.001). The POL unsuccessful rate was more than 4 times (4.4% vs 0.9%) the rate for non-POLs and more than twice (4.4% vs 1.8%) the rate for the POLs using laboratory professionals (P<.001). Conclusions.-Significant differences exist among POLs, POLs using licensed clinical laboratory scientists (medical technologists), and non-POLs. Testing personnel in many POLs might lack the necessary education, training, and oversight common to larger facilities, We must better understand the contributing factors that result in the poorer results of POLs relative to non-POLs, In the meantime, patients should be aware that preliminary findings suggest that differences in quality of laboratory tests based on testing site may exist. Laboratory directors at all testing sites must ensure that they understand laboratory practice sufficiently to minimize errors and maximize accuracy and reliability, Directors must understand their obligation when they elect to oversee those assigned testing responsibility. Legislators may wish to reconsider the wisdom of further easing restrictions on those to whom we entrust our laboratory specimens.	Calif Dept Hlth Serv, Lab Field Serv, Berkeley, CA 94704 USA; Univ Calif Los Angeles, Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA; Rand Corp, Hlth Program, Santa Monica, CA USA	California Department of Health Care Services; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; RAND Corporation	Hilborne, LH (corresponding author), Univ Calif Los Angeles, Med Ctr, Qual Management Serv, 10833 Le Conte Ave,CHS A7-118H, Los Angeles, CA 90095 USA.							[Anonymous], 1987, WALL STR J, P1; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P193; JENNY RW, 1993, CLIN CHEM, V39, P76; LUNZ ME, 1992, ARCH PATHOL LAB MED, V116, P820; MENNEMEYER ST, 1993, JAMA-J AM MED ASSOC, V269, P1030, DOI 10.1001/jama.269.8.1030; Winkelman J W, 1996, Am J Med Qual, V11, P25, DOI 10.1177/0885713x9601100105	6	35	35	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	1998	279	6					468	471		10.1001/jama.279.6.468	http://dx.doi.org/10.1001/jama.279.6.468			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV580	9466642				2022-12-28	WOS:000071839800037
J	Hathaway, WR; Peterson, ED; Wagner, GS; Granger, CB; Zabel, KM; Pieper, KS; Clark, KA; Woodlief, LH; Califf, RM				Hathaway, WR; Peterson, ED; Wagner, GS; Granger, CB; Zabel, KM; Pieper, KS; Clark, KA; Woodlief, LH; Califf, RM		GUSTO-I Investigators	Prognostic significance of the initial electrocardiogram in patients with acute myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ST-SEGMENT DEPRESSION; THROMBOLYTIC THERAPY; TRIAL; MORTALITY; ANGIOPLASTY; PREDICTORS; SIZE; ERA	Context.-Early risk stratification of patients with myocardial infarction is critical to determine optimum treatment strategies and enhance outcomes, but knowledge of the prognostic importance of the initial electrocardiogram (ECG) is limited. Objective.-To assess the independent value of the initial ECG for short-term risk stratification after acute myocardial infarction. Design.-Retrospective analysis of the Global Utilization of Streptokinase and t-PA (alteplase) for Occluded Coronary Arteries (GUSTO-I) clinical trial database. Setting.-A total of 1081 hospitals in 15 countries. Patients.-From the 41 021 patients enrolled in the overall study, we selected those who presented within 6 hours of chest pain onset with ST-segment elevation and no confounding factors (paced rhythms, ventricular rhythms, or left bundle-branch block) on the ECG performed before thrombolysis was administered (n=34 166). Main Outcome Measure.-Ability of initial ECG to predict all-cause mortality at 30 days. Results.-Most ECG variables were associated with 30-day mortality in a univariable analysis, In a multivariable analysis combining the initial ECG variables and clinical predictors of mortality, the sum of the absolute ST-segment deviation (both ST elevation and ST depression: odds ratio [OR], 1.53; 95% confidence interval [CI], 1.38-1.69), ECG, heart rate (OR, 1.49; 95% CI, 1.41-1.59), QRS duration (for anterior infarct: OR, 1.55; 95% CI, 1.43-1.68), and ECG evidence of prior infarction (for new inferior infarct: OR, 2.47; 95% CI, 2.02-3.00) were the strongest ECG predictors of mortality, A nomogram based on the multivariable model produced excellent discrimination of 30-day mortality (C-index, 0.830). Conclusions.-In patients presenting with myocardial infarction accompanied by ST-segment elevation, components of the initial ECG help predict 30-day mortality, This information should be valuable in early risk stratification, when the opportunity to reduce mortality is greatest, and may help in assessing outcomes adjusted for patient risk.	Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA	Duke University	Hathaway, WR (corresponding author), Care of Williams P, Duke Clin Res Inst, 2024 W Main St,Bay A-2, Durham, NC 27705 USA.		Granger, Christopher B/D-3458-2014; Peterson, Eric David/ABF-5033-2021	Granger, Christopher B/0000-0002-0045-3291; 				ALDRICH HR, 1988, AM J CARDIOL, V61, P749, DOI 10.1016/0002-9149(88)91060-0; BATES ER, 1989, J AM COLL CARDIOL, V13, P12, DOI 10.1016/0735-1097(89)90542-1; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; CAPONE RJ, 1991, J AM COLL CARDIOL, V18, P1434, DOI 10.1016/0735-1097(91)90671-U; CRIMM A, 1984, AM J MED, V76, P983, DOI 10.1016/0002-9343(84)90846-5; DESANCTIS RW, 1972, CIRCULATION, V45, P681, DOI 10.1161/01.CIR.45.3.681; Devlin TF., 1986, P 11 ANN SAS US GROU, P646; EDMUNDS JJ, 1994, AM J CARDIOL, V73, P143, DOI 10.1016/0002-9149(94)90205-4; Efron B., 1994, MONOGRAPHS STAT APPL; FLETCHER WO, 1993, AM HEART J, V126, P526, DOI 10.1016/0002-8703(93)90400-4; GRANGER C, 1994, CIRCULATION, V90, P324; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HINDMAN NB, 1985, AM J CARDIOL, V55, P1485, DOI 10.1016/0002-9149(85)90958-0; HLATKY MA, 1985, AM J CARDIOL, V55, P325, DOI 10.1016/0002-9149(85)90369-8; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; MAURI F, 1989, AM J CARDIOL, V63, P1291, DOI 10.1016/0002-9149(89)91037-0; MIRVIS DM, 1988, AM HEART J, V116, P1308, DOI 10.1016/0002-8703(88)90456-5; Peterson ED, 1996, J AM COLL CARDIOL, V28, P305, DOI 10.1016/0735-1097(96)00133-7; SEVILLA DC, 1990, AM J CARDIOL, V66, P792, DOI 10.1016/0002-9149(90)90353-3; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001	20	127	130	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					387	391		10.1001/jama.279.5.387	http://dx.doi.org/10.1001/jama.279.5.387			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459474	Bronze			2022-12-28	WOS:000071731300031
J	Kurtz, Z; Tookey, P; Ross, E				Kurtz, Z; Tookey, P; Ross, E			Epilepsy in young people: 23 year follow up of the British national child development study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; PROGNOSIS	Objective: To estimate the incidence and prevalence of epilepsy during childhood and early adult life in England, Scotland, and Wales. Design: Prospective study of 17 414 children born in England, Scotland, and Wales between 3 and 9 March 1958, followed up at 7, 11, 16, and 23 years of age, with a review of those with epilepsy at age 28. Subjects: People with epilepsy developing at or before age 23. Main outcome measures: The age specific incidence, cumulative incidence, and prevalence of epilepsy. Results: 124 young people had a confirmed diagnosis of epilepsy during their first 23 years (cumulative incidence 8.4 per 1000; 95% confidence interval 6.8 to 10.0). 6 had died by age 23. 46 (37%) had neurological impairment or another major health problem in addition to epilepsy. The prevalence of active epilepsy at age 23 was 6.3 per 1000 (4.9 to 7.7). Conclusions: A wide variety of seizure disorders is included under the term epilepsy. A third of cases had generalised seizures. In only a quarter was the onset of seizures attributed to a specific cause. Children with additional health problems were more likely to continue to have seizures in early adult life than those with epilepsy alone. 1 in 8 were prescribed drug treatment for 6 years or more after their last seizure. All deaths occurred in young adults over the age of 16.	UCL, Sch Med, Dept Epidemiol & Publ Hlth, Inst Child Hlth, London WC1N 1EH, England; Kings Coll London, Sch Med, Dept Community Paediat, London SE11 4QW, England	University of London; University College London; UCL Medical School; University of London; King's College London	Tookey, P (corresponding author), UCL, Sch Med, Dept Epidemiol & Publ Hlth, Inst Child Hlth, Mortimer St, London WC1N 1EH, England.	p.tookey@ich.ucl.ac.uk	Tookey, Pat A/G-2732-2010	Tookey, Pat A/0000-0001-6258-0387				[Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Breslow NE., 1987, STAT METHODS CANC RE, P81; BRITTEN N, 1986, DEV MED CHILD NEUROL, V28, P719; BRORSON LO, 1987, EPILEPSIA, V28, P324, DOI 10.1111/j.1528-1157.1987.tb03651.x; BUTLER NR, 1965, PERINATAL MORTALITY; COWAN LD, 1989, EPILEPSIA, V30, P94, DOI 10.1111/j.1528-1157.1989.tb05289.x; FOGELMAN K, 1993, GROWING UP GREAT BRI; HARRISON RM, 1976, LANCET, V1, P948; HAUSER WA, 1980, EPILEPSIA, V21, P399, DOI 10.1111/j.1528-1157.1980.tb04088.x; HOLDSWORTH L, 1974, DEV MED CHILD NEUROL, V16, P746; LIP GYH, 1992, J ROY SOC MED, V85, P609; OKUMA T, 1981, EPILEPSIA, V22, P35, DOI 10.1111/j.1528-1157.1981.tb04331.x; Power C, 1992, Paediatr Perinat Epidemiol, V6, P81, DOI 10.1111/j.1365-3016.1992.tb00748.x; REYNOLDS EH, 1990, BRIT MED J, V301, P1112, DOI 10.1136/bmj.301.6761.1112; Roger J, 1992, EPILEPTIC SYNDROMES; ROSS EM, 1980, BRIT MED J, V280, P207, DOI 10.1136/bmj.280.6209.207; ROSS EM, 1983, RES PROGR EPILEPSY, P46; SANDER JWAS, 1987, J NEUROL NEUROSUR PS, V50, P829, DOI 10.1136/jnnp.50.7.829; SCAMBLER G, 1987, EPILEPSY, P497; STORES G, 1978, DEV MED CHILD NEUROL, V20, P502; VERITY CM, 1992, BMJ-BRIT MED J, V305, P857, DOI 10.1136/bmj.305.6858.857	21	95	97	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 31	1998	316	7128					339	342		10.1136/bmj.316.7128.339	http://dx.doi.org/10.1136/bmj.316.7128.339			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487166	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000071863900021
J	Shou, WN; Aghdasi, B; Armstrong, DL; Guo, QX; Bao, SD; Charng, MJ; Mathews, LM; Schneider, MD; Hamilton, SL; Matzuk, MM				Shou, WN; Aghdasi, B; Armstrong, DL; Guo, QX; Bao, SD; Charng, MJ; Mathews, LM; Schneider, MD; Hamilton, SL; Matzuk, MM			Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12	NATURE			English	Article							FK506 BINDING-PROTEIN; CALCIUM-RELEASE; MOUSE; GENE	FKBP12, a cis-trans prolyl isomerase that binds the immunosuppressants FK506 and rapamycin, is ubiquitously expressed and interacts with proteins in several intracellular signal transduction systems(1). Although FKBP12 interacts with the cytoplasmic domains of type I receptors of the transforming growth factor-beta (TGF-beta) superfamily in vitro, the function of FKBP12 in TGF-beta superfamily signalling is controversial(2-6). FKBP12 also physically interacts stoichiometrically with multiple intracellular calcium release channels including the tetrameric skeletal muscle ryanodine dine receptor (RyR1)(7,8). In contrast, the cardiac ryanodine receptor, RyR2, appears to bind selectively the FKBP12 homologue, FKBP12.6 (refs 9, 10). To define the functions of FKBP12 in vivo, we generated mutant mice deficient in FKBP12 using embryonic stem (ES) cell technology. FKBP12-deficient mice have normal skeletal muscle but have severe dilated cardiomyopathy and ventricular septal defects that mimic a human congenital heart disorder, noncompaction of left ventricular myocardium(11,12). About 9% of the mutants exhibit exencephaly secondary to a defect in neural tube closure. Physiological studies demonstrate that FKBP12 is dispensable for TGF-beta-mediated signalling, but modulates the calcium release activity of both skeletal and cardiac ryanodine receptors.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Geneet, Houston, TX 77030 USA; Baylor Coll Med, Dept Physiol & Mol Biophys, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Michigan System; University of Michigan	Matzuk, MM (corresponding author), Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.	mmatzuk@bcm.tmc.edu		Hamilton, Susan/0000-0003-0241-9369				Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; Albrecht U, 1997, MOL CELLULAR METHODS, P23; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; ATKISON P, 1995, LANCET, V345, P894, DOI 10.1016/S0140-6736(95)90011-X; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Charng MJ, 1996, J BIOL CHEM, V271, P22941, DOI 10.1074/jbc.271.38.22941; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; CHIN TK, 1990, CIRCULATION, V82, P507, DOI 10.1161/01.CIR.82.2.507; DILELLA AG, 1992, BIOCHEM BIOPH RES CO, V189, P819, DOI 10.1016/0006-291X(92)92276-4; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; LAM E, 1995, J BIOL CHEM, V270, P26511, DOI 10.1074/jbc.270.44.26511; Lamb GD, 1996, J PHYSIOL-LONDON, V494, P569, DOI 10.1113/jphysiol.1996.sp021514; LAU AL, 1997, INHIBIN ACTIVIN FOLL, P220; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; Okadome T, 1996, J BIOL CHEM, V271, P21687, DOI 10.1074/jbc.271.36.21687; OKATA K, 1996, CIRCULATION S1, V94, P1; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; Ritter M, 1997, MAYO CLIN PROC, V72, P26, DOI 10.4065/72.1.26; Rossant J, 1996, CIRC RES, V78, P349, DOI 10.1161/01.RES.78.3.349; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; Timerman AP, 1996, J BIOL CHEM, V271, P20385, DOI 10.1074/jbc.271.34.20385; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Zhao Q, 1996, NAT GENET, V13, P275, DOI 10.1038/ng0796-275; Zimmerman CM, 1996, BIOCHEM SOC SYMP, P25	30	350	370	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	1998	391	6666					489	492		10.1038/35146	http://dx.doi.org/10.1038/35146			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461216	Green Submitted			2022-12-28	WOS:000071701800051
J	Ishijima, A; Kojima, H; Funatsu, T; Tokunaga, M; Higuchi, H; Tanaka, H; Yanagida, T				Ishijima, A; Kojima, H; Funatsu, T; Tokunaga, M; Higuchi, H; Tanaka, H; Yanagida, T			Simultaneous observation of individual ATPase and mechanical events by a single myosin molecule during interaction with actin	CELL			English	Article							ADENOSINE-TRIPHOSPHATE HYDROLYSIS; MUSCLE-CONTRACTION; NANO-MANIPULATION; KINESIN MOLECULES; SLIDING DISTANCE; ACTOMYOSIN MOTOR; SKELETAL-MUSCLE; IN-VITRO; FILAMENTS; FORCE	We have developed a technique that allows mechanical and ligand-binding events in a single myosin molecule to be monitored simultaneously. We describe how steps in the ATPase reaction are temporally related to mechanical events at the single molecule level. The results show that the force generation does not always coincide with the release of bound nucleotide, presumably ADP. Instead the myosin head produces force several hundreds of milliseconds after bound nucleotide is released. This finding does not support the widely accepted view that force generation is directly coupled to the release of bound ligands. It suggests that myosin has a hysteresis or memory state, which stores chemical energy from ATP hydrolysis.	ERATO, Biomotron Project, JST, Osaka 562, Japan; HONDA R&D Co, Wako Res Ctr, Wako, Saitama, Japan; Osaka Univ, Sch Med, Dept Physiol, Suita, Osaka 565, Japan	Honda Motor Company; Osaka University	Ishijima, A (corresponding author), ERATO, Biomotron Project, JST, Osaka 562, Japan.		Yanagida, Toshio/D-1919-2009; Ishijima, Akihiko/F-4603-2012; Funatsu, Takashi/Q-1404-2015	Funatsu, Takashi/0000-0002-9656-8308; Ishijima, Akihiko/0000-0002-8919-9268				BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Conibear PB, 1996, BIOCHEMISTRY-US, V35, P2299, DOI 10.1021/bi951824+; Dickson RM, 1997, NATURE, V388, P355, DOI 10.1038/41048; Eccleston J. F., 1996, Biophysical Journal, V70, pA159; EISENBERG E, 1980, BIOPHYS J, V29, P195, DOI 10.1016/S0006-3495(80)85126-5; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FRIEDEN C, 1970, J BIOL CHEM, V245, P5788; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GEEVES MA, 1984, J MUSCLE RES CELL M, V5, P351, DOI 10.1007/BF00818255; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P629; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P637, DOI 10.1146/annurev.ph.49.030187.003225; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; Guilford WH, 1997, BIOPHYS J, V72, P1006, DOI 10.1016/S0006-3495(97)78753-8; Ha T, 1996, P NATL ACAD SCI USA, V93, P6264, DOI 10.1073/pnas.93.13.6264; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; Harada Y, 1998, METHOD CELL BIOL, V55, P117; HIGUCHI H, 1991, NATURE, V352, P352, DOI 10.1038/352352a0; Higuchi H, 1997, P NATL ACAD SCI USA, V94, P4395, DOI 10.1073/pnas.94.9.4395; HUXLEY AF, 1954, NATURE, V173, P971, DOI 10.1038/173971a0; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY H, 1954, NATURE, V173, P973, DOI 10.1038/173973a0; HUXLEY HE, 1990, J BIOL CHEM, V265, P8347; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; Ishii Y., 1997, Biophysical Journal, V72, pA283; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; Ishijima A, 1996, BIOPHYS J, V70, P383, DOI 10.1016/S0006-3495(96)79582-6; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; Iwane AH, 1997, FEBS LETT, V407, P235, DOI 10.1016/S0014-5793(97)00359-1; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KODAMA T, 1985, PHYSIOL REV, V65, P467, DOI 10.1152/physrev.1985.65.2.467; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; LANDAOU L, 1969, STAT PHYSICS, P111; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MIYATA H, 1994, J BIOCHEM, V115, P644, DOI 10.1093/oxfordjournals.jbchem.a124389; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; OHNO T, 1991, J PHYSIOL-LONDON, V441, P685, DOI 10.1113/jphysiol.1991.sp018773; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SIMMONS RM, 1993, ADV EXP MED BIOL, V332, P331; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Tanaka H., 1997, Biophysical Journal, V72, pA55; Tokunaga M, 1997, BIOCHEM BIOPH RES CO, V235, P47, DOI 10.1006/bbrc.1997.6732; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; TRENTHAM DR, 1976, Q REV BIOPHYS, V9, P217, DOI 10.1017/S0033583500002419; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; WAKABAYASHI K, 1992, SCIENCE, V258, P443, DOI 10.1126/science.1411537; WOLEDGE RC, 1985, MONOGR PHYSL SOC, V41, P119; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0; YANAGIDA T, 1993, TRENDS BIOCHEM SCI, V18, P319, DOI 10.1016/0968-0004(93)90064-T; YOUNT RG, 1995, BIOPHYS J, V68, pS44; [No title captured]	60	400	428	0	37	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					161	171		10.1016/S0092-8674(00)80911-3	http://dx.doi.org/10.1016/S0092-8674(00)80911-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458041	Bronze			2022-12-28	WOS:000071672600006
J	Lieb, JD; Albrecht, MR; Chuang, PT; Meyer, BJ				Lieb, JD; Albrecht, MR; Chuang, PT; Meyer, BJ			MIX-1: An essential component of the C-elegans mitotic machinery executes x chromosome dosage compensation	CELL			English	Article							CAENORHABDITIS-ELEGANS; SEX DETERMINATION; GENE; SEGREGATION; MUTATIONS; NEMATODE; PROTEIN; XOL-1	We show that a functional component of the C. elegans mitotic machinery regulates X chromosome gene expression. This protein, MIX-1, is a member of the dosage compensation complex that associates specifically with hermaphrodite X chromosomes to reduce their gene expression during interphase. MIX-1 also associates with all mitotic chromosomes to ensure their proper segregation. Both dosage compensation and mitosis are severely disrupted by mix-1 mutations. MIX-1 belongs to the SMC protein family required for mitotic chromosome condensation and segregation in yeast and frogs. Thus, an essential, conserved component of mitotic chromosomes has been recruited to the dosage compensation process. Rather than dosage compensation and mitosis being achieved by two separate sets of related genes, these two processes share an identical component, indicating a common mechanism for establishing higher order chromosome structure and proper X chromosome gene expression.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Meyer, BJ (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.			Lieb, Jason/0000-0001-7601-8061; Meyer, Barbara/0000-0002-6530-4588	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030702, T32GM007127, R01GM030702] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM30702, R01 GM030702, T32 GM07127] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Chuang PT, 1996, SCIENCE, V274, P1736, DOI 10.1126/science.274.5293.1736; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; Davis TL, 1997, DEVELOPMENT, V124, P1019; DELONG L, 1993, GENETICS, V133, P875; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Harlow E., 1988, ANTIBODIES LABORATOR, P353; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; HERMAN RK, 1978, GENETICS, V88, P49; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; KEMPHUES KJ, 1988, GENETICS, V120, P977; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Kuroda MI, 1997, CELL, V91, P9, DOI 10.1016/S0092-8674(01)80003-9; Lieb JD, 1996, SCIENCE, V274, P1732, DOI 10.1126/science.274.5293.1732; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; NUSBAUM C, 1989, GENETICS, V122, P579; PLENEFISCH JD, 1989, GENETICS, V121, P57; RHIND NR, 1995, CELL, V80, P71, DOI 10.1016/0092-8674(95)90452-2; Willard HF, 1996, CELL, V86, P5, DOI 10.1016/S0092-8674(00)80071-9	25	142	150	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					265	277		10.1016/S0092-8674(00)80920-4	http://dx.doi.org/10.1016/S0092-8674(00)80920-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458050	Bronze			2022-12-28	WOS:000071672600015
J	McKinney, PA; Juszczak, E; Findlay, E; Smith, K				McKinney, PA; Juszczak, E; Findlay, E; Smith, K			Case-control study of childhood leukaemia and cancer in Scotland: findings for neonatal intramuscular vitamin K	BRITISH MEDICAL JOURNAL			English	Article							LEUKEMIA; RISK	Objective: To test the hypothesis of an association between neonatal intramuscular vitamin K and childhood leukaemia and other cancers. Design: Population based case-control study with data abstracted from hospital records. Setting: Scotland. Subjects: Children aged 0-14 years resident in Scotland from 1991-4 and diagnosed with leukaemia (150), lymphomas (46), central nervous system tumours (79), a range of other solid tumours (142), and a subset of acute lymphoblastic leukaemia (129). Controls were 777 children matched for age and sex, providing 417 matched sets (360 triplets and 57 pairs) for analysis. Main outcome measure: Odds ratios for the risk of childhood leukaemia and cancer and intramuscular vitamin K versus a combined group of oral doses, none, and no record. Results are given for information recorded in medical notes and data supplemented by hospital policy. Results: Odds ratios based on medical record abstractions showed no significant positive association for leukaemias (odds ratio 1.30; 95% confidence interval 0.83 to 2.03), acute lymphoblastic leukaemia (1.21; 0.74 to 1.97), lymphomas (1.06; 0.46 to 2.42), central nervous system tumours (0.74; 0.40 to 1.34), and other solid tumours (0.59; 0.37 to 0.96). There was no association with acute lymphoblastic leukaemia in children aged 1 to 6 years. Imputation of exposure from hospital policy gave similar results. Adjustment for deprivation and type of delivery moved risk estimates closer to unity for all major diagnostic groups. Conclusions: The observation of an increased risk of childhood leukaemia and cancer associated with intramuscular vitamin K is not confirmed by this independent population based study.	Common Serv Agcy Natl Hlth Serv Scotland, Informat & Stat Div, Edinburgh EH5 3SQ, Midlothian, Scotland		McKinney, PA (corresponding author), Common Serv Agcy Natl Hlth Serv Scotland, Informat & Stat Div, Trin Pk House, Edinburgh EH5 3SQ, Midlothian, Scotland.	p.a.mckinney@leeds.ac.uk						Ansell P, 1996, BRIT MED J, V313, P204, DOI 10.1136/bmj.313.7051.204; BIRCH JM, 1987, INT J CANCER, V40, P620, DOI 10.1002/ijc.2910400508; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; Carstairs V., 1991, DEPRIVATION HLTH SCO; DOLL R, 1989, J ROY STAT SOC A STA, V152, P341, DOI 10.2307/2983131; DRAPER G, 1994, BRIT MED J, V308, P867, DOI 10.1136/bmj.308.6933.867; EKLUND H, 1993, BRIT MED J, V307, P89; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; KLEBANOFF MA, 1993, NEW ENGL J MED, V329, P905, DOI 10.1056/NEJM199309233291301; McKinney P A, 1995, Health Bull (Edinb), V53, P222; MCKINNEY PA, 1994, BRIT J CANCER, V70, P973, DOI 10.1038/bjc.1994.432; OLSEN JH, 1994, BRIT MED J, V308, P895, DOI 10.1136/bmj.308.6933.895; Roman E, 1997, BRIT J CANCER, V76, P406, DOI 10.1038/bjc.1997.399; *STAT, 1997, STAT STAT SOFTW REL; STILLER CA, 1995, EUR J CANCER, V202, P8; vonKries R, 1996, BRIT MED J, V313, P199, DOI 10.1136/bmj.313.7051.199; Zipursky A, 1996, BMJ-BRIT MED J, V313, P179, DOI 10.1136/bmj.313.7051.179	17	30	30	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					173	177						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468680	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000071616400019
J	Scott, S				Scott, S			Fortnightly review - Aggressive behaviour in childhood	BRITISH MEDICAL JOURNAL			English	Review							CONDUCT PROBLEMS; ANTISOCIAL-BEHAVIOR; HYPERACTIVITY; ADJUSTMENT; ATTACHMENT; DISORDERS; CHILDREN; FAMILIES		Inst Psychiat, Dept Child & Adolescent Psychiat, London SE5 8AF, England	University of London; King's College London	Scott, S (corresponding author), Inst Psychiat, Dept Child & Adolescent Psychiat, De Crespigny Pk,Denmark Hill, London SE5 8AF, England.	Stephen.Scott@iop.bpmf.ac.uk						Bailey V, 1978, J R Coll Gen Pract, V28, P621; BANK L, 1991, J ABNORM CHILD PSYCH, V19, P15, DOI 10.1007/BF00910562; BOHMAN M, 1996, CIBA FDN S, V194; DADDS MR, 1992, J CONSULT CLIN PSYCH, V60, P252, DOI 10.1037/0022-006X.60.2.252; FARRINGTON DP, 1995, J CHILD PSYCHOL PSYC, V36, P929, DOI 10.1111/j.1469-7610.1995.tb01342.x; FARRINGTON DP, 1994, CRIMINAL BEHAV MENTA, V0004; FARRINGTON P, 1996, UNDERSTANDING PREVEN; FONAGY P, 1991, CHILD DEV, V62, P891, DOI 10.1111/j.1467-8624.1991.tb01578.x; GARDNER EM, 1992, EDUC PSYCHOL REV, V2, P135; GARRALDA ME, 1989, ARCH DIS CHILD, V64, P1727, DOI 10.1136/adc.64.12.1727; GOLDSMITH HH, 1995, FRONTIERS DEV PSYCHO; GOODMAN R, 1989, J CHILD PSYCHOL PSYC, V30, P671, DOI 10.1111/j.1469-7610.1989.tb00781.x; HANNON P, 1995, LIT HOME SCH RES PRA; HINSHAW SP, 1992, PSYCHOL BULL, V111, P127, DOI 10.1037/0033-2909.111.1.127; Kazdin A., 1995, CONDUCT DISORDERS CH, V2nd ed.; KUPERSMIDT KB, 1990, PEER REJECTION CHILD; LEVIN DE, 1992, YOUNG CHILDREN, V47, P4; LOCHMAN JE, 1994, J CONSULT CLIN PSYCH, V62, P366, DOI 10.1037/0022-006X.62.2.366; LOEBER R, 1991, J AM ACAD CHILD PSY, V30, P393, DOI 10.1097/00004583-199105000-00007; LyonsRuth K, 1996, J CONSULT CLIN PSYCH, V64, P64, DOI 10.1037/0022-006X.64.1.64; MCCORD J, 1994, INT J BEHAV DEV, V17, P739, DOI 10.1177/016502549401700410; MCCORD J, 1992, PREVENTING ANTISOCIA; MOFFITT TE, 1994, CRIMINOLOGY, V32, P101; Patterson G.R., 1992, ANTISOCIAL BOYS; PFIFFNER LJ, 1991, ATTENTION DEFICIT HY; PRINZ RJ, 1994, J CLIN CHILD PSYCHOL, V23, P193, DOI 10.1207/s15374424jccp2302_8; Puckering C., 1994, CHILD ABUSE REV, V3, P299, DOI DOI 10.1002/CAR.2380030409; QUINTON D, 1993, DEV PSYCHOPATHOL, V5, P703; ROBINS LN, 1991, PSYCHIATRY, V54, P116; RUTTER M, 1975, BRIT J PSYCHIAT, V126, P493, DOI 10.1192/bjp.126.6.493; Rutter M., 1970, ED HLTH BEHAV; Rutter M., 1983, JUVENILE DELINQUENCY; RUTTER M, 1996, GENETICS CRIMINAL AN; SCHWEINHART L, 1993, SUMMARY SIGNIFICANT; SCOTT S, 1994, CHILD ADOLESCENT PSY; SCOTT S, 1996, CHILD PSYCHOL PSYCHI, V1, P104; Spender Q, 1996, CURR OPIN PSYCHIATR, V9, P273, DOI 10.1097/00001504-199607000-00008; Taylor E, 1996, J AM ACAD CHILD PSY, V35, P1213, DOI 10.1097/00004583-199609000-00019; Webster-Stratton C., 1994, TROUBLED FAMILIES PR; WEBSTERSTRATTON C, 1989, J CONSULT CLIN PSYCH, V57, P550, DOI 10.1037/0022-006X.57.4.550	40	49	55	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					202	206						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YT531	9468689				2022-12-28	WOS:000071616400031
J	Bland, JM; Kerry, SM				Bland, JM; Kerry, SM			Statistics notes - Weighted comparison of means	BRITISH MEDICAL JOURNAL			English	Review									Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; Univ London St Georges Hosp, Sch Med, Div Gen Practice & Primary Care, London SW17 0RE, England	St Georges University London; St Georges University London	Bland, JM (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England.							Kerry SM, 1998, BMJ-BRIT MED J, V316, P54, DOI 10.1136/bmj.316.7124.54; OAKESHOTT P, 1994, BRIT J GEN PRACT, V44, P197	2	139	140	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 10	1998	316	7125					129	129						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR408	9462320				2022-12-28	WOS:000071492300027
J	Nightingale, SL				Nightingale, SL			FDA Modernization Act of 1997	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					346	346		10.1001/jama.279.5.346	http://dx.doi.org/10.1001/jama.279.5.346			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459455				2022-12-28	WOS:000071731300008
J	Nightingale, SL				Nightingale, SL			Two new warnings added to labeling for Mibefradil	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					346	346		10.1001/jama.279.5.346	http://dx.doi.org/10.1001/jama.279.5.346			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459455				2022-12-28	WOS:000071731300005
J	Schwartz, BS; Stewart, WF; Simon, D; Lipton, RB				Schwartz, BS; Stewart, WF; Simon, D; Lipton, RB			Epidemiology of tension-type headache	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	8th Congress of the International-Headache-Society	JUN 10-14, 1997	AMSTERDAM, NETHERLANDS	Int Headache Soc			PREVALENCE; MIGRAINE; POPULATION; RACE	Context.-Tension-type headache is a highly prevalent condition, Because few population-based studies have been performed, little is known about its epidemiology. Objectives.-To estimate the 1-year period prevalence of episodic tension-type headache (ETTH) and chronic tension-type headache (CTTH) in a population-based study; to describe differences in 1-year period prevalence by sex, age, education, and race; and to describe attack frequency and headache pain intensity, Design.-Telephone survey conducted 1993 to 1994. Setting.-Baltimore County, Maryland. Participants.-A total of 13 345 subjects from the community. Main Outcome Measures.-Percentage of respondents with diagnoses of headache using International Headache Society criteria. Workdays lost and reduced effectiveness at work, home, and school because of headache, based on self-report. Results.-The overall prevalence of ETTH in the past year was 38.3%, Women had a higher 1-year ETTH prevalence than men in all age, race, and education groups, with an overall prevalence ratio of 1.16. Prevalence peaked in the 30- to 39-year-old age group in both men (42.3%) and women (46.9%). Whites had a higher 1-year prevalence than African Americans in men (40.1% vs. 22.8%) and women (46.8% vs 30.9%). Prevalence increased with increasing educational levels in both sexes, reaching a peak in subjects with graduate school educations of 48.5% for men and 48.9% for women. The 1-year period prevalence of CTTH was 2.2%; prevalence was higher in women and declined with increasing education. Of subjects with ETTH, 8.3% reported lost workdays because of their headaches, while 43.6% reported decreased effectiveness at work, home, or school, Subjects with CTTH reported more lost workdays (mean of 27.4 days vs 8.9 days for those reporting lost workdays) and reduced-effectiveness days (mean of 20.4 vs 5.0 days for those reporting reduced effectiveness) compared with subjects with ETTH. Conclusions.-Episodic tension-type headache is a highly prevalent condition with a significant functional impact at work, home, and school. Chronic tension-type headache is much less prevalent than ETTH; despite its greater individual impact, CTTH has a smaller societal impact than ETTH.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Div Occupat & Environm Hlth, Baltimore, MD 21205 USA; Albert Einstein Coll Med, Dept Neurol, New York, NY USA; Albert Einstein Coll Med, Dept Epidemiol, New York, NY USA; Albert Einstein Coll Med, Dept Social Med, New York, NY USA; Innovat Med Res, Towson, MD USA	Johns Hopkins University; Johns Hopkins University; Yeshiva University; Yeshiva University; Yeshiva University	Stewart, WF (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, 615 N Wolfe St, Baltimore, MD 21205 USA.		Lipton, Richard Bruce/AAY-2818-2021; Lipton, Richard B/B-5060-2011					ABUAREFEH I, 1994, BRIT MED J, V309, P765, DOI 10.1136/bmj.309.6957.765; GOBEL H, 1994, CEPHALALGIA, V14, P97, DOI 10.1046/j.1468-2982.1994.1402097.x; MATUJA WBP, 1995, HEADACHE, V35, P273, DOI 10.1111/j.1526-4610.1995.hed3505273.x; MERIKANGAS KR, 1993, CEPHALALGIA, V13, P47, DOI 10.1177/0333102493013S1210; MITSIKOSTAS DD, 1994, HEADACHE, V34, P539, DOI 10.1111/j.1526-4610.1994.hed3409539.x; MONTEIRO JMP, 1994, NEUROEPIDEMIOLOGY, V13, P103; PRYSEPHILLIPS W, 1992, CAN J NEUROL SCI, V19, P333, DOI 10.1017/S0317167100041950; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; SACHS H, 1985, HEADACHE, V25, P190, DOI 10.1111/j.1526-4610.1985.hed2504190.x; Schwartz BS, 1997, J OCCUP ENVIRON MED, V39, P320, DOI 10.1097/00043764-199704000-00009; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; SRIKIATKHACHORN A, 1991, HEADACHE, V31, P677, DOI 10.1111/j.1526-4610.1991.hed3110677.x; STEWART WF, 1989, BIOMED PHARMACOTHER, V43, P711, DOI 10.1016/0753-3322(89)90159-5; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; Stewart WF, 1996, NEUROLOGY, V47, P52, DOI 10.1212/WNL.47.1.52; WONG TW, 1995, NEUROEPIDEMIOLOGY, V14, P82, DOI 10.1159/000109782	16	437	453	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					381	383		10.1001/jama.279.5.381	http://dx.doi.org/10.1001/jama.279.5.381			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YU572	9459472				2022-12-28	WOS:000071731300029
